PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Goldstone, AR; Callaghan, CJ; Mackay, J; Charman, S; Nashef, SAM				Goldstone, AR; Callaghan, CJ; Mackay, J; Charman, S; Nashef, SAM			Should surgeons take a break after an intraoperative death? Attitude survey and outcome evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To investigate attitudes of cardiac surgeons and anaesthetists towards working immediately after an intraoperative death and to establish whether an intraoperative death affects the outcome of subsequent surgery. Design Questionnaire on attitudes to working after an intraoperative death and matched cohort study. Setting UK adult cardiac surgery centres and regional cardiothoracic surgical centre. Participants 371 consultant cardiac surgeons and anaesthetists in the United Kingdom were asked to complete a questionnaire, and seven surgeons from one centre who continued to operate after intraoperative death. Main outcome measures Outcome for 233 patients operated on by a surgeon who had experienced an intraoperative death within the preceding 48 hours compared with outcome of 932 matched controls. Hospital mortality and length of stay as a surrogate for hospital morbidity. Results The questionnaire response rate was 76%. Around a quarter of surgeons and anaesthetists thought they should stop work after an intraoperative death and most wanted guidelines on this subject. Overall, there was no increased mortality in patients operated on in the 48 hours after an intraoperative death. However, mortality was higher if the preceding intraoperative death was in an emergency or high risk case. Survivors operated on within 48 hours after an intraoperative death had longer stay in intensive care (odds ratio 1.64, 95% confidence interval 1.08 to 2.52, P = 0.02) and longer stay in hospital (relative change 1.15, 1.03 to 1.24, P = 0.02). Conclusion Mortality is not increased in operations performed in the immediate aftermath of an intraoperative death, but survivors have longer stays in intensive care and on the hospital ward.	Papworth Hosp, Cambridge CB3 8RE, England; Univ Cambridge, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Surg, Cambridge CB2 2QQ, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	Papworth Hospital; University of Cambridge; University of Cambridge; MRC Biostatistics Unit; University of Cambridge	Nashef, SAM (corresponding author), Papworth Hosp, Cambridge CB3 8RE, England.	sam.nashef@papworth.nhs.uk						Briffa N, 2001, BRIT MED J, V323, P341, DOI 10.1136/bmj.323.7308.341/a; Nashef SAM, 1999, EUR J CARDIO-THORAC, V16, P9, DOI 10.1016/S1010-7940(99)00134-7; PARSONNET V, 1989, CIRCULATION, V79, P1; SEINFERT BC, 2001, BRIT MED J, V323, P341; Sheehan AV, 1999, FATAL ACCIDENTS SUDD; Smith IC, 2001, BMJ-BRIT MED J, V322, P896, DOI 10.1136/bmj.322.7291.896; *SOC CARD SURG GRE, 1999, NAT AD CARD SURG DAT; White SM, 2003, ANAESTHESIA, V58, P515, DOI 10.1046/j.1365-2044.2003.03241.x	8	32	33	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	2004	328	7436					379	382		10.1136/bmj.37985.371343.EE	http://dx.doi.org/10.1136/bmj.37985.371343.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	775GA	14734519	Green Submitted, Bronze, Green Published, Green Accepted			2022-12-28	WOS:000189031300019
J	Samore, MH; Evans, RS; Lassen, A; Gould, P; Lloyd, J; Gardner, RM; Abouzelof, R; Taylor, C; Woodbury, DA; Willy, M; Bright, RA				Samore, MH; Evans, RS; Lassen, A; Gould, P; Lloyd, J; Gardner, RM; Abouzelof, R; Taylor, C; Woodbury, DA; Willy, M; Bright, RA			Surveillance of medical device - Related hazards and adverse events in hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLOSED CLAIMS ANALYSIS; INTENSIVE-CARE-UNIT; DRUG EVENTS; QUALITY IMPROVEMENT; SAFETY; ANESTHESIA; DESIGN	Context Although adverse drug events have been extensively evaluated by computer-based surveillance, medical device errors have no comparable surveillance techniques. Objectives To determine whether computer-based surveillance can reliably identify medical device-related hazards (no known harm to patient) and adverse medical device events (AMDEs; patient experienced harm) and to compare alternative methods of detection of device-related problems. Design, Setting, and Participants This descriptive study was conducted from January through September 2000 at a 520-bed tertiary teaching institution in the United States with experience in using computer tools to detect and prevent adverse drug events. All 20441 regular and short-stay patients (excluding obstetric and newborn patients) were included. Main Outcome Measures Medical device events as detected by computer-based flags, telemetry problem checklists, International Classification of Diseases, Ninth Revision (ICD-9) discharge code (which could include AMDEs present at admission), clinical engineering work logs, and patient survey results were compared with each other and with routine voluntary incident reports to determine frequencies, proportions, positive predictive values, and incidence rates by each technique. Results Of the 7059 flags triggered, 552 (7.8%) indicate a device-related hazard or AMDE. The estimated 9-month incidence rates (number per 1000 admissions [95% confidence intervals]) for AMDEs were 1.6 (0.9-2.5) for incident reports, 27.7 (24.9-30.7) for computer flags, and 64.6 (60.4-69.1) for ICD-9 discharge codes. Few of these events were detected by more than 1 surveillance method, giving an overall incidence of AMDE detected by at least 1 of these methods of 83.7 per 1000 (95% confidence interval, 78.8-88.6) admissions. The positive predictive value of computer flags for detecting device-related hazards and AMDEs ranged from 0% to 38%. Conclusions More intensive surveillance methods yielded higher rates of medical device problems than found with traditional voluntary reporting, with little overlap between methods. Several detection methods had low efficiency in detecting AMDEs. The high rite of AMDEs suggests that AMDEs are an important patient safety issue, but additional research is necessary to identify optimal AMIDE detection strategies.	Univ Utah, Sch Med, Salt Lake City, UT 84132 USA; LDS Hosp Intermt Hlth Care, Salt Lake City, UT USA; Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA; US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA	Utah System of Higher Education; University of Utah; Intermountain Healthcare; US Department of Veterans Affairs; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Samore, MH (corresponding author), Univ Utah, Sch Med, 50 N Med Dr,Room AC104, Salt Lake City, UT 84132 USA.		Bright, Roselie A/D-2240-2016		PHS HHS [223-99-6101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amoore J, 2002, BRIT MED J, V325, P272, DOI 10.1136/bmj.325.7358.272; Austin A, 2000, BRIT J PLAST SURG, V53, P313, DOI 10.1054/bjps.2000.3353; Badea C, 1996, Stud Health Technol Inform, V28, P157; BATES DW, 1995, MED CARE, V33, P452, DOI 10.1097/00005650-199505000-00002; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; Brown S L, 1997, J Intraven Nurs, V20, P41; Brown S L, 1997, J Intraven Nurs, V20, P311; Brown S Lori, 2002, Curr Rheumatol Rep, V4, P293, DOI 10.1007/s11926-002-0037-6; Chambrin MC, 2001, CRIT CARE, V5, P184, DOI 10.1186/cc1021; CHENEY FW, 1994, ANESTHESIOLOGY, V80, P806, DOI 10.1097/00000542-199404000-00012; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8; Dillard Sharon F, 2002, AORN J, V76, P88, DOI 10.1016/S0001-2092(06)61098-3; Domino KB, 1999, ANESTHESIOLOGY, V91, P1703, DOI 10.1097/00000542-199912000-00023; Dwyer D, 2001, Int J Trauma Nurs, V7, P70, DOI 10.1067/mtn.2001.115213; Evans R S, 1991, Proc Annu Symp Comput Appl Med Care, P23; Evans R S, 1992, Proc Annu Symp Comput Appl Med Care, P437; Fuller J, 2001, J AM DENT ASSOC, V132, P1540, DOI 10.14219/jada.archive.2001.0087; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; Garner JS, 1988, AM J INFECT CONTROL, V16, P128, DOI DOI 10.1016/0196-6553(88)90053-3; Gosbee J, 2003, QUAL SAF HEALTH CARE, V12, P119, DOI 10.1136/qhc.12.2.119; Gosbee J, 2002, QUAL SAF HEALTH CARE, V11, P352, DOI 10.1136/qhc.11.4.352; HART GK, 1994, ANAESTH INTENS CARE, V22, P556, DOI 10.1177/0310057X9402200509; Jha AK, 1998, J AM MED INFORM ASSN, V5, P305, DOI 10.1136/jamia.1998.0050305; Kennelly RJ, 1997, INT J CLIN MONIT COM, V14, P143, DOI 10.1023/A:1016930319825; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lin L, 2001, J BIOMED INFORM, V34, P274, DOI 10.1006/jbin.2001.1028; Reid M H, 1999, Int J Trauma Nurs, V5, P68, DOI 10.1016/S1075-4210(99)90034-2; Rosenheimer L, 1998, AM J INFECT CONTROL, V26, P359, DOI 10.1016/S0196-6553(98)80018-7; Rosenqvist M, 1998, CIRCULATION, V98, P663, DOI 10.1161/01.CIR.98.7.663; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; Tsien CL, 1997, CRIT CARE MED, V25, P614, DOI 10.1097/00003246-199704000-00010; Ward RA, 2002, ARTIF ORGANS, V26, P305, DOI 10.1046/j.1525-1594.2002.00913.x; White G G, 1998, CRNA, V9, P139; 1998, HLTH DEVICES, V27, P277	36	86	86	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					325	334		10.1001/jama.291.3.325	http://dx.doi.org/10.1001/jama.291.3.325			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734595	Bronze			2022-12-28	WOS:000188243100032
J	Garry, R; Fountain, J; Mason, S; Napp, V; Brown, J; Hawe, J; Clayton, R; Abbott, J; Phillips, G; Whittaker, M; Lilford, R; Bridgman, S				Garry, R; Fountain, J; Mason, S; Napp, V; Brown, J; Hawe, J; Clayton, R; Abbott, J; Phillips, G; Whittaker, M; Lilford, R; Bridgman, S			The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy	BRITISH MEDICAL JOURNAL			English	Article							MULTICENTER	Objective To compare the effects of laparoscopic hysterectomy and abdominal hysterectomy in the abdominal trial, and laparoscopic hysterectomy and vaginal hysterectomy in the vaginal trial. Design Two parallel, multicentre, randomised trials. Setting 28 UK centres and two South African centres. Participants 1380 women were recruited; 1346 had surgery; 937 were followed up at one year. Primary outcome Rate of major complications. Results In the abdominal trial laparoscopic hysterectomy was associated with a higher rate, of major complications than abdominal hysterectomy (11.1% v 6.2%, P = 0.02; difference 4.9%,95% confidence interval 0.9% to 9.1%) and the number needed to treat to harm was 20. Laparoscopic hysterectomy also took longer to perform (84 minutes v 50 minutes) but was less painful (visual analogue scale 3.51 v 3.88, P = 0.0 1) and resulted in a shorter stay in hospital after the operation 3 days v 4 days). Six weeks after the operation, laparoscopic hysterectomy was associated with less pain and better quality of life than abdominal hysterectomy (SF-12, body image scale, and sexual activity questionnaires). In the vaginal trial we found no evidence of a difference in major complication rates between laparoscopic hysterectomy and vaginal hysterectomy (9.8% v 9.5%, P = 0.92; difference 6.3%, - 5.2% to 5.8%), and the number needed to treat to harm was 333. We found no evidence of other differences between laparoscopic hysterectomy and vaginal hysterectomy except that laparoscopic hysterectomy took longer to perform (72 minutes v 39 minutes) and was associated with a higher rate of detecting unexpected pathology (16.4% v 4.8%, P = < 0.01). However, this trial was underpowered. Conclusions Laparoscopic hysterectomy was associated with a significantly higher rate of major complications than abdominal hysterectomy. It also took longer to perform but was ' associated with less pain, quicker recovery, and better short term quality of life. The trial comparing vaginal hysterectomy with laparoscopic hysterectomy was underpowered and is inconclusive on the rate of major complications; however, vaginal hysterectomy took less time.	Univ Western Australia, King Edward Mem Hosp, Dept Obstet & Gynaecol, Perth, WA 6008, Australia; Univ Leeds, No & Yorkshire Clin Trials & Res Unit, Leeds LS2 9NG, W Yorkshire, England; James Cook Univ Hosp, Middlesbrough TS4 3BW, Cleveland, England; Univ New S Wales, Royal Womens Hosp, Randwick, NSW 2031, Australia; St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2UP, W Midlands, England; Newcastle Lyme Primary Care Trust, Newcastle Under Lyme ST5 7NJ, Staffs, England	King Edward Memorial Hospital; University of Western Australia; University of Leeds; James Cook University Hospital; University of New South Wales Sydney; Saint James's University Hospital; University of Birmingham	Garry, R (corresponding author), Univ Western Australia, King Edward Mem Hosp, Dept Obstet & Gynaecol, Perth, WA 6008, Australia.	rgarry@obsgyn.uwa.edu.au		Napp, Vicky/0000-0001-6726-2222; brown, julia/0000-0002-2719-7064				CASEY MJ, 1994, J GYNECOL SURG, V10, P7, DOI 10.1089/gyn.1994.10.7; Elashoff JD, 2000, NQUERY ADVISOR VERSI; ELSAHOFF JD, 2000, NQUERY ADVISOR VERS; Falcone T, 1999, AM J OBSTET GYNECOL, V180, P955, DOI 10.1016/S0002-9378(99)70667-8; Farquhar CM, 2002, OBSTET GYNECOL, V99, P229, DOI 10.1016/S0029-7844(01)01723-9; Hopwood P, 2001, EUR J CANCER, V37, P189, DOI 10.1016/S0959-8049(00)00353-1; Langebrekke A, 1996, ACTA OBSTET GYN SCAN, V75, P404, DOI 10.3109/00016349609033340; Lumsden MA, 2000, BRIT J OBSTET GYNAEC, V107, P1386, DOI 10.1111/j.1471-0528.2000.tb11653.x; Marana R, 1999, AM J OBSTET GYNECOL, V180, P270, DOI 10.1016/S0002-9378(99)70199-7; Maresh MJA, 2002, BJOG-INT J OBSTET GY, V109, P302, DOI 10.1111/j.1471-0528.2002.01282.x; NEZHAT F, 1992, J REPROD MED, V37, P247; OLLSON J, 1996, BRIT J OBSTET GYNAEC, V103, P345; Ottosen C, 2000, BRIT J OBSTET GYNAEC, V107, P1380; Perino A, 1999, HUM REPROD, V14, P2996, DOI 10.1093/humrep/14.12.2996; PHIPPS JH, 1993, BRIT J OBSTET GYNAEC, V100, P698, DOI 10.1111/j.1471-0528.1993.tb14246.x; RAJU KS, 1994, BRIT J OBSTET GYNAEC, V101, P1068, DOI 10.1111/j.1471-0528.1994.tb13583.x; RICHARDSON RE, 1995, LANCET, V345, P36, DOI 10.1016/S0140-6736(95)91158-8; Soriano D, 2001, ACTA OBSTET GYN SCAN, V80, P337, DOI 10.1034/j.1600-0412.2001.080004337.x; Stovall TG, 1996, NEW ENGL J MED, V335, P512, DOI 10.1056/NEJM199608153350712; SUMMITT RL, 1992, OBSTET GYNECOL, V80, P895; Summitt RL, 1998, OBSTET GYNECOL, V92, P321, DOI 10.1016/S0029-7844(98)00229-4; Thirlaway K, 1996, QUAL LIFE RES, V5, P81, DOI 10.1007/BF00435972; Ware JE, 1995, SF 12 PHYSICAL MENTA	23	389	419	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					129	133		10.1136/bmj.37984.623889.F6	http://dx.doi.org/10.1136/bmj.37984.623889.F6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14711749	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000188249900015
J	Grenfell, BT; Pybus, OG; Gog, JR; Wood, JLN; Daly, JM; Mumford, JA; Holmes, EC				Grenfell, BT; Pybus, OG; Gog, JR; Wood, JLN; Daly, JM; Mumford, JA; Holmes, EC			Unifying the epidemiological and evolutionary dynamics of pathogens	SCIENCE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; STRAIN STRUCTURE; HIV-1; INTERFERENCE; VARIABILITY; PERSISTENCE; ADAPTATION; INFECTION; FIXATION	A key priority for infectious disease research is to clarify how pathogen genetic variation, modulated by host immunity, transmission bottlenecks, and epidemic dynamics, determines the wide variety of pathogen phylogenies observed at scales that range from individual host to population. We call the melding of immunodynamics, epidemiology, and evolutionary biology required to achieve this synthesis pathogen "phylodynamics." We introduce a phylodynamic framework for the dissection of dynamic forces that determine the diversity of epidemiological and phylogenetic patterns observed in RNA viruses of vertebrates. A central pillar of this model is the Evolutionary Infectivity Profile, which captures the relationship between immune selection and pathogen transmission.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Anim Hlth Trust, Newmarket CB8 7UU, Suffolk, England	University of Cambridge; University of Oxford; Animal Health Trust	Grenfell, BT (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	btg11@cam.ac.uk	Pybus, Oliver G/B-2640-2012; Holmes, Edward/Y-2789-2019; Wood, James/A-1626-2008; Daly, Janet/G-9797-2011; Holmes, Edward/GVR-9499-2022	Pybus, Oliver G/0000-0002-8797-2667; Holmes, Edward/0000-0001-9596-3552; Wood, James/0000-0002-0258-3188; Gog, Julia/0000-0003-1240-7214; Daly, Janet/0000-0002-1912-4500	Biotechnology and Biological Sciences Research Council [BB/B524092/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ANDERSON R M, 1991; Andreasen V, 1997, J MATH BIOL, V35, P825, DOI 10.1007/s002850050079; Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921; COG JR, 2002, P NATL ACAD SCI USA, V99, P17209; Daly JM, 1996, J GEN VIROL, V77, P661, DOI 10.1099/0022-1317-77-4-661; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; Ferguson N, 1999, P NATL ACAD SCI USA, V96, P790, DOI 10.1073/pnas.96.2.790; Ferguson NM, 2003, NATURE, V422, P428, DOI 10.1038/nature01509; Galvani AP, 2003, TRENDS ECOL EVOL, V18, P132, DOI 10.1016/S0169-5347(02)00050-2; Gog JR, 2003, P NATL ACAD SCI USA, V100, P11143, DOI 10.1073/pnas.1830296100; Grenfell BT, 2002, ECOL MONOGR, V72, P185, DOI 10.1890/0012-9615(2002)072[0185:DOMESN]2.0.CO;2; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; GRENFELL BT, 1995, ECOLOGY INFECTIOUS D; Gupta S, 1998, SCIENCE, V280, P912, DOI 10.1126/science.280.5365.912; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; Haydon DT, 2001, GENETICS, V157, P7; Heyndrickx L, 2000, J VIROL, V74, P363, DOI 10.1128/JVI.74.1.363-370.2000; HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835; KIMURA M, 1962, GENETICS, V47, P713; Miralles R, 1999, SCIENCE, V285, P1745, DOI 10.1126/science.285.5434.1745; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; MUMFORD JA, 1990, EQUINE VET J, V22, P93, DOI 10.1111/j.2042-3306.1990.tb04217.x; MUMFORD JA, 1998, TXB INFLUENZA, P146; Nicholson KG, 1998, TXB INFLUENZA, P219; NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012; Nowak MA., 2000, VIRUS DYNAMICS MATH; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pybus OG, 2000, GENETICS, V155, P1429; Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321; Ray SC, 1999, J VIROL, V73, P2938, DOI 10.1128/JVI.73.4.2938-2946.1999; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Rohani P, 2003, NATURE, V422, P885, DOI 10.1038/nature01542; Rossi G, 1997, BLOOD, V90, P1309, DOI 10.1182/blood.V90.3.1309.1309_1309_1314; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; SIMMONDS P, 1995, HEPATOLOGY, V21, P570, DOI 10.1002/hep.1840210243; Smith DJ, 1997, J THEOR BIOL, V189, P141, DOI 10.1006/jtbi.1997.0495; Swofford DL, 2002, PAUP VERSION 4; Twiddy SS, 2003, INFECT GENET EVOL, V3, P87, DOI 10.1016/S1567-1348(02)00153-3; Williamson S, 2003, MOL BIOL EVOL, V20, P1318, DOI 10.1093/molbev/msg144; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Yamaguchi-Kabata Y, 2000, J VIROL, V74, P4335, DOI 10.1128/JVI.74.9.4335-4350.2000	41	859	880	1	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					327	332		10.1126/science.1090727	http://dx.doi.org/10.1126/science.1090727			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726583				2022-12-28	WOS:000188111800031
J	Rogowski, JA; Horbar, JD; Staiger, DO; Kenny, M; Carpenter, J; Geppert, J				Rogowski, JA; Horbar, JD; Staiger, DO; Kenny, M; Carpenter, J; Geppert, J			Indirect vs direct hospital quality indicators for very low-birth-weight infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEONATAL INTENSIVE-CARE; LONGITUDINAL DATA; PERFORMANCE DATA; PATIENT VOLUME; MORTALITY; LEVEL; UNITS; SEVERITY; OUTCOMES; MODELS	Context Evidence-based selective referral strategies are being used by an increasing number of insurers to ensure that medical care is provided by high-quality providers. In the absence of direct-quality measures based on patient outcomes, the standards currently in place for many conditions rely on indirect-quality measures such as patient volume. Objectives To assess the potential usefulness of volume as a quality indicator for very low-birth-weight (VLBW) infants and compare volume with other potential indicators based on readily available hospital characteristics and patient outcomes. Design, Setting, and Participants A retrospective study of 94110 VLBW infants weighing 501 to 1500 g born in 332 Vermont Oxford Network hospitals with neonatal intensive care units between January 1, 1995, and December 31, 2000. Main Outcome Measures Mortality among VLBW infants prior to discharge home; detailed case-mix adjustment was performed by using patient characteristics available immediately after birth. Results In hospitals with less than 50 annual admissions of VLBW infants, an additional 10 admissions were associated with an 11% reduction in mortality (95% confidence interval [CI], 5%-16%; P<.001). The annual volume of admissions only explained 9% of the variation across hospitals in mortality rates, and other readily available hospital characteristics explained an additional 7%. Historical volume was not significantly related to mortality rates in 1999-2000, implying that volume cannot prospectively identify high-quality providers. In contrast, hospitals in the lowest mortality quintile between 1995 and 1998 were found to have significantly lower mortality rates in 1999-2000 (odds ratio [OR], 0.64; 95% CI, 0.55-0.76; P<.001) and hospitals in the highest mortality quintile between 1995 and 1998 had significantly higher mortality rates in 1999-2000 (OR, 1.37; 95% CI, 1.16-1.64; P<.001). The percentage of hospital-level variation in mortality in 1999-2000 that was forecasted by the highest and lowest quintiles based on patient mortality was 34% compared with only 1% for the highest and lowest quintiles of volume. Conclusions Referral of VLBW infants based on indirect-quality indicators such as patient volume may be minimally effective. Direct measures based on patient outcomes are more useful quality indicators for the purposes of selective referral, as they are better predictors of future mortality rates among providers and could save more lives.	RAND Corp, Arlington, VA 22202 USA; Univ Vermont, Coll Med, Dept Pediat, Burlington, VT USA; Vermont Oxford Network, Burlington, VT USA; Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA; Univ Vermont, Div Biometry, Burlington, VT USA; Natl Bur Econ Res, Palo Alto, CA USA	RAND Corporation; University of Vermont; Dartmouth College; National Bureau of Economic Research; University of Vermont; National Bureau of Economic Research	Rogowski, JA (corresponding author), RAND Corp, 1200 S Hayes St, Arlington, VA 22202 USA.		Kenny, Michael/N-3244-2013	Kenny, Michael/0000-0002-7750-654X	AHRQ HHS [R01 HS13371, R01 HS10328] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010328, R01HS013371] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AG HEALTHC RES QU, 2001, HCUP QUAL IND VERS 1; Bentley J M, 1998, Jt Comm J Qual Improv, V24, P40; Cifuentes J, 2002, PEDIATRICS, V109, P745, DOI 10.1542/peds.109.5.745; Cleveland WS., 1993, VISUALIZING DATA; COCKBURN F, 1993, LANCET, V342, P193; Conway M.R., 1990, BIOMETRICS, V46, P317; Davies HTO, 1999, LANCET, V353, P1639, DOI 10.1016/S0140-6736(99)90047-8; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Harris C, 2001, BRIT MED J, V323, P709, DOI 10.1136/bmj.323.7315.709; Horbar J D, 1999, Pediatrics, V103, P350; Horbar JD, 1997, PEDIATRICS, V99, P149, DOI 10.1542/peds.99.2.149; HORBAR JD, 1995, FUTURE CHILD, V5, P139, DOI 10.2307/1602512; *LEAPFR GROUP, SURV RES EXPL HER CO; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Mennemeyer ST, 1997, INQUIRY-J HEALTH CAR, V34, P117; PANETH N, 1987, AM J DIS CHILD, V141, P60, DOI 10.1001/archpedi.1987.04460010060024; Parry GJ, 1998, BRIT MED J, V316, P1931, DOI 10.1136/bmj.316.7149.1931; Phibbs CS, 1996, JAMA-J AM MED ASSOC, V276, P1054, DOI 10.1001/jama.276.13.1054; Pollack MM, 2002, LANCET, V359, P95, DOI 10.1016/S0140-6736(02)07334-8; Richardson D, 1999, Pediatrics, V103, P255; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; Tucker J, 2002, LANCET, V359, P99; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	25	104	107	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					202	209		10.1001/jama.291.2.202	http://dx.doi.org/10.1001/jama.291.2.202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722146	Bronze			2022-12-28	WOS:000188040900028
J	Khaw, PT; Shah, P; Elkington, AR				Khaw, PT; Shah, P; Elkington, AR			ABC of eyes - Glaucoma - 1: Diagnosis	BRITISH MEDICAL JOURNAL			English	Article									Moorfields Eye Hosp, London, England; Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England; Univ Southampton, Southampton SO9 5NH, Hants, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of Southampton	Khaw, PT (corresponding author), Moorfields Eye Hosp, London, England.		Khaw, Peng T/C-1881-2008	Khaw, Sir Peng Tee/0000-0002-8087-2268					0	37	44	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 10	2004	328	7431					97	99		10.1136/bmj.328.7431.97	http://dx.doi.org/10.1136/bmj.328.7431.97			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MP	14715605	Green Published			2022-12-28	WOS:000187976400021
J	Anderson, MC; Ochsner, KN; Kuhl, B; Cooper, J; Robertson, E; Gabrieli, SW; Glover, GH; Gabrieli, JDE				Anderson, MC; Ochsner, KN; Kuhl, B; Cooper, J; Robertson, E; Gabrieli, SW; Glover, GH; Gabrieli, JDE			Neural systems underlying the suppression of unwanted memories	SCIENCE			English	Article							PREFRONTAL CORTEX; BRAIN ACTIVATION; INHIBITION; RETRIEVAL; HIPPOCAMPUS; MECHANISMS; MONKEYS; HUMANS; AREAS; TASK	Over a century ago, Freud proposed that unwanted memories can be excluded from awareness, a process called repression. It is unknown, however, how repression occurs in the brain. We used functional magnetic resonance imaging to identify the neural systems involved in keeping unwanted memories out of awareness. Controlling unwanted memories was associated with increased dorsolateral prefrontal activation, reduced hippocampal activation, and impaired retention of those memories. Both prefrontal cortical and right hippocampal activations predicted the magnitude of forgetting. These results confirm the existence of an active forgetting process and establish a neurobiological model for guiding inquiry into motivated forgetting.	Univ Oregon, Dept Psychol, Eugene, OR 97403 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA	University of Oregon; Stanford University; Stanford University	Anderson, MC (corresponding author), Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.	mcanders@darkwing.uoregon.edu	Gabrieli, John/AAJ-2869-2020	Anderson, Michael/0000-0001-9505-9299	NIMH NIH HHS [MH59940, MH62126] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059940, R01MH062126] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON MC, 1995, PSYCHOL REV, V102, P68, DOI 10.1037/0033-295X.102.1.68; Anderson MC, 2001, NATURE, V410, P366, DOI 10.1038/35066572; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Barbas H, 1999, J COMP NEUROL, V410, P343, DOI 10.1002/(SICI)1096-9861(19990802)410:3<343::AID-CNE1>3.0.CO;2-1; BJORK EL, 1997, INTENTIONAL FORGETTI, P103; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Conway MA, 2003, CORTEX, V39, P667, DOI 10.1016/S0010-9452(08)70859-1; Davachi L, 2003, P NATL ACAD SCI USA, V100, P2157, DOI 10.1073/pnas.0337195100; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Dougall AL, 1999, PSYCHOSOM MED, V61, P38, DOI 10.1097/00006842-199901000-00008; Eldridge LL, 2000, NAT NEUROSCI, V3, P1149, DOI 10.1038/80671; Erdelyi MH, 2001, AM PSYCHOL, V56, P761, DOI 10.1037/0003-066X.56.9.761; Fernandez G, 1999, SCIENCE, V285, P1582, DOI 10.1126/science.285.5433.1582; FREUD S, 1966, STANDARD EDITION COM, V1, P117; Freyd J.J., 1996, BETRAYAL TRAUMA LOGI; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Jonides J, 1998, P NATL ACAD SCI USA, V95, P8410, DOI 10.1073/pnas.95.14.8410; Kastner S, 2000, ANNU REV NEUROSCI, V23, P315, DOI 10.1146/annurev.neuro.23.1.315; Knight RT, 1999, ACTA PSYCHOL, V101, P159, DOI 10.1016/S0001-6918(99)00004-9; Lepage M, 2000, P NATL ACAD SCI USA, V97, P506, DOI 10.1073/pnas.97.1.506; Levy BJ, 2002, TRENDS COGN SCI, V6, P299, DOI 10.1016/S1364-6613(02)01923-X; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Menon V, 2001, HUM BRAIN MAPP, V12, P131, DOI 10.1002/1097-0193(200103)12:3<131::AID-HBM1010>3.0.CO;2-C; Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138; Nakahara K, 2002, SCIENCE, V295, P1532, DOI 10.1126/science.1067653; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; Picard N, 2001, CURR OPIN NEUROBIOL, V11, P663, DOI 10.1016/S0959-4388(01)00266-5; Shimamura AP, 2000, PSYCHOBIOLOGY, V28, P207; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188	30	655	683	4	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					232	235		10.1126/science.1089504	http://dx.doi.org/10.1126/science.1089504			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	761KT	14716015				2022-12-28	WOS:000187908500049
J	Donnay, F; Weil, L				Donnay, F; Weil, L			Obstetric fistula: the international response	LANCET			English	Article							NORTHERN NIGERIA; HEALTH		UN Populat Fund, Tech Support Div, Reprod Hlth Branch, New York, NY 10017 USA	United Nations Population Fund	Donnay, F (corresponding author), UN Populat Fund, Tech Support Div, Reprod Hlth Branch, New York, NY 10017 USA.							Bangser M, 1999, SAFE MOTHERHOOD INIT, P157; Buekens P, 2003, BRIT MED J, V326, P136, DOI 10.1136/bmj.326.7381.136; HARRISON KA, 1985, BRIT J OBSTET GYNAEC, V92, P1; Lopez A, 1998, HLTH DIMENSIONS SEX; MURPHY M, 1981, J BIOSOC SCI, V13, P139, DOI 10.1017/S0021932000013304; *UNFPA AMDD FIGO, 2001, M PREV TREATM OBST F; *UNFPA MIN HLTH GO, 2002, TANZ FIST SURV 2001; Wall LL, 2002, INCONTINENCE, 2ND EDITION, P893; *WHO, 1989, WHOFHE895 DIV FAM HL; *WHO UNFPA UNICEF, 1997, GUID MON US OBST SER	10	35	35	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					71	72		10.1016/S0140-6736(03)15177-X	http://dx.doi.org/10.1016/S0140-6736(03)15177-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14724002				2022-12-28	WOS:000187711300031
J	Sarkar, DA; Smith, EEJ; Brecker, SJ				Sarkar, DA; Smith, EEJ; Brecker, SJ			Giant coronary aneurysms	LANCET			English	Editorial Material									Univ London St Georges Hosp, Dept Cardiol, London SW17 0QT, England; Univ London St Georges Hosp, Dept Surg, London SW17 0QT, England	St Georges University London; St Georges University London	Sarkar, DA (corresponding author), Univ London St Georges Hosp, Dept Cardiol, London SW17 0QT, England.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					37	37		10.1016/S0140-6736(03)15167-7	http://dx.doi.org/10.1016/S0140-6736(03)15167-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723992				2022-12-28	WOS:000187711300012
J	Tsu, VD				Tsu, VD			New and underused technologies to reduce maternal mortality	LANCET			English	Article									PATH, Seattle, WA 98107 USA		Tsu, VD (corresponding author), PATH, 1455 NW Leary Way, Seattle, WA 98107 USA.							Duley L, 2003, COCHRANE LIB; Katz J, 2003, B WORLD HEALTH ORGAN, V81, P717; Strong MA, 1992, HLTH TRANSITION REV, V2, P215; Tsu VD, 2003, INT J GYNECOL OBSTET, V83, P103, DOI 10.1016/S0020-7292(03)00186-3; *WHO, 1998, WHORHTMSM9411REV1; World Health Organisation, 1999, RED MAT MORT JOINT W	6	31	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					75	76		10.1016/S0140-6736(03)15180-X	http://dx.doi.org/10.1016/S0140-6736(03)15180-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14724005				2022-12-28	WOS:000187711300034
J	Ni, XJ; Wang, YQ; Hu, YM; Li, CK				Ni, XJ; Wang, YQ; Hu, YM; Li, CK			A euprimate skull from the early Eocene of China	NATURE			English	Article							TRICHROMATIC VISION; EVOLUTION; OMOMYIDAE; PRIMATES; ADAPTATIONS; ORIENTATION; PATTERNS; BASIN	The debut of undoubted euprimates (primates of modern aspect(1,2)) was in the early Eocene, about 55 Myr ago. Since their first appearance, the earliest euprimates can be distinguished as Cantius, Donrussellia and Teilhardina(2-4). Nonetheless, the earliest euprimates are primarily known from isolated teeth or fragmentary jaws. Here we describe a partially preserved euprimate skull with nearly complete upper and lower dentition, which represents a new species of Teilhardina and constitutes the first discovery of the genus in Asia. The new species is from the upper section of Lingcha Formation, Hunan Province, China, with an estimated age of 54.97 Myr ago(5). Morphology and phylogeny analyses reveal that the new species is the most primitive species of Teilhardina, positioned near the root of euprimate radiation. This discovery of the earliest euprimate skull known to date casts new light on the debate(6-12) concerning the adaptive origin of euprimates, and suggests that the last common ancestor of euprimates was probably a small, diurnal, visually oriented predator.	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; CUNY, Grad Sch & City Coll, Biol Program, New York, NY 10016 USA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; American Museum of Natural History (AMNH); City University of New York (CUNY) System	Ni, XJ (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China.	ni_xj@263.net						Bloch JI, 2002, SCIENCE, V298, P1606, DOI 10.1126/science.1078249; Bowen GJ, 2002, SCIENCE, V295, P2062, DOI 10.1126/science.1068700; BOWN TM, 1987, J PALEONTOL, V61, P1; Cartmill M., 1972, FUNCTIONAL EVOLUTION, P97, DOI DOI 10.4324/9781315132129; Covert HH, 1995, CREATURES OF THE DARK, P495; FLEAGLE JG, 1999, PRIMATE ADAPTATION E; GINGERICH PD, 1981, J HUM EVOL, V10, P345, DOI 10.1016/S0047-2484(81)80057-7; GODINOT M, 1987, MUNCHNER GEOWISS ABH, V10, P237; Gunnell GF, 2002, CAM S BIO EVOL ANTHR, V33, P45; Heesy CP, 2001, J HUM EVOL, V40, P111, DOI 10.1006/jhev.2000.0447; Kay RF, 2000, AM J PHYS ANTHROPOL, V113, P235, DOI 10.1002/1096-8644(200010)113:2<235::AID-AJPA7>3.0.CO;2-9; KAY RF, 1975, AM J PHYS ANTHROPOL, V43, P195, DOI 10.1002/ajpa.1330430207; KAY RF, 1977, J HUM EVOL, V6, P19, DOI 10.1016/S0047-2484(77)80040-7; Kay RF, 1997, SCIENCE, V275, P797, DOI 10.1126/science.275.5301.797; KAY RF, 1974, AM J PHYS ANTHROPOL, V40, P227, DOI 10.1002/ajpa.1330400210; Kirk EC, 2003, SCIENCE, V300; Li WH, 2000, AM J PHYS ANTHROPOL, P318; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; Martin R.D., 1990, PRIMATE ORIGINS EVOL; Ravosa MJ, 2000, J HUM EVOL, V38, P667, DOI 10.1006/jhev.1999.0380; ROSE KD, 1991, P NATL ACAD SCI USA, V88, P98, DOI 10.1073/pnas.88.1.98; Rose Kenneth D., 1994, P1; Ross C, 1998, J HUM EVOL, V35, P221, DOI 10.1006/jhev.1998.0254; ROSS CF, 1995, J HUM EVOL, V29, P201, DOI 10.1006/jhev.1995.1057; Simons EL, 1972, PRIMATE EVOLUTION IN; Surridge AK, 2003, TRENDS ECOL EVOL, V18, P198, DOI 10.1016/S0169-5347(03)00012-0; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Szalay F.S., 1979, EVOLUTIONARY HIST PR; Tan Y, 1999, NATURE, V402, P36, DOI 10.1038/46947; WILLIAMS BA, 1994, AM J PHYS ANTHROPOL, V93, P323, DOI 10.1002/ajpa.1330930305	30	102	117	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					65	68		10.1038/nature02126	http://dx.doi.org/10.1038/nature02126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	758YP	14702085				2022-12-28	WOS:000187710000034
J	Nishiguchi, KM; Sandberg, MA; Kooijman, AC; Martemyanov, KA; Pott, JWR; Hagstrom, SA; Arshavsky, VY; Berson, EL; Dryja, TP				Nishiguchi, KM; Sandberg, MA; Kooijman, AC; Martemyanov, KA; Pott, JWR; Hagstrom, SA; Arshavsky, VY; Berson, EL; Dryja, TP			Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation	NATURE			English	Article							GTPASE-ACCELERATING PROTEIN; RETINITIS-PIGMENTOSA; MEMBRANE ANCHOR; EXPRESSION; ACTIVATION; ROD; ELECTRORETINOGRAPHY; PHOTOTRANSDUCTION; STANDARD; RECOVERY	The RGS proteins are GTPase activating proteins that accelerate the deactivation of G proteins in a variety of signalling pathways in eukaryotes(1-6). RGS9 deactivates the G proteins (transducins) in the rod and cone phototransduction cascades(7,8). It is anchored to photoreceptor membranes by the transmembrane protein R9AP (RGS9 anchor protein), which enhances RGS9 activity up to 70-fold(9-11). If RGS9 is absent or unable to interact with R9AP, there is a substantial delay in the recovery from light responses in mice(4,12,13). We identified five unrelated patients with recessive mutations in the genes encoding either RGS9 or R9AP who reported difficulty adapting to sudden changes in luminance levels mediated by cones. Standard visual acuity was normal to moderately subnormal, but the ability to see moving objects, especially with low-contrast, was severely reduced despite full visual fields; we have termed this condition bradyopsia. To our knowledge, these patients represent the first identified humans with a phenotype associated with reduced RGS activity in any organ.	Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA 02114 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Howe Lab Ophthalmol, Boston, MA 02114 USA; Univ Groningen Hosp, Dept Ophthalmol, NL-9700 RB Groningen, Netherlands	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Groningen	Dryja, TP (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA 02114 USA.	Thaddeus_Dryja@meei.harvard.edu						ANDREASSON SOL, 1988, AM J OPHTHALMOL, V105, P500, DOI 10.1016/0002-9394(88)90241-3; BERSON EL, 1968, ARCH OPHTHALMOL-CHIC, V80, P58; BERSON EL, 1968, ARCH OPHTHALMOL-CHIC, V80, P77; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; KOOIJMAN AC, 1991, CLIN VISION SCI, V6, P379; KOOIJMAN AC, 1991, DOC OPHTHALMOL, V78, P245, DOI 10.1007/BF00165687; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Lyubarsky A, 2001, MOL VIS, V7, P71; MARMOR MF, 1989, DOC OPHTHALMOL, V73, P299, DOI 10.1007/BF00154485; MARMOR MF, 1995, DOC OPHTHALMOL, V89, P199, DOI 10.1007/BF01203373; Martemyanov KA, 2003, J NEUROSCI, V23, P10175; Martemyanov KA, 2002, J BIOL CHEM, V277, P32843, DOI 10.1074/jbc.M205170200; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Rahman Z, 1999, J NEUROSCI, V19, P2016; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Sandberg MA, 1999, INVEST OPHTH VIS SCI, V40, P2457; Sandberg MA, 1998, ARCH OPHTHALMOL-CHIC, V116, P867, DOI 10.1001/archopht.116.7.867; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Zhang K, 1999, GENE, V240, P23, DOI 10.1016/S0378-1119(99)00393-5	27	122	129	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					75	78		10.1038/nature02170	http://dx.doi.org/10.1038/nature02170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702087				2022-12-28	WOS:000187710000037
J	Vissing, J; Haller, RG				Vissing, J; Haller, RG			The effect of oral sucrose on exercise tolerance in patients with McArdle's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY; PLACEBO-CONTROLLED-CROSSOVER; CHAIN AMINO-ACIDS; HIGH-PROTEIN-DIET; CREATINE THERAPY; DOUBLE-BLIND; 2ND WIND; GLUCOSE; PHOSPHORYLASE; METABOLISM	Background: Energy metabolism in muscles relies predominantly on the breakdown of glycogen early in exercise. In patients with McArdle's disease, blocked glycogenolysis in muscles results in low exercise tolerance and can lead to muscle injury, particularly in the first minutes of exercise. We hypothesized that ingesting sucrose before exercise would increase the availability of glucose and would therefore improve exercise tolerance in patients with McArdle's disease. Methods: In a single-blind, randomized, placebo-controlled crossover study, 12 patients with McArdle's disease drank 660 ml of a beverage that had been sweetened with artificial sweeteners (placebo) or with 75 g of sucrose after an overnight fast. Thirty to 40 minutes later, the patients rode a stationary bicycle at a constant workload for 15 minutes while the heart rate, level of perceived exertion, and venous blood glucose levels were monitored. Results: Supplemental sucrose increased the mean plasma glucose level by more than 36 mg per deciliter (2.0 mmol per liter) and resulted in a marked improvement in exercise tolerance in all patients. The mean (+/-SE) heart rate dropped by a maximum of 34+/-3 beats per minute (P<0.001), and the level of perceived exertion fell dramatically when the patients ingested glucose as compared with when they received the placebo. Conclusions: This study suggests that the ingestion of sucrose before exercise can markedly improve exercise tolerance in patients with McArdle's disease. The treatment takes effect during the time when muscle injury commonly develops in these patients. In addition to increasing the patients' exercise capacity and sense of well-being, the treatment may protect against exercise-induced rhabdomyolysis.	Rigshosp, Natl Univ Hosp, Dept Neurol, DK-2100 Copenhagen, Denmark; Rigshosp, Natl Univ Hosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; Vet Affairs Med Ctr, Dept Neurol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Presbyterian Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, Dallas, TX USA	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Vissing, J (corresponding author), Rigshosp, Natl Univ Hosp, Dept Neurol 2082, Neuromuscular Clin, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	vissing@rh.dk						ANDERSEN KL, 1969, SCAND J CLIN LAB INV, V24, P105, DOI 10.3109/00365516909080140; Astrand P.O., 1986, TXB WORK PHYSL PHYSL; BAQUE S, 1994, BIOCHEM J, V304, P1009, DOI 10.1042/bj3041009; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BRAAKHEKKE JP, 1986, BRAIN, V109, P1087, DOI 10.1093/brain/109.6.1087; ENGEL AG, 1994, MYOLOGY BASIC CLIN, V2, P1563; FELIG P, 1975, NEW ENGL J MED, V293, P1078; HALLER RG, 1991, NEW ENGL J MED, V324, P364, DOI 10.1056/NEJM199102073240603; Haller RG, 2002, ARCH NEUROL-CHICAGO, V59, P1395, DOI 10.1001/archneur.59.9.1395; HALLER RG, 1985, ANN NEUROL, V17, P196, DOI 10.1002/ana.410170216; JENSEN KE, 1990, ACTA NEUROL SCAND, V81, P499, DOI 10.1111/j.1600-0404.1990.tb01007.x; Kazemi-Esfarjani P, 2002, ANN NEUROL, V52, P153, DOI 10.1002/ana.10263; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; LEWIS SF, 1985, J APPL PHYSIOL, V59, P1991, DOI 10.1152/jappl.1985.59.6.1991; MacLean D, 1998, NEUROLOGY, V51, P1456, DOI 10.1212/WNL.51.5.1456; Nielsen JN, 2002, J PHYSIOL-LONDON, V541, P979, DOI 10.1113/jphysiol.2002.018044; Nielsen JN, 2002, AM J PHYSIOL-ENDOC M, V282, pE1267, DOI 10.1152/ajpendo.00526.2001; Orngreen MC, 2002, NEUROLOGY, V59, P1046, DOI 10.1212/WNL.59.7.1046; Pari G, 1999, NEUROLOGY, V53, P1352, DOI 10.1212/WNL.53.6.1352; PEARSON CM, 1961, AM J MED, V30, P502, DOI 10.1016/0002-9343(61)90075-4; PERNOW BB, 1967, ACTA MED SCAND, VS, P294; Phoenix J, 1998, NEUROMUSCULAR DISORD, V8, P210, DOI 10.1016/S0960-8966(98)00004-2; PORTE D, 1966, NEW ENGL J MED, V275, P406, DOI 10.1056/NEJM196608252750802; Richter EA, 2001, INT J SPORT NUTR EXE, V11, pS71, DOI 10.1123/ijsnem.11.s1.s71; SLONIM AE, 1985, NEW ENGL J MED, V312, P355, DOI 10.1056/NEJM198502073120607; Steele IC, 1996, J NEUROL SCI, V136, P174, DOI 10.1016/0022-510X(95)00320-2; Vissing J, 1998, J CLIN INVEST, V101, P1654, DOI 10.1172/JCI555; VISSING J, 1992, J APPL PHYSIOL, V72, P1773; Vissing J, 1996, NEUROLOGY, V47, P766, DOI 10.1212/WNL.47.3.766; Vissing J, 2001, J PHYSIOL-LONDON, V537, P641, DOI 10.1111/j.1469-7793.2001.00641.x; Vissing J., 2001, NEUROMUSCULAR DIS EX, P393; Vorgerd M, 2000, ARCH NEUROL-CHICAGO, V57, P956, DOI 10.1001/archneur.57.7.956; Vorgerd M, 2002, ARCH NEUROL-CHICAGO, V59, P97, DOI 10.1001/archneur.59.1.97; WAGENMAKERS AJM, 1990, INT J SPORTS MED, V11, pS101, DOI 10.1055/s-2007-1024861	34	130	133	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2503	2509		10.1056/NEJMoa031836	http://dx.doi.org/10.1056/NEJMoa031836			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695410				2022-12-28	WOS:000187529500005
J	Kittner, T; Aust, D; Illmer, T				Kittner, T; Aust, D; Illmer, T			Clinical picture - Intracranial haemopoiesis	LANCET			English	Editorial Material									Tech Univ Dresden Hosp, Dept Radiol, D-01307 Dresden, Germany; Tech Univ Dresden Hosp, Dept Pathol, D-01307 Dresden, Germany; Tech Univ Dresden Hosp, Med Clin 1, D-01307 Dresden, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Kittner, T (corresponding author), Tech Univ Dresden Hosp, Dept Radiol, D-01307 Dresden, Germany.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2065	2065		10.1016/S0140-6736(03)15101-X	http://dx.doi.org/10.1016/S0140-6736(03)15101-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697806				2022-12-28	WOS:000187429600011
J	Lai, CL; Ratziu, V; Yuen, MF; Poynard, T				Lai, CL; Ratziu, V; Yuen, MF; Poynard, T			Viral hepatitis B	LANCET			English	Review							ADEFOVIR DIPIVOXIL; VIRUS-DNA; GENOTYPE-B; HBEAG SEROCONVERSION; HBV GENOTYPE; L-FMAU; LAMIVUDINE; ANTIGEN; RESISTANT; INFECTION	More than 400 million people worldwide are chronically infected by the hepatitis B virus. The virus is responsible for more than 300000 cases of liver cancer every year and for similar numbers of gastrointestinal haemorrhage and ascites. Major breakthroughs have been achieved in diagnosis and treatment of this virus. Hepatitis B vaccine reduces incidence of liver cancer. As with hepatitis C, advances have been made in molecular virology, especially for naturally occurring and treatment-induced mutant viruses. The clinical significance of low viral load and genotypes are also under investigation. Currently available monotherapies-interferon, lamivudine, and adefovir dipivoxil-very rarely eradicate the virus, but greatly reduce its replication, necroinflammatory histological activity, and progression of fibrosis. Lamivudine, and presumably other nucleoside analogues, can reverse cirrhosis of the liver.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Paris, Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France	University of Hong Kong; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Lai, CL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	hrmelcl@hkucc.hku.hk	Lai, Ching Lung/C-4298-2009; Yuen, Man-Fung/C-4466-2009; Reis, Helena/A-7228-2019; Poynard, Thierry/C-1355-2010	Yuen, Man-Fung/0000-0001-7985-7725; Reis, Helena/0000-0003-3376-5256; Poynard, Thierry/0000-0002-3726-7230; Lai, Ching-Lung/0000-0002-5927-2436; Poynard, Thierry/0000-0002-2050-640X				Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; Angus P, 2003, GASTROENTEROLOGY, V125, P292, DOI 10.1016/S0016-5085(03)00939-9; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Benhamou Y, 2001, LANCET, V358, P718, DOI 10.1016/S0140-6736(01)05840-8; Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172; Bryant ML, 2001, ANTIMICROB AGENTS CH, V45, P229, DOI 10.1128/AAC.45.1.229-235.2001; Chan HLY, 2000, HEPATOLOGY, V31, P763, DOI 10.1002/hep.510310330; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chu CJ, 2002, HEPATOLOGY, V36, P1408, DOI 10.1053/jhep.2002.36949; Chu CJ, 2002, GASTROENTEROLOGY, V122, P1756, DOI 10.1053/gast.2002.33588; Chu CK, 1998, ANTIVIR THER, V3, P113; Colonno RJ, 2001, J INFECT DIS, V184, P1236, DOI 10.1086/324003; Das K, 2001, J VIROL, V75, P4771, DOI 10.1128/JVI.75.10.4771-4779.2001; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Hadziyannis SJ, 2003, NEW ENGL J MED, V348, P800, DOI 10.1056/NEJMoa021812; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HYAMS KC, 1995, CLIN INFECT DIS, V20, P992, DOI 10.1093/clinids/20.4.992; Kao JH, 2000, J HEPATOL, V33, P998, DOI 10.1016/S0168-8278(00)80135-X; Kapoor D, 2000, J HEPATOL, V33, P308, DOI 10.1016/S0168-8278(00)80372-4; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lai CL, 2002, GASTROENTEROLOGY, V123, P1831, DOI 10.1053/gast.2002.37058; Lai CL, 2002, HEPATOLOGY, V36, p301A; Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083; LAI CL, 2003, GUIDE HEPATITIS B VI, P193; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Lewin S, 2002, ANTIVIR RES, V55, P381, DOI 10.1016/S0166-3542(02)00071-2; Liaw YF, 2000, HEPATOLOGY, V32, P604, DOI 10.1053/jhep.2000.9717; Lin SM, 1999, HEPATOLOGY, V29, P971, DOI 10.1002/hep.510290312; Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; Martinot-Peignoux M, 2002, J HEPATOL, V36, P543, DOI 10.1016/S0168-8278(02)00004-1; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; Nelson M, 2003, AIDS, V17, pF7, DOI 10.1097/00002030-200301030-00002; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Orito E, 2001, HEPATOLOGY, V34, P590, DOI 10.1053/jhep.2001.27221; Perrillo R, 2000, HEPATOLOGY, V32, P129, DOI 10.1053/jhep.2000.8626; Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4; Puoti Massimo, 2002, AIDS Reviews, V4, P27; Rapicetta M, 2002, J MED VIROL, V67, P454, DOI 10.1002/jmv.10096; Reifenberg K, 1998, VIROLOGY, V243, P45, DOI 10.1006/viro.1998.9033; Sanchez-Tapias JM, 2002, GASTROENTEROLOGY, V123, P1848, DOI 10.1053/gast.2002.37041; Schalm SW, 2000, GUT, V46, P562, DOI 10.1136/gut.46.4.562; Sugauchi F, 2002, J VIROL, V76, P5985, DOI 10.1128/JVI.76.12.5985-5992.2002; Sumi H, 2003, HEPATOLOGY, V37, P19, DOI 10.1053/jhep.2003.50036; Sung JJY, 2003, J HEPATOL, V38, P25, DOI 10.1016/S0168-8278(03)80485-3; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321; Torresi J, 2002, J CLIN VIROL, V25, P97, DOI 10.1016/S1386-6532(02)00049-5; van Bommel F, 2002, HEPATOLOGY, V36, P507, DOI 10.1053/jhep.2002.35328; Wai CT, 2002, HEPATOLOGY, V36, P1425, DOI 10.1053/jhep.2002.37139; Webster GJM, 2000, LANCET, V356, P379, DOI 10.1016/S0140-6736(00)02529-0; Webster GJM, 2000, HEPATOLOGY, V32, P1117, DOI 10.1053/jhep.2000.19324; WHO, 1996, WORLD HLTH REP 1996; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; Yao FY, 2001, HEPATOLOGY, V34, P411, DOI 10.1053/jhep.2001.26512; Ying C, 2000, J VIRAL HEPATITIS, V7, P161; Yuen M F, 2001, Lancet Infect Dis, V1, P232, DOI 10.1016/S1473-3099(01)00118-9; Yuen MF, 2001, HEPATOLOGY, V34, P785, DOI 10.1053/jhep.2001.27563; Yuen MF, 2003, CLIN INFECT DIS, V36, P979, DOI 10.1086/374226; Yuen MF, 2003, HEPATOLOGY, V37, P562, DOI 10.1053/jhep.2003.50098; Yuen MF, 2002, J INFECT DIS, V186, P1335, DOI 10.1086/344327; Yuen MF, 2000, J GASTROEN HEPATOL, V15, pE20, DOI 10.1046/j.1440-1746.2000.02123.x; YUEN MF, IN PRESS HEPATITIS B; Yuen MF, 1999, VIRAL HEPATITIS REV, V5, P159	65	635	714	3	87	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2089	2094		10.1016/S0140-6736(03)15108-2	http://dx.doi.org/10.1016/S0140-6736(03)15108-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697813				2022-12-28	WOS:000187429600027
J	Gibbs, RA; Belmont, JW; Hardenbol, P; Willis, TD; Yu, FL; Yang, HM; Ch'ang, LY; Huang, W; Liu, B; Shen, Y; Tam, PKH; Tsui, LC; Waye, MMY; Wong, JTF; Zeng, CQ; Zhang, QR; Chee, MS; Galver, LM; Kruglyak, S; Murray, SS; Oliphant, AR; Montpetit, A; Hudson, TJ; Chagnon, F; Ferretti, V; Leboeuf, M; Phillips, MS; Verner, A; Kwok, PY; Duan, SH; Lind, DL; Miller, RD; Rice, JP; Saccone, NL; Taillon-Miller, P; Xiao, M; Nakamura, Y; Sekine, A; Sorimachi, K; Tanaka, T; Tanaka, Y; Tsunoda, T; Yoshino, E; Bentley, DR; Deloukas, P; Hunt, S; Powell, D; Altshuler, D; Gabriel, SB; Qiu, RZ; Ken, A; Dunston, GM; Kato, K; Niikawa, N; Knoppers, BM; Foster, MW; Clayton, EW; Wang, VO; Watkin, J; Gibbs, RA; Belmont, JW; Sodergren, E; Weinstock, GM; Wilson, RK; Fulton, LL; Rogers, J; Birren, BW; Han, H; Wang, HG; Godbout, M; Wallenburg, JC; L'Archeveque, P; Bellemare, G; Todani, K; Fujita, T; Tanaka, S; Holden, AL; Lai, EH; Collins, FS; Brooks, LD; McEwen, JE; Guyer, MS; Jordan, E; Peterson, JL; Spiegel, J; Sung, LM; Zacharia, LF; Kennedy, K; Dunn, MG; Seabrook, R; Shillito, M; Skene, B; Stewart, JG; Valle, DL; Clayton, EW; Jorde, LB; Belmont, JW; Chakravarti, A; Cho, MK; Duster, T; Foster, MW; Jasperse, M; Knoppers, BM; Kwok, PY; Licinio, J; Long, JC; Marshall, PA; Ossorio, PN; Wang, VO; Rotimi, CN; Royal, CDM; Spallone, P; Terry, SF; Lander, ES; Lai, EH; Nickerson, DA; Abecasis, GR; Altshuler, D; Bentley, DR; Boehnke, M; Cardon, LR; Daly, MJ; Deloukas, P; Douglas, JA; Gabriel, SB; Hudson, RR; Hudson, TJ; Kruglyak, L; Kwok, PY; Nakamura, Y; Nussbaum, RL; Royal, CDM; Schaffner, SF; Sherry, ST; Stein, LD; Tanaka, T				Gibbs, RA; Belmont, JW; Hardenbol, P; Willis, TD; Yu, FL; Yang, HM; Ch'ang, LY; Huang, W; Liu, B; Shen, Y; Tam, PKH; Tsui, LC; Waye, MMY; Wong, JTF; Zeng, CQ; Zhang, QR; Chee, MS; Galver, LM; Kruglyak, S; Murray, SS; Oliphant, AR; Montpetit, A; Hudson, TJ; Chagnon, F; Ferretti, V; Leboeuf, M; Phillips, MS; Verner, A; Kwok, PY; Duan, SH; Lind, DL; Miller, RD; Rice, JP; Saccone, NL; Taillon-Miller, P; Xiao, M; Nakamura, Y; Sekine, A; Sorimachi, K; Tanaka, T; Tanaka, Y; Tsunoda, T; Yoshino, E; Bentley, DR; Deloukas, P; Hunt, S; Powell, D; Altshuler, D; Gabriel, SB; Qiu, RZ; Ken, A; Dunston, GM; Kato, K; Niikawa, N; Knoppers, BM; Foster, MW; Clayton, EW; Wang, VO; Watkin, J; Gibbs, RA; Belmont, JW; Sodergren, E; Weinstock, GM; Wilson, RK; Fulton, LL; Rogers, J; Birren, BW; Han, H; Wang, HG; Godbout, M; Wallenburg, JC; L'Archeveque, P; Bellemare, G; Todani, K; Fujita, T; Tanaka, S; Holden, AL; Lai, EH; Collins, FS; Brooks, LD; McEwen, JE; Guyer, MS; Jordan, E; Peterson, JL; Spiegel, J; Sung, LM; Zacharia, LF; Kennedy, K; Dunn, MG; Seabrook, R; Shillito, M; Skene, B; Stewart, JG; Valle, DL; Clayton, EW; Jorde, LB; Belmont, JW; Chakravarti, A; Cho, MK; Duster, T; Foster, MW; Jasperse, M; Knoppers, BM; Kwok, PY; Licinio, J; Long, JC; Marshall, PA; Ossorio, PN; Wang, VO; Rotimi, CN; Royal, CDM; Spallone, P; Terry, SF; Lander, ES; Lai, EH; Nickerson, DA; Abecasis, GR; Altshuler, D; Bentley, DR; Boehnke, M; Cardon, LR; Daly, MJ; Deloukas, P; Douglas, JA; Gabriel, SB; Hudson, RR; Hudson, TJ; Kruglyak, L; Kwok, PY; Nakamura, Y; Nussbaum, RL; Royal, CDM; Schaffner, SF; Sherry, ST; Stein, LD; Tanaka, T		Int HapMap Consortium	The International HapMap Project	NATURE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LINKAGE-DISEQUILIBRIUM; HUMAN GENOME; ESTIMATING RECOMBINATION; SEQUENCE VARIATION; GENETIC-VARIATION; CROHNS-DISEASE; SUSCEPTIBILITY; DIVERSITY; COMPLEX		Baylor Coll Med, Dept Mol & Human Genet, Human Genome Sequencing Ctr, Houston, TX 77030 USA; ParAllele Biosci, San Francisco, CA 94080 USA; Chinese Acad Sci, Beijing Genom Inst, Beijing 100300, Peoples R China; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Chinese Natl Human Genome Ctr Beijing, Beijing Econ & Technol Dev Zone, Beijing 100176, Peoples R China; Univ Hong Kong, Genome Res Ctr, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Knowloon, Hong Kong, Peoples R China; Illumina, San Diego, CA 92121 USA; McGill Univ, Montreal, PQ H3A 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; RIKEN, SNP Res Ctr, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN, Technol Transfer & Res Coordinat Div, Wako, Saitama 35101, Japan; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Whitehead Inst MIT, Ctr Genome Res, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Beijing Normal Univ, Beijing 100875, Peoples R China; Hlth Sci Univ Hokkaido, Ezuko Inst Dev Disabil, Kumamoto 575, Japan; Shinshu Univ, Sch Med, Dept Med Genet, Matsumoto, Nagano 3908621, Japan; Univ Tsukuba, Eubios Eth Inst, Tsukuba, Ibaraki 3058691, Japan; Howard Univ, Natl Human Genome Ctr, Washington, DC 20059 USA; Univ Ibadan, Coll Med, Ibadan, Oyo, Nigeria; Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH 44106 USA; Univ Utah, Dept Human Genet, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; N Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA; NIH, NHGRI, Bethesda, MD 20892 USA; NIH, Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Chinese Acad Social Sci, Ctr Appl Eth, Beijing 100054, Peoples R China; Genet Interest Grp, London N1 3QP, England; Kyoto Univ, Inst Res Human, Sakyo Ku, Kyoto 6068501, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Human Genet, Nagasaki 8528523, Japan; Univ Montreal, Publ Law Res Ctr, CRDP, Montreal, PQ H3C 3J7, Canada; Univ Oklahoma, Dept Anthropol, Norman, OK 73019 USA; Vanderbilt Univ, Ctr Genet & Hlth Policy, Nashville, TN 37232 USA; Wellcome Trust Res Labs, London NW1 2BE, England; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Whitehead Inst MIT, Ctr Genome Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Chinese Acad Sci, Beijing 100864, Peoples R China; Chinese Minist Sci & Technol, Beijing 100862, Peoples R China; Genome Canada, Ottawa, ON K2P 1P1, Canada; McGill Univ, Off Technol Transfer, Montreal, PQ H3A 2A7, Canada; Genome Quebec, Montreal, PQ H3B 1S6, Canada; Minist Educ Culture Sports Sci & Technol, Chiyoda Ku, Tokyo, Japan; Hiraka & Associates, Minato Ku, Tokyo 1050001, Japan; SNP Consortium, Deerfield, IL 60015 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; NIH, NHGRI, Bethesda, MD 20892 USA; Fdn Natl Inst Hlth, Bethesda, MD 20892 USA; NIH, Off Technol Transfer, Rockville, MD 20852 USA; Univ Maryland, Sch Law, Baltimore, MD 21201 USA; Exchange House, London EC2A 2HS, England; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Stanford Ctr Biomed Eth, Palo Alto, CA 94304 USA; NYU, Dept Sociol, New York, NY 10003 USA; Univ Calif Berkeley, Dept Sociol, Berkeley, CA 94720 USA; Univ New Mexico, Hlth Sci Ctr, Gallup, NM 87301 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Wisconsin, Sch Law, Madison, WI 53706 USA; Univ London London Sch Econ & Polit Sci, London WC2A 2AE, England; Genet Alliance, Washington, DC 20008 USA; Univ Washington, Dept Genome Sci, Washington, DC 98125 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; NIH, NHGRI, Bethesda, MD 20892 USA	Baylor College of Medicine; Beijing Genomics Institute (BGI); Chinese Academy of Sciences; Academia Sinica - Taiwan; University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Hong Kong University of Science & Technology; Illumina; McGill University; University of California System; University of California San Francisco; Washington University (WUSTL); University of Tokyo; RIKEN; RIKEN; Wellcome Trust Sanger Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Beijing Normal University; Health Sciences University of Hokkaido; Shinshu University; University of Tsukuba; Howard University; University of Ibadan; Case Western Reserve University; Utah System of Higher Education; University of Utah; Cold Spring Harbor Laboratory; Johns Hopkins University; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Michigan System; University of Michigan; University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Chinese Academy of Social Sciences; Kyoto University; Nagasaki University; Universite de Montreal; University of Oklahoma System; University of Oklahoma - Norman; Vanderbilt University; Washington University (WUSTL); Massachusetts Institute of Technology (MIT); Whitehead Institute; Chinese Academy of Sciences; McGill University; GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; University System of Maryland; University of Maryland Baltimore; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Stanford University; New York University; University of California System; University of California Berkeley; University of New Mexico; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison; University of London; London School Economics & Political Science; University of Washington; University of Chicago; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Bentley, DR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Human Genome Sequencing Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.	drb@sanger.ac.uk; fost1848@msmailhub.oulan.ou.edu	Greiver, Michelle/N-8764-2015; Tsunoda, Tatsuhiko/K-2061-2014; Tsui, Lap-chee/A-1081-2010; Weinstock, George M/C-6314-2013; Altshuler, David M/A-4476-2009; Tanaka, Toshihiro/J-9310-2014; Belmont, John/AAH-6084-2021; Xiao, Ming/E-7448-2012; 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; Daly, Mark J/B-2453-2017; Belmont, John W/AAI-2494-2019; Schaffner, Stephen F/D-1189-2011; Kwok, Pui-Yan/F-7725-2014; Tam, Paul Kwong Hang/C-4405-2009; Deloukas, Panos/B-2922-2013; Abecasis, Goncalo R/B-7840-2010; Wilson, Richard K./AAF-4139-2019; Licinio, Julio/L-4244-2013; Adebamowo, Clement/C-8778-2011; Pillay, Nischalan/F-9536-2012; Thorisson, Gudmundur/E-7359-2010	Greiver, Michelle/0000-0001-8957-0285; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Weinstock, George M/0000-0002-2997-4592; Altshuler, David M/0000-0002-7250-4107; Tanaka, Toshihiro/0000-0001-6201-9784; 韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; Daly, Mark J/0000-0002-0949-8752; Belmont, John W/0000-0001-7409-3578; Kwok, Pui-Yan/0000-0002-5087-3059; Deloukas, Panos/0000-0001-9251-070X; Wilson, Richard K./0000-0002-1992-1358; Licinio, Julio/0000-0001-6905-5884; Adebamowo, Clement/0000-0002-6571-2880; Hunt, Sarah/0000-0002-8350-1235; Macer, Darryl/0000-0001-9335-4235; Thorisson, Gudmundur/0000-0001-5635-1860; Wong, J. Tze-Fei/0000-0001-8539-8537; Sherry, Stephen/0000-0002-7982-076X; Cunningham, Fiona/0000-0002-7445-2419				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Clayton EW, 2002, J LAW MED ETHICS, V30, P290, DOI 10.1111/j.1748-720X.2002.tb00395.x; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Dahlback B, 1997, THROMB HAEMOSTASIS, V78, P483; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Dawson E, 2002, NATURE, V418, P544, DOI 10.1038/nature00864; Dawson KJ, 2000, THEOR POPUL BIOL, V58, P1, DOI 10.1006/tpbi.2000.1471; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; DORMAN JS, 1990, P NATL ACAD SCI USA, V87, P7370, DOI 10.1073/pnas.87.19.7370; Fearnhead P, 2001, GENETICS, V159, P1299; Foster MW, 2002, GENOME RES, V12, P844, DOI 10.1101/gr.99202; Foster MW, 2000, TRENDS GENET, V16, P93, DOI 10.1016/S0168-9525(99)01895-8; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Goldstein DB, 2003, TRENDS GENET, V19, P615, DOI 10.1016/j.tig.2003.09.006; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; HUDSON RR, 1987, GENET RES, V50, P245, DOI 10.1017/S0016672300023776; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Jorde LB, 1997, P NATL ACAD SCI USA, V94, P3100, DOI 10.1073/pnas.94.7.3100; Juengst ET, 2000, J LAW MED ETHICS, V28, P52, DOI 10.1111/j.1748-720X.2000.tb00316.x; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KING RA, 1992, GENETIC BASIS COMMON, V20; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LANGLEY CH, 1974, GENETICS, V78, P937; LEWONTIN RC, 1964, GENETICS, V49, P49; LI WH, 1991, GENETICS, V129, P513; Maniatis N, 2002, P NATL ACAD SCI USA, V99, P2228, DOI 10.1073/pnas.042680999; Marshall PA, 2001, AM J MED SCI, V322, P241, DOI 10.1097/00000441-200111000-00001; McVean G, 2002, GENETICS, V160, P1231; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; OHTA T, 1969, GENET RES, V13, P47, DOI 10.1017/S001667230000272X; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Paabo S, 2003, NATURE, V421, P409, DOI 10.1038/nature01400; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sharp RR, 2000, J LAW MED ETHICS, V28, P41, DOI 10.1111/j.1748-720X.2000.tb00315.x; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Taillon-Miller P, 2000, NAT GENET, V25, P324, DOI 10.1038/77100; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	68	3629	3775	4	293	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					789	796		10.1038/nature02168	http://dx.doi.org/10.1038/nature02168			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685227	hybrid, Green Published			2022-12-28	WOS:000187342000046
J	Sundby, J				Sundby, J			Female genital mutilation	LANCET			English	Article									Univ Oslo, Inst Community Med, N-0138 Oslo, Norway	University of Oslo	Sundby, J (corresponding author), Univ Oslo, Inst Community Med, N-0138 Oslo, Norway.	johanna-sundby@samfunnsmed-uio.no						Essen B, 2003, ACTA OBSTET GYN SCAN, V82, P683, DOI 10.1034/j.1600-0412.2003.00317.x; *WHO, 2003, FEM GEN MUT TEACH GU	2	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC	2003	362			S			S26	S27		10.1016/S0140-6736(03)15064-7	http://dx.doi.org/10.1016/S0140-6736(03)15064-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698118				2022-12-28	WOS:000187790200014
J	Lee, HY; Kleber, M; Hari, L; Brault, V; Suter, U; Taketo, MM; Kemler, R; Sommer, L				Lee, HY; Kleber, M; Hari, L; Brault, V; Suter, U; Taketo, MM; Kemler, R; Sommer, L			Instructive role of Wnt/beta-catenin in sensory fate specification in neural crest stem cells	SCIENCE			English	Article							BETA-CATENIN; PRECURSORS; LINEAGE; SOX10; GROWTH; TRUNK; GENE; CNS	Wnt signaling has recently emerged as a key factor in controlling stem cell expansion. In contrast, we show here that Wnt/beta-catenin signal activation in emigrating neural crest stem cells (NCSCs) has little effect on the population size and instead regulates fate decisions. Sustained beta-catenin activity in neural crest cells promotes the formation of sensory neural cells in vivo at the expense of virtually all other neural crest derivatives. Moreover, Wnt1 is able to instruct early NCSCs (eNCSCs) to adopt a sensory neuronal fate in a beta-catenin-dependent manner. Thus, the role of Wnt/beta-catenin in stem cells is cell-type dependent.	ETH Honggerberg, Swiss Fed Inst Technol, Dept Biol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Max Planck Inst Immunbiol, Dept Mol Embryol, D-79108 Freiburg, Germany; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society; Kyoto University	Sommer, L (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Dept Biol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	lukas.sommer@cell.biol.ethz.ch	Suter, Ueli/A-1624-2010	Brault, Veronique/0000-0002-1418-5849				BAROFFIO A, 1991, DEVELOPMENT, V112, P301; Brault V, 2001, DEVELOPMENT, V128, P1253; BRONNERFRASER M, 1989, NEURON, V3, P755, DOI 10.1016/0896-6273(89)90244-4; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chai Y, 2000, DEVELOPMENT, V127, P1671; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Dorsky RI, 2000, BIOESSAYS, V22, P708, DOI 10.1002/1521-1878(200008)22:8<708::AID-BIES4>3.3.CO;2-E; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; FRANK E, 1991, DEVELOPMENT, V111, P895; FRASER SE, 1991, DEVELOPMENT, V112, P913; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Greenwood AL, 1999, DEVELOPMENT, V126, P3545; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Le Douarin NM, 1999, NEURAL CREST, V2; Megason SG, 2002, DEVELOPMENT, V129, P2087; NODEN DM, 1993, J NEUROBIOL, V24, P248, DOI 10.1002/neu.480240210; Paratore C, 2002, HUM MOL GENET, V11, P3075, DOI 10.1093/hmg/11.24.3075; Paratore C, 2001, DEVELOPMENT, V128, P3949; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SIEBERBLUM M, 1989, SCIENCE, V243, P1608, DOI 10.1126/science.2564699; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Zirlinger M, 2002, P NATL ACAD SCI USA, V99, P8084, DOI 10.1073/pnas.122231199	29	334	362	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1020	1023		10.1126/science.1091611	http://dx.doi.org/10.1126/science.1091611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14716020				2022-12-28	WOS:000188918000048
J	Soinio, M; Marniemi, J; Laakso, M; Lehto, S; Ronnemaa, T				Soinio, M; Marniemi, J; Laakso, M; Lehto, S; Ronnemaa, T			Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							PROTEIN-C ACTIVATION; RISK-FACTOR; CARDIOVASCULAR-DISEASE; SERUM HOMOCYSTEINE; VASCULAR-DISEASE; ENDOTHELIAL DYSFUNCTION; MYOCARDIAL-INFARCTION; JAPANESE PATIENTS; FOLLOW-UP; HYPERHOMOCYSTEINEMIA	Background: High plasma homocysteine level has been associated with increased risk for coronary heart disease (CHD) events in nondiabetic individuals, especially in those with previously diagnosed CHD. In persons with type 2 diabetes mellitus, the association between homocysteine level and cardiovascular disease may be stronger than that in nondiabetic individuals, but no large prospective studies have examined the relationship between homocysteine level and CHD mortality in persons with type 2 diabetes. Objective: To investigate whether moderately elevated plasma homocysteine levels are independently related to increased incidence of fatal and nonfatal CHD events in persons with type 2 diabetes. Design: Prospective study. Setting: Finnish sample of patients with type 2 diabetes. Patients: 462 men and 368 women who were 45 to 64 years of age at baseline. Measurements: Coronary heart disease mortality and incidence of nonfatal myocardial infarction during the 7-year follow-up. Results: Participants with plasma homocysteine levels of 15 mumol/L or more at baseline had a higher risk for CHD death than those with plasma homocysteine levels less than 15 mumol/L (26.1% and 13.5%, respectively; P = 0.005). The risks for all CHID events were 36.2% and 22.6%, respectively (P = 0.011). In Cox regression analyses, elevated plasma homocysteine level was significantly associated with CHD mortality (P < 0.001) and all CHID events (P = 0.002) even after adjustment for confounding variables, including creatinine clearance. In participants without myocardial infarction at baseline, moderate hyperhomocysteinemia was also associated with CHD mortality and all CHD events in univariate (P < 0.001 and P = 0.006, respectively) and multivariate Cox regression analyses (P < 0.001 and P = 0.004, respectively). Conclusions: in this large cohort of patients with type 2 diabetes, plasma homocysteine level was a strong and independent risk factor for CHD events.	Turku Univ, FIN-20520 Turku, Finland; Social Insurance Inst Finland, Turku, Finland; Univ Kuopio, FIN-70211 Kuopio, Finland	University of Turku; University of Eastern Finland	Soinio, M (corresponding author), Turku Univ, Cent Hosp, Dept Med, POB 52, FIN-20521 Turku, Finland.	minna.soinio@tyks.fi		Lehto, Seppo/0000-0003-0414-5285				Al-Obaidi MK, 2000, CIRCULATION, V101, P372, DOI 10.1161/01.CIR.101.4.372; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARAKI A, 1993, ATHEROSCLEROSIS, V103, P149, DOI 10.1016/0021-9150(93)90258-V; Bots ML, 1999, ARCH INTERN MED, V159, P38, DOI 10.1001/archinte.159.1.38; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Friedman AN, 2001, J AM SOC NEPHROL, V12, P2181, DOI 10.1681/ASN.V12102181; Hoogeveen EK, 1998, ARTERIOSCL THROM VAS, V18, P133, DOI 10.1161/01.ATV.18.1.133; Hoogeveen EK, 2000, CIRCULATION, V101, P1506, DOI 10.1161/01.CIR.101.13.1506; Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161; Kark JD, 1999, LANCET, V353, P1936, DOI 10.1016/S0140-6736(98)05381-1; Khajurla A, 2000, BLOOD, V96, P966, DOI 10.1182/blood.V96.3.966.015k12_966_972; Knekt P, 2001, ARCH INTERN MED, V161, P1589, DOI 10.1001/archinte.161.13.1589; KOSTNER GM, 1976, CLIN CHEM, V22, P695; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Li H, 2002, CIRCULATION, V105, P1037, DOI 10.1161/hc0902.104713; Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; Malinow MR, 1999, CIRCULATION, V99, P178, DOI 10.1161/01.CIR.99.1.178; Munshi MN, 1996, METABOLISM, V45, P133, DOI 10.1016/S0026-0495(96)90211-5; Nurk E, 2002, ARCH INTERN MED, V162, P1374, DOI 10.1001/archinte.162.12.1374; Okada E, 1999, DIABETES CARE, V22, P484, DOI 10.2337/diacare.22.3.484; Omland T, 2000, ARCH INTERN MED, V160, P1834, DOI 10.1001/archinte.160.12.1834; RODGERS GM, 1990, BLOOD, V75, P895; Rose G, 1982, CARDIOVASCULAR SURVE; SAMPSON MJ, 1992, DIABETES CARE, V15, P609, DOI 10.2337/diacare.15.5.609; Smulders YM, 1999, DIABETES CARE, V22, P125, DOI 10.2337/diacare.22.1.125; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Stehouwer CDA, 1999, KIDNEY INT, V55, P308, DOI 10.1046/j.1523-1755.1999.00256.x; Stehouwer CDA, 1998, ARTERIOSCL THROM VAS, V18, P1895, DOI 10.1161/01.ATV.18.12.1895; Stuhlinger MC, 2001, CIRCULATION, V104, P2569, DOI 10.1161/hc4601.098514; Tawakol A, 1997, CIRCULATION, V95, P1119; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Voutilainen S, 1999, ARTERIOSCL THROM VAS, V19, P1263, DOI 10.1161/01.ATV.19.5.1263; Voutilainen S, 1998, ANN MED, V30, P300, DOI 10.3109/07853899809005859; *WHO, 1983, WHOMNC821; Woo KS, 1997, CIRCULATION, V96, P2542, DOI 10.1161/01.CIR.96.8.2542	41	104	121	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					94	100		10.7326/0003-4819-140-2-200401200-00009	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734331				2022-12-28	WOS:000188211700003
J	Hearnshaw, H				Hearnshaw, H			Comparison of requirements of research ethics committees in 11 European countires for a non-invasive interventional study	BRITISH MEDICAL JOURNAL			English	Article									Univ Warwick, Warwick Med Sch, Ctr Primary Hlth Care Studies, Coventry CV4 7AL, W Midlands, England	University of Warwick	Hearnshaw, H (corresponding author), Univ Warwick, Warwick Med Sch, Ctr Primary Hlth Care Studies, Coventry CV4 7AL, W Midlands, England.	Hilary.Hearnshaw@Warwick.ac.uk						Doll R, 2001, BRIT MED J, V323, P1421; Grol R, 2000, BRIT J GEN PRACT, V50, P882; Maskell NA, 2003, QJM-INT J MED, V96, P305, DOI 10.1093/qjmed/hcg042; *WORLD MED ASS, 2002, DECL HELS	4	79	79	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					140	141		10.1136/bmj.328.7432.140	http://dx.doi.org/10.1136/bmj.328.7432.140			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726341	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000188249900018
J	Lodders, K				Lodders, K			Brown dwarfs - Faint at heart, rich in chemistry	SCIENCE			English	Editorial Material							SPECTRAL CLASSIFICATION; T-DWARFS; ATMOSPHERES; MODELS; RESOLUTION; JUPITER; CLOUDS; STARS; DUST		Washington Univ, Dept Earth & Planetary Sci, Planetary Chem Lab, St Louis, MO 63130 USA	Washington University (WUSTL)	Lodders, K (corresponding author), Washington Univ, Dept Earth & Planetary Sci, Planetary Chem Lab, St Louis, MO 63130 USA.	lodders@levee.wustl.edu		Lodders, Katharina/0000-0001-7531-626X				Ackerman AS, 2001, ASTROPHYS J, V556, P872, DOI 10.1086/321540; Burgasser AJ, 2002, ASTROPHYS J, V564, P421, DOI 10.1086/324033; Burrows A, 2002, ASTROPHYS J, V573, P394, DOI 10.1086/340584; Burrows A, 2001, REV MOD PHYS, V73, P719, DOI 10.1103/RevModPhys.73.719; FEGLEY B, 1994, ICARUS, V110, P117, DOI 10.1006/icar.1994.1111; Fegley B, 1996, ASTROPHYS J, V472, pL37, DOI 10.1086/310356; Geballe TR, 2002, ASTROPHYS J, V564, P466, DOI 10.1086/324078; Jayawardhana R, 2004, SCIENCE, V303, P322, DOI 10.1126/science.1091840; Kirkpatrick JD, 1999, ASTROPHYS J, V519, P802, DOI 10.1086/307414; LEWIS JS, 1969, ICARUS, V10, P393, DOI 10.1016/0019-1035(69)90094-3; Lodders K, 2002, ASTROPHYS J, V577, P974, DOI 10.1086/342241; Lodders K, 1999, ASTROPHYS J, V519, P793, DOI 10.1086/307387; Marley MS, 2002, ASTROPHYS J, V568, P335, DOI 10.1086/338800; Martin EL, 1999, ASTRON J, V118, P2466, DOI 10.1086/301107; McLean IS, 2003, ASTROPHYS J, V596, P561, DOI 10.1086/377636; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; Tsuji T, 2002, ASTROPHYS J, V575, P264, DOI 10.1086/341262; Tsuji T, 1996, ASTRON ASTROPHYS, V305, pL1	19	20	20	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					323	324		10.1126/science.1092865	http://dx.doi.org/10.1126/science.1092865			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726581				2022-12-28	WOS:000188111800029
J	Ferguson, AD; Deisenhofer, J				Ferguson, AD; Deisenhofer, J			Metal import through microbial membranes	CELL			English	Review							ATP-BINDING CASSETTE; RETRACTED ARTICLE. SEE; ENERGY-COUPLING MOTIF; COLI OUTER-MEMBRANE; IN-VIVO EVIDENCE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ABC TRANSPORTER; TONB PROTEIN; CYTOPLASMIC MEMBRANE		Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	johann.deisenhofer@utsouthwestern.edu						BELL PE, 1990, J BACTERIOL, V172, P3826, DOI 10.1128/jb.172.7.3826-3829.1990; Bohm J, 2001, CURR BIOL, V11, P1168, DOI 10.1016/S0960-9822(01)00349-9; BOHM J, 2001, CURR BIOL, V15, P1850; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Bonhivers M, 2001, BIOCHEMISTRY-US, V40, P2606, DOI 10.1021/bi001725i; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; Braun M, 2003, J BACTERIOL, V185, P5508, DOI 10.1128/JB.185.18.5508-5518.2003; Braun M, 2002, EUR J BIOCHEM, V269, P4948, DOI 10.1046/j.1432-1033.2002.03195.x; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Cadieux N, 2003, P NATL ACAD SCI USA, V100, P10688, DOI 10.1073/pnas.1932538100; Cadieux N, 2002, J BACTERIOL, V184, P706, DOI 10.1128/JB.184.3.706-717.2002; Cadieux N, 2000, J BACTERIOL, V182, P5954, DOI 10.1128/JB.182.21.5954-5961.2000; Cao ZH, 2003, J BIOL CHEM, V278, P1022, DOI 10.1074/jbc.M210360200; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Clarke TE, 2002, J BIOL CHEM, V277, P13966, DOI 10.1074/jbc.M109385200; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Delcour AH, 1997, FEMS MICROBIOL LETT, V151, P115, DOI 10.1016/S0378-1097(97)00166-3; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Endriss F, 2003, J BACTERIOL, V185, P4683, DOI 10.1128/JB.185.16.4683-4692.2003; Fanucci GE, 2003, P NATL ACAD SCI USA, V100, P11382, DOI 10.1073/pnas.1932486100; Faraldo-Gomez JD, 2003, BIOPHYS J, V85, P1406, DOI 10.1016/S0006-3495(03)74573-1; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2001, STRUCTURE, V9, P707, DOI 10.1016/S0969-2126(01)00631-1; Ferguson AD, 2000, PROTEIN SCI, V9, P956, DOI 10.1110/ps.9.5.956; Ferguson AD, 2000, STRUCTURE, V8, P585; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; HELLER KJ, 1988, GENE, V64, P147, DOI 10.1016/0378-1119(88)90488-X; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Howard SP, 2001, J BACTERIOL, V183, P5885, DOI 10.1128/JB.183.20.5885-5895.2001; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KADNER RJ, 1995, J BACTERIOL, V177, P4829, DOI 10.1128/jb.177.17.4829-4835.1995; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Karpowich NK, 2003, J BIOL CHEM, V278, P8429, DOI 10.1074/jbc.M212239200; Kurisu G, 2003, NAT STRUCT BIOL, V10, P948, DOI 10.1038/nsb997; Larsen RA, 2003, MOL MICROBIOL, V49, P211, DOI 10.1046/j.1365-2958.2003.03579.x; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; Liu PQ, 1999, J BIOL CHEM, V274, P18310, DOI 10.1074/jbc.274.26.18310; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; Mademidis A, 1997, MOL MICROBIOL, V26, P1109, DOI 10.1046/j.1365-2958.1997.6592008.x; Merianos HJ, 2000, NAT STRUCT BIOL, V7, P205; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; Ogierman M, 2003, J BACTERIOL, V185, P1870, DOI 10.1128/JB.185.6.1870-1885.2003; Plancon L, 2002, J MOL BIOL, V318, P557, DOI 10.1016/S0022-2836(02)00089-X; Postle K, 2002, SCIENCE, V295, P1658; Raymond KN, 2003, P NATL ACAD SCI USA, V100, P3584, DOI 10.1073/pnas.0630018100; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; Scott DC, 2002, J BACTERIOL, V184, P4906, DOI 10.1128/JB.184.17.4906-4911.2002; SEN K, 1988, J BIOL CHEM, V263, P1182; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SKARE JT, 1993, J BIOL CHEM, V268, P16302; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; Vakharia HL, 2002, J BACTERIOL, V184, P5508, DOI 10.1128/JB.184.19.5508-5512.2002; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Yue WW, 2003, J MOL BIOL, V332, P353, DOI 10.1016/S0022-2836(03)00855-6	77	107	111	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					15	24		10.1016/S0092-8674(03)01030-4	http://dx.doi.org/10.1016/S0092-8674(03)01030-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718163	Bronze			2022-12-28	WOS:000187960800005
J	Wilson, PD				Wilson, PD			Mechanisms of disease: Polycystic kidney disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXTRACELLULAR-MATRIX PROTEINS; RENAL CYSTIC-DISEASE; PKD1 GENE; TRANSGENIC MICE; EPITHELIAL-CELLS; PRIMARY CILIUM; EARLY-ONSET; IN-VITRO; NEPHRONOPHTHISIS; ENCODES		CUNY Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wilson, PD (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Nephrol, 1425 Madison Ave,E Bldg,Rm 11-23, New York, NY 10029 USA.	pat.wilson@mssm.edu	Wilson, Patricia/AAW-8481-2021	Wilson, Patricia/0000-0003-0902-188X				[Anonymous], 1994, Cell, V78, P725; ANTIGNAC C, 1993, NAT GENET, V3, P342, DOI 10.1038/ng0493-342; Ariza M, 1997, J MED GENET, V34, P587, DOI 10.1136/jmg.34.7.587; Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; AVNER ED, 1984, LAB INVEST, V50, P208; Baboolal K, 1997, KIDNEY INT, V52, P607, DOI 10.1038/ki.1997.373; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; Burrow CR, 1999, AM J PHYSIOL-RENAL, V277, pF391, DOI 10.1152/ajprenal.1999.277.3.F391; Burrow CR, 2000, PEDIATR NEPHROL, V14, P240, DOI 10.1007/s004670050049; BURROW CR, 1997, MOL BIOL CELL, V8, P441; CHAPMAN AB, 1991, SEMIN NEPHROL, V11, P653; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; Chatterjee S, 1996, J LIPID RES, V37, P1334; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF169, DOI 10.1152/ajprenal.1996.271.1.F169; DU J, 1995, AM J PHYSIOL-CELL PH, V269, pC487, DOI 10.1152/ajpcell.1995.269.2.C487; Fuchshuber A, 2001, GENOMICS, V72, P278, DOI 10.1006/geno.2000.6486; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; Geng L, 2000, BBA-MOL BASIS DIS, V1535, P21, DOI 10.1016/S0925-4439(00)00079-X; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GRANTHAM JJ, 1995, J AM SOC NEPHROL, V6, P1242; Hanaoka K, 1996, AM J PHYSIOL-CELL PH, V270, pC389, DOI 10.1152/ajpcell.1996.270.1.C389; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hanaoka K, 2000, J AM SOC NEPHROL, V11, P1179, DOI 10.1681/ASN.V1171179; HANAOKA K, 1996, AM J PHYSL 3 C, V271; HANAOKA K, 1996, AM J PHYSL 1 C, V271; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; Hateboer N, 1999, LANCET, V353, P103, DOI 10.1016/S0140-6736(98)03495-3; Hateboer N, 2001, KIDNEY INT, V60, P1233, DOI 10.1046/j.1523-1755.2001.00932.x; Hildebrandt F, 2000, J AM SOC NEPHROL, V11, P1753, DOI 10.1681/ASN.V1191753; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Hyink Deborah P., 2000, Journal of the American Society of Nephrology, V11, p392A; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Lebeau C., 1999, Journal of the American Society of Nephrology, V10, p36A; Li HP, 1999, BIOCHEM BIOPH RES CO, V259, P356, DOI 10.1006/bbrc.1999.0780; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; Lo SH, 1997, J CELL BIOL, V136, P1349, DOI 10.1083/jcb.136.6.1349; Longa L, 1997, NEPHROL DIAL TRANSPL, V12, P1900, DOI 10.1093/ndt/12.9.1900; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Lu WN, 1999, NAT GENET, V21, P160, DOI 10.1038/5944; MACKAY K, 1987, KIDNEY INT, V32, P827, DOI 10.1038/ki.1987.283; Malhas AN, 2002, J AM SOC NEPHROL, V13, P19, DOI 10.1681/ASN.V13119; Metcalf D, 2002, P NATL ACAD SCI USA, V99, P943, DOI 10.1073/pnas.022628499; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1462; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Omran H, 2001, J AM SOC NEPHROL, V12, P107, DOI 10.1681/ASN.V121107; Ong ACM, 1999, KIDNEY INT, V55, P2091; Ong ACM, 1999, KIDNEY INT, V56, P1324, DOI 10.1046/j.1523-1755.1999.00659.x; Onuchic LF, 2002, AM J HUM GENET, V70, P1305, DOI 10.1086/340448; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 1997, J AM SOC NEPHROL, V8, pA1748; Pei Y, 1998, J AM SOC NEPHROL, V9, P1853; Pei Y, 2001, AM J HUM GENET, V68, P355, DOI 10.1086/318188; Polgar K, 2002, J AM SOC NEPHROL, V13, p112A; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Rossetti S, 2002, J AM SOC NEPHROL, V13, P1230, DOI 10.1097/01.ASN.0000013300.11876.37; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sandford R, 2002, J AM SOC NEPHROL, V13, p46A; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; SEDMAN A, 1987, KIDNEY INT, V31, P1000, DOI 10.1038/ki.1987.98; Stayner C, 2001, TRENDS PHARMACOL SCI, V22, P543, DOI 10.1016/S0165-6147(00)01832-0; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; Sweeney WE, 2000, KIDNEY INT, V57, P33, DOI 10.1046/j.1523-1755.2000.00829.x; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; Weston BS, 2001, BBA-MOL BASIS DIS, V1536, P161, DOI 10.1016/S0925-4439(01)00046-1; Wilson P D, 1995, Curr Top Pathol, V88, P1; Wilson PD, 2001, J AM SOC NEPHROL, V12, P834, DOI 10.1681/ASN.V124834; Wilson PD, 2000, AM J PATHOL, V156, P253, DOI 10.1016/S0002-9440(10)64726-8; Wilson PD, 1999, LAB INVEST, V79, P1311; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; Wilson PD, 1997, AM J PHYSIOL-RENAL, V272, pF434, DOI 10.1152/ajprenal.1997.272.4.F434; WILSON PD, 1996, POLYCYSTIC KIDNEY DI, P125; WILSON PD, 2003, PEDIAT NEPHROLOGY, P269; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Zerres K, 1998, J MOL MED, V76, P303, DOI 10.1007/s001090050221; 1995, CELL, V81, P1170	102	544	605	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					151	164		10.1056/NEJMra022161	http://dx.doi.org/10.1056/NEJMra022161			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711914				2022-12-28	WOS:000187858500009
J	Watters, ER				Watters, ER			Living with the patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Wayne State Univ, Sch Med, Detroit, MI 48202 USA	Wayne State University	Watters, ER (corresponding author), Wayne State Univ, Sch Med, Detroit, MI 48202 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					123	123		10.1001/jama.291.1.123	http://dx.doi.org/10.1001/jama.291.1.123			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709590				2022-12-28	WOS:000187836000032
J	Young, J; De Geest, S; Spirig, R; Flepp, M; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Telenti, A; Vernazza, P; Battegay, M; Bucher, HC				Young, J; De Geest, S; Spirig, R; Flepp, M; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Telenti, A; Vernazza, P; Battegay, M; Bucher, HC		Swiss HIV Cohort Study Grp	Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL SUPPORT; MYOCARDIAL-INFARCTION; ALAMEDA COUNTY; MORTALITY; MEN; HEALTH; ASSOCIATION; DEPRESSION; POPULATION; ADHERENCE	Objectives To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART). Design Prospective cohort study of adults with HIV (Swiss HIV cohort study). Setting Seven outpatient clinics throughout Switzerland. Participants The 3736. patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years). Main outcome measures Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound. Results During follow up 2985 (80%) participants reported a stable partnership on at least one occasion. When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership. In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without. Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/mul or more, and 1.06 (0.98 to 1.14) for optimal viral suppression. Conclusions A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.	Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Infect Dis & Hosp Hyg, CH-4031 Basel, Switzerland; Univ Basel, Inst Nursing Sci, Basel, Switzerland; Univ Zurich, Div Infect Dis, Zurich, Switzerland; Univ Lausanne, Swiss HIV Cohort Study, Ctr Data, Lausanne, Switzerland; Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland; Osped Civ, Ambulattorio Malattie Infett, Lugano, Switzerland; Hop Univ Geneve, Div Malad Infect, Geneva, Switzerland; CHU Vaudois, Div Malad Infect, Lausanne, Switzerland; Cantonal Hosp St Gall, Div Internal Med, St Gallen, Switzerland	University of Basel; University of Basel; University of Basel; University of Zurich; University of Lausanne; University of Bern; University Hospital of Bern; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Kantonsspital St. Gallen	Bucher, HC (corresponding author), Univ Basel Hosp, Basel Inst Clin Epidemiol, Hebelstr 10, CH-4031 Basel, Switzerland.		VALLET, Yannick/F-9979-2011; Furrer, Hansjakob/G-6768-2013; De Geest, Sabina M/F-7724-2010	Furrer, Hansjakob/0000-0002-1375-3146; Young, Jim/0000-0002-4314-3007; De Geest, Sabina/0000-0001-6596-7237				ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Berkman LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4; BERKMAN LF, 1995, PSYCHOSOM MED, V57, P245, DOI 10.1097/00006842-199505000-00006; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; Eng PM, 2002, AM J EPIDEMIOL, V155, P700, DOI 10.1093/aje/155.8.700; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; HANSON BS, 1989, AM J EPIDEMIOL, V130, P100, DOI 10.1093/oxfordjournals.aje.a115301; Ingram KM, 1999, AIDS CARE, V11, P313, DOI 10.1080/09540129947947; Johnson JG, 2001, J CONSULT CLIN PSYCH, V69, P1056, DOI 10.1037//0022-006X.69.6.1056; Kimberly JA, 1999, AIDS EDUC PREV, V11, P465; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Leserman J, 2000, AM J PSYCHIAT, V157, P1221, DOI 10.1176/appi.ajp.157.8.1221; LEVINE C, 1990, MILBANK Q, V68, P33, DOI 10.2307/3350175; PageShafer K, 1996, ANN EPIDEMIOL, V6, P420, DOI 10.1016/S1047-2797(96)00064-6; Penninx BWJH, 1997, AM J EPIDEMIOL, V146, P510, DOI 10.1093/oxfordjournals.aje.a009305; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; SEEMAN TE, 1987, AM J EPIDEMIOL, V126, P714, DOI 10.1093/oxfordjournals.aje.a114711; Spire B, 2002, SOC SCI MED, V54, P1481, DOI 10.1016/S0277-9536(01)00125-3; THEORELL T, 1995, PSYCHOSOM MED, V57, P32, DOI 10.1097/00006842-199501000-00005; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520	25	34	39	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 3	2004	328	7430					15	18B		10.1136/bmj.328.7430.15	http://dx.doi.org/10.1136/bmj.328.7430.15			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	761QG	14703538	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000187919000014
J	Kato, Y; Myers, RC; Gossard, AC; Awschalom, DD				Kato, Y; Myers, RC; Gossard, AC; Awschalom, DD			Coherent spin manipulation without magnetic fields in strained semiconductors	NATURE			English	Article							INVERSION ASYMMETRY; PRECESSION; RESONANCE; BAND	A consequence of relativity is that in the presence of an electric field, the spin and momentum states of an electron can be coupled; this is known as spin-orbit coupling. Such an interaction opens a pathway to the manipulation of electron spins within non-magnetic semiconductors, in the absence of applied magnetic fields. This interaction has implications for spin-based quantum information processing(1) and spintronics(2,3), forming the basis of various device proposals(4-8). For example, the concept of spin field-effect transistors(4,5) is based on spin precession due to the spin-orbit coupling. Most studies, however, focus on non-spin-selective electrical measurements in quantum structures. Here we report the direct measurement of coherent electron spin precession in zero magnetic field as the electrons drift in response to an applied electric field. We use ultrafast optical techniques to spatiotemporally resolve spin dynamics in strained gallium arsenide and indium gallium arsenide epitaxial layers. Unexpectedly, we observe spin splitting in these simple structures arising from strain in the semiconductor films. The observed effect provides a flexible approach for enabling electrical control over electron spins using strain engineering. Moreover, we exploit this strain-induced field to electrically drive spin resonance with Rabi frequencies of up to similar to30 MHz.	Univ Calif Santa Barbara, Ctr Spintron & Quantum Computat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Awschalom, DD (corresponding author), Univ Calif Santa Barbara, Ctr Spintron & Quantum Computat, Santa Barbara, CA 93106 USA.	awsch@physics.ucsb.edu	Kato, Yuichiro K./B-5051-2008; Myers, Roberto/B-4431-2008	Kato, Yuichiro K./0000-0002-9942-1459; Myers, Roberto/0000-0002-3695-2244				Awschalom DD, 2002, NANOSCI TECHNOL, P147; Crooker SA, 1997, PHYS REV B, V56, P7574, DOI 10.1103/PhysRevB.56.7574; DAS B, 1990, PHYS REV B, V41, P8278, DOI 10.1103/PhysRevB.41.8278; DATTA S, 1990, APPL PHYS LETT, V56, P665, DOI 10.1063/1.102730; DRESSELHAUS PD, 1992, PHYS REV LETT, V68, P106, DOI 10.1103/PhysRevLett.68.106; Flatte ME, 2000, PHYS REV LETT, V84, P4220, DOI 10.1103/PhysRevLett.84.4220; GOSSARD AC, 1986, IEEE J QUANTUM ELECT, V22, P1649, DOI 10.1109/JQE.1986.1073165; Gupta JA, 2001, SCIENCE, V292, P2458, DOI 10.1126/science.1061169; JUSSERAND B, 1992, PHYS REV LETT, V69, P848, DOI 10.1103/PhysRevLett.69.848; KALEVICH VK, 1990, JETP LETT+, V52, P230; Kato Y, 2003, SCIENCE, V299, P1201, DOI 10.1126/science.1080880; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; Kiselev AA, 2001, APPL PHYS LETT, V78, P775, DOI 10.1063/1.1347023; Knap W, 1996, PHYS REV B, V53, P3912, DOI 10.1103/PhysRevB.53.3912; Koga T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126601; LAROCCA GC, 1988, PHYS REV B, V38, P7595, DOI 10.1103/PhysRevB.38.7595; LOMMER G, 1988, PHYS REV LETT, V60, P728, DOI 10.1103/PhysRevLett.60.728; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; LUO J, 1990, PHYS REV B, V41, P7685, DOI 10.1103/PhysRevB.41.7685; Nitta J, 1997, PHYS REV LETT, V78, P1335, DOI 10.1103/PhysRevLett.78.1335; Pfeffer P, 1999, PHYS REV B, V59, P15902, DOI 10.1103/PhysRevB.59.15902; Rashba EI, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.126405; RASHBA EI, 1961, FIZ TVERD TELA, V3, P1257; Salis G, 2001, NATURE, V414, P619, DOI 10.1038/414619a; Schliemann J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.146801; Voskoboynikov A, 2000, J APPL PHYS, V87, P387, DOI 10.1063/1.371872; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389	30	394	401	2	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					50	53		10.1038/nature02202	http://dx.doi.org/10.1038/nature02202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702080				2022-12-28	WOS:000187710000029
J	Gold, BD; Westra, SJ; Harris, NL; Winter, HS; Doody, DP; Graeme-Cook, FM; Griffiths, E; Pasternack, MS; Basgoz, N; Barron, RF				Gold, BD; Westra, SJ; Harris, NL; Winter, HS; Doody, DP; Graeme-Cook, FM; Griffiths, E; Pasternack, MS; Basgoz, N; Barron, RF			Case 40-2003: A 14-month-old boy with recurrent abdominal distention and diarrhea - Tuberculous enterocolitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INTESTINAL TUBERCULOSIS; ENDOSCOPIC BIOPSY; CHILDREN; SARCOIDOSIS; INFECTIONS; VASCULITIS; FEATURES; SPECTRUM		Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Mt Auburn Hosp, Cambridge, MA USA	Emory University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Mount Auburn Hospital	Gold, BD (corresponding author), Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.			Westra, Sjirk/0000-0002-9952-6891				Abdel-Haq NM, 2000, PEDIATR INFECT DIS J, V19, P954, DOI 10.1097/00006454-200010000-00002; [Anonymous], 2000, MMWR-MORBID MORTAL W, V51, P101; BAERT F, 1994, ACTA CLIN BELG, V49, P76, DOI 10.1080/17843286.1994.11718368; Baldassano RN, 1999, GASTROENTEROL CLIN N, V28, P445, DOI 10.1016/S0889-8553(05)70064-9; Bernstein C N, 2001, Curr Gastroenterol Rep, V3, P477; Buller H, 2002, J PEDIATR GASTR NUTR, V35, pS151, DOI 10.1097/00005176-200208002-00013; Chandra Suresh, 2003, Indian J Gastroenterol, V22, P145; Chutkan RK, 2001, PRIMARY CARE, V28, P539, DOI 10.1016/S0095-4543(05)70052-X; Crawford JT, 2002, EMERG INFECT DIS, V8, P1192; DEVANEY K, 1993, AM J SURG PATHOL, V17, P1272, DOI 10.1097/00000478-199312000-00009; Eklund A, 2003, J INTERN MED, V253, P2, DOI 10.1046/j.1365-2796.2003.01072.x; Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6; Ferry GD, 1999, J PEDIATR GASTR NUTR, V28, pS15, DOI 10.1097/00005176-199904001-00001; Fox VL, 2000, GASTROENTEROL CLIN N, V29, P37, DOI 10.1016/S0889-8553(05)70107-2; Gan HT, 2002, AM J GASTROENTEROL, V97, P1446, DOI 10.1111/j.1572-0241.2002.05686.x; Geboes K, 2002, ACTA GASTRO-ENT BELG, V65, P204; Giuffrida TJ, 2002, DERMATOL CLIN, V20, P435, DOI 10.1016/S0733-8635(02)00010-4; Griffiths AM, 1998, NUTRITION, V14, P788, DOI 10.1016/S0899-9007(98)00085-9; Hochart L, 2002, SAMJ S AFR MED J, V92, P519; Horton KM, 2000, RADIOGRAPHICS, V20, P399, DOI 10.1148/radiographics.20.2.g00mc15399; Hyams JS, 1996, PEDIATR CLIN N AM, V43, P255, DOI 10.1016/S0031-3955(05)70405-3; Jones Richard E., 1999, Current Opinion in Rheumatology, V11, P83, DOI 10.1097/00002281-199901000-00015; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kim KM, 1998, AM J GASTROENTEROL, V93, P606, DOI 10.1111/j.1572-0241.1998.173_b.x; Kokkonen J, 2002, AM J GASTROENTEROL, V97, P667; LEE LA, 1990, NEW ENGL J MED, V322, P984, DOI 10.1056/NEJM199004053221407; Lundstedt C, 1996, ACTA RADIOL, V37, P489; Manouvrier-Hanu S, 1998, AM J MED GENET, V76, P217, DOI 10.1002/(SICI)1096-8628(19980319)76:3<217::AID-AJMG4>3.0.CO;2-N; Marx G, 2002, J PEDIATR-US, V140, P470, DOI 10.1067/mpd.2002.123281; Oliva-Hemker M, 2002, INFLAMM BOWEL DIS, V8, P112, DOI 10.1097/00054725-200203000-00008; OSTROFF SM, 1992, J INFECT DIS, V166, P812, DOI 10.1093/infdis/166.4.812; Ozen S, 2002, BEST PRACT RES CL RH, V16, P411, DOI 10.1053/berh.2002.0237; Ramanan AV, 2002, CURR OPIN RHEUMATOL, V14, P658, DOI 10.1097/00002281-200211000-00005; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Schulster L., 2003, MMWR RECOMM REP, V52, P1; Shetty AK, 2003, J AM ACAD DERMATOL, V48, P150, DOI 10.1067/mjd.2003.133; Tarumi K, 2002, GASTROINTEST ENDOSC, V55, P743, DOI 10.1067/mge.2002.122797; Thornton MA, 2000, CLIN OTOLARYNGOL, V25, P433, DOI 10.1046/j.1365-2273.2000.00335.x; Toungoussova OS, 2003, CLIN INFECT DIS, V37, P665, DOI 10.1086/377205; Valla D C, 2000, Clin Liver Dis, V4, P269, DOI 10.1016/S1089-3261(05)70108-2; Witte J, 2000, SCAND J GASTROENTERO, V35, P1272; 2003, MMWR MORB MORTAL WKL, V52, P222; 2003, MMWR MORB MORTAL WKL, V52, P217	43	3	3	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2541	2549		10.1056/NEJMcpc030030	http://dx.doi.org/10.1056/NEJMcpc030030			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695415				2022-12-28	WOS:000187529500011
J	Cyranoski, D				Cyranoski, D			China - From SARS to the stars	NATURE			English	News Item																		Chen Y, 2003, CELL RES, V13, P251, DOI 10.1038/sj.cr.7290170; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	3	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					752	753		10.1038/426752a	http://dx.doi.org/10.1038/426752a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685192	Bronze, Green Published			2022-12-28	WOS:000187342000015
J	Humeau, Y; Shaban, H; Bissiere, S; Luthi, A				Humeau, Y; Shaban, H; Bissiere, S; Luthi, A			Presynaptic induction of heterosynaptic associative plasticity in the mammalian brain	NATURE			English	Article							LONG-TERM POTENTIATION; LATERAL AMYGDALA; SYNAPTIC TRANSMISSION; BASOLATERAL AMYGDALA; NMDA RECEPTORS; DEPRESSION; RAT; LOCALIZATION; CORTEX; MEMORY	The induction of associative synaptic plasticity in the mammalian central nervous system classically depends on coincident presynaptic and postsynaptic activity(1,2). According to this principle, associative homosynaptic long-term potentiation (LTP) of excitatory synaptic transmission can be induced only if synaptic release occurs during postsynaptic depolarization(1,2). In contrast, heterosynaptic plasticity in mammals is considered to rely on activity-independent, non-associative processes(3-8). Here we describe a novel mechanism underlying the induction of associative LTP in the lateral amygdala ( LA). Simultaneous activation of converging cortical and thalamic afferents specifically induced associative, N-methyl-D-aspartate (NMDA)-receptor-dependent LTP at cortical, but not at thalamic, inputs. Surprisingly, the induction of associative LTP at cortical inputs was completely independent of postsynaptic activity, including depolarization, postsynaptic NMDA receptor activation or an increase in postsynaptic Ca2+ concentration, and did not require network activity. LTP expression was mediated by a persistent increase in the presynaptic probability of release at cortical afferents. Our study shows the presynaptic induction and expression of heterosynaptic and associative synaptic plasticity on simultaneous activity of converging afferents. Our data indicate that input specificity of associative LTP can be determined exclusively by presynaptic properties.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Basel	Luthi, A (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Shaban, Hamdy/ABD-5617-2021; shaban, Hamdy/C-1939-2014	Shaban, Hamdy/0000-0003-3760-6113; shaban, Hamdy/0000-0003-3760-6113				ABRAHAM WC, 1991, BRAIN RES, V546, P336, DOI 10.1016/0006-8993(91)91498-P; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Bailey CH, 2000, NAT REV NEUROSCI, V1, P11, DOI 10.1038/35036191; Bauer EP, 2002, J NEUROSCI, V22, P5239, DOI 10.1523/JNEUROSCI.22-12-05239.2002; Berretta N, 1996, NEUROSCIENCE, V75, P339, DOI 10.1016/0306-4522(96)00301-6; Bissiere S, 2003, NAT NEUROSCI, V6, P587, DOI 10.1038/nn1058; Blair HT, 2001, LEARN MEMORY, V8, P229, DOI 10.1101/lm.30901; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Doyere V, 2003, EUR J NEUROSCI, V17, P2703, DOI 10.1046/j.1460-9568.2003.02707.x; FARB CR, 1995, J COMP NEUROL, V362, P86, DOI 10.1002/cne.903620106; Farb CR, 1999, SYNAPSE, V33, P218, DOI 10.1002/(SICI)1098-2396(19990901)33:3<218::AID-SYN6>3.0.CO;2-1; GRACY KN, 1995, J COMP NEUROL, V362, P71, DOI 10.1002/cne.903620105; GUSTAFSSON B, 1990, SEMIN NEUROSCI, V2, P321; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; Huang YY, 1998, NEURON, V21, P169, DOI 10.1016/S0896-6273(00)80524-3; Humeau Y, 2002, J NEUROSCI, V22, P7968; Lang EJ, 1997, J NEUROPHYSIOL, V77, P341, DOI 10.1152/jn.1997.77.1.341; Lang EJ, 1998, NEUROSCIENCE, V83, P877, DOI 10.1016/S0306-4522(97)00420-X; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; McDonald AJ, 1996, NEUROSCIENCE, V75, P407, DOI 10.1016/0306-4522(96)00269-2; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Quirk GJ, 1997, NEURON, V19, P613, DOI 10.1016/S0896-6273(00)80375-X; Rosenkranz JA, 2002, NATURE, V417, P282, DOI 10.1038/417282a; Royer S, 2003, NATURE, V422, P518, DOI 10.1038/nature01530; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; Szinyei C, 2000, J NEUROSCI, V20, P8909; Tsukamoto M, 2003, J PHYSIOL-LONDON, V546, P665, DOI 10.1113/jphysiol.2002.033803; Tsvetkov E, 2002, NEURON, V34, P289, DOI 10.1016/S0896-6273(02)00645-1; Weisskopf MG, 1999, J NEUROSCI, V19, P10512	30	199	201	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					841	845		10.1038/nature02194	http://dx.doi.org/10.1038/nature02194			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685239				2022-12-28	WOS:000187342000059
J	Schiermeier, Q				Schiermeier, Q			Climate change - The long road from Kyoto	NATURE			English	News Item																		Christensen JH, 2003, NATURE, V421, P805, DOI 10.1038/421805a; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333	3	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					756	756		10.1038/426756a	http://dx.doi.org/10.1038/426756a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685198	Bronze			2022-12-28	WOS:000187342000019
J	Tong, LM; Gattass, RR; Ashcom, JB; He, SL; Lou, JY; Shen, MY; Maxwell, I; Mazur, E				Tong, LM; Gattass, RR; Ashcom, JB; He, SL; Lou, JY; Shen, MY; Maxwell, I; Mazur, E			Subwavelength-diameter silica wires for low-loss optical wave guiding	NATURE			English	Article							TAPERED FIBERS; FABRICATION; GUIDES; LASER; ROUGHNESS; NANOWIRES; NANOTUBES; GROWTH	Silica waveguides with diameters larger than the wavelength of transmitted light are widely used in optical communications, sensors and other applications(1-3). Minimizing the width of the waveguides is desirable for photonic device applications, but the fabrication of low-loss optical waveguides with subwavelength diameters remains challenging because of strict requirements on surface roughness and diameter uniformity(4-7). Here we report the fabrication of subwavelength-diameter silica 'wires' for use as low-loss optical waveguides within the visible to near-infrared spectral range. We use a two-step drawing process to fabricate long free-standing silicawires with diameters down to 50 nm that show surface smoothness at the atomic level together with uniformity of diameter. Light can be launched into these wires by optical evanescent coupling. The wires allow single-mode operation, and have an optical loss of less than 0.1 dB mm(-1). We believe that these wires provide promising building blocks for future microphotonic devices with subwavelength-width structures.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Zhejiang Univ, Ctr Opt & Electromagnet Res, Hangzhou 310027, Peoples R China; Zhejiang Univ, Dept Phys, Hangzhou 310027, Peoples R China; Tohoku Univ, Grad Sch Sci, Dept Phys, Sendai, Miyagi 9808578, Japan	Harvard University; Harvard University; Zhejiang University; Zhejiang University; Tohoku University	Mazur, E (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.		He, Sailing/C-2438-2009; Mazur, Eric/B-8918-2009	He, Sailing/0000-0002-3401-1125; Gattass, Rafael/0000-0002-5286-6178				Birks TA, 2000, OPT LETT, V25, P1415, DOI 10.1364/OL.25.001415; Boys C V, 1887, PHILOS MAG, V23, P489; Cai M, 2001, OPT LETT, V26, P884, DOI 10.1364/OL.26.000884; Dimmick TE, 1999, APPL OPTICS, V38, P6845, DOI 10.1364/AO.38.006845; Grellier AJC, 1998, OPT COMMUN, V152, P324, DOI 10.1016/S0030-4018(98)00164-3; Hu JQ, 2003, ADV MATER, V15, P70, DOI 10.1002/adma.200390014; Ito T, 2000, NATURE, V406, P1027, DOI 10.1038/35023233; Kakarantzas G, 2001, OPT LETT, V26, P1137, DOI 10.1364/OL.26.001137; Knight JC, 1997, OPT LETT, V22, P1129, DOI 10.1364/OL.22.001129; KRAUSE JT, 1979, PHYS CHEM GLASSES, V20, P135; LABELLE HE, 1967, NATURE, V216, P574, DOI 10.1038/216574b0; Ladouceur F, 1997, J LIGHTWAVE TECHNOL, V15, P1020, DOI 10.1109/50.588676; Lee KK, 2001, OPT LETT, V26, P1888, DOI 10.1364/OL.26.001888; Lee KK, 2000, APPL PHYS LETT, V77, P2258, DOI 10.1063/1.1320897; Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852; Maier SA, 2002, APPL PHYS LETT, V81, P1714, DOI 10.1063/1.1503870; MARCUSE D, 1969, AT&T TECH J, V48, P3187, DOI 10.1002/j.1538-7305.1969.tb01742.x; MARCUSE D, 1969, AT&T TECH J, V48, P3217, DOI 10.1002/j.1538-7305.1969.tb01743.x; MATTHEWSON MJ, 1986, J AM CERAM SOC, V69, P815, DOI 10.1111/j.1151-2916.1986.tb07366.x; Morales AM, 1998, SCIENCE, V279, P208, DOI 10.1126/science.279.5348.208; Murata H, 1996, HDB OPTICAL FIBERS C, V2nd; Mynbaev D. K., 2001, FIBER OPTIC COMMUNIC; Pan ZW, 2002, J AM CHEM SOC, V124, P1817, DOI 10.1021/ja017284n; Snyder A.W., 1983, OPTICAL WAVEGUIDE TH; Taflove A., 1995, COMPUTATIONAL ELECTR; Takahara J, 1997, OPT LETT, V22, P475, DOI 10.1364/OL.22.000475; THRELFALL R, 1898, LAB ARTS; Wang ZL, 2000, ADV MATER, V12, P1938, DOI 10.1002/1521-4095(200012)12:24<1938::AID-ADMA1938>3.3.CO;2-W; Xia YN, 1999, CHEM REV, V99, P1823, DOI 10.1021/cr980002q; Yamane M., 2009, GLASSES PHOTONICS, DOI [10.1017/CBO9780511541308, DOI 10.1017/CBO9780511541308]	30	1344	1425	42	746	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					816	819		10.1038/nature02193	http://dx.doi.org/10.1038/nature02193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685232				2022-12-28	WOS:000187342000051
J	Etminan, M; Hemmelgarn, B; Delaney, JAC; Suissa, S				Etminan, M; Hemmelgarn, B; Delaney, JAC; Suissa, S			Use of lithium and the risk of injurious motor vehicle crash in elderly adults: case-control study nested within a cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIPOLAR DISORDER		McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada	McGill University; Royal Victoria Hospital; University of Calgary; University of Calgary	Suissa, S (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Clin Epidemiol, 687 Pine Ave, Montreal, PQ H3A 1A1, Canada.	Samy.suissa@dinepi.mcgill.ca	Delaney, Joseph A/J-8204-2019	Delaney, Joseph A/0000-0003-1771-1776				Goodwin FK, 2003, JAMA-J AM MED ASSOC, V290, P1467, DOI 10.1001/jama.290.11.1467; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; Honig A, 1999, INT CLIN PSYCHOPHARM, V14, P167, DOI 10.1097/00004850-199905030-00003; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; Verster JC, 2003, PSYCHOPHARMACOLOGY, V169, P84, DOI 10.1007/s00213-003-1462-6	5	18	18	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2004	328	7439					558	559		10.1136/bmj.38002.514838.94	http://dx.doi.org/10.1136/bmj.38002.514838.94			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JI	14732760	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220091800020
J	D'Alessandro, U				D'Alessandro, U			Commentary: Treating severe and complicated malaria	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Institute of Tropical Medicine (ITM)	D'Alessandro, U (corresponding author), Inst Trop Med Prince Leopold, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	udalessandro@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				Barennes H, 2001, Sante, V11, P145; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; D'Alessandro U, 1997, T ROY SOC TROP MED H, V91, P638, DOI 10.1016/S0035-9203(97)90502-2; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; *WHO, 2001, US ANT DRUGS REP WHO; Winstanley P, 2001, Lancet Infect Dis, V1, P242, DOI 10.1016/S1473-3099(01)00119-0	6	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2004	328	7432					155	155		10.1136/bmj.328.7432.155	http://dx.doi.org/10.1136/bmj.328.7432.155			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726348	Green Published			2022-12-28	WOS:000188249900027
J	Garabato, ACN; Polzin, KL; King, BA; Heywood, KJ; Visbeck, M				Garabato, ACN; Polzin, KL; King, BA; Heywood, KJ; Visbeck, M			Widespread intense turbulent mixing in the Southern Ocean	SCIENCE			English	Article							WIND; OCEANOGRAPHY; TOPOGRAPHY; ATLANTIC; WORK; SEA	Observations of internal wave velocity fluctuations show that enhanced turbulent mixing over rough topography in the Southern Ocean is remarkably intense and widespread. Mixing rates exceeding background values by a factor of 10 to 1000 are common above complex bathymetry over a distance of 2000 to 3000 kilometers at depths greater than 500 to 1000 meters. This suggests that turbulent mixing in the Southern Ocean may contribute crucially to driving the upward transport of water closing the ocean's meridional overturning circulation, and thus needs to be represented in numerical simulations of the global ocean circulation and the spreading of biogeochemical tracers.	Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England; Lamont Doherty Earth Observ, Palisades, NY 10964 USA	University of East Anglia; Woods Hole Oceanographic Institution; NERC National Oceanography Centre; University of Southampton; Columbia University	Garabato, ACN (corresponding author), Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England.	a.naveira-garabato@uea.ac.uk	Garabato, Alberto Naveira/AAQ-1114-2020; Visbeck, Martin H/B-6541-2016; Visbeck, Martin/G-2461-2011; Heywood, Karen J/L-1757-2016; zhu, xiaoting/E-9873-2011	Garabato, Alberto Naveira/0000-0001-6071-605X; Visbeck, Martin H/0000-0002-0844-834X; Visbeck, Martin/0000-0002-0844-834X; Heywood, Karen J/0000-0001-9859-0026; 				Alford MH, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016614; Finnigan TD, 2002, J PHYS OCEANOGR, V32, P2988, DOI 10.1175/1520-0485(2002)032<2988:OOEDMN>2.0.CO;2; Garrett C, 2003, NATURE, V422, P477, DOI 10.1038/422477a; GARRETT C, 1975, J GEOPHYS RES, V80, P291, DOI 10.1029/JC080i003p00291; GREGG MC, 1987, J GEOPHYS RES-OCEANS, V92, P5249, DOI 10.1029/JC092iC05p05249; HENYEY FS, 1986, J GEOPHYS RES-OCEANS, V91, P8487, DOI 10.1029/JC091iC07p08487; Heywood KJ, 2002, NATURE, V415, P1011, DOI 10.1038/4151011a; Hughes CW, 2002, NATURE, V416, P136, DOI 10.1038/416136a; Karsten R, 2002, J PHYS OCEANOGR, V32, P39, DOI 10.1175/1520-0485(2002)032<0039:TROETI>2.0.CO;2; Law CS, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2002JC001604; LEAMAN KD, 1975, J GEOPHYS RES, V80, P1975, DOI 10.1029/JC080i015p01975; Ledwell JR, 2000, NATURE, V403, P179, DOI 10.1038/35003164; Ledwell JR, 1998, J GEOPHYS RES-OCEANS, V103, P21499, DOI 10.1029/98JC01738; LIVERMORE RA, 1993, EARTH PLANET SC LETT, V117, P475, DOI 10.1016/0012-821X(93)90098-T; Mauritzen C, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC001114; Munk W, 1998, DEEP-SEA RES PT I, V45, P1977, DOI 10.1016/S0967-0637(98)00070-3; OLBERS D, 1989, NATO ADV SCI I C-MAT, V284, P95; ORSI AH, 1995, DEEP-SEA RES PT I, V42, P641, DOI 10.1016/0967-0637(95)00021-W; OSBORN TR, 1980, J PHYS OCEANOGR, V10, P83, DOI 10.1175/1520-0485(1980)010<0083:EOTLRO>2.0.CO;2; Polzin K, 2002, J ATMOS OCEAN TECH, V19, P205, DOI 10.1175/1520-0426(2002)019<0205:TFROLA>2.0.CO;2; POLZIN KL, 1995, J PHYS OCEANOGR, V25, P306, DOI 10.1175/1520-0485(1995)025<0306:FPOTD>2.0.CO;2; Polzin KL, 1997, SCIENCE, V276, P93, DOI 10.1126/science.276.5309.93; POLZIN KL, 1999, SPECIAL PUBLICATION, P117; POLZIN KL, 1997, INT WOCE NEWSL, V29, P39; POLZIN KL, IN PRESS J PHYS OCEA; Rintoul S. R., 2001, OCEAN CIRCULATION CL, P271, DOI DOI 10.1016/S0074-6142(01)80124-8; Smith WHF, 1997, SCIENCE, V277, P1956, DOI 10.1126/science.277.5334.1956; Speer K, 2000, J PHYS OCEANOGR, V30, P3212, DOI 10.1175/1520-0485(2000)030<3212:TDDC>2.0.CO;2; Toggweiler JR, 1998, J PHYS OCEANOGR, V28, P1832, DOI 10.1175/1520-0485(1998)028<1832:OTOSLS>2.0.CO;2; Webb DJ, 2001, NATURE, V409, P37, DOI 10.1038/35051171; Wunsch C, 1998, J PHYS OCEANOGR, V28, P2332, DOI 10.1175/1520-0485(1998)028<2332:TWDBTW>2.0.CO;2; WUNSCH C, IN PRESS ANN REV FLU	32	291	299	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					210	213		10.1126/science.1090929	http://dx.doi.org/10.1126/science.1090929			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716008				2022-12-28	WOS:000187908500042
J	Thielman, NM; Guerrant, RL				Thielman, NM; Guerrant, RL			Acute infectious diarrhea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; DOUBLE-BLIND; TRAVELERS DIARRHEA; ANTIBIOTIC-TREATMENT; TRIMETHOPRIM-SULFAMETHOXAZOLE; CLOSTRIDIUM-DIFFICILE; BISMUTH SUBSALICYLATE; CIPROFLOXACIN; THERAPY; PLACEBO		Univ Virginia, Sch Med, Ctr Global Hlth, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Med, Div Infect Dis & Int Hlth, Durham, NC USA	University of Virginia; University of Virginia; Duke University	Guerrant, RL (corresponding author), Univ Virginia, Sch Med, Ctr Global Hlth, HSC 801379, Charlottesville, VA 22908 USA.	rlg9a@virginia.edu						ANDERS BJ, 1982, LANCET, V1, P131; Armon K, 2001, ARCH DIS CHILD, V85, P132, DOI 10.1136/adc.85.2.132; Bartlett JG, 2002, NEW ENGL J MED, V346, P334, DOI 10.1056/NEJMcp011603; Bauer TH, 2001, JAMA-J AM MED ASSOC, V285, P313, DOI 10.1001/jama.285.3.313; BENNISH ML, 1990, J INFECT DIS, V162, P711, DOI 10.1093/infdis/162.3.711; Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P41; Cheng Allen C., 2002, Curr Infect Dis Rep, V4, P70, DOI 10.1007/s11908-002-0070-7; Choi SW, 1996, J CLIN MICROBIOL, V34, P928, DOI 10.1128/JCM.34.4.928-932.1996; CIMOLAI N, 1994, CLIN NEPHROL, V42, P85; Dryden MS, 1996, CLIN INFECT DIS, V22, P1019, DOI 10.1093/clinids/22.6.1019; DUPONT HL, 1990, AM J MED, V88, pS15, DOI 10.1016/0002-9343(90)90270-N; DuPont HL, 1997, AM J GASTROENTEROL, V92, P1962; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; DUPONT HL, 1977, GASTROENTEROLOGY, V73, P715; DUPONT HL, 1987, JAMA-J AM MED ASSOC, V257, P1347, DOI 10.1001/jama.257.10.1347; FDA, 2003, FED REGISTER, V68, P18869; FIGUEROAQUINTANILLA D, 1993, NEW ENGL J MED, V328, P1653, DOI 10.1056/NEJM199306103282301; Fine KD, 1998, AM J GASTROENTEROL, V93, P1300; Gill CJ, 2003, CLIN INFECT DIS, V37, P365, DOI 10.1086/375896; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; Guerrant RL, 2001, CLIN INFECT DIS, V32, P331, DOI 10.1086/318514; Guerrant RL, 2002, TRENDS PARASITOL, V18, P281; Guerrant RL, 2002, TRENDS PARASITOL, V18, P191, DOI 10.1016/S1471-4922(02)02253-5; Haque R, 2003, NEW ENGL J MED, V348, P1565, DOI 10.1056/NEJMra022710; Herikstad H, 2002, EPIDEMIOL INFECT, V129, P9, DOI 10.1017/S0950268801006628; JOHNSON PC, 1986, JAMA-J AM MED ASSOC, V255, P757, DOI 10.1001/jama.255.6.757; JOHNSON S, 1992, ANN INTERN MED, V117, P297, DOI 10.7326/0003-4819-117-4-297; Khan WA, 1997, ANN INTERN MED, V126, P697, DOI 10.7326/0003-4819-126-9-199705010-00004; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Manatsathit S, 2002, J GASTROEN HEPATOL, V17, pS54, DOI 10.1046/j.1440-1746.17.s1.11.x; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; MURPHY GS, 1993, ANN INTERN MED, V118, P582, DOI 10.7326/0003-4819-118-8-199304150-00002; Murphy MS, 1998, ARCH DIS CHILD, V79, P279, DOI 10.1136/adc.79.3.279; Nachamkin I, 2002, EMERG INFECT DIS, V8, P1501, DOI 10.3201/eid0812.020115; Nazarian LF, 1996, PEDIATRICS, V97, P424; NEILL MA, 1991, ANN INTERN MED, V114, P195, DOI 10.7326/0003-4819-114-3-195; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; PETRUCCELLI BP, 1992, J INFECT DIS, V165, P557, DOI 10.1093/infdis/165.3.557; Rossignol JFA, 2001, J INFECT DIS, V184, P103, DOI 10.1086/321008; Safdar N, 2002, JAMA-J AM MED ASSOC, V288, P996, DOI 10.1001/jama.288.8.996; SALAZARLINDO E, 1986, J PEDIATR-US, V109, P355, DOI 10.1016/S0022-3476(86)80404-8; SANCHEZ C, 1993, J INFECT DIS, V168, P1304, DOI 10.1093/infdis/168.5.1304; Smith KE, 1999, NEW ENGL J MED, V340, P1525, DOI 10.1056/NEJM199905203402001; Steffen R, 2003, AM J GASTROENTEROL, V98, P1073, DOI [10.1016/S0002-9270(02)06005-7, 10.1111/j.1572-0241.2003.07283.x]; STEFFEN R, 1986, ANTIMICROB AGENTS CH, V29, P625, DOI 10.1128/AAC.29.4.625; STEINHOFF MC, 1980, GASTROENTEROLOGY, V78, P1495; THIELMAN NM, 1997, J CLIN OUTCOMES MANA, V4, P36; TONG MJ, 1970, J AMER MED ASSOC, V214, P1841, DOI 10.1001/jama.214.10.1841; Verdier RI, 2000, ANN INTERN MED, V132, P885, DOI 10.7326/0003-4819-132-11-200006060-00006; WISTROM J, 1992, ANN INTERN MED, V117, P202, DOI 10.7326/0003-4819-117-3-202; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601; Zhang XP, 2000, J INFECT DIS, V181, P664, DOI 10.1086/315239; ZIMBASA Dysentery Study Grp, 2002, PEDIATR INFECT DIS J, V21, P1136, DOI [10.1097/00006454-200212000-00010, 10.1097/01.inf.0000040824.83814.a9]; 2003, MMWR MORB MORTAL WKL, V52, P340; 2003, MMWR MORB MORTAL WKL, V52, P113	57	221	242	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					38	47		10.1056/NEJMcp031534	http://dx.doi.org/10.1056/NEJMcp031534			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702426				2022-12-28	WOS:000187659900008
J	Head, JW; Mustard, JF; Kreslavsky, MA; Milliken, RE; Marchant, DR				Head, JW; Mustard, JF; Kreslavsky, MA; Milliken, RE; Marchant, DR			Recent ice ages on Mars	NATURE			English	Article							MIOCENE GLACIER ICE; SURFACE GROUND ICE; CHAOTIC OBLIQUITY; NEAR-SURFACE; CLIMATE; ANTARCTICA; DEPOSITS; WATER; HYDROGEN; ODYSSEY	A key pacemaker of ice ages on the Earth is climatic forcing due to variations in planetary orbital parameters. Recent Mars exploration has revealed dusty, water-ice-rich mantling deposits that are layered, metres thick and latitude dependent, occurring in both hemispheres from mid-latitudes to the poles. Here we show evidence that these deposits formed during a geologically recent ice age that occurred from about 2.1 to 0.4 Myr ago. The deposits were emplaced symmetrically down to latitudes of similar to30degrees equivalent to Saudi Arabia and the southern United States on the Earth - in response to the changing stability of water ice and dust during variations in obliquity ( the angle between Mars' pole of rotation and the ecliptic plane) reaching 30 - 35degrees. Mars is at present in an 'interglacial' period, and the ice-rich deposits are undergoing reworking, degradation and retreat in response to the current instability of near-surface ice. Unlike the Earth, martian ice ages are characterized by warmer polar climates and enhanced equatorward transport of atmospheric water and dust to produce widespread smooth deposits down to mid-latitudes.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Kharkov Natl Univ, Astron Inst, UA-61077 Kharkov, Ukraine; Boston Univ, Dept Earth Sci, Boston, MA 02215 USA	Brown University; Ministry of Education & Science of Ukraine; VN Karazin Kharkiv National University; Boston University	Head, JW (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Kreslavsky, Mikhail/J-3425-2013	Kreslavsky, Mikhail/0000-0002-1900-826X				Bockheim JG, 2002, S AFR J SCI, V98, P82; Boynton WV, 2002, SCIENCE, V297, P81, DOI 10.1126/science.1073722; CABROL NA, 2002, LUNAR PLANET SCI, V33; Carr MH, 2001, J GEOPHYS RES-PLANET, V106, P23571, DOI 10.1029/2000JE001316; Christensen PR, 2003, NATURE, V422, P45, DOI 10.1038/nature01436; CHRISTIEBLICK N, 1982, ICARUS, V50, P408; Costard F, 2002, SCIENCE, V295, P110, DOI 10.1126/science.1064419; DIXON JC, 1992, BINGHAMPTON S GEOMOR, V22; Fanale F.P., 1992, MARS, P1135; FANALE FP, 1994, ICARUS, V111, P305, DOI 10.1006/icar.1994.1147; Feldman WC, 2002, SCIENCE, V297, P75, DOI 10.1126/science.1073541; FELDMAN WC, 2003, 6 INT MARS C; Haberle RA, 2003, ICARUS, V161, P66, DOI 10.1016/S0019-1035(02)00017-9; Hecht MH, 2002, ICARUS, V156, P373, DOI 10.1006/icar.2001.6794; IMBRIE J, 1982, ICARUS, V50, P408, DOI 10.1016/0019-1035(82)90132-4; Imbrie J., 1986, ICE AGES SOLVING MYS; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; JAKOSKY BM, 1985, NATURE, V315, P559, DOI 10.1038/315559a0; Johnson JB, 2000, GEOPHYS RES LETT, V27, P2769, DOI 10.1029/1999GL011077; Kieffer H. H., 1992, MARS, P1180; Kolb EJ, 2001, ICARUS, V154, P22, DOI 10.1006/icar.2001.6676; KOSTAMA VP, 2003, LUNAR PLANET SCI, V34; Kreslavsky MA, 2000, J GEOPHYS RES-PLANET, V105, P26695, DOI 10.1029/2000JE001259; KRESLAVSKY MA, 2002, GEOPHYS RES LETT, V29; KRESLAVSKY MA, 2003, LUNAR PLANET SCI, V34; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; Laskar J, 2002, NATURE, V419, P375, DOI 10.1038/nature01066; Leovy C, 2001, NATURE, V412, P245, DOI 10.1038/35084192; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; Malin MC, 2000, SCIENCE, V288, P2330, DOI 10.1126/science.288.5475.2330; MANGOLD M, 2002, LUNAR PLANET SCI, V33; Marchant DR, 2002, GEOL SOC AM BULL, V114, P718, DOI 10.1130/0016-7606(2002)114<0718:FOPGAS>2.0.CO;2; MELLON MT, 1995, J GEOPHYS RES-PLANET, V100, P11781, DOI 10.1029/95JE01027; MELLON MT, 2003, LUNAR PLANET SCI, V34; MILLIKEN RE, 2003, J GEOPHYS RES, V108; MISCHNA MA, 2003, J GEOPHYS RES, V108; Mitrofanov I, 2002, SCIENCE, V297, P78, DOI 10.1126/science.1073616; Mustard JF, 2001, NATURE, V412, P411, DOI 10.1038/35086515; RICHARDSON MI, 2003, LUNAR PLANET SCI, V34; RICHARDSON MI, 2002, J GEOPHYS RES, V107; Seibert NM, 2001, GEOPHYS RES LETT, V28, P899, DOI 10.1029/2000GL012093; Squyres S. W., 1992, MARS, P523; SUGDEN DE, 1995, NATURE, V376, P412, DOI 10.1038/376412a0; TANAKA KL, 1987, MISC INVEST SER US G; Thomas P., 1992, MARS, P767; TOKAR RL, 2002, GEOPHYS RES LETT, V29; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; Ward W. R., 1992, MARS, P298; Williams P, 1989, FROZEN EARTH; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	50	555	561	1	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					797	802		10.1038/nature02114	http://dx.doi.org/10.1038/nature02114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685228				2022-12-28	WOS:000187342000047
J	Beall, CM				Beall, CM			High-altitude adaptations	LANCET			English	Article									Case Western Reserve Univ, Dept Anthropol, Cleveland, OH 44106 USA	Case Western Reserve University	Beall, CM (corresponding author), Case Western Reserve Univ, Dept Anthropol, 238 Mather Mem Bldg,11220 Bellflower Rd, Cleveland, OH 44106 USA.			Beall, Cynthia/0000-0003-1462-8299				SEVERINGHAUS J, HIGH ALTITUDE MED BI	1	47	50	1	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S14	S15		10.1016/S0140-6736(03)15058-1	http://dx.doi.org/10.1016/S0140-6736(03)15058-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698112				2022-12-28	WOS:000187790200008
J	Thor, J				Thor, J			Realities of rodeo	LANCET			English	Article											Thor, J (corresponding author), 1200 N 36 St, Norfolk, NE 68701 USA.								0	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S52	S53		10.1016/S0140-6736(03)15077-5	http://dx.doi.org/10.1016/S0140-6736(03)15077-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698131				2022-12-28	WOS:000187790200027
J	Sculpher, M; Manca, A; Abbott, J; Fountain, J; Mason, S; Garry, R				Sculpher, M; Manca, A; Abbott, J; Fountain, J; Mason, S; Garry, R			Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASSISTED VAGINAL HYSTERECTOMY; ABDOMINAL-HYSTERECTOMY	Objective To assess the cost effectiveness of laparoscopic hysterectomy compared with conventional hysterectomy (abdominal or vaginal). Design Cost effectiveness analysis based on two parallel trials: laparoscopic (n = 324) compared with vaginal hysterectomy (n = 163); and laparoscopic (n = 573) compared with abdominal hysterectomy (n = 286). Participants 1346 women requiring a hysterectomy for reasons other than malignancy. Main outcome measure One year costs estimated from NHS perspective. Health outcomes expressed in terms of QALYs based on women's responses to the EQ-5D at baseline and at three points during up to 52 weeks' follow up. Results Laparoscopic hysterectomy cost an average of pound401 ($708; C571) more (95% confidence interval pound271 to pound542) than vaginal hysterectomy but produced little difference in mean QALYs (0.0015, 0.0 15 to 0.0 18). Mean differences in cost and QALYs generated an incremental cost per QALY gained of pound267 333 ($471789; E380 437). The, probability that laparoscopic hysterectomy is cost effective was below 50% for a large range of values of willingness to pay for an additional QALY. Laparoscopic hysterectomy cost an average of pound186 ($328; E265) more than abdominal hysterectomy, although 95% confidence intervals crossed zero -pound26 to pound375); there was little difference in mean QALYs (0.007, - 0.008 to 0,023), resulting in an incremental cost per QALY gained of pound26 571 ($46 893; E37 813). If the NHS is willing to pay pound30 0 00 for an additional QALY, the probability that laparoscopic hysterectomy is cost effective is 56%. Conclusions Laparoscopic hysterectomy is not cost effective relative to vaginal hysterectomy. Its cost effectiveness relative to the abdominal procedure is finely balanced.	Univ Western Australia, King Edward Mem Hosp, Sch Womens & Infants Hlth, Perth, WA 6008, Australia; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Univ New S Wales, Royal Hosp Women, Dept Endogynaecol, Randwick, NSW 2031, Australia; Univ Leeds, No & Yorkshire Clin Trials & Res Unit, Leeds LS2 9NG, W Yorkshire, England	King Edward Memorial Hospital; University of Western Australia; University of York - UK; University of New South Wales Sydney; University of Leeds	Sculpher, M (corresponding author), Univ Western Australia, King Edward Mem Hosp, Sch Womens & Infants Hlth, Perth, WA 6008, Australia.	mjs23@york.ac.uk		Sculpher, Mark/0000-0003-3746-9913				Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; BOOTH C, 2000, CMND4563; Chapron C, 2000, EUR J OBSTET GYN R B, V89, P141, DOI 10.1016/S0301-2115(99)00220-1; *CIPFA, 2000, HLTH SERV DAT 2000; Dolan P., 1995, SOCIAL TARIFF EUROQO; Efron B., 1994, MONOGRAPHS STAT APPL; Ellstrom M, 1998, OBSTET GYNECOL, V91, P30, DOI 10.1016/S0029-7844(97)00579-6; Garry R, 2004, BRIT MED J, V328, P129, DOI 10.1136/bmj.37984.623889.F6; GARRY R, 2004, IMJ, DOI DOI 10.1136/BMJ.37958.696840.5A; GARRY R, IN PRESS HLTH TECHNO; GOUGH CB, 2000, CMND4562; Kind P, 1996, QUALITY LIFE PHARMAC; Lepine L A, 1997, MMWR CDC Surveill Summ, V46, P1; Lin DY, 1997, BIOMETRICS, V53, P419, DOI 10.2307/2533947; Lowell L, 2000, J REPROD MED, V45, P738; Lumsden MA, 2000, BRIT J OBSTET GYNAEC, V107, P1386, DOI 10.1111/j.1471-0528.2000.tb11653.x; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Netten A.P., 2000, UNIT COSTS HLTH SOCI; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; Schneider A, 1997, ARCH GYNECOL OBSTET, V259, P79, DOI 10.1007/BF02505313; Sculpher MJ, 2002, EUR HEART J, V23, P1291, DOI 10.1053/euhj.2001.3075; SCULPHER MJ, 2001, THEORY PRACTICE EC E; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; Willan AR, 2001, STAT MED, V20, P1563, DOI 10.1002/sim.789	25	125	133	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2004	328	7432					134	137		10.1136/bmj.37942.601331.EE	http://dx.doi.org/10.1136/bmj.37942.601331.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14711748	Green Published, Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000188249900016
J	Jenike, MA				Jenike, MA			Obsessive-compulsive disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLEX SEGREGATION ANALYSIS; SEROTONIN REUPTAKE INHIBITORS; CONTROLLED-TRIAL; PHARMACOLOGICAL-TREATMENTS; CLOMIPRAMINE; AUGMENTATION; STIMULATION; FLUOXETINE; EFFICACY; EXPOSURE		Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; McLean Hosp, Belmont, MA 02178 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; McLean Hospital; Harvard University; Harvard Medical School	Jenike, MA (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.	jenike@comcast.net			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH113250] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abramowitz JS, 1997, J CONSULT CLIN PSYCH, V65, P44, DOI 10.1037/0022-006X.65.1.44; ALSOBROOK JP, 1998, OBSESSIVE COMPULSIVE, P276; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], CURRENT INSIGHTS OCD; CAREY G, 2000, ANXIETY NEW RES CHAN, P117; Cavallini MC, 2000, AM J MED GENET, V96, P384, DOI 10.1002/1096-8628(20000612)96:3<384::AID-AJMG28>3.0.CO;2-P; Cavallini MC, 1999, AM J MED GENET, V88, P38, DOI 10.1002/(SICI)1096-8628(19990205)88:1<38::AID-AJMG7>3.0.CO;2-#; COSGROVE GR, 1995, NEUROSURG CLIN N AM, V6, P167; Dannon PN, 2000, EUR NEUROPSYCHOPHARM, V10, P165, DOI 10.1016/S0924-977X(00)00065-1; DOUGHERTY D, 1997, OBSESSIVE COMPULSIVE, P145; *EXP CONS PAN OBS, 1997, J CLIN PSYCHIAT S4, V58, P2; Fallon BA, 1998, ARCH GEN PSYCHIAT, V55, P918, DOI 10.1001/archpsyc.55.10.918; Fineberg NA, 2003, J CLIN PSYCHIAT, V64, P152, DOI 10.4088/JCP.v64n0207; Foa EB, 2002, BIOL PSYCHIAT, V52, P987, DOI 10.1016/S0006-3223(02)01552-4; Foa EB, 2002, OBSESSIVE COMPULSIVE, P93; FONTAINE R, 1989, PSYCHIAT ANN, V19, P88, DOI 10.3928/0048-5713-19890201-09; Gabriels L, 2003, ACTA PSYCHIAT SCAND, V107, P275, DOI 10.1034/j.1600-0447.2003.00066.x; Goldsmith TD, 2000, AM J PSYCHIAT, V157, P839; GOODMAN WK, 1992, J CLIN PSYCHIAT, V53, P29; GRAVITZ HL, 1998, OBSESSIVE COMPULSIVE; Greenberg BD, 1997, AM J PSYCHIAT, V154, P867; Harvey K V, 1995, Ann Clin Psychiatry, V7, P143, DOI 10.3109/10401239509149042; HEWLETT WA, 1992, J CLIN PSYCHOPHARM, V12, P420; Hohagen F, 1998, BRIT J PSYCHIAT, V173, P71, DOI 10.1192/S0007125000297924; Jenike MA, 1997, AM J PSYCHIAT, V154, P1261; JENIKE MA, 1993, HARVARD REV PSYCHIAT, V1, P17, DOI 10.3109/10673229309017053; JENIKE MA, 1993, PSYCHOPHARMACOL BULL, V29, P487; Jenike MA, 1998, OBSESSIVE COMPULSIVE; Kobak KA, 1998, PSYCHOPHARMACOLOGY, V136, P205, DOI 10.1007/s002130050558; LEONARD HL, 1991, ARCH GEN PSYCHIAT, V48, P922; Lindsay M, 1997, BRIT J PSYCHIAT, V171, P135, DOI 10.1192/bjp.171.2.135; MAJ M, 2002, OBSESIVE COMPULSIVE; MARKS IM, 1975, BRIT J PSYCHIAT, V127, P349, DOI 10.1192/bjp.127.4.349; MCDOUGLE CJ, 1991, J CLIN PSYCHOPHARM, V11, P175; MCDOUGLE CJ, 1997, OBSESSIVE COMPULSIVE, P203; Mundo E, 1997, J CLIN PSYCHOPHARM, V17, P436, DOI 10.1097/00004714-199710000-00024; Nestadt G, 2000, AM J HUM GENET, V67, P1611, DOI 10.1086/316898; Nestadt G, 2000, ARCH GEN PSYCHIAT, V57, P358, DOI 10.1001/archpsyc.57.4.358; NICOLINI H, 1991, URSUS MED, V1, P25; O'Connor K, 1999, CAN J PSYCHIAT, V44, P64, DOI 10.1177/070674379904400108; PATO MT, 1988, AM J PSYCHIAT, V145, P1521; PATO MT, 1990, PSYCHOPHARMACOL BULL, V26, P211; Pato MT, 1998, OBSESSIVE-COMPULSIVE DISORDER, P327; PATO MT, 1991, AM J PSYCHIAT, V148, P127; PAULS DL, 1995, AM J PSYCHIAT, V152, P76; PIGOTT TA, 1991, J CLIN PSYCHOPHARM, V11, P242; Pigott TA, 1999, J CLIN PSYCHIAT, V60, P101, DOI 10.4088/JCP.v60n0206; Rauch Scott L., 1996, P201; Ravizza L, 1996, PSYCHOPHARMACOL BULL, V32, P167; Shapira N A, 1997, Depress Anxiety, V6, P170, DOI 10.1002/(SICI)1520-6394(1997)6:4<170::AID-DA7>3.3.CO;2-W; Steiner M., 1995, 148 ANN M AM PSYCH A; STEKETEE G, 1998, COMPREHENSIVE CLIN P, V6; Steketee G. S, 1993, TREATMENT OBSESSIVE; SWINSON RP, 1998, OBSESSIVE COMPULSIVE; VANBALKOM AJLM, 1994, CLIN PSYCHOL REV, V14, P359, DOI 10.1016/0272-7358(94)90033-7	55	143	150	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					259	265		10.1056/NEJMcp031002	http://dx.doi.org/10.1056/NEJMcp031002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	763HF	14724305				2022-12-28	WOS:000188078400009
J	Landolfi, R; Marchioli, R; Kutti, J; Gisslinger, H; Tognoni, G; Patrono, C; Barbui, T; Landolfi, R; Marchioli, R; Kutti, J; Gisslinger, H; Tognoni, G; Patrono, C; Barbui, T; Gisslinger, H; Barbui, T; Finazzi, G; Pusterla, S; Falanga, A; Galli, M; Kutti, J; Wadenvik, H; Gastl, G; Ludescher, C; Lutz, D; Girschikofsky, M; Michlmayr, G; Rechberger, E; Niessner, H; Ivansich, E; Rain, JD; Chommienne-Thomas, C; Hehlmann, R; Engelich, G; Kohne, E; Kramer, A; Christakis, JI; Papaioannou, M; Gerotziafas, G; O'Donnell, R; Bennett, M; Lugassy, G; Ellis, M; Eldor, A; Naparstek, E; Marilus, R; Leoni, P; Rupoli, S; Scortechini, AR; Agostini, V; Volpe, E; Calmieri, F; Volpe, A; Storti, G; Ciampa, A; Dammacco, F; Lauta, VM; Ranieri, G; Rizzi, R; Orsola, S; Tura, S; Finelli, C; Marino, G; Rossi, G; Almici, C; Capucci, A; Zanetti, F; Giustolisi, R; Cacciola, RR; Cacciola, E; Peta, A; Magro, D; Frigerio, G; Alberio, F; Beretta, A; Bonferroni, M; Raviolo, A; Ferrini, PRL; Grossi, A; Fabbri, A; Nardelli, S; Centra, A; Musolino, C; Bellomo, G; Trincali, O; Spatari, G; Foa, P; Gerli, G; Carraro, MC; Zanella, A; Lurlo, A; Barraco, F; Torelli, G; Marietta, M; Pogliani, E; Miccolis, IR; La Rocca, A; Puglisi, A; Sardeo, G; Rotoli, B; Martinelli, V; Ciancia, R; Cardarelli, A; Cimino, R; Fasanaro, A; Randi, ML; Rizzoli, V; Caramatti, C; Gaeta, L; Lazzarino, M; Passamonti, F; Lazzola, M; Malabarba, L; Natale, D; Pulini, S; Davi, G; Gugliotta, L; Ilariucci, F; Landolfi, R; De Candia, E; Eugenio, S; Amadori, S; Buccisano, F; Mandelli, F; Montefusco, E; Petti, MC; Spadea, A; Carotenuto, M; Morelli, A; Nobile, M; Longinotti, M; Pardini, SM; Lauria, F; Buccalossi, A; Gentili, S; Mazza, P; Cervellera, M; Maggi, A; Di Francesco, A; Pasqualoni, E; Chisesi, T; Polacco, A; Chisesi, T; Capnist, G; Rodeghiero, F; Ruggeri, M; Arrizabalaga, B; Remacha, A; De Mendiguren, BP; Hernandez-Nieto, L; Hernandez-Garcia, MT; Gonzalez-Brito, G; Machado, P; Garcia, G; Villegas, A; Pena, A; Fernandez, AG; Carbonell, F; Del Arco, A; Back, H; Stenke, L; Hansen, S; Larsson, G; Stromblad, G; Lauri, B; Ryden, BO; Linder, O; Lundholm, BG; Lannemyr, O; Strandberg, M; Andreasson, B; Stockelberg, D; Pasquariello, F; Tichelli, A; Otremba, B; Hinrichs, HF; Weber-Stadelmann, W; Bareford, D; Oscier, DG; Bowey, N; Taylor, PC; Landolfi, R; Barbui, T; de Gaetano, G; Marchioli, R; Najean, Y; Patrono, C; Pearson, TC; Marchioli, R; Di Blasio, A; Atashkar, S; Finazzi, G; Gisslinger, H; Mari, E; Tamayo, D; Tognoni, G; Borelli, G; Ferri, B; Marfisi, RM; Olivieri, M; Polidoro, A; Spoltore, R; Landolfi, R; Levantesi, G; Di Mascio, R; Finazzi, G; Miceli, G; Sperti, G; Correale, E; Vermjlen, J; Collins, R				Landolfi, R; Marchioli, R; Kutti, J; Gisslinger, H; Tognoni, G; Patrono, C; Barbui, T; Landolfi, R; Marchioli, R; Kutti, J; Gisslinger, H; Tognoni, G; Patrono, C; Barbui, T; Gisslinger, H; Barbui, T; Finazzi, G; Pusterla, S; Falanga, A; Galli, M; Kutti, J; Wadenvik, H; Gastl, G; Ludescher, C; Lutz, D; Girschikofsky, M; Michlmayr, G; Rechberger, E; Niessner, H; Ivansich, E; Rain, JD; Chommienne-Thomas, C; Hehlmann, R; Engelich, G; Kohne, E; Kramer, A; Christakis, JI; Papaioannou, M; Gerotziafas, G; O'Donnell, R; Bennett, M; Lugassy, G; Ellis, M; Eldor, A; Naparstek, E; Marilus, R; Leoni, P; Rupoli, S; Scortechini, AR; Agostini, V; Volpe, E; Calmieri, F; Volpe, A; Storti, G; Ciampa, A; Dammacco, F; Lauta, VM; Ranieri, G; Rizzi, R; Orsola, S; Tura, S; Finelli, C; Marino, G; Rossi, G; Almici, C; Capucci, A; Zanetti, F; Giustolisi, R; Cacciola, RR; Cacciola, E; Peta, A; Magro, D; Frigerio, G; Alberio, F; Beretta, A; Bonferroni, M; Raviolo, A; Ferrini, PRL; Grossi, A; Fabbri, A; Nardelli, S; Centra, A; Musolino, C; Bellomo, G; Trincali, O; Spatari, G; Foa, P; Gerli, G; Carraro, MC; Zanella, A; Lurlo, A; Barraco, F; Torelli, G; Marietta, M; Pogliani, E; Miccolis, IR; La Rocca, A; Puglisi, A; Sardeo, G; Rotoli, B; Martinelli, V; Ciancia, R; Cardarelli, A; Cimino, R; Fasanaro, A; Randi, ML; Rizzoli, V; Caramatti, C; Gaeta, L; Lazzarino, M; Passamonti, F; Lazzola, M; Malabarba, L; Natale, D; Pulini, S; Davi, G; Gugliotta, L; Ilariucci, F; Landolfi, R; De Candia, E; Eugenio, S; Amadori, S; Buccisano, F; Mandelli, F; Montefusco, E; Petti, MC; Spadea, A; Carotenuto, M; Morelli, A; Nobile, M; Longinotti, M; Pardini, SM; Lauria, F; Buccalossi, A; Gentili, S; Mazza, P; Cervellera, M; Maggi, A; Di Francesco, A; Pasqualoni, E; Chisesi, T; Polacco, A; Chisesi, T; Capnist, G; Rodeghiero, F; Ruggeri, M; Arrizabalaga, B; Remacha, A; De Mendiguren, BP; Hernandez-Nieto, L; Hernandez-Garcia, MT; Gonzalez-Brito, G; Machado, P; Garcia, G; Villegas, A; Pena, A; Fernandez, AG; Carbonell, F; Del Arco, A; Back, H; Stenke, L; Hansen, S; Larsson, G; Stromblad, G; Lauri, B; Ryden, BO; Linder, O; Lundholm, BG; Lannemyr, O; Strandberg, M; Andreasson, B; Stockelberg, D; Pasquariello, F; Tichelli, A; Otremba, B; Hinrichs, HF; Weber-Stadelmann, W; Bareford, D; Oscier, DG; Bowey, N; Taylor, PC; Landolfi, R; Barbui, T; de Gaetano, G; Marchioli, R; Najean, Y; Patrono, C; Pearson, TC; Marchioli, R; Di Blasio, A; Atashkar, S; Finazzi, G; Gisslinger, H; Mari, E; Tamayo, D; Tognoni, G; Borelli, G; Ferri, B; Marfisi, RM; Olivieri, M; Polidoro, A; Spoltore, R; Landolfi, R; Levantesi, G; Di Mascio, R; Finazzi, G; Miceli, G; Sperti, G; Correale, E; Vermjlen, J; Collins, R		European Collaboration Low Dose As	Efficacy and safety of low-dose aspirin in polycythemia vera	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; MYELOPROLIFERATIVE DISORDERS; MYOCARDIAL-INFARCTION; PLATELET ACTIVATION; DEATH; RISK; PREVENTION; THERAPY	Background: The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial. Methods: We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. Results: Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). Conclusions: Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment.	Univ Cattolica Sacro Cuore, Ist Med Interna & Geriatria, Sch Med, I-00168 Rome, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; Univ Vienna, Dept Hematol & Blood Coagulat, Vienna, Austria; Univ Roma La Sapienza, Rome, Italy; Osped Riuniti Bergamo, I-24100 Bergamo, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Sahlgrenska University Hospital; University of Vienna; Sapienza University Rome; Ospedali Riuniti di Bergamo	Landolfi, R (corresponding author), Univ Cattolica Sacro Cuore, Ist Med Interna & Geriatria, Sch Med, Largo Gemelli 8, I-00168 Rome, Italy.		De Candia, Erica/K-9632-2016; Lanas, Fernando/AAE-8842-2022; Cazzola, Mario/AAQ-8854-2021; ilariucci, fiorella/AAA-8256-2019; Passamonti, Francesco/AAB-2262-2022; Finelli, Carlo/AAB-9686-2019; Miceli, Gabriele/J-8908-2014; Landolfi, Raffaele/AAL-4496-2020	De Candia, Erica/0000-0003-0942-2819; Cazzola, Mario/0000-0001-6984-8817; ilariucci, fiorella/0000-0002-4279-3358; Passamonti, Francesco/0000-0001-8068-5289; Finelli, Carlo/0000-0001-9372-1197; Landolfi, Raffaele/0000-0002-7913-8576; Patrono, Carlo/0000-0002-6447-2424; Rizzi, Rita/0000-0002-2557-1235				Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barbui T, 1997, BRIT J HAEMATOL, V97, P453; BERK PD, 1986, SEMIN HEMATOL, V23, P132; CHIEVITZ E, 1962, ACTA MED SCAND, V172, P513; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P893; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Landolfi R, 1997, SEMIN THROMB HEMOST, V23, P473, DOI 10.1055/s-2007-996124; LANDOLFI R, 1992, BLOOD, V80, P1965; Landolfi R, 1997, THROMB HAEMOSTASIS, V78, P617; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; RIUNITI O, 1995, ANN INTERN MED, V123, P656, DOI 10.7326/0003-4819-123-9-199511010-00003; Streiff MB, 2002, BLOOD, V99, P1144, DOI 10.1182/blood.V99.4.1144; TARTAGLIA AP, 1986, SEMIN HEMATOL, V23, P172; Tefferi A, 1999, SEMIN HEMATOL, V36, P1; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; VEJAR M, 1990, THROMB HAEMOSTASIS, V63, P163; WALLENTIN L, 1990, LANCET, V336, P827	21	657	679	0	20	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					114	124		10.1056/NEJMoa035572	http://dx.doi.org/10.1056/NEJMoa035572			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711910				2022-12-28	WOS:000187858500005
J	Wald, NJ				Wald, NJ			Folic acid and the prevention of neural-tube defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, London, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, London, England.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					Mills JL, 2003, AM J CLIN NUTR, V77, P1474, DOI 10.1093/ajcn/77.6.1474; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Wald N, 2002, LANCET, V359, P630; WALD N, 1991, LANCET, V338, P131	4	84	94	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					101	103		10.1056/NEJMp038186	http://dx.doi.org/10.1056/NEJMp038186			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711907				2022-12-28	WOS:000187858500002
J	Paterson, DL; Ko, WC; Von Gottberg, A; Mohapatra, S; Casellas, JM; Goossens, H; Mulazimoglu, L; Trenholme, G; Klugman, KP; Bonomo, RA; Rice, LB; Wagener, MM; McCormack, JG; Yu, VL				Paterson, DL; Ko, WC; Von Gottberg, A; Mohapatra, S; Casellas, JM; Goossens, H; Mulazimoglu, L; Trenholme, G; Klugman, KP; Bonomo, RA; Rice, LB; Wagener, MM; McCormack, JG; Yu, VL			International prospective study Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial infections	ANNALS OF INTERNAL MEDICINE			English	Article							CEFTAZIDIME RESISTANCE; ANTIBIOTIC-RESISTANCE; OUTBREAK; THERAPY; EPIDEMIOLOGY; MONOTHERAPY; INHIBITORS	Background: Commonly encountered nosocomially acquired gram-negative bacteria, especially Klebsiella pneumoniae, produce extended-spectrum beta-lactamases (ESBLs) as an antibiotic resistance mechanism. Objective: To determine whether microbiology laboratories should report the presence of ESBLs and to establish the infection-control implications of ESBL-producing organisms. Design: Prospective observational study. Setting: 12 hospitals in South Africa, Taiwan, Australia, Argentina, the United States, Belgium, and Turkey. Patients: 440 patients with 455 consecutive episodes of K. pneumoniae bacteremia between 1 January 1996 and 31 December 1997; of these, 253 episodes were nosocomially acquired. Measurements: The K. pneumoniae isolates were examined for the presence of ESBLs. Pulsed-field gel electrophoresis was used to analyze the molecular epidemiology of nosocomial bacteremia with ESBL-producing K. pneumoniae. Results: Overall, 30.8% (78 of 253) episodes of nosocomial bacteremia and 43.5% (30 of 69) episodes acquired in intensive care units were due to ESBL-producing organisms. After adjustment for potentially confounding variables, previous administration of beta-lactam antibiotics containing an oxyimino group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated with bacteremia due to ESBL-producing strains (risk ratio, 3.9 [95% Cl, 1.1 to 13.8]). In 7 of 10 hospitals with more than 1 ESBL-producing isolate, multiple strains with the same genotypic pattern were observed, indicating patient-to-patient spread of the organism. Conclusions: Production of ESBLs; by Klebsiella pneumoniae is a widespread nosocomial problem. Appropriate infection control and antibiotic management strategies are needed to stem the spread of this emerging form of resistance.	Vet Affairs Med Ctr, Infect Dis Sect, Pittsburgh, PA 15240 USA; Univ Queensland, Mater Adults Hosp, Brisbane, Qld, Australia; Natl Cheng Kung Univ, Coll Med, Dept Med, Tainan 70101, Taiwan; S African Inst Med Res, Johannesburg, South Africa; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Sanatorio San Lucas, Buenos Aires, DF, Argentina; Univ Antwerp Hosp, Antwerp, Belgium; Marmara Univ, Istanbul, Turkey; Vet Affairs Med Ctr, Cleveland, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Queensland; National Cheng Kung University; Rush University; University of Antwerp; Marmara University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Yu, VL (corresponding author), Vet Affairs Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.	vly+@pitt.edu	Ko, Wen-Chien/ABG-4316-2020; Paterson, David L/A-9258-2010	Ko, Wen-Chien/0000-0001-7497-149X; Paterson, David/0000-0003-2079-4437; von Gottberg, Anne/0000-0002-0243-7455				Amyes SGB, 1998, J ANTIMICROB CHEMOTH, V42, P415, DOI 10.1093/jac/42.4.415; CASELLAS JM, 1989, INFECTION, V17, P434, DOI 10.1007/BF01645567; CASEWELL MW, 1981, AM J MED, V70, P459, DOI 10.1016/0002-9343(81)90788-9; Chow JW, 1999, INT J ANTIMICROB AG, V11, P7, DOI 10.1016/S0924-8579(98)00060-0; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; COULTER C, 1995, AUST NZ J MED, V25, P572; EISEN D, 1995, J CLIN MICROBIOL, V33, P713, DOI 10.1128/JCM.33.3.713-717.1995; Gaillot O, 1998, J CLIN MICROBIOL, V36, P1357, DOI 10.1128/JCM.36.5.1357-1360.1998; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Hobson RP, 1996, J HOSP INFECT, V33, P249, DOI 10.1016/S0195-6701(96)90011-0; JACOBY GA, 1994, EUR J CLIN MICROBIOL, V13, P2, DOI 10.1007/BF02390679; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; KORVICK JA, 1992, ANTIMICROB AGENTS CH, V36, P2639, DOI 10.1128/AAC.36.12.2639; Leggiadro RJ, 1997, INFECT DIS CLIN N AM, V11, P875, DOI 10.1016/S0891-5520(05)70395-0; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; Monnet DL, 1997, INFECT CONT HOSP EP, V18, P492; *NAT COMM CLIN LAB, 1999, 9 INF S; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; Paterson DL, 2000, CLIN INFECT DIS, V30, P473, DOI 10.1086/313719; Paterson DL, 1999, CLIN INFECT DIS, V29, P1419, DOI 10.1086/313559; PAYNE DJ, 1990, J MED MICROBIOL, V32, P131, DOI 10.1099/00222615-32-2-131; Pena C, 1997, J HOSP INFECT, V35, P9, DOI 10.1016/S0195-6701(97)90163-8; Piroth L, 1998, CLIN INFECT DIS, V27, P76, DOI 10.1086/514643; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; Rice LB, 1996, CLIN INFECT DIS, V23, P118, DOI 10.1093/clinids/23.1.118; TENOVER FC, 1998, CLIN INFECT DIS, V27, P1064; 2000, MMWR MORB MORTAL WKL, V48, P1167	29	489	522	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					26	32		10.7326/0003-4819-140-1-200401060-00008	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706969				2022-12-28	WOS:000187855600004
J	Eddleston, M; Phillips, MR				Eddleston, M; Phillips, MR			Self poisoning with pesticides	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; SUICIDE; CHINA	WHO's recent recommendations on reducing deaths from self harm will not help cut the high death rate from self poisoning in the Asia Pacific region.	Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX1 2JD, England; Beijing Hui Long Guan Hosp, Beijing Suicide Res & Prevent Ctr, Beijing, Peoples R China	University of Oxford	Eddleston, M (corresponding author), Fac Med, Dept Clin Med, Ox Col Collaborat, POB 271,25 Kynsey Rd, Colombo 08, Sri Lanka.	eddlestonm@eureka.lk	Phillips, Michael Robert/AAE-7585-2021	Phillips, Michael Robert/0000-0002-5973-2439	Wellcome Trust [063560] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABEYASINGHE R, UNPUB COMMUNITY SURV; Bertolote JM, 2002, LANCET, V359, P2274, DOI 10.1016/S0140-6736(02)09268-1; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; Eddleston M, 2000, QJM-INT J MED, V93, P715, DOI 10.1093/qjmed/93.11.715; Eddleston M, 2003, LANCET, V362, P1041, DOI 10.1016/S0140-6736(03)14415-7; Eddleston M, 1999, TROP MED INT HEALTH, V4, P266, DOI 10.1046/j.1365-3156.1999.00397.x; Eddleston M, 2002, LANCET, V360, P1163, DOI 10.1016/S0140-6736(02)11204-9; Eddleston M, 1997, J CEYLON COLL PHYS, V30, P11; Gunnell D, 1999, LANCET, V353, P556, DOI 10.1016/S0140-6736(99)00408-0; GUNNELL D, IN PRESS EMERG MED J; GURURAJ G, 2001, PUBLICATION NATL I M, V43; Harris J, 1998, INTERDISCIPL SCI REV, V23, P1; HAWTON K, 1996, MEDICINE, V24, P77; [李献云 Li Xianyun], 2002, [中国心理卫生杂志, Chinese Mental Health Journal], V16, P681; Marecek J, 1998, SUICIDE LIFE-THREAT, V28, P69; *MIN HLTH, 2002, ANN HLTH B SRI LANK; *OFF NAT STAT, 2002, MORT STAT INJ POIS, P81; Phillips MR, 2002, LANCET, V360, P1728, DOI 10.1016/S0140-6736(02)11681-3; Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0; SOMASUNDARAM DJ, 1995, ACTA PSYCHIAT SCAND, V91, P1, DOI 10.1111/j.1600-0447.1995.tb09733.x; Teoh J., 1974, ANN ACADEMY MED SING, V3, P117; World Health Organization, 2002, WORLD REPORT VIOLENC; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Zhang B, 2000, SHANGHAI J PREV MED, V12, P282	24	337	356	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	2004	328	7430					42	44		10.1136/bmj.328.7430.42	http://dx.doi.org/10.1136/bmj.328.7430.42			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703547	Green Published			2022-12-28	WOS:000187919000024
J	Berkovitch, F; Nicolet, Y; Wan, JT; Jarrett, JT; Drennan, CL				Berkovitch, F; Nicolet, Y; Wan, JT; Jarrett, JT; Drennan, CL			Crystal structure of biotin synthase, an S-adenosylmethionine-dependent radical enzyme	SCIENCE			English	Article							LYASE ACTIVATING ENZYME; IRON-SULFUR CENTER; CLUSTER BINDING-SITES; ESCHERICHIA-COLI; RIBONUCLEOTIDE REDUCTASE; <4FE-4S>(2+) CLUSTER; 4FE-4S CLUSTERS; COENZYME B-12; IN-VITRO; MOSSBAUER	The crystal structure of biotin synthase from Escherichia coli in complex with S-adenosyl-L-methionine and dethiobiotin has been determined to 3.4 angstrom resolution. This structure addresses how "AdoMet radical" or "radical SAM" enzymes use Fe4S4 clusters and S-adenosyl-L-methionine to generate organic radicals. Biotin synthase catalyzes the radical-mediated insertion of sulfur into dethiobiotin to form biotin. The structure places the substrates between the Fe4S4 cluster, essential for radical generation, and the Fe2S2 cluster, postulated to be the source of sulfur, with both clusters in unprecedented coordination environments.	MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Johnson Res Fdn, Philadelphia, PA 19104 USA	Massachusetts Institute of Technology (MIT); University of Pennsylvania; University of Pennsylvania	Drennan, CL (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.		Yvain, Nicolet/AAP-9763-2020	Yvain, Nicolet/0000-0002-4189-7067; Jarrett, Joseph/0000-0002-3737-7464	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229, R01GM059175, R01GM065337] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059175, R01-GM65337, T32-GM07229, R01-GM59175] Funding Source: Medline; NINDS NIH HHS [NSLS X25] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aoki S, 2002, J AM CHEM SOC, V124, P5256, DOI 10.1021/ja020029y; Baranska M, 2002, J INORG BIOCHEM, V92, P112, DOI 10.1016/S0162-0134(02)00485-3; Benda R, 2002, BIOCHEMISTRY-US, V41, P15000, DOI 10.1021/bi026590q; Bui BTS, 2003, BIOCHEMISTRY-US, V42, P8791, DOI 10.1021/bi034426c; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Bui BTS, 1999, FEBS LETT, V459, P411, DOI 10.1016/S0014-5793(99)01300-9; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Cosper MM, 2003, PROTEIN SCI, V12, P1573, DOI 10.1110/ps.0302203; Cosper MM, 2002, FEBS LETT, V529, P332, DOI 10.1016/S0014-5793(02)03390-2; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; DeLano W.L, PYMOL MOL GRAPHICS S; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Escalettes F, 1999, J AM CHEM SOC, V121, P3571, DOI 10.1021/ja9811748; Fairlie DP, 1997, INORG CHEM, V36, P1020, DOI 10.1021/ic961138e; FREY PA, 1993, FASEB J, V7, P662, DOI 10.1096/fasebj.7.8.8500691; Frey PA, 2001, ADV PROTEIN CHEM, V58, P1; Frey PA, 2000, ARCH BIOCHEM BIOPHYS, V382, P6, DOI 10.1006/abbi.2000.2010; Hewitson KS, 2000, FEBS LETT, V466, P372, DOI 10.1016/S0014-5793(00)01101-7; Hewitson KS, 2002, J BIOL INORG CHEM, V7, P83, DOI 10.1007/s007750100268; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Masuda J, 2000, STRUCTURE, V8, P775, DOI 10.1016/S0969-2126(00)00164-7; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; Padovani D, 2001, BIOCHEMISTRY-US, V40, P6713, DOI 10.1021/bi002936q; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Ugulava NB, 2000, BIOCHEMISTRY-US, V39, P5206, DOI 10.1021/bi9926227; Ugulava NB, 2003, BIOCHEMISTRY-US, V42, P2708, DOI 10.1021/bi0261084; Ugulava NB, 2002, J AM CHEM SOC, V124, P9050, DOI 10.1021/ja027004j; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; Walsby CJ, 2002, J AM CHEM SOC, V124, P11270, DOI 10.1021/ja027078v; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s	41	326	334	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					76	79		10.1126/science.1088493	http://dx.doi.org/10.1126/science.1088493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704425	Green Accepted			2022-12-28	WOS:000187710600036
J	Forst, CJ; Ashman, CR; Schwarz, K; Blochl, PE				Forst, CJ; Ashman, CR; Schwarz, K; Blochl, PE			The interface between silicon and a high-k oxide	NATURE			English	Article							SI; GROWTH; FILMS; BA	The ability of the semiconductor industry to continue scaling microelectronic devices to ever smaller dimensions (a trend known as Moore's Law(1)) is limited by quantum mechanical effects: as the thickness of conventional silicon dioxide (SiO2) gate insulators is reduced to just a few atomic layers, electrons can tunnel directly through the films. Continued device scaling will therefore probably require the replacement of the insulator with high-dielectric-constant (high-k) oxides(2), to increase its thickness, thus preventing tunnelling currents while retaining the electronic properties of an ultrathin SiO2 film. Ultimately, such insulators will require an atomically defined interface with silicon without an interfacial SiO2 layer for optimal performance. Following the first reports of epitaxial growth of AO and ABO(3) compounds on silicon(3-7), the formation of an atomically abrupt crystalline interface between strontium titanate and silicon was demonstrated(8-10). However, the atomic structure proposed for this interface is questionable because it requires silicon atoms that have coordinations rarely found elsewhere in nature. Here we describe first-principles calculations of the formation of the interface between silicon and strontium titanate and its atomic structure. Our study shows that atomic control of the interfacial structure by altering the chemical environment can dramatically improve the electronic properties of the interface to meet technological requirements. The interface structure and its chemistry may provide guidance for the selection process of other high-k gate oxides and for controlling their growth.	Tech Univ Clausthal, Inst Theoret Phys, D-38678 Clausthal Zellerfeld, Germany; Vienna Univ Technol, Inst Mat Chem, A-1060 Vienna, Austria	TU Clausthal; Technische Universitat Wien	Blochl, PE (corresponding author), Tech Univ Clausthal, Inst Theoret Phys, Leibnitzstr 10, D-38678 Clausthal Zellerfeld, Germany.	peter.bloechl@tu-clausthal.de	Blöchl, Peter E/B-3448-2012	Blöchl, Peter E/0000-0002-1416-5207				Alexe M, 1998, APPL PHYS LETT, V72, P2283, DOI 10.1063/1.121337; ASHMAN C, IN PRESS PHYS REV B, V69; BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953; Chambers SA, 2001, J VAC SCI TECHNOL A, V19, P934, DOI 10.1116/1.1365132; Droopad R, 2001, J CRYST GROWTH, V227, P936, DOI 10.1016/S0022-0248(01)00931-9; FAN WC, 1990, PHYS REV B, V42, P1254, DOI 10.1103/PhysRevB.42.1254; GILLAN MJ, 1989, J PHYS-CONDENS MAT, V1, P689, DOI 10.1088/0953-8984/1/4/005; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; ISHIWARA H, 1988, MATER RES SOC S P, V116, P369; KADO Y, 1987, J APPL PHYS, V61, P2398, DOI 10.1063/1.337957; KIM TW, 1994, APPL PHYS LETT, V64, P2676, DOI 10.1063/1.111489; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Liang Y, 2001, APPL PHYS LETT, V79, P3591, DOI 10.1063/1.1415372; McKee RA, 1998, PHYS REV LETT, V81, P3014, DOI 10.1103/PhysRevLett.81.3014; McKee RA, 2001, SCIENCE, V293, P468, DOI 10.1126/science.293.5529.468; MCKEE RA, 1993, Patent No. 5225031; Moore G., 1965, ELECTRONICS, V38, P114, DOI [DOI 10.1109/N-SSC.2006.4785860, DOI 10.1109/JPROC.1998.658762]; MORI H, 1991, JPN J APPL PHYS 2, V30, pL1415, DOI 10.1143/JJAP.30.L1415; NOLAND JA, 1954, PHYS REV, V94, P724, DOI 10.1103/PhysRev.94.724; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Robertson J, 2003, MATER RES SOC SYMP P, V747, P99; Robertson J, 2000, J VAC SCI TECHNOL B, V18, P1785, DOI 10.1116/1.591472; Semiconductor Industry Association, 2001, INT TECHN ROADM SEM; Wang J, 1999, PHYS REV B, V60, P4968, DOI 10.1103/PhysRevB.60.4968; WANG J, 2001, Patent No. 6238459; Yao X, 1999, PHYS REV B, V59, P5115, DOI 10.1103/PhysRevB.59.5115; Zhang X, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.125323	28	263	266	3	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					53	56		10.1038/nature02204	http://dx.doi.org/10.1038/nature02204			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702081	Green Submitted			2022-12-28	WOS:000187710000030
J	Saltiel, AR				Saltiel, AR			Putting the brakes on insulin signaling	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a	5	27	29	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2560	2562		10.1056/NEJMcibr031668	http://dx.doi.org/10.1056/NEJMcibr031668			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695419				2022-12-28	WOS:000187529500015
J	Lewer, N				Lewer, N			Non-lethal weapons: operational and policy developments	LANCET			English	Article									Univ Bradford, Dept Peace Studies, Ctr Conflict Resolut, Bradford BD7 1DP, W Yorkshire, England; Univ Bradford, Nonlethal Weap Res Project, Bradford BD7 1DP, W Yorkshire, England	University of Bradford; University of Bradford	Lewer, N (corresponding author), Univ Bradford, Dept Peace Studies, Ctr Conflict Resolut, Bradford BD7 1DP, W Yorkshire, England.							*NAT RES COUNC NAT, 2003, ASS NONL WEAP SCI TE; Nick Lewer, 2002, FUTURE NONLETHAL WEA; RAPPERT B, 2003, NONLETHAL WEAPONS LE	3	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S20	S21		10.1016/S0140-6736(03)15061-1	http://dx.doi.org/10.1016/S0140-6736(03)15061-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698115	Bronze			2022-12-28	WOS:000187790200011
J	Todd, R				Todd, R			Health and safety in hostile environments	LANCET			English	Article									BBC Technol, Televis Ctr, London W12 7RJ, England		Todd, R (corresponding author), BBC Technol, Televis Ctr, Wood Lane, London W12 7RJ, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S54	S55		10.1016/S0140-6736(03)15078-7	http://dx.doi.org/10.1016/S0140-6736(03)15078-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698132				2022-12-28	WOS:000187790200028
J	Dobberstein, B; Sinning, I				Dobberstein, B; Sinning, I			Surprising news from the PCC	SCIENCE			English	Editorial Material							PROTEIN-CONDUCTING CHANNEL; ENDOPLASMIC-RETICULUM; ER MEMBRANE; COMPLEX; TRANSLOCATION; INTEGRATION; TRANSPORT; BILAYER; SECYEG		Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Dobberstein, B (corresponding author), Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany.		Sinning, Irmgard/A-2982-2010					Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Locher KP, 2003, SCIENCE, V301, P603, DOI 10.1126/science.1088621; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Morgan DG, 2002, J MOL BIOL, V324, P871, DOI 10.1016/S0022-2836(02)01111-7; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393	16	6	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					320	322		10.1126/science.1094664	http://dx.doi.org/10.1126/science.1094664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726579				2022-12-28	WOS:000188111800027
J	Lecuit, M; Abachin, E; Martin, A; Poyart, C; Pochart, P; Suarez, F; Bengoufa, D; Feuillard, J; Lavergne, A; Gordon, JI; Berche, P; Guillevin, L; Lortholary, O				Lecuit, M; Abachin, E; Martin, A; Poyart, C; Pochart, P; Suarez, F; Bengoufa, D; Feuillard, J; Lavergne, A; Gordon, JI; Berche, P; Guillevin, L; Lortholary, O			Immunoproliferative small intestinal disease associated with Campylobacter jejuni	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-CHAIN DISEASE; HELICOBACTER-PYLORI; LYMPHOID-TISSUE; IDENTIFICATION; HYBRIDIZATION; COLONIZATION; ERADICATION; REGRESSION; INFECTION; EMPHASIS	BACKGROUND: Immunoproliferative small intestinal disease (also known as alpha chain disease) is a form of lymphoma that arises in small intestinal mucosa-associated lymphoid tissue (MALT) and is associated with the expression of a monotypic truncated immunoglobulin (alpha) heavy chain without an associated light chain. Early-stage disease responds to antibiotics, suggesting a bacterial origin. We attempted to identify a causative agent. METHODS: We performed polymerase chain reaction (PCR), DNA sequencing, fluorescence in situ hybridization, and immunohistochemical studies on intestinal-biopsy specimens from a series of patients with immunoproliferative small intestinal disease. RESULTS: Analysis of frozen intestinal tissue obtained from an index patient with immunoproliferative small intestinal disease who had a dramatic response to antibiotics revealed the presence of Campylobacter jejuni. A follow-up retrospective analysis of archival intestinal-biopsy specimens disclosed campylobacter species in four of six additional patients with immunoproliferative small intestinal disease. CONCLUSIONS: These results indicate that campylobacter and immunoproliferative small intestinal disease are associated and that C. jejuni should be added to the growing list of human pathogens responsible for immunoproliferative states.	Hop Avicenne, Paris, France; Inst Pasteur, Paris, France; Hop Necker Enfants Malad, Paris, France; Conservatoire Natl Arts & Metiers, Paris, France; Hop St Louis, Paris, France; Washington Univ, Sch Med, St Louis, MO USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; heSam Universite; Conservatoire National Arts & Metiers (CNAM); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Washington University (WUSTL)	Lecuit, M (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, Serv Malad Infect & Trop, 149 Rue Sevres, F-75743 Paris 15, France.		Lecuit, Marc/J-4073-2013; Lecuit, Marc/M-4126-2019; POYART, Claire/P-4225-2017; Feuillard, Jean/O-8587-2016	Lecuit, Marc/0000-0002-4491-1063; Lecuit, Marc/0000-0002-4491-1063; POYART, Claire/0000-0003-2158-6293; ABACHIN, ERIC/0000-0002-3794-2371; Feuillard, Jean/0000-0001-6223-2454				BOOSINGER TR, 1988, AM J VET RES, V49, P456; Coker AO, 2002, EMERG INFECT DIS, V8, P237, DOI 10.3201/eid0803.010233; FAUCHERE JL, 1985, J MED MICROBIOL, V20, P215, DOI 10.1099/00222615-20-2-215; Fischbach W, 1997, LANCET, V349, P31, DOI 10.1016/S0140-6736(05)62165-4; GALIAN A, 1977, CANCER-AM CANCER SOC, V39, P2081, DOI 10.1002/1097-0142(197705)39:5<2081::AID-CNCR2820390526>3.0.CO;2-E; GREISEN K, 1994, J CLIN MICROBIOL, V32, P335, DOI 10.1128/JCM.32.2.335-351.1994; HARZIC M, 1985, GASTROEN CLIN BIOL, V9, P472; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; ISAACSON PG, 1989, AM J SURG PATHOL, V13, P1023, DOI 10.1097/00000478-198912000-00004; ISAACSON PG, 1994, EXTRANODAL LYMPHOMAS, P340; Kwok AYC, 1999, INT J SYST BACTERIOL, V49, P1181, DOI 10.1099/00207713-49-3-1181; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Linton D, 1997, J CLIN MICROBIOL, V35, P2568, DOI 10.1128/JCM.35.10.2568-2572.1997; Malekzadeh R, 1999, ARCH IRAN MED, V2, P1; MONTONE KT, 1995, AM J CLIN PATHOL, V103, P48, DOI 10.1093/ajcp/103.1.48; NEWELL DG, 1986, J HYG-CAMBRIDGE, V96, P131, DOI 10.1017/S0022172400065906; OGRA PL, 1999, MUCOSAL IMMUNOLOGY, V1; Pagano JS, 2002, NEW ENGL J MED, V347, P78, DOI 10.1056/NEJMp020056; PONKA A, 1984, INFECTION, V12, P175, DOI 10.1007/BF01640893; Puri A S, 1992, Indian J Gastroenterol, V11, P141; Rambaud JC, 1994, HDB MUCOSAL IMMUNOLO, P425; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROLLINS DM, 1986, APPL ENVIRON MICROB, V52, P531, DOI 10.1128/AEM.52.3.531-538.1986; Rossello-Mora R, 2001, FEMS MICROBIOL REV, V25, P39, DOI 10.1016/S0168-6445(00)00040-1; SALEM P, 1986, CANCER-AM CANCER SOC, V58, P1162, DOI 10.1002/1097-0142(19860901)58:5<1162::AID-CNCR2820580531>3.0.CO;2-8; SELIGMANN M, 1968, SCIENCE, V162, P1396, DOI 10.1126/science.162.3860.1396; Skirrow Martin B., 1995, P825; SUERBAUM S, 1993, J BACTERIOL, V175, P3278, DOI 10.1128/jb.175.11.3278-3288.1993; Trebesius K, 2000, GUT, V46, P608, DOI 10.1136/gut.46.5.608; Waller DF, 2000, APPL ENVIRON MICROB, V66, P4115, DOI 10.1128/AEM.66.9.4115-4118.2000; WEISS LM, 1991, J HISTOCHEM CYTOCHEM, V39, P1237, DOI 10.1177/39.9.1918942; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Yodoi J, 1987, Int Rev Immunol, V2, P117, DOI 10.3109/08830188709044750	35	315	326	0	20	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					239	248		10.1056/NEJMoa031887	http://dx.doi.org/10.1056/NEJMoa031887			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724303				2022-12-28	WOS:000188078400007
J	Maguire, JH				Maguire, JH			Tapeworms and seizures - Treatment and prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Dis Control & Prevent, Parasit Dis Epidemiol Branch, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Maguire, JH (corresponding author), Ctr Dis Control & Prevent, Parasit Dis Epidemiol Branch, Atlanta, GA 30333 USA.								0	18	18	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					215	217		10.1056/NEJMp038204	http://dx.doi.org/10.1056/NEJMp038204			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724299				2022-12-28	WOS:000188078400003
J	Wong, BCY; Lam, SK; Wong, WM; Chen, JS; Zheng, TT; Feng, RE; Lai, KC; Hu, WHC; Yuen, ST; Leung, SY; Fong, DYT; Ho, J; Ching, CK; Chen, JS				Wong, BCY; Lam, SK; Wong, WM; Chen, JS; Zheng, TT; Feng, RE; Lai, KC; Hu, WHC; Yuen, ST; Leung, SY; Fong, DYT; Ho, J; Ching, CK; Chen, JS		China Gastric Canc Study Grp	Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION; ASSOCIATION; CARCINOMA	Context Although chronic Helicobacter pylori infection is associated with gastric cancer, the effect of H pylori treatment on prevention of gastric cancer development in chronic carriers is unknown. Objective To determine whether treatment of H pylori infection reduces the incidence of gastric cancer. Design, Setting, and Participants Prospective, randomized, placebo-controlled, population-based primary prevention study of 1630 healthy carriers of H pylori infection from Fujian Province, China, recruited in July 1994 and followed up until January 2002. A total of 988 participants did not have precancerous lesions (gastric atrophy, intestinal metaplasia, or gastric dysplasia) on study entry. Intervention Patients were randomly assigned to receive H pylori eradication treatment: a 2-week course of omeprazole, 20 mg, a combination product of amoxicillin and clavulanate potassium, 750 mg, and metronidazole, 400 mg, all twice daily (n=817); or placebo (n=813). Main Outcome Measures The primary outcome measure was incidence of gastric cancer during follow-up, compared between H pylori eradication and placebo groups. The secondary outcome measure was incidence of gastric cancer in patients with or without precancerous lesions, compared between the 2 groups. Results Among the 18 new cases of gastric cancers that developed, no overall reduction was observed in participants who received H pylori eradication treatment (n=7) compared with those who did not (n=11) (P=.33). In a subgroup of patients with no precancerous lesions on presentation, no patient developed gastric cancer during a follow-up of 7.5 years after H pylori eradication treatment compared with those who received placebo (0 vs 6; P=.02). Smoking (hazard ratio [HR], 6.2; 95% confidence interval [CI] 2.3-16.5; P<.001) and older age (HR, 1.10; 95% CI, 1.05-1.15; P<.001) were independent risk factors for the development of gastric cancer in this cohort. Conclusions We found that the incidence of gastric cancer development at the population level was similar between participants receiving H pylori eradication treatment and those receiving placebo during a period of 7.5 years in a high-risk region of China. In the subgroup of H pylori carriers without precancerous lesions, eradication of H pylori significantly decreased the development of gastric cancer. Further studies to investigate the role of H pylori eradication in participants with precancerous lesions are warranted.	Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China; Changle Inst Canc Res, Fujian, Peoples R China; Chinese Acad Prevent Med, Inst Nutr & Food Hyg, Beijing, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; Chinese Center for Disease Control & Prevention; National Institute for Nutrition & Health, Chinese Center for Disease Control & Prevention	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	bcywong@hku.hk	Wong, Benjamin Chun Yu/C-4436-2009; Fong, Daniel YT/C-4269-2009; Yuen, Siu/K-6311-2014; Wong, Benjamin Chun Yu/ABB-1962-2020; Leung, Suet Yi/C-4340-2009; Leung, Suet Yi/T-9620-2019	Fong, Daniel YT/0000-0001-7365-9146; Leung, Suet Yi/0000-0001-8614-4619				Chen J., 1992, FUJIAN MED COLL J, V26, P1168; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; CORREA P, 1988, CANCER RES, V48, P3554; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Eslick GD, 1999, AM J GASTROENTEROL, V94, P2373, DOI 10.1111/j.1572-0241.1999.01360.x; FONTHAM ETH, 1995, AM J GASTROENTEROL, V90, P1094; FORMAN D, 1993, LANCET, V341, P1359; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; FUKUDA H, 1995, JPN J CANCER RES, V86, P64, DOI 10.1111/j.1349-7006.1995.tb02989.x; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, V61, P177; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Rugge M, 1996, DIGEST DIS SCI, V41, P950, DOI 10.1007/BF02091536; SanzOrtega J, 1996, PATHOL RES PRACT, V192, P1206, DOI 10.1016/S0344-0338(96)80152-X; SIPPONEN P, 1993, SCAND J GASTROENTERO, V28, P3, DOI 10.3109/00365529309098333; SIPPONEN P, 1994, EUR J GASTROEN HEPAT, V6, pS79; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; Tsubono Y, 2001, NEW ENGL J MED, V344, P632, DOI 10.1056/NEJM200103013440903; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Uemura N, 1997, CANCER EPIDEM BIOMAR, V6, P639; Wong BCY, 1999, J GASTROEN HEPATOL, V14, P120, DOI 10.1046/j.1440-1746.1999.01823.x; Wong BCY, 2001, ALIMENT PHARM THERAP, V15, P505, DOI 10.1046/j.1365-2036.2001.00947.x; Wong BCY, 1999, ALIMENT PHARM THER, V13, P1295; Wong WM, 2000, ALIMENT PHARM THER, V14, P1353, DOI 10.1046/j.1365-2036.2000.00843.x; Wright NA, 1998, HELICOBACTER PYLORI, P325; You WC, 2000, J NATL CANCER I, V92, P1607, DOI 10.1093/jnci/92.19.1607	27	1046	1147	2	63	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					187	194		10.1001/jama.291.2.187	http://dx.doi.org/10.1001/jama.291.2.187			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722144	Bronze			2022-12-28	WOS:000188040900026
J	Jefferis, GSXE; Komiyama, T; Luo, LQ				Jefferis, GSXE; Komiyama, T; Luo, LQ			Calcium and CREST for healthy dendrites	SCIENCE			English	Editorial Material							CAM KINASE-IV; TRANSCRIPTION FACTORS; NEURONS		Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Neurosci Program, Stanford, CA 94305 USA	Stanford University; Stanford University	Jefferis, GSXE (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		Jefferis, Gregory/C-6386-2012	Komiyama, Takaki/0000-0001-9609-4600; Luo, Liqun/0000-0001-5467-9264; Jefferis, Gregory/0000-0002-0587-9355				Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Grueber WB, 2003, CELL, V112, P805, DOI 10.1016/S0092-8674(03)00160-0; Komiyama T, 2003, CELL, V112, P157, DOI 10.1016/S0092-8674(03)00030-8; Moore AW, 2002, SCIENCE, V297, P1355, DOI 10.1126/science.1072387; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Scott EK, 2001, NAT NEUROSCI, V4, P359, DOI 10.1038/86006; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987	9	4	4	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					179	181		10.1126/science.1093472	http://dx.doi.org/10.1126/science.1093472			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14715999				2022-12-28	WOS:000187908500033
J	Spivak, J				Spivak, J			Daily aspirin - Only half the answer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Div Hematol, Baltimore, MD 21218 USA	Johns Hopkins University	Spivak, J (corresponding author), Johns Hopkins Univ, Sch Med, Div Hematol, Baltimore, MD 21218 USA.								0	14	14	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					99	101		10.1056/NEJMp038177	http://dx.doi.org/10.1056/NEJMp038177			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711906				2022-12-28	WOS:000187858500001
J	Merenstein, D				Merenstein, D			Winners and losers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71	1	89	89	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					15	16		10.1001/jama.291.1.15	http://dx.doi.org/10.1001/jama.291.1.15			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709561				2022-12-28	WOS:000187836000001
J	Rosenson, J; Tabas, JA; Patterson, P				Rosenson, J; Tabas, JA; Patterson, P			Teaching invasive procedures to medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SKILLS IMPROVES; PATIENT SAFETY; RECENTLY DEAD; EMERGENCY; PERFORMANCE; COMPETENCE; MODELS		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rosenson, J (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							*AM MED ASS COUNC, 2002, ACAD MED, V77, P1212; Custalow CB, 2002, ACAD EMERG MED, V9, P575, DOI 10.1197/aemj.9.6.575; Denny CJ, 1999, J EMERG MED, V17, P949, DOI 10.1016/S0736-4679(99)00121-3; Engum SA, 2003, AM J SURG, V186, P67, DOI 10.1016/S0002-9610(03)00109-0; Fourre MW, 2002, ACAD EMERG MED, V9, P595, DOI 10.1197/aemj.9.6.595; Homan C S, 1994, Acad Emerg Med, V1, P382; Hudson T S, 2000, JONAS Healthc Law Ethics Regul, V2, P22, DOI 10.1097/00128488-200002010-00005; ISERSON KV, 1993, J MED ETHICS, V19, P92, DOI 10.1136/jme.19.2.92; Ludmerer K., 1999, TIME HEAL AM MED ED; Martin M, 2003, AM SURGEON, V69, P437; Martin M, 1998, SURGERY, V124, P313, DOI 10.1016/S0039-6060(98)70136-9; McCarthy MC, 2002, J AM COLL SURGEONS, V195, P627, DOI 10.1016/S1072-7515(02)01337-6; NELSON MS, 1990, ANN EMERG MED, V19, P333, DOI 10.1016/S0196-0644(05)82058-X; Oxentenko AS, 2003, TEACH LEARN MED, V15, P127, DOI 10.1207/S15328015TLM1502_10; WEAVER ME, 1986, MED EDUC, V5, P407	15	5	5	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					119	120		10.1001/jama.291.1.119	http://dx.doi.org/10.1001/jama.291.1.119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709587				2022-12-28	WOS:000187836000029
J	Bartlett, LA; Purdin, S; McGinn, T				Bartlett, LA; Purdin, S; McGinn, T			Forced migrants - turning rights into reproductive health	LANCET			English	Article									CDCP, Maternal & Infant Hlth Branch, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, New York, NY USA	Centers for Disease Control & Prevention - USA; Columbia University	Bartlett, LA (corresponding author), CDCP, Maternal & Infant Hlth Branch, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.		McGinn, Therese J/B-3280-2009					[Anonymous], 1996, GLOBAL BURDEN DIS CO; BARTLETT L, 2001, LANCET, V359, P639; CASEY S, 2003, REPR HLTH RESP CONFL; Hynes M, 2002, JAMA-J AM MED ASSOC, V288, P595, DOI 10.1001/jama.288.5.595; KEELY CB, IN PRESS ROUNDTABLE; Swiss S, 1998, JAMA-J AM MED ASSOC, V279, P625, DOI 10.1001/jama.279.8.625; US Committee for Refugees, 2001, WORLD REF SURV 2001; *WHO UNFPA UNICEF, 1999, REPR HLTH REF SETT I	8	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					76	77		10.1016/S0140-6736(03)15181-1	http://dx.doi.org/10.1016/S0140-6736(03)15181-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14724006				2022-12-28	WOS:000187711300035
J	Collins, SJ; Lawson, VA; Masters, CL				Collins, SJ; Lawson, VA; Masters, CL			Transmissible spongiform encephalopathies	LANCET			English	Review							CREUTZFELDT-JAKOB-DISEASE; FATAL FAMILIAL INSOMNIA; PRION PROTEIN GENE; PHENOTYPIC VARIABILITY; SCRAPIE PATHOGENESIS; CEREBROSPINAL-FLUID; TRANSGENIC MICE; INCUBATION-TIME; UNITED-KINGDOM; COPPER-BINDING	Nosologically, transmissible spongiform encephalopathies (TSE or prion diseases) should be grouped with other neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, which are all caused by toxic gain of function of an aberrant form of a constitutively expressed protein. Failure to clear these proteins from the brain induces neuronal dysfunction. Transmissibility is the property that separates TSE from other neurodegenerative diseases, and this property seems to reside within the structure of the abnormal protein. The human phenotypic range of these encephalopathies includes Creutzfeldt-Jakob disease and its variant form, kuru, Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia. Notwithstanding the generally low incidence of TSE and their limited infectiousness, major epidemics such as bovine spongiform encephalopathy and kuru arise in situations where intraspecies recycling of the abnormal protein is sustained. Moreover, evidence of chronic subclinical infection in animals offers insights into pathogenesis and prompts re-evaluation of the notion of species barriers and present infection control measures. Since case-to-case transmission is the only known mechanism underlying epidemics of TSE, potential reservoirs of infectivity in the tails of epidemics need continued vigilance.	Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Australian Natl Creutzfeldt Jakob Dis Registry, Melbourne, Vic, Australia; Mental Hlth Res Inst Victoria, Melbourne, Vic, Australia	University of Melbourne	Collins, SJ (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	stevenjc@unimelb.edu.au	Lawson, Victoria/AAJ-7392-2021	Lawson, Victoria/0000-0002-7362-7176				ANDREWS NJ, 2003, INCIDENCE VARIANT CR; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Barret A, 2003, J VIROL, V77, P8462, DOI 10.1128/JVI.77.15.8462-8469.2003; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Beaudry P, 1999, DEMENT GERIATR COGN, V10, P40, DOI 10.1159/000017095; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bosque PJ, 2002, P NATL ACAD SCI USA, V99, P3812, DOI 10.1073/pnas.052707499; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Brown P, 2002, NEUROLOGY, V58, P1720, DOI 10.1212/WNL.58.12.1720; Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Cervenakova L, 1998, P NATL ACAD SCI USA, V95, P13239, DOI 10.1073/pnas.95.22.13239; Collie DA, 2001, CLIN RADIOL, V56, P726, DOI 10.1053/crad.2001.0771; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; Collins S, 2002, ANN NEUROL, V52, P115, DOI 10.1002/ana.10224; Collins S, 2002, NEUROLOGY, V59, P1365, DOI 10.1212/01.WNL.0000031793.11602.8C; Collins S, 2001, J CLIN NEUROSCI, V8, P387, DOI 10.1054/jocn.2001.0919; Collins SJ, 2002, ANN NEUROL, V52, P503, DOI 10.1002/ana.10336; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; d'Aignaux JNH, 2001, SCIENCE, V294, P1729, DOI 10.1126/science.1064748; Dagvadorj A, 2002, ANN NEUROL, V52, P355, DOI 10.1002/ana.10267; Daude N, 2003, J CELL SCI, V116, P2775, DOI 10.1242/jcs.00494; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; DOHURA K, 1991, NATURE, V353, P801, DOI 10.1038/353801b0; Donnelly CA, 2002, P ROY SOC B-BIOL SCI, V269, P2179, DOI 10.1098/rspb.2002.2156; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Frigg R, 1999, J VIROL, V73, P9584, DOI 10.1128/JVI.73.11.9584-9588.1999; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Garnett AP, 2003, J BIOL CHEM, V278, P6795, DOI 10.1074/jbc.M209280200; Glatzel M, 2002, LANCET, V360, P139, DOI 10.1016/S0140-6736(02)09384-4; Glatzel M, 2003, NEW ENGL J MED, V349, P1812, DOI 10.1056/NEJMoa030351; GOLDFARB LG, 1991, EUR J EPIDEMIOL, V7, P477, DOI 10.1007/BF00143125; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Green AJE, 2001, J NEUROL NEUROSUR PS, V70, P744, DOI 10.1136/jnnp.70.6.744; Guinan E, 1998, B I PASTEUR, V96, P207; HADLOW WJ, 1959, LANCET, V2, P289; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Kaneko K, 2000, J MOL BIOL, V295, P997, DOI 10.1006/jmbi.1999.3386; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KLITZMAN R L, 1984, Neuroepidemiology, V3, P3, DOI 10.1159/000110837; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Lee HS, 2001, J INFECT DIS, V183, P192, DOI 10.1086/317935; Lewis V, 2003, NEUROLOGY, V60, P1620, DOI 10.1212/01.WNL.0000065887.14609.0E; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; MASTERS CL, 1976, J NEUROPATH EXP NEUR, V35, P593, DOI 10.1097/00005072-197611000-00001; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; Mastrianni JA, 1999, NEW ENGL J MED, V340, P1630, DOI 10.1056/NEJM199905273402104; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; McLean CA, 1997, NEUROLOGY, V49, P552, DOI 10.1212/WNL.49.2.552; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MEDORI R, 1992, NEUROLOGY, V42, P669, DOI 10.1212/WNL.42.3.669; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; NIETO A, 1991, LANCET, V337, P622, DOI 10.1016/0140-6736(91)91696-R; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Otto M, 2002, NEUROLOGY, V58, P192, DOI 10.1212/WNL.58.2.192; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PERANI D, 1993, NEUROLOGY, V43, P2565, DOI 10.1212/WNL.43.12.2565; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Priola SA, 2001, J VIROL, V75, P4673, DOI 10.1128/JVI.75.10.4673-4680.2001; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Race R, 2002, J INFECT DIS, V186, pS166, DOI 10.1086/344267; Race R, 2001, J VIROL, V75, P10106, DOI 10.1128/JVI.75.21.10106-10112.2001; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Rutala WA, 2001, CLIN INFECT DIS, V32, P1348, DOI 10.1086/319997; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; Sanchez-Valle R, 2002, NEUROSCI LETT, V320, P69, DOI 10.1016/S0304-3940(02)00045-9; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; Spencer MD, 2002, BRIT MED J, V324, P1479, DOI 10.1136/bmj.324.7352.1479; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; Stern K, 1939, BRAIN, V62, P157, DOI 10.1093/brain/62.2.157; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; Taylor DM, 2000, VET J, V159, P10, DOI 10.1053/tvjl.1999.0406; Thackray AM, 2002, J VIROL, V76, P2510, DOI 10.1128/JVI.76.5.2510-2517.2002; *UK CREUTZF JAK DI, CJD STAT; Valleron AJ, 2001, SCIENCE, V294, P1726, DOI 10.1126/science.1066838; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Ward HJT, 2002, NEUROLOGY, V59, P543, DOI 10.1212/WNL.59.4.543; Watts J, 2001, LANCET, V358, P991; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Will RG, 2000, ANN NEUROL, V47, P575; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1998, ANN NEUROL, V43, P763, DOI 10.1002/ana.410430611; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zerr I, 2000, NEUROLOGY, V55, P811, DOI 10.1212/WNL.55.6.811; Zerr I, 1998, NEUROLOGY, V51, P1398, DOI 10.1212/WNL.51.5.1398; ZIGAS V, 1957, Med J Aust, V44, P745; Zobeley E, 1999, MOL MED, V5, P240, DOI 10.1007/BF03402121	128	171	183	2	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					51	61		10.1016/S0140-6736(03)15171-9	http://dx.doi.org/10.1016/S0140-6736(03)15171-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723996				2022-12-28	WOS:000187711300025
J	Miley, GK; Overzier, RA; Tsvetanov, ZI; Bouwens, RJ; Benitez, N; Blakeslee, JP; Ford, HC; Illingworth, GD; Postman, M; Rosati, P; Clampin, M; Hartig, GF; Zirm, AW; Rottgering, HJA; Venemans, BP; Ardila, DR; Bartko, F; Broadhurst, TJ; Brown, RA; Burrows, CJ; Cheng, ES; Cross, NJG; De Breuck, C; Feldman, PD; Franx, M; Golimowski, DA; Gronwall, C; Infante, L; Martel, AR; Menanteau, F; Meurer, GR; Sirianni, M; Kimble, RA; Krist, JE; Sparks, WB; Tran, HD; White, RL; Zheng, W				Miley, GK; Overzier, RA; Tsvetanov, ZI; Bouwens, RJ; Benitez, N; Blakeslee, JP; Ford, HC; Illingworth, GD; Postman, M; Rosati, P; Clampin, M; Hartig, GF; Zirm, AW; Rottgering, HJA; Venemans, BP; Ardila, DR; Bartko, F; Broadhurst, TJ; Brown, RA; Burrows, CJ; Cheng, ES; Cross, NJG; De Breuck, C; Feldman, PD; Franx, M; Golimowski, DA; Gronwall, C; Infante, L; Martel, AR; Menanteau, F; Meurer, GR; Sirianni, M; Kimble, RA; Krist, JE; Sparks, WB; Tran, HD; White, RL; Zheng, W			A large population of 'Lyman-break' galaxies in a protocluster at redshift z approximate to 4.1	NATURE			English	Article							SPECTRUM RADIO-SOURCES; PROTO-CLUSTER; EVOLUTION; Z-SIMILAR-TO-3	The most massive galaxies and the richest clusters are believed to have emerged from regions with the largest enhancements of mass density(1-4) relative to the surrounding space. Distant radio galaxies may pinpoint the locations of the ancestors of rich clusters, because they are massive systems associated with 'over-densities' of galaxies that are bright in the Lyman-alpha line of hydrogen(5-7). A powerful technique for detecting high-redshift galaxies is to search for the characteristic 'Lyman break' feature in the galaxy colour, at wavelengths just shortwards of Lyalpha, which is due to absorption of radiation from the galaxy by the intervening intergalactic medium. Here we report multicolour imaging of the most distant candidate(7-9) protocluster, TNJ1338-1942 at a redshift zapproximate to4.1. We find a large number of objects with the characteristic colours of galaxies at that redshift, and we show that this excess is concentrated around the targeted dominant radio galaxy. Our data therefore indicate that TNJ1338-1942 is indeed the most distant cluster progenitor of a rich local cluster, and that galaxy clusters began forming when the Universe was only ten per cent of its present age.	Leiden Univ, Leiden Observ, NL-2300 RA Leiden, Netherlands; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Univ Calif Santa Cruz, Lick Observ, Santa Cruz, CA 95064 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; European So Observ, D-85748 Garching, Germany; Bartko Sci & Technol, Mead, CO 80542 USA; Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Pontificia Univ Catolica Chile, Dept Astron & Astrofis, Santiago 22, Chile	Leiden University; Leiden University - Excl LUMC; Johns Hopkins University; University of California System; University of California Santa Cruz; Space Telescope Science Institute; European Southern Observatory; Hebrew University of Jerusalem; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Pontificia Universidad Catolica de Chile	Miley, GK (corresponding author), Leiden Univ, Leiden Observ, POB 9513, NL-2300 RA Leiden, Netherlands.	miley@strw.leidenuniv.nl	Clampin, mark/D-2738-2012; Broadhurst, Thomas/AAF-9891-2019; Rosati, Piero/ABI-7507-2020; Overzier, Roderik/U-1473-2019; Benitez, Narciso/C-2065-2017	Broadhurst, Thomas/0000-0002-8785-8979; Overzier, Roderik/0000-0002-8214-7617; Menanteau, Felipe/0000-0002-1372-2534; De Breuck, Carlos/0000-0002-6637-3315; White, Richard/0000-0002-9194-2807; Gronwall, Caryl/0000-0001-6842-2371; Meurer, Gerhardt/0000-0002-0163-2507; Ardila, David/0000-0002-2564-8116; Benitez, Narciso/0000-0002-0403-7455; Illingworth, Garth/0000-0002-8096-2837; Blakeslee, John/0000-0002-5213-3548				Bahcall NA, 1998, ASTROPHYS J, V504, P1, DOI 10.1086/306088; Baugh CM, 1998, ASTROPHYS J, V498, P504, DOI 10.1086/305563; Bertin E, 1996, ASTRON ASTROPHYS SUP, V117, P393, DOI 10.1051/aas:1996164; Blakeslee J. P., 2003, ASP C SER, V295, P257; Bouwens R, 2003, ASTROPHYS J, V593, P640, DOI 10.1086/376588; De Breuck C, 2000, ASTRON ASTROPHYS SUP, V143, P303, DOI 10.1051/aas:2000181; De Breuck C, 2002, ASTRON J, V123, P637, DOI 10.1086/324632; De Breuck C, 1999, ASTRON ASTROPHYS, V352, pL51; Dey A, 1997, ASTROPHYS J, V490, P698, DOI 10.1086/304911; Ford H, 1998, P SOC PHOTO-OPT INS, V3356, P234, DOI 10.1117/12.324464; GIAVALISCO M, IN PRESS ASTROPHYS J; KAISER N, 1984, ASTROPHYS J, V284, pL9, DOI 10.1086/184341; MADAU P, 1995, ASTROPHYS J, V441, P18, DOI 10.1086/175332; Miley G, 2000, ESO ASTROPHY SYMP, P32, DOI 10.1007/10720961_4; Pentericci L, 2000, ASTRON ASTROPHYS, V361, pL25; Pentericci L, 1998, ASTROPHYS J, V504, P139, DOI 10.1086/306087; Rosati P, 1999, ASTRON J, V118, P76, DOI 10.1086/300934; Shimasaku K, 2003, ASTROPHYS J, V586, pL111, DOI 10.1086/374880; SOMERVILLE RS, 2003, IN PRESS ASTROPHYS J; Steidel CC, 1999, ASTROPHYS J, V519, P1, DOI 10.1086/307363; Steidel CC, 2000, ASTROPHYS J, V532, P170, DOI 10.1086/308568; Steidel CC, 1998, ASTROPHYS J, V492, P428, DOI 10.1086/305073; STEIDEL CC, 1999, ASTROPHYS J, V462, pL1; VANOIJK R, 1995, GAS DISTANT RADIO GA; Venemans BP, 2002, ASTROPHYS J, V569, pL11, DOI 10.1086/340563	27	107	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					47	50		10.1038/nature02125	http://dx.doi.org/10.1038/nature02125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702079	Green Submitted			2022-12-28	WOS:000187710000028
J	Makhnevych, T; Lusk, CP; Anderson, AM; Aitchison, JD; Wozniak, RW				Makhnevych, T; Lusk, CP; Anderson, AM; Aitchison, JD; Wozniak, RW			Cell cycle regulated transport controlled by alterations in the nuclear pore complex	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOPORIN NUP153; PROTEOMIC ANALYSIS; IMPORT RECEPTOR; PROTEIN; YEAST; RAN; LOCALIZATION; BINDING; PHOSPHORYLATION	Eukaryotic cells have developed mechanisms for regulating the nuclear transport of macromolecules that control various cellular events including movement through defined stages of the cell cycle. In yeast cells, where the nuclear envelope remains intact throughout the cell cycle, these transport regulatory mechanisms must also function during mitosis. We have uncovered a mechanism for regulating transport that is controlled by M phase specific molecular rearrangements in the nuclear pore complex (NPC). These changes allow a transport inhibitory nucleoporin, Nup53p, to bind the karyopherin Kap121p specifically during mitosis, slowing its movement through the NPC and inducing cargo release. Yeast strains that possess defects in the function of Kap121p or the fidelity of the inhibitory pathway are delayed in mitosis. We propose that fluctuations in Kap121p transport mediated by the NPC contribute to controlling the subcellular distribution of molecules that direct progression through mitosis.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Inst Syst Biol, Seattle, WA 98103 USA	University of Alberta; Institute for Systems Biology (ISB)	Aitchison, JD (corresponding author), Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.	jaitchison@systemsbiology.org; rick.wozniak@ualberta.ca		Lusk, C. Patrick/0000-0003-4703-0533				AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Asakawa K, 2002, GENETICS, V162, P1545; Basrai MA, 1996, MOL CELL BIOL, V16, P2838; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DELORME E, 1989, APPL ENVIRON MICROB, V55, P2242, DOI 10.1128/AEM.55.9.2242-2246.1989; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Favreau C, 1996, BIOCHEMISTRY-US, V35, P8035, DOI 10.1021/bi9600660; FELDHERR CM, 1994, EXP CELL RES, V215, P206, DOI 10.1006/excr.1994.1333; FELDHERR CM, 1993, EXP CELL RES, V205, P179, DOI 10.1006/excr.1993.1073; Fontoura BMA, 2000, J BIOL CHEM, V275, P31289, DOI 10.1074/jbc.M004651200; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Harvey SL, 2003, CURR BIOL, V13, P264, DOI 10.1016/S0960-9822(03)00049-6; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jensen S, 2002, CELL CYCLE, V1, P300, DOI 10.4161/cc.1.5.142; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Leslie DM, 2002, MOL CELL BIOL, V22, P2544, DOI 10.1128/MCB.22.8.2544-2555.2002; Lusk CP, 2002, J CELL BIOL, V159, P267, DOI 10.1083/jcb.200203079; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Marelli M, 1998, J CELL BIOL, V143, P1813, DOI 10.1083/jcb.143.7.1813; Marelli M, 2001, J CELL BIOL, V153, P709, DOI 10.1083/jcb.153.4.709; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Pyhtila B, 2003, J BIOL CHEM, V278, P42699, DOI 10.1074/jbc.M307135200; Ribbeck K, 2002, EMBO J, V21, P2664, DOI 10.1093/emboj/21.11.2664; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Schwoebel ED, 2002, J CELL BIOL, V157, P963, DOI 10.1083/jcb.200111077; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Sherman F., 1983, METHODS YEAST GENETI; Shou WY, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-4; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Yuste-Rojas M, 2000, MOL GEN GENET, V263, P60, DOI 10.1007/PL00008676; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	57	122	128	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	2003	115	7					813	823		10.1016/S0092-8674(03)00986-3	http://dx.doi.org/10.1016/S0092-8674(03)00986-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697200	Bronze			2022-12-28	WOS:000187664700006
J	Mitchell, AA				Mitchell, AA			Systematic identification of drugs that cause birth defects - A new opportunity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACID; PREGNANCY		Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA	Boston University	Mitchell, AA (corresponding author), Boston Univ, Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA.			Mitchell, Allen/0000-0003-0950-6799				Chambers CD, 2001, TERATOLOGY, V64, P252, DOI 10.1002/tera.1071; Hernandez-Diaz S, 2001, NEW ENGL J MED, V344, P934; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LENZ W, 1962, LANCET, V1, P45; MITCHELL AA, 1981, JAMA-J AM MED ASSOC, V245, P2311; MITCHELL AA, 2001, PHARMACOEPIDEM DR S, V10, pS341; MITCHELL AA, 2000, PHARMACOEPIDEM DR S, P595; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; ROSA FW, 1991, NEW ENGL J MED, V324, P674, DOI 10.1056/NEJM199103073241006; Slone D, 1977, EPIDEMIOLOGICAL EVAL, P59; Werler MM, 2002, AM J EPIDEMIOL, V155, P26, DOI 10.1093/aje/155.1.26; Wilson JG, 1973, ENV BIRTH DEFECTS, P146; Yoon PW, 2001, PUBLIC HEALTH REP, V116, P32, DOI 10.1093/phr/116.S1.32	14	88	96	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2556	2559		10.1056/NEJMsb031395	http://dx.doi.org/10.1056/NEJMsb031395			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695418				2022-12-28	WOS:000187529500014
J	Abbott, A				Abbott, A			Membrane proteins - Channel voyager makes waves	NATURE			English	News Item							DEPENDENT K+ CHANNEL; X-RAY-STRUCTURE; POTASSIUM CHANNEL; MOLECULAR-BASIS; SELECTIVITY; CONDUCTION											Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	8	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					755	755		10.1038/426755a	http://dx.doi.org/10.1038/426755a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685197	Bronze			2022-12-28	WOS:000187342000018
J	Parker, AR; Welch, VL; Driver, D; Martini, N				Parker, AR; Welch, VL; Driver, D; Martini, N			Structural colour - Opal analogue discovered in a weevil	NATURE			English	Editorial Material									Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Parker, AR (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	andrew.parker@zoo.ox.ac.uk						Ajgaonkar M, 2002, J OPT SOC AM B, V19, P1391, DOI 10.1364/JOSAB.19.001391; Blackwell J., 1984, P257; Land M F, 1972, Prog Biophys Mol Biol, V24, P75, DOI 10.1016/0079-6107(72)90004-1; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; Parker AR, 1998, J EXP BIOL, V201, P1307; Parker AR, 2000, J OPT A-PURE APPL OP, V2, pR15, DOI 10.1088/1464-4258/2/6/201; Parker AR, 2001, NATURE, V409, P36, DOI 10.1038/35051168; PHILIPSE AP, 1989, J MATER SCI LETT, V8, P1371, DOI 10.1007/BF00720190; Sanders J. V., 1971, MINERAL REC, V2, P261; SANDERS JV, 1964, NATURE, V204, P1151, DOI 10.1038/2041151a0; SCHULTZ T D, 1986, Bulletin of the Entomological Society of America, V32, P142	11	205	221	6	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					786	787		10.1038/426786a	http://dx.doi.org/10.1038/426786a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685223				2022-12-28	WOS:000187342000042
J	Thomson, KS; Sutton, M; Thomas, B				Thomson, KS; Sutton, M; Thomas, B			A larval Devonian lungfish	NATURE			English	Article								Perhaps the most enduring of puzzles in palaeontology has been the identity of Palaeospondylus gunni Traquair, a tiny (5-60-mm) vertebrate fossil from the Middle Devonian period (similar to385 Myr ago) of Scotland, first discovered in 1890 (refs 1 - 3). It is known principally from a single site (Achanarras Quarry, Caithness) where, paradoxically, it is extremely abundant, preserved in varved lacustrine deposits along with 13 other genera of fishes(4). Here we show that Palaeospondylus is the larval stage of a lungfish, most probably Dipterus valenciennesi Sedgwick and Murchison 1828 (ref. 5), and that development of the adult form requires a distinct metamorphosis. Palaeospondylus is the oldest known true larva of a vertebrate.	Univ Oxford, Museum Nat Hist, Oxford OX1 3PW, England	University of Oxford	Thomson, KS (corresponding author), Univ Oxford, Museum Nat Hist, Parks Rd, Oxford OX1 3PW, England.							Agassiz A., 1879, P AM ACAD ARTS SCI, V14, P65; FOREY P., 1981, B BRIT MUS NAT HIST, V35, P131; FOX HAROLD, 1965, J ZOOL PROC ZOOL SOC LONDON, V146, P470; Kerr JG, 1900, P CAMB PHILOS SOC, V10, P298; MOY-THOMAS J. A., 1940, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V230, P391, DOI 10.1098/rstb.1940.0004; Rayner D. H., 1963, Proceedings of the Yorkshire Geological Society, V34, P117; SEDGWICK A, 1828, T GEOL SOC LOND, V3, P125; SOLLAS WJ, 1903, PHILOS T ROY SOC LON, V196, P267; Sutton MD, 2002, P ROY SOC B-BIOL SCI, V269, P1195, DOI 10.1098/rspb.2002.1986; SUTTON MD, 2000, PALEONT ELECT, V4, DOI ARTN 2; THOMSON KEITH STEWART, 1965, PROC ZOOL SOC LONDON, V145, P207; THOMSON KS, 1992, AM SCI, V80, P216; Traquair R. H., 1890, Annals of Natural History, V(6), P479; TREWIN N H, 1986, Transactions of the Royal Society of Edinburgh Earth Sciences, V77, P21; J MORPHOL S	15	19	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					833	834		10.1038/nature02175	http://dx.doi.org/10.1038/nature02175			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685237				2022-12-28	WOS:000187342000056
J	Bower, EA				Bower, EA			Use of amphetamines in the military environment	LANCET			English	Article									Naval Hosp Pensacola, Dept Internal Med, Pensacola, FL 32512 USA; USN, Med Corps, Washington, DC USA	United States Department of Defense; United States Navy	Bower, EA (corresponding author), Naval Hosp Pensacola, Dept Internal Med, 6000 W Highway 98, Pensacola, FL 32512 USA.								0	9	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S18	S19		10.1016/S0140-6736(03)15060-X	http://dx.doi.org/10.1016/S0140-6736(03)15060-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698114				2022-12-28	WOS:000187790200010
J	Kastrati, A; Mehilli, J; Schuhlen, H; Dirschinger, J; Dotzer, F; ten Berg, JM; Neumann, F; Bollwein, H; Volmer, C; Gawaz, M; Berger, PB; Schomig, A				Kastrati, A; Mehilli, J; Schuhlen, H; Dirschinger, J; Dotzer, F; ten Berg, JM; Neumann, F; Bollwein, H; Volmer, C; Gawaz, M; Berger, PB; Schomig, A		ISAR-REACT Study Investigators	A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLYCOPROTEIN-IIB/IIIA BLOCKADE; ANTIPLATELET THERAPY; PLATELET-FUNCTION; STENT PLACEMENT; TICLOPIDINE; ANGIOPLASTY; REGIMEN; EVENTS; REVASCULARIZATION; HEPARIN	BACKGROUND: Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown. METHODS: We enrolled 2159 patients with coronary artery disease who underwent a percutaneous coronary intervention: 1079 patients were randomly assigned in a double-blind manner to receive abciximab and 1080 patients to receive placebo. All patients were pretreated with a 600-mg dose of clopidogrel at least two hours before the procedure. The primary end point of the trial was the composite of death, myocardial infarction, and urgent target-vessel revascularization within 30 days after randomization. RESULTS: The incidence of the primary end point was 4 percent (45 patients) in the abciximab group, as compared with 4 percent (43 patients) in the placebo group (relative risk, 1.05; 95 percent confidence interval, 0.69 to 1.59; P=0.82). Most adverse events were myocardial infarctions: the incidence was 4 percent (40 patients) in the abciximab group and 4 percent (41 patients) in the placebo group (P=0.91). Twelve patients (1 percent) in the abciximab group and eight patients (1 percent) in the placebo group had major bleeding complications (P=0.37). Profound thrombocytopenia occurred in 10 patients (1 percent) in the abciximab group but in none in the placebo group (P=0.002). CONCLUSIONS: Our data suggest that in patients at low-to-intermediate risk who undergo elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel, abciximab is associated with no clinically measurable benefit within the first 30 days.	Deutsch Herzzentrum, D-80636 Munich, Germany; First Med Klin Rechts Isar, Munich, Germany; Med Klin 1, Garmisch Partenkirchen, Germany; St Antonius Hosp, Nieuwegein, Netherlands; HerzZentrum, Bad Krozingen, Germany; Mayo Clin, Rochester, MN USA	German Heart Center Berlin; German Heart Centre Munich; St. Antonius Hospital Utrecht; Mayo Clinic	Kastrati, A (corresponding author), Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.		Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019	Schuhlen, Helmut/0000-0001-8630-4264				Berger PB, 2002, CIRCULATION, V106, P2284, DOI 10.1161/01.CIR.0000035924.70846.20; Bhatt DL, 2000, J AM COLL CARDIOL, V35, P922, DOI 10.1016/S0735-1097(99)00650-6; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Chew DP, 2001, CIRCULATION, V103, P961; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; Gawaz M, 2001, AM J CARDIOL, V87, P332, DOI 10.1016/S0002-9149(00)01369-2; Gurbel PA, 2003, CIRCULATION, V107, P2908, DOI 10.1161/01.CIR.0000072771.11429.83; Helft G, 2000, ARTERIOSCL THROM VAS, V20, P2316, DOI 10.1161/01.ATV.20.10.2316; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; LINCOFF AM, 2003, JAMA-J AM MED ASSOC, V289, P1638; Muller I, 2001, HEART, V85, P92, DOI 10.1136/heart.85.1.92; Pache J, 2002, CATHETER CARDIO INTE, V55, P436, DOI 10.1002/ccd.10092; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667; Savcic M, 1999, SEMIN THROMB HEMOST, V25, P15; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schuhlen H, 1998, CIRCULATION, V98, P104, DOI 10.1161/01.CIR.98.2.104; Sharis PJ, 1998, ANN INTERN MED, V129, P394, DOI 10.7326/0003-4819-129-5-199809010-00009; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Steinhubl SR, 1998, J AM COLL CARDIOL, V32, P1366, DOI 10.1016/S0735-1097(98)00376-3; Steinhubl SR, 2003, JAMA-J AM MED ASSOC, V289, P987; Tcheng JE, 2000, LANCET, V356, P2037; The ESPRIT Investigators, 2001, LANCET, V357, P1370; Thebault JJ, 1999, SEMIN THROMB HEMOST, V25, P3; *TIMI STUD GROUP, DEF TIMI TRIALS; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502	32	405	418	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					232	238		10.1056/NEJMoa031859	http://dx.doi.org/10.1056/NEJMoa031859			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724302				2022-12-28	WOS:000188078400006
J	Lee, TH				Lee, TH			"Me-too" products - Friend or foe?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Partners Healthcare Syst, Boston, MA 02199 USA; Harvard Univ, Sch Med, Boston, MA USA	Partners Healthcare System; Harvard University; Harvard Medical School	Lee, TH (corresponding author), Partners Healthcare Syst, Boston, MA 02199 USA.							Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843	1	53	56	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					211	212		10.1056/NEJMp038215	http://dx.doi.org/10.1056/NEJMp038215			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724297				2022-12-28	WOS:000188078400001
J	Barba, C; Cavalli-Sforza, T; Cutter, J; Darnton-Hill, I; Deurenberg, P; Deurenberg-Yap, M; Gill, T; James, P; Ko, G; Miu, AH; Kosulwat, V; Kumanyika, S; Kurpad, A; Mascie-Taylor, N; Moon, HK; Nishida, C; Noor, MI; Reddy, KS; Rush, E; Schultz, JT; Seidell, J; Stevens, J; Swinburn, B; Tan, K; Weisell, R; Wu, ZS; Yajnik, CS; Yoshiike, N; Zimmet, P				Barba, C; Cavalli-Sforza, T; Cutter, J; Darnton-Hill, I; Deurenberg, P; Deurenberg-Yap, M; Gill, T; James, P; Ko, G; Miu, AH; Kosulwat, V; Kumanyika, S; Kurpad, A; Mascie-Taylor, N; Moon, HK; Nishida, C; Noor, MI; Reddy, KS; Rush, E; Schultz, JT; Seidell, J; Stevens, J; Swinburn, B; Tan, K; Weisell, R; Wu, ZS; Yajnik, CS; Yoshiike, N; Zimmet, P		WHO Expert Consultation	Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies	LANCET			English	Article							WAIST CIRCUMFERENCE; FAT; PERCENTAGE; CHINESE; OBESITY; CUTOFF; WHITES; RISK	A WHO expert consultation addressed the debate about interpretation of recommended body-mass index (BMI) cut-off points for determining overweight and obesity in Asian populations, and considered whether population-specific cut-off points for BMI are necessary. They reviewed scientific evidence that suggests that Asian populations have different associations between BMI, percentage of body fat, and health risks than do European populations. The consultation concluded that the proportion of Asian people with a high risk of type 2 diabetes and cardiovascular disease is substantial at BMIs lower than the existing WHO cut-off point for overweight (greater than or equal to25 kg/m(2)). However, available data do not necessarily indicate a clear BMI cut-off point for all Asians for overweight or obesity. The cut-off point for observed risk varies from 22 kg/m(2) to 25 kg/m(2) in different Asian populations; for high risk it varies from 26 kg/m(2) to 31 kg/m(2). No attempt was made, therefore, to redefine cut-off points for each population separately. The consultation also agreed that the WHO BMI cut-off points should be retained as international classifications. The consultation identified further potential public health action, points (23.0, 27.5, 32.5, and 37.5 kg/m(2)) along the continuum of BMI, and proposed methods by which countries could make decisions about the definitions of increased risk for their population.	WHO, Dept Nutr Hlth & Dev, CH-1211 Geneva 27, Switzerland; Food & Nutr Inst, Manila, Philippines; WHO, Reg Off Western Pacific, Manila, Philippines; Minist Hlth, Singapore, Singapore; Columbia Univ, New York, NY USA; Hlth Promot Board, Singapore, Singapore; Univ Sydney, Int Obes Task force Asia Pacific, Sydney, NSW 2006, Australia; Int Obes Task Force, London, England; Ling Nethersole Hosp, Hong Kong, Hong Kong, Peoples R China; Mahidol Univ, Bangkok 10700, Thailand; Univ Penn, Philadelphia, PA 19104 USA; St Johns Med Coll, Inst Populat Hlth & Clin Res, Bangalore, Karnataka, India; Univ Cambridge, Cambridge, England; Dankook Univ Seoul, Seoul, South Korea; Osaka Prefecture Coll Nursing, Osaka, Japan; Univ Kebangsaan Malaysia, Kuala Lumpur, Malaysia; All India Inst Med Sci, New Delhi, India; Auckland Univ Technol, Auckland, New Zealand; Secretariat S Pacific, Noumea, New Caledonia; Free Univ Amsterdam, Dept Nutr & Hlth, NL-1081 HV Amsterdam, Netherlands; Univ N Carolina, Sch Publ Sch, Chapel Hill, NC USA; Deakin Univ, Phys Act & Nutr Res Unit, Geelong, Vic 3217, Australia; Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; UN, Food & Agr Org, Rome, Italy; Anzhen Hosp, Inst Heart Lung & Vasc Dis, Beijing, Peoples R China; King Edward Mem Hosp, Diabet Unit, Pune, Maharashtra, India; Natl Inst Hlth & Nutr, Tokyo 162, Japan; Int Diabet Inst, Melbourne, Vic, Australia	World Health Organization; Food & Nutrition Research Institute - Philippines; WHO Western Pacific Regional Office; World Health Organization; Ministry of Health-Singapore; Columbia University; University of Sydney; Alice Ho Miu Ling Nethersole Hospital; Mahidol University; University of Pennsylvania; St. John's National Academy of Health Sciences; St. John's Medical College; University of Cambridge; Dankook University; Osaka Metropolitan University; Universiti Kebangsaan Malaysia; All India Institute of Medical Sciences (AIIMS) New Delhi; Auckland University of Technology; Vrije Universiteit Amsterdam; University of North Carolina; University of North Carolina Chapel Hill; Deakin University; University of Hong Kong; Food & Agriculture Organization of the United Nations (FAO); National Institute of Health & Nutrition - Japan	Nishida, C (corresponding author), WHO, Dept Nutr Hlth & Dev, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	nishidac@who.int	Zimmet, Paul/O-8486-2019; seidell, jacob/AAF-5362-2019; seidell, jacob c/N-7427-2013; Gill, Timothy/N-9592-2014; Gill, Timothy/AAR-1848-2020	Zimmet, Paul/0000-0003-0627-0776; seidell, jacob/0000-0002-9262-9062; Gill, Timothy/0000-0002-8645-9255; Gill, Timothy/0000-0002-8645-9255				[Anonymous], 1995, PHYS STAT US INT ANT; [Anonymous], 2000, TECHN REP SER WHO; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; Deurenberg P, 1998, INT J OBESITY, V22, P1164, DOI 10.1038/sj/ijo/0800741; Deurenberg P., 1992, Annual Report - Nestle Foundation for the Study of the Problems of Nutrition of the World, P35; Deurenberg P, 2003, ACTA DIABETOL, V40, pS246, DOI 10.1007/s00592-003-0077-z; Deurenberg P, 1997, Asia Pac J Clin Nutr, V6, P102; Deurenberg-Yap M, 2000, INT J OBESITY, V24, P1011, DOI 10.1038/sj.ijo.0801353; Deurenberg-Yap M, 2001, INT J OBESITY, V25, P1554, DOI 10.1038/sj.ijo.0801739; Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733; Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694; Gurrici S, 1998, EUR J CLIN NUTR, V52, P779, DOI 10.1038/sj.ejcn.1600637; He M, 2001, INT J OBESITY, V25, P748, DOI 10.1038/sj.ijo.0801612; HEYMSFIELD SB, 1991, NUTR REV, V49, P97, DOI 10.1111/j.1753-4887.1991.tb02997.x; James W P T, 2002, Obes Rev, V3, P139, DOI 10.1046/j.1467-789X.2002.00063.x; Ko GTC, 1999, INT J OBESITY, V23, P1136, DOI 10.1038/sj.ijo.0801043; Lahmann PH, 2000, OBES RES, V8, P620, DOI 10.1038/oby.2000.80; Lauderdale DS, 2000, INT J OBESITY, V24, P1188, DOI 10.1038/sj.ijo.0801365; Luke A, 2001, ANNU REV NUTR, V21, P47, DOI 10.1146/annurev.nutr.21.1.47; NORGAN NG, 1994, EUR J CLIN NUTR, V48, pS10; Roche A., 1996, HUMAN BODY COMPOSITI, P167; Seidell Jaap C., 2001, American Journal of Clinical Nutrition, V73, P123; Stevens J, 2002, AM J CLIN NUTR, V75, P986, DOI 10.1093/ajcn/75.6.986; Swinburn BA, 1999, INT J OBESITY, V23, P1178, DOI 10.1038/sj.ijo.0801053; Wagner DR, 2000, AM J CLIN NUTR, V71, P1392; WANG J, 1994, AM J CLIN NUTR, V60, P23, DOI 10.1093/ajcn/60.1.23; WANG ZM, 1992, AM J CLIN NUTR, V56, P19, DOI 10.1093/ajcn/56.1.19; WHO/IASO/IOTF, 2000, ASIA PACIFIC PERSPEC; Yajnik C S, 2002, Obes Rev, V3, P217, DOI 10.1046/j.1467-789X.2002.00072.x; Zhou Beifan, 2002, Zhonghua Liu Xing Bing Xue Za Zhi, V23, P5; Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P83	31	5603	5731	24	344	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					157	163		10.1016/s0140-6736(03)15268-3	http://dx.doi.org/10.1016/s0140-6736(03)15268-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726171				2022-12-28	WOS:000187939200021
J	Fedoriw, AM; Stein, P; Svoboda, P; Schultz, RM; Bartolomei, MS				Fedoriw, AM; Stein, P; Svoboda, P; Schultz, RM; Bartolomei, MS			Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting	SCIENCE			English	Article							DNA METHYLATION; H19/IGF2 LOCUS; CONTROL REGION; MOUSE OOCYTES; CPG ISLAND; INSULATOR; IGF2; EXPRESSION; PROMOTER; PARENT	The imprinted regulation of H19 and Insulin-like growth factor 2 expression involves binding of the vertebrate insulator protein, CCCTC binding factor (CTCF), to the maternally hypomethylated differentially methylated domain (DMD). How this hypomethylated state is maintained during oogenesis and the role of CTCF, if any, in this process are not understood. With the use of a transgenic RNA interference (RNAi)-based approach to generate oocytes with reduced amounts of CTCF protein, we found increased methylation of the H19 DMD and decreased developmental competence of CTCF-deficient oocytes. Our results suggest that CTCF protects the H19 DMD from de novo methylation during oocyte growth and is required for normal preimplantation development.	Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Bartolomei, MS (corresponding author), Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Svoboda, Petr/G-3890-2012; Stein, Paula/ABE-9388-2020	Svoboda, Petr/0000-0002-4370-3705; Stein, Paula/0000-0002-2040-4593	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042026, T32HD007516] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-42026, T32 HD-07516] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; FEDORIW AM, UNPUB; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Kaffer CR, 2000, GENE DEV, V14, P1908; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Lucifero D, 2002, GENOMICS, V79, P530, DOI 10.1006/geno.2002.6732; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; Reik W, 2001, NAT GENET, V27, P255, DOI 10.1038/85804; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Stein P, 2003, DEV BIOL, V256, P187, DOI 10.1016/S0012-1606(02)00122-7; Svoboda P, 2000, DEVELOPMENT, V127, P4147; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; Thorvaldsen JL, 2000, SCIENCE, V288, P2145, DOI 10.1126/science.288.5474.2145; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	25	218	229	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					238	240		10.1126/science.1090934	http://dx.doi.org/10.1126/science.1090934			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716017				2022-12-28	WOS:000187908500051
J	Looijenga, LHJ; Oosterhuis, JW				Looijenga, LHJ; Oosterhuis, JW			Clinical value of the X chromosome in testicular germ-cell tumours	LANCET			English	Editorial Material							XIST EXPRESSION; INACTIVATION; TESTIS		Erasmus Univ, Med Ctr Rotterdam, Dr Daniel den Hoed Canc Ctr, Erasmus MC,Dept Pathol,Lab Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Looijenga, LHJ (corresponding author), Erasmus Univ, Med Ctr Rotterdam, Dr Daniel den Hoed Canc Ctr, Erasmus MC,Dept Pathol,Lab Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands.		Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911				Carrel L, 1998, NAT GENET, V19, P211, DOI 10.1038/878; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Looijenga LHJ, 2002, ANAL QUANT CYTOL, V24, P263; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; Mayer F, 2003, ONCOGENE, V22, P3859, DOI 10.1038/sj.onc.1206469; Oosterhuis JW, 1997, CANCER GENET CYTOGEN, V95, P96, DOI 10.1016/S0165-4608(96)00275-0; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070	13	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					6	8		10.1016/S0140-6736(03)15245-2	http://dx.doi.org/10.1016/S0140-6736(03)15245-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723985				2022-12-28	WOS:000187711300006
J	Clanet, C; Hersen, F; Bocquet, L				Clanet, C; Hersen, F; Bocquet, L			Secrets of successful stone-skipping	NATURE			English	Editorial Material									CNRS, UMR 6594, Inst Rech Phenomenes Hors Equilibre, F-13384 Marseille, France; Ecole Polytech, F-91128 Palaiseau, France; Univ Lyon 1, CNRS, UMR 5586, Lab PMCN, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Clanet, C (corresponding author), CNRS, UMR 6594, Inst Rech Phenomenes Hors Equilibre, BP 146, F-13384 Marseille, France.	clanet@irphe.univ-mrs.fr	bocquet, lyderic/A-2241-2012	bocquet, lyderic/0000-0003-3577-5335; clanet, christophe/0000-0003-2448-0443				BOCQUET I, 2001, AM J PHYS, V71, P150; Crane, 1988, PHYS TEACH, V26, P300, DOI 10.1119/1.2342541; GUYORT E, 1991, HYDRODYNAMIQUE PHYS; Landau LD., 1959, FLUID MECH, P168; STONG CL, 1968, SCI AM, V219, P112; THOMSON D, 2000, ALLIAGO, V44, P77; TRITTON DJ, 1988, PHYSICAL FLUID DYNAM, P97; 1744, ENCY DIDEROT DALEMBE, P221; 1751, ENCY DIDEROT DALEMBE, P221	9	62	68	9	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 1	2004	427	6969					29	29		10.1038/427029a	http://dx.doi.org/10.1038/427029a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702075				2022-12-28	WOS:000187710000023
J	Pilmanis, AA				Pilmanis, AA			Physiological hazards of flight at high altitude	LANCET			English	Article									USAF, Res Lab, AFRL HEPR, Brooks AFB, TX 78235 USA	United States Department of Defense; United States Air Force	Pilmanis, AA (corresponding author), 309 Driftwind, San Antonio, TX 78239 USA.								0	7	7	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S16	S17		10.1016/S0140-6736(03)15059-3	http://dx.doi.org/10.1016/S0140-6736(03)15059-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698113	Bronze, Green Submitted			2022-12-28	WOS:000187790200009
J	Sando, B				Sando, B			Olympic medicine	LANCET			English	Article									Wakefield Sports Clin, Adelaide, SA 5000, Australia		Sando, B (corresponding author), Wakefield Sports Clin, 270 Wakefield St, Adelaide, SA 5000, Australia.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S50	S51		10.1016/S0140-6736(03)15076-3	http://dx.doi.org/10.1016/S0140-6736(03)15076-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698130	Bronze			2022-12-28	WOS:000187790200026
J	Webb, P				Webb, P			Can famine relief meet health and hunger goals simultaneously?	LANCET			English	Article									UN, World Food Programme, I-00148 Rome, Italy; Tufts Univ, Friedman Sch Nutr Sci & Policy, Food Policy & Appl Nutr Programme, Boston, MA 02111 USA	Tufts University	Webb, P (corresponding author), UN, World Food Programme, Via GC Viola 68-70,Parco Medici, I-00148 Rome, Italy.		Webb, Patrick/P-3420-2017	Webb, Patrick/0000-0002-9857-3354				DEWAAL A, 2003, NEW VARIANT FAMINE H; Sen A, 1981, POVERTY FAMINES	2	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S40	S41		10.1016/S0140-6736(03)15071-4	http://dx.doi.org/10.1016/S0140-6736(03)15071-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698125				2022-12-28	WOS:000187790200021
J	Young, C; McLellan, F; Barbour, V				Young, C; McLellan, F; Barbour, V			Extreme medicine	LANCET			English	Editorial Material														Barbour, Virginia/0000-0002-2358-2440; McLellan, Faith/0000-0003-0744-1450					0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S1	S1		10.1016/S0140-6736(03)15051-9	http://dx.doi.org/10.1016/S0140-6736(03)15051-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698105				2022-12-28	WOS:000187790200001
J	Focia, PJ; Shepotinovskaya, IV; Seidler, JA; Freymann, DM				Focia, PJ; Shepotinovskaya, IV; Seidler, JA; Freymann, DM			Heterodimeric GTPase core of the SRP targeting complex	SCIENCE			English	Article							SIGNAL-RECOGNITION PARTICLE; THERMUS-AQUATICUS FFH; CRYSTAL-STRUCTURE; NG DOMAIN; ENDOPLASMIC-RETICULUM; SEQUENCE RECOGNITION; CONSERVED GTPASE; STRUCTURAL BASIS; FTSY; BINDING	Two structurally homologous guanosine triphosphatase ( GTPase) domains interact directly during signal recognition particle (SRP)-mediated cotranslational targeting of proteins to the membrane. The 2.05 angstrom structure of a complex of the NG GTPase domains of Ffh and FtsY reveals a remarkably symmetric heterodimer sequestering a composite active site that contains two bound nucleotides. The structure explains the coordinate activation of the two GTPases. Conformational changes coupled to formation of their extensive interface may function allosterically to signal formation of the targeting complex to the signal-sequence binding site and the translocon. We propose that the complex represents a molecular "latch" and that its disengagement is regulated by completion of assembly of the GTPase active site.	Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Freymann, DM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, 303 E Chicago Ave, Chicago, IL 60611 USA.			Freymann, Douglas/0000-0002-5231-8841	NCRR NIH HHS [P41 RR007707, RR07707] Funding Source: Medline; NIGMS NIH HHS [R01 GM058500, GM58500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058500] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; Cleverley RM, 2002, J BIOL CHEM, V277, P46763, DOI 10.1074/jbc.M207427200; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; Focia PJ, 2004, PROTEINS, V54, P222, DOI 10.1002/prot.10598; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Freymann DM, 1999, NAT STRUCT BIOL, V6, P793, DOI 10.1038/11572; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Lu Y, 2001, EMBO J, V20, P6724, DOI 10.1093/emboj/20.23.6724; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Millman JS, 2001, J BIOL CHEM, V276, P25982, DOI 10.1074/jbc.M011331200; Montoya G, 2000, STRUCTURE, V8, P515, DOI 10.1016/S0969-2126(00)00131-3; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; Padmanabhan S, 2001, STRUCTURE, V9, P859, DOI 10.1016/S0969-2126(01)00641-4; Peluso P, 2001, BIOCHEMISTRY-US, V40, P15224, DOI 10.1021/bi011639y; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Ramirez UD, 2002, J MOL BIOL, V320, P783, DOI 10.1016/S0022-2836(02)00476-X; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Shepotinovskaya IV, 2003, ACTA CRYSTALLOGR D, V59, P1834, DOI 10.1107/S0907444903016573; Shepotinovskaya IV, 2002, BBA-PROTEIN STRUCT M, V1597, P107, DOI 10.1016/S0167-4838(02)00287-X; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023	34	217	218	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					373	377		10.1126/science.1090827	http://dx.doi.org/10.1126/science.1090827			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726591	Green Accepted			2022-12-28	WOS:000188111800044
J	Dong, XP; Donoghue, PCJ; Cheng, H; Liu, JB				Dong, XP; Donoghue, PCJ; Cheng, H; Liu, JB			Fossil embryos from the Middle and Late Cambrian period of Hunan, South China	NATURE			English	Article								Comparative embryology is integral to uncovering the pattern and process of metazoan phylogeny(1), but it relies on the assumption that life histories of living taxa are representative of their antecedents. Fossil embryos provide a crucial test of this assumption and, potentially, insight into the evolution of development, but because discoveries so far(2-5) lack phylogenetic constraint, their significance is moot. Here we describe a collection of embryos from the Middle and Late Cambrian period (500 million years ago) of Hunan, south China, that preserves stages of development from cleavage to the pre-hatching embryo of a direct-developing animal comparable to living Scalidophora (phyla Priapulida, Kinorhyncha, Loricifera). The latest-stage embryos show affinity to the Lower Cambrian embryo Markuelia(3), whose life-history strategy contrasts both with the primitive condition inferred for metazoan phyla and with many proposed hypotheses of affinity(3,6), all of which prescribe indirect development. Phylogenetic tests based on these embryological data suggest a stem Scalidophora affinity. These discoveries corroborate, rather than contradict, the predictions of comparative embryology, providing direct historical support for the view that the life-history strategies of living taxa are representative of their stem lineages.	Peking Univ, Dept Geol, Beijing 100871, Peoples R China; Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University; University of Bristol; Peking University	Dong, XP (corresponding author), Peking Univ, Dept Geol, Beijing 100871, Peoples R China.	dongxp@pku.edu.cn; phil.donoghue@bristol.ac.uk	Dong, Xi-ping/N-5741-2014; Donoghue, Philip/A-3873-2008	Dong, Xi-ping/0000-0001-5917-7159; Donoghue, Philip/0000-0003-3116-7463				Bengtson S, 1997, SCIENCE, V277, P1645, DOI 10.1126/science.277.5332.1645; Bohall PJ, 1997, INVERTEBR BIOL, V116, P26, DOI 10.2307/3226921; BRIGGS DEG, 1993, J GEOL SOC LONDON, V150, P1035, DOI 10.1144/gsjgs.150.6.1035; Budd GE, 2000, BIOL REV, V75, P253, DOI 10.1017/S000632310000548X; Budd GE, 2003, SYST ASSOC SPEC VOL, P166; CRIMES TP, 1987, GEOL MAG, V124, P97; Eriksson BJ, 2000, ARTHROPOD STRUCT DEV, V29, P197, DOI 10.1016/S1467-8039(00)00027-X; Jenkins RJF, 2002, J GEOL SOC LONDON, V159, P645, DOI 10.1144/0016-764901-127; Kouchinsky A, 1999, GEOLOGY, V27, P609, DOI 10.1130/0091-7613(1999)027<0609:CLEAWT>2.3.CO;2; Lemburg C., 1999, ULTRASTRUKTURELLE UN; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; Morris SC, 1998, BIOESSAYS, V20, P676, DOI 10.1002/(SICI)1521-1878(199808)20:8<676::AID-BIES11>3.0.CO;2-W; MORRIS SC, 1985, PHILOS T R SOC B, V307, P507, DOI 10.1098/rstb.1985.0005; Nielsen C, 2012, ANIMAL EVOLUTION: INTERRELATIONSHIPS OF THE LIVING PHYLA, 3RD EDITION, P1; Schmidt-Rhaesa A, 1998, ZOOL ANZ, V236, P203; Schmidt-Rhaesa A, 1998, J MORPHOL, V238, P263, DOI 10.1002/(SICI)1097-4687(199812)238:3<263::AID-JMOR1>3.0.CO;2-L; VOLKOV AK, 1983, POZDNIJ DOKEMBRIJ RA, P37; Wills MA, 1998, PALEOBIOLOGY, V24, P177; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318; ZHANG XG, 1994, SCIENCE, V266, P637, DOI 10.1126/science.266.5185.637	20	98	125	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					237	240		10.1038/nature02215	http://dx.doi.org/10.1038/nature02215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724636				2022-12-28	WOS:000188068100041
J	Hallem, EA; Fox, AN; Zwiebel, LJ; Carlson, JR				Hallem, EA; Fox, AN; Zwiebel, LJ; Carlson, JR			Olfaction - Mosquito receptor for human-sweat odorant	NATURE			English	Editorial Material							ANOPHELES-GAMBIAE		Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Vanderbilt Univ, Dept Biol Sci, Program Dev Biol, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37235 USA	Yale University; Vanderbilt University; Vanderbilt University	Hallem, EA (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	john.carlson@yale.edu		Zwiebel, Laurence/0000-0001-6686-7289; Hallem, Elissa/0000-0003-0260-3174				Cork A, 1996, MED VET ENTOMOL, V10, P269, DOI 10.1111/j.1365-2915.1996.tb00742.x; Dobritsa AA, 2003, NEURON, V37, P827, DOI 10.1016/S0896-6273(03)00094-1; Fox AN, 2001, P NATL ACAD SCI USA, V98, P14693, DOI 10.1073/pnas.261432998; Gross SP, 2003, CURR BIOL, V13, P1660, DOI 10.1016/j.cub.2003.08.032; Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196; Takken W, 1996, CIBA F SYMP, V200, P302; Takken W, 2001, J INSECT PHYSIOL, V47, P303, DOI 10.1016/S0022-1910(00)00107-4; VALE GA, 1988, B ENTOMOL RES, V78, P293, DOI 10.1017/S0007485300013055	8	150	182	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					212	213		10.1038/427212a	http://dx.doi.org/10.1038/427212a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724626				2022-12-28	WOS:000188068100031
J	Kording, KP; Wolpert, DM				Kording, KP; Wolpert, DM			Bayesian integration in sensorimotor learning	NATURE			English	Article							UNCERTAINTY; INFORMATION; TRANSFORMATIONS; REPRESENTATION; DECISION; CONTEXT; CODES	When we learn a new motor skill, such as playing an approaching tennis ball, both our sensors and the task possess variability. Our sensors provide imperfect information about the ball's velocity, so we can only estimate it. Combining information from multiple modalities can reduce the error in this estimate(1-4). On a longer time scale, not all velocities are a priori equally probable, and over the course of a match there will be a probability distribution of velocities. According to bayesian theory(5,6), an optimal estimate results from combining information about the distribution of velocities-the prior-with evidence from sensory feedback. As uncertainty increases, when playing in fog or at dusk, the system should increasingly rely on prior knowledge. To use a bayesian strategy, the brain would need to represent the prior distribution and the level of uncertainty in the sensory feedback. Here we control the statistical variations of a new sensorimotor task and manipulate the uncertainty of the sensory feedback. We show that subjects internally represent both the statistical distribution of the task and their sensory uncertainty, combining them in a manner consistent with a performance-optimizing bayesian process(4,5). The central nervous system therefore employs probabilistic models during sensorimotor learning.	UCL, Inst Neurol, Sobell Dept Motor Neurosci, London WC1N 3BG, England	University of London; University College London	Kording, KP (corresponding author), UCL, Inst Neurol, Sobell Dept Motor Neurosci, Queen Sq, London WC1N 3BG, England.	konrad@koerding.de	Ahmed, Shobi/AAE-4817-2022; Kording, Konrad P/A-1233-2007	Kording, Konrad P/0000-0001-8408-4499; Wolpert, Daniel/0000-0003-2011-2790				Basso MA, 1998, J NEUROSCI, V18, P7519; Bernardo JM, 1994, BAYESIAN THEORY; BERROU C, 1993, IEEE INTERNATIONAL CONFERENCE ON COMMUNICATIONS 93 : TECHNICAL PROGRAM, CONFERENCE RECORD, VOLS 1-3, P1064, DOI 10.1109/ICC.1993.397441; CARPENTER RHS, 1995, NATURE, V377, P59, DOI 10.1038/377059a0; COX RT, 1946, AM J PHYS, V14, P1, DOI 10.1119/1.1990764; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fiorillo CD, 2003, SCIENCE, V299, P1898, DOI 10.1126/science.1077349; Gold JI, 2003, J NEUROSCI, V23, P632, DOI 10.1523/JNEUROSCI.23-02-00632.2003; Goodbody SJ, 1998, J NEUROPHYSIOL, V79, P1825, DOI 10.1152/jn.1998.79.4.1825; Harris CM, 1998, NATURE, V394, P780, DOI 10.1038/29528; Hillis JM, 2002, SCIENCE, V298, P1627, DOI 10.1126/science.1075396; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; Jacobs RA, 1999, VISION RES, V39, P3621, DOI 10.1016/S0042-6989(99)00088-7; Krakauer JW, 2000, J NEUROSCI, V20, P8916, DOI 10.1523/jneurosci.20-23-08916.2000; Lacquaniti F, 1998, EUR J NEUROSCI, V10, P195; Olshausen BA, 2000, ADV NEUR IN, V12, P841; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Rao RPN, 1999, VISION RES, V39, P1963, DOI 10.1016/S0042-6989(98)00279-X; Sahani M, 2003, NEURAL COMPUT, V15, P2255, DOI 10.1162/089976603322362356; Scheidt RA, 2001, J NEUROPHYSIOL, V86, P971, DOI 10.1152/jn.2001.86.2.971; Simoncelli EP, 1996, INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, PROCEEDINGS - VOL I, P379; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P595, DOI 10.1152/jn.1989.62.2.595; Todorov E, 2002, NAT NEUROSCI, V5, P1226, DOI 10.1038/nn963; van Beers RJ, 2002, CURR BIOL, V12, P834, DOI 10.1016/S0960-9822(02)00836-9; van Beers RJ, 1999, J NEUROPHYSIOL, V81, P1355, DOI 10.1152/jn.1999.81.3.1355; van Beers RJ, 2002, PHILOS T R SOC B, V357, P1137, DOI 10.1098/rstb.2002.1101; Vetter P, 2000, J NEUROPHYSIOL, V84, P1026, DOI 10.1152/jn.2000.84.2.1026; Weiss Y, 2002, NAT NEUROSCI, V5, P598, DOI 10.1038/nn858; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; Yu AJ, 2002, NEURAL NETWORKS, V15, P719, DOI 10.1016/S0893-6080(02)00058-8	30	1112	1120	6	184	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					244	247		10.1038/nature02169	http://dx.doi.org/10.1038/nature02169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724638				2022-12-28	WOS:000188068100043
J	Stone, GW; Ellis, SG; Cox, DA; Hermiller, J; O'Shaughnessy, C; Mann, JT; Turco, M; Caputo, R; Bergin, P; Greenberg, J; Popma, JJ; Russell, ME				Stone, GW; Ellis, SG; Cox, DA; Hermiller, J; O'Shaughnessy, C; Mann, JT; Turco, M; Caputo, R; Bergin, P; Greenberg, J; Popma, JJ; Russell, ME		TAXUS-IV Investigators	A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE CELL-PROLIFERATION; LOCAL-DRUG DELIVERY; BALLOON ANGIOPLASTY; HUMAN-NEUTROPHILS; SLOW-RELEASE; IN-VIVO; RESTENOSIS; INHIBITION; PREDICTORS; PREVENTION	BACKGROUND: Restenosis after coronary stenting necessitates repeated percutaneous or surgical revascularization procedures. The delivery of paclitaxel to the site of vascular injury may reduce the incidence of neointimal hyperplasia and restenosis. METHODS: At 73 U.S. centers, we enrolled 1314 patients who were receiving a stent in a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm) in a prospective, randomized, double-blind study. A total of 652 patients were randomly assigned to receive a bare-metal stent, and 662 to receive an identical-appearing, slow-release, polymer-based, paclitaxel-eluting stent. Angiographic follow-up was prespecified at nine months in 732 patients. RESULTS: In terms of base-line characteristics, the two groups were well matched. Diabetes mellitus was present in 24.2 percent of patients; the mean reference-vessel diameter was 2.75 mm, and the mean lesion length was 13.4 mm. A mean of 1.08 stents (length, 21.8 mm) were implanted per patient. The rate of ischemia-driven target-vessel revascularization at nine months was reduced from 12.0 percent with the implantation of a bare-metal stent to 4.7 percent with the implantation of a paclitaxel-eluting stent (relative risk, 0.39; 95 percent confidence interval, 0.26 to 0.59; P<0.001). Target-lesion revascularization was required in 3.0 percent of the group that received a paclitaxel-eluting stent, as compared with 11.3 percent of the group that received a bare-metal stent (relative risk, 0.27; 95 percent confidence interval, 0.16 to 0.43; P<0.001). The rate of angiographic restenosis was reduced from 26.6 percent to 7.9 percent with the paclitaxel-eluting stent (relative risk, 0.30; 95 percent confidence interval, 0.19 to 0.46; P<0.001). The nine-month composite rates of death from cardiac causes or myocardial infarction (4.7 percent and 4.3 percent, respectively) and stent thrombosis (0.6 percent and 0.8 percent, respectively) were similar in the group that received a paclitaxel-eluting stent and the group that received a bare-metal stent. CONCLUSIONS: As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.	Cardiovasc Res Fdn, New York, NY 10022 USA; Lenox Hill Heart & Vasc Inst, New York, NY USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Mid Carolina Cardiol, Charlotte, NC USA; St Vincents Hosp, Indianapolis, IN USA; Elyria Mem Hosp, Elyria, OH USA; WakeMed, Raleigh, NC USA; Washington Adventist Hosp, Takoma Pk, MD USA; St Josephs Hosp, Syracuse, NY USA; Sacred Heart Med Ctr, Eugene, OR USA; Florida Hosp, Orlando, FL USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Boston Sci, Natick, MA USA	Cardiovascular Research Foundation (CRF); Lenox Hill Heart & Vascular Institute of New York; Cleveland Clinic Foundation; Adventist Health Services; AdventHealth; Harvard University; Brigham & Women's Hospital; Boston Scientific	Stone, GW (corresponding author), Cardiovasc Res Fdn, 55 E 59th St,6th Fl, New York, NY 10022 USA.							Al Suwaidi J, 2000, JAMA-J AM MED ASSOC, V284, P1828, DOI 10.1001/jama.284.14.1828; Axel DI, 1997, CIRCULATION, V96, P636; Babapulle MN, 2002, CIRCULATION, V106, P2859, DOI 10.1161/01.CIR.0000038984.30279.89; Belotti D, 1996, CLIN CANCER RES, V2, P1843; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; Farb A, 1999, CIRCULATION, V99, P44, DOI 10.1161/01.CIR.99.1.44; Farb A, 2001, CIRCULATION, V104, P473, DOI 10.1161/hc3001.092037; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Grube E, 2003, CIRCULATION, V107, P38, DOI 10.1161/01.CIR.0000047700.58683.A1; Herdeg C, 2000, J AM COLL CARDIOL, V35, P1969, DOI 10.1016/S0735-1097(00)00614-8; Ho KKL, 1998, CIRCULATION, V98, P362; Hoffmann R, 2000, EUR HEART J, V21, P1739, DOI 10.1053/euhj.2000.2153; Hui A, 1998, ARTHRITIS RHEUM, V41, P869, DOI 10.1002/1529-0131(199805)41:5<869::AID-ART15>3.0.CO;2-3; Jackson JK, 1997, IMMUNOLOGY, V90, P502, DOI 10.1046/j.1365-2567.1997.d01-2178.x; Kasaoka S, 1998, J AM COLL CARDIOL, V32, P1630, DOI 10.1016/S0735-1097(98)00404-5; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; Mehran R, 1999, CIRCULATION, V100, P1872, DOI 10.1161/01.CIR.100.18.1872; Mercado N, 2001, J AM COLL CARDIOL, V38, P645, DOI 10.1016/S0735-1097(01)01431-0; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Oberhoff M, 2001, BASIC RES CARDIOL, V96, P275, DOI 10.1007/s003950170058; Peterson ED, 1999, J AM COLL CARDIOL, V33, P1610, DOI 10.1016/S0735-1097(99)00051-0; ROBERTS RL, 1982, J IMMUNOL, V129, P2134; Serruys PW, 1999, J AM COLL CARDIOL, V34, P1067, DOI 10.1016/S0735-1097(99)00308-3; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Signore PE, 2001, J VASC INTERV RADIOL, V12, P79, DOI 10.1016/S1051-0443(07)61408-0; SOLLOTT SJ, 1995, J CLIN INVEST, V95, P1869, DOI 10.1172/JCI117867; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Steinhubl SR, 2003, JAMA-J AM MED ASSOC, V289, P987; VANDERZWET PMJ, 1994, J AM COLL CARDIOL, V24, P216, DOI 10.1016/0735-1097(94)90566-5; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928	33	2136	2303	3	243	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					221	231		10.1056/NEJMoa032441	http://dx.doi.org/10.1056/NEJMoa032441			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724301	Bronze			2022-12-28	WOS:000188078400005
J	Maund, JR; Smartt, SJ; Kudritzki, RP; Podsiadlowski, P; Gilmore, GF				Maund, JR; Smartt, SJ; Kudritzki, RP; Podsiadlowski, P; Gilmore, GF			The massive binary companion star to the progenitor of supernova 1993J	NATURE			English	Article							QUANTITATIVE SPECTRAL-ANALYSIS; SN 1993J; B-SUPERGIANTS; IB SUPERNOVAE; GIANT BRANCH; MODEL; 1987A; M81	The massive star that underwent a collapse of its core to produce supernova (SN) 1993J was subsequently identified as a non-variable red supergiant star in images of the galaxy M81 taken before explosion(1,2). It showed an excess in ultraviolet and B-band colours, suggesting either the presence of a hot, massive companion star or that it was embedded in an unresolved young stellar association(1). The spectra of SN1993J underwent a remarkable transformation from the signature of a hydrogen-rich type II supernova to one of a helium-rich (hydrogen-deficient) type Ib(3,4). The spectral and photometric peculiarities were best explained by models in which the 13 - 20 solar mass supergiant had lost almost its entire hydrogen envelope to a close binary companion(5-7), producing a 'type IIb' supernova, but the hypothetical massive companion stars for this class of supernovae have so far eluded discovery. Here we report photometric and spectroscopic observations of SN1993J ten years after the explosion. At the position of the fading supernova we detect the unambiguous signature of a massive star: the binary companion to the progenitor.	Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; Univ Hawaii Manoa, Inst Astron, Honolulu, HI 96822 USA; Univ Oxford, Oxford OX1 3RH, England	University of Cambridge; University of Hawaii System; University of Hawaii Manoa; University of Oxford	Maund, JR (corresponding author), Univ Cambridge, Inst Astron, Madingley Rd, Cambridge CB3 0HA, England.	jrm@ast.cam.ac.uk		Maund, Justyn/0000-0003-0733-7215				ALDERING G, 1994, ASTRON J, V107, P662, DOI 10.1086/116886; BRANDT N, 1995, MON NOT R ASTRON SOC, V274, P461, DOI 10.1093/mnras/274.2.461; Bresolin F, 2002, ASTROPHYS J, V577, pL107, DOI 10.1086/344241; COHEN JG, 1995, ASTRON J, V110, P308, DOI 10.1086/117520; Ferrarese L, 2000, ASTROPHYS J SUPPL S, V128, P431, DOI 10.1086/313391; Fesen RA, 1999, ASTRON J, V117, P725, DOI 10.1086/300751; FILIPPENKO AV, 1993, ASTROPHYS J, V415, pL103, DOI 10.1086/187043; Fransson C, 1996, ASTROPHYS J, V461, P993, DOI 10.1086/177119; HUBENY I, 1995, ASTROPHYS J, V439, P875, DOI 10.1086/175226; Kudritzki RP, 1999, ASTRON ASTROPHYS, V350, P970; Marggraf O, 2000, ASTRON ASTROPHYS, V363, P733; Matheson T, 2000, ASTRON J, V120, P1499, DOI 10.1086/301519; McErlean ND, 1999, ASTRON ASTROPHYS, V349, P553; NOMOTO K, 1993, NATURE, V364, P507, DOI 10.1038/364507a0; PAVLOVSKY C, 2002, ACS INSTRUMENT HDB V; PODSIADLOWSKI P, 1989, NATURE, V338, P401, DOI 10.1038/338401a0; PODSIADLOWSKI P, 1993, NATURE, V364, P509, DOI 10.1038/364509a0; PODSIADLOWSKI P, 1992, PUBL ASTRON SOC PAC, V104, P717, DOI 10.1086/133043; Ryans RSI, 2003, ASTRON ASTROPHYS, V401, P1119, DOI 10.1051/0004-6361:20030191; Smartt SJ, 2002, ASTRON ASTROPHYS, V391, P979, DOI 10.1051/0004-6361:20020829; SWARTZ DA, 1993, NATURE, V365, P232, DOI 10.1038/365232a0; Urbaneja MA, 2003, ASTROPHYS J, V584, pL73, DOI 10.1086/368406; Van Dyk SD, 2002, PUBL ASTRON SOC PAC, V114, P1322, DOI 10.1086/344382; WOOSLEY SE, 1994, ASTROPHYS J, V429, P300, DOI 10.1086/174319	25	238	239	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					129	131		10.1038/nature02161	http://dx.doi.org/10.1038/nature02161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712269	Green Submitted			2022-12-28	WOS:000187863900028
J	Thomas, CD; Cameron, A; Green, RE; Bakkenes, M; Beaumont, LJ; Collingham, YC; Erasmus, BFN; de Siqueira, MF; Grainger, A; Hannah, L; Hughes, L; Huntley, B; van Jaarsveld, AS; Midgley, GF; Miles, L; Ortega-Huerta, MA; Peterson, AT; Phillips, OL; Williams, SE				Thomas, CD; Cameron, A; Green, RE; Bakkenes, M; Beaumont, LJ; Collingham, YC; Erasmus, BFN; de Siqueira, MF; Grainger, A; Hannah, L; Hughes, L; Huntley, B; van Jaarsveld, AS; Midgley, GF; Miles, L; Ortega-Huerta, MA; Peterson, AT; Phillips, OL; Williams, SE			Extinction risk from climate change	NATURE			English	Article							BIODIVERSITY; IMPACTS; DEFORESTATION; CO2; VULNERABILITY	Climate change over the past similar to30 years has produced numerous shifts in the distributions and abundances of species(1,2) and has been implicated in one species-level extinction(3). Using projections of species' distributions for future climate scenarios, we assess extinction risks for sample regions that cover some 20% of the Earth's terrestrial surface. Exploring three approaches in which the estimated probability of extinction shows a powerlaw relationship with geographical range size, we predict, on the basis of mid-range climate-warming scenarios for 2050, that 15 - 37% of species in our sample of regions and taxa will be 'committed to extinction'. When the average of the three methods and two dispersal scenarios is taken, minimal climate-warming scenarios produce lower projections of species committed to extinction (similar to18%) than mid-range (similar to24%) and maximum-change (similar to35%) scenarios. These estimates show the importance of rapid implementation of technologies to decrease greenhouse gas emissions and strategies for carbon sequestration.	Univ Leeds, Sch Biol, Ctr Biodivers & Conservat, Leeds LS2 9JT, W Yorkshire, England; Royal Soc Protect Birds, Sandy SG19 2DL, Beds, England; Univ Cambridge, Dept Zool, Conservat Biol Grp, Cambridge CB2 3EJ, England; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Macquarie Univ, Dept Biol Sci, N Ryde, NSW 2109, Australia; Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Witwatersrand, ZA-2050 Johannesburg, South Africa; Ctr Referencia Informacao Ambiental, BR-13083885 Campinas, SP, Brazil; Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England; Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20036 USA; Univ Stellenbosch, Dept Zool, ZA-7602 Stellenbosch, South Africa; Natl Bot Inst, Kirstenbosch Res Ctr, Climate Change Res Grp, ZA-7735 Cape Town, South Africa; Univ Nacl Autonoma Mexico, Inst Biol, Unidad Occidente, Mexico City 04510, DF, Mexico; Univ Kansas, Museum Nat Hist, Lawrence, KS 66045 USA; Univ Kansas, Biodivers Res Ctr, Lawrence, KS 66045 USA; James Cook Univ N Queensland, Sch Trop Biol, Cooperat Res Ctr Trop Rainforest Ecol, Townsville, Qld 4811, Australia	University of Leeds; Royal Society for Protection of Birds; University of Cambridge; Netherlands National Institute for Public Health & the Environment; Macquarie University; Durham University; University of Witwatersrand; University of Leeds; Conservation International; Stellenbosch University; Universidad Nacional Autonoma de Mexico; University of Kansas; University of Kansas; James Cook University	Thomas, CD (corresponding author), Univ Leeds, Sch Biol, Ctr Biodivers & Conservat, Leeds LS2 9JT, W Yorkshire, England.	c.d.thomas@leeds.ac.uk	Williams, Stephen E/A-7250-2008; Erasmus, Barend/G-3411-2012; Midgley, Guy F./H-3585-2014; Peterson, A. Townsend/I-5697-2013; Beaumont, Linda J/D-5499-2012; Phillips, Oliver/A-1523-2011; Thomas, Chris D/A-1460-2014; Cameron, Alison/D-3911-2009; Thomas, Chris D/A-1894-2012; de Siqueira, Marinez Ferreira/I-9205-2012; Fapesp, Biota/F-8655-2017; Miles, Lera/C-7334-2009; van Jaarsveld, Albert/H-5368-2013	Williams, Stephen E/0000-0002-2510-7408; Erasmus, Barend/0000-0003-1869-8091; Midgley, Guy F./0000-0001-8264-0869; Peterson, A. Townsend/0000-0003-0243-2379; Beaumont, Linda J/0000-0001-6307-1680; Phillips, Oliver/0000-0002-8993-6168; Thomas, Chris D/0000-0003-2822-1334; Cameron, Alison/0000-0001-8236-7954; Thomas, Chris D/0000-0003-2822-1334; de Siqueira, Marinez Ferreira/0000-0002-6869-0293; Fapesp, Biota/0000-0002-9887-8449; Miles, Lera/0000-0003-0377-5904; Hughes, Lesley/0000-0003-0313-9780	Natural Environment Research Council [NE/B503384/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; Baker RHA, 2000, AGR ECOSYST ENVIRON, V82, P57, DOI 10.1016/S0167-8809(00)00216-4; Bakkenes M, 2002, GLOBAL CHANGE BIOL, V8, P390, DOI 10.1046/j.1354-1013.2001.00467.x; Beaumont LJ, 2002, GLOBAL CHANGE BIOL, V8, P954, DOI 10.1046/j.1365-2486.2002.00490.x; BEERLING DJ, 1993, J BIOGEOGR, V20, P45, DOI 10.2307/2845738; Benton MJ, 2003, TRENDS ECOL EVOL, V18, P358, DOI 10.1016/S0169-5347(03)00093-4; Bond WJ, 2003, GLOBAL CHANGE BIOL, V9, P973, DOI 10.1046/j.1365-2486.2003.00577.x; Brooks TM, 1999, CONSERV BIOL, V13, P1140, DOI 10.1046/j.1523-1739.1999.98341.x; Brooks TM, 1997, CONSERV BIOL, V11, P382, DOI 10.1046/j.1523-1739.1997.95493.x; Erasmus BFN, 2002, GLOBAL CHANGE BIOL, V8, P679, DOI 10.1046/j.1365-2486.2002.00502.x; Gaston KJ, 2003, P ROY SOC B-BIOL SCI, V270, P1293, DOI 10.1098/rspb.2002.2303; Houghton JT, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P1; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; IUCN, 2001, IUCN RED LIST CAT CR; Lackner KS, 2003, SCIENCE, V300, P1677, DOI 10.1126/science.1079033; Midgley GF, 2002, GLOBAL ECOL BIOGEOGR, V11, P445, DOI 10.1046/j.1466-822X.2002.00307.x; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Overpeck J, 2003, GLO CH IGBP, P81; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Pearson RG, 2003, GLOBAL ECOL BIOGEOGR, V12, P361, DOI 10.1046/j.1466-822X.2003.00042.x; Peterson AT, 2001, BIOSCIENCE, V51, P363, DOI 10.1641/0006-3568(2001)051[0363:PSIUEN]2.0.CO;2; Peterson AT, 2002, NATURE, V416, P626, DOI 10.1038/416626a; Pounds JA, 1999, NATURE, V398, P611, DOI 10.1038/19297; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Rouget M, 2003, BIOL CONSERV, V112, P63, DOI 10.1016/S0006-3207(02)00395-6; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Whittaker JB, 1999, EUR J ENTOMOL, V96, P149; Williams SE, 2003, P ROY SOC B-BIOL SCI, V270, P1887, DOI 10.1098/rspb.2003.2464; Woodward FI, 2002, CURR OPIN PLANT BIOL, V5, P207, DOI 10.1016/S1369-5266(02)00253-4	30	4719	5039	134	5467	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					145	148		10.1038/nature02121	http://dx.doi.org/10.1038/nature02121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712274	Green Published, Green Accepted			2022-12-28	WOS:000187863900033
J	Farber, JM				Farber, JM			Enterobacter sakazakii - new foods for thought?	LANCET			English	Editorial Material							INFECTIONS; MILK		Hlth Canada, Food Directorate, Bur Microbial Hazards, Ottawa, ON K1A 0L2, Canada	Health Canada	Farber, JM (corresponding author), Hlth Canada, Food Directorate, Bur Microbial Hazards, AL 2203G3, Ottawa, ON K1A 0L2, Canada.	Jeff_Farber@hc-sc.gc.ca						Block C, 2002, EUR J CLIN MICROBIOL, V21, P613, DOI 10.1007/s10096-002-0774-5; Breeuwer P, 2003, J APPL MICROBIOL, V95, P967, DOI 10.1046/j.1365-2672.2003.02067.x; FARMER JJ, 1980, INT J SYST BACTERIOL, V30, P569, DOI 10.1099/00207713-30-3-569; *FOOD ADV COMM, 2003, M ENT SAK CONT POWD; Hamilton JV, 2003, EMERG INFECT DIS, V9, P1355; MUYTJENS HL, 1988, J CLIN MICROBIOL, V26, P743, DOI 10.1128/JCM.26.4.743-746.1988; NazarowecWhite M, 1997, J FOOD PROTECT, V60, P226, DOI 10.4315/0362-028X-60.3.226; NazarowecWhite M, 1997, INT J FOOD MICROBIOL, V34, P103, DOI 10.1016/S0168-1605(96)01172-5; Pagotto FJ, 2003, J FOOD PROTECT, V66, P370, DOI 10.4315/0362-028X-66.3.370; Sanders WE, 1997, CLIN MICROBIOL REV, V10, P220, DOI 10.1128/CMR.10.2.220; SIMMONS BP, 1989, INFECT CONT HOSP EP, V10, P398, DOI 10.1086/646060; Van Acker J, 2001, J CLIN MICROBIOL, V39, P293, DOI 10.1128/JCM.39.1.293-297.2001	12	34	35	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					5	6		10.1016/S0140-6736(03)15244-0	http://dx.doi.org/10.1016/S0140-6736(03)15244-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723984				2022-12-28	WOS:000187711300005
J	Gannoun, A; Burton, KW; Thomas, LE; Parkinson, IJ; van Calsteren, P; Schiano, P				Gannoun, A; Burton, KW; Thomas, LE; Parkinson, IJ; van Calsteren, P; Schiano, P			Osmium isotope heterogeneity in the constituent phases of mid-ocean ridge basalts	SCIENCE			English	Article							MID-ATLANTIC RIDGE; ABYSSAL PERIDOTITES; MELT INCLUSIONS; UPPER-MANTLE; FAMOUS AREA; GEOCHEMISTRY; SYSTEMATICS; OLIVINE; MORB	Radiogenic isotope variations in mid-ocean ridge basalts (MORB) are commonly attributed to compositional variations in Earth's upper mantle. For the rhenium-osmium isotope system, constituent MORB phases are shown to possess exceptionally high Re/Os (parent/daughter) ratios, consequently radiogenic (187)Os is produced from the decay of (187)Re over short periods of time. Thus, in the absence of precise age constraints, Os isotope variations cannot be unambiguously attributed to their source, although Re-Os isotope data for constituent minerals can yield crystallization ages, details of equilibration, and initial Os isotope values that relate directly to the mantle source.	Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England; Univ Clermont Ferrand, Lab Magmas & Volcans, F-63038 Clermont Ferrand, France	Open University - UK	Gannoun, A (corresponding author), Open Univ, Dept Earth Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.	a.gannoun@open.ac.uk	Parkinson, Ian/C-7398-2009	Burton, Kevin/0000-0002-3381-7004				ALLEGRE CJ, 1980, EARTH PLANET SC LETT, V48, P148, DOI 10.1016/0012-821X(80)90177-6; Birck JL, 1997, GEOSTANDARD NEWSLETT, V21, P19, DOI 10.1111/j.1751-908X.1997.tb00528.x; Brandon AD, 2000, EARTH PLANET SC LETT, V177, P319, DOI 10.1016/S0012-821X(00)00044-3; Burton KW, 2002, EARTH PLANET SC LETT, V198, P63, DOI 10.1016/S0012-821X(02)00518-6; CLOCCHIATTI R, 1979, CR ACAD SCI II-MEC P, V285, P1155; CONDOMINES M, 1981, EARTH PLANET SC LETT, V55, P247, DOI 10.1016/0012-821X(81)90104-7; Hauri EH, 2002, PHILOS T R SOC A, V360, P2371, DOI 10.1098/rsta.2002.1073; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; HOFMANN AW, 1978, EARTH PLANET SC LETT, V38, P44, DOI 10.1016/0012-821X(78)90125-5; Kamenetsky V, 1996, EARTH PLANET SC LETT, V142, P479, DOI 10.1016/0012-821X(96)00117-3; LEROEX AP, 1981, CONTRIB MINERAL PETR, V77, P24, DOI 10.1007/BF01161499; Meisel T, 1996, NATURE, V383, P517, DOI 10.1038/383517a0; NABLECK PI, 1986, CONTRIB MINERAL PETR, V93, P1; PEGRAM WJ, 1992, EARTH PLANET SC LETT, V111, P59, DOI 10.1016/0012-821X(92)90169-V; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V58, P5043, DOI 10.1016/0016-7037(94)90230-5; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; SELO M, 1979, CR ACAD SCI D NAT, V289, P1125; Shimizu N, 1998, PHYS EARTH PLANET IN, V107, P183, DOI 10.1016/S0031-9201(97)00133-7; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; SIGURDSSON H, 1976, EARTH PLANET SC LETT, V29, P7, DOI 10.1016/0012-821X(76)90021-2; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X; SU Y, 2002, PETDB PETROLOGICAL D; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	23	49	50	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					70	72		10.1126/science.1090266	http://dx.doi.org/10.1126/science.1090266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704423				2022-12-28	WOS:000187710600034
J	Levitt, P				Levitt, P			Sealing cortical cell fate	SCIENCE			English	Editorial Material							PROGENITORS; IDENTITY		Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37203 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37203 USA	Vanderbilt University; Vanderbilt University	Levitt, P (corresponding author), Vanderbilt Univ, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37203 USA.							Belliveau MJ, 2000, J NEUROSCI, V20, P2247; Eagleson KL, 1997, DEVELOPMENT, V124, P1623; Frantz GD, 1996, NEURON, V17, P55, DOI 10.1016/S0896-6273(00)80280-9; Hanashima C, 2004, SCIENCE, V303, P56, DOI 10.1126/science.1090674; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Levitt P, 1993, Perspect Dev Neurobiol, V1, P65; MCCONNELL SK, 1995, J NEUROSCI, V15, P6987; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; William CM, 2003, DEVELOPMENT, V130, P1523, DOI 10.1242/dev.00358	10	4	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					48	49		10.1126/science.1093398	http://dx.doi.org/10.1126/science.1093398			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704417				2022-12-28	WOS:000187710600025
J	Lineweaver, CH; Fenner, Y; Gibson, BK				Lineweaver, CH; Fenner, Y; Gibson, BK			The Galactic habitable zone and the age distribution of complex life in the Milky Way	SCIENCE			English	Article							METALLICITY; PLANETS; STARS	We modeled the evolution of the Milky Way Galaxy to trace the distribution in space and time of four prerequisites for complex life: the presence of a host star, enough heavy elements to form terrestrial planets, sufficient time for biological evolution, and an environment free of life-extinguishing supernovae. We identified the Galactic habitable zone (GHZ) as an annular region between 7 and 9 kiloparsecs from the Galactic center that widens with time and is composed of stars that formed between 8 and 4 billion years ago. This GHZ yields an age distribution for the complex life that may inhabit our Galaxy. We found that 75% of the stars in the GHZ are older than the Sun.	Univ New S Wales, Dept Astrophys, Sydney, NSW 2052, Australia; Macquarie Univ, Australian Ctr Astrobiol, N Ryde, NSW 2109, Australia; Swinburne Univ, Ctr Astrophys & Supercomp, Hawthorn, Vic 3122, Australia	University of New South Wales Sydney; Macquarie University; Swinburne University of Technology	Lineweaver, CH (corresponding author), Univ New S Wales, Dept Astrophys, Sydney, NSW 2052, Australia.	charley@bat.phys.unsw.edu.au; yfenner@astro.swin.edu.au	Gibson, Brad/M-3592-2015	Gibson, Brad/0000-0003-4446-3130; Lineweaver, Charles/0000-0003-2047-1558				CARTER B, 1983, PHILOS T R SOC A, V310, P347, DOI 10.1098/rsta.1983.0096; CLARK DH, 1977, NATURE, V265, P318, DOI 10.1038/265318a0; CLARKE JN, 1981, ICARUS, V46, P94, DOI 10.1016/0019-1035(81)90078-6; Fenner Y, 2003, PUBL ASTRON SOC AUST, V20, P189, DOI 10.1071/AS02047; Gonzalez G, 2001, SCI AM, V285, P60, DOI 10.1038/scientificamerican1001-60; Gonzalez G, 2001, ICARUS, V152, P185, DOI 10.1006/icar.2001.6617; KROUPA P, 1993, MON NOT R ASTRON SOC, V262, P545, DOI 10.1093/mnras/262.3.545; Laws C, 2003, ASTRON J, V125, P2664, DOI 10.1086/374626; Lineweaver CH, 2001, ICARUS, V151, P307, DOI 10.1006/icar.2001.6607; Livio M, 1999, ASTROPHYS J, V511, P429, DOI 10.1086/306668; McKay C.P., 1996, CIRCUMSTELLAR HABITA, P105; Santos NC, 2003, ASTRON ASTROPHYS, V398, P363, DOI 10.1051/0004-6361:20021637; Scalo J, 2002, ASTROPHYS J, V566, P723, DOI 10.1086/338329; Trimble V, 1997, ORIGINS LIFE EVOL B, V27, P3, DOI 10.1023/A:1006561811750; TUCKER WH, 1981, LIFE UNIVERSE, P287; ZINNECKER H, IN PRESS INT ASTR UN	17	215	222	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					59	62		10.1126/science.1092322	http://dx.doi.org/10.1126/science.1092322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704421				2022-12-28	WOS:000187710600030
J	Martinez-Perez, E; Moore, G				Martinez-Perez, E; Moore, G			Promiscuous maize chromosomes	SCIENCE			English	Editorial Material							RECOMBINATION PROTEIN; MEIOTIC PROPHASE; SYNAPSIS; BOUQUET; RAD51; GENE		Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	Stanford University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Martinez-Perez, E (corresponding author), Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA.							Armstrong SJ, 2002, J CELL SCI, V115, P3645, DOI 10.1242/jcs.00048; Franklin AE, 1999, PLANT CELL, V11, P809, DOI 10.1105/tpc.11.5.809; Golubovskaya IN, 2002, GENETICS, V162, P1979; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; Lipkin SM, 2002, NAT GENET, V31, P385, DOI 10.1038/ng931; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Pawlowski WP, 2004, SCIENCE, V303, P89, DOI 10.1126/science.1091110; Pawlowski WP, 2003, PLANT CELL, V15, P1807, DOI 10.1105/tpc.012898; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Scherthan H, 2001, NAT REV MOL CELL BIO, V2, P621, DOI 10.1038/35085086	10	1	1	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					49	50		10.1126/science.1093532	http://dx.doi.org/10.1126/science.1093532			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704418				2022-12-28	WOS:000187710600026
J	van der Werf, GR; Randerson, JT; Collatz, GJ; Giglio, L; Kasibhatla, PS; Arellano, AF; Olsen, SC; Kasischke, ES				van der Werf, GR; Randerson, JT; Collatz, GJ; Giglio, L; Kasibhatla, PS; Arellano, AF; Olsen, SC; Kasischke, ES			Continental-scale partitioning of fire emissions during the 1997 to 2001 El Nino/La Nina period	SCIENCE			English	Article							CARBON-CYCLE; INTERANNUAL VARIABILITY; FOREST-FIRES; GROWTH-RATE; CO; ENSO	During the 1997 to 1998 El Nino, drought conditions triggered widespread increases in. re activity, releasing CH4 and CO2 to the atmosphere. We evaluated the contribution of. res from different continents to variability in these greenhouse gases from 1997 to 2001, using satellite-based estimates of. re activity, biogeochemical modeling, and an inverse analysis of atmospheric CO anomalies. During the 1997 to 1998 El Nino, the. re emissions anomaly was 2.1 +/- 0.8 petagrams of carbon, or 66 +/- 24% of the CO2 growth rate anomaly. The main contributors were Southeast Asia (60%), Central and South America (30%), and boreal regions of Eurasia and North America (10%).	Foreign Agr Serv, USDA, NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; NASA, Goddard Space Flight Ctr, Sci & Syst Applicat Inc, Greenbelt, MD 20771 USA; Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA; Univ Maryland, Dept Geog, College Pk, MD 20742 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; United States Department of Agriculture (USDA); California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Science Systems and Applications Inc; Duke University; University System of Maryland; University of Maryland College Park	van der Werf, GR (corresponding author), Foreign Agr Serv, USDA, NASA, Goddard Space Flight Ctr, Code 923,Greenbelt Rd, Greenbelt, MD 20771 USA.	guido@ltpmailx.gsfc.nasa.gov	Kasibhatla, Prasad/A-2574-2010; van der Werf, Guido/M-8260-2016; Arellano, Avelino/R-5795-2019; Randerson, James/Y-2550-2019; collatz, george j/D-5381-2012; Arellano, Avelino, Jr./F-5674-2010	van der Werf, Guido/0000-0001-9042-8630; Arellano, Avelino/0000-0002-2615-5831; Randerson, James/0000-0001-6559-7387; Giglio, Louis/0000-0001-6312-7955; Kasibhatla, Prasad/0000-0003-3562-3737				Andreae MO, 2001, GLOBAL BIOGEOCHEM CY, V15, P955, DOI 10.1029/2000GB001382; Battle M, 2000, SCIENCE, V287, P2467, DOI 10.1126/science.287.5462.2467; Bergamaschi P, 2000, J GEOPHYS RES-ATMOS, V105, P1909, DOI 10.1029/1999JD900818; Bey I, 2001, J GEOPHYS RES-ATMOS, V106, P23073, DOI 10.1029/2001JD000807; Bousquet P, 2000, SCIENCE, V290, P1342, DOI 10.1126/science.290.5495.1342; Carter A., 1989, GEOPHYS MONOGR SER, V55, P165, DOI DOI 10.1029/GM055P0165; Clark DA, 2003, P NATL ACAD SCI USA, V100, P5852, DOI 10.1073/pnas.0935903100; Conard SG, 2002, CLIMATIC CHANGE, V55, P197, DOI 10.1023/A:1020207710195; CONWAY TJ, 1994, J GEOPHYS RES-ATMOS, V99, P22831, DOI 10.1029/94JD01951; Curtis S, 2001, INT J CLIMATOL, V21, P961, DOI 10.1002/joc.643; DLUGOKENCKY EJ, 1994, J GEOPHYS RES-ATMOS, V99, P17021, DOI 10.1029/94JD01245; Dlugokencky EJ, 2001, GEOPHYS RES LETT, V28, P499, DOI 10.1029/2000GL012119; Gloor M, 2000, GLOBAL BIOGEOCHEM CY, V14, P407, DOI 10.1029/1999GB900052; Houghton JT, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P1; Jones CD, 2001, J CLIMATE, V14, P4113, DOI 10.1175/1520-0442(2001)014<4113:TCCRTE>2.0.CO;2; Kaminski T, 2001, J GEOPHYS RES-ATMOS, V106, P4703, DOI 10.1029/2000JD900581; Kasischke ES, 2002, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD000461; Korner C, 2003, SCIENCE, V300, P1242, DOI 10.1126/science.1084460; Langenfelds RL, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001466; Lee K, 1998, NATURE, V396, P155, DOI 10.1038/24139; Nemani RR, 2003, SCIENCE, V300, P1560, DOI 10.1126/science.1082750; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; Novelli PC, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003031; Page SE, 2002, NATURE, V420, P61, DOI 10.1038/nature01131; PEYLIN P, 2001, SCIENCE, V294, P5541; Phulpin T, 2002, INT J REMOTE SENS, V23, P1943, DOI 10.1080/01431160110076135; Rodenbeck C, 2003, ATMOS CHEM PHYS, V3, P1919; Schimel D, 2002, NATURE, V420, P29, DOI 10.1038/420029a; van der Werf GR, 2003, GLOBAL CHANGE BIOL, V9, P547, DOI 10.1046/j.1365-2486.2003.00604.x; [No title captured]	30	442	458	0	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					73	76		10.1126/science.1090753	http://dx.doi.org/10.1126/science.1090753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704424	Green Submitted			2022-12-28	WOS:000187710600035
J	Zimmer, C				Zimmer, C			A distant mirror for the brain	SCIENCE			English	Editorial Material																		Dumit Joseph, 2004, PICTURING PERSONHOOD; Finger S, 2000, MINDS BRAIN; FRANK R, 1980, HARVEY OXFORD CIRCLE; French R.K., 1999, DISSECTION VIVISECTI; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Kandel ER, 2000, SCIENCE, V290, P1113, DOI 10.1126/science.290.5494.1113; MacDonald Michael, 1981, MYSTICAL BEDLAM MADN; Martenson RL., 1999, SHORT HIST NEUROLOGY, P19; NEUBURGER M, 1981, HIST DEV EXPT BRAIN, P23; Shorter E, 1997, HIST PSYCHIATR, V1st; Willis T., 1965, ANATOMY BRAIN NERVES; Zimmer C, 2004, SOUL MADE FLESH	12	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					43	44		10.1126/science.1090319	http://dx.doi.org/10.1126/science.1090319			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704413				2022-12-28	WOS:000187710600021
J	Malone, CJ; Misner, L; Le Bot, N; Tsai, MC; Campbell, JM; Ahringer, J; White, JG				Malone, CJ; Misner, L; Le Bot, N; Tsai, MC; Campbell, JM; Ahringer, J; White, JG			The C-elegans hook protein, ZYG-12, mediates the essential attachment between the centrosome and nucleus	CELL			English	Article							LIGHT INTERMEDIATE CHAIN; CAENORHABDITIS-ELEGANS; CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; MICROTUBULE ORGANIZATION; MEMBRANE-PROTEINS; GAMMA-TUBULIN; MIGRATION; DROSOPHILA; EMBRYOS	The centrosome and nucleus are intimately associated in most animal cells, yet the significance of this interaction is unknown. Mutations in the zyg-12 gene of Caenorhabditis elegans perturb the attachment of the centrosome to the nucleus, giving rise to aberrant spindles and ultimately, DNA segregation defects and lethality. These phenotypes indicate that the attachment is essential. ZYG-12 is a member of the Hook family of cytoskeletal linker proteins and localizes to both the nuclear envelope (via SUN-1) and centrosomes. ZYG-12 is able to bind the dynein subunit DLI-1 in a two-hybrid assay and is required for dynein localization to the nuclear envelope. Loss of dynein function causes a low percentage of defective centrosome/nuclei interactions in both Drosophila and Caenorhabditis elegans. We propose that dynein and ZYG-12 move the centrosomes toward the nucleus, followed by a ZYG-12/SUN-1-dependent anchorage.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Anat, Madison, WI 53706 USA; Wellcome CRC Inst, Cambridge CB2 1QR, England	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Malone, CJ (corresponding author), Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA.	cjmalone@facstaff.wisc.edu		Tsai, Miao-Chih/0000-0003-4471-4825; Ahringer, Julie/0000-0002-7074-4051; Le Bot, Nathalie/0000-0002-5258-2837	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM052454] Funding Source: Medline; Wellcome Trust [054523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARONSON JF, 1971, J CELL BIOL, V51, P579, DOI 10.1083/jcb.51.2.579; BOMENS M, 1977, NATURE, V270, P80; BRENNER S, 1974, GENETICS, V77, P71; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; FRASER AG, 2000, BRIT J SOC PSYCHOL 4, V408, P325; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; Gonzalez C, 1998, J CELL SCI, V111, P2697; Hamill DR, 2002, DEV CELL, V3, P673, DOI 10.1016/S1534-5807(02)00327-1; Hannak E, 2002, J CELL BIOL, V157, P591, DOI 10.1083/jcb.200202047; HEDGECOCK EM, 1982, CELL, V30, P321, DOI 10.1016/0092-8674(82)90038-1; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Jakubowski J, 1999, GENETICS, V153, P743; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Keating HH, 1998, J CELL SCI, V111, P3027; Kitagawa R, 1999, NAT CELL BIOL, V1, P514, DOI 10.1038/70309; Kramer H, 1999, GENETICS, V151, P675; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Lee KK, 2002, MOL BIOL CELL, V13, P892, DOI 10.1091/mbc.01-06-0294; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malone CJ, 1999, DEVELOPMENT, V126, P3171; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; McDonald K, 1999, METH MOL B, V117, P77; NADEZHDINA ES, 1979, EUR J CELL BIOL, V19, P109; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; O'Connell KF, 2000, DEV BIOL, V222, P55, DOI 10.1006/dbio.2000.9714; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Praitis V, 2001, GENETICS, V157, P1217; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; RAFF JW, 1989, CELL, V57, P611, DOI 10.1016/0092-8674(89)90130-X; Raff JW, 1999, CURR BIOL, V9, pR708, DOI 10.1016/S0960-9822(99)80446-1; Reinsch S, 1997, CURR BIOL, V7, P211, DOI 10.1016/S0960-9822(97)70092-7; Reinsch S, 1998, J CELL SCI, V111, P2283; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Siomos MF, 2001, CURR BIOL, V11, P1825, DOI 10.1016/S0960-9822(01)00588-7; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 2002, SCIENCE, V298, P406, DOI 10.1126/science.1075119; Starr DA, 2001, DEVELOPMENT, V128, P5039; Strome S, 2001, MOL BIOL CELL, V12, P1751, DOI 10.1091/mbc.12.6.1751; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; Walther P, 2002, J MICROSC-OXFORD, V208, P3, DOI 10.1046/j.1365-2818.2002.01064.x; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; Yoder JH, 2001, MOL BIOL CELL, V12, P2921, DOI 10.1091/mbc.12.10.2921; Zipperlen P, 2001, EMBO J, V20, P3984, DOI 10.1093/emboj/20.15.3984	52	308	325	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 26	2003	115	7					825	836		10.1016/S0092-8674(03)00985-1	http://dx.doi.org/10.1016/S0092-8674(03)00985-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697201	Bronze			2022-12-28	WOS:000187664700007
J	Pead, PJ				Pead, PJ			Benjamin Jesty: new light in the dawn of vaccination	LANCET			English	Review									Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Pead, PJ (corresponding author), Univ Southampton, Southampton Gen Hosp, Mailpoint 814,Level C,S Block, Southampton SO16 6YD, Hants, England.							BARON J, 1827, LIFE E JENNEER; BAXBY D, 1994, VACCINATION JENNERS; CREASER T, 1803, OBSERVATIONS PEARSON; Crookshank EM, 1889, HIST PATHOLOGY VACCI; Gould GM, 1903, J AMER MED ASSOC, V40, P1477; Hammarsten J F, 1979, Trans Am Clin Climatol Assoc, V90, P44; HART FD, 1988, BRIT J CLIN PRACT, V42, P33; Haviland A., 1862, LANCET, V2, P291; HAYWARD N, 1989, BADGES BEANS; HAYWARD N, 2000, COMMUNICATION   0515; Hopkins D. R., 1983, PRINCES PEASANTS SMA; HORTON R, 1995, BRIT MED J, V310, P62, DOI 10.1136/bmj.310.6971.62a; HORTON R, 1992, LONDON REV BOOKS, V14, P22; Jenner G. C., 1805, EVIDENCE LARGE LAID; LEWER D, 1994, SWANAGE, V2; ODONNELL M, 2002, MED STRANGEST CASES; Pearson G, 1805, EDIN MED SURG J, V1, P513; Plotkin Stanley A., 1994, VACCINES; WALLACE M, 1981, 1 VACCINATOR; Yeatman RJ., 1930, 1066 ALL	20	22	22	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2104	2109		10.1016/S0140-6736(03)15111-2	http://dx.doi.org/10.1016/S0140-6736(03)15111-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697816				2022-12-28	WOS:000187429600030
J	Curry, R; Dickson, B; Yashayaev, I				Curry, R; Dickson, B; Yashayaev, I			A change in the freshwater balance of the Atlantic Ocean over the past four decades	NATURE			English	Article							ARCTIC-OCEAN; NORTH; VARIABILITY; PACIFIC; OSCILLATION; SALINITY; LAYER	The oceans are a global reservoir and redistribution agent for several important constituents of the Earth's climate system, among them heat, fresh water and carbon dioxide. Whereas these constituents are actively exchanged with the atmosphere, salt is a component that is approximately conserved in the ocean. The distribution of salinity in the ocean is widely measured, and can therefore be used to diagnose rates of surface freshwater fluxes(1), freshwater transport(2) and local ocean mixing(3) - important components of climate dynamics. Here we present a comparison of salinities on a long transect (50degrees S to 60degrees N) through the western basins of the Atlantic Ocean between the 1950s and the 1990s. We find systematic freshening at both poleward ends contrasted with large increases of salinity pervading the upper water column at low latitudes. Our results extend a growing body of evidence indicating that shifts in the oceanic distribution of fresh and saline waters are occurring worldwide in ways that suggest links to global warming and possible changes in the hydrologic cycle of the Earth.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Ctr Environm Fisheries & Aquaculture Sci, Lowestoft NR33 OHT, Suffolk, England; Bedford Inst Oceanog, Dartmouth, NS B2Y 4A2, Canada	Woods Hole Oceanographic Institution; Centre for Environment Fisheries & Aquaculture Science; Bedford Institute of Oceanography	Curry, R (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.			Yashayaev, Igor/0000-0002-6976-7803				Abdalati W, 1997, J CLIMATE, V10, P165, DOI 10.1175/1520-0442(1997)010<0165:SOTGIS>2.0.CO;2; Bindoff NL, 2000, J PHYS OCEANOGR, V30, P1207, DOI 10.1175/1520-0485(2000)030<1207:DCAAIO>2.0.CO;2; BLANKE B, 2003, J GEOPHYS RES, V107, P1; Blindheim J, 2000, DEEP-SEA RES PT I, V47, P655, DOI 10.1016/S0967-0637(99)00070-9; Bryden HL, 1996, J CLIMATE, V9, P3162, DOI 10.1175/1520-0442(1996)009<3162:DCIWMC>2.0.CO;2; CURRY RG, 2002, HYDROBASE2 DATABASE; DESER C, 1993, J CLIMATE, V6, P1743, DOI 10.1175/1520-0442(1993)006<1743:SCVOTN>2.0.CO;2; Dickson B, 2002, NATURE, V416, P832, DOI 10.1038/416832a; Dickson RR, 2000, J CLIMATE, V13, P2671, DOI 10.1175/1520-0442(2000)013<2671:TAORTT>2.0.CO;2; Houghton J. T., 2001, CLIMATE CHANGE 2001; Joyce TM, 1999, DEEP-SEA RES PT II, V46, P245, DOI 10.1016/S0967-0645(98)00102-7; Joyce TM, 1996, J CLIMATE, V9, P3121, DOI 10.1175/1520-0442(1996)009<3121:TLTHRA>2.0.CO;2; LAZIER JRN, 1995, NATURAL CLIMATE VARI, P295; LEVITUS S, 1989, J GEOPHYS RES-OCEANS, V94, P9679, DOI 10.1029/JC094iC07p09679; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; LUKAS R, 1991, J GEOPHYS RES-OCEANS, V96, P3343, DOI 10.1029/90JC01951; Marshall J, 2001, INT J CLIMATOL, V21, P1863, DOI 10.1002/joc.693; Mignot J, 2003, CLIM DYNAM, V20, P555, DOI 10.1007/s00382-002-0294-0; Moulin C, 1997, NATURE, V387, P691, DOI 10.1038/42679; PARILLA G, 1994, NATURE, V369, P48; PEIXOTO JP, 1992, PHYSICS CLIMATE, V53; Peterson BJ, 2002, SCIENCE, V298, P2171, DOI 10.1126/science.1077445; Roether W, 1996, SCIENCE, V271, P333, DOI 10.1126/science.271.5247.333; SCHMITT RW, 1995, REV GEOPHYS, V33, P1395, DOI 10.1029/95RG00184; SCHMITT RW, 1989, J PHYS OCEANOGR, V10, P1210; Vinje T, 2001, J CLIMATE, V14, P3508, DOI 10.1175/1520-0442(2001)014<3508:FSIFAA>2.0.CO;2; WIJFFELS SE, 1992, J PHYS OCEANOGR, V22, P155, DOI 10.1175/1520-0485(1992)022<0155:TOFBTO>2.0.CO;2; Wong APS, 1999, NATURE, V400, P440, DOI 10.1038/22733; Wong APS, 2001, J CLIMATE, V14, P1613, DOI 10.1175/1520-0442(2001)014<1613:FAHCIT>2.0.CO;2; Wust G, 1936, LANDERKUNDLICHE FORS, P347	30	403	416	2	109	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					826	829		10.1038/nature02206	http://dx.doi.org/10.1038/nature02206			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685235				2022-12-28	WOS:000187342000054
J	Johnston, RJ; Hobert, O				Johnston, RJ; Hobert, O			A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans	NATURE			English	Article							CHEMOSENSORY NEURONS; NERVOUS-SYSTEM; EXPRESSION; RNAS; LIM-6	How left/right functional asymmetry is layered on top of an anatomically symmetrical nervous system is poorly understood. In the nematode Caenorhabditis elegans, two morphologically bilateral taste receptor neurons, ASE left (ASEL) and ASE right (ASER), display a left/right asymmetrical expression pattern of putative chemoreceptor genes that correlates with a diversification of chemosensory specificities(1,2). Here we show that a previously undefined microRNA termed lsy-6 controls this neuronal left/right asymmetry of chemosensory receptor expression. lsy-6 mutants that we retrieved from a genetic screen for defects in neuronal left/right asymmetry display a loss of the ASEL-specific chemoreceptor expression profile with a concomitant gain of the ASER-specific profile. Alsy-6 reporter gene construct is expressed in less than ten neurons including ASEL, but not ASER. lsy-6 exerts its effects on ASEL through repression of cog-1, an Nkx-type homeobox gene, which contains a lsy-6 complementary site in its 30 untranslated region and that has been shown to control ASE-specific chemoreceptor expression profiles(3). lsy-6 is the first microRNA to our knowledge with a role in neuronal patterning, providing new insights into left/right axis formation.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University	Hobert, O (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, 701 W 168th St, New York, NY 10032 USA.	or38@columbia.edu		Hobert, Oliver/0000-0002-7634-2854				Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Chang S, 2003, GENE DEV, V17, P2123, DOI 10.1101/gad.1117903; Grad Y, 2003, MOL CELL, V11, P1253, DOI 10.1016/S1097-2765(03)00153-9; Halpern ME, 2003, TRENDS NEUROSCI, V26, P308, DOI 10.1016/S0166-2236(03)00129-2; Hobert O, 2002, NAT REV NEUROSCI, V3, P629, DOI 10.1038/nrn897; Hobert O, 1999, DEVELOPMENT, V126, P1547; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Lanjuin A, 2003, DEV CELL, V5, P621, DOI 10.1016/S1534-5807(03)00293-4; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Palmer RE, 2002, DEV BIOL, V252, P202, DOI 10.1006/dbio.2002.0850; Pierce-Shimomura JT, 2001, NATURE, V410, P694, DOI 10.1038/35070575; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Troemel ER, 1999, CELL, V99, P387, DOI 10.1016/S0092-8674(00)81525-1; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878; Yost HJ, 1998, DEV GENET, V23, P159; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	22	583	663	0	29	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					845	849		10.1038/nature02255	http://dx.doi.org/10.1038/nature02255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685240				2022-12-28	WOS:000187342000060
J	Caulford, P				Caulford, P			SARS: aftermath of an outbreak	LANCET			English	Article									Scarborough Gen Hosp, Family Med Serv, Scarborough, ON, Canada; Scarborough Gen Hosp, Community Serv, Scarborough, ON, Canada; Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada	Scarborough Hospital; Scarborough Hospital; University of Toronto	Caulford, P (corresponding author), Suite 207,3030 Lawrence Ave E, Scarborough, ON M1P 2T7, Canada.								0	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S2	S3		10.1016/S0140-6736(03)15052-0	http://dx.doi.org/10.1016/S0140-6736(03)15052-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698106	Green Published, Bronze			2022-12-28	WOS:000187790200002
J	Thompson, J				Thompson, J			Surviving a disaster	LANCET			English	Article									Middlesex Hosp, Royal Free & Univ Coll London Med Sch, London W1N 8AA, England	University of London; University College London	Thompson, J (corresponding author), Middlesex Hosp, Royal Free & Univ Coll London Med Sch, London W1N 8AA, England.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S56	S57		10.1016/S0140-6736(03)15079-9	http://dx.doi.org/10.1016/S0140-6736(03)15079-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698133				2022-12-28	WOS:000187790200029
J	Vaernes, RJ				Vaernes, RJ			Human reactions to deep-water conditions	LANCET			English	Article									Univ Bergen, Inst Biol & Med Psychol, NO-5848 Bergen, Norway; Univ Bergen, Inst Personal Psychol, NO-5848 Bergen, Norway	University of Bergen; University of Bergen	Vaernes, RJ (corresponding author), Univ Bergen, Inst Biol & Med Psychol, POB 6, NO-5848 Bergen, Norway.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S10	S11		10.1016/S0140-6736(03)15056-8	http://dx.doi.org/10.1016/S0140-6736(03)15056-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698110				2022-12-28	WOS:000187790200006
J	Piepoli, MF; Davos, C; Francis, DP; Coats, AJS; Belardinelli, R; Purcaro, A; Dubach, P; Myers, J; Giannuzzi, P; Temporelli, PL; Hambrecht, R; Linke, A; Kiilavuori, K; Leinonen, H; McKelvie, RS; Teo, KK; Volterrani, M; Giordano, A; Wielenga, RP; Baselier, MRP; Willenheimer, R; Rydberg, E; Adamopoulos, S; Dickestein, K; Gordon, A; Kostis, JB; Sellier, P; Toman, J				Piepoli, MF; Davos, C; Francis, DP; Coats, AJS; Belardinelli, R; Purcaro, A; Dubach, P; Myers, J; Giannuzzi, P; Temporelli, PL; Hambrecht, R; Linke, A; Kiilavuori, K; Leinonen, H; McKelvie, RS; Teo, KK; Volterrani, M; Giordano, A; Wielenga, RP; Baselier, MRP; Willenheimer, R; Rydberg, E; Adamopoulos, S; Dickestein, K; Gordon, A; Kostis, JB; Sellier, P; Toman, J		ExTraMATCH Collaborative	Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; CAPACITY; MEN	Objective To determine the effect of exercise training on survival in patients with heart failure due to left ventricular systolic dysfunction. Design Collaborative meta-analysis. Inclusion criteria Randomised parallel group controlled trials of exercise training, for at least eight weeks with individual patient data on survival for at least three months. Studies reviewed Nine datasets, totalling 801 patients: 395 received exercise training and 406 were controls. Main outcome measure Death from all causes. Results During a mean (SD) follow up of 705 (729) days there were 88 (22%) deaths in the exercise arm and 105 (26%) in the control arm. Exercise training significantly reduced mortality (hazard ratio 0.65, 95% confidence interval, 0.46 to 0.92; log rank chi(2) = 5.9; P = 0.015). The secondary end point of death or admission to hospital was also reduced (0.72, 0.56 to 0.93; log rank chi(2) = 6.4; P = 0.011). No statistically significant subgroup specific treatment effect was observed. Conclusion Meta-analysis of randomised trials to date gives no evidence that properly supervised medical training programmes for patients with heart failure might be dangerous, and indeed there is clear evidence of an overall reduction in mortality. Further research should focus on optimising exercise programmes and identifying appropriate patient groups to target.	Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Clin Cardiol, London SW3 6NP, England; Lancisi Inst, Div Cardiol, Ancona, Italy; Kantonsspital, Dept Cardiol, Chur, Switzerland; IRCCS, Ist Sci Veruno, Fdn Salvatore Maugeri, Novara, Italy; Univ Leipzig, Herzzentrum, Leipzig, Germany; Univ Helsinki, Cent Hosp, Div Cardiol, FIN-00014 Helsinki, Finland; McMaster Univ, Hamilton, ON, Canada; IRCCS, Ctr Med Gussago, Fdn Salvatore Maugeri, Brescia, Italy; Amphia Hosp, Breda, Netherlands; Univ Hosp, Dept Cardiol, Malmo, Sweden; Onassis Cardiac Surg Ctr, Dept Cardiol, Athens, Greece; Cent Hosp Rogaland, Div Cardiol, Stavanger, Norway; Huddinge Univ Hosp, Karolinska Inst, Dept Cardiol, Stockholm, Sweden; UMDNJ Robert Wood Inst, Johnson Med Sch, Dept Med, New Brunswick, NJ USA; Hop Broussais, Serv Readaptat Cardiaque, F-75674 Paris, France; Masaryk Univ, Dept Med 1, Brno, Czech Republic	Imperial College London; Royal Brompton Hospital; Kantonsspital Aarau AG (KSA); Istituti Clinici Scientifici Maugeri IRCCS; Heart Center Leipzig GMBH; Leipzig University; University of Helsinki; Helsinki University Central Hospital; McMaster University; IRCCS Fatebenefratelli; Istituti Clinici Scientifici Maugeri IRCCS; Amphia Hospital; Lund University; Skane University Hospital; Onassis Cardiac Surgery Center; Karolinska Institutet; Rutgers State University New Brunswick; Rutgers State University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Masaryk University Brno	Piepoli, MF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Clin Cardiol, London SW3 6NP, England.	m.piepoli@imperial.ac.uk	Coats, Andrew J Stewart/E-4451-2012; Temporelli, Pier Luigi/AAB-9754-2020; Davos, Constantinos/AAR-3259-2021; Davos, Constantinos H./AAR-9392-2020; Giannuzzi, Pantaleo/K-2797-2016; Piepoli, Massimo F/J-9437-2016; volterrani, maurizio/K-5919-2016; Piepoli, Massimo/HHC-3488-2022	Coats, Andrew J Stewart/0000-0002-2771-4260; Temporelli, Pier Luigi/0000-0002-6220-2471; Davos, Constantinos/0000-0002-0321-7569; Giannuzzi, Pantaleo/0000-0002-2313-9115; Piepoli, Massimo F/0000-0003-1124-234X; volterrani, maurizio/0000-0002-2624-9213; Piepoli, Massimo/0000-0003-1124-234X				BEGG C. B., 1994, HDB RES SYNTHESIS, P400; Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; Dubach P, 1997, J AM COLL CARDIOL, V29, P1591, DOI 10.1016/S0735-1097(97)82540-5; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Giannuzzi P, 1997, CIRCULATION, V96, P1790, DOI 10.1161/01.CIR.96.6.1790; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hambrecht R, 2000, JAMA-J AM MED ASSOC, V283, P3095, DOI 10.1001/jama.283.23.3095; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; Kiilavuori K, 2000, EUR J HEART FAIL, V2, P53, DOI 10.1016/S1388-9842(00)00058-1; LAUGHLIN MH, 1992, J APPL PHYSIOL, V73, P2209, DOI 10.1152/jappl.1992.73.6.2209; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; Maugeri FS, 1998, EUR HEART J, V19, P466; McKelvie RS, 2002, AM HEART J, V144, P23, DOI 10.1067/mhj.2002.123310; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Myers J, 2002, AM HEART J, V144, P719, DOI 10.1067/mhj.2002.124401; Quittan M, 1999, SCAND J REHABIL MED, V31, P223; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; VANOLI E, 1991, CIRC RES, V68, P1471, DOI 10.1161/01.RES.68.5.1471; WHITE FC, 1993, COLLATERAL CIRCULATI, P261; Wielenga RP, 1999, EUR HEART J, V20, P872, DOI 10.1053/euhj.1999.1485; Willenheimer R, 1998, EUR HEART J, V19, P774, DOI 10.1053/euhj.1997.0853; Zanelli E., 1997, European Heart Journal, V18, P647; ZANELLI F, 1997, EUR HEART J SUPPL, V18, P647	23	664	699	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2004	328	7433					189	192		10.1136/bmj.37938.645220.EE	http://dx.doi.org/10.1136/bmj.37938.645220.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14729656	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000188652200011
J	Pfleiderer, C; Reznik, D; Pintschovius, L; von Lohneysen, H; Garst, M; Rosch, A				Pfleiderer, C; Reznik, D; Pintschovius, L; von Lohneysen, H; Garst, M; Rosch, A			Partial order in the non-Fermi-liquid phase of MnSi	NATURE			English	Article							TRANSITION; SCATTERING; STRIPES; NMR	Only a few metallic phases have been identified in pure crystalline materials. These include normal, ferromagnetic and antiferromagnetic metals, systems with spin and charge density wave order, and superconductors. Fermi-liquid theory provides a basis for the description of all of these phases. It has been suggested that non-Fermi-liquid phases of metals may exist in some heavy-fermion compounds(1,2) and oxide materials(3-6), but the discovery of a characteristic microscopic signature of such phases presents a major challenge. The transition-metal compound MnSi above a certain pressure (p(c)=14.6 kbar) provides what may be the cleanest example of an extended non-Fermi-liquid phase in a three-dimensional metal(7-9). The bulk properties of MnSi suggest that long-range magnetic order is suppressed at p(c) (refs 7-12). Here we report neutron diffraction measurements of MnSi, revealing that sizeable quasi-static magnetic moments survive far into the non-Fermi-liquid phase. These moments are organized in an unusual pattern with partial long-range order. Our observation supports the existence of novel metallic phases with partial ordering of the conduction electrons (reminiscent of liquid crystals), as proposed for the high-temperature superconductors(4-6) and heavy-fermion compounds(13).	Univ Karlsruhe, Inst Phys, D-76128 Karlsruhe, Germany; Univ Karlsruhe, Inst Theorie Kondensierten Mat, D-76128 Karlsruhe, Germany; Forschungszentrum Karlsruhe, Inst Festkorperphys, D-76021 Karlsruhe, Germany; CEA Saclay, Lab Leon Brillouin, F-91191 Gif Sur Yvette, France	Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Pfleiderer, C (corresponding author), Univ Karlsruhe, Inst Phys, D-76128 Karlsruhe, Germany.	Christian.Pfleiderer@physik.uni-karlsruhe.de	Loehneysen, Hilbert/W-2490-2019; Garst, Markus/B-6740-2012; Rosch, Achim/A-2962-2009; Rosch, Achim/AAY-7730-2020; Pfleiderer, Christian/P-3575-2014	Garst, Markus/0000-0001-5390-3316; Rosch, Achim/0000-0002-6586-5721; Rosch, Achim/0000-0002-6586-5721; Pfleiderer, Christian/0000-0001-7749-7965				BAK P, 1980, J PHYS C SOLID STATE, V13, pL881, DOI 10.1088/0022-3719/13/31/002; BARZYKIN V, 1993, PHYS REV LETT, V70, P2479, DOI 10.1103/PhysRevLett.70.2479; BLOCH D, 1975, PHYS LETT A, VA 51, P259, DOI 10.1016/0375-9601(75)90438-7; Chandra P, 2002, NATURE, V417, P831, DOI 10.1038/nature00795; Dagotto E, 2001, PHYS REP, V344, P1, DOI 10.1016/S0370-1573(00)00121-6; Doiron-Leyraud N, 2003, NATURE, V425, P595, DOI 10.1038/nature01968; Fawcett E., 1970, International Journal of Magnetism, V1, P29; Grosche FM, 2000, J PHYS-CONDENS MAT, V12, pL533, DOI 10.1088/0953-8984/12/32/101; Huxley A, 2003, J PHYS-CONDENS MAT, V15, pS1945, DOI 10.1088/0953-8984/15/28/306; ISHIKAWA Y, 1984, J PHYS SOC JPN, V53, P2726, DOI 10.1143/JPSJ.53.2726; ISHIKAWA Y, 1985, PHYS REV B, V31, P5884, DOI 10.1103/PhysRevB.31.5884; KOISTINEN EP, 1995, PHYS REV LETT, V74, P4460, DOI 10.1103/PhysRevLett.74.4460; Koyama K, 2000, PHYS REV B, V62, P986, DOI 10.1103/PhysRevB.62.986; LAMMERT PE, 1993, PHYS REV LETT, V70, P1650, DOI 10.1103/PhysRevLett.70.1650; Lebech B., 1993, RECENT ADV MAGNETISM, P167; Mena FP, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.241101; Mydosh J. A., 1993, SPIN GLASSES EXPT IN; NAKANISHI O, 1980, SOLID STATE COMMUN, V35, P995, DOI 10.1016/0038-1098(80)91004-2; Pfleiderer C, 1997, PHYS REV B, V55, P8330, DOI 10.1103/PhysRevB.55.8330; Pfleiderer C, 2003, PHYSICA B, V328, P100, DOI 10.1016/S0921-4526(02)01818-5; Pfleiderer C, 2001, NATURE, V414, P427, DOI 10.1038/35106527; TAILLEFER L, 1986, J MAGN MAGN MATER, V54-7, P957, DOI 10.1016/0304-8853(86)90332-X; Thessieu C, 1997, J PHYS-CONDENS MAT, V9, P6677, DOI 10.1088/0953-8984/9/31/019; Thessieu C, 1998, J MAGN MAGN MATER, V177, P609, DOI 10.1016/S0304-8853(97)00478-2; VONSOVSKIJ SV, 1974, MAGNETISM 3, V2; WRIGHT DC, 1989, REV MOD PHYS, V61, P385, DOI 10.1103/RevModPhys.61.385; YASUOKA H, 1978, J PHYS SOC JPN, V44, P842, DOI 10.1143/JPSJ.44.842; Zaanen J, 2001, PHILOS MAG B, V81, P1485, DOI 10.1080/13642810110051791	30	295	296	1	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					227	231		10.1038/nature02232	http://dx.doi.org/10.1038/nature02232			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724633				2022-12-28	WOS:000188068100038
J	Studdert, DM; Mello, MM; Brennan, TA				Studdert, DM; Mello, MM; Brennan, TA			Medical malpractice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVERSE EVENTS; NO-FAULT; DEFENSIVE MEDICINE; PATIENT SAFETY; NEGLIGENT CARE; TORT REFORMS; CLAIMS; LIABILITY; LITIGATION; PHYSICIANS		Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Studdert, DM (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537; Mello, Michelle/0000-0003-2877-4270				ABRAHAM KS, 1994, HARVARD LAW REV, V108, P381, DOI 10.2307/1341896; BALDWIN LM, 1995, JAMA-J AM MED ASSOC, V274, P1606, DOI 10.1001/jama.274.20.1606; Berwick DM, 1999, BRIT MED J, V319, P136, DOI 10.1136/bmj.319.7203.136; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Born PH, 1998, BROOKINGS PAP ECO AC, P55; Bovbjerg RR, 1998, U CINCI LAW REV, V67, P53; Bovbjerg RR, 2001, J LAW MED ETHICS, V29, P369, DOI 10.1111/j.1748-720X.2001.tb00354.x; BOVBJERG RR, 1991, JAMA-J AM MED ASSOC, V265, P2836, DOI 10.1001/jama.265.21.2836; Bovbjerg RR, 1989, UC DAVIS LAW REV, V22, P499; BOVBJERG RR, UNDERSTANDING PENNSY; BOYLE LV, 2002, TRIAL            APR; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 1996, NEW ENGL J MED, V335, P1963, DOI 10.1056/NEJM199612263352606; BRENNAN TA, 2000, INDIANA LAW REV, V33, P1643; Calabresi G, 1970, COST ACCIDENTS LEGAL; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; Corrigan J., 2003, FOSTERING RAPID ADV; DANZON P, 1984, J LAW ECON, V27, P115, DOI 10.1086/467060; DANZON PM, 1990, AM ECON REV, V80, P122; DANZON PM, 1994, J LEGAL MED, V15, P199, DOI 10.1080/01947649409510944; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DANZON PM, 1985, MED MALPRACTICE THEO; Dauer EA, 1997, LAW CONTEMP PROBL, V60, P185, DOI 10.2307/1191999; De Ville Kenneth Allen, 1990, MED MALPRACTICE 19 C; *DEP HLTH ED WELF, 1973, MED MALPR REP SECR C; Dubay L, 1999, J HEALTH ECON, V18, P491, DOI 10.1016/S0167-6296(99)00004-1; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; Epstein Richard A., 1976, AM BAR FDN RES J, V1, DOI DOI 10.1111/J.1747-4469.1976.TB00953.X; *FL GOV SEL TASK F, 2003, REP REC; *GEN ACC OFF, 2003, GAO03836; *GEN ACC OFF, 2003, MED MALPR INS MULT F; Gostin L, 2000, JAMA-J AM MED ASSOC, V283, P1742, DOI 10.1001/jama.283.13.1742; HAVIGHURST CC, 1973, MILBANK FUND Q, V51, P125, DOI 10.2307/3349578; HAVIGHURST CC, 1998, HLTH CARE LAW POLICY; HAVIGHURST CC, 1995, HLTH CARE CHOICES PR; HELLINGER FJ, 2003, IMPACT STATE LAWS LI; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; Hickson GB, 2002, JAMA-J AM MED ASSOC, V287, P2951, DOI 10.1001/jama.287.22.2951; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; HOWARD PK, 2003, NY TIMES        0721, pA15; Hyams AL, 1996, J HEALTH POLIT POLIC, V21, P289, DOI 10.1215/03616878-21-2-289; JOHNSON KB, 1989, VANDERBILT LAW REV, V42, P1365; KAKALIK JS, 1986, R3391ICJ RAND; Keeton W., 1984, PROSSER KEETON LAW T; Kessler D, 1996, Q J ECON, V111, P353, DOI 10.2307/2946682; KINNEY ED, 1995, J HEALTH POLIT POLIC, V20, P99, DOI 10.1215/03616878-20-1-99; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Kritzer Herbert M, 1990, JUSTICE BROKER LAWYE; Lamb RM, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.2.73; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Liang BA, 2000, HEALTH AFFAIR, V19, P112, DOI 10.1377/hlthaff.19.5.112; LOCALIO AR, 1993, JAMA-J AM MED ASSOC, V269, P366, DOI 10.1001/jama.269.3.366; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; Mello MM, 2003, NEW ENGL J MED, V349, P1280, DOI 10.1056/NEJMhpr035095; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; Mello MM, 2002, TEX LAW REV, V80, P1595; Mello MM, 2001, U PENN LAW REV, V149, P645, DOI 10.2307/3312867; MILLS DH, 1977, CALIFORNIA MED ASS C; Mohr JC, 2000, JAMA-J AM MED ASSOC, V283, P1731, DOI 10.1001/jama.283.13.1731; MORLOCK LL, 1999, MANAGING QUALITY CAR; *NAT C STAT LEG, STAT MED LIAB LAWS T; O'Connell J, 1979, LAWSUIT LOTTERY ONLY; OCONNELL J, 1982, NORTHWEST U LAW REV, V77, P589; OCONNELL J, 1986, LAW CONTEMP PROBL, V49, P125, DOI 10.2307/1191419; *OFF ASS SECR PLAN, 2003, ADDR NEW HLTH CAR CR; PALMISANO DJ, 2003, STATEMENT AM MED ASS; PETERS PG, 2002, IOWA LAW REV     MAR, P909; *PHYS INS ASS AM, 2001, DAT SHAR PROJ INF MA; *PHYS INS ASS AM, 2003, STAT PHYS INS ASS AM; *PRES FELL HARV CO, 1990, PAT DOCT LAW MED INJ; RABIN RL, 1995, PERSPECTIVES TORT LA; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; REED M, 2003, DATA B CTR STUD HLTH, V24, P1; ROBINSON GO, 1986, LAW CONTEMP PROBL, V49, P5, DOI 10.2307/1191413; RUBIN RJ, 1994, J AM HEALTH POLICY, V4, P7; Rustad Michael L., 2002, BROOKLYN LAW REV, V68, P1; Sage WM, 2003, HEALTH AFFAIR, V22, P26, DOI 10.1377/hlthaff.22.4.26; SAGE WM, 1994, AM J LAW MED, V20, P1; SAGE WM, 2003, HLTH LAW HDB, P1; Schwartz GT, 1998, U ILLINOIS LAW REV, P885; SCHWARTZ GT, 1994, UCLA LAW REV, V42, P377; SCHWARTZ WB, 1989, JAMA-J AM MED ASSOC, V262, P1335, DOI 10.1001/jama.262.10.1335; Shavell S., 1987, EC ANAL ACCIDENT LAW; SLOAN FA, 1995, MED CARE, V33, P700, DOI 10.1097/00005650-199507000-00006; SLOAN FA, 1985, J HEALTH POLIT POLIC, V9, P629, DOI 10.1215/03616878-9-4-629; SLOAN FA, 1990, LAW SOC REV, V24, P997, DOI 10.2307/3053617; SLOAN FA, 1989, J HEALTH POLIT POLIC, V14, P663, DOI 10.1215/03616878-14-4-663; Sloan Frank A., 1993, SUING MED MALPRACTIC; Studdert DM, 2000, MED CARE, V38, P250, DOI 10.1097/00005650-200003000-00002; Studdert DM, 2001, JAMA-J AM MED ASSOC, V286, P217, DOI 10.1001/jama.286.2.217; Studdert DM, 1997, LAW CONTEMP PROBL, V60, pA1; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; TUSSING AD, 1992, MED CARE, V30, P529, DOI 10.1097/00005650-199206000-00006; *US C OFF TECHN AS, 1994, OTAH602 US C; VIDMAR N, 1995, MED MALPRACTICE AM J; VISCUSI WK, 1993, J RISK UNCERTAINTY, V6, P165, DOI 10.1007/BF01065357; WEILER PC, 1991, MED MALPRACTICE TRIA; Weiler PC, 1993, MD L REV, V52, P908; Weiler PC, 1993, MEASURE MALPRACTICE; WHITE MJ, 1994, HEALTH AFFAIR, V13, P75, DOI 10.1377/hlthaff.13.4.75; ZUCKERMAN S, 1990, INQUIRY-J HEALTH CAR, V27, P167; 1957, JAMA, V164, P1583	104	261	265	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					283	292		10.1056/NEJMhpr035470	http://dx.doi.org/10.1056/NEJMhpr035470			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	763HF	14724310				2022-12-28	WOS:000188078400015
J	Bhopal, R; Vettini, A; Hunt, S; Wiebe, S; Hanna, L; Amos, A				Bhopal, R; Vettini, A; Hunt, S; Wiebe, S; Hanna, L; Amos, A			Review of prevalence data in, and evaluation of methods for cross cultural adaptation of, UK surveys on tobacco and alcohol in ethnic minority groups	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; HEALTH; TRANSLATION; EQUIVALENCE; CONSUMPTION; BANGLADESHI; KNOWLEDGE; DRINKING; SMOKING	Objective To assess the adequacy of cross cultural adaptations of survey questions on self reported tobacco and alcohol consumption in the United Kingdom. Design Assessment of consistency of data between studies identified through literature review. Studies evaluated with 12 guidelines developed from the research literature on achieving cross cultural comparability. Results The literature review identified 18 key studies, five of them on national samples. Survey instruments were obtained for 15 of these. The comparison of prevalence data in national surveys showed some important discrepancies, greater for tobacco than for alcohol. For example, prevalence of cigarette smoking in Bangladeshi women was 6% in a national survey in 1994 and 1% in a national survey in 1999; in Chinese men it was 31% in a survey in 1993-4 and 17% in one in 1999; in African-Caribbean men it was 29% in a 1992 survey and 42% in one in 1993-4. The most guidelines met by any study was three, although one study partly met a fourth. Two studies met no guidelines. Only four studies consulted with ethnic minority communities in developing the questionnaire, none checked each language version with all others, and two stated the questionnaire had not been validated. Conclusions Surveys have not followed best practice in relation to measurement of risk factors in cross cultural settings. There is inconsistency in the prevalence data on smoking provided by different major national UK studies. Users of such data should be aware of their limitations. Research is needed to help achieve linguistic equivalence of survey questions in cross cultural research.	Univ Edinburgh, Sch Med, Publ Hlth Sci Sect, Div Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Bhopal, R (corresponding author), Univ Edinburgh, Sch Med, Publ Hlth Sci Sect, Div Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.	Raj.Bhopal@ed.ac.uk						AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ahmed S, 1997, BRIT J GEN PRACT, V47, P431; Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Bowden A, 2003, SOC SCI MED, V57, P1289, DOI 10.1016/S0277-9536(02)00503-8; Bullinger M, 1994, QUALITY LIFE ASSESSM, P33, DOI Heidelberg; COCHRANE R, 1990, BRIT J ADDICT, V85, P759; Denscombe M., 2000, Health Education Journal, V59, P340, DOI 10.1177/001789690005900407; DENSCOMBE M, 1995, PUBLIC HEALTH, V109, P133, DOI 10.1016/S0033-3506(05)80007-1; DEUTSCHER I, 1973, COMP RES METHODS, P163; ERENS B, 2001, HLTH ENGLAND HLTH MI, V2; ERENS B, 2001, HLTH SURVEY ENGLAND, V2; ERENS B, 2001, HLTH ENGLAND HLTH MI, V1; ERENS B, 2001, HLTH SURVEY ENGLAND, V1; *EUR GROUP QUAL LI, 1992, EUR GUID NOTT HLTH P; GILL PS, IN PRESS EPIDEMIOLOG; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; HENDRICSON WD, 1989, MED CARE, V27, P959, DOI 10.1097/00005650-198910000-00006; Herdman M, 1997, QUAL LIFE RES, V6, P237; Herdman M, 1998, QUAL LIFE RES, V7, P323, DOI 10.1023/A:1024985930536; Hunt S, 2003, BRIT MED J, V327, P352, DOI 10.1136/bmj.327.7411.352; HUNT S, IN PRESS J EPIDEMIOL; HUNT SM, 1991, HEALTH POLICY, V19, P33, DOI 10.1016/0168-8510(91)90072-6; Hunt SM, 1998, OX MED PUBL, P51; Hunt SM, 2000, QUAL LIFE RES, V9, P709, DOI 10.1023/A:1008969721968; Hunt SM, 1995, QUALITY OF LIFE AND HEALTH, P15; Hunt SM, 1986, MEASURING HLTH STATU; Johnson MC, 2000, BLACK ETHNIC MINORIT; KOHLI HS, 1989, PUBLIC HEALTH, V103, P433, DOI 10.1016/S0033-3506(89)80053-8; NAZROO JY, 1997, HLTH BRITAINS ETHNIC; PEARSON N, 2001, BR DENT J, V186, P517; Rudat K., 1994, BLACK MINORITY ETHNI; Shetty KV, 1999, COMMUNITY DENT HLTH, V16, P227; SPROSTON K, 2001, HLTH LIFESTYLES CHIN; Stewart AL, 2000, MED CARE, V38, P102; Summers R M, 1994, Community Dent Health, V11, P12; Szabo S., 1996, QUALITY LIFE PHARMAC, P355; TRIANDIS H, 1974, READINGS CROSS CULTU, P26; VETTINI A, 2001, MEASUREMENT RISK FAC, P1; White M, 2001, PUBLIC HEALTH, V115, P62, DOI 10.1038/sj.ph.1900722; WILLIAMS R, 1993, J EPIDEMIOL COMMUN H, V47, P96, DOI 10.1136/jech.47.2.96	40	44	44	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2004	328	7431					76	80A		10.1136/bmj.37963.426308.9A	http://dx.doi.org/10.1136/bmj.37963.426308.9A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	762MP	14707032	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000187976400014
J	Lewis, BP; Shih, IH; Jones-Rhoades, MW; Bartel, DP; Burge, CB				Lewis, BP; Shih, IH; Jones-Rhoades, MW; Bartel, DP; Burge, CB			Prediction of mammalian microRNA targets	CELL			English	Article							C-ELEGANS; SMALL RNAS; IDENTIFICATION; COMPLEMENTARY; CONSERVATION; EXPRESSION; SEQUENCE; ENCODES; LIN-28; TIME	MicroRNAs (miRNAs) can play important gene regulatory roles in nematodes, insects, and plants by base-pairing to mRNAs to specify posttranscriptional repression of these messages. However, the mRNAs regulated by vertebrate miRNAs are all unknown. Here we predict more than 400 regulatory target genes for the conserved vertebrate miRNAs by identifying mRNAs with conserved pairing to the 5' region of the miRNA and evaluating the number and quality of these complementary sites. Rigorous tests using shuffled miRNA controls supported a majority of these predictions, with the fraction of false positives estimated at 31% for targets identified in human, mouse, and rat and 22% for targets identified in pufferfish as well as mammals. Eleven predicted targets (out of 15 tested) were supported experimentally using a HeLa cell reporter system. The predicted regulatory targets of mammalian miRNAs were enriched for genes involved in transcriptional regulation but also encompassed an unexpectedly broad range of other functions.	MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Bartel, DP (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	dbartel@wi.mit.edu; cburge@mit.edu	Burge, Christopher B./AAH-2177-2020					Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Ashburner M, 2001, GENOME RES, V11, P1425; Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; BARTEL DP, 2004, IN PESS CELL; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dostie J, 2003, RNA, V9, P631; Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Iseli C, 2002, GENOME RES, V12, P1068, DOI 10.1101/gr.62002; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2003, CURR BIOL, V13, pR925, DOI 10.1016/j.cub.2003.11.017; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; NUSSINOV R, 1981, J BIOL CHEM, V256, P8458; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1	44	3994	4344	4	389	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	2003	115	7					787	798		10.1016/S0092-8674(03)01018-3	http://dx.doi.org/10.1016/S0092-8674(03)01018-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697198	Bronze			2022-12-28	WOS:000187664700004
J	Walther, DJ; Peter, JU; Winter, S; Holtje, M; Paulmann, N; Grohmann, M; Vowinckel, J; Alamo-Bethencourt, V; Wilhelm, CS; Ahnert-Hilger, G; Bader, M				Walther, DJ; Peter, JU; Winter, S; Holtje, M; Paulmann, N; Grohmann, M; Vowinckel, J; Alamo-Bethencourt, V; Wilhelm, CS; Ahnert-Hilger, G; Bader, M			Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release	CELL			English	Article							VON-WILLEBRAND-FACTOR; SEROTONIN REUPTAKE INHIBITORS; TISSUE-TRANSGLUTAMINASE; INDUCED ACTIVATION; THROMBUS FORMATION; ENDOTHELIAL-CELLS; SH-SY5Y CELLS; RHO GTPASES; RAT; 5-HYDROXYTRYPTAMINE	Serotonin is a neurotransmitter in the central nervous system. In the periphery, serotonin functions as a ubiquitous hormone involved in vasoconstriction and platelet function. Serotonin is synthesized independently in peripheral tissues and neurons by two different rate-limiting tryptophan hydroxylase (TPH) isoenzymes. Here, we show that mice selectively deficient in peripheral TPH and serotonin exhibit impaired hemostasis, resulting in a reduced risk of thrombosis and thromboembolism, although the ultrastructure of the platelets is not affected. While the aggregation of serotonin-deficient platelets in vitro is apparently normal, their adhesion in vivo is reduced due to a blunted secretion of adhesive alpha-granular proteins. In elucidating the mechanism further, we demonstrate that serotonin is transamidated to small GTPases by transglutaminases during activation and aggregation of platelets, rendering these GTPases constitutively active. Our data provides evidence for a receptor-independent signaling mechanism, termed herein as "serotonylation," which leads to alpha-granule exocytosis from platelets.	Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Humbolt Univ Berlin, Inst Anat, Charite, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Walther, DJ (corresponding author), Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.		Bader, Michael/K-2124-2013	Holtje, Markus/0000-0003-3193-4140; Bader, Michael/0000-0003-4780-4164				Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Azim AC, 2000, BLOOD, V95, P959, DOI 10.1182/blood.V95.3.959.003k22_959_964; Azmitia EC, 2001, BRAIN RES BULL, V56, P413, DOI 10.1016/S0361-9230(01)00614-1; BARRADAS MA, 1983, BRIT J CLIN PHARMACO, V16, P459, DOI 10.1111/j.1365-2125.1983.tb02198.x; Bodie SL, 2001, BIOCHEM BIOPH RES CO, V287, P71, DOI 10.1006/bbrc.2001.5547; BUCZKO W, 1975, BRIT J PHARMACOL, V53, P563, DOI 10.1111/j.1476-5381.1975.tb07395.x; Case A, 2003, BIOCHEMISTRY-US, V42, P9466, DOI 10.1021/bi030084z; Citron BA, 2000, NEUROCHEM INT, V37, P337, DOI 10.1016/S0197-0186(00)00044-9; COHEN RA, 1983, SCIENCE, V221, P273, DOI 10.1126/science.6574604; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; DECLERCK F, 1984, AGENTS ACTIONS, V15, P627; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Eddahibi S, 2002, J LAB CLIN MED, V139, P194, DOI 10.1067/mlc.2002.122181; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; HOLLAND JM, 1976, P SOC EXP BIOL MED, V151, P32; Holtje M, 2003, J BIOL CHEM, V278, P15850, DOI 10.1074/jbc.M212816200; Jackson SP, 2003, J THROMB HAEMOST, V1, P1602, DOI 10.1046/j.1538-7836.2003.00267.x; Katayama T, 2000, CIRC RES, V86, P1031, DOI 10.1161/01.RES.86.10.1031; KILLAM AL, 1991, THROMB RES, V64, P331, DOI 10.1016/0049-3848(91)90004-G; Lee SK, 2000, J HISTOCHEM CYTOCHEM, V48, P1565, DOI 10.1177/002215540004801113; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Maayani S, 2001, PLATELETS, V12, P279, DOI 10.1080/09537100120071004; Maayani S, 2001, PLATELETS, V12, P359; Maggio N, 2001, BRAIN RES BULL, V56, P173, DOI 10.1016/S0361-9230(01)00649-9; Masuda M, 2000, EMBO J, V19, P521, DOI 10.1093/emboj/19.4.521; McNicol A, 1999, THROMB RES, V95, P1, DOI 10.1016/S0049-3848(99)00015-8; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MOHAMMAD SF, 1975, AM J PATHOL, V79, P81; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Nishioka H, 2001, BIOCHEM BIOPH RES CO, V280, P970, DOI 10.1006/bbrc.2001.4237; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; PALMER DS, 1994, THROMB HAEMOSTASIS, V72, P132; PUSZKIN EG, 1985, J BIOL CHEM, V260, P6012; RAPPORT MM, 1948, SCIENCE, V108, P329, DOI 10.1126/science.108.2804.329; Schluter T, 1999, BIOCHEM PHARMACOL, V57, P1191, DOI 10.1016/S0006-2952(99)00011-8; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt G, 1999, J BIOL CHEM, V274, P31875, DOI 10.1074/jbc.274.45.31875; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Serafeim A, 2002, BLOOD, V99, P2545, DOI 10.1182/blood.V99.7.2545; Serebruany VL, 2001, PHARMACOL RES, V43, P453, DOI 10.1006/phrs.2001.0817; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; SIESS W, 1989, PHYSIOL REV, V69, P59; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Szasz R, 2002, BLOOD, V100, P2827, DOI 10.1182/blood-2002-02-0354; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Walther DJ, 1999, MOL BRAIN RES, V68, P55, DOI 10.1016/S0169-328X(99)00046-7; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197	51	349	358	3	19	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	2003	115	7					851	862		10.1016/S0092-8674(03)01014-6	http://dx.doi.org/10.1016/S0092-8674(03)01014-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697203	Bronze			2022-12-28	WOS:000187664700009
J	Sitia, R; Braakman, I				Sitia, R; Braakman, I			Quality control in the endoplasmic reticulum protein factory	NATURE			English	Article							SECRETORY PATHWAY; MOLECULAR CHAPERONES; DISULFIDE BONDS; ER STRESS; CELLS; NEURODEGENERATION; AGGREGATION; METABOLISM; RECEPTOR; CYTOSOL	The endoplasmic reticulum (ER) is a factory where secretory proteins are manufactured, and where stringent quality-control systems ensure that only correctly folded proteins are sent to their final destinations. The changing needs of the ER factory are monitored by integrated signalling pathways that constantly adjust the levels of folding assistants. ER chaperones and signalling molecules are emerging as drug targets in amyloidoses and other protein-conformational diseases.	Univ Vita Salute, San Raffaele Sci Inst, I-20132 Milan, Italy; Univ Utrecht, NL-3584 CH Utrecht, Netherlands	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Utrecht University	Sitia, R (corresponding author), Univ Vita Salute, San Raffaele Sci Inst, I-20132 Milan, Italy.		Sitia, Roberto/AAB-5005-2019	Sitia, Roberto/0000-0001-7086-4152; Braakman, Ineke/0000-0003-1592-4364	Telethon [GP0117Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aridor M, 2000, SCIENCE, V287, P816, DOI 10.1126/science.287.5454.816; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bouvier M, 2003, MOL IMMUNOL, V39, P697, DOI 10.1016/S0161-5890(02)00261-4; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hegde RS, 2003, TRENDS NEUROSCI, V26, P337, DOI 10.1016/S0166-2236(03)00143-7; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hendershot LM, 2000, NAT CELL BIOL, V2, pE105, DOI 10.1038/35014100; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; Higashio H, 2002, BIOCHEM BIOPH RES CO, V296, P568, DOI 10.1016/S0006-291X(02)00923-3; Hosokawa N, 2000, FEBS LETT, V466, P19, DOI 10.1016/S0014-5793(99)01713-5; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Papp S, 2003, J CELL BIOL, V160, P475, DOI 10.1083/jcb.200207136; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Wang T, 2003, NAT STRUCT BIOL, V10, P319, DOI 10.1038/nsb0503-319; Yoneda T, 2002, GENE DEV, V16, P1307, DOI 10.1101/gad.1000902; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4	42	552	582	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					891	894		10.1038/nature02262	http://dx.doi.org/10.1038/nature02262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685249	Green Published			2022-12-28	WOS:000187342000071
J	Freer, L				Freer, L			Wilderness medicine	LANCET			English	Article									Yellowstone Natl Pk, Yellowstone Natl Pk, WY USA; Himalayan Rescue Assoc, Everest Base Camp Med Clin, Kathmandu, Nepal		Freer, L (corresponding author), 220 Deer Path, Bozeman, MT 59718 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S6	S7		10.1016/S0140-6736(03)15054-4	http://dx.doi.org/10.1016/S0140-6736(03)15054-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698108				2022-12-28	WOS:000187790200004
J	Lewin, M				Lewin, M			The Gobi Desert medical kit	LANCET			English	Article									Univ Calif San Francisco, San Francisco, CA 94143 USA; Calif State Univ Fresno, Fresno, CA 93740 USA	University of California System; University of California San Francisco; California State University System; California State University Fresno	Lewin, M (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.								0	1	1	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S4	S5		10.1016/S0140-6736(03)15053-2	http://dx.doi.org/10.1016/S0140-6736(03)15053-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698107	Bronze			2022-12-28	WOS:000187790200003
J	Chow, KY; Lee, CE; Ling, ML; Heng, DMK; Yap, SG				Chow, KY; Lee, CE; Ling, ML; Heng, DMK; Yap, SG			Outbreak of severe acute respiratory syndrome in a tertiary hospital in Singapore, linked to an index patient with atypical presentation: epidemiological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To describe an outbreak of severe acute respiratory syndrome (SARS) in a tertiary hospital in Singapore, linked to an index patient with atypical presentation, and the lessons learnt from it. Design Descriptive study. Setting A tertiary hospital in Singapore. Participants Patients, healthcare workers, and visitors who contracted SARS in Singapore General Hospital. Main outcome measures Probable SARS as defined by the World Health Organization. Results The index patient presented with gastrointestinal bleeding, initially without changes to his chest radiograph. Altogether 24 healthcare workers, 15 patients, and 12 family members and visitors were infected. The incubation period ranged from three to eight days. Only 13 patients were isolated on their dates of onset. Conclusions Atypical presentation of SARS infection must be taken into consideration when managing patients with a history of contact with SARS patients. The main gap in the containment strategy in this outbreak was the failure to identify the index patient as someone who had been discharged from a ward in another hospital that managed probable SARS cases. Strict infection control measures, a good surveillance system, early introduction of isolation procedures, and vigilant healthcare professionals are essential for controlling outbreaks.	Singapore Gen Hosp, Singapore 169608, Singapore; Hlth Promot Board, Adult Hlth Div, Hlth Screening Dept, Singapore 168937, Singapore; Minist Hlth Singapore, Coll Med, Planning & Dev Div, Casemix Project Off, Singapore 169854, Singapore; Singapore Gen Hosp, Dept Ear Nose & Throat, Singapore, Singapore; Clin Trials & Epidemiol Res Unit, Singapore 169039, Singapore	Singapore General Hospital; Ministry of Health-Singapore; Singapore General Hospital	Ling, ML (corresponding author), Singapore Gen Hosp, Outram Rd, Singapore 169608, Singapore.	gptlml@sgh.com.sg	Ling, Moi Lin/W-2125-2019					*CDCP, 2003, MMWR-MORBID MORTAL W, V52, P391; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P255; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; HSU LY, 2003, EMERG INFECT DIS, V9, P108; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; TWU SJ, 2003, EMERG INFECT DIS, V9, P1; *WHO, DIS OUTBR REP WHO IS	9	32	35	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2004	328	7433					195	198		10.1136/bmj.37939.465729.44	http://dx.doi.org/10.1136/bmj.37939.465729.44			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14726369	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000188652200013
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Serv Task Force	Screening for thyroid disease: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article								This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for thyroid disease and updates the 1996 recommendations on this topic. The complete USPSTF recommendation statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned. The recommendation statement and article are also available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse.	Univ Washington, Seattle, WA 98195 USA; Univ Maryland, Baltimore, MD 21201 USA; Tricty Family Med, Cohocton, NY USA; Univ Rochester, Sch Med, Rochester, NY 14627 USA; Natl Initiat Childrens Healthcare, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Harvard Univ, Pilgrim Hlth Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA; Univ Michigan, Ann Arbor, MI 48109 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Baltimore; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard University; Harvard Medical School; Robert Wood Johnson Foundation (RWJF); Women & Infants Hospital Rhode Island; University of Michigan System; University of Michigan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), Univ Washington, Seattle, WA 98195 USA.							*AACE THYR TASK FO, 2002, ENDOCR PRACT, V8, P457; *AM AC FAM PHYS, 2002, 510 AM AC FAM PHYS; *AM COLL OBST GYN, 2002, TECHNICAL B AM COLL, V37; Canadian Task Force on the Periodic Health Examination, 1994, CAN GUID CLIN PREV H, P611; Helfand M, 1998, ANN INTERN MED, V129, P141, DOI 10.7326/0003-4819-129-2-199807150-00020; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573	6	54	59	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					125	127		10.7326/0003-4819-140-2-200401200-00014	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734336				2022-12-28	WOS:000188211700008
J	Jorgensen, KJ; Gotzsche, PC				Jorgensen, KJ; Gotzsche, PC			Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAMMOGRAPHY; IMPACT; WOMEN	Objective To investigate whether information on mammographic screening presented on websites by interest groups is balanced, is independent of source of funding, and reflects recent findings. Design Cross sectional study using a checklist with 17 information items. Setting 27 websites in Scandinavian and English speaking countries. Results The 13 sites from advocacy groups and the 11 from governmental institutions all recommended mammographic screening, whereas the three from consumer organisations questioned screening (P = 0.0007). All the advocacy groups accepted industry funding, apparently without restrictions. In contrast the three consumer organisations acknowledged the risk of bias related to industry funding, and two of them did not accept such funding at all. Advocacy groups and governmental organisations favoured information items that shed positive light on screening. The major harms of screening, overdiagnosis and overtreatment, were mentioned by only four of these groups, but by all three sites from consumer organisations (P = 0.02). In addition, the chosen information was often misleading or erroneous. The selection of information items for websites did not reflect recent findings, apart from the consumer sites, which were much more balanced and comprehensive than other sites (median of 9 information items v 3 items, P = 0.03). Conclusions The information material provided by professional advocacy groups and governmental organisations is information poor and severely biased in favour of screening. Few websites live up to accepted standards for informed consent such as those stated in the General Medical Council's guidelines.	Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen O, Denmark.	pcg@cochrane.dk		Jorgensen, Karsten/0000-0001-8554-0388				ABE O, 1995, NEW ENGL J MED, V333, P1444; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Croft E, 2002, J FAM PRACTICE, V51, P858; Davey Heather M, 2002, Health Expect, V5, P330, DOI 10.1046/j.1369-6513.2002.00194.x; DOUEK M, 2003, BR J SURG S1, V90; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Elwood M, 1998, NEW ZEAL MED J, V111, P180; *ET RAD, 1999, SCREEN RED; *EUR OP RES GROUP, 2003, EUR UN CIT SOURC INF; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; GOTZASCHE PC, IN PRESS INT J EPIDE; Gotzsche PC, 2002, LANCET, V360, P338, DOI 10.1016/S0140-6736(02)09524-7; Gotzsche PC, 2001, LANCET, V358, P2167, DOI 10.1016/S0140-6736(01)07198-7; Gotzsche PC, 2001, BRIT MED J, V323, P1131, DOI 10.1136/bmj.323.7321.1131a; GOTZSCHE PC, IN PRESS INT J EPIDE; Horton R, 2002, LANCET, V359, P441, DOI 10.1016/S0140-6736(02)07570-0; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; MATEAU TM, 2001, HLTH EXPECT, V4, P99; McNoe B, 1996, WOMENS EXPERIENCE OT; MILLER AB, 1993, AM J PREV MED, V9, P175, DOI 10.1016/S0749-3797(18)30734-7; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; *NHS, 2001, BREAST SCREEN FACTS; Nystrom L, 1996, J Med Screen, V3, P85; Nystrom L, 2002, LANCET, V360, P339, DOI 10.1016/S0140-6736(02)09527-2; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; NYSTROM L, 2002, LANCET, V360, P1178; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Olsen O, 2001, COCHRANE DB SYST REV, V4, P1877; OLSEN O, 2001, SYSTEMATIC REV SCREE; Raffle A E, 2001, Health Expect, V4, P92, DOI 10.1046/j.1369-6513.2001.00138.x; Ransohoff DF, 1997, ANN INTERN MED, V127, P1029, DOI 10.7326/0003-4819-127-11-199712010-00016; Ries LA, 2002, SEER CANC STAT REV 1; Schwartz LM, 2000, BMJ-BRIT MED J, V320, P1635, DOI 10.1136/bmj.320.7250.1635; Slaytor EK, 1998, BRIT MED J, V317, P263, DOI 10.1136/bmj.317.7153.263; Sundhedsstyrelsen. Statusrapport, 1997, TIDL OPSP BEH BRYSTK; Thornton H, 2000, LANCET, V356, P1033, DOI 10.1016/S0140-6736(05)72655-6; *US PREV SERV TASK, 2000, ANN INTERN MED, V137, P344; Wolf AMD, 1996, ARCH INTERN MED, V156, P1333, DOI 10.1001/archinte.156.12.1333	40	92	93	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2004	328	7432					148	151		10.1136/bmj.328.7432.148	http://dx.doi.org/10.1136/bmj.328.7432.148			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726344	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000188249900023
J	McKee, M				McKee, M			Commentary: Not everything that counts can be counted; not everything that can be counted counts	BRITISH MEDICAL JOURNAL			English	Editorial Material							LEAGUE TABLES; PERFORMANCE; CARE		Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	martin.mckee@lshtm.ac.uk	Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X				*BBC, 2003, TENTS PREP A E PAT; Broder MS, 2004, BRIT MED J, V328, P152, DOI 10.1136/bmj.328.7432.152; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Jacobson B, 2003, BRIT MED J, V326, P777, DOI 10.1136/bmj.326.7393.777; Leyland AH, 1998, LANCET, V351, P555, DOI 10.1016/S0140-6736(97)09362-8; Magee H, 2003, J ROY SOC MED, V96, P338, DOI 10.1258/jrsm.96.7.338; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406	9	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					153	153		10.1136/bmj.328.7432.153	http://dx.doi.org/10.1136/bmj.328.7432.153			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726346	Green Submitted, Bronze, Green Published, Green Accepted			2022-12-28	WOS:000188249900025
J	Dhugga, KS; Barreiro, R; Whitten, B; Stecca, K; Hazebroek, J; Randhawa, GS; Dolan, M; Kinney, AJ; Tomes, D; Nichols, S; Anderson, P				Dhugga, KS; Barreiro, R; Whitten, B; Stecca, K; Hazebroek, J; Randhawa, GS; Dolan, M; Kinney, AJ; Tomes, D; Nichols, S; Anderson, P			Guar seed beta-mannan synthase is a member of the cellulose synthase super gene family	SCIENCE			English	Article							HIGHER-PLANTS; GALACTOMANNAN BIOSYNTHESIS; ARABIDOPSIS; ENZYME; GALACTOSYLTRANSFERASE; IDENTIFICATION; PURIFICATION; SYNTHETASE; ENCODES; GROWTH	Genes for the enzymes that make plant cell wall hemicellulosic polysaccharides remain to be identified. We report here the isolation of a complementary DNA ( cDNA) clone encoding one such enzyme, mannan synthase (ManS), that makes the beta-1, 4-mannan backbone of galactomannan, a hemicellulosic storage polysaccharide in guar seed endosperm walls. The soybean somatic embryos expressing ManS cDNA contained high levels of ManS activities that localized to Golgi. Phylogenetically, ManS is closest to group A of the cellulose synthase-like (Csl) sequences from Arabidopsis and rice. Our results provide the biochemical proof for the involvement of the Csl genes in beta-glycan formation in plants.	Pioneer HiBred Int Inc, Crop Genet Res & Dev, Johnston, IA 50131 USA; Indian Inst Technol, Dept Biosci & Biotechnol, Roorkee 247667, Uttar Pradesh, India; DuPont Co Inc, Expt Stn, Crop Genet Res & Dev, Wilmington, DE 19880 USA; DuPont Co Inc, Expt Stn, Cent Res & Dev, Wilmington, DE 19880 USA	DuPont; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Roorkee; DuPont; DuPont	Dhugga, KS (corresponding author), Pioneer HiBred Int Inc, Crop Genet Res & Dev, 7300 NW 62nd Ave, Johnston, IA 50131 USA.			Dhugga, Kanwarpal/0000-0003-2477-3422; Randhawa, Gursharn/0000-0003-1374-8360				Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; CUTLER S, 1997, CURR BIOL, V7, P108; DHUGGA KS, 1994, EUR J BIOCHEM, V220, P943, DOI 10.1111/j.1432-1033.1994.tb18698.x; EDWARDS M, 1992, PLANTA, V187, P67, DOI 10.1007/BF00201625; Edwards ME, 1999, PLANT J, V19, P691, DOI 10.1046/j.1365-313x.1999.00566.x; Faik A, 2002, P NATL ACAD SCI USA, V99, P7797, DOI 10.1073/pnas.102644799; Favery B, 2001, GENE DEV, V15, P79, DOI 10.1101/gad.188801; Goubet F, 2003, PLANT PHYSIOL, V131, P547, DOI 10.1104/pp.014555; Hazen SP, 2002, PLANT PHYSIOL, V128, P336, DOI 10.1104/pp.010875; Joersbo M, 2001, MOL BREEDING, V7, P211, DOI 10.1023/A:1011375605835; KANG MS, 1984, J BIOL CHEM, V259, P4966; KOOIMAN P, 1971, CARBOHYD RES, V20, P329, DOI 10.1016/S0008-6215(00)81387-7; Kudlicka K, 1997, PLANT PHYSIOL, V115, P643, DOI 10.1104/pp.115.2.643; Maier H., 1993, IND GUMS, P181, DOI DOI 10.1016/B978-0-08-092654-4.50012-7; MUJER CV, 1984, PHYTOCHEMISTRY, V33, P893; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; Perrin RM, 1999, SCIENCE, V284, P1976, DOI 10.1126/science.284.5422.1976; RAY PM, 1969, P NATL ACAD SCI USA, V64, P605, DOI 10.1073/pnas.64.2.605; REID JSG, 1995, PLANTA, V195, P489, DOI 10.1007/BF00195705; Reid JSG, 2003, PLANT PHYSIOL, V131, P1487, DOI 10.1104/pp.102.016840; REID JSG, 1992, BIOCHEM SOC T, V20, P23, DOI 10.1042/bst0200023; Richmond TA, 2000, PLANT PHYSIOL, V124, P495, DOI 10.1104/pp.124.2.495; Saxena IM, 1997, CELLULOSE, V4, P33, DOI 10.1023/A:1018411101036; Taylor NG, 1999, PLANT CELL, V11, P769, DOI 10.1105/tpc.11.5.769; Wang X, 2001, PLANT PHYSIOL, V126, P575, DOI 10.1104/pp.126.2.575; Wee EGT, 1998, PLANT CELL, V10, P1759, DOI 10.1105/tpc.10.10.1759; Whistler R.L., 1993, INTRO IND GUMS IND G, P1, DOI 10.1016/B978-0-08-092654-4.50005-X; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	29	259	285	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					363	366		10.1126/science.1090908	http://dx.doi.org/10.1126/science.1090908			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726589				2022-12-28	WOS:000188111800041
J	Treanor, J				Treanor, J			Influenza vaccine - Outmaneuvering antigentic shift and drift	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							VIRUS		Univ Rochester, Med Ctr, Infect Dis Unit, Rochester, NY 14642 USA	University of Rochester	Treanor, J (corresponding author), Univ Rochester, Med Ctr, Infect Dis Unit, Rochester, NY 14642 USA.							Belshe RB, 2000, J PEDIATR-US, V136, P168, DOI 10.1016/S0022-3476(00)70097-7; Hay AJ, 2001, PHILOS T R SOC B, V356, P1861, DOI 10.1098/rstb.2001.0999; Kilbourne ED, 1999, NAT MED, V5, P1119, DOI 10.1038/13436; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513	5	147	166	1	28	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					218	220		10.1056/NEJMp038238	http://dx.doi.org/10.1056/NEJMp038238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724300				2022-12-28	WOS:000188078400004
J	Trenberth, KE				Trenberth, KE			Climatology - Rural land-use change and climate	NATURE			English	Editorial Material							DIURNAL TEMPERATURE-RANGE		Natl Ctr Atmospher Res, Boulder, CO 80307 USA	National Center Atmospheric Research (NCAR) - USA	Trenberth, KE (corresponding author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA.	trenbert@ucar.edu	Trenberth, Kevin Edward/A-5683-2012	Trenberth, Kevin Edward/0000-0002-1445-1000				Bonan GB, 2001, J CLIMATE, V14, P2430, DOI 10.1175/1520-0442(2001)014&lt;2430:OEFROD&gt;2.0.CO;2; Dai A, 1999, J CLIMATE, V12, P2451, DOI [10.1175/1520-0442(1999)012<2451:EOCSMP>2.0.CO;2, 10.1175/1520-0442(1999)012&lt;2451:EOCSMP&gt;2.0.CO;2]; Durre I, 2001, J CLIMATE, V14, P3263, DOI 10.1175/1520-0442(2001)014<3263:FITCSD>2.0.CO;2; Durre I, 2001, J CLIMATE, V14, P354, DOI 10.1175/1520-0442(2001)014<0354:TWSDID>2.0.CO;2; Kalnay E, 2003, NATURE, V423, P528, DOI 10.1038/nature01675; Milly PCD, 2001, GEOPHYS RES LETT, V28, P1219, DOI 10.1029/2000GL012321; Myhre G, 2003, J CLIMATE, V16, P1511, DOI 10.1175/1520-0442-16.10.1511; Trenberth KE, 2001, CLIM DYNAM, V17, P259, DOI 10.1007/PL00007927	8	64	77	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					213	213		10.1038/427213a	http://dx.doi.org/10.1038/427213a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724627	Bronze			2022-12-28	WOS:000188068100032
J	Liu, YL; Masson, JY; Shah, R; O'Regan, P; West, SC				Liu, YL; Masson, JY; Shah, R; O'Regan, P; West, SC			RAD51C is required for Holliday junction processing in mammalian cells	SCIENCE			English	Article							DNA-REPAIR PROTEINS; COMPLEX-FORMATION; IN-VITRO; RECOMBINATION; XRCC3; IDENTIFICATION; STABILITY; PARALOGS; BINDING; VIVO	During genetic recombination and the recombinational repair of chromosome breaks, DNA molecules become linked at points of strand exchange. Branch migration and resolution of these crossovers, or Holliday junctions (HJs), complete the recombination process. Here, we show that extracts from cells carrying mutations in the recombination/repair genes RAD51C or XRCC3 have reduced levels of HJ resolvase activity. Moreover, depletion of RAD51C from fractionated human extracts caused a loss of branch migration and resolution activity, but these functions were restored by complementation with a variety of RAD51 paralog complexes containing RAD51C. We conclude that the RAD51 paralogs are involved in HJ processing in human cells.	Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, S Mimms, S Mimms EN6 3LD, Herts, England.			Masson, Jean Yves/0000-0002-4403-7169; West, Stephen/0000-0001-8848-9418				Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; BLEUYARD JY, IN PRESS EMBO J; Braybrooke JP, 2000, J BIOL CHEM, V275, P29100, DOI 10.1074/jbc.M002075200; Braybrooke JP, 2003, J BIOL CHEM, V278, P48357, DOI 10.1074/jbc.M308838200; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Ciccia A, 2003, J BIOL CHEM, V278, P25172, DOI 10.1074/jbc.M302882200; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; ELBOROUGH KM, 1988, NUCLEIC ACIDS RES, V16, P3603, DOI 10.1093/nar/16.9.3603; French CA, 2003, J BIOL CHEM, V278, P45445, DOI 10.1074/jbc.M308621200; French CA, 2002, J BIOL CHEM, V277, P19322, DOI 10.1074/jbc.M201402200; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Kurumizaka H, 2002, J BIOL CHEM, V277, P14315, DOI 10.1074/jbc.M105719200; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Lio YC, 2003, J BIOL CHEM, V278, P2469, DOI 10.1074/jbc.M211038200; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Liu Y., UNPUB; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Wiese C, 2002, NUCLEIC ACIDS RES, V30, P1001, DOI 10.1093/nar/30.4.1001; Yokoyama H, 2003, J BIOL CHEM, V278, P2767, DOI 10.1074/jbc.M210899200	25	245	258	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					243	246		10.1126/science.1093037	http://dx.doi.org/10.1126/science.1093037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716019				2022-12-28	WOS:000187908500053
J	Pecot, MY; Malhotra, V				Pecot, MY; Malhotra, V			Golgi membranes remain segregated from the endoplasmic reticulum during mitosis in mammalian cells	CELL			English	Article							HELA-CELLS; MITOTIC GOLGI; BREFELDIN-A; PROTEIN; FRAGMENTATION; COMPLEX; APPARATUS; INTERPHASE; VESICLES; DYNAMICS	What happens to organelles during mitosis, and how they are apportioned to each of the daughter cells, is not completely clear. We have devised a procedure to address whether Golgi membranes fuse with the Endoplasmic Reticulum (ER) during mitosis via the detection of interactions between ER and Golgi proteins. This procedure involves coexpressing an FKBP-tagged Golgi enzyme with an ER-retained protein fused to FRAP in COS cells. Since treatment with rapamycin induces a tight association between FKBP and FRAP, one would expect rapamycin to trap the FKBP-fused Golgi protein in the ER if it ever visits the ER during mitosis. However, after the doubly transfected cells progress through mitosis in the presence of rapamycin, we find the Golgi protein in the newly formed Golgi stacks and not in the ER. Based on these results, we conclude that Golgi membranes remain separate from the ER during mitosis in mammalian cells.	Univ Calif San Diego, Cell & Dev Biol Dept, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Malhotra, V (corresponding author), Univ Calif San Diego, Cell & Dev Biol Dept, La Jolla, CA 92093 USA.	Malhotra@biomail.ucsd.edu	Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; Jesch SA, 2001, TRAFFIC, V2, P873, DOI 10.1034/j.1600-0854.2001.21203.x; Jokitalo E, 2001, J CELL BIOL, V154, P317, DOI 10.1083/jcb.200104073; Khalil H, 2003, INT IMMUNOL, V15, P1249, DOI 10.1093/intimm/dxg124; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MAUL GG, 1970, CANCER RES, V30, P2326; Nebenfuhr A, 2001, TRENDS PLANT SCI, V6, P160, DOI 10.1016/S1360-1385(01)01891-X; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; Puthenveedu MA, 2001, EXP CELL RES, V271, P22, DOI 10.1006/excr.2001.5367; ROBBINS E, 1964, J HISTOCHEM CYTOCHEM, V12, P704, DOI 10.1177/12.9.704; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHUTZE MP, 1994, EMBO J, V7, P1696; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; THYBERG J, 1992, J SUBMICR CYTOL PATH, V24, P495; Uchiyama K, 2003, J CELL BIOL, V161, P1067, DOI 10.1083/jcb.200303048; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029; Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2	32	68	73	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	2004	116	1					99	107		10.1016/S0092-8674(03)01068-7	http://dx.doi.org/10.1016/S0092-8674(03)01068-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718170	Bronze			2022-12-28	WOS:000187960800012
J	Ruiz-Pesini, E; Mishmar, D; Brandon, M; Procaccio, V; Wallace, DC				Ruiz-Pesini, E; Mishmar, D; Brandon, M; Procaccio, V; Wallace, DC			Effects of purifying and adaptive selection on regional variation in human mtDNA	SCIENCE			English	Article							MITOCHONDRIAL-DNA; CYTOCHROME-B; DISEASE; LONGEVITY; POPULATION; HAPLOGROUPS; INHIBITION; UBIQUINOL; EVOLUTION; VARIANTS	A phylogenetic analysis of 1125 global human mitochondrial DNA (mtDNA) sequences permitted positioning of all nucleotide substitutions according to their order of occurrence. The relative frequency and amino acid conservation of internal branch replacement mutations was found to increase from tropical Africa to temperate Europe and arctic northeastern Siberia. Particularly highly conserved amino acid substitutions were found at the roots of multiple mtDNA lineages from higher latitudes. These same lineages correlate with increased propensity for energy deficiency diseases as well as longevity. Thus, specific mtDNA replacement mutations permitted our ancestors to adapt to more northern climates, and these same variants are influencing our health today.	Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Gen & Bioinformat, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Wallace, DC (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.		Mishmar, Dan/AAJ-6109-2020; Brandon, Marty C/A-1699-2009	Mishmar, Dan/0000-0003-3488-8792; procaccio, Vincent/0000-0002-1537-4684	NHLBI NIH HHS [HL64017] Funding Source: Medline; NIA NIH HHS [AG13154] Funding Source: Medline; NINDS NIH HHS [NS21328, NS37167] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS037167, R01NS021328, R01NS037167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013154] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ambrose SH, 1998, J HUM EVOL, V34, P623, DOI 10.1006/jhev.1998.0219; Bonafe M, 2002, GENE, V286, P121, DOI 10.1016/S0378-1119(01)00812-5; Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2; Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8; Brown MD, 1997, AM J HUM GENET, V60, P381; Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463; Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K; Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100; De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; Fisher N, 2001, EUR J BIOCHEM, V268, P1155, DOI 10.1046/j.1432-1327.2001.02010.x; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474; Ivanova R, 1998, GERONTOLOGY, V44, P349, DOI 10.1159/000022041; JOHNSON MJ, 1983, J MOL EVOL, V19, P255, DOI 10.1007/BF02099973; Kalman B, 1996, J NEUROL SCI, V140, P75, DOI 10.1016/0022-510X(96)00112-8; Leonard WR, 2002, AM J HUM BIOL, V14, P609, DOI 10.1002/ajhb.10072; Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100; Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y; Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8; Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040; Shinkarev VP, 2000, BIOCHEMISTRY-US, V39, P14232, DOI 10.1021/bi001179t; Templeton AR, 1996, GENETICS, V144, P1263; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4	26	612	634	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					223	226		10.1126/science.1088434	http://dx.doi.org/10.1126/science.1088434			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716012				2022-12-28	WOS:000187908500046
J	Joliveau, E; Smith, J; Wolfe, J				Joliveau, E; Smith, J; Wolfe, J			Acoustics - Tuning of vocal tract resonance by sopranos	NATURE			English	Editorial Material							JAW		Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Joliveau, E (corresponding author), Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia.	john.smith@unsw.edu.au		Wolfe, Joe/0000-0001-8030-0561				BERLIOZ H, 1882, GRAND TRAITE INSTRUM; DOWD A, 1997, LANG SPEECH, V41, P1; Epps J, 1997, MEAS SCI TECHNOL, V8, P1112, DOI 10.1088/0957-0233/8/10/012; Hollien H, 2000, J VOICE, V14, P287, DOI 10.1016/S0892-1997(00)80038-7; LINDBLOM BE, 1971, J ACOUST SOC AM, V50, P1166, DOI 10.1121/1.1912750; PANG T, 1973, SPEECH SOUNDS FEATUR; SUNDBERG J, 1975, ACUSTICA, V32, P89; Sundberg J, 1997, J VOICE, V11, P301, DOI 10.1016/S0892-1997(97)80008-2; Sundberg J., 1987, SCI SINGING VOICE; 1973, SPEECH SOUNDS FEATUR	10	59	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					116	116		10.1038/427116a	http://dx.doi.org/10.1038/427116a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712266				2022-12-28	WOS:000187863900025
J	Hersh, AL; Stefanick, ML; Stafford, RS				Hersh, AL; Stefanick, ML; Stafford, RS			National use of postmenopausal hormone therapy - Annual trends and response to recent evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; RANDOMIZED CONTROLLED-TRIAL; CALCIUM-CHANNEL BLOCKERS; HEALTH INITIATIVE MEMORY; CORONARY-HEART-DISEASE; REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; UNITED-STATES; NONCONTRACEPTIVE ESTROGENS; PRIMARY PREVENTION	Context Postmenopausal hormone therapy use increased dramatically during the past 2 decades because of a prevailing belief in its health benefits. Recent evidence from randomized trials published in July 2002 demonstrated adverse cardiovascular disease events and other risks with hormone therapy in the form of oral estrogen combined with progestin. Objective To describe patterns of hormone therapy use from 1995 until July 2003, including the impact of recent evidence. Design, Setting, and Population Two databases were used to describe national trends in hormone therapy use from January 1995 to July 2003. The National Prescription Audit database provided data on the number of hormone therapy prescriptions filled by retail pharmacies and the National Disease and Therapeutic Index database provided data on patient visits to office-based physicians during which hormone therapy was prescribed. Main Outcome Measures Annual number of hormone therapy prescriptions and characteristics of visits to physicians during which hormone therapy was prescribed. Results Annual hormone therapy prescriptions increased from 58 million in 1995 to 90 million in 1999, representing approximately 15 million women per year, then remained stable through June 2002. Adoption of new oral estrogen/progestin combinations, primarily Prempro, accounted for most of this growth. Obstetrician/gynecologists provided more than 70% of hormone therapy prescriptions, and more than one third of patients were older than 60 years. Following the publication of trial results in July 2002, hormone therapy prescriptions declined in successive months. Relative to January-June 2002, prescriptions from January-June 2003 declined by 66% for Prempro and 33% for Premarin. Small increases were observed in vaginal formulations and in new prescriptions for low-dose Premarin. If prescription rates observed through July 2003 remain stable, a decline to 57 million prescriptions for 2003, similar to the rate in 1995, is projected. Conclusions Clinical practice responded rapidly to recent evidence of harms associated with hormone therapy. Since July 2002, many patients have discontinued hormone therapy or are tapering to lower doses.	Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA	Stanford University	Stafford, RS (corresponding author), Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA.		Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013405] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS013405] Funding Source: Medline; NHLBI NIH HHS [5T32-HL07034] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ascott-Evans BH, 2003, ARCH INTERN MED, V163, P789, DOI 10.1001/archinte.163.7.789; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Erblich J, 2000, PREV MED, V31, P714, DOI 10.1006/pmed.2000.0765; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; Maclure M, 1998, LANCET, V352, P943, DOI 10.1016/S0140-6736(97)11390-3; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P882, DOI 10.1001/jama.288.7.882; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Solomon CG, 2003, NEW ENGL J MED, V348, P579, DOI 10.1056/NEJMp030006; STAFFORD RS, IN PRESS ARCH INTERN; *US CENS BUR, RES POP EST US AG SE; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; *WHI, HRT UPD 2001; Whitlock EP, 1998, J WOMENS HEALTH, V7, P1017, DOI 10.1089/jwh.1998.7.1017; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	31	728	738	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					47	53		10.1001/jama.291.1.47	http://dx.doi.org/10.1001/jama.291.1.47			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709575				2022-12-28	WOS:000187836000018
J	Glasziou, P; Vandenbroucke, J; Chalmers, I				Glasziou, P; Vandenbroucke, J; Chalmers, I			Assessing the quality of research	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; DISEASE	Inflexible use of evidence hierarchies confuses practitioners and irritates researchers. So how can we improve the way we assess research?	Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England; Leiden Univ, Sch Med, NL-9600 RC Leiden, Netherlands; James Lind Initiat, James Lind Lib, Oxford OX2 7LG, England	University of Oxford; Leiden University; Leiden University - Excl LUMC	Glasziou, P (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England.	paul.glasziou@dphpc.ox.ac.uk	Vandenbroucke, Jan/AAM-3928-2020; Glasziou, Paul/A-7832-2008	Vandenbroucke, Jan/0000-0001-5668-6716; Glasziou, Paul/0000-0001-7564-073X				Aronson JK, 2003, BRIT MED J, V326, P1346, DOI 10.1136/bmj.326.7403.1346; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Campbell D. T., 1963, EXPT QUASIEXPERIMENT, P171; Centre for Evidence-Based Medicine, LEV EV; ChasanTaber L, 1997, AM J EPIDEMIOL, V146, P258; COOK HH, 1961, AM J OBSTET GYNECOL, V82, P437; Gallo MF, 2003, COCHRANE DB SYST REV; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GRANT A, 1985, SCI BASIS OBSTETRICS, P49; Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290; Hannaford PC, 1998, BMJ-BRIT MED J, V316, P984, DOI 10.1136/bmj.316.7136.984; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; IYER V, 2003, COCHRANE DATABASE SY; JENICEK M, 1999, CLIN CASE REPORTING; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; KUNZ R, 2003, COCHRANE LIB; Mallett Susan, 2003, ACP J Club, V139, pA11; PINCUS G, FIELD TRIALS NORETHY; PROCTOR ML, 2003, COCHRANE DATABASE SY; Rosendaal FR, 2001, CURR CONTR TRIALS C, V2, P109; Sackett DL, 1997, BRIT MED J, V315, P1636, DOI 10.1136/bmj.315.7123.1636; Schunemann HJ, 2003, CAN MED ASSOC J, V169, P677; Skegg DCG, 1999, BMJ-BRIT MED J, V318, P69, DOI 10.1136/bmj.318.7176.69; Sterne JAC, 2002, STAT MED, V21, P1513, DOI 10.1002/sim.1184; van Schoor NM, 2002, OSTEOPOROSIS INT, V13, P917, DOI 10.1007/s001980200128; Vandenbroucke JP, 2001, ANN INTERN MED, V134, P330, DOI 10.7326/0003-4819-134-4-200102200-00017; Vandenbroucke JP, 1998, J CLIN EPIDEMIOL, V51, P467; Vandenbroucke JP, 2001, ANN INTERN MED, V135, P507, DOI 10.7326/0003-4819-135-7-200110020-00010; VENNING GR, 1982, BMJ-BRIT MED J, V284, P249, DOI 10.1136/bmj.284.6311.249; *WHO, 1998, WHO TECHN REP SER, V877; 1979, CAN MED ASS J, V121, P1193	31	240	258	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	2004	328	7430					39	41		10.1136/bmj.328.7430.39	http://dx.doi.org/10.1136/bmj.328.7430.39			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703546	Green Published, Green Submitted			2022-12-28	WOS:000187919000023
J	Kawakami, T; Okamoto, K; Ogawa, O; Okada, Y				Kawakami, T; Okamoto, K; Ogawa, O; Okada, Y			XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer	LANCET			English	Article							GERM-CELL TUMORS; METHYLATION; EXPRESSION	Testicular germ-cell tumours (TGCTs) are the most common malignant diseases among men aged 20-40 years. We developed a DNA tumour marker for TGCTs based on the unmethylated DNA profile of a neoplasm. The 5' end of the XIST gene is mainly hypomethylated in TGCTs irrespective of XIST expression. Male somatic cells, however, show complete methylation through the CpG sites, including the minimum promoter and XIST-conserved repeats. Identification of a XIST unmethylated fragment in male plasma might be diagnostic for TGCTs.	Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan	Shiga University of Medical Science; Kyoto University	Okamoto, K (corresponding author), Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan.							BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488	5	93	102	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					40	42		10.1016/S0140-6736(03)15170-7	http://dx.doi.org/10.1016/S0140-6736(03)15170-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723995				2022-12-28	WOS:000187711300015
J	Marsh, RL; Ellerby, DJ; Carr, JA; Henry, HT; Buchanan, CI				Marsh, RL; Ellerby, DJ; Carr, JA; Henry, HT; Buchanan, CI			Partitioning the energetics of walking and running: Swinging the limbs is expensive	SCIENCE			English	Article							GENERATING MUSCULAR FORCE; SKELETAL-MUSCLE; BLOOD-FLOW; TREADMILL EXERCISE; METABOLIC COST; RAT MUSCLES; CONTRACTION; LOCOMOTION; HYPEREMIA; PATTERNS	Explaining the energetics of walking and running has been difficult because the distribution of energy use among individual muscles has not been known. We estimated energy use by measuring blood flow to the hindlimb muscles in guinea fowl. Blood flow to skeletal muscles is controlled locally and varies directly with metabolic rate. We estimate that the swing-phase muscles consume 26% of the energy used by the limbs and the stance-phase muscles consume the remaining 74%, independent of speed. Thus, contrary to some previous suggestions, swinging the limbs requires an appreciable fraction of the energy used during terrestrial legged locomotion. Models integrating the energetics and mechanics of running will benefit from more detailed information on the distribution of energy use by the muscles.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Northeastern Univ, Dept Phys Therapy, Boston, MA 02115 USA	Northeastern University; Northeastern University	Marsh, RL (corresponding author), Northeastern Univ, Dept Biol, 360 Huntington Ave, Boston, MA 02115 USA.	r.marsh@neu.edu	Ellerby, David/B-7975-2013	Marsh, Richard/0000-0002-4264-9890; Ellerby, David/0000-0003-4045-0201	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047337] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47337] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altringham JD, 1999, J EXP BIOL, V202, P3397; ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794; ARMSTRONG RB, 1988, AM J CARDIOL, V62, pE9, DOI 10.1016/S0002-9149(88)80003-1; ARMSTRONG RB, 1986, J APPL PHYSIOL, V61, P683, DOI 10.1152/jappl.1986.61.2.683; ARMSTRONG RB, 1983, J PHYSIOL-LONDON, V344, P189, DOI 10.1113/jphysiol.1983.sp014933; Brooks GA, 1998, COMP BIOCHEM PHYS B, V120, P89, DOI 10.1016/S0305-0491(98)00025-X; CAVAGNA GA, 1977, AM J PHYSIOL, V233, P243; Ellerby DJ, 2003, PHYSIOL BIOCHEM ZOOL, V76, P695, DOI 10.1086/376430; ENGLISH AW, 1987, J MORPHOL, V191, P161, DOI 10.1002/jmor.1051910207; FEDAK MA, 1982, J EXP BIOL, V79, P23; Gatesy SM, 1999, J MORPHOL, V240, P127, DOI 10.1002/(SICI)1097-4687(199905)240:2<127::AID-JMOR4>3.0.CO;2-Q; Griffin TM, 2003, J APPL PHYSIOL, V95, P172, DOI 10.1152/japplphysiol.00944.2002; GRUBB B, 1983, J EXP BIOL, V104, P193; Hedrick TL, 2003, J EXP BIOL, V206, P1363, DOI 10.1242/jeb.00272; Holloszy John O., 1998, Frontiers in Bioscience, V3, pD1011; Johnston RM, 1996, J COMP PHYSIOL A, V179, P169, DOI 10.1007/BF00222784; KLABUNDE RE, 1977, AM J PHYSIOL, V232, pH411, DOI 10.1152/ajpheart.1977.232.4.H411; KRAM R, 1990, NATURE, V346, P265, DOI 10.1038/346265a0; Kram R, 2000, Exerc Sport Sci Rev, V28, P138; Laughlin MH, 2001, MED SCI SPORT EXER, V33, P81; LAUGHLIN MH, 1983, AM J PHYSIOL, V244, pH814, DOI 10.1152/ajpheart.1983.244.6.H814; Murrant CL, 2000, ACTA PHYSIOL SCAND, V168, P531, DOI 10.1046/j.1365-201x.2000.00706.x; MYERS MJ, 1985, J EXP BIOL, V116, P363; Roberts TJ, 1998, J EXP BIOL, V201, P2745; Roberts TJ, 1997, SCIENCE, V275, P1113, DOI 10.1126/science.275.5303.1113; Saibene F, 2003, EUR J APPL PHYSIOL, V88, P297, DOI 10.1007/s00421-002-0654-9; STEUDEL K, 1990, J EXP BIOL, V154, P287; TAYLOR CR, 1980, J EXP BIOL, V86, P9; TAYLOR CR, 1994, COMP VERTEBRATE EXER, P181; TYML K, 1986, MICROVASC RES, V32, P84, DOI 10.1016/0026-2862(86)90045-2; Vanden Berge JC., 1993, HDB AVIAN ANATOMY NO, P189	31	162	163	5	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					80	83		10.1126/science.1090704	http://dx.doi.org/10.1126/science.1090704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704426				2022-12-28	WOS:000187710600037
J	Guan, Y; Peiris, JSM; Zheng, B; Poon, LLM; Chan, KH; Zeng, FY; Chan, CWM; Chan, MN; Chen, JD; Chow, KYC; Hon, CC; Hui, KH; Li, J; Li, VYY; Wang, Y; Leung, SW; Yuen, KY; Leung, FC				Guan, Y; Peiris, JSM; Zheng, B; Poon, LLM; Chan, KH; Zeng, FY; Chan, CWM; Chan, MN; Chen, JD; Chow, KYC; Hon, CC; Hui, KH; Li, J; Li, VYY; Wang, Y; Leung, SW; Yuen, KY; Leung, FC			Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome	LANCET			English	Article							SPIKE GLYCOPROTEIN; GENOME SEQUENCE; VIRUS; PROTEINS; OUTBREAK; SPREAD; GENES	Background Severe acute respiratory syndrome (SARS) is a newly emerged disease caused by a novel coronavirus (SARS-CoV), which spread globally in early 2003, affecting over 30 countries. We have used molecular epidemiology to define the patterns of spread of the virus in Hong Kong and beyond. Methods The case definition of SARS was based on that recommended by WHO. We genetically sequenced the gene for the S1 unit of the viral spike protein of viruses from patients with SARS in Hong Kong (138) and Guangdong (three) in February to April, 2003. We undertook phylogenetic comparisons with 27 other sequences available from public databases (Genbank). Findings Most of the Hong Kong viruses (139/142), including those from a large outbreak in an apartment block, clustered closely together with the isolate from a single index case (HKU-33) who came from Guangdong to Hong Kong in late February. Three other isolates were genetically distinct from HKU-33 in Hong Kong during February, but none of these contributed substantially to the subsequent local outbreak. Viruses identified in Guangdong and Beijing were genetically more diverse. Interpretation The molecular epidemiological evidence suggests that most SARS-CoV from the outbreak in Hong Kong, as well as the viruses from Canada, Vietnam, and Singapore, are genetically closely linked. Three viruses found in Hong Kong in February were phylogenetically distinct from the major cluster, which suggests that several introductions of the virus had occurred, but that only one was associated with the subsequent outbreak in Hong Kong, which in turn spread globally.	Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Leung, FC (corresponding author), Univ Hong Kong, Dept Zool, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	fcleung@hkucc.hku.hk	Chan, Kwok Hung/ABD-5399-2021; Poon, Leo Lit Man/C-4382-2009; Poon, Leo/AAP-6887-2020; Leung, Cynthia/C-4601-2009; Yuen, Kwok Yung/C-4465-2009	Poon, Leo Lit Man/0000-0002-9101-7953; Hon, Chung-Chau/0000-0002-3741-7577; Yuen, Kwok-yung/0000-0002-2083-1552; Guan, Yi/0000-0001-6057-9243; LEUNG, Sai Wing Peter/0000-0002-4326-2604	PHS HHS [A195357] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRITTON P, 1991, VIRUS RES, V21, P181, DOI 10.1016/0168-1702(91)90032-Q; Casais R, 2003, J VIROL, V77, P9084, DOI 10.1128/JVI.77.16.9084-9089.2003; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P241; Clewley J P, 1997, Methods Mol Biol, V70, P119; *DEP HLTH HONG KON, 2003, OUTBR SEV AC RESP SY; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Enserink M, 2003, SCIENCE, V300, P715, DOI 10.1126/science.300.5620.715; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Haijema BJ, 2003, J VIROL, V77, P4528, DOI 10.1128/JVI.77.8.4528-4538.2003; Hasoksuz M, 2002, VIRUS RES, V84, P101, DOI 10.1016/S0168-1702(02)00004-7; Hays JP, 1998, J VIROL METHODS, V75, P179, DOI 10.1016/S0166-0934(98)00116-5; Krokhin O, 2003, MOL CELL PROTEOMICS, V2, P346, DOI 10.1074/mcp.M300048-MCP200; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lee CW, 2001, VIRUS RES, V80, P33, DOI 10.1016/S0168-1702(01)00345-8; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Ng SKC, 2003, LANCET, V362, P570, DOI 10.1016/S0140-6736(03)14121-9; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Phillips JJ, 2002, VIROLOGY, V301, P109, DOI 10.1006/viro.2002.1551; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Tsui SKW, 2003, NEW ENGL J MED, V349, P187, DOI 10.1056/NEJM200307103490216; World Health Organization, CUM NUMB REP PROB CA; Zeng FY, 2003, EXP BIOL MED, V228, P866, DOI 10.1177/15353702-0322807-13; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	27	96	106	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					99	104		10.1016/S0140-6736(03)15259-2	http://dx.doi.org/10.1016/S0140-6736(03)15259-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726162	Bronze, Green Published			2022-12-28	WOS:000187939200006
J	Orchard, JA; Ibbotson, RE; Davis, Z; Wiestner, A; Rosenwald, A; Thomas, PW; Hamblin, TJ; Staudt, LM; Oscier, DG				Orchard, JA; Ibbotson, RE; Davis, Z; Wiestner, A; Rosenwald, A; Thomas, PW; Hamblin, TJ; Staudt, LM; Oscier, DG			ZAP-70 expression and prognosis in chronic lymphocytic leukaemia	LANCET			English	Article							VARIABLE-REGION MUTATIONS; PROTEIN-TYROSINE KINASE; CD38 EXPRESSION; GENE-EXPRESSION; B-CELLS; PHENOTYPE	Background Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease; many patients never need treatment, whereas some have poor outcomes. New treatments, which can induce complete remissions, allow patients with poor outlook to be treated while they are still asymptomatic. Whether or not the IgVH gene is mutated is the best predictor of clinical outcome, but this assay is unsuited to the routine laboratory. The gene coding for ZAP-70, a tyrosine kinase protein normally expressed in T and NK cells, has been shown by gene-expression profiling to be differentially expressed between patients with mutated and unmutated IgVH genes. We assessed whether ZAP-70 could be used as a prognostic marker in CLL. Methods We developed a flow cytometry assay for ZAP-70 protein expression and investigated its concordance with ZAP-70 mRNA expression, IgVH gene mutational status, and clinical outcome in 167 patients with CLL. Findings We showed high concordance between ZAP-70 protein expression and IgVH gene mutations. 108 patients (65%) had mutated IgVH genes and were ZAP-70 negative; 46 (28%) had unmutated IgVH genes and were ZAP-70 positive. Findings were discordant in 13 patients: six (4%) had mutated IgVH genes but were ZAP-70 positive, and seven (4%) had unmutated IgVH genes and were ZAP-70 negative. Expression of mRNA showed 97% concordance with ZAP-70 protein. Median survival was 24.4 years (95% CI 15.1-33.8) in ZAP-70 negative patients and 9.3 years (7.0-11.5) in those who were ZAP-70 positive (hazard ratio 5.5, 2.8-10.8). Interpretation ZAP-70 protein, which can be measured by flow cytometry in the general laboratory, is a reliable prognostic marker in CLL, equivalent to that of IgVH gene mutational status.	Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England; NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Poole Hosp, Dorset Res & Dev Support Unit, Poole, Dorset, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Poole Hospital	Oscier, DG (corresponding author), Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England.		Staudt, Louis/AAC-5324-2019	Thomas, Peter/0000-0003-2478-4324				Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armitage P., 1987, STAT METHODS MED RES; Byrd JC, 2000, SEMIN ONCOL, V27, P587; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Chevallier P, 2002, BRIT J HAEMATOL, V116, P142, DOI 10.1046/j.0007-1048.2001.3205.x; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Geisler C, 1999, JNCI-J NATL CANCER I, V91, P861; Gurrieri C, 2002, J EXP MED, V196, P629, DOI 10.1084/jem.20011693; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Kipps TJ, 2000, CURR OPIN HEMATOL, V7, P223, DOI 10.1097/00062752-200007000-00005; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; Krober A, 2002, BLOOD, V100, P1410, DOI 10.1182/blood.V100.4.1410.h81602001410_1410_1416; Lanham S, 2003, BLOOD, V101, P1087, DOI 10.1182/blood-2002-06-1822; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Schweighoffer E, 2003, IMMUNITY, V18, P523, DOI 10.1016/S1074-7613(03)00082-7; TALBOT D, 1989, TRANSPLANTATION, V47, P552, DOI 10.1097/00007890-198903000-00030; Tobin G, 2002, BLOOD, V99, P2262, DOI 10.1182/blood.V99.6.2262; Toyabe S, 2001, IMMUNOLOGY, V103, P164, DOI 10.1046/j.1365-2567.2001.01246.x; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306	30	442	467	1	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					105	111		10.1016/S0140-6736(03)15260-9	http://dx.doi.org/10.1016/S0140-6736(03)15260-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726163				2022-12-28	WOS:000187939200007
J	Hites, RA; Foran, JA; Carpenter, DO; Hamilton, MC; Knuth, BA; Schwager, SJ				Hites, RA; Foran, JA; Carpenter, DO; Hamilton, MC; Knuth, BA; Schwager, SJ			Global assessment of organic contaminants in farmed salmon	SCIENCE			English	Article							AQUATIC FOOD WEBS; UNITED-STATES; AQUACULTURE; CHEMICALS; DIELDRIN; MIXTURES; SALAR; FEED	The annual global production of farmed salmon has increased by a factor of 40 during the past two decades. Salmon from farms in northern Europe, North America, and Chile are now available widely year-round at relatively low prices. Salmon farms have been criticized for their ecological effects, but the potential human health risks of farmed salmon consumption have not been examined rigorously. Having analyzed over 2 metric tons of farmed and wild salmon from around the world for organochlorine contaminants, we show that concentrations of these contaminants are significantly higher in farmed salmon than in wild. European-raised salmon have significantly greater contaminant loads than those raised in North and South America, indicating the need for further investigation into the sources of contamination. Risk analysis indicates that consumption of farmed Atlantic salmon may pose health risks that detract from the beneficial effects of fish consumption.	Indiana Univ, Sch Publ & Environm Affairs, Bloomington, IN 47405 USA; Citizens Better Environm, Milwaukee, WI 53202 USA; Univ Albany, Inst Hlth & Environm, Rensselaer, NY 12144 USA; AXYS Analyt Serv, Sidney, BC V8L 3S8, Canada; Cornell Univ, Dept Nat Resources, Ithaca, NY 14853 USA; Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA	Indiana University System; Indiana University Bloomington; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Cornell University; Cornell University	Hites, RA (corresponding author), Indiana Univ, Sch Publ & Environm Affairs, Bloomington, IN 47405 USA.							Calciu C, 1997, TOXICOLOGY, V124, P153, DOI 10.1016/S0300-483X(97)00145-5; Carpenter D O, 1998, Int J Occup Med Environ Health, V11, P291; Carpenter DO, 2002, ENVIRON HEALTH PERSP, V110, P25, DOI 10.1289/ehp.02110s125; CHARRON B, 1999, INTRAFISH COM IND RE; Daviglus M., 2002, COMMENTS TOXICOL, V8, P345, DOI DOI 10.1080/08865140215064; Easton MDL, 2002, CHEMOSPHERE, V46, P1053, DOI 10.1016/S0045-6535(01)00136-9; FORAN JA, UNPUB; Harper CR, 2001, ARCH INTERN MED, V161, P2185, DOI 10.1001/archinte.161.18.2185; *IARC, 2001, SOME THYROTROPHIC AG, V79, P569; Jacobs M, 2002, CHEMOSPHERE, V47, P183, DOI 10.1016/S0045-6535(01)00201-6; Jacobs MN, 2002, ENVIRON SCI TECHNOL, V36, P2797, DOI 10.1021/es011287i; Jorgenson JL, 2001, ENVIRON HEALTH PERSP, V109, P113, DOI 10.2307/3434852; Kocik JF, 2002, SUSTAINING NORTH AMERICAN SALMON: PERSPECTIVES ACROSS REGIONS AND DISCIPLINES, P3; Naylor RL, 2000, NATURE, V405, P1017, DOI 10.1038/35016500; *OFF SCI TECHN FIS, 2003, FOR TRAD INF; REINERT RE, 1991, FISHERIES, V16, P5, DOI 10.1577/1548-8446(1991)016<0005:RARMAF>2.0.CO;2; Russell RW, 1999, ENVIRON TOXICOL CHEM, V18, P1250, DOI [10.1002/etc.5620180626, 10.1897/1551-5028(1999)018&lt;1250:ROCAEF&gt;2.3.CO;2]; Smith AG, 2002, FOOD CHEM TOXICOL, V40, P767, DOI 10.1016/S0278-6915(02)00046-7; THOMANN RV, 1992, ENVIRON TOXICOL CHEM, V11, P615, DOI 10.1897/1552-8618(1992)11[615:AEMOOC]2.0.CO;2; *UN FAO, 2001, FISH OIL GLOB; *UN FAO, 2002, GLOB; *US FDA, FISH FISH PROD HAZ C, pCH9; US-EPA, 2000, GUID ASS CHEM CONT D, V3rd; Wade MG, 1997, REPROD TOXICOL, V11, P791, DOI 10.1016/S0890-6238(97)00062-2; *WHO JOINT FISH AG, 2001, POS PAP DIOX DIOX LI; Zahm SH, 1998, ENVIRON HEALTH PERSP, V106, P893, DOI 10.2307/3434207; 1984, FED REG, V49, P21514; 2002, INT FISH AQ NEWS MAR, P19; 1992, FED REG, V57, P60859	29	636	671	2	269	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					226	229		10.1126/science.1091447	http://dx.doi.org/10.1126/science.1091447			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716013	Green Submitted			2022-12-28	WOS:000187908500047
J	Holdsworth, RE				Holdsworth, RE			Weak faults - Rotten cores	SCIENCE			English	Editorial Material							EARTHQUAKES; STRENGTH		Univ Durham, Dept Earth Sci, Durham DH1 3LE, England	Durham University	Holdsworth, RE (corresponding author), Univ Durham, Dept Earth Sci, Durham DH1 3LE, England.	r.e.holdsworth@durham.ac.uk	Holdsworth, Robert E/C-2381-2008	Holdsworth, Robert/0000-0002-3467-835X				Axen GJ, 1999, GEOPHYS RES LETT, V26, P3693, DOI 10.1029/1999GL005405; Bos B, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000301; Gueydan F, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000611; Holdsworth RE, 2001, GEOL SOC SPEC PUBL, V184, P115, DOI 10.1144/GSL.SP.2001.184.01.07; Imber J, 2001, TECTONICS, V20, P601, DOI 10.1029/2000TC001250; KOHLSTEDT DL, 1995, J GEOPHYS RES-SOL EA, V100, P17587, DOI 10.1029/95JB01460; Scholz CH, 1996, NATURE, V381, P556, DOI 10.1038/381556a0; WINTSCH RP, 1995, J GEOPHYS RES-SOL EA, V100, P13021, DOI 10.1029/94JB02622; Zoback MD, 2000, NATURE, V405, P31, DOI 10.1038/35011181	9	138	142	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					181	182		10.1126/science.1092491	http://dx.doi.org/10.1126/science.1092491			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716000				2022-12-28	WOS:000187908500034
J	Hughes, T; Andrews, B; Boone, C				Hughes, T; Andrews, B; Boone, C			Old drugs, new tricks: Using genetically sensitized yeast to reveal drug targets	CELL			English	Editorial Material							CHEMICAL GENETICS; DISCOVERY; EXPRESSION		Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1L6, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Hughes, T (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1L6, Canada.							Conklin DS, 2003, CHEMBIOCHEM, V4, P1033, DOI 10.1002/cbic.200300686; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; GIAEVER G, 2004, IN PRESS P NATL ACAD; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Mayer TU, 2003, TRENDS CELL BIOL, V13, P270, DOI 10.1016/S0962-8924(03)00077-1; PARSONS AB, 2003, NATURE BIOTECHNOLOGY; Stockwell BR, 2000, NAT REV GENET, V1, P116, DOI 10.1038/35038557; Zhu H, 2003, ANNU REV BIOCHEM, V72, P783, DOI 10.1146/annurev.biochem.72.121801.161511	10	17	20	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					5	7		10.1016/S0092-8674(03)01070-5	http://dx.doi.org/10.1016/S0092-8674(03)01070-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718160	Bronze			2022-12-28	WOS:000187960800004
J	Bastow, R; Mylne, JS; Lister, C; Lippman, Z; Martienssen, RA; Dean, C				Bastow, R; Mylne, JS; Lister, C; Lippman, Z; Martienssen, RA; Dean, C			Vernalization requires epigenetic silencing of FLC by histone methylation	NATURE			English	Article							FLOWERING LOCUS-C; MADS DOMAIN PROTEIN; METHYLTRANSFERASE ACTIVITY; LYSINE 9; ARABIDOPSIS; H3; GENE; REPRESSOR; COMPLEX; ROLES	To ensure flowering in favourable conditions, many plants flower only after an extended period of cold, namely winter. In Arabidopsis, the acceleration of flowering by prolonged cold, a process called vernalization, involves downregulation of the protein FLC, which would otherwise prevent flowering(1,2). This lowered FLC expression is maintained through subsequent development by the activity of VERNALIZATION (VRN) genes(3,4). VRN1 encodes a DNA-binding protein(4) whereas VRN2 encodes a homologue of one of the Polycomb group proteins, which maintain the silencing of genes during animal development(3). Here we show that vernalization causes changes in histone methylation in discrete domains within the FLC locus, increasing dimethylation of lysines 9 and 27 on histone H3. Such modifications identify silenced chromatin states in Drosophila and human cells(5-7). Dimethylation of H3 K27 was lost only in vrn2 mutants, but dimethylation of H3 K9 was absent from both vrn1 and vrn2, consistent with VRN1 functioning downstream of VRN2. The epigenetic memory of winter is thus mediated by a 'histone code' that specifies a silent chromatin state conserved between animals and plants.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Cold Spring Harbor Laboratory	Dean, C (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	caroline.dean@bbsrc.ac.uk	Mylne, Joshua S/A-5581-2009; Mylne, Josh/GMX-4544-2022	Mylne, Joshua S/0000-0003-4957-6388; Mylne, Josh/0000-0003-4957-6388; Lippman, Zachary/0000-0001-7668-9025				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Birve A, 2001, DEVELOPMENT, V128, P3371; BURN JE, 1993, P NATL ACAD SCI USA, V90, P287, DOI 10.1073/pnas.90.1.287; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chandler J, 1996, PLANT J, V10, P637, DOI 10.1046/j.1365-313X.1996.10040637.x; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gazzani S, 2003, PLANT PHYSIOL, V132, P1107, DOI 10.1104/pp.103.021212; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Goodrich J, 2002, ANNU REV CELL DEV BI, V18, P707, DOI 10.1146/annurev.cellbio.18.040202.114836; Henderson IR, 2003, ANNU REV GENET, V37, P371, DOI 10.1146/annurev.genet.37.110801.142640; Hepworth SR, 2002, EMBO J, V21, P4327, DOI 10.1093/emboj/cdf432; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Levy YY, 2002, SCIENCE, V297, P243, DOI 10.1126/science.1072147; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Michaels SD, 2003, P NATL ACAD SCI USA, V100, P10102, DOI 10.1073/pnas.1531467100; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Sheldon CC, 2002, PLANT CELL, V14, P2527, DOI 10.1105/tpc.004564; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007	29	675	742	10	231	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					164	167		10.1038/nature02269	http://dx.doi.org/10.1038/nature02269			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712277				2022-12-28	WOS:000187863900037
J	Mempel, TR; Henrickson, SE; von Andrian, UH				Mempel, TR; Henrickson, SE; von Andrian, UH			T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases	NATURE			English	Article							IMMUNOLOGICAL SYNAPSE; ANTIGEN PRESENTATION; ACTIVATION; EXPRESSION; CHEMOKINE; INDUCTION	Primary T-cell responses in lymph nodes (LNs) require contact-dependent information exchange between T cells and dendritic cells (DCs). Because lymphocytes continually enter and leave normal LNs, the resident lymphocyte pool is composed of nonsynchronized cells with different dwell times that display heterogeneous behaviour in mouse LNs in vitro(1-3). Here we employ two-photon microscopy in vivo to study antigen-presenting DCs and naive T cells whose dwell time in LNs was synchronized. During the first 8 h after entering from the blood, T cells underwent multiple short encounters with DCs, progressively decreased their motility, and upregulated activation markers. During the subsequent 12 h T cells formed long-lasting stable conjugates with DCs and began to secrete interleukin-2 and interferon-gamma. On the second day, coinciding with the onset of proliferation, T cells resumed their rapid migration and short DC contacts. Thus, T-cell priming by DCs occurs in three successive stages: transient serial encounters during the first activation phase are followed by a second phase of stable contacts culminating in cytokine production, which makes a transition into a third phase of high motility and rapid proliferation.	Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	von Andrian, UH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	uva@cbr.med.harvard.edu	von Andrian, Ulrich H/A-5775-2008	Henrickson, Sarah/0000-0001-5569-4132	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bajenoff M, 2003, J EXP MED, V198, P715, DOI 10.1084/jem.20030167; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Cahalan MD, 2002, NAT REV IMMUNOL, V2, P872, DOI 10.1038/nri935; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Faroudi M, 2003, J IMMUNOL, V171, P1128, DOI 10.4049/jimmunol.171.3.1128; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; Hurez V, 2003, J EXP MED, V198, P123, DOI 10.1084/jem.20022230; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Miller MJ, 2003, P NATL ACAD SCI USA, V100, P2604, DOI 10.1073/pnas.2628040100; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Stefanova I, 2002, NATURE, V420, P429, DOI 10.1038/nature01146; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; van Stipdonk MJB, 2003, NAT IMMUNOL, V4, P361, DOI 10.1038/ni912; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; von Andrian UH, 2002, SCIENCE, V296, P1815, DOI 10.1126/science.296.5574.1815; Von Andrian Ulrich H., 1996, Microcirculation (Philadelphia), V3, P287, DOI 10.3109/10739689609148303	30	1265	1312	0	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					154	159		10.1038/nature02238	http://dx.doi.org/10.1038/nature02238			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712275	Bronze			2022-12-28	WOS:000187863900035
J	Schneider, EC; Zaslavsky, AM; Epstein, AM				Schneider, EC; Zaslavsky, AM; Epstein, AM			Use of high-cost operative procedures by medicare beneficiaries enrolled in for-profit and not-for-profit health plans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORTALITY-RATES; MANAGED CARE; QUALITY; METAANALYSIS; ASSESSMENTS; HOSPITALS; HMOS	Background: It is widely believed that for-profit health plans are more likely than not-for-profit health plans to respond to financial incentives by restricting access to care, especially access to high-cost procedures. Until recently, data to address this question have been limited. Methods: We tested the hypothesis that the rates of use of 12 common high-cost procedures would be lower in for-profit health plans than in not-for-profit plans. Using standardized Medicare HEDIS data on 3,726,065 Medicare beneficiaries 65 years of age or older who were enrolled in 254 health plans during 1997, we compared for-profit and not-for-profit plans with respect to rates of cardiac catheterization, coronary-artery bypass grafting, percutaneous transluminal coronary angioplasty, carotid endarterectomy, reduction of femur fracture, total hip replacement, total knee replacement, partial colectomy, open cholecystectomy, closed cholecystectomy, hysterectomy, and prostatectomy. We adjusted the comparisons for sociodemographic case mix and for characteristics of the health plans other than their tax status, including the plans' location. Results: The rates of carotid endarterectomy, cardiac catheterization, coronary-artery bypass grafting, and percutaneous transluminal coronary angioplasty were higher in for-profit health plans than they were in not-for-profit health plans; the rates of use of other common costly operative procedures were similar in the two types of plan. After adjustment for enrollee case mix and other characteristics of the plans, the for-profit plans had significantly higher rates than the not-for-profit plans for 2 of the 12 procedures we studied and had lower rates for none. The geographic locations of the health plans did not explain these findings. Conclusions: Contrary to our expectations about the likely effects of financial incentives, the rates of use of high-cost operative procedures were not lower among beneficiaries enrolled in for-profit health plans than among those enrolled in not-for-profit health plans.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Sect Hlth Policy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Schneider, EC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.			Schneider, Eric/0000-0002-1132-5084	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS010803] Funding Source: NIH RePORTER; AHRQ HHS [P01HS10803] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; Blustein J, 2000, HEALTH AFFAIR, V19, P210, DOI 10.1377/hlthaff.19.1.210; Born PH, 2001, HEALTH AFFAIR, V20, P167, DOI 10.1377/hlthaff.20.2.167; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; *CTR MED MED SERV, 2003, MOR CHOIC BETT BEN M; *DEC RES, 1998, INTERSTUDY COMP EDG; Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; Devereaux PJ, 2002, JAMA-J AM MED ASSOC, V288, P2449, DOI 10.1001/jama.288.19.2449; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; Himmelstein DU, 1999, JAMA-J AM MED ASSOC, V282, P159, DOI 10.1001/jama.282.2.159; Landon BE, 1999, JAMA-J AM MED ASSOC, V282, P1769, DOI 10.1001/jama.282.18.1769; Landon BE, 2001, HEALTH AFFAIR, V20, P274, DOI 10.1377/hlthaff.20.2.274; *MED PAYM ADV COMM, 2002, REP C MED PAYM POL, P203; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; National Watermelon Promotion Board, 1998, 1997 MED HEDIS 3 0 1, V1, P1; Nudelman PM, 1996, NEW ENGL J MED, V334, P1057, DOI 10.1056/NEJM199604183341611; PAULY MV, 1990, MED CARE, V28, P1013, DOI 10.1097/00005650-199011000-00004; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; *SAS I, 1999, SAS ONL DOC VERS 7 1; Tu HT, 2002, NEW ENGL J MED, V346, P1288, DOI 10.1056/NEJMsa011250; Yuan Z, 2000, MED CARE, V38, P231, DOI 10.1097/00005650-200002000-00012	26	26	26	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					143	150		10.1056/NEJMsa035634	http://dx.doi.org/10.1056/NEJMsa035634			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	760WP	14711913	Bronze			2022-12-28	WOS:000187858500008
J	Whitney, SN; McGuire, AL; McCullough, LB				Whitney, SN; McGuire, AL; McCullough, LB			A typology of shared decision making, informed consent, and simple consent	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNCERTAINTY; ENCOUNTER; MODEL	Enhancing patient choice is a central theme of medical ethics and law. informed consent is the legal process used to promote patient autonomy; shared decision making is a widely promoted ethical approach. These processes may most usefully be seen as distinct in clinically and ethically important respects. The approach outlined in this article uses a model that arrays all medical decisions along 2 axes: risk and certainty. At the extremes of these continua, 4 decision types are produced, each of which constrains the principal actors in predictable ways. Shared decision making is most appropriate in situations of uncertainty, in which 2 or more clinically reasonable alternatives exist. When there is only 1 realistic choice, patient and physician may gather and exchange information; however, the patient cannot be empowered to make choices that do not exist. In contrast, informed consent does not require the presence of clinical choice; it is appropriate for all decisions of significant risk, even if there is only one option. When a clinical decision contains both risk and uncertainty, shared decision making and informed consent are both appropriate. For decisions of lower risk, consent should still be present, but it can be simple rather than informed. Clinicians may use this analysis as a guide to their own interactions with patients. In the continuing effort to provide patients with appropriate decisional authority over their own medical choices, shared decision making, informed consent, and simple consent each has a distinct role to play.	Baylor Coll Med, Dept Family & Community Med, Houston, TX 77098 USA; Univ Texas, Med Branch, Inst Med Humanities, Galveston, TX 77550 USA; Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine	Whitney, SN (corresponding author), Baylor Coll Med, Dept Family & Community Med, 3701 Kirby Dr,Suite 600, Houston, TX 77098 USA.	swhitney@bcm.tmc.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS011289] Funding Source: NIH RePORTER; AHRQ HHS [K08 HS11289] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1986, HIST THEORY INFORM C; ARNOLD RM, 1995, ENCY BIOETHICS, P1250; Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; BERG JW, 2001, INFORMED CONSENT LEG; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; BRODY H, 1992, HEALERS POWER; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8; Elwyn G, 1999, BRIT MED J, V319, P753, DOI 10.1136/bmj.319.7212.753; Fox Renee C., 1979, ESSAYS MED SOCIOLOGY; Jacoby LH, 1999, BONE MARROW TRANSPL, V23, P711, DOI 10.1038/sj.bmt.1701631; KATZ J, 1984, SILENT WORLD DOCTOR, P98; Katz J., 1984, SILENT WORLD DOCTOR; LIDZ CW, 1988, ARCH INTERN MED, V148, P1385, DOI 10.1001/archinte.148.6.1385; Lidz CW, 1984, INFORMED CONSENT STU; LIGHT D, 1979, J HEALTH SOC BEHAV, V20, P310, DOI 10.2307/2955407; Prince A.E.R., HEALTH MATRIX; Schneider CE, 1998, PRACTICE AUTONOMY PA; Towle A, 1999, BRIT MED J, V319, P766, DOI 10.1136/bmj.319.7212.766; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VEATCH RM, 1995, HASTINGS CENT REP, V25, P5, DOI 10.2307/3562859; Whitney SN, 2003, MED DECIS MAKING, V23, P275, DOI 10.1177/0272989X03256006	22	290	295	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					54	59		10.7326/0003-4819-140-1-200401060-00012	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706973				2022-12-28	WOS:000187855600008
J	Woolf, SH				Woolf, SH			Patient safety is not enough: Targeting quality improvements to optimize the health of the population	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL ERRORS; CHRONIC DISEASES; UNITED-STATES; DEATHS; CARE; RISK; NEED; PREVENTABILITY; MANAGEMENT	Ensuring patient safety is essential for better health care, but preoccupation with niches of medicine, such as patient safety, can inadvertently compromise outcomes if it distracts from other problems that pose a greater threat to health. The greatest benefit for the population comes from a comprehensive view of population needs and making improvements in proportion with their potential effect on public health; anything less subjects an excess of people to morbidity and death. Patient safety, in context, is a subset of health problems affecting Americans. Safety is a subcategory of medical errors, which also includes mistakes in health promotion and chronic disease management that cost lives but do not affect "safety." These errors are a subset of lapses in quality, which result not only from errors but also from systemic problems, such as lack of access, inequity, and flawed system designs. Lapses in quality are a subset of deficient caring, which encompasses gaps in therapeutics, respect, and compassion that are undetected by normative quality indicators. These larger problems arguably cost hundreds of thousands more lives than do lapses in safety, and the system redesigns to correct them should receive proportionately greater emphasis. Ensuring such rational prioritization requires policy and medical leaders to eschew parochialism and take a global perspective in gauging health problems. The public's well-being requires policymakers to view the system as a whole and consider the potential effect on overall population health when prioritizing care improvements and system redesigns.	Virginia Commonwealth Univ, Med Ctr, Dept Family Practice, Fairfax, VA 22033 USA	Virginia Commonwealth University	Woolf, SH (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Family Practice, 3712 Charles Stewart Dr, Fairfax, VA 22033 USA.	swoolf@vcu.edu						Adams K., 2003, PRIORITY AREAS NATL; *AG HEALTHC RES QU, 2004, JUST BUDG EST APPR C; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; CALLAHAN D, 1991, HEALTH AFFAIR, V10, P78, DOI 10.1377/hlthaff.10.2.78; *CDC, 2002, MMWR-MORBID MORTAL W, V51, P300; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Chyka PA, 2000, AM J MED, V109, P122, DOI 10.1016/S0002-9343(00)00460-5; Coffield AB, 2001, AM J PREV MED, V21, P1, DOI 10.1016/S0749-3797(01)00308-7; Cooper J, 2001, CURRENT RES PATIENT; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Feinstein Alvan R., 2001, LOST ART CARING CHAL, P201; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; *I MED, 2002, CAR WITH COV TOO LIT; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kelley MA, 2001, BMJ-BRIT MED J, V323, P61, DOI 10.1136/bmj.323.7304.61; Kirsner JB, 2002, JAMA-J AM MED ASSOC, V287, P1909, DOI 10.1001/jama.287.15.1909; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; LAMBREW JM, 2003, SMALL SIGNIFICANT ST; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Lee TH, 2002, NEW ENGL J MED, V347, P1965, DOI 10.1056/NEJMe020149; Manuel DG, 2002, AM J PUBLIC HEALTH, V92, P1481, DOI 10.2105/AJPH.92.9.1481; MCCRERY J, 2002, C MUST FINALLY SOLVE; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; *NAT COMM QUAL ASS, 2003, STAT HLTH CAR QUAL; Phillips KA, 2000, JAMA-J AM MED ASSOC, V284, P2748, DOI 10.1001/jama.284.21.2748; Rundall TG, 2002, BMJ-BRIT MED J, V325, P958, DOI 10.1136/bmj.325.7370.958; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; Smedley BD, 2003, UNEQUAL TREATMENT CO; Stafford RS, 1998, CIRCULATION, V97, P1231, DOI 10.1161/01.CIR.97.13.1231; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Wagner EH, 2002, BMJ-BRIT MED J, V325, P913, DOI 10.1136/bmj.325.7370.913; Woolf SH, 1999, JAMA-J AM MED ASSOC, V282, P2358, DOI 10.1001/jama.282.24.2358; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; 2001, EVIT REP TECHNOL ASS, V43, P1	41	48	50	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					33	36		10.7326/0003-4819-140-1-200401060-00009	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706970				2022-12-28	WOS:000187855600005
J	Duffy, PE; Mutabingwa, TK				Duffy, PE; Mutabingwa, TK			Drug combinations for malaria: time to ACT?	LANCET			English	Editorial Material							ARTEMISININ; ARTESUNATE; QINGHAOSU		Seattle Biomed Res Inst, Malaria Antigen Discovery Program, Seattle, WA 98109 USA; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD USA; London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1, England; Natl Inst Med Res, Dar Es Salaam, Tanzania	Center for Infectious Disease Research; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of London; London School of Hygiene & Tropical Medicine; National Institute of Medical Research	Duffy, PE (corresponding author), Seattle Biomed Res Inst, Malaria Antigen Discovery Program, 4 Nickerson St, Seattle, WA 98109 USA.	patrick.duffy@sbri.org						CHAWIRA AN, 1987, J TROP MED HYG, V90, P1; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; KUMAR N, 1990, PARASITOL RES, V76, P214, DOI 10.1007/BF00930817; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860, DOI 10.1046/j.1360-2276.2003.01114.x; SY ND, 1993, AM J TROP MED HYG, V48, P398, DOI 10.4269/ajtmh.1993.48.398; World Health Organization (WHO), 2003, ASS SAF ART COMP PRE	8	33	33	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					3	4		10.1016/S0140-6736(03)15230-0	http://dx.doi.org/10.1016/S0140-6736(03)15230-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723982				2022-12-28	WOS:000187711300003
J	Graham, W; Hussein, J				Graham, W; Hussein, J			The right to count	LANCET			English	Article									Univ Aberdeen, Dugald baird Ctr Res Womens Hlth, Dept Obstet & Gynaecol, Aberdeen AB25 2ZL, Scotland	University of Aberdeen	Graham, W (corresponding author), Univ Aberdeen, Dugald baird Ctr Res Womens Hlth, Dept Obstet & Gynaecol, Aberdeen AB25 2ZL, Scotland.	w.graham@abdn.ac.uk		Graham, Wendy/0000-0003-1473-5342				BOUVIERCOLLE MH, 1991, INT J EPIDEMIOL, V20, P717, DOI 10.1093/ije/20.3.717; *SAFE INT RES PART, 2003, SAFE STRAT DEV TOOL; WHO UNICEF and UNFPA, 2003, MAT MORT 2000 EST DE	3	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					67	68		10.1016/S0140-6736(03)15174-4	http://dx.doi.org/10.1016/S0140-6736(03)15174-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723999				2022-12-28	WOS:000187711300028
J	Boughn, S; Crittenden, R				Boughn, S; Crittenden, R			A correlation between the cosmic microwave background and large-scale structure in the Universe	NATURE			English	Article							PROBE WMAP OBSERVATIONS; SKY	Observations of distant supernovae and the fluctuations in the cosmic microwave background (CMB) indicate that the expansion of the Universe may be accelerating(1) under the action of a 'cosmological constant' or some other form of 'dark energy'. This dark energy now appears to dominate the Universe and not only alters its expansion rate, but also affects the evolution of fluctuations in the density of matter, slowing down the gravitational collapse of material (into, for example, clusters of galaxies) in recent times. Additional fluctuations in the temperature of CMB photons are induced as they pass through large-scale structures(2) and these fluctuations are necessarily correlated with the distribution of relatively nearby matter(3). Here we report the detection of correlations between recent CMB data(4) and two probes of large-scale structure: the X-ray background(5) and the distribution of radio galaxies(6). These correlations are consistent with those predicted by dark energy, indicating that we are seeing the imprint of dark energy on the growth of structure in the Universe.	Univ Portsmouth, Inst Cosmol & Gravitat, Portsmouth PO1 2EG, Hants, England; Haverford Coll, Dept Astron, Haverford, PA 19041 USA	University of Portsmouth; Haverford College	Crittenden, R (corresponding author), Univ Portsmouth, Inst Cosmol & Gravitat, Portsmouth PO1 2EG, Hants, England.	Robert.Crittenden@port.ac.uk		Crittenden, Robert/0000-0002-5743-1528				Bahcall NA, 1999, SCIENCE, V284, P1481, DOI 10.1126/science.284.5419.1481; Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P97, DOI 10.1086/377252; Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; BOLDT E, 1987, PHYS REP, V146, P215, DOI 10.1016/0370-1573(87)90108-6; Boughn SP, 1998, NEW ASTRON, V3, P275, DOI 10.1016/S1384-1076(98)00009-8; Boughn SP, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.021302; Boughn SP, 1998, ASTROPHYS J, V499, P533, DOI 10.1086/305674; Boughn SP, 2002, ASTROPHYS J, V580, P672, DOI 10.1086/343861; Condon JJ, 1998, ASTRON J, V115, P1693, DOI 10.1086/300337; Cowie LL, 2003, ASTROPHYS J, V584, pL57, DOI 10.1086/368404; Crittenden RG, 1996, PHYS REV LETT, V76, P575, DOI 10.1103/PhysRevLett.76.575; DUNLOP JS, 1990, MON NOT R ASTRON SOC, V247, P19; Kinkhabwala A, 1999, PHYS REV LETT, V82, P4172, DOI 10.1103/PhysRevLett.82.4172; Kogut A, 1996, ASTROPHYS J, V470, P653, DOI 10.1086/177898; NOLTA MR, 2003, 1 YEAR WILKINSON MIC; Peiris HV, 2000, ASTROPHYS J, V540, P605, DOI 10.1086/309373; SACHS RK, 1967, ASTROPHYS J, V147, P73, DOI 10.1086/148982; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; TEGMARK M, 2003, HIGH RESOLUTION FORE	19	297	299	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					45	47		10.1038/nature02139	http://dx.doi.org/10.1038/nature02139			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702078	Green Submitted			2022-12-28	WOS:000187710000027
J	Attal, M; Harousseau, JL; Facon, T; Guilhot, F; Doyen, C; Fuzibet, JG; Monconduit, M; Hulin, C; Caillot, D; Bouabdallah, R; Voillat, L; Sotto, JJ; Grosbois, B; Bataille, R				Attal, M; Harousseau, JL; Facon, T; Guilhot, F; Doyen, C; Fuzibet, JG; Monconduit, M; Hulin, C; Caillot, D; Bouabdallah, R; Voillat, L; Sotto, JJ; Grosbois, B; Bataille, R		InterGrp Francophone Myelome	Single versus double autologous stem-cell transplantation for multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DOSE THERAPY; PROSPECTIVE RANDOMIZED TRIAL; BONE-MARROW TRANSPLANTATION; ABSC TRANSPLANTATION; CLINICAL-TRIAL; CHEMOTHERAPY; BLOOD; MELPHALAN; MULTICENTER; BORTEZOMIB	Background: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. Methods: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. Results: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta(sub 2)-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). Conclusions: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.	Hop Purpan, Hematol Serv, Dept Hematol, F-31059 Toulouse, France; Hop Purpan, Dept Biostat, F-31059 Toulouse, France; Hop Hotel Dieu, Nantes, France; Hop C Huriez, Lille, France; Ctr Hosp Mileterie, Poitiers, France; Ctr Univ St Luc, Brussels, Belgium; Hop Cimiez, F-06003 Nice, France; Ctr Henri Becquerel, F-76038 Rouen, France; Ctr Hosp Brabois, Nancy, France; Ctr Hosp Le Bocage, Dijon, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Hop Jean Minjoz, F-25030 Besancon, France; Hop Albert Michallon, Grenoble, France; Hop Sud, Rennes, France	CHU de Toulouse; CHU de Toulouse; Nantes Universite; CHU de Nantes; Universite de Lille - ISITE; CHU Lille; CHU Poitiers; Universite de Poitiers; CHU Nice; UNICANCER; Centre Henri Becquerel; CHU de Nancy; CHU Dijon Bourgogne; UNICANCER; Institut Paoli-Calmette (IPC); Universite de Franche-Comte; CHU Besancon; CHU Grenoble Alpes; CHU Rennes	Attal, M (corresponding author), Hop Purpan, Hematol Serv, Dept Hematol, Pl Dr Baylac, F-31059 Toulouse, France.			Guilhot, Francois/0000-0001-7222-487X				Attal M, 2001, SEMIN HEMATOL, V38, P226, DOI 10.1053/shem.2001.26005; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Barlogie B, 1999, BLOOD, V93, P55, DOI 10.1182/blood.V93.1.55.401k04_55_65; BARLOGIE B, 1991, BONE MARROW TRANSPL, V7, P71; Bjorkstrand B, 2001, SEMIN HEMATOL, V38, P219, DOI 10.1053/shem.2001.26009; Blade J, 2001, BLOOD, V98, p815A; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Cavo M, 2002, BLOOD, V100, p179A; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; Fermand JP, 2001, BLOOD, V98, p815A; Fermand JP, 1999, BLOOD, V94, p396A; GORE ME, 1989, LANCET, V2, P879; HAROUSSEAU JL, 1992, BLOOD, V79, P2827; Moreau P, 2002, BLOOD, V99, P731, DOI 10.1182/blood.V99.3.731; Palumbo A, 2001, BLOOD, V98, p849A; Pasquali S, 1998, J CLIN ONCOL, V16, P3832; Richardson P, 2002, BLOOD, V100, p104A; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Segeren CM, 2003, BLOOD, V101, P2144, DOI 10.1182/blood-2002-03-0889; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Singhal S, 2000, NEW ENGL J MED, V342, P364; Sirohi B, 2002, BONE MARROW TRANSPL, V29, pS12; VESOLE DH, 1994, BLOOD, V84, P950	24	787	836	0	23	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2495	2502		10.1056/NEJMoa032290	http://dx.doi.org/10.1056/NEJMoa032290			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695409				2022-12-28	WOS:000187529500004
J	Antoch, G; Vogt, FM; Freudenberg, LS; Nazaradeh, F; Goehde, SC; Barkhausen, J; Dahmen, G; Bockisch, A; Debatin, JF; Ruehm, SG				Antoch, G; Vogt, FM; Freudenberg, LS; Nazaradeh, F; Goehde, SC; Barkhausen, J; Dahmen, G; Bockisch, A; Debatin, JF; Ruehm, SG			Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; PELVIC LYMPH-NODES; FDG-PET; NECK-CANCER; BRONCHOGENIC-CARCINOMA; COMPUTED-TOMOGRAPHY; CLINICAL ONCOLOGY; SPIRAL CT; METASTASES	Context Deciding on the appropriate therapy for patients with malignant diseases mandates accurate tumor staging with whole-body coverage. Magnetic resonance imaging (MRI) and a combined modality including positron emission tomography (PET) and computed tomography (CT) provide whole-body tumor staging in a single session. Objective To determine the staging accuracies of both whole-body PET/CT and whole-body MR] for different malignant diseases. Design, Setting, and Patients Prospective, blinded, investigator-initiated study of 98 patients (mean age, 58 years; range, 27-94 years) with various oncological diseases who underwent back-to-back whole-body glucose analog [18F]fluorodeoxyglucose-PET/CT and whole-body MRI for tumor staging. The study was conducted at a university hospital from December 2001 through October 2002 and had a mean follow-up of 273 days (range, 75-515 days). The images were evaluated by 2 different, blinded reader teams. The diagnostic, accuracies of the 2 imaging procedures were compared. Main Outcome Measures Correct classification of the primary tumor, regional lymph nodes, and distant metastasis (overall TNM stage) using whole-body PET/CT and whole-body MRI. Secondary outcome measures were accurate assessment of T-stage, N-stage, and M-stage by the 2 imaging procedures. Results Of 98 patients, the overall TNM stage was correctly determined in 75 with PET/CT (77%; 95% confidence interval [CI], 67%-85%) and in 53 with MRI (54%; 95% Cl, 44%-64%) (P<.001). Compared with MRI, PET/CT had a direct impact on patient management in 12 patients. Results from MR] changed the therapy regimen in 2 patients compared with PET/CT. Separate assessment of T-stage (with pathological verification) in 46 patients revealed PET/CT to be accurate in 37 (80%; 95% Cl, 66%-91%) and MR[ to be accurate in 24 (52%; 95% Cl, 37%-67%) (P<.001). Of 98 patients, N-stage was correctly determined in 91 patients with PET/CT (93%; 95% Cl, 86%-97%) and in 77 patients with MRI (79%; 95% Cl, 69%-86%) (P=.001). Both imaging procedures showed a similar performance in detecting distant metastases. Conclusions The feasibility and diagnostic accuracy of the whole-body staging strategies of PET/CT and MRI are established. Superior performance in overall TNM staging suggests the use of [18F]-fluorodeoxyglucose-PET/CT as a possible first-line modality for whole-body tumor staging.	Univ Hosp Essen, Dept Diagnost & Intervent Radiol, D-45122 Essen, Germany; Univ Hosp Essen, Dept Nucl Med, D-45122 Essen, Germany; Med Univ Lubeck, Inst Med Biometry & Stat, D-23538 Lubeck, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Lubeck	Antoch, G (corresponding author), Univ Hosp Essen, Dept Diagnost & Intervent Radiol, Hufelandstr 55, D-45122 Essen, Germany.		Barkhausen, Joerg/E-3921-2010					*AM JOINT COMM CAN, 2002, AJCC CANC STAG MAN; Antoch G, 2003, RADIOLOGY, V229, P526, DOI 10.1148/radiol.2292021598; Antoch G, 2002, AM J ROENTGENOL, V179, P1555, DOI 10.2214/ajr.179.6.1791555; Antoch G, 2002, J NUCL MED, V43, P1339; Barkhausen J, 2001, RADIOLOGY, V220, P252, DOI 10.1148/radiology.220.1.r01jn07252; Beggs AD, 2002, EUR J NUCL MED MOL I, V29, P542, DOI 10.1007/s00259-001-0736-7; Beyer T, 2003, EUR J NUCL MED MOL I, V30, P588, DOI 10.1007/s00259-002-1097-6; Beyer T, 2002, Q J NUCL MED, V46, P24; Bockisch A, 2003, ACTA MED AUST, V30, P22, DOI 10.1046/j.1563-2571.2003.02045.x; Cohade C, 2003, J NUCL MED, V44, P412; Daldrup-Link HE, 2001, AM J ROENTGENOL, V177, P229, DOI 10.2214/ajr.177.1.1770229; Deslauriers J, 2000, CHEST, V117, p96S, DOI 10.1378/chest.117.4_suppl_1.96S; Dizendorf E, 2003, J NUCL MED, V44, P732; DORFMAN RE, 1991, RADIOLOGY, V180, P319, DOI 10.1148/radiology.180.2.2068292; Feind CR, 1972, LYMPHATICS CANCER, P60; Ferraris R, 2001, SEMIN SURG ONCOL, V20, P122, DOI 10.1002/ssu.1025; Flamen P, 1999, J CLIN ONCOL, V17, P894, DOI 10.1200/JCO.1999.17.3.894; Franzius C, 2002, ANN ONCOL, V13, P157, DOI 10.1093/annonc/mdf012; Gdeedo A, 1997, EUR J CARDIO-THORAC, V12, P224, DOI 10.1016/S1010-7940(97)00084-5; GLAZER GM, 1985, AM J ROENTGENOL, V144, P261, DOI 10.2214/ajr.144.2.261; Gould MK, 2001, JAMA-J AM MED ASSOC, V285, P914, DOI 10.1001/jama.285.7.914; Haberkorn U, 2001, LUNG CANCER, V34, pS13; Hany TF, 2002, RADIOLOGY, V225, P575, DOI 10.1148/radiol.2252011568; Harisinghani MG, 1997, JMRI-J MAGN RESON IM, V7, P161, DOI 10.1002/jmri.1880070124; Hawighorst H, 1998, J COMPUT ASSIST TOMO, V22, P75, DOI 10.1097/00004728-199801000-00013; Irie H, 1997, ABDOM IMAGING, V22, P429, DOI 10.1007/s002619900226; Kinkel K, 2002, RADIOLOGY, V224, P748, DOI 10.1148/radiol.2243011362; Kresnik E, 2001, EUR J NUCL MED, V28, P816, DOI 10.1007/s002590100554; Lardinois D, 2003, NEW ENGL J MED, V348, P2500, DOI 10.1056/NEJMoa022136; Lauenstein TC, 2002, AM J ROENTGENOL, V179, P445, DOI 10.2214/ajr.179.2.1790445; Layer G, 1999, CANCER, V85, P1004; MANCUSO AA, 1983, RADIOLOGY, V148, P709, DOI 10.1148/radiology.148.3.6878691; Martinelli, 2000, Clin Positron Imaging, V3, P161, DOI 10.1016/S1095-0397(00)00073-X; Osman MM, 2003, J NUCL MED, V44, P240; Pastorino U, 2003, LANCET, V362, P593, DOI 10.1016/S0140-6736(03)14188-8; PATZ EF, 1993, RADIOLOGY, V188, P487, DOI 10.1148/radiology.188.2.8327702; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Popperl G, 2002, ROFO-FORTSCHR RONTG, V174, P714, DOI 10.1055/s-2002-32215; Reinhardt MJ, 2001, RADIOLOGY, V218, P776, DOI 10.1148/radiology.218.3.r01mr19776; Semelka RC, 1997, JMRI-J MAGN RESON IM, V7, P1040, DOI 10.1002/jmri.1880070616; Semelka RC, 2001, J MAGN RESON IMAGING, V13, P397, DOI 10.1002/jmri.1057; STAPLES CA, 1988, RADIOLOGY, V167, P367, DOI 10.1148/radiology.167.2.3357944; Taupitz M, 1999, RADIOLOGY, V213P, P369; Toloza EM, 2003, CHEST, V123, p137S, DOI 10.1378/chest.123.1_suppl.137S; Walker R E, 2001, Semin Musculoskelet Radiol, V5, P5; Yang M, 2003, J MAGN RESON IMAGING, V17, P343, DOI 10.1002/jmri.10265	46	414	442	0	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2003	290	24					3199	3206		10.1001/jama.290.24.3199	http://dx.doi.org/10.1001/jama.290.24.3199			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756TR	14693872	Bronze			2022-12-28	WOS:000187499300023
J	Hughes, RJ; Hopkins, RJ; Hill, S; Weatherall, M; Van de Water, N; Nowitz, M; Milne, D; Ayling, J; Wilsher, M; Beasley, R				Hughes, RJ; Hopkins, RJ; Hill, S; Weatherall, M; Van de Water, N; Nowitz, M; Milne, D; Ayling, J; Wilsher, M; Beasley, R			Frequency of venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller's Thrombosis (NZATT) study	LANCET			English	Article							DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; CLINICAL-MODEL; HAUL FLIGHTS; DIAGNOSIS; ULTRASONOGRAPHY; PROBABILITY; PREVENTION; UTILITY; US	Background The frequency and role of risk factors for venous thromboembolism related to air travel is uncertain. We aimed to establish the frequency of this disorder in a group of long distance air travellers and to investigate the role of potential risk factors. Methods We designed a prospective study into which we recruited individuals aged between 18 and 70 years, travelling for 4 h or more by aircraft. D-dimer measurement was done before and after travel. Participants with a negative D-dimer (<500 ng/L) before travel were included in the study. Those who became D-dimer positive or developed high clinical probability symptoms during the 3 months after travel were investigated with bilateral compression ultrasonography and CT pulmonary angiography. Suspected clinical and thrombophilic risk factors, and use of prophylactic measures, were assessed. Findings 1000 individuals were recruited, with 878 meeting inclusion criteria and completing the study. All participants travelled at least 10 h, with a mean total duration of air travel of 39 h (SD 12.5). 112 patients underwent radiological assessment on return. Frequency of venous thromboembolism associated with travel was 1.0% (9/878, 95% Cl 0.5-1.9), which included four cases of pulmonary embolism and five of deep venous thrombosis. Six patients with venous thromboembolism had pre-existing clinical risk factors, two had a recognised thrombophilic risk factor, two travelled exclusively in business class, five used aspirin, and four wore compression stockings Interpretation Our results suggest an association between multiple long distance air flights and venous thromboembolism, even in individuals at low to moderate risk. The role of traditional risk factors and prophylactic measures in air travel-related venous thromboembolism needs further investigation.	Med Res Inst New Zealand, Wellington, New Zealand; Green Lane Hosp, Auckland 3, New Zealand; Wellington Sch Med & Hlth Sci, Wellington, New Zealand; Auckland Sch Med, Auckland, New Zealand; P3 Res, Wellington, New Zealand; Univ Southampton, Southampton, Hants, England	Medical Research Institute Of New Zealand; University of Otago; University of Auckland; University of Southampton	Beasley, R (corresponding author), Med Res Inst New Zealand, POB 10055, Wellington, New Zealand.	Richard.beasley@mrinz.ac.nz	Beasley, Richard/AAH-3908-2019; Weatherall, Mark/Y-6824-2019	Beasley, Richard/0000-0003-0337-406X; Weatherall, Mark/0000-0002-0051-9107; Hopkins, Raewyn/0000-0003-2168-6235; Hill, Sarah/0000-0003-3555-433X				Arya R, 2002, BRIT J HAEMATOL, V116, P653, DOI 10.1046/j.0007-1048.2001.03330.x; Belcaro G, 2001, ANGIOLOGY, V52, P369, DOI 10.1177/000331970105200601; Bernardi E, 1998, BRIT MED J, V317, P1037; Bounameaux H, 2000, LANCET, V356, P182, DOI 10.1016/S0140-6736(00)02476-4; Brill-Edwards P, 1999, THROMB HAEMOSTASIS, V82, P688; Campbell IA, 2003, THORAX, V58, P470; Cesarone MR, 2002, ANGIOLOGY, V53, P1, DOI 10.1177/000331970205300101; Cornuz J, 1999, RADIOLOGY, V211, P637, DOI 10.1148/radiology.211.3.r99jn24637; CRUICKSHANK JM, 1988, LANCET, V2, P497, DOI 10.1016/S0140-6736(88)90134-1; Eekhoff EMW, 2000, THROMB HAEMOSTASIS, V83, P408, DOI 10.1055/s-0037-1613828; Eklof B, 1996, DERMATOL SURG, V22, P637, DOI 10.1111/j.1524-4725.1996.tb00610.x; HOMANS J, 1954, NEW ENGL J MED, V250, P148, DOI 10.1056/NEJM195401282500404; *HOUS LORDS SEL CO, 1999, 5 HOUS LORDS SEL COM, P1; Kesteven P. L. J., 2000, Thorax, V55, pS32, DOI 10.1136/thorax.55.suppl_1.S32; Kesteven PJL, 2001, AVIAT SPACE ENVIR MD, V72, P125; Lapostolle F, 2001, NEW ENGL J MED, V345, P779, DOI 10.1056/NEJMoa010378; Mendis S, 2002, B WORLD HEALTH ORGAN, V80, P403; Mercer A, 1998, AVIAT SPACE ENVIR MD, V69, P154; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; Perrier A, 1997, AM J RESP CRIT CARE, V156, P492, DOI 10.1164/ajrccm.156.2.9702032; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; Perrier A, 2001, ANN INTERN MED, V135, P88, DOI 10.7326/0003-4819-135-2-200107170-00008; QUINN RJ, 1994, RADIOLOGY, V190, P509, DOI 10.1148/radiology.190.2.8284407; Scurr JH, 2001, LANCET, V357, P1485, DOI 10.1016/S0140-6736(00)04645-6; Simpson K, 1940, LANCET, V2, P744; SYMINGTON IS, 1977, BRIT J DIS CHEST, V71, P138, DOI 10.1016/0007-0971(77)90097-3; Tapson VF, 1999, AM J RESP CRIT CARE, V160, P1043; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; Wells PS, 1999, THROMB HAEMOSTASIS, V81, P493; Wells PS, 2000, THROMB HAEMOSTASIS, V83, P416	30	97	100	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2039	2044		10.1016/S0140-6736(03)15097-0	http://dx.doi.org/10.1016/S0140-6736(03)15097-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697802				2022-12-28	WOS:000187429600007
J	Clyde, DE; Corado, MSG; Wu, XL; Pare, A; Papatsenko, D; Small, S				Clyde, DE; Corado, MSG; Wu, XL; Pare, A; Papatsenko, D; Small, S			A self-organizing system of repressor gradients establishes segmental complexity in Drosophila	NATURE			English	Article							PAIR-RULE STRIPES; BINDING-SITES; IN-VIVO; EMBRYO; GENE; EXPRESSION; MORPHOGEN; HUNCHBACK; KRUPPEL; ACTIVATORS	Gradients of regulatory factors are essential for establishing precise patterns of gene expression during development(1-3); however, it is not clear how patterning information in multiple gradients is integrated to generate complex body plans. Here we show that opposing gradients of two Drosophila transcriptional repressors, Hunchback (Hb) and Knirps (Kni), position several segments by differentially repressing two distinct regulatory regions (enhancers) of the pair-rule gene even-skipped (eve). Computational and in vivo analyses suggest that enhancer sensitivity to repression is controlled by the number and affinity of repressor-binding sites. Because the kni expression domain is positioned between two gradients of Hb, each enhancer directs expression of a pair of symmetrical stripes, one on each side of the kni domain. Thus, only two enhancers are required for the precise positioning of eight stripe borders (four stripes), or more than half of the whole eve pattern. Our results show that complex developmental expression patterns can be generated by simple repressor gradients. They also support the utility of computational analyses for defining and deciphering regulatory information contained in genomic DNA.	NYU, Dept Biol, New York, NY 10003 USA	New York University	Small, S (corresponding author), NYU, Dept Biol, New York, NY 10003 USA.		Papatsenko, Dmitri/G-7375-2016	Papatsenko, Dmitri/0000-0002-4390-5446				Andrioli LPM, 2002, DEVELOPMENT, V129, P4931; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Fujioka M, 1999, DEVELOPMENT, V126, P2527; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; HOU XS, 1996, CELL, V85, P290; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Kosman D, 1997, DEVELOPMENT, V124, P1343; KRAUT R, 1991, DEVELOPMENT, V111, P611; LANGELAND JA, 1994, DEVELOPMENT, V120, P2945; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; Lifanov AP, 2003, GENOME RES, V13, P579, DOI 10.1101/gr.668403; Nambu PA, 1996, DEVELOPMENT, V122, P3467; Papatsenko DA, 2002, GENOME RES, V12, P470, DOI 10.1101/gr.212502. Article published online before print in February ; Small S, 2000, METHOD ENZYMOL, V326, P146; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	31	145	150	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					849	853		10.1038/nature02189	http://dx.doi.org/10.1038/nature02189			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685241				2022-12-28	WOS:000187342000061
J	Arcury, TA; Quandt, SA				Arcury, TA; Quandt, SA			Pesticides at work and at home: exposure of migrant farmworkers	LANCET			English	Editorial Material									Wake Forest Univ, Bowman Gray Sch Med, Dept Family & Community Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Arcury, TA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Family & Community Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008739] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES08739] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARR DB, 2003, ENV HLTH PERSPE 1104; *GOV ACC OFF, 2000, GAORCED0040; Lindell A. R., 2003, NATL PESTICIDE COMPE	3	33	39	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 13	2003	362	9400					2021	2021		10.1016/S0140-6736(03)15027-1	http://dx.doi.org/10.1016/S0140-6736(03)15027-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	753BC	14686376				2022-12-28	WOS:000187210700029
J	Downey, M				Downey, M			The importance of being earnest	LANCET			English	Article									Amer Obes Assoc, Washington, DC 20037 USA		Downey, M (corresponding author), Amer Obes Assoc, Suite 300,1250 24th St NW, Washington, DC 20037 USA.								0	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S42	S43		10.1016/S0140-6736(03)15072-6	http://dx.doi.org/10.1016/S0140-6736(03)15072-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698126				2022-12-28	WOS:000187790200022
J	Goodacre, S; Nicholl, J; Dixon, S; Cross, E; Angelini, K; Arnold, J; Revill, S; Locker, T; Capewell, SJ; Quinney, D; Campbell, S; Morris, F				Goodacre, S; Nicholl, J; Dixon, S; Cross, E; Angelini, K; Arnold, J; Revill, S; Locker, T; Capewell, SJ; Quinney, D; Campbell, S; Morris, F			Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC TROPONIN-T; EMERGENCY-DEPARTMENT; MYOCARDIAL-INFARCTION; CLINICAL-TRIAL; ISCHEMIA; PROTOCOL	Objectives To measure the effectiveness and cost effectiveness of providing care in a chest pain observation unit compared with routine care for patients with acute, undifferentiated chest pain. Design Cluster randomised controlled trial, with 442 days randomised to the chest pain observation unit or routine care, and cost effectiveness analysis from a health service costing perspective. Setting The emergency department at the Northern General Hospital, Sheffield, United Kingdom. Participants 972 patients with acute, undifferentiated chest pain (479 attending on days when care was delivered in the chest pain observation unit, 493 on days of routine care) followed up until six months after initial attendance. Main outcome measures The proportion of participants admitted to hospital, the proportion with acute coronary syndrome sent home inappropriately, major adverse cardiac events over six months, health utility, hospital reattendance and readmission, and costs per patient to the health service. Results Use of a chest pain observation unit reduced the proportion of patients admitted from 54% to 37% (difference 17%, odds ratio 0.50, 95% confidence interval 0.39 to 0.65, P < 0.001) and the proportion discharged with acute coronary syndrome from 14% to 6% (8%, -7% to 23%, P = 0.264). Rates of cardiac event were unchanged. Care in the chest pain observation unit was associated with improved health utility during follow up (0.0137 quality adjusted life years gained, 95% confidence interval 0.0030 to 0.0254, P = 0.022) and a saving of 178 per patient (-&POUND;56 to &POUND;210, P = 0.252). Conclusions Care in a chest pain observation unit can improve outcomes and may reduce costs to the health service. It seems to be more effective and more cost effective than routine care.	Univ Sheffield, Sch Hlth Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England; No Gen Hosp, Med Care Res Unit, Dept Emergency, Sheffield S5 7AU, S Yorkshire, England; No Gen Hosp, Dept Cardiol, Sheffield S5 7AU, S Yorkshire, England; Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England	University of Sheffield; Northern General Hospital; University of Sheffield; Northern General Hospital; University of Liverpool	Goodacre, S (corresponding author), Univ Sheffield, Sch Hlth Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England.	s.goodacre@sheffield.ac.uk	Nicholl, Jon/B-8257-2008	Goodacre, Steve/0000-0003-0803-8444; Dixon, Simon/0000-0001-7394-7009; Locker, Thomas/0000-0002-7960-0572				Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; Capewell S, 2000, BRIT MED J, V320, P951, DOI 10.1136/bmj.320.7240.951; Clancy M, 2002, BRIT MED J, V325, P116, DOI 10.1136/bmj.325.7356.116; Collinson PO, 2000, BRIT MED J, V320, P1702, DOI 10.1136/bmj.320.7251.1702; *DEP HLTH, 2002, NAT SCHED REF COSTS; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Farkouh ME, 1998, NEW ENGL J MED, V339, P1882, DOI 10.1056/NEJM199812243392603; Fesmire FM, 1998, AM HEART J, V136, P237, DOI 10.1053/hj.1998.v136.89571; Fesmire FM, 1998, ANN EMERG MED, V31, P3, DOI 10.1016/S0196-0644(98)70274-4; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Gomez MA, 1996, J AM COLL CARDIOL, V28, P25, DOI 10.1016/0735-1097(96)00093-9; GOODACRE S, 2003, BR J CARDIOL, V10, P50; Goodacre SW, 2000, J ACCID EMERG MED, V17, P1; Goodacre SW, 2002, EMERG MED J, V19, P117, DOI 10.1136/emj.19.2.117; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; HANIM CW, 1997, NEW ENGL J MED, V337, P1648; Kirk JD, 1998, ANN EMERG MED, V32, P1, DOI 10.1016/S0196-0644(98)70091-5; Lindahl B, 1998, EUR HEART J, V19, pN51; Netten A., 2001, UNIT COSTS HLTH SOCI; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; Roberts RR, 1997, JAMA-J AM MED ASSOC, V278, P1670, DOI 10.1001/jama.278.20.1670	25	183	188	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2004	328	7434					254	257		10.1136/bmj.37956.664236.EE	http://dx.doi.org/10.1136/bmj.37956.664236.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771LC	14724129	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000188786000016
J	Jordt, SE; Bautista, DM; Chuang, HH; McKemy, DD; Zygmunt, PM; Hogestatt, ED; Meng, ID; Julius, D				Jordt, SE; Bautista, DM; Chuang, HH; McKemy, DD; Zygmunt, PM; Hogestatt, ED; Meng, ID; Julius, D			Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1	NATURE			English	Article							NEUROGENIC PLASMA EXTRAVASATION; CAPSAICIN RECEPTOR; VANILLOID RECEPTOR; PAIN PATHWAY; SUBSTANCE-P; ANANDAMIDE; THERMOSENSATION; INFLAMMATION; STIMULI; NEURONS	Wasabi, horseradish and mustard owe their pungency to isothiocyanate compounds. Topical application of mustard oil (allyl isothiocyanate) to the skin activates underlying sensory nerve endings, thereby producing pain, inflammation and robust hypersensitivity to thermal and mechanical stimuli(1,2). Despite their widespread use in both the kitchen and the laboratory, the molecular mechanism through which isothiocyanates mediate their effects remains unknown. Here we show that mustard oil depolarizes a subpopulation of primary sensory neurons that are also activated by capsaicin, the pungent ingredient in chilli peppers, and by Delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana. Both allyl isothiocyanate and THC mediate their excitatory effects by activating ANKTM1, a member of the transient receptor potential (TRP) ion channel family recently implicated in the detection of noxious cold(3,4). These findings identify a cellular and molecular target for the pungent action of mustard oils and support an emerging role for TRP channels as ionotropic cannabinoid receptors(5-8).	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Lund Hosp, Inst Lab Med, Dept Clin Pharmacol, SE-22185 Lund, Sweden	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Lund University; Skane University Hospital	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	julius@cmp.ucsf.edu	Jordt, Sven-Eric/ABE-6517-2020	Jordt, Sven-Eric/0000-0001-6171-5622; Zygmunt, Peter/0000-0002-5102-8199				Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Di Marzo V, 2001, TRENDS PHARMACOL SCI, V22, P346, DOI 10.1016/S0165-6147(00)01712-0; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; JANCSO N, 1967, BRIT J PHARM CHEMOTH, V31, P138, DOI 10.1111/j.1476-5381.1967.tb01984.x; Jaquemar D, 1999, J BIOL CHEM, V274, P7325, DOI 10.1074/jbc.274.11.7325; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2003, CURR OPIN NEUROBIOL, V13, P487, DOI 10.1016/S0959-4388(03)00101-6; LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282; LOUIS SM, 1989, NEUROSCIENCE, V32, P581, DOI 10.1016/0306-4522(89)90281-9; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; PATACCHINI R, 1990, N-S ARCH PHARMACOL, V342, P72; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; RANG HP, 1994, TXB PAIN, P57; REEH PW, 1986, BRAIN RES, V384, P42, DOI 10.1016/0006-8993(86)91217-5; Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467; Simons CT, 2003, CHEM SENSES, V28, P459, DOI 10.1093/chemse/28.6.459; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Wall PD., 1999, TXB PAIN, V4th; Wilson RK, 2002, LIFE SCI, V71, P497, DOI 10.1016/S0024-3205(02)01708-3; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761; Zygmunt PM, 2002, J NEUROSCI, V22, P4720, DOI 10.1523/JNEUROSCI.22-11-04720.2002	29	1423	1504	2	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					260	265		10.1038/nature02282	http://dx.doi.org/10.1038/nature02282			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14712238				2022-12-28	WOS:000188068100047
J	Wenzel, V; Krismer, AC; Arntz, HR; Sitter, H; Stadlbauer, KH; Lindner, KH; Chamberlain, DA; Dick, WF; Bossaert, LL; Bruyneel, P; Sitter, H; Prunte, H; Wenzel, V; Krismer, AC; Stadlbauer, KH; Mayr, VD; Lienhart, HG; Arntz, HR; Breckwoldt, J; Baubin, MA; Voelckel, W; Menges, MM; Jenner, A; Prause, G; Kainz, J; Messelken, M; Roper, A; Bertschat, FL; Burkle, G; Koberne, F; Bandemer, G; Callies, A; Schmitz, B; Schuttler, J; Wilde, T; Ellinger, K; Burfeind, S; Genzwurker, HV; Koppenberg, J; Ebmeyer, U; Dirks, B; Lehle, B; Ummenhofer, W; Albrecht, R; Trimmel, H; Gaberszig, N; Beneker, J; Schlechtriemen, T; Altemeyer, KH; Wauer, H; Geyer, T; Kleinschmidt, S; Wilhelm, W; Lauber, P; Cartarius, R; Bottiger, BW; Bujard, M; Switalski, J; Hemicker, G; Lenz, R; Koster, J; Hahne, FU; Edelhoff, G; Besmer, I; Tietze-Schnur, P; Fischer, L; Poppelbaum, D				Wenzel, V; Krismer, AC; Arntz, HR; Sitter, H; Stadlbauer, KH; Lindner, KH; Chamberlain, DA; Dick, WF; Bossaert, LL; Bruyneel, P; Sitter, H; Prunte, H; Wenzel, V; Krismer, AC; Stadlbauer, KH; Mayr, VD; Lienhart, HG; Arntz, HR; Breckwoldt, J; Baubin, MA; Voelckel, W; Menges, MM; Jenner, A; Prause, G; Kainz, J; Messelken, M; Roper, A; Bertschat, FL; Burkle, G; Koberne, F; Bandemer, G; Callies, A; Schmitz, B; Schuttler, J; Wilde, T; Ellinger, K; Burfeind, S; Genzwurker, HV; Koppenberg, J; Ebmeyer, U; Dirks, B; Lehle, B; Ummenhofer, W; Albrecht, R; Trimmel, H; Gaberszig, N; Beneker, J; Schlechtriemen, T; Altemeyer, KH; Wauer, H; Geyer, T; Kleinschmidt, S; Wilhelm, W; Lauber, P; Cartarius, R; Bottiger, BW; Bujard, M; Switalski, J; Hemicker, G; Lenz, R; Koster, J; Hahne, FU; Edelhoff, G; Besmer, I; Tietze-Schnur, P; Fischer, L; Poppelbaum, D		European Resuscitation Council Vas	A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	76th Annual Scientific Session of the American-Heart-Association	NOV 07-12, 2003	ORLANDO, FL	Amer Heart Assoc			CORONARY PERFUSION-PRESSURE; PROLONGED CARDIAC-ARREST; ORGAN BLOOD-FLOW	Background: Vasopressin is an alternative to epinephrine for vasopressor therapy during cardiopulmonary resuscitation, but clinical experience with this treatment has been limited. Methods: We randomly assigned adults who had had an out-of-hospital cardiac arrest to receive two injections of either 40 IU of vasopressin or 1 mg of epinephrine, followed by additional treatment with epinephrine if needed. The primary end point was survival to hospital admission, and the secondary end point was survival to hospital discharge. Results: A total of 1219 patients underwent randomization; 33 were excluded because of missing study-drug codes. Among the remaining 1186 patients, 589 were assigned to receive vasopressin and 597 to receive epinephrine. The two treatment groups had similar clinical profiles. There were no significant differences in the rates of hospital admission between the vasopressin group and the epinephrine group either among patients with ventricular fibrillation (46.2 percent vs. 43.0 percent, P=0.48) or among those with pulseless electrical activity (33.7 percent vs. 30.5 percent, P=0.65). Among patients with asystole, however, vasopressin use was associated with significantly higher rates of hospital admission (29.0 percent, vs. 20.3 percent in the epinephrine group; P=0.02) and hospital discharge (4.7 percent vs. 1.5 percent, P=0.04). Among 732 patients in whom spontaneous circulation was not restored with the two injections of the study drug, additional treatment with epinephrine resulted in significant improvement in the rates of survival to hospital admission and hospital discharge in the vasopressin group, but not in the epinephrine group (hospital admission rate, 25.7 percent vs. 16.4 percent; P=0.002; hospital discharge rate, 6.2 percent vs. 1.7 percent; P=0.002). Cerebral performance was similar in the two groups. Conclusions: The effects of vasopressin were similar to those of epinephrine in the management of ventricular fibrillation and pulseless electrical activity, but vasopressin was superior to epinephrine in patients with asystole. Vasopressin followed by epinephrine may be more effective than epinephrine alone in the treatment of refractory cardiac arrest.	Univ Innsbruck, Dept Anesthesiol & Crit Care Med, A-6020 Innsbruck, Austria; Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Med, Div Cardiol Pulmonol, D-1000 Berlin, Germany; Univ Marburg, Inst Theoret Surg, Marburg, Germany	University of Innsbruck; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Philipps University Marburg	Lindner, KH (corresponding author), Univ Innsbruck, Dept Anesthesiol & Crit Care Med, Anichstr 35, A-6020 Innsbruck, Austria.	volker.wenzel@uibk.ac.at						Babar SI, 1999, RESUSCITATION, V41, P185, DOI 10.1016/S0300-9572(99)00071-4; BERG RA, 1994, CRIT CARE MED, V22, P282, DOI 10.1097/00003246-199402000-00020; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; FOX AW, 1992, J CARDIOVASC PHARM, V20, P282, DOI 10.1097/00005344-199208000-00014; Gottlieb R., 1896, ARCH EXPT PATHOLOGIE, V38, P99; GRMEC S, 2002, CRIT CARE S1, V6, pP162; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Holzer M, 2002, NEW ENGL J MED, V346, P549; Human Milk Banking Association of North America, 1995, GUID GOOD CLIN PRACT, P1; *INT CONS SCI, 2000, CIRCULATION S1, V102, P1; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; Mayr VD, 2001, CIRCULATION, V104, P1651, DOI 10.1161/hc3901.095896; Morris DC, 1997, ACAD EMERG MED, V4, P878, DOI 10.1111/j.1553-2712.1997.tb03813.x; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Paradis Norman A., 2002, Cardiology Clinics, V20, P61; Prengel AW, 1996, STROKE, V27, P1241, DOI 10.1161/01.STR.27.7.1241; Schneider T, 2000, CIRCULATION, V102, P1780; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Wenzel V, 2000, J AM COLL CARDIOL, V35, P527, DOI 10.1016/S0735-1097(99)00562-8; Wenzel V, 1999, CRIT CARE MED, V27, P486, DOI 10.1097/00003246-199903000-00022; Wenzel V, 1999, CIRCULATION, V99, P1379, DOI 10.1161/01.CIR.99.10.1379; 2000, CIRCULATION S1, V102, P1	29	407	427	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					105	113		10.1056/NEJMoa025431	http://dx.doi.org/10.1056/NEJMoa025431			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	760WP	14711909				2022-12-28	WOS:000187858500004
J	Morton, A; Muir, J; Lim, D				Morton, A; Muir, J; Lim, D			Drug points - Rash and acute nephritic syndrome due to candesartan	BRITISH MEDICAL JOURNAL			English	Article									Mater Adult Hosp, Brisbane, Qld 4101, Australia		Morton, A (corresponding author), Mater Adult Hosp, Brisbane, Qld 4101, Australia.		morton, adam/I-1771-2013; Muir, James B/ABI-2711-2020	morton, adam/0000-0001-9887-714X; Muir, James/0000-0003-3791-161X				Andersson OK, 1998, BASIC RES CARDIOL, V93, P54; Bosch X, 1998, ARCH INTERN MED, V158, P191, DOI 10.1001/archinte.158.2.191-b; Brouard M, 2001, BRIT J DERMATOL, V145, P362, DOI 10.1046/j.1365-2133.2001.04361.x	3	6	6	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 3	2004	328	7430					25	25		10.1136/bmj.328.7430.25	http://dx.doi.org/10.1136/bmj.328.7430.25			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703542	Green Published			2022-12-28	WOS:000187919000018
J	De Caterina, R; Zampolli, A				De Caterina, R; Zampolli, A			From asthma to atherosclerosis - 5-lipoxygenase, leukotrienes, and inflammation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ G DAnnunzio, Div Cardiol, Chieti, Italy; Univ G DAnnunzio, Ctr Excellence Aging, Chieti, Italy; CNR, Inst Clin Physiol, Lab Thrombosis & Vasc Res, Pisa, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	De Caterina, R (corresponding author), Univ G DAnnunzio, Div Cardiol, Chieti, Italy.		De Caterina, Raffaele/K-3857-2016	De Caterina, Raffaele/0000-0003-1637-574X					0	131	134	0	7	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					4	7		10.1056/NEJMp038190	http://dx.doi.org/10.1056/NEJMp038190			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702420				2022-12-28	WOS:000187659900002
J	Zuger, A				Zuger, A			Dissatisfaction with medical practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAREER SATISFACTION; GENERAL INTERNISTS; JOB-SATISFACTION; WOMEN PHYSICIANS; MANAGED-CARE; HEALTH; RISK		Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Yeshiva University; Albert Einstein College of Medicine	Zuger, A (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA.	abzug@panix.com						*AM ASS MED COLL D, APPL MATR FIL; *AM MED ASS, 1913, JAMA-J AM MED ASSOC, V60, P1998; [Anonymous], 5 CTR STUD HLTH SYST; Barondess JA, 2003, ARCH INTERN MED, V163, P145, DOI 10.1001/archinte.163.2.145; BHARGAVA R, 2001, WHAT HAPPENED; Burdi MD, 1999, HEALTH AFFAIR, V18, P134, DOI 10.1377/hlthaff.18.4.134; *CDCP, PHYS ACC ACT PLAC ME; CHUCK JM, 1993, WESTERN J MED, V159, P665; Daugird A, 1996, ARCH FAM MED, V5, P497, DOI 10.1001/archfami.5.9.497; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Donelan K, 1997, HEALTH AFFAIR, V16, P139, DOI 10.1377/hlthaff.16.5.139; Dunstone DC, 2001, SOC SCI MED, V52, P825, DOI 10.1016/S0277-9536(00)00186-6; Forster HP, 2002, ARCH INTERN MED, V162, P1217, DOI 10.1001/archinte.162.11.1217; Frank E, 1999, ARCH INTERN MED, V159, P1417, DOI 10.1001/archinte.159.13.1417; GREENHOUSE S, 1999, NY TIMES        0204, pA1; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; Haas JS, 2000, J GEN INTERN MED, V15, P122, DOI 10.1046/j.1525-1497.2000.02219.x; Hadley J, 1997, HEALTH AFFAIR, V16, P99, DOI 10.1377/hlthaff.16.6.99; HADLEY J, 1992, ACAD MED, V67, P180, DOI 10.1097/00001888-199203000-00010; Kaiser Family Foundation, 2002, NAT SURV PHYS 3; KLETKE PR, 2000, HEALTH SERV RES, P35; KRAVITZ RL, 1989, AM J PUBLIC HEALTH, V79, P1227, DOI 10.2105/AJPH.79.9.1227; Landon BE, 2003, JAMA-J AM MED ASSOC, V289, P442, DOI 10.1001/jama.289.4.442; Leigh JP, 2002, ARCH INTERN MED, V162, P1577, DOI 10.1001/archinte.162.14.1577; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; Linzer M, 2000, J GEN INTERN MED, V15, P441, DOI 10.1046/j.1525-1497.2000.05239.x; Lipp M, 1980, BEDEUTUNG NATURRECHT, P147; *MASS MED SOC, 2001, PHYS SAT SURV; McMurray JE, 2000, J GEN INTERN MED, V15, P372, DOI 10.1111/j.1525-1497.2000.im9908009.x; Mechanic D, 2001, NEW ENGL J MED, V344, P198, DOI 10.1056/NEJM200101183440307; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; *MERR HAWK ASS, SUMM REP 2003 SURV F; *NAT CTR ED STAT, 1997, JOB SAT AM TEACH EFF; NEWMAN M, 2003, NY TIMES        0510, pB1; NICHOLSON S, 8536 NAT BUR EC RES; O'Connor John P, 2002, Physician Exec, V28, P17; Pathman Donald E, 2002, J Fam Pract, V51, P593; PETROZZI MC, 1992, J GEN INTERN MED, V7, P363, DOI 10.1007/BF02598096; Schiltz PJ, 1999, VANDERBILT LAW REV, V52, P871; Sibbald B, 2003, BMJ-BRIT MED J, V326, P22, DOI 10.1136/bmj.326.7379.22; Spickard A, 2002, JAMA-J AM MED ASSOC, V288, P1447, DOI 10.1001/jama.288.12.1447; STARR P, 1982, SOCIAL TRANSFORMATIO, P82; Steinbrook R, 2002, NEW ENGL J MED, V346, P1757, DOI 10.1056/NEJM200205303462225; VERESSAYEV VV, 1916, MEMOIRS PHYSICIAN, P260; Williams ES, 2002, HEALTH SERV RES, V37, P121; YANRALL KS, 2003, AM J PUBLIC HEALTH, V93, P635	46	183	192	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					69	75		10.1056/NEJMsr031703	http://dx.doi.org/10.1056/NEJMsr031703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	758PT	14702431				2022-12-28	WOS:000187659900013
J	Si, K; Lindquist, S; Kandel, ER				Si, K; Lindquist, S; Kandel, ER			A neuronal isoform of the Aplysia CPEB has prion-like properties	CELL			English	Article							CHAPERONE PROTEIN HSP104; YEAST SUP35 PROTEIN; CYTOPLASMIC POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; OOCYTE MATURATION; MESSENGER-RNA; URE3 PRION; PSI+ PRION; IN-VITRO; PROPAGATION	Prion proteins have the unusual capacity to fold into two functionally distinct conformations, one of which is self-perpetuating. When yeast prion proteins switch state, they produce heritable phenotypes. We report prion-like properties in a neuronal member of the CPEB family (cytoplasmic polyadenylation element binding protein), which regulates mRNA translation. Compared to other CPEB family members, the neuronal protein has an N-terminal extension that shares characteristics of yeast prion-determinants: a high glutamine content and predicted conformational flexibility. When fused to a reporter protein in yeast, this region confers upon it the epigenetic changes in state that characterize yeast prions. Full-length CPEB undergoes similar changes, but surprisingly it is the dominant, self-perpetuating prion-like form that has the greatest capacity to stimulate translation of CPEB-regulated mRNA. We hypothesize that conversion of CPEB to a prion-like state in stimulated synapses helps to maintain long-term synaptic changes associated with memory storage.	New York State Psychiat Inst & Hosp, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; New York State Psychiatry Institute; New York State Psychiatry Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Si, K (corresponding author), New York State Psychiat Inst & Hosp, Coll Phys & Surg, Howard Hughes Med Inst, 722 W 168th St, New York, NY 10032 USA.	ks560@columbia.edu; erk5@columbia.edu						CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; Crist CG, 2003, GENES CELLS, V8, P603, DOI 10.1046/j.1365-2443.2003.00661.x; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Dichtl B, 2002, EMBO J, V21, P4125, DOI 10.1093/emboj/cdf390; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hake LE, 1998, MOL CELL BIOL, V18, P685, DOI 10.1128/MCB.18.2.685; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Roberts BT, 2003, GENE DEV, V17, P2083, DOI 10.1101/gad.1115803; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Stumpf G, 1996, SCIENCE, V274, P1517, DOI 10.1126/science.274.5292.1517; Theis M, 2003, P NATL ACAD SCI USA, V100, P9602, DOI 10.1073/pnas.1133424100; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; Tuite MF, 2000, CELL, V100, P289, DOI 10.1016/S0092-8674(00)80663-7; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1996, CURR TOP MICROBIOL, V207, P147	38	435	448	1	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	2003	115	7					879	891		10.1016/S0092-8674(03)01020-1	http://dx.doi.org/10.1016/S0092-8674(03)01020-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697205	Bronze			2022-12-28	WOS:000187664700011
J	Thurnham, DI; McCabe, GP; Northrop-Clewes, CA; Nestel, P				Thurnham, DI; McCabe, GP; Northrop-Clewes, CA; Nestel, P			Effects of subclinical infection on plasma retinol concentrations and assessment of prevalence of vitamin A deficiency: meta-analysis	LANCET			English	Article							PHASE PROTEIN RESPONSE; CHILDREN; MORBIDITY	Background Vitamin A deficiency adversely affects child morbidity and survival. This deficiency is estimated by measurement of plasma retinol concentrations, but because plasma retinol is reduced by clinical and subclinical infection, this proxy measure can lead to overestimation. Infection and trauma are accompanied by rises in concentrations of acute-phase proteins in plasma. We aimed to estimate vitamin A deficiency more accurately by measuring changes in plasma retinol and acute-phase proteins associated with subclinical infection or convalescence. Methods We analysed data for concentrations of plasma retinol and one or more acute-phase proteins (alpha1-acid-glycoprotein, (alpha1-antichymotrypsin, C-reactive protein, or serum amyloid A) from 15 studies of apparently healthy individuals. We generated summary estimates of differences in retinol concentrations for incubation, early, and late convalescent phases of infection between people with none and those with one or more raised acute-phase proteins. We compared these groups in two, three, and four group analyses. We also compared a subgroup of apparently healthy preschool (1-5 years) children with results from all other studies. Findings For all four proteins, retinol values were much higher in people with normal concentrations of protein, than in individuals with raised concentrations (16% higher for alpha1-antichymotrypsin, 18% for alpha1-acid-glycoprotein, 25% for C-reactive protein, and 32% for serum amyloid A). Estimates of the reduction in plasma retinol for individuals with infection compared with healthy individuals, were 13% (incubation), 24% (early convalescent), and 11% (late convalescent). Estimates of vitamin A deficiency in individuals with no raised acute-phase proteins (healthy group) were much the same as those obtained by adjustment of plasma retinol concentrations in the whole group using acute-phase proteins. Interpretation We recommend that surveys to estimate vitamin A deficiency should include measurements of serum C-reactive protein and alpha1-acid-glycoprotein concentrations. Information about acute-phase proteins will enable plasma retinol concentrations to be corrected where sub-clinical infection exists, and the healthy sub-group to be identified.	Univ Ulster, Fac Life & Hlth Sci, No Ireland Ctr Food & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland; Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA; Int Life Sci Inst, MGL Project, Washington, DC USA	Ulster University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Thurnham, DI (corresponding author), Univ Ulster, Fac Life & Hlth Sci, No Ireland Ctr Food & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland.	di.thurnham@ulster.ac.uk						Adelekan DA, 2003, BRIT J NUTR, V90, P353, DOI 10.1079/BJN2003907; Beaton G., 1993, EFFECTIVENESS VITAMI; CALVIN J, 1988, ANN CLIN BIOCHEM, V25, P60, DOI 10.1177/000456328802500108; Christian P, 1998, AM J CLIN NUTR, V67, P1237, DOI 10.1093/ajcn/67.6.1237; CRUICKSHANK AM, 1989, BRIT J SURG, V76, P165, DOI 10.1002/bjs.1800760220; DENAVARRO LC, 1996, DEFICIENCIA HIERRO V; DOHERTY JF, 1993, CLIN SCI, V84, P169, DOI 10.1042/cs0840169; FILTEAU SM, 1995, AM J CLIN NUTR, V62, P434, DOI 10.1093/ajcn/62.2.434; FILTEAU SM, 1994, EUR J CLIN NUTR, V48, P669; FILTEAU SM, 1993, AM J CLIN NUTR, V58, P192, DOI 10.1093/ajcn/58.2.192; Fleck A, 1985, ACUTE PHASE RESPONSE, P249; Freire WB, 1988, DIAGNOSTICO SITUACIO; Gregory JR, 1995, NATL DIET NUTR SURVE; Jahoor F, 1999, AM J PHYSIOL-ENDOC M, V276, pE1092, DOI 10.1152/ajpendo.1999.276.6.E1092; LOUW JA, 1992, CRIT CARE MED, V20, P934, DOI 10.1097/00003246-199207000-00007; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MBURU ASW, 2000, THESIS U ULSTER; Mitra AK, 1998, AM J CLIN NUTR, V68, P1095, DOI 10.1093/ajcn/68.5.1095; Nestel P, 1999, Rev Panam Salud Publica, V6, P34, DOI 10.1590/S1020-49891999000600005; Paracha PI, 2000, AM J CLIN NUTR, V72, P1164; Rosales FJ, 1996, J LIPID RES, V37, P962; SANN L, 1981, EUR J PEDIATR, V136, P181, DOI 10.1007/BF00441921; Shankar AH, 1999, LANCET, V354, P203, DOI 10.1016/S0140-6736(98)08293-2; Sommer A, 2002, J NUTR, V132, p2845S, DOI 10.1093/jn/132.9.2845S; SOMMER A, 1996, VITAMIN A DEFICIENCY, P335; Stephensen CB, 2002, AM J CLIN NUTR, V76, P1351, DOI 10.1093/ajcn/76.6.1351; STUART J, 1988, ARCH DIS CHILD, V63, P115, DOI 10.1136/adc.63.2.115; THOMPSON D, 1992, ANN CLIN BIOCHEM, V29, P123, DOI 10.1177/000456329202900201; Thurnham DI, 2002, J NUTR, V132, p2979S	29	303	318	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2052	2058		10.1016/S0140-6736(03)15099-4	http://dx.doi.org/10.1016/S0140-6736(03)15099-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697804				2022-12-28	WOS:000187429600009
J	Schroeter, H; Holt, RR; Orozoco, TJ; Schmitz, HH; Keen, CL				Schroeter, H; Holt, RR; Orozoco, TJ; Schmitz, HH; Keen, CL			Nutrition - Milk and absorption of dietary flavanols	NATURE			English	Editorial Material							CHOCOLATE; FLAVAN-3-OLS; CONSUMPTION; PLASMA; COCOA; RICH		Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; Masterfoods US, Analyt & Appl Sci, Hackettstown, NJ 07840 USA	University of California System; University of California Davis; University of California System; University of California Davis	Schroeter, H (corresponding author), Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.		Holt, Roberta/P-7710-2019	Schroeter, Hagen/0000-0001-6569-382X				Abd El Mohsen MM, 2002, FREE RADICAL BIO MED, V33, P1693, DOI 10.1016/S0891-5849(02)01137-1; Corder R, 2001, NATURE, V414, P863, DOI 10.1038/414863a; Heiss C, 2003, JAMA-J AM MED ASSOC, V290, P1030, DOI 10.1001/jama.290.8.1030; Holt RR, 2002, AM J CLIN NUTR, V76, P798, DOI 10.1093/ajcn/76.4.798; Holt RR, 2002, JAMA-J AM MED ASSOC, V287, P2212, DOI 10.1001/jama.287.17.2212; LISSI E, 1995, FREE RADICAL BIO MED, V18, P153, DOI 10.1016/0891-5849(94)00117-3; Serafini M, 2003, NATURE, V424, P1013, DOI 10.1038/4241013a; Spencer JPE, 2001, ANTIOXID REDOX SIGN, V3, P1023, DOI 10.1089/152308601317203558; Taubert D, 2003, JAMA-J AM MED ASSOC, V290, P1029, DOI 10.1001/jama.290.8.1029	9	91	92	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					787	788		10.1038/426787b	http://dx.doi.org/10.1038/426787b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685225				2022-12-28	WOS:000187342000044
J	Hall, DE				Hall, DE			When clinical medicine collides with religion	LANCET			English	Article									Duke Univ, Med Ctr, Ctr Aging, Durham, NC 27710 USA; Univ Chicago, Sch Med, Chicago, IL 60637 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27710 USA	Duke University; University of Chicago; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hall, DE (corresponding author), Duke Univ, Med Ctr, Ctr Aging, Durham, NC 27710 USA.		Hall, Daniel E./H-4843-2013	Hall, Daniel/0000-0001-6382-0522	NCRR NIH HHS [L30 RR019756] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Campbell C S, 1992, Kennedy Inst Ethics J, V2, P253	1	6	6	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S28	S29						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	760BG	14698119				2022-12-28	WOS:000187790200015
J	Verdel, A; Jia, ST; Gerber, S; Sugiyama, T; Gygi, S; Grewal, SIS; Moazed, D				Verdel, A; Jia, ST; Gerber, S; Sugiyama, T; Gygi, S; Grewal, SIS; Moazed, D			RNAi-mediated targeting of heterochromatin by the RITS complex	SCIENCE			English	Article							H3 LYSINE-9 METHYLATION; FISSION YEAST; HISTONE H3; EPIGENETIC CONTROL; GENE; DNA; DOMAIN; TRANSCRIPTION; INTERFERENCE; TETRAHYMENA	RNA interference (RNAi) is a widespread silencing mechanism that acts at both the posttranscriptional and transcriptional levels. Here, we describe the purification of an RNAi effector complex termed RITS (RNA-induced initiation of transcriptional gene silencing) that is required for heterochromatin assembly in fission yeast. The RITS complex contains Ago1 ( the fission yeast Argonaute homolog), Chp1 ( a heterochromatin-associated chromodomain protein), and Tas3 ( a novel protein). In addition, the complex contains small RNAs that require the Dicer ribonuclease for their production. These small RNAs are homologous to centromeric repeats and are required for the localization of RITS to heterochromatic domains. The results suggest a mechanism for the role of the RNAi machinery and small RNAs in targeting of heterochromatin complexes and epigenetic gene silencing at specific chromosomal loci.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Moazed, D (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov; danesh@hms.harvard.edu	Verdel, André/M-5201-2013	Sugiyama, Tomoyasu/0000-0001-5704-6606; VERDEL, Andre/0000-0001-6048-3794; Gerber, Scott/0000-0002-2964-5051	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM072805, R01 GM072805-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072805] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Doe CL, 1998, NUCLEIC ACIDS RES, V26, P4222, DOI 10.1093/nar/26.18.4222; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Grewal SIS, 2000, J CELL PHYSIOL, V184, P311, DOI 10.1002/1097-4652(200009)184:3<311::AID-JCP4>3.0.CO;2-D; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Partridge JF, 2000, GENE DEV, V14, P783; Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; Taverna SD, 2002, CELL, V110, P701, DOI 10.1016/S0092-8674(02)00941-8; Thon G, 2000, GENETICS, V155, P551; Vaistij FE, 2002, PLANT CELL, V14, P857, DOI 10.1105/tpc.010480; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	25	920	1028	4	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					672	676		10.1126/science.1093686	http://dx.doi.org/10.1126/science.1093686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14704433	Green Accepted			2022-12-28	WOS:000188530800041
J	Leroy, EM; Rouquet, P; Formenty, P; Souquiere, S; Kilbourne, A; Froment, JM; Bermejo, M; Smit, S; Karesh, W; Swanepoel, R; Zaki, SR; Rollin, PE				Leroy, EM; Rouquet, P; Formenty, P; Souquiere, S; Kilbourne, A; Froment, JM; Bermejo, M; Smit, S; Karesh, W; Swanepoel, R; Zaki, SR; Rollin, PE			Multiple Ebola virus transmission events and rapid decline of central African wildlife	SCIENCE			English	Article							HEMORRHAGIC-FEVER; SEQUENCE-ANALYSIS; OUTBREAK; REEMERGENCE; CONGO	Several human and animal Ebola outbreaks have occurred over the past 4 years in Gabon and the Republic of Congo. The human outbreaks consisted of multiple simultaneous epidemics caused by different viral strains, and each epidemic resulted from the handling of a distinct gorilla, chimpanzee, or duiker carcass. These animal populations declined markedly during human Ebola outbreaks, apparently as a result of Ebola infection. Recovered carcasses were infected by a variety of Ebola strains, suggesting that Ebola outbreaks in great apes result from multiple virus introductions from the natural host. Surveillance of animal mortality may help to predict and prevent human Ebola outbreaks.	Ctr Int Rech Med Franceville, UR034, Inst Rech Dev, Franceville, Gabon; WHO, Dept Communicable Dis Surveillance & Response, Global Alert & Response Team, Geneva, Switzerland; Wildlife Conservat Soc, Bronx, NY 10460 USA; Programme Conservat & Utilisat Rat Ecosyst Forest, Libreville, Gabon; Natl Inst Communicable Dis, Special Pathogens Unit, ZA-2131 Johannesburg, South Africa; Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA	Institut de Recherche pour le Developpement (IRD); World Health Organization; Wildlife Conservation Society; National Institute for Communicable Diseases (NICD); Centers for Disease Control & Prevention - USA	Leroy, EM (corresponding author), Ctr Int Rech Med Franceville, UR034, Inst Rech Dev, BP 769, Franceville, Gabon.	Eric.Leroy@ird.fr	LEROY, Eric M/I-4347-2016; Karesh, William/AAU-9084-2020	LEROY, Eric M/0000-0003-0022-0890; Karesh, William/0000-0001-6042-2860; Rollin, Pierre/0000-0002-4608-2641				[Anonymous], 2001, Wkly Epidemiol Rec, V76, P41; Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; BARON RC, 1983, B WORLD HEALTH ORGAN, V61, P997; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247; Feldmann H, 1993, Arch Virol Suppl, V7, P81; Formenty P, 2003, Med Trop (Mars), V63, P291; Formenty P, 1999, J INFECT DIS, V179, pS120, DOI 10.1086/514296; Georges AJ, 1999, J INFECT DIS, V179, pS65, DOI 10.1086/514290; Khan AS, 1999, J INFECT DIS, V179, pS76, DOI 10.1086/514306; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; LEGUENNO B, 1995, LANCET, V345, P1271, DOI 10.1016/S0140-6736(95)90925-7; Leroy EM, 2000, J MED VIROL, V60, P463, DOI 10.1002/(SICI)1096-9071(200004)60:4&lt;463::AID-JMV15&gt;3.0.CO;2-M; Leroy EM, 2002, LANCET, V359, P712, DOI 10.1016/S0140-6736(02)07796-6; Leroy EM, 2002, J GEN VIROL, V83, P67, DOI 10.1099/0022-1317-83-1-67; LEROY EM, UNPUB; Rodriguez LL, 1999, J INFECT DIS, V179, pS170, DOI 10.1086/514291; SANCHEZ A, 1993, VIRUS RES, V29, P215, DOI 10.1016/0168-1702(93)90063-S; Suzuki Y, 1997, MOL BIOL EVOL, V14, P800, DOI 10.1093/oxfordjournals.molbev.a025820; Walsh PD, 2003, NATURE, V422, P611, DOI 10.1038/nature01566; Zaki SR, 1999, J INFECT DIS, V179, pS36, DOI 10.1086/514319	21	446	474	1	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					387	390		10.1126/science.1092528	http://dx.doi.org/10.1126/science.1092528			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726594				2022-12-28	WOS:000188111800048
J	Park, S; Lim, JH; Chung, SW; Mirkin, CA				Park, S; Lim, JH; Chung, SW; Mirkin, CA			Self-assembly of mesoscopic metal-polymer amphiphiles	SCIENCE			English	Article							GOLD NANORODS; SUPRAMOLECULAR MATERIALS; NANOSTRUCTURES; NANOTUBES; CARBON; SHAPE	The assembly properties of two- and three-component rod-like building blocks consisting of gold and polymer block domains have been investigated. These structures behave like mesoscopic amphiphiles and form a series of single-layer superstructures consisting of bundles, tubes, and sheets depending upon the compositional periodicity. Unlike molecular systems, the template used to initially synthesize them plays a critical role in the assembly process by prealigning them in a manner that facilitates their assembly by optimizing the correct collisional orientation upon dissolution of the template. Tubular structures with tailorable diameters can be assembled in a predictable manner on the basis of an estimate of the hybrid rod packing parameters.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Inst Nanotechnol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	camirkin@chem.northwestern.edu	Mirkin, Chad A/E-3911-2010; Chung, Sungwook/ABH-7052-2020; Chung, Sungwook/H-6248-2012	Chung, Sungwook/0000-0001-7479-8025; Mirkin, Chad/0000-0002-6634-7627				[Anonymous], 1992, INTERMOLECULAR SURFA; Caswell KK, 2003, J AM CHEM SOC, V125, P13914, DOI 10.1021/ja037969i; Dal HJ, 1996, CHEM PHYS LETT, V260, P471, DOI 10.1016/0009-2614(96)00862-7; Duan XF, 2003, NATURE, V421, P241, DOI 10.1038/nature01353; Dujardin E, 2001, CHEM COMMUN, P1264, DOI 10.1039/b102319p; Hadjichristidis N., 2002, BLOCK COPOLYMERS SYN; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Jana NR, 2002, J MATER CHEM, V12, P2909, DOI 10.1039/b205225c; Kim F, 2001, J AM CHEM SOC, V123, P4360, DOI 10.1021/ja0059138; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Kovtyukhova NI, 2002, CHEM-EUR J, V8, P4355, DOI 10.1002/1521-3765(20021004)8:19<4354::AID-CHEM4354>3.0.CO;2-1; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Love JC, 2003, J AM CHEM SOC, V125, P12696, DOI 10.1021/ja037642h; MacLachlan MJ, 1999, NATURE, V397, P681, DOI 10.1038/17776; MARTIN CR, 1995, ACCOUNTS CHEM RES, V28, P61, DOI 10.1021/ar00050a002; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Nikoobakht B, 2000, J PHYS CHEM B, V104, P8635, DOI 10.1021/jp001287p; Ozin GA, 1999, CAN J CHEM, V77, P2001, DOI 10.1139/cjc-77-12-2001; Patzke GR, 2002, ANGEW CHEM INT EDIT, V41, P2446, DOI 10.1002/1521-3773(20020715)41:14<2446::AID-ANIE2446>3.0.CO;2-K; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Rueckes T, 2000, SCIENCE, V289, P94, DOI 10.1126/science.289.5476.94; Steinhart M, 2002, SCIENCE, V296, P1997, DOI 10.1126/science.1071210; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; Terfort A, 1997, NATURE, V386, P162, DOI 10.1038/386162a0; Xia YN, 2003, ADV MATER, V15, P353, DOI 10.1002/adma.200390087	26	642	660	9	270	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					348	351		10.1126/science.1093276	http://dx.doi.org/10.1126/science.1093276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726585				2022-12-28	WOS:000188111800036
J	King, RD; Whelan, KE; Jones, FM; Reiser, PGK; Bryant, CH; Muggleton, SH; Kell, DB; Oliver, SG				King, RD; Whelan, KE; Jones, FM; Reiser, PGK; Bryant, CH; Muggleton, SH; Kell, DB; Oliver, SG			Functional genomic hypothesis generation and experimentation by a robot scientist	NATURE			English	Article								The question of whether it is possible to automate the scientific process is of both great theoretical interest(1,2) and increasing practical importance because, in many scientific areas, data are being generated much faster than they can be effectively analysed. We describe a physically implemented robotic system that applies techniques from artificial intelligence(3-8) to carry out cycles of scientific experimentation. The system automatically originates hypotheses to explain observations, devises experiments to test these hypotheses, physically runs the experiments using a laboratory robot, interprets the results to falsify hypotheses inconsistent with the data, and then repeats the cycle. Here we apply the system to the determination of gene function using deletion mutants of yeast (Saccharomyces cerevisiae) and auxotrophic growth experiments(9). We built and tested a detailed logical model (involving genes, proteins and metabolites) of the aromatic amino acid synthesis pathway. In biological experiments that automatically reconstruct parts of this model, we show that an intelligent experiment selection strategy is competitive with human performance and significantly outperforms, with a cost decrease of 3-fold and 100-fold (respectively), both cheapest and random-experiment selection.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Wales, Dept Comp Sci, Aberystwyth SY23 3DB, Dyfed, Wales; Robert Gordon Univ, Sch Comp, Aberdeen AB10 1FR, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Comp, London SW7 2AZ, England; Univ Manchester, Dept Chem, Manchester M60 1QD, Lancs, England	University of Manchester; Aberystwyth University; Robert Gordon University; Imperial College London; University of Manchester	Oliver, SG (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.	steve.oliver@man.ac.uk	Oliver, Stephen/AAQ-5992-2021; Kell, Douglas/E-8318-2011	Oliver, Stephen/0000-0003-3410-6439; Kell, Douglas/0000-0001-5838-7963; Bryant, Christopher/0000-0002-9002-8343; King, Ross/0000-0001-7208-4387	Engineering and Physical Sciences Research Council [GR/R60621/01, GR/R54071/01] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [E19354] Funding Source: Medline	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; Brachmann CB, 1998, YEAST, V14, P115; BRYANT J, 2001, HEALTH TECHNOL ASSES, V5, P1; Buchanan B. G., 1969, MACH INTELL, V4, P209; Cochran W.G., 1992, EXPT DESIGNS; Cohn DA, 1996, J ARTIF INTELL RES, V4, P129, DOI 10.1613/jair.295; Fedorov V.V., 1972, THEORY OPTIMAL EXPT; Flach P. A., 2000, ABDUCTION INDUCTION; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; King RD, 1996, P NATL ACAD SCI USA, V93, P438, DOI 10.1073/pnas.93.1.438; Langley P, 2000, INT J HUM-COMPUT ST, V53, P393, DOI 10.1006/ijhc.2000.0396; Langley P., 1996, ELEMENTS MACHINE LEA; Langley P., 1987, SCI DISCOVERY COMPUT; Lin FR, 1997, ANN OPER RES, V75, P105, DOI 10.1023/A:1018999110972; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Mitchell T.M, 2003, MACH LEARN; MUGGLETON S, 1995, NEW GENERAT COMPUT, V13, P245, DOI 10.1007/BF03037227; MUGGLETON S, 1999, MACH INTELL, V15, P248; PIERCE CS, 1958, COLLECTED PAPERS CS; Popper K.R., 1972, LOGIC SCI DISCOVERY; Rabitz H, 2000, SCIENCE, V288, P824, DOI 10.1126/science.288.5467.824; Reiser PGK., 2001, ELECT T ARTIF INTELL, V5, P223; Sloman A., 1978, COMPUTER REVOLUTION; Valdes-Perez RE, 1999, COMMUN ACM, V42, P37, DOI 10.1145/319382.319389; ZUPAN B, 2001, P 8 EUR C ART INT ME, P304; ZYTKOW JM, 1990, PROCEEDINGS : EIGHTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P889	27	339	350	3	87	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					247	252		10.1038/nature02236	http://dx.doi.org/10.1038/nature02236			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724639				2022-12-28	WOS:000188068100044
J	Gilliland, FD; Li, YF; Saxon, A; Diaz-Sanchez, D				Gilliland, FD; Li, YF; Saxon, A; Diaz-Sanchez, D			Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study	LANCET			English	Article							DIESEL EXHAUST PARTICLES; AIR-POLLUTION; IN-VIVO; NASAL CHALLENGE; CYTOKINE PRODUCTION; TOBACCO-SMOKE; LUNG-CANCER; ASTHMA; EXPOSURE; IGE	Background Particulate pollution is associated with the occurrence of asthma and allergy. The model pollutant, diesel exhaust particles, can participate with allergens in starting and exacerbating allergic airway diseases in part by production of reactive oxygen species. Glutathione-S-transferases (GSTs) can metabolise reactive oxygen species and detoxify xenobiotics present in diesel exhaust particles. We tested the hypothesis that null genotypes for GSTM1 and GSTT1, and GSTP1 codon 105 variants (I105 and V105) are key regulators of the adjuvant effects of diesel exhaust particles on allergic responses. Methods Patients sensitive to the ragweed allergen were challenged intranasally with allergen alone and with allergen plus diesel exhaust particles in a randomised order at separate visits. Nasal allergen-specific IgE, histamine, interleukin 4, and interferon gamma concentrations were measured before and 24 h after challenge. Findings Individuals with GSTM1 null or the GSTP1 I105 wildtype genotypes showed enhanced nasal allergic responses in the presence of diesel exhaust particles. Compared with patients with a functional GSTM1 genotype, GSTM1 null patients had a significantly larger increase in IgE (median 102.5 U/mL [range 1.0-510.5] vs 45.5 U/mL [1.5-60.6], p=0.03) and histamine (14.0 nmol/L [-0.2-24.7] vs 7.4 nmol/L [1.2-12.3], p=0.02) after diesel exhaust particles plus allergen challenge. The I105 GSTP1 genotype was associated with an increase in IgE (120.3 U/mL [6.7-510.5] vs 27.7 U/mL [-1.5-60.6], p=0.03) and histamine (13.8 nmol/L [3.1-24.7] vs 5.2 nmol/L [-0.2-19.6], p=0.01) after challenge with diesel exhaust particles and allergens. The diesel exhaust particles enhancement was largest in patients with both the GSTM1 null and GSTP1 I/I genotypes. Interpretation GSTM1 and GSTP1 modify the adjuvant effect of diesel exhaust particles on allergic inflammation.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA USA	University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gilliland, FD (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu	LI, YU-FEN/F-4770-2010	LI, YU-FEN/0000-0002-3960-6101	NHLBI NIH HHS [HL-61768] Funding Source: Medline; NIAID NIH HHS [AI-40945] Funding Source: Medline; NIEHS NIH HHS [ES-09581, ES-07048] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040945, R21AI040945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009581, P30ES007048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al-Humadi NH, 2002, ENVIRON HEALTH PERSP, V110, P349, DOI 10.1289/ehp.02110349; Barfknecht T R, 1982, Dev Toxicol Environ Sci, V10, P277; BASCOM R, 1991, PHARMACOGENETICS, V1, P102, DOI 10.1097/00008571-199111000-00008; BASCOM R, 1990, AM REV RESPIR DIS, V142, P594, DOI 10.1164/ajrccm/142.3.594; D'Amato G, 2002, Monaldi Arch Chest Dis, V57, P136; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573, DOI 10.1289/ehp.02110s4573; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Diaz-Sanchez D, 2000, IMMUNOLOGY, V101, P11, DOI 10.1046/j.1365-2567.2000.00108.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403, DOI 10.1289/ehp.99107s3403; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P346, DOI 10.1164/rccm.2111048; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hiura TS, 2000, J IMMUNOL, V165, P2703, DOI 10.4049/jimmunol.165.5.2703; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; MANCHESTER J, 2001, DETERMINATION ELEM B, P1; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505, DOI 10.1016/S0091-6749(97)70143-X; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Ng D, 1998, J IMMUNOL, V161, P942; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161, DOI 10.1164/ajrccm.162.1.9908092; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103, DOI 10.1289/ehp.02110s1103; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; SAGAI M, 1998, INVOLVEMENTS SUPEROX; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Strand V, 1997, AM J RESP CRIT CARE, V155, P881, DOI 10.1164/ajrccm.155.3.9117021; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Trenga CA, 1999, OCCUP ENVIRON MED, V56, P544, DOI 10.1136/oem.56.8.544; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; WILLIAMS PT, 1986, FUEL, V65, P1150, DOI 10.1016/0016-2361(86)90184-5; XU GB, 1987, AEROSOL SCI TECH, V7, P117, DOI 10.1080/02786828708959152	44	254	264	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					119	125		10.1016/S0140-6736(03)15262-2	http://dx.doi.org/10.1016/S0140-6736(03)15262-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726165				2022-12-28	WOS:000187939200009
J	Lukowitz, W; Roeder, A; Parmenter, D; Somerville, C				Lukowitz, W; Roeder, A; Parmenter, D; Somerville, C			A MAPKK kinase gene regulates extra-embryonic cell fate in Arabidopsis	CELL			English	Article							BASAL PATTERN-FORMATION; GNOM ARF-GEF; EARLY EMBRYOGENESIS; PLANT CYTOKINESIS; INNATE IMMUNITY; AUXIN GRADIENTS; PROTEIN; EMBRYO; THALIANA; SUSPENSOR	The Arabidopsis zygote divides asymmetrically into an embryonic apical cell and a basal cell with mostly extra-embryonic fate. This fundamental asymmetry sets the stage for further embryonic development, but the events mediating it are poorly understood. We have identified a MAPKK kinase gene, named YODA, that promotes extra-embryonic cell fates in the basal lineage. In loss-of-function mutants, the zygote does not elongate properly, and the cells of the basal lineage are eventually incorporated into the embryo instead of differentiating the extra-embryonic suspensor. Gain-of-function alleles cause exaggerated growth of the suspensor and can suppress embryonic development to a degree where no recognizable proembryo is formed. Our results imply that a MAP kinase cascade acts as a molecular switch promoting extra-embryonic fate.	Stanford Univ, Carnegie Inst, Dept Plant Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Carnegie Institution for Science; Stanford University; Stanford University	Somerville, C (corresponding author), Stanford Univ, Carnegie Inst, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	crs@stanford.edu	Roeder, Adrienne/ABF-5334-2021; Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094; Roeder, Adrienne/0000-0001-6685-2984				Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Asamizu E, 2000, DNA RES, V7, P175, DOI 10.1093/dnares/7.3.175; BERLETH T, 1993, DEVELOPMENT, V118, P575; Berleth T, 2002, ARABIDOPSIS BOOK; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DEVIC M, 1995, CR ACAD SCI III-VIE, V318, P121; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hamann T, 2002, GENE DEV, V16, P1610, DOI 10.1101/gad.229402; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; HERNANDEZ LF, 1993, PLANT CELL, V5, P1725, DOI 10.1105/tpc.5.12.1725; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Jin HL, 2002, DEV CELL, V3, P291, DOI 10.1016/S1534-5807(02)00205-8; Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6; Jurgens G, 2001, EMBO J, V20, P3609, DOI 10.1093/emboj/20.14.3609; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Krysan PJ, 2002, PLANT CELL, V14, P1109, DOI 10.1105/tpc.001164; Lukowitz W, 2000, PLANT PHYSIOL, V123, P795, DOI 10.1104/pp.123.3.795; Maheshwari P., 1950, INTRO EMBRYOLOGY ANG; MANSFIELD SG, 1991, CAN J BOT, V69, P447, DOI 10.1139/b91-062; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; MAYER U, 1993, DEVELOPMENT, V117, P149; MCELROY D, 1995, MOL BREEDING, V1, P27, DOI 10.1007/BF01682087; Nishihama R, 2001, GENE DEV, V15, P352, DOI 10.1101/gad.863701; Ptashne M, 2003, SCIENCE, V299, P1025, DOI 10.1126/science.1081519; Sagasti A, 2001, CELL, V105, P221, DOI 10.1016/S0092-8674(01)00313-0; Scheres B, 1999, ANNU REV PLANT PHYS, V50, P505, DOI 10.1146/annurev.arplant.50.1.505; Soyano T, 2002, PHILOS T R SOC B, V357, P767, DOI 10.1098/rstb.2002.1094; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; VERNON DM, 1994, DEV BIOL, V165, P566, DOI 10.1006/dbio.1994.1276; Waizenegger I, 2000, CURR BIOL, V10, P1371, DOI 10.1016/S0960-9822(00)00775-2; WEBB MC, 1991, PLANTA, V184, P187, DOI 10.1007/BF00197947; Weterings K, 2001, PLANT CELL, V13, P2409, DOI 10.1105/tpc.13.11.2409; YEUNG EC, 1993, PLANT CELL, V5, P1371, DOI 10.1105/tpc.5.10.1371; Zhang JZ, 1997, P NATL ACAD SCI USA, V94, P7349, DOI 10.1073/pnas.94.14.7349	39	288	309	0	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					109	119		10.1016/S0092-8674(03)01067-5	http://dx.doi.org/10.1016/S0092-8674(03)01067-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718171	Bronze			2022-12-28	WOS:000187960800013
J	Cook, RJ; Bevilacqua, MBG				Cook, RJ; Bevilacqua, MBG			Invoking human rights to reduce maternal deaths	LANCET			English	Article									Univ Toronto, Fac Law, Toronto, ON M5S 2C5, Canada; Advocacia Cidada Direitos Humanos ADVOCACI, Rio De Janeiro, Brazil	University of Toronto	Cook, RJ (corresponding author), Univ Toronto, Fac Law, Toronto, ON M5S 2C5, Canada.	rebecca.cook@utoronto.ca						CESCR, 2003, EC121ADD87 CESCR; *CLADEM, 2003, MON ALT REP SIT MAT; *COM PARL INQ MOT, 2001, REL FIN BRAZ; Cook R, 2003, REPROD HLTH HUMAN RI; GALLI B, 2003, PROMOVENDO MATERNIDA, P97; WHO UNICEF and UNFPA, 2003, MAT MORT 2000 EST DE	6	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					73	73		10.1016/S0140-6736(03)15178-1	http://dx.doi.org/10.1016/S0140-6736(03)15178-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14724003				2022-12-28	WOS:000187711300032
J	Gwatkin, DR				Gwatkin, DR			Assessing inequalities in maternal mortality	LANCET			English	Editorial Material									World Bank, Washington, DC 20433 USA	The World Bank	Gwatkin, DR (corresponding author), World Bank, 1818 H St NW, Washington, DC 20433 USA.							Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; *WHO UNICEF UNFPA, MAT MORT 2000	2	6	6	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					5	5		10.1016/S0140-6736(03)15231-2	http://dx.doi.org/10.1016/S0140-6736(03)15231-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723983				2022-12-28	WOS:000187711300004
J	Kandhai, MC; Reij, MW; Gorris, LGM; Guillaume-Gentil, O; van Schothorst, M				Kandhai, MC; Reij, MW; Gorris, LGM; Guillaume-Gentil, O; van Schothorst, M			Occurrence of Enterobacter sakazakii in food production environments and households	LANCET			English	Article							FORMULA	Enterobacter sakazakii occasionally causes illness in premature babies and neonates. Contamination of infant formulae during factory production or bottle preparation is implicated. Advice to health-care professionals focuses on bottle preparation, but the effectiveness of prevention depends on the degree of contamination and contamination sites, which are generally unknown. To keep contamination to a minimum in the finished product depends on knowledge of the occurrence of E sakazakii. We used a refined isolation and detection method to investigate the presence of this micro-organism in various food factories and households. Environmental samples from eight of nine food factories and from five of 16 households contained E sakazakii. The widespread nature of this microorganism needs to be taken into account when designing preventive control measures.	Univ Wageningen & Res Ctr, Food Microbiol Lab, NL-6700 EV Wageningen, Netherlands; Nestle Res Ctr, Qual & Safety Assurance Dept, CH-1000 Lausanne, Switzerland	Wageningen University & Research; Nestle SA	Kandhai, MC (corresponding author), Univ Wageningen & Res Ctr, Food Microbiol Lab, POB 8129, NL-6700 EV Wageningen, Netherlands.		Reij, Martine/F-3330-2011	Gorris, Leon/0000-0001-7275-6681				Lai KK, 2001, MEDICINE, V80, P113, DOI 10.1097/00005792-200103000-00004; Leclercq A, 2002, APPL ENVIRON MICROB, V68, P1631, DOI 10.1128/AEM.68.4.1631-1638.2002; MUYTJENS HL, 1988, J CLIN MICROBIOL, V26, P743, DOI 10.1128/JCM.26.4.743-746.1988; MUYTJENS HL, 1990, PEDIATR INFECT DIS J, V9, P372, DOI 10.1097/00006454-199005000-00016; NazarowecWhite M, 1997, LETT APPL MICROBIOL, V24, P9, DOI 10.1046/j.1472-765X.1997.00328.x	5	243	258	0	38	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					39	40		10.1016/S0140-6736(03)15169-0	http://dx.doi.org/10.1016/S0140-6736(03)15169-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723994				2022-12-28	WOS:000187711300014
J	Randak, C; Welsh, MJ				Randak, C; Welsh, MJ			An intrinsic adenylate kinase activity regulates gating of the ABC transporter CFTR	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ATP-BINDING-CASSETTE; RECOMBINANT POLYPEPTIDE MODEL; CYSTIC-FIBROSIS; CRYSTAL-STRUCTURE; CHLORIDE CHANNELS; DOMAIN; SITE; MECHANISM; HYDROLYSIS	Cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel in the ATP binding cassette (ABC) transporter family. Like other ABC transporters, it can hydrolyze ATP. Yet while ATP hydrolysis influences channel gating, it has long seemed puzzling that CFTR would require this reaction because anions flow passively through CFTR. Moreover, no other ion channel is known to require the large energy of ATP hydrolysis to gate. We found that CFTR also has adenylate kinase activity (ATP + AMP reversible arrow ADP + ADP) that regulates gating. When functioning as an adenylate kinase, CFTR showed positive cooperativity for ATP suggesting its two nucleotide binding domains may dimerize. Thus, channel activity could be regulated by two different enzymatic reactions, ATPase and adenylate kinase, that share a common ATP binding site in the second nucleotide binding domain. At physiologic nucleotide concentrations, adenylate kinase activity, rather than ATPase activity may control gating, and therefore involve little energy consumption.	Univ Iowa, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Dept Phys & Biophys, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu		Welsh, Michael/0000-0002-1646-6206; Randak, Christoph/0000-0003-3264-4137	NHLBI NIH HHS [HL29851-21, HL1234-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL029851, R01HL029851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Basso C, 2003, J GEN PHYSIOL, V122, P333, DOI 10.1085/jgp.200308798; Berger AL, 2002, J BIOL CHEM, V277, P2125, DOI 10.1074/jbc.M109539200; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BOZZI A, 1994, BIOCHEM MOL BIOL INT, V32, P95; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Cotten JF, 1998, J BIOL CHEM, V273, P31873, DOI 10.1074/jbc.273.48.31873; Dassa E., 2003, ABC PROTEINS BACTERI, P3; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DIEDERICHS K, 1990, BIOCHEMISTRY-US, V29, P8138, DOI 10.1021/bi00487a022; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FONT B, 1980, BIOCHIM BIOPHYS ACTA, V611, P299, DOI 10.1016/0005-2744(80)90065-0; Fontanella L, 1999, ANAL BIOCHEM, V269, P353, DOI 10.1006/abio.1999.4042; Frederich M, 2002, J BIOL CHEM, V277, P1928, DOI 10.1074/jbc.M107128200; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hanrahan JW, 2003, ABC PROTEINS BACTERI, P589; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V273, pC1278, DOI 10.1152/ajpcell.1997.273.4.C1278; ITO Y, 1980, EUR J BIOCHEM, V105, P85, DOI 10.1111/j.1432-1033.1980.tb04477.x; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Kosloff M, 2003, J MOL BIOL, V331, P1157, DOI 10.1016/S0022-2836(03)00847-7; Levitzki A, 1976, Curr Top Cell Regul, V10, P1; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; MENENDEZ M, 1985, BIOPHYS CHEM, V21, P249, DOI 10.1016/0301-4622(85)80012-0; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; OKAJIMA T, 1993, J BIOCHEM-TOKYO, V114, P627, DOI 10.1093/oxfordjournals.jbchem.a124228; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; OSBORNE L, 1992, HUM GENET, V89, P653, DOI 10.1007/BF00221957; Ostedgaard LS, 2002, P NATL ACAD SCI USA, V99, P3093, DOI 10.1073/pnas.261714599; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; Randak C, 1996, FEBS LETT, V398, P97, DOI 10.1016/S0014-5793(96)01217-3; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Szellas T, 2003, FEBS LETT, V535, P141, DOI 10.1016/S0014-5793(02)03892-9; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vonrhein C, 1998, J MOL BIOL, V282, P167, DOI 10.1006/jmbi.1998.2003; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311; Zeltwanger S, 1999, J GEN PHYSIOL, V113, P541, DOI 10.1085/jgp.113.4.541	75	50	52	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	2003	115	7					837	850		10.1016/S0092-8674(03)00983-8	http://dx.doi.org/10.1016/S0092-8674(03)00983-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697202	Bronze			2022-12-28	WOS:000187664700008
J	Vargason, JM; Szittya, G; Burgyan, J; Hall, TMT				Vargason, JM; Szittya, G; Burgyan, J; Hall, TMT			Size selective recognition of siRNA by an RNA silencing suppressor	CELL			English	Article							BUSHY-STUNT-VIRUS; SHORT INTERFERING RNA; NICOTIANA-BENTHAMIANA; VIRAL SUPPRESSOR; PROTEIN; PLANTS; DNA; EXPRESSION; INDUCTION; SYSTEM	RNA silencing in plants likely exists as a defense mechanism against molecular parasites such as RNA viruses, retrotransposons, and transgenes. As a result, many plant viruses have adapted mechanisms to evade and suppress gene silencing. Tombusviruses express a 19 kDa protein (p19), which has been shown to suppress RNA silencing in vivo and bind silencing-generated and synthetic small interfering RNAs (siRNAs) in vitro. Here we report the 2.5 Angstrom crystal structure of p19 from the Carnation Italian ringspot virus (CIRV) bound to a 21 nt siRNA and demonstrate in biochemical and in vivo assays that CIRV p19 protein acts as a molecular caliper to specifically select siRNAs based on the length of the duplex region of the RNA.	NIEHS, Lab Struct Biol, NIH, Res Triangle Pk, NC 27709 USA; Plant Biol Inst, Agr Biotechnol Ctr, Godollo, Hungary	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hall, TMT (corresponding author), NIEHS, Lab Struct Biol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Szittya, Gyorgy/M-9199-2019; Hall, Traci/F-5849-2019; Burgyan, Jozsef/C-7511-2012; Szittya, Gyorgy/A-2905-2012	Szittya, Gyorgy/0000-0003-2040-2851; Hall, Traci/0000-0001-6166-3009; Szittya, Gyorgy/0000-0003-2040-2851	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050165, Z01ES050165] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Ahlquist P, 2002, SCIENCE, V296, P1270, DOI 10.1126/science.1069132; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Baulcombe D, 2002, TRENDS MICROBIOL, V10, P306, DOI 10.1016/S0966-842X(02)02387-9; Baulcombe D, 2002, CURR BIOL, V12, pR82, DOI 10.1016/S0960-9822(02)00665-6; Baulcombe DC, 1999, CURR OPIN PLANT BIOL, V2, P109, DOI 10.1016/S1369-5266(99)80022-3; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Brunger A. T., 1992, NATURE, V355, P472; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgyan J, 1996, J GEN VIROL, V77, P1967, DOI 10.1099/0022-1317-77-8-1967; Chu M, 2000, VIROLOGY, V266, P79, DOI 10.1006/viro.1999.0071; Cogoni C, 2000, CURR OPIN GENET DEV, V10, P638, DOI 10.1016/S0959-437X(00)00134-9; DALMAY T, 1993, VIROLOGY, V194, P697, DOI 10.1006/viro.1993.1310; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2002, PYMOL USERS MANUAL; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hull R., 2002, MATTHEWS PLANT VIROL; Johansen LK, 2001, PLANT PHYSIOL, V126, P930, DOI 10.1104/pp.126.3.930; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung J, 2001, PROTEIN SCI, V10, P1881, DOI 10.1110/ps.05801; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2001, CURR OPIN BIOTECH, V12, P150, DOI 10.1016/S0958-1669(00)00190-7; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Luscombe NM, 1997, NUCLEIC ACIDS RES, V25, P4940, DOI 10.1093/nar/25.24.4940; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikulin A, 2003, NAT STRUCT BIOL, V10, P104, DOI 10.1038/nsb886; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papp I, 2003, PLANT PHYSIOL, V132, P1382, DOI 10.1104/pp.103.021980; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199; Qiu WP, 2002, MOL PLANT MICROBE IN, V15, P269, DOI 10.1094/MPMI.2002.15.3.269; Qu F, 2002, MOL PLANT MICROBE IN, V15, P193, DOI 10.1094/MPMI.2002.15.3.193; SCHOLTHOF HB, 1995, PLANT CELL, V7, P1157, DOI 10.1105/tpc.7.8.1157; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Silhavy D, 2002, EMBO J, V21, P3070, DOI 10.1093/emboj/cdf312; Szittya G, 2002, PLANT CELL, V14, P359, DOI 10.1105/tpc.010366; Szittya G, 2003, EMBO J, V22, P633, DOI 10.1093/emboj/cdg74; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; Voinnet O, 2002, CURR OPIN PLANT BIOL, V5, P444, DOI 10.1016/S1369-5266(02)00291-1; Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Waterhouse PM, 1999, TRENDS PLANT SCI, V4, P452, DOI 10.1016/S1360-1385(99)01493-4; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	66	427	464	2	44	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	2003	115	7					799	811		10.1016/S0092-8674(03)00984-X	http://dx.doi.org/10.1016/S0092-8674(03)00984-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697199	Green Submitted, Bronze			2022-12-28	WOS:000187664700005
J	Lukic, IK; Gluncic, V; Ivkic, G; Hubenstorf, M; Marusic, A				Lukic, IK; Gluncic, V; Ivkic, G; Hubenstorf, M; Marusic, A			Virtual dissection: a lesson from the 18th century	LANCET			English	Review							MODELS		Univ Zagreb, Sch Med, Croatian Inst Brain Res, HR-10000 Zagreb, Croatia; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT USA; Univ Vienna, Inst Hist Med, Vienna, Austria	University of Zagreb; Yale University; University of Vienna	Lukic, IK (corresponding author), Univ Zagreb, Sch Med, Dept Anat, Salata 3B, HR-10000 Zagreb, Croatia.	iklukic@mef.hr	Marusic, Ana/E-7683-2013	Marusic, Ana/0000-0001-6272-0917				ALLMER K, 1965, KATALOG J SAMMLUNG A; Aziz M. Ashraf, 2002, Anatomical Record, V269, P20, DOI 10.1002/ar.10046; BERLIS A, 1992, RADIOLOGE, V32, P436; Chen JCT, 1999, NEUROSURGERY, V45, P883, DOI 10.1097/00006123-199910000-00031; Choudhry R, 1999, SURG RADIOL ANAT, V21, P201, DOI 10.1007/BF01630902; Dyer GSM, 2000, ACAD MED, V75, P969, DOI 10.1097/00001888-200010000-00008; Federative Committee on Anatomical Terminology, 1998, TERM AN; Glass N, 2000, LANCET, V355, P734, DOI 10.1016/S0140-6736(05)72149-8; HILLOOWALA R, 1985, ANAT ANZEIGER, V159, P141; HOLUBAR K, 1991, ARCH SURG-CHICAGO, V126, P421; KESSEL FRANZ, 1928, ANAT AM, V65, P162; Key A., 1875, STUDIEN ANATOMIE NER; Keyes JEL, 1935, ARCH OPHTHALMOL-CHIC, V13, P538; LABUICK D, 1993, CAN MED ASSOC J, V148, P1385; Maraldi NM, 2000, ANAT REC, V261, P5; McCulloch NA, 2001, CLIN ANAT, V14, P210, DOI 10.1002/ca.1035; PORTER R, 1995, GREATEST BENEFIT MAN; Rumboldt Z, 2002, AM J ROENTGENOL, V179, P267, DOI 10.2214/ajr.179.1.1790267; TRELEASE RB, 2000, ANAT REC, V269, P224; WILLIAMS PL, 1995, ANATOMICAL BASIS MED, P1264; WILLIS T, 1664, CEREBRI ANATOMIA CUI	21	37	37	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2110	2113		10.1016/S0140-6736(03)15114-8	http://dx.doi.org/10.1016/S0140-6736(03)15114-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697818				2022-12-28	WOS:000187429600032
J	Butler, D				Butler, D			Developing-world health - The fightback starts here	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					754	754		10.1038/426754a	http://dx.doi.org/10.1038/426754a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685194	Bronze			2022-12-28	WOS:000187342000016
J	Hostetter, MK				Hostetter, MK			Stitches	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					282	282		10.1001/jama.291.3.282	http://dx.doi.org/10.1001/jama.291.3.282			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734571				2022-12-28	WOS:000188243100001
J	Saydah, SH; Fradkin, J; Cowie, CC				Saydah, SH; Fradkin, J; Cowie, CC			Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; BLOOD-PRESSURE; UNITED-STATES; US ADULTS; PREVALENCE; CARE; HYPERTENSION; QUALITY; MANAGEMENT; MORTALITY	Context Control of blood glucose levels, blood pressure, and cholesterol levels is proven to reduce the risk of vascular disease among individuals with diabetes mellitus; however, the current state of control of these risk factors among individuals in the United States is uncertain. Objectives To examine 1999-2000 national data on control of risk factors for vascular disease among adults with previously diagnosed diabetes and to assess trends during the past decade. Design, Setting,and Participants Review of data from the Third National Health and Nutrition Examination Survey (NHANES III, conducted 1988-1994) and NHANES 1999-2000, cross-sectional surveys of a nationally representative sample of the non-institutionalized civilian US population. Participants were adults aged 20 years and older with previously diagnosed diabetes who participated in both the interview and examination in either NHANES III (n=1265) or NHANES 1999-2000 (n=441). Main Outcome Measures Levels of glycosylated hemoglobin (HbA(1c)), blood pressure, and total serum cholesterol in reference to target goals. Results Compared with NHANES III, participants with previously diagnosed diabetes in NHANES 1999-2000 were similar by age and sex, were less likely to be non-Hispanic white, were diagnosed at,an earlier age, had a higher body mass index, and were more likely to use insulin in combination with oral agents. In NHANES 19992000, only 37.0% of participants achieved the target goal of HbA(1c) level less than 7.0% and 37.2% of participants were above the recommended "take action" HbA(1c) level of greater than 8.0%; these percentages did not change significantly from NHANES III (P=.11 and P=.87, respectively). Only 35.8% of participants achieved the target of systolic blood pressure (SBP) less than 130 mm Hg and diastolic blood pressure (DBP) less than 80 mm Hg, and 40.4% had hypertensive blood pressure levels (SBP 140 or DBP 90 mm Hg). These percentages did not change significantly from NHANES III (P=.10 and P=.56, respectively). Over half (51.8%) of the participants in NHANES 1999-2000 had total cholesterol levels of 200 mg/dL or greater (vs 66.1% in NHANES III; P<.001). In total, only 7.3% (95% confidence interval, 2.8%-11.9%) of adults with diabetes in NHANES 1999-2000 attained recommended goals of HbA(1c) level less than 7%, blood pressure less than 130/80 mm Hg, and total cholesterol level less than 200 mg/dL (5.18 mmol/L). Conclusion Further public health efforts are needed to control risk factors for vascular disease among individuals with diagnosed diabetes.	NIDDKD, Diabet Epidemiol Program, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Cowie, CC (corresponding author), NIDDKD, Diabet Epidemiol Program, 6707 Democracy Blvd,Room 691,MSC 5460, Bethesda, MD 20892 USA.	cowiec@extra.niddk.nih.gov						American Diabetes Association, 2003, DIABETES CARE, V26, ps33, DOI DOI 10.2337/DIACARE.26.2007.S33; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clark CM, 2001, DIABETES CARE, V24, P617, DOI 10.2337/diacare.24.4.617; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cooper ME, 2000, JAMA-J AM MED ASSOC, V283, P3177, DOI 10.1001/jama.283.24.3177; Cowie C. C., 2003, Morbidity and Mortality Weekly Report, V52, P833; Eastman RC, 1995, DIABETES AM, P339; Egede LE, 2002, ARCH INTERN MED, V162, P427, DOI 10.1001/archinte.162.4.427; Engel S, 2003, NEW ENGL J MED, V348, P2294; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fleming BB, 2001, DIABETES CARE, V24, P1815, DOI 10.2337/diacare.24.10.1815; GABREL C, 2000, VITAL HLTH STAT, V146, P1; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Geiss LS, 2002, AM J PREV MED, V22, P42, DOI 10.1016/S0749-3797(01)00399-3; Genuth S, 2002, JAMA-J AM MED ASSOC, V287, P2563; George PB, 2001, AM HEART J, V142, P857, DOI 10.1067/mhj.2001.119132; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; GUNTER EW, 1997, LAB PROCEDURES USED; Haffner SM, 1998, DIABETES CARE, V21, P160, DOI 10.2337/diacare.21.1.160; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Harris M, 1995, DIABETES AM, P1; Harris MI, 1999, DIABETES CARE, V22, P403, DOI 10.2337/diacare.22.3.403; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Inzucchi SE, 2002, JAMA-J AM MED ASSOC, V287, P360, DOI 10.1001/jama.287.3.360; JOHNSON C, 2002, ANAL APPROACHES CAVE; JONES A, 2002, VITAL HLTH STAT, V152, P1; Jorgenson WA, 2002, DIABETES EDUCATOR, V28, P989, DOI 10.1177/014572170202800613; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KLEIN R, 1995, DIABETES AM, P293; KORN EL, 1999, WILEY S PRO STAT SUR, P1; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; *NAT CTR HLTH STAT, NHANES CURR DAT FIL; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V32, P3; *NAT CTR HLTH STAT, 1997, AN REP GUID 3 NAT HL; National Center for Health Statistics, NHANES 1999 2000 DAT; Petersen M, 2003, DIABETES CARE, V26, P917; PLEIS JR, 2003, VITAL HLTH STAT, V215, P28; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Rundall TG, 2002, BMJ-BRIT MED J, V325, P958, DOI 10.1136/bmj.325.7370.958; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Steinberg EP, 2003, NEW ENGL J MED, V348, P2681, DOI 10.1056/NEJMe030085; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Szklo M, 2000, EPIDEMIOLOGY BASICS, P265; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *US DEP HHS, 1997, NAT HLTH NUTR EX SUR; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167; Wingard DL., 1995, DIABETES AM, P429	52	1003	1037	1	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					335	342		10.1001/jama.291.3.335	http://dx.doi.org/10.1001/jama.291.3.335			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734596				2022-12-28	WOS:000188243100033
J	Gillespie, R				Gillespie, R			Community assembly through adaptive radiation in Hawaiian spiders	SCIENCE			English	Article							GENUS TETRAGNATHA; SPECIATION; COLONIZATION; EVOLUTION; ISLANDS	Communities arising through adaptive radiation are generally regarded as unique, with speciation and adaptation being quite different from immigration and ecological assortment. Here, I use the chronological arrangement of the Hawaiian Islands to visualize snapshots of evolutionary history and stages of community assembly. Analysis of an adaptive radiation of habitat-associated, polychromatic spiders shows that (i) species assembly is not random; (ii) within any community, similar sets of ecomorphs arise through both dispersal and evolution; and (iii) species assembly is dynamic with maximum species numbers in communities of intermediate age. The similar patterns of species accumulation through evolutionary and ecological processes suggest universal principles underlie community assembly.	Univ Calif Berkeley, Div Insect Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Gillespie, R (corresponding author), Univ Calif Berkeley, Div Insect Biol, 201 Wellman Hall, Berkeley, CA 94720 USA.	gillespi@nature.berkeley.edu	Gillespie, Rosemary/AAF-4244-2019	Gillespie, Rosemary/0000-0003-0086-7424				Arthur W., 1987, NICHE COMPETITION EV; CHOWN SL, 1990, SYST ENTOMOL, V15, P283, DOI 10.1111/j.1365-3113.1990.tb00064.x; ELTON C, 1946, J ANIM ECOL, V15, P54, DOI 10.2307/1625; Gillespie RG, 1999, J INSECT CONSERV, V3, P263, DOI 10.1023/A:1009654820519; Gillespie RG, 2002, J ARACHNOL, V30, P159, DOI 10.1636/0161-8202(2002)030[0159:HSOTGT]2.0.CO;2; Gillespie RG, 2002, ANNU REV ENTOMOL, V47, P595, DOI 10.1146/annurev.ento.47.091201.145244; GILLESPIE RG, 1991, J ARACHNOL, V19, P174; Gillespie Rosemary G., 1997, Pacific Science, V51, P380; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; Losos JB, 2000, NATURE, V408, P847, DOI 10.1038/35048558; LOSOS JB, 1992, SYST BIOL, V41, P403, DOI 10.2307/2992583; Ricklefs R.E., 1993, J EVOLUTION BIOL, DOI DOI 10.1046/J.1420-9101.1993.6020171.X; Roderick GK, 1998, MOL ECOL, V7, P519, DOI 10.1046/j.1365-294x.1998.00309.x; Ruber L, 1999, P NATL ACAD SCI USA, V96, P10230, DOI 10.1073/pnas.96.18.10230; Schluter D, 2000, AM NAT, V156, pS4, DOI 10.1086/303412; Scott J. M., 1986, STUD AVIAN BIOL SER, V9, P431; SIMBERLOFF D, 1976, SCIENCE, V194, P572, DOI 10.1126/science.194.4265.572; SIMBERLOFF DS, 1969, ECOLOGY, V50, P278, DOI 10.2307/1934856; Wagner WL, 1995, HAWAIIAN BIOGEOGRAPH; Webb CO, 2002, ANNU REV ECOL SYST, V33, P475, DOI 10.1146/annurev.ecolsys.33.010802.150448; Weiher E., 1999, ECOLOGICAL ASSEMBLY, DOI DOI 10.1017/CBO9780511542237	21	437	448	0	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					356	359		10.1126/science.1091875	http://dx.doi.org/10.1126/science.1091875			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726588				2022-12-28	WOS:000188111800039
J	Towse, A; Mills, A; Tangcharoensathien, V				Towse, A; Mills, A; Tangcharoensathien, V			Learning from Thailand's health reforms	BRITISH MEDICAL JOURNAL			English	Editorial Material							SCHEME		Off Hlth Econ, London SW1A 2DY, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Int Hlth Policy Programme, Bangkok, Thailand	University of London; London School of Hygiene & Tropical Medicine	Towse, A (corresponding author), Off Hlth Econ, London SW1A 2DY, England.		Towse, Adrian/M-3760-2014	Mills, Anne/0000-0001-9863-9950				FIGUERAS J, 1999, REFORMING HLTH SECTO, P246; Green A, 2000, INT J HEALTH PLAN M, V15, P39, DOI 10.1002/(SICI)1099-1751(200001/03)15:1<39::AID-HPM567>3.0.CO;2-9; *HLTH SYST RES I, 2002, UN HLTH CAR COV THAI; Mills A, 2000, HEALTH POLICY, V51, P163, DOI 10.1016/S0168-8510(00)00059-2; Mills A., 2002, FUNDING HLTH CARE OP, P206; MILLS A, 1998, ACHIEVING UNIVERSAL, P284; Nitayarumphong S., 1998, ACHIEVING UNIVERSAL, P258; Pannarunothai S, 2000, HEALTH POLICY PLANN, V15, P303, DOI 10.1093/heapol/15.3.303; Pannarunothai S, 2002, SUSTAINABLE UNIVERSA; PATMASIRIWAT D, 2003, THAI J DEV ADM, V43, P23; PRAKONGSAI P, 2002, J HEALTH SCI, V11, P599; Pramualratana P., 2002, HLTH INSURANCE SYSTE; TANGCHAREONSATH.V, 2002, J HEALTH SCI, V11, P759; Tangcharoensathien V, 1999, SOC SCI MED, V48, P913, DOI 10.1016/S0277-9536(98)00392-X	14	80	83	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 10	2004	328	7431					103	105		10.1136/bmj.328.7431.103	http://dx.doi.org/10.1136/bmj.328.7431.103			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	762MP	14715608	Green Submitted, Green Published			2022-12-28	WOS:000187976400024
J	Woodcock, M; Shah, S; Smith, RJ				Woodcock, M; Shah, S; Smith, RJ			Recent advances in customising cataract surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BEAVER DAM EYE; POSTERIOR SUBCAPSULAR CATARACTS; LENS OPACITIES; RISK-FACTORS; POPULATION; NUCLEAR	Cataract surgery has advanced a lot over the years. This review describes the latest techniques and how they are used to customise the surgery to the needs of the individual patient.	City Hosp, Birmingham & Midland Eye Ctr, Birmingham B18 7QH, W Midlands, England; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of Birmingham; University of California System; University of California Los Angeles	Shah, S (corresponding author), City Hosp, Birmingham & Midland Eye Ctr, Dudley Rd, Birmingham B18 7QH, W Midlands, England.	sunilshah@doctors.org.uk						Delcourt C, 2000, AM J EPIDEMIOL, V151, P497; Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336; DOLIN P, 1998, EPIDEMIOLOGY EYE DIS, P103; Ernest P, 1998, J CATARACT REFR SURG, V24, P482, DOI 10.1016/S0886-3350(98)80288-5; Findl O, 2001, J CATARACT REFR SURG, V27, P861, DOI 10.1016/S0886-3350(00)00699-4; Klein BEK, 1997, OPHTHALMOLOGY, V104, P573, DOI 10.1016/S0161-6420(97)30267-X; Leske MC, 1997, INT J EPIDEMIOL, V26, P1314, DOI 10.1093/ije/26.6.1314; NIELSEN PJ, 1995, J CATARACT REFR SURG, V21, P43, DOI 10.1016/S0886-3350(13)80478-6; OLSEN T, 1992, J CATARACT REFR SURG, V18, P125, DOI 10.1016/S0886-3350(13)80917-0; Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841; Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643; Retzlaff J, 1980, J Am Intraocul Implant Soc, V6, P148; RITTER LL, 1993, ARCH OPHTHALMOL-CHIC, V111, P113, DOI 10.1001/archopht.1993.01090010117037; *ROYAL COLL OPHTH, 2001, CAT SURG GUID, P7; SANDERS D, 1981, AM INTRAOCULAR IMPLA, V7, P337; Sanders D R, 1980, J Am Intraocul Implant Soc, V6, P263; SANDERS DR, 1983, ARCH OPHTHALMOL-CHIC, V101, P965; SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P202; WEST SK, 1998, JAMA-J AM MED ASSOC, V289, P714; Wong TY, 2002, BRIT J OPHTHALMOL, V86, P152, DOI 10.1136/bjo.86.2.152; Zodpey S P, 1999, J Indian Med Assoc, V97, P13	21	19	21	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2004	328	7431					92	96A		10.1136/bmj.328.7431.92	http://dx.doi.org/10.1136/bmj.328.7431.92			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MP	14715604	Green Published			2022-12-28	WOS:000187976400018
J	Bard, E; Rostek, F; Menot-Combes, G				Bard, E; Rostek, F; Menot-Combes, G			A better radiocarbon clock	SCIENCE			English	Editorial Material							PROJECT ICE CORE; C-14 AGES; CAL BP; CALIBRATION; GREENLAND; ISOTOPE; KA; SEDIMENTS; RECORDS; SUMMIT		CEREGE, UMR 6635, F-13545 Aix En Provence, France; Coll France, F-13545 Aix En Provence, France	UDICE-French Research Universities; PSL Research University Paris; College de France; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; PSL Research University Paris; College de France	Bard, E (corresponding author), CEREGE, UMR 6635, F-13545 Aix En Provence, France.		Bard, Edouard/G-7717-2014; Ménot, Guillemette/A-5403-2017	Ménot, Guillemette/0000-0003-2423-8294				Bard E, 1998, RADIOCARBON, V40, P1085, DOI 10.1017/S0033822200019135; BARD E, IN PRESS QUAT RES; Baumgartner S, 1997, J GEOPHYS RES-OCEANS, V102, P26659, DOI 10.1029/97JC00166; Beck JW, 2001, SCIENCE, V292, P2453, DOI 10.1126/science.1056649; CARCAILLET J, IN PRESS EATH PLANET; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; Johnsen SJ, 2001, J QUATERNARY SCI, V16, P299, DOI 10.1002/jqs.622; Kitagawa H, 1998, SCIENCE, V279, P1187, DOI 10.1126/science.279.5354.1187; Kitagawa H, 2000, RADIOCARBON, V42, P369; Reimer PJ, 2002, RADIOCARBON, V44, P653, DOI 10.1017/S0033822200032100; Schramm A, 2000, EARTH PLANET SC LETT, V175, P27, DOI 10.1016/S0012-821X(99)00279-4; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; THOUVENY N, IN PRESS EARTH PLANE; Ton-That T, 2001, EARTH PLANET SC LETT, V184, P645, DOI 10.1016/S0012-821X(00)00358-7; Valladas H, 2001, NATURE, V413, P479, DOI 10.1038/35097160; Voelker AHL, 1998, RADIOCARBON, V40, P517; Yiou F, 1997, J GEOPHYS RES-OCEANS, V102, P26783, DOI 10.1029/97JC01265; Yokoyama Y, 2000, RADIOCARBON, V42, P383, DOI 10.1017/S0033822200030320	19	55	55	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					178	179		10.1126/science.1091964	http://dx.doi.org/10.1126/science.1091964			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14715998	Green Submitted			2022-12-28	WOS:000187908500032
J	Crookes, WJ; Ding, LL; Huang, QL; Kimbell, JR; Horwitz, J; McFall-Ngai, MJ				Crookes, WJ; Ding, LL; Huang, QL; Kimbell, JR; Horwitz, J; McFall-Ngai, MJ			Reflectins: The unusual proteins of squid reflective tissues	SCIENCE			English	Article							PHYSIOLOGICAL COLOR-CHANGE; LOLLIGUNCULA-BREVIS; IRIDOPHORES; CEPHALOPODS; MORPHOLOGY; ORGAN	A family of unusual proteins is deposited in flat, structural platelets in reflective tissues of the squid Euprymna scolopes. These proteins, which we have named reflectins, are encoded by at least six genes in three subfamilies and have no reported homologs outside of squids. Reflectins possess five repeating domains, which are highly conserved among members of the family. The proteins have a very unusual composition, with four relatively rare residues (tyrosine, methionine, arginine, and tryptophan) comprising similar to57% of a reflectin, and several common residues (alanine, isoleucine, leucine, and lysine) occurring in none of the family members. These protein-based reflectors in squids provide a marked example of nanofabrication in animal systems.	Univ Hawaii Manoa, Pacific Biomed Res Ctr, Kewalo Marine Lab, Honolulu, HI 96813 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of Hawaii System; University of Hawaii Manoa; University of California System; University of California Los Angeles	McFall-Ngai, MJ (corresponding author), Univ Hawaii Manoa, Pacific Biomed Res Ctr, Kewalo Marine Lab, 41 Ahui St, Honolulu, HI 96813 USA.				NEI NIH HHS [NEI R01 EY3897] Funding Source: Medline; PHS HHS [R01 A150661] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003897] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARNOLD JM, 1974, BIOL BULL, V147, P522, DOI 10.2307/1540737; CLONEY RA, 1983, AM ZOOL, V23, P581, DOI 10.1093/icb/23.3.581; COOPER KM, 1990, CELL TISSUE RES, V259, P15, DOI 10.1007/BF00571425; DENTON EJ, 1971, PROC R SOC SER B-BIO, V178, P43, DOI 10.1098/rspb.1971.0051; HANLON RT, 1990, CELL TISSUE RES, V259, P3, DOI 10.1007/BF00571424; Johnsen S, 2003, LIMNOL OCEANOGR, V48, P1277, DOI 10.4319/lo.2003.48.3.1277; Johnsen S, 2002, P ROY SOC B-BIOL SCI, V269, P243, DOI 10.1098/rspb.2001.1855; Land M F, 1972, Prog Biophys Mol Biol, V24, P75, DOI 10.1016/0079-6107(72)90004-1; MCFALLNGAI M, 1990, BIOL BULL, V179, P332, DOI 10.2307/1542325; MONTGOMERY MK, 1992, J BIOL CHEM, V267, P20999; Steinberg-Yfrach G, 1998, NATURE, V392, P479, DOI 10.1038/33116; Vukusic P, 2003, NATURE, V424, P852, DOI 10.1038/nature01941; WEISS JL, 2002, CAC86921 NAT CTR BIO; Wise KJ, 2002, TRENDS BIOTECHNOL, V20, P387, DOI 10.1016/S0167-7799(02)02023-1; Zhang SG, 2002, CURR OPIN CHEM BIOL, V6, P865, DOI 10.1016/S1367-5931(02)00391-5	15	164	166	2	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					235	238		10.1126/science.1091288	http://dx.doi.org/10.1126/science.1091288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716016				2022-12-28	WOS:000187908500050
J	Nadeau, RM; McEvilly, TV				Nadeau, RM; McEvilly, TV			Periodic pulsing of characteristic microearthquakes on the San Andreas Fault	SCIENCE			English	Article							ASEISMIC SLIP; PARKFIELD; CALIFORNIA; INVERSION; EVENT	Deep fault slip information from characteristically repeating microearthquakes reveals previously unrecognized patterns of extensive, large-amplitude, long-duration, quasiperiodic repetition of aseismic events along much of a 175-kilometer segment of the central San Andreas fault. Pulsing occurs both in conjunction with and independent of transient slip from larger earthquakes. It extends to depths of similar to10 to 11 kilometers but may be deeper, and it may be related to similar phenomena occurring in subduction zones. Over much of the study area, pulse onset periods also show a higher probability of larger earthquakes, which may provide useful information for earthquake forecasting.	Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Nadeau, RM (corresponding author), Univ Calif Berkeley, Berkeley Seismol Lab, 211 McCone Hall, Berkeley, CA 94720 USA.	nadeau@seismo.berkeley.edu	Nadeau, Robert/G-1884-2017	Nadeau, Robert/0000-0003-1255-0643				BAKUN WH, 1984, J GEOPHYS RES, V89, P3051, DOI 10.1029/JB089iB05p03051; Burgmann R, 2000, SCIENCE, V289, P1178, DOI 10.1126/science.289.5482.1178; Dieterich J. H., 1986, EARTHQUAKE SOURCE ME, P37; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; Du WX, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002008; Gao SS, 2000, J GEOPHYS RES-SOL EA, V105, P2955, DOI 10.1029/1999JB900383; GWYTHER RL, 2000, P 3 C TECT PROBL SAN; Langbein J, 1999, GEOPHYS RES LETT, V26, P2529, DOI 10.1029/1999GL900557; Linde AT, 1996, NATURE, V383, P65, DOI 10.1038/383065a0; LISOWSKI M, 1981, B SEISMOL SOC AM, V71, P1607; Matthews MV, 2002, B SEISMOL SOC AM, V92, P2233, DOI 10.1785/0120010267; Miller MM, 2002, SCIENCE, V295, P2423, DOI 10.1126/science.1071193; Murray JR, 2001, GEOPHYS RES LETT, V28, P359, DOI 10.1029/2000GL011933; Nadeau RM, 1999, SCIENCE, V285, P718, DOI 10.1126/science.285.5428.718; Nedimovic MR, 2003, NATURE, V424, P416, DOI 10.1038/nature01840; Ozawa S, 2002, SCIENCE, V298, P1009, DOI 10.1126/science.1076780; Ozawa S, 2001, J GEOPHYS RES-SOL EA, V106, P787, DOI 10.1029/2000JB900317; REASENBERG PA, 1997, US GEOL SURV PROF D, V1550; Roeloffs EA, 2001, J GEOPHYS RES-SOL EA, V106, P16525, DOI 10.1029/2001JB000352; Shibazaki B, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017047; Uhrhammer R., 1999, SEISMOL RES LETT, V70, P10, DOI [10.1785/gssrl.70.1.10, DOI 10.1785/GSSRL.70.1.10]; *US GEOL SURV WORK, 1999, 99517 US GEOL SURV; Wallace R.E., 1990, US GEOL SURV PROF PA, V1515	23	101	104	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					220	222		10.1126/science.1090353	http://dx.doi.org/10.1126/science.1090353			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716011				2022-12-28	WOS:000187908500045
J	Ricardo, A; Carrigan, MA; Olcott, AN; Benner, SA				Ricardo, A; Carrigan, MA; Olcott, AN; Benner, SA			Borate minerals stabilize ribose	SCIENCE			English	Article									Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ So Calif, Dept Geol, Los Angeles, CA 90089 USA	State University System of Florida; University of Florida; University of Southern California	Benner, SA (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	sab@scinq.org	Olcott, Alison N./AAL-2020-2021	Olcott, Alison/0000-0002-6854-646X; Carrigan, Matthew/0000-0003-1459-2265				Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BRESLOW R, 1959, TETRAHEDRON LETT, P22; Hollis JM, 2001, ASTROPHYS J, V554, pL81, DOI 10.1086/320930; Kawakami T, 2001, J METAMORPH GEOL, V19, P61, DOI 10.1046/j.0263-4929.2000.00298.x; LARRALDE R, 1995, P NATL ACAD SCI USA, V92, P8158, DOI 10.1073/pnas.92.18.8158; SHAPIRO R, 1988, ORIGINS LIFE EVOL B, V18, P71, DOI 10.1007/BF01808782	8	412	426	1	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					196	196		10.1126/science.1092464	http://dx.doi.org/10.1126/science.1092464			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716004				2022-12-28	WOS:000187908500038
J	Izard, T; Evans, G; Borgon, RA; Rush, CL; Bricogne, G; Bois, PRJ				Izard, T; Evans, G; Borgon, RA; Rush, CL; Bricogne, G; Bois, PRJ			Vinculin activation by talin through helical bundle conversion	NATURE			English	Article							ALPHA-CATENIN; BINDING-SITE; INTRAMOLECULAR ASSOCIATION; CRYSTAL-STRUCTURE; TAIL DOMAINS; ADHESION; PAXILLIN; KINASE; ACTIN; REGION	Vinculin is a conserved component and an essential regulator of both cell-cell (cadherin-mediated) and cell-matrix (integrin talin- mediated focal adhesions) junctions, and it anchors these adhesion complexes to the actin cytoskeleton by binding to talin in integrin complexes or to alpha-actinin in cadherin junctions(1-3). In its resting state, vinculin is held in a closed conformation through interactions between its head (Vh) and tail (Vt) domains(4-6). The binding of vinculin to focal adhesions requires its association with talin. Here we report the crystal structures of human vinculin in its inactive and talin- activated states. Talin binding induces marked conformational changes in Vh, creating a novel helical bundle structure, and this alteration actively displaces Vt from Vh. These results, as well as the ability of alpha-actinin to also bind to Vh and displace Vt from pre-existing Vh Vt complexes, support a model whereby Vh functions as a domain that undergoes marked structural changes that allow vinculin to direct cytoskeletal assembly in focal adhesions and adherens junctions. Notably, talin's effects on Vh structure establish helical bundle conversion as a signalling mechanism by which proteins direct cellular responses.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; Global Phasing Ltd, Cambridge CB3 0AX, England; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Global Phasing Limited; University of Tennessee System; University of Tennessee Health Science Center	Izard, T (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	tina.izard@stjude.org	Evans, Gwyndaf/R-5524-2016	Evans, Gwyndaf/0000-0002-6079-2201; Borgon, Robert/0000-0002-5908-3395				Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Hoellerer MK, 2003, STRUCTURE, V11, P1207, DOI 10.1016/j.str.2003.08.010; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Pokutta S, 2002, CURR OPIN STRUC BIOL, V12, P255, DOI 10.1016/S0959-440X(02)00318-4; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; WEISS EE, 1997, J CELL BIOL, V131, P755; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xu WM, 1998, DEVELOPMENT, V125, P327; Yang J, 2001, EMBO J, V20, P3645, DOI 10.1093/emboj/20.14.3645; Zamir E, 2001, J CELL SCI, V114, P3583	23	186	193	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 8	2004	427	6970					171	175		10.1038/nature02281	http://dx.doi.org/10.1038/nature02281			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14702644				2022-12-28	WOS:000187863900039
J	Adjuik, M; Agnamey, P; Babiker, A; Baptista, J; Borrmann, S; Brasseur, P; Carnevale, P; Cisse, M; Collins, R; D'Alessandro, U; Day, N; de Boom, W; Doherty, T; Dorsey, G; Garner, P; Gikunda, S; Gil, V; Greenwood, B; Guthmann, JP; Henry, MC; Kamya, MR; Kremsner, PG; Konate, E; Krishna, S; Lalloo, D; Lange, P; Loolpapit, M; Malenga, G; Marquino, W; Marsh, K; Milligan, P; Molyneux, M; Mugittu, K; Niangue, J; Nosten, F; Ntoumi, F; Obonyo, C; Ochieng, F; Olliaro, P; Oloo, AJ; Osorio, L; Pinoges, L; Priotto, G; Rosenthal, PJ; Ruebush, T; Simpson, J; Sirima, S; Some, E; Taylor, W; ter Kuile, F; Tiono, A; von Seidlein, L; Watkins, B; White, N				Adjuik, M; Agnamey, P; Babiker, A; Baptista, J; Borrmann, S; Brasseur, P; Carnevale, P; Cisse, M; Collins, R; D'Alessandro, U; Day, N; de Boom, W; Doherty, T; Dorsey, G; Garner, P; Gikunda, S; Gil, V; Greenwood, B; Guthmann, JP; Henry, MC; Kamya, MR; Kremsner, PG; Konate, E; Krishna, S; Lalloo, D; Lange, P; Loolpapit, M; Malenga, G; Marquino, W; Marsh, K; Milligan, P; Molyneux, M; Mugittu, K; Niangue, J; Nosten, F; Ntoumi, F; Obonyo, C; Ochieng, F; Olliaro, P; Oloo, AJ; Osorio, L; Pinoges, L; Priotto, G; Rosenthal, PJ; Ruebush, T; Simpson, J; Sirima, S; Some, E; Taylor, W; ter Kuile, F; Tiono, A; von Seidlein, L; Watkins, B; White, N		Int Artemisinin Study Grp	Artesunate combinations for treatment of malaria: meta-analysis	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; UNCOMPLICATED MALARIA; RESISTANCE; MEFLOQUINE; AMODIAQUINE; OVERVIEWS; CHILDREN	Background Addition of artemisinin derivatives to existing drug regimens for malaria could reduce treatment failure and transmission potential. We assessed the evidence for this hypothesis from randomised controlled trials. Methods We undertook a meta-analysis of individual patients' data from 16 randomised trials (n=5948) that studied the effects of the addition of artesunate to standard treatment of Plasmodium falciparum malaria. We estimated odds ratios (OR) of parasitological failure at days 14 and 28 (artesunate combination compared with standard treatment) and calculated combined summary ORs across trials using standard methods. Findings For all trials combined, parasitological failure was lower with 3 days of artesunate at day 14 (OR 0.20, 95% CI 0.17-0.25, n=4504) and at day 28 (excluding new infections, 0.23, 0.19-0.28, n=2908; including re-infections, 0.30, 0.26-0.35, n=4332). Parasite clearance was significantly faster (rate ratio 1.98, 95% CI 1.85-2.12, n=3517) with artesunate. In participants with no gametocytes at baseline, artesunate reduced gametocyte count on day 7 (OR 0.11, 95% CI 0.09-0.15, n=2734), with larger effects at days 14 and 28. Adding artesunate for 1 day (six trials) was associated with fewer failures by day 14 (0.61, 0.48-0.77, n=1980) and day 28 (adjusted to exclude new infections 0.68, 0.53-0.89, n=1205; unadjusted including reinfections 0.77, 0.63-0.95, n=1958). In these trials, gametocytes were reduced by day 7 (in participants with no gametocytes at baseline 0.11, 0.09-0.15, n=2734). The occurrence of serious adverse events did not differ significantly between artesunate and placebo. Interpretation The addition of 3 days of artesunate to standard antimalarial treatments substantially reduce treatment failure, recrudescence, and gametocyte carriage.	Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Res Grp, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Garner, P (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Res Grp, Liverpool L3 5QA, Merseyside, England.	pgarner@liv.ac.uk	D'Alessandro, Umberto/D-3457-2015; Obonyo, Charles/AAX-5992-2020; White, Nick/AAC-6527-2019; Garner, Paul/Y-8385-2019; Simpson, Julie A/P-7299-2014; Oloo, James Aggrey/CAF-3948-2022; Kuile, Feiko ter/ABD-6681-2020; Priotto, Gerardo/AAS-9027-2021; Nosten, Francois/AAC-5509-2019; Garner, Paul/HII-5856-2022; Krishna, Supriya/HIR-5986-2022; White, Nicholas J/I-4629-2012; Borrmann, Steffen/G-1838-2013	D'Alessandro, Umberto/0000-0001-6341-5009; Obonyo, Charles/0000-0003-0741-8533; White, Nick/0000-0002-1897-1978; Garner, Paul/0000-0002-0607-6941; Oloo, James Aggrey/0000-0001-7495-1827; Kuile, Feiko ter/0000-0003-3663-5617; Nosten, Francois/0000-0002-7951-0745; Borrmann, Steffen/0000-0001-9189-4393				Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; Breman JG, 2001, AM J TROP MED HYG, V64, pIV, DOI 10.4269/ajtmh.2001.64.iv; DEMETS DL, 1987, STAT MED, V6, P341, DOI 10.1002/sim.4780060325; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; *INT ART STUD GROU, 2002, COCHR LIB; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; MANTEL N, 1959, J NATL CANCER I, V22, P719; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Olliaro P, 2001, TROP MED INT HEALTH, V6, P922, DOI 10.1046/j.1365-3156.2001.00752.x; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; PRICE RN, 1995, T ROY SOC TROP MED H, V89, P523, DOI 10.1016/0035-9203(95)90094-2; Price RN, 2001, DRUG RESIST UPDATE, V4, P187, DOI 10.1054/drup.2001.0195; Sharp S, 1998, STATA TECH B, V7, DOI DOI 10.1002/SIM.1187/FULL); Snounou G, 1998, PARASITOL TODAY, V14, P462, DOI 10.1016/S0169-4758(98)01340-4; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689; TAYLOR WRJ, 1998, UNPUB ANAL PLAN COMB; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; WHITE N, 1998, UNPUB RANDOMIZED DOU; White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413, DOI 10.1128/AAC.41.7.1413; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X	27	407	414	0	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					9	17						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723987				2022-12-28	WOS:000187711300008
J	Niittyla, T; Messerli, G; Trevisan, M; Chen, J; Smith, AM; Zeeman, SC				Niittyla, T; Messerli, G; Trevisan, M; Chen, J; Smith, AM; Zeeman, SC			A previously unknown maltose transporter essential for starch degradation in leaves	SCIENCE			English	Article							ARABIDOPSIS; BREAKDOWN; CARBON	A previously unknown maltose transporter is essential for the conversion of starch to sucrose in Arabidopsis leaves at night. The transporter was identified by isolating two allelic mutants with high starch levels and very high maltose, an intermediate of starch breakdown. The mutations affect a gene of previously unknown function, MEX1. We show that MEX1 is a maltose transporter that is unrelated to other sugar transporters. The severe mex1 phenotype demonstrates that MEX1 is the predominant route of carbohydrate export from chloroplasts at night. Homologous genes in plants including rice and potato indicate that maltose export is of widespread significance.	John Innes Ctr Plant Sci Res, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England; Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Bern; Academia Sinica - Taiwan	Smith, AM (corresponding author), John Innes Ctr Plant Sci Res, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England.	alison.smith@bbsrc.ac.uk	Smith, Steven/HDM-9496-2022; Smith, Steven M/G-7183-2015	Smith, Steven M/0000-0001-5661-9994; Niittyla, Totte/0000-0001-8029-1503; Zeeman, Samuel/0000-0002-2791-0915				Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; CASPAR T, 1991, PLANT PHYSIOL, V95, P1181, DOI 10.1104/pp.95.4.1181; CASPAR T, 1985, PLANT PHYSIOL, V79, P11, DOI 10.1104/pp.79.1.11; Critchley JH, 2001, PLANT J, V26, P89, DOI 10.1046/j.1365-313x.2001.01012.x; Hausler RE, 1998, PLANTA, V204, P366, DOI 10.1007/s004250050268; RIESMEIER JW, 1993, P NATL ACAD SCI USA, V90, P6160, DOI 10.1073/pnas.90.13.6160; Rost S, 1996, BBA-GEN SUBJECTS, V1291, P221, DOI 10.1016/S0304-4165(96)00068-2; Scheidig A, 2002, PLANT J, V30, P581, DOI 10.1046/j.1365-313X.2002.01317.x; Schleucher J, 1998, PLANT PHYSIOL, V118, P1439, DOI 10.1104/pp.118.4.1439; Servaites JC, 2002, J EXP BOT, V53, P1581, DOI 10.1093/jxb/erf009; Smith AM, 2003, J EXP BOT, V54, P577, DOI 10.1093/jxb/erg036; SMITH AM, 2002, J APPL GLYCOSCI, V50, P173; STITT M, 1981, PLANT PHYSIOL, V68, P755, DOI 10.1104/pp.68.3.755; Trethewey Richard N., 2000, VVolume 9, P205; Tsugeki R, 1999, P NATL ACAD SCI USA, V96, P12941, DOI 10.1073/pnas.96.22.12941; Weber A, 2000, PLANT CELL, V12, P787, DOI 10.1105/tpc.12.5.787; Zeeman SC, 1998, PLANT J, V15, P357, DOI 10.1046/j.1365-313X.1998.00213.x	17	335	354	7	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					87	89		10.1126/science.1091811	http://dx.doi.org/10.1126/science.1091811			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704427				2022-12-28	WOS:000187710600039
J	Steel, GJ; Fullerton, DM; Tyson, JR; Stirling, CJ				Steel, GJ; Fullerton, DM; Tyson, JR; Stirling, CJ			Coordinated activation of Hsp70 chaperones	SCIENCE			English	Article							YEAST ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; ATPASE ACTIVITY; KAR2P; BIP; PRECURSORS; COMPLEXES; HOMOLOG; BINDING	Hsp70s are a ubiquitous family of molecular chaperones involved in many cellular processes. Two Hsp70s, Lhs1p and Kar2p, are required for protein biogenesis in the yeast endoplasmic reticulum. Here, we found that Lhs1p and Kar2p specifically interacted to couple, and coordinately regulate, their respective activities. Lhs1p stimulated Kar2p by providing a specific nucleotide exchange activity, whereas Kar2p reciprocally activated the Lhs1p adenosine triphosphatase (ATPase). The two ATPase activities are coupled, and their coordinated regulation is essential for normal function in vivo.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Stirling, CJ (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.	colin.stirling@man.ac.uk						Baxter BK, 1996, MOL CELL BIOL, V16, P6444; Boisrame A, 1998, J BIOL CHEM, V273, P30903, DOI 10.1074/jbc.273.47.30903; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; Craven RA, 1997, TRENDS CELL BIOL, V7, P277, DOI 10.1016/S0962-8924(97)01079-9; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Misselwitz E, 1999, J BIOL CHEM, V274, P20110, DOI 10.1074/jbc.274.29.20110; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; Saris N, 1997, J CELL BIOL, V137, P813, DOI 10.1083/jcb.137.4.813; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	20	149	159	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					98	101		10.1126/science.1092287	http://dx.doi.org/10.1126/science.1092287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704430				2022-12-28	WOS:000187710600043
J	Reding, R; Gras, J; Sokal, E; Otte, JB; Davies, HFS				Reding, R; Gras, J; Sokal, E; Otte, JB; Davies, HFS			Steroid-free liver transplantation in children	LANCET			English	Article							WITHDRAWAL	Although corticosteroids have been part of immunosuppressive regimens since the early days of transplantation, steroid avoidance could be beneficial. To test this hypothesis in paediatric liver transplantation, we compared liver-transplantation under steroid-free immunosuppression in 20 children, who received combined tacrolimus and basiliximab, with. that under tacrolimus and steroids in 20 matched historical recipients as a historical control group. 12-month rejection-free survival was 75% in the tacrolimus-basiliximab group compared with 50% in the steroid group (p=0.05). Growth in the first year after transplantation was significantly better in the tacrolimus-basiliximab group than in the steroid group. Steroid avoidance was, therefore, not harmful to our patients, and combining tacrolimus with basiliximab as a steroid substitution seems a safe alternative to tacrolimus and steroid immunosuppression.	Catholic Univ Louvain, Clin Univ St Luc, Paediat Liver Transplant Program, B-1200 Brussels, Belgium; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Reding, R (corresponding author), Catholic Univ Louvain, Clin Univ St Luc, Paediat Liver Transplant Program, 10 Hippocrate Ave, B-1200 Brussels, Belgium.	reding@chex.ucl.ac.be		Sokal, Etienne/0000-0001-5597-4708				Diem HVT, 2003, TRANSPLANTATION, V75, P1664, DOI 10.1097/01.TP.0000063938.49112.C2; Kelly D., 2002, AM J TRANSPLANT S3, V2, P351; Mazariegos GV, 2003, AM J TRANSPLANT, V3, P689, DOI 10.1034/j.1600-6143.2003.00109.x; Reding R, 2000, TRANSPLANTATION, V70, P405, DOI 10.1097/00007890-200008150-00001; Wang CM, 2001, TRANSPLANTATION, V72, P44, DOI 10.1097/00007890-200107150-00011	5	83	85	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2068	2070		10.1016/S0140-6736(03)15104-5	http://dx.doi.org/10.1016/S0140-6736(03)15104-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697809				2022-12-28	WOS:000187429600014
J	Jiang, GQ; Kennedy, MJ; Christie-Blick, N				Jiang, GQ; Kennedy, MJ; Christie-Blick, N			Stable isotopic evidence for methane seeps in Neoproterozoic postglacial cap carbonates	NATURE			English	Article							GAS HYDRATE; EXCURSIONS; DEPOSITS; PRECIPITATION; DISSOCIATION; RECORD	The Earth's most severe glaciations are thought to have occurred about 600 million years ago, in the late Neoproterozoic era(1,2). A puzzling feature of glacial deposits from this interval is that they are overlain by 1-5-m-thick 'cap carbonates' (particulate deepwater marine carbonate rocks) associated with a prominent negative carbon isotope excursion(3-8). Cap carbonates have been controversially ascribed to the aftermath of almost complete shutdown of the ocean ecosystems for millions of years during such ice ages - the 'snowball Earth' hypothesis(4,5). Conversely, it has also been suggested that these carbonate rocks were the result of destabilization of methane hydrates during deglaciation and concomitant flooding of continental shelves and interior basins(3). The most compelling criticism of the latter 'methane hydrate' hypothesis has been the apparent lack of extreme isotopic variation in cap carbonates inferred locally to be associated with methane seeps. Here we report carbon isotopic and petrographic data from a Neoproterozoic postglacial cap carbonate in south China that provide direct evidence for methane-influenced processes during deglaciation. This evidence lends strong support to the hypothesis that methane hydrate destabilization contributed to the enigmatic cap carbonate deposition and strongly negative carbon isotopic anomalies following Neoproterozoic ice ages. This explanation requires less extreme environmental disturbance than that implied by the snowball Earth hypothesis(4,5).	Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	University of California System; University of California Riverside; Columbia University; Columbia University	Jiang, GQ (corresponding author), Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA.	ganqing@mail.ucr.edu	Jiang, Ganqing/A-9557-2011; Jiang, Ganqing/GZM-7526-2022; Jiang, Ganqing/AAX-7756-2020	Jiang, Ganqing/0000-0002-6627-2848; Jiang, Ganqing/0000-0002-6627-2848; Kennedy, Martin/0000-0002-1330-6864				Aiello IW, 2001, GEOLOGY, V29, P1111, DOI 10.1130/0091-7613(2001)029<1111:AAOOCS>2.0.CO;2; Barfod GH, 2002, EARTH PLANET SC LETT, V201, P203, DOI 10.1016/S0012-821X(02)00687-8; Boetius A, 2000, NATURE, V407, P623, DOI 10.1038/35036572; Cavagna S, 1999, SEDIMENT GEOL, V126, P253, DOI 10.1016/S0037-0738(99)00044-5; CROWELL JC, 1999, MEM GEOL SOC AM, V192; Dickens G., 2003, GEOL SOC AM SPEC PAP, V369, P11, DOI [10.1130/0-8137-2369-8.11, DOI 10.1130/0-8137-2369-8.11]; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Gautier D. L., 1984, AAPG BULL, V37, P111; Greinert J, 2002, EARTH PLANET SC LETT, V203, P165, DOI 10.1016/S0012-821X(02)00830-0; Grotzinger JP, 1995, PALAIOS, V10, P578, DOI 10.2307/3515096; Hesselbo SP, 2000, NATURE, V406, P392, DOI 10.1038/35019044; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hoffman PF, 2002, GEOLOGY, V30, P286, DOI 10.1130/0091-7613(2002)030<0286:APCCAI>2.0.CO;2; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; IRWIN H, 1977, NATURE, V269, P209, DOI 10.1038/269209a0; James NP, 2001, CAN J EARTH SCI, V38, P1229, DOI 10.1139/e01-046; Katz ME, 1999, SCIENCE, V286, P1531, DOI 10.1126/science.286.5444.1531; Kauffman EG, 1996, GEOLOGY, V24, P799, DOI 10.1130/0091-7613(1996)024<0799:WVOMRF>2.3.CO;2; Kennedy MJ, 2001, GEOLOGY, V29, P1135, DOI 10.1130/0091-7613(2001)029<1135:CICONG>2.0.CO;2; Kennedy MJ, 1996, J SEDIMENT RES, V66, P1050, DOI 10.2110/jsr.66.1050; Kennedy MJ, 2001, GEOLOGY, V29, P443, DOI 10.1130/0091-7613(2001)029<0443:APCCAI>2.0.CO;2; Kvenvolden KA, 1998, GEOL SOC SPEC PUBL, V137, P9, DOI 10.1144/GSL.SP.1998.137.01.02; Peckmann J, 2002, SEDIMENTOLOGY, V49, P855, DOI 10.1046/j.1365-3091.2002.00474.x; Sohl LE, 1999, GEOL SOC AM BULL, V111, P1120, DOI 10.1130/0016-7606(1999)111<1120:PPRIMC>2.3.CO;2; Stakes DS, 1999, MAR GEOL, V159, P93, DOI 10.1016/S0025-3227(98)00200-X; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318	26	290	370	6	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					822	826		10.1038/nature02201	http://dx.doi.org/10.1038/nature02201			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685234	Green Published			2022-12-28	WOS:000187342000053
J	Burton, DR; Desrosiers, RC; Doms, RW; Feinberg, MB; Gallo, RC; Hahn, B; Hoxie, JA; Hunter, E; Korber, B; Landay, A; Lederman, MM; Lieberman, J; McCune, JM; Moore, JP; Nathanson, N; Picker, L; Richman, D; Rinaldo, C; Stevenson, M; Watkins, DI; Wolinsky, SM; Zack, JA				Burton, DR; Desrosiers, RC; Doms, RW; Feinberg, MB; Gallo, RC; Hahn, B; Hoxie, JA; Hunter, E; Korber, B; Landay, A; Lederman, MM; Lieberman, J; McCune, JM; Moore, JP; Nathanson, N; Picker, L; Richman, D; Rinaldo, C; Stevenson, M; Watkins, DI; Wolinsky, SM; Zack, JA			Public health - A sound rationale needed for phase IIIHIV-1 vaccine trials	SCIENCE			English	Editorial Material							RECOMBINANT GP120; RESPONSES; TYPE-1; ADULTS		Scripps Res Inst, La Jolla, CA 92037 USA; Harvard Med Sch, Boston, MA USA; Univ Penn, Philadelphia, PA 19104 USA; Emory Univ, Atlanta, GA 30322 USA; Inst Human Virol, Baltimore, MD USA; Univ Alabama, Birmingham, AL USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Rush Med Coll, Chicago, IL 60612 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Gladstone Inst Virol & Immunol, San Francisco, CA USA; Cornell Univ, Weill Med Coll, New York, NY USA; Oregon Hlth & Sci Univ, Portland, OR USA; Univ Calif San Diego, San Diego, CA 92103 USA; San Diego Vet Affairs Healthcare Syst, San Diego, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Univ Wisconsin, Madison, WI USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Calif Los Angeles, Los Angeles, CA USA	Scripps Research Institute; Harvard University; Harvard Medical School; University of Pennsylvania; Emory University; University System of Maryland; University of Maryland Baltimore; University of Alabama System; University of Alabama Birmingham; The Santa Fe Institute; Rush University; Case Western Reserve University; University of California System; University of California San Francisco; The J David Gladstone Institutes; Cornell University; Oregon Health & Science University; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester; University of Wisconsin System; University of Wisconsin Madison; Northwestern University; University of California System; University of California Los Angeles	Burton, DR (corresponding author), Scripps Res Inst, La Jolla, CA 92037 USA.		Wolinsky, Steven/B-2893-2012; Lieberman, Judy/A-2717-2015	Korber, Bette/0000-0002-2026-5757; Hahn, Beatrice/0000-0002-9400-9887; Wolinsky, Steven/0000-0002-9625-6697				Clements-Mann ML, 1998, J INFECT DIS, V177, P1230, DOI 10.1086/515288; Cohen J, 2003, SCIENCE, V302, P1309; Cohen J, 2003, SCIENCE, V299, P1290, DOI 10.1126/science.299.5611.1290; Cohen J, 2002, SCIENCE, V295, P1616, DOI 10.1126/science.295.5560.1616; Cohen Jon, 2001, SHOTS DARK WAYWARD S; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Gorse GJ, 2001, VACCINE, V19, P1806, DOI 10.1016/S0264-410X(00)00378-9; Ratto-Kim S, 2003, JAIDS-J ACQ IMM DEF, V32, P9, DOI 10.1097/00126334-200301010-00003	8	101	103	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					316	316		10.1126/science.1094620	http://dx.doi.org/10.1126/science.1094620			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726576				2022-12-28	WOS:000188111800024
J	Zhang, ZW; Gildersleeve, J; Yang, YY; Xu, R; Loo, JA; Uryu, S; Wong, CH; Schultz, PG				Zhang, ZW; Gildersleeve, J; Yang, YY; Xu, R; Loo, JA; Uryu, S; Wong, CH; Schultz, PG			A new strategy for the synthesis of glycoproteins	SCIENCE			English	Article							ESCHERICHIA-COLI; GENETIC-CODE; NUCLEOCYTOPLASMIC PROTEINS; AMINO-ACID; GLYCOSYLATION; GLYCOBIOLOGY	Posttranslational modifications of proteins regulate many biological processes, including metabolism, signal transduction, and gene expression. The synthetic challenges associated with generating homogeneous populations of selectively modified proteins, however, have hindered detailed studies of the effects of these modi. cations on protein structure and function. Here, we report an approach to the cotranslational synthesis of selectively glycosylated proteins in which the modified amino acid is genetically encoded. We show that myoglobin containing beta-N-acetylglucosamine ( GlcNAc) serine at a defined position can be expressed in Escherichia coli in good yield and with high fidelity. The beta-GlcNAc moiety can be recognized by a saccharide-binding protein, or subsequently modified with a galactosyltransferase to build more complex carbohydrates. This approach should be generally applicable to other posttranslational modifications such as protein phosphorylation, acetylation, and methylation.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Biochem & Biol Chem, Los Angeles, CA 90095 USA	Scripps Research Institute; University of California System; University of California Los Angeles	Schultz, PG (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Gildersleeve, Jeffrey/N-3392-2014	Gildersleeve, Jeffrey/0000-0002-3744-6423	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM066494] Funding Source: NIH RePORTER; NIAID NIH HHS [5 F32 AI10419] Funding Source: Medline; NIGMS NIH HHS [GM66494] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arslan T, 1997, J AM CHEM SOC, V119, P10877, DOI 10.1021/ja971927a; Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; Chin JW, 2002, P NATL ACAD SCI USA, V99, P11020, DOI 10.1073/pnas.172226299; Chin JW, 2002, J AM CHEM SOC, V124, P9026, DOI 10.1021/ja027007w; Davis BG, 2002, CHEM REV, V102, P579, DOI 10.1021/cr0004310; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; EBISU S, 1978, CARBOHYD RES, V61, P129, DOI 10.1016/S0008-6215(00)84473-0; Hang HC, 2001, ACCOUNTS CHEM RES, V34, P727, DOI 10.1021/ar9901570; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Lamarre-Vincent N, 2003, J AM CHEM SOC, V125, P6612, DOI 10.1021/ja028200t; Santoro SW, 2002, NAT BIOTECHNOL, V20, P1044, DOI 10.1038/nbt742; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; Sears P, 2001, SCIENCE, V291, P2344, DOI 10.1126/science.1058899; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wang L, 2003, P NATL ACAD SCI USA, V100, P56, DOI 10.1073/pnas.0234824100; Wang L, 2002, J AM CHEM SOC, V124, P1836, DOI 10.1021/ja012307j; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Witte K, 1997, J AM CHEM SOC, V119, P2114, DOI 10.1021/ja961846z; Zhang ZW, 2003, BIOCHEMISTRY-US, V42, P6735, DOI 10.1021/bi0300231; Zhang ZW, 2002, ANGEW CHEM INT EDIT, V41, P2840, DOI 10.1002/1521-3773(20020802)41:15<2840::AID-ANIE2840>3.0.CO;2-#	22	128	166	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					371	373		10.1126/science.1089509	http://dx.doi.org/10.1126/science.1089509			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726590				2022-12-28	WOS:000188111800043
J	Dang, DY; Cromwell, D				Dang, DY; Cromwell, D			Intussusception	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Med Ctr, Ann Arbor, MI 48019 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	University of Michigan System; University of Michigan; Johns Hopkins University	Dang, DY (corresponding author), Univ Michigan, Med Ctr, Ann Arbor, MI 48019 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					E2	E2		10.1056/ENEJMicm020033	http://dx.doi.org/10.1056/ENEJMicm020033			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724319				2022-12-28	WOS:000188078400011
J	Hanada, K; Yewdell, JW; Yang, JC				Hanada, K; Yewdell, JW; Yang, JC			Immune recognition of a human renal cancer antigen through post-translational protein splicing	NATURE			English	Article							ENDOPLASMIC-RETICULUM; PROCESSING PATHWAY; CONCANAVALIN-A; LIGATION; CYTOSOL	Cytotoxic T lymphocytes (CTLs) detect and destroy cells displaying class I molecules of the major histocompatibility complex (MHC) that present oligopeptides derived from aberrant self or foreign proteins. Most class I peptide ligands are created from proteins that are degraded by proteasomes and transported, by the transporter associated with antigen processing, from the cytosol into the endoplasmic reticulum, where peptides bind MHC class I molecules and are conveyed to the cell surface(1). C2 CTLs, cloned from human CTLs infiltrating a renal cell carcinoma, kill cancer cells overexpressing fibroblast growth factor-5 (FGF-5)(2). Here we show that C2 cells recognize human leukocyte antigen-A3 MHC class I molecules presenting a nine-residue FGF-5 peptide generated by protein splicing. This process, previously described strictly in plants(3) and unicellular organisms(4), entails post-translational excision of a polypeptide segment followed by ligation of the newly liberated carboxyterminal and amino-terminal residues. The occurrence of protein splicing in vertebrates has important implications for the complexity of the vertebrate proteome and for the immune recognition of self and foreign peptides.	NCI, Surg Branch, NIH, Bethesda, MD 20892 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hanada, K (corresponding author), NCI, Surg Branch, NIH, 9000 Rockville Pike,Bldg 10,Room 2B42, Bethesda, MD 20892 USA.	khanada@nih.gov; jamesyang@mail.nih.gov	Hanada, Ken-ichi/A-4642-2008; Hanada, Kenichi/L-2481-2013; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Hanada, Kenichi/0000-0003-2959-1257; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC010555] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC006660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000653, ZIAAI000653] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Hanada K, 2001, CANCER RES, V61, P5511; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; MIN W, 1994, NAT STRUCT BIOL, V1, P502, DOI 10.1038/nsb0894-502; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250	13	238	252	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					252	256		10.1038/nature02240	http://dx.doi.org/10.1038/nature02240			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724640				2022-12-28	WOS:000188068100045
J	Harris, H				Harris, H			Tumour suppression: Putting on the brakes	NATURE			English	Editorial Material									Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Harris, H (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.							CAVENEE W, 1989, RECESSIVE ONCOGENES; Harris H, 2003, DNA CELL BIOL, V22, P225, DOI 10.1089/104454903321908601; HARRIS H, 1985, J CELL SCI, V79, P83; HARRIS H, 1995, CELLS BODY, P211; Mechler B. M., 1994, LEGACY CELL FUSION, P183	5	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					201	201		10.1038/427201a	http://dx.doi.org/10.1038/427201a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724616				2022-12-28	WOS:000188068100023
J	Flasar, FM; Kunde, VG; Achterberg, RK; Conrath, BJ; Simon-Miller, AA; Nixon, CA; Gierasch, PJ; Romani, PN; Bezard, B; Irwin, P; Bjoraker, GL; Brasunas, JC; Jennings, DE; Pearl, JC; Smith, MD; Orton, GS; Spilker, LJ; Carlson, R; Calcutt, SB; Read, PL; Taylor, FW; Parrish, P; Barucci, A; Courtin, R; Coustenis, A; Gautier, D; Lellouch, E; Marten, A; Prange, R; Biraud, Y; Fouchet, T; Ferrari, C; Owen, TC; Abbas, MM; Samuelson, RE; Raulin, F; Ade, P; Cesarsky, CJ; Grossman, KU; Coradini, A				Flasar, FM; Kunde, VG; Achterberg, RK; Conrath, BJ; Simon-Miller, AA; Nixon, CA; Gierasch, PJ; Romani, PN; Bezard, B; Irwin, P; Bjoraker, GL; Brasunas, JC; Jennings, DE; Pearl, JC; Smith, MD; Orton, GS; Spilker, LJ; Carlson, R; Calcutt, SB; Read, PL; Taylor, FW; Parrish, P; Barucci, A; Courtin, R; Coustenis, A; Gautier, D; Lellouch, E; Marten, A; Prange, R; Biraud, Y; Fouchet, T; Ferrari, C; Owen, TC; Abbas, MM; Samuelson, RE; Raulin, F; Ade, P; Cesarsky, CJ; Grossman, KU; Coradini, A			An intense stratospheric jet on Jupiter	NATURE			English	Article							UPPER TROPOSPHERE; SPATIAL-ORGANIZATION; TIME-DEPENDENCE; THERMAL WAVES; OSCILLATION; SATELLITES; TEMPERATURES; PLANETS	The Earth's equatorial stratosphere shows oscillations in which the east - west winds reverse direction and the temperatures change cyclically with a period of about two years(1,2). This phenomenon, called the quasi-biennial oscillation, also affects the dynamics of the mid- and high-latitude stratosphere and weather in the lower atmosphere(2). Ground-based observations have suggested(3-5) that similar temperature oscillations (with a 4-5-yr cycle) occur on Jupiter, but these data suffer from poor vertical resolution and Jupiter's stratospheric wind velocities have not yet been determined. Here we report maps of temperatures and winds with high spatial resolution, obtained from spacecraft measurements of infrared spectra of Jupiter's stratosphere. We find an intense, high-altitude equatorial jet with a speed of similar to140 m s(-1), whose spatial structure resembles that of a quasi-quadrennial oscillation. Wave activity in the stratosphere also appears analogous to that occurring on Earth. A strong interaction between Jupiter and its plasma environment produces hot spots in its upper atmosphere and stratosphere near its poles(6-9), and the temperature maps define the penetration of the hot spots into the stratosphere.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA; Sci Syst & Applicat Inc, Lanham, MD 20706 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Observ Paris, LESIA, CNRS, FRE 2461, F-91925 Meudon, France; Univ Oxford, Clarendon Lab, Oxford OX1 3PU, England; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; CEA Saclay, Serv Astrophys, F-91191 Gif Sur Yvette, France; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; NASA, George C Marshall Space Flight Ctr, Huntsville, AL 35812 USA; Univ Paris 7 & 12, LISA, CNRS, UMR 7583, F-94010 Creteil, France; Univ Cardiff, Dept Phys & Astron, Cardiff CF24 3YB, S Glam, Wales; European So Observ, D-85748 Garching, Germany; Gesamthsch Wuppertal, Dept Phys, D-5600 Wuppertal 1, Germany; CNR, Inst Astrofis Spaziale, Area Recerca Tor Vergata, I-00133 Rome, Italy	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University System of Maryland; University of Maryland College Park; Science Systems and Applications Inc; Cornell University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Universite Paris Cite; University of Oxford; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Cardiff University; European Southern Observatory; University of Wuppertal; Consiglio Nazionale delle Ricerche (CNR)	Flasar, FM (corresponding author), NASA, Goddard Space Flight Ctr, Code 693, Greenbelt, MD 20771 USA.	f.m.flasar@nasa.gov	Flasar, F Michael/C-8509-2012; Simon, Amy/C-8020-2012; brasunas, john/I-2798-2013; Bjoraker, Gordon L/D-5032-2012; Jennings, Donald/D-7978-2012; Nixon, Conor A/A-8531-2009; Elbaz, David/AAB-4141-2020; Fouchet, Thierry/C-6374-2017; Smith, Michael/C-8875-2012; Romani, Paul N/D-2729-2012; Orton, Glenn/AAD-9862-2020; Ferrari, Cécile/P-9735-2016	Simon, Amy/0000-0003-4641-6186; Nixon, Conor A/0000-0001-9540-9121; Elbaz, David/0000-0002-7631-647X; Fouchet, Thierry/0000-0001-9040-8285; Ferrari, Cécile/0000-0001-5962-7439; Taylor, Fred/0000-0002-0675-9769; Bezard, Bruno/0000-0002-5433-5661; Irwin, Patrick Gerard Joseph/0000-0002-6772-384X; Achterberg, Richard/0000-0002-7643-7626; Calcutt, Simon/0000-0002-0102-3170; Ade, Peter/0000-0002-5127-0401				Achterberg RK, 1996, ICARUS, V119, P350, DOI 10.1006/icar.1996.0024; Andrews D. G., 1987, MIDDLE ATMOSPHERE DY; Baldwin MP, 2001, REV GEOPHYS, V39, P179, DOI 10.1029/1999RG000073; BEEBE R, 1994, JUPITER; CALDWELL J, 1980, ICARUS, V44, P667, DOI 10.1016/0019-1035(80)90135-9; CALDWELL J, 1988, ICARUS, V74, P331, DOI 10.1016/0019-1035(88)90045-0; Deming D, 1997, ICARUS, V126, P301, DOI 10.1006/icar.1996.5658; DEMING D, 1989, ASTROPHYS J, V343, P456, DOI 10.1086/167719; DROSSART P, 1993, J GEOPHYS RES-PLANET, V98, P18803, DOI 10.1029/93JE01801; Friedson AJ, 1999, ICARUS, V137, P34, DOI 10.1006/icar.1998.6038; Gladstone GR, 2002, NATURE, V415, P1000, DOI 10.1038/4151000a; Holton J. R., 1992, INTRO DYNAMIC METEOR; Kunde V, 1996, P SOC PHOTO-OPT INS, V2803, P162, DOI 10.1117/12.253416; Li X, 2000, PLANET SPACE SCI, V48, P637, DOI 10.1016/S0032-0633(00)00033-7; LIMAYE SS, 1986, ICARUS, V65, P335, DOI 10.1016/0019-1035(86)90142-9; MAGALHAES JA, 1990, ICARUS, V88, P39, DOI 10.1016/0019-1035(90)90176-A; ORTON GS, 1991, SCIENCE, V252, P537, DOI 10.1126/science.252.5005.537; ORTON GS, 1994, SCIENCE, V265, P625, DOI 10.1126/science.265.5172.625; Pallier L, 2001, PLANET SPACE SCI, V49, P1159, DOI 10.1016/S0032-0633(01)00023-X; Porco CC, 2003, SCIENCE, V299, P1541, DOI 10.1126/science.1079462; RIDDLE AC, 1976, ICARUS, V27, P457, DOI 10.1016/0019-1035(76)90025-7; Seidelmann PK, 2002, CELEST MECH DYN ASTR, V82, P83, DOI 10.1023/A:1013939327465; Simon AA, 1999, ICARUS, V141, P29, DOI 10.1006/icar.1999.6163; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; Waite JH, 2001, NATURE, V410, P787, DOI 10.1038/35071018	28	83	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 8	2004	427	6970					132	135		10.1038/nature02142	http://dx.doi.org/10.1038/nature02142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712270				2022-12-28	WOS:000187863900029
J	Hornbach, MJ; Saffer, DM; Holbrook, WS				Hornbach, MJ; Saffer, DM; Holbrook, WS			Critically pressured free-gas reservoirs below gas-hydrate provinces	NATURE			English	Article							BOTTOM SIMULATING REFLECTOR; MARINE-SEDIMENTS; METHANE HYDRATE; CONTINENTAL-MARGIN; VELOCITY STRUCTURE; BLAKE RIDGE; GULF; MIGRATION; BENEATH; STRESS	Palaeoceanographic data have been used to suggest that methane hydrates play a significant role in global climate change. The mechanism by which methane is released during periods of global warming is, however, poorly understood(1). In particular, the size and role of the free-gas zone below gas-hydrate provinces remain relatively unconstrained, largely because the base of the free-gas zone is not a phase boundary and has thus defied systematic description. Here we evaluate the possibility that the maximum thickness of an interconnected free-gas zone is mechanically regulated by valving caused by fault slip in overlying sediments(2). Our results suggest that a critical gas column exists below most hydrate provinces in basin settings, implying that these provinces are poised for mechanical failure and are therefore highly sensitive to changes in ambient conditions(3). We estimate that the global free-gas reservoir may contain from one-sixth to two-thirds of the total methane trapped in hydrate(4). If gas accumulations are critically thick along passive continental slopes, we calculate that a 5 degreesC temperature increase at the sea floor could result in a release of similar to2,000 Gt of methane from the free-gas zone, offering a mechanism for rapid methane release during global warming events.	Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA	University of Wyoming	Hornbach, MJ (corresponding author), Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA.	mhornbac@uwyo.edu	Hornbach, Matthew/C-1071-2008; Holbrook, Steven/G-9800-2011	Holbrook, Steven/0000-0003-0065-8841				ANDREASSEN K, 1995, J GEOPHYS RES-SOL EA, V100, P12659, DOI 10.1029/95JB00961; Andreassen K., 1990, 1 BREAK, V8, P237; BANGS NLB, 1993, GEOLOGY, V21, P905, DOI 10.1130/0091-7613(1993)021<0905:FGATBO>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Dickens GR, 2001, ORG GEOCHEM, V32, P1179, DOI 10.1016/S0146-6380(01)00086-9; ENGELDER T, 1994, GEOLOGY, V22, P949, DOI 10.1130/0091-7613(1994)022<0949:IOPBOT>2.3.CO;2; Finkbeiner T, 2001, AAPG BULL, V85, P1007; Flemings PB, 2003, GEOLOGY, V31, P1057, DOI 10.1130/G19863.1; Gorman AR, 2002, GEOLOGY, V30, P327, DOI 10.1130/0091-7613(2002)030<0327:MOMGTT>2.0.CO;2; Grevemeyer I, 2000, GEOPHYS J INT, V140, P295, DOI 10.1046/j.1365-246x.2000.00009.x; Guerin G, 1999, J GEOPHYS RES-SOL EA, V104, P17781, DOI 10.1029/1999JB900127; HAMILTON EL, 1979, J ACOUST SOC AM, V66, P1093, DOI 10.1121/1.383344; Helgerud MB, 1999, GEOPHYS RES LETT, V26, P2021, DOI 10.1029/1999GL900421; Holbrook WS, 1996, SCIENCE, V273, P1840, DOI 10.1126/science.273.5283.1840; Hovland M, 1997, MAR PETROL GEOL, V14, P245, DOI 10.1016/S0264-8172(97)00012-3; Hyndman R.D., 2001, NATURAL GAS HYDRATES, V124, P273; Katz ME, 1999, SCIENCE, V286, P1531, DOI 10.1126/science.286.5444.1531; KVENVOLDEN KA, 1993, REV GEOPHYS, V31, P173, DOI 10.1029/93RG00268; MATTAR L, 1975, J CAN PETROL TECHNOL, V14, P77; MEINERT J, 2000, GAS HYDRATES CHALLEN, P200; MILKOV AV, IN PRESS EARTH SCI R; MILLER AT, 1996, P ODP INIT REP LEG, V164, P179; MINSHULL T, 1989, J GEOPHYS RES-SOLID, V94, P7387, DOI 10.1029/JB094iB06p07387; MINSHULL TA, 1994, J GEOPHYS RES-SOL EA, V99, P4715, DOI 10.1029/93JB03282; Paull CK, 1996, GEOLOGY, V24, P143, DOI 10.1130/0091-7613(1996)024<0143:ICMSFD>2.3.CO;2; Pecher IA, 1996, EARTH PLANET SC LETT, V139, P459, DOI 10.1016/0012-821X(95)00242-5; Sain K, 2000, MAR GEOL, V164, P3, DOI 10.1016/S0025-3227(99)00122-X; SCHOLL DW, 1993, US GEOL SURV PROF PA, V1570, P331; Tinivella U, 1998, GEOL SOC SPEC PUBL, V137, P141, DOI 10.1144/GSL.SP.1998.137.01.11; Tryon MD, 2002, EARTH PLANET SC LETT, V201, P541, DOI 10.1016/S0012-821X(02)00732-X; WHITE RS, 1979, EARTH PLANET SC LETT, V42, P114, DOI 10.1016/0012-821X(79)90196-1; WHITE RS, 1977, EARTH PLANET SC LETT, V37, P29, DOI 10.1016/0012-821X(77)90143-1	32	124	127	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					142	144		10.1038/nature02172	http://dx.doi.org/10.1038/nature02172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712273				2022-12-28	WOS:000187863900032
J	Frank, RN				Frank, RN			Diabetic retinopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; RETINAL OXYGENATION RESPONSE; PIGMENT-EPITHELIUM; IRIS NEOVASCULARIZATION; EXPRESSION; ISCHEMIA; VEGF; INHIBITION; AMINOGUANIDINE		Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA	Wayne State University	Frank, RN (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, 4717 St Antoine Blvd, Detroit, MI 48201 USA.	mfrank@med.wayne.edu	Rao, Rajesh C./N-1107-2017; Cerviño, Alejandro/L-5853-2014; Aljawadi, Mohammad H/R-7589-2017	Rao, Rajesh C./0000-0002-5776-8366; Cerviño, Alejandro/0000-0001-8014-3279; Aljawadi, Mohammad H/0000-0002-5114-1343				Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363; AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Aiello LP, 1999, INVEST OPHTH VIS SCI, V40, pS192; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36; [Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1997, LANCET, V350, P155; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1988, Ophthalmology, V95, P1321; [Anonymous], 1976, Am J Ophthalmol, V81, P383; Becerra SP, 2001, INVEST OPHTH VIS SCI, V42, pS772; Beck RW, 2001, OPHTHALMOLOGY, V108, P2266; Berkowitz BA, 1996, INVEST OPHTH VIS SCI, V37, P2089; Berkowitz BA, 2001, MAGN RESON MED, V46, P412, DOI 10.1002/mrm.1206; Berkowitz BA, 1999, INVEST OPHTH VIS SCI, V40, P2100; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; BROWNLEE M, 1981, ANNU REV BIOCHEM, V50, P385, DOI 10.1146/annurev.bi.50.070181.002125; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098; Chantelau E, 1997, BMJ-BRIT MED J, V315, P1105; CUSICK M, 2002, INVEST OPHTHALMOL VI, V43; Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; *DIAB CONTR COMPL, 1998, ARCH OPHTHALMOL-CHIC, V116, P1469; Diabet Contr Complicat Trial Res Grp, 1998, ARCH OPHTHALMOL-CHIC, V116, P874; Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829; Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589; Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907; FRANK RN, 1975, ARCH OPHTHALMOL-CHIC, V93, P591; Freedman BI, 1999, CONTROL CLIN TRIALS, V20, P493, DOI 10.1016/S0197-2456(99)00024-0; Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X; Grant MB, 2000, DIABETES CARE, V23, P504, DOI 10.2337/diacare.23.4.504; GRUNWALD JE, 1986, ARCH OPHTHALMOL-CHIC, V104, P991; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; HENKIND P, 1978, AM J OPHTHALMOL, V85, P287, DOI 10.1016/S0002-9394(14)77719-0; HENNEKENS, 1990, ARCH OPHTHALMOL-CHIC, V108, P1234; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; KENNY SJ, 1995, DIABETES AM; Kern TS, 2001, DIABETES, V50, P1636, DOI 10.2337/diabetes.50.7.1636; Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115; Kim SH, 2000, J NUCL MED, V41, p93P; King GL, 2000, NEW ENGL J MED, V342, P349, DOI 10.1056/NEJM200002033420511; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1995, OPHTHALMOLOGY, V102, P7; Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; KUNISAKI M, 1995, AM J PHYSIOL-ENDOC M, V269, pE239, DOI 10.1152/ajpendo.1995.269.2.E239; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P3281; LUNDBAEK K, 1968, PUBLIC HLTH SERVICE, V1890; Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011; Machemer R, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P813; MANCINI MA, 1986, INVEST OPHTH VIS SCI, V27, P336; Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135; Milton R, 2003, DIABETES, V52, pA127; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168; PATZ A, 1982, AM J OPHTHALMOL, V94, P715, DOI 10.1016/0002-9394(82)90297-5; POULSEN JE, 1953, DIABETES, V2, P7, DOI 10.2337/diab.2.1.7; Rasmussen H, 2001, Hum Gene Ther, V12, P2029; Rivellese M, 2000, OPHTHALMIC SURG LAS, V31, P192; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; Rosen Lee S, 2002, Cancer Control, V9, P36; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shannon H, 2000, NEW ENGL J MED, V342, P381; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Sundkvist Goran, 1992, Journal of Diabetes and its Complications, V6, P123, DOI 10.1016/1056-8727(92)90023-E; The Diabetic Retinopathy Study Research Group, 1979, ARCH OPHTHALMOL-CHIC, V97, P654; The Diabetic Retinopathy Vitrectomy Study Research Group, 1985, ARCH OPHTHALMOL-CHIC, V103, P1644; Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010; Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Van Wyk J J, 1974, Recent Prog Horm Res, V30, P259; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; 1985, ARCH OPHTHALMOL-CHIC, V103, P1796	97	830	880	4	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					48	58		10.1056/NEJMra021678	http://dx.doi.org/10.1056/NEJMra021678			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702427				2022-12-28	WOS:000187659900009
J	West, MJ; Cote, P; Marzke, RO; Jordan, A				West, MJ; Cote, P; Marzke, RO; Jordan, A			Reconstructing galaxy histories from globular clusters	NATURE			English	Review							SPACE-TELESCOPE OBSERVATIONS; STAR-CLUSTERS; KECK SPECTROSCOPY; LUMINOSITY FUNCTION; DWARF GALAXIES; SYSTEMS; HALO; AGE; EVOLUTION; YOUNG	Nearly a century after the true nature of galaxies as distant 'island universes' was established, their origin and evolution remain great unsolved problems of modem astrophysics. One of the most promising ways to investigate galaxy formation is to study the ubiquitous globular star clusters that surround most galaxies. Globular clusters are compact groups of up to a few million stars. They generally formed early in the history of the Universe, but have survived the interactions and mergers that after substantially their parent galaxies. Recent advances in our understanding of the globular cluster systems of the Milky Way and other galaxies point to a complex picture of galaxy genesis driven by cannibalism, collisions, bursts of star formation and other tumultuous events.	Univ Hawaii, Dept Phys & Astron, Hilo, HI 96720 USA; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; San Francisco State Univ, Dept Phys & Astron, San Francisco, CA 94132 USA	University of Hawaii System; University Hawaii Hilo; Rutgers State University New Brunswick; California State University System; San Francisco State University	West, MJ (corresponding author), Univ Hawaii, Dept Phys & Astron, 200 W Kawili St, Hilo, HI 96720 USA.	westm@hawaii.edu						Abel T, 1998, ASTROPHYS J, V508, P518, DOI 10.1086/306410; Abraham RG, 2001, SCIENCE, V293, P1273, DOI 10.1126/science.1060855; ASHMAN KM, 1992, ASTROPHYS J, V384, P50, DOI 10.1086/170850; ASHMAN KM, 1993, ASTRON J, V106, P2281, DOI 10.1086/116799; Barger AJ, 1998, NATURE, V394, P248, DOI 10.1038/28338; Barmby P, 2000, ASTRON J, V119, P727, DOI 10.1086/301213; BASSINO LP, 1994, ASTROPHYS J, V431, P634, DOI 10.1086/174514; BAUM WA, 1955, PUBL ASTRON SOC PAC, V67, P328, DOI 10.1086/126829; Beasley MA, 2002, MON NOT R ASTRON SOC, V333, P383, DOI 10.1046/j.1365-8711.2002.05402.x; Beasley MA, 2003, MON NOT R ASTRON SOC, V340, P341, DOI 10.1046/j.1365-8711.2003.06304.x; Bekki K, 2002, ASTROPHYS J, V566, P245, DOI 10.1086/337984; Blain AW, 1999, MON NOT R ASTRON SOC, V302, P632, DOI 10.1046/j.1365-8711.1999.02178.x; Brodie JP, 2002, ASTRON J, V124, P1410, DOI 10.1086/341824; BRODIE JP, 1991, ASTROPHYS J, V379, P157, DOI 10.1086/170492; Bromm V, 2002, ASTROPHYS J, V566, pL1, DOI 10.1086/339440; Cohen JG, 2003, ASTROPHYS J, V592, P866, DOI 10.1086/375865; Cohen JG, 1998, ASTROPHYS J, V496, P808, DOI 10.1086/305429; Cote P, 1999, ASTRON J, V118, P406, DOI 10.1086/300930; Cote P, 2003, ASTROPHYS J, V591, P850, DOI 10.1086/375488; Cote P, 2001, ASTROPHYS J, V559, P828, DOI 10.1086/322347; Cote P, 1998, ASTROPHYS J, V501, P554, DOI 10.1086/305838; Cote P, 2002, ASTROPHYS J, V567, P853, DOI 10.1086/338670; Cote P, 2000, ASTROPHYS J, V533, P869, DOI 10.1086/308709; COUTURE J, 1990, ASTROPHYS J SUPPL S, V73, P671, DOI 10.1086/191484; Cowie LL, 1996, ASTRON J, V112, P839, DOI 10.1086/118058; Drinkwater MJ, 2003, NATURE, V423, P519, DOI 10.1038/nature01666; EGGEN OJ, 1962, ASTROPHYS J, V136, P748, DOI 10.1086/147433; Ferguson AMN, 2002, ASTRON J, V124, P1452, DOI 10.1086/342019; Forbes D. A., 2001, APJ, V563, P143; Forbes DA, 1997, ASTRON J, V113, P1652, DOI 10.1086/118382; Forbes DA, 2001, MON NOT R ASTRON SOC, V322, P257, DOI 10.1046/j.1365-8711.2001.04052.x; FORTE JC, 1982, ASTRON J, V87, P1465, DOI 10.1086/113236; Freeman K, 2002, ANNU REV ASTRON ASTR, V40, P487, DOI 10.1146/annurev.astro.40.060401.093840; Gebhardt K, 1999, ASTRON J, V118, P1526, DOI 10.1086/301059; Gnedin OY, 2002, ASTROPHYS J, V568, pL23, DOI 10.1086/340319; Goudfrooij P, 2001, MON NOT R ASTRON SOC, V322, P643, DOI 10.1046/j.1365-8711.2001.04154.x; Harris WE, 1998, ASTRON J, V115, P1801, DOI 10.1086/300322; Harris WE, 2001, ASTRON J, V122, P3065, DOI 10.1086/323928; HARRIS WE, 1991, ANNU REV ASTRON ASTR, V29, P543, DOI 10.1146/annurev.aa.29.090191.002551; Helmi A, 1999, NATURE, V402, P53, DOI 10.1038/46980; HOLTZMAN JA, 1992, ASTRON J, V103, P691, DOI 10.1086/116094; IBATA RA, 1994, NATURE, V370, P194, DOI 10.1038/370194a0; Ibata RA, 2003, MON NOT R ASTRON SOC, V340, pL21, DOI 10.1046/j.1365-8711.2003.06545.x; Jiang LH, 2003, ASTRON J, V125, P727, DOI 10.1086/345885; Jordan A, 2003, ASTRON J, V125, P1642, DOI 10.1086/368393; Jordan AS, 2002, ASTROPHYS J, V576, pL113, DOI 10.1086/343759; KINMAN TD, 1959, MON NOT R ASTRON SOC, V119, P538, DOI 10.1093/mnras/119.5.538; Kissler-Patig M, 1998, ASTRON J, V115, P105, DOI 10.1086/300186; Klypin A, 1999, ASTROPHYS J, V522, P82, DOI 10.1086/307643; KRAVTSOV AV, IN PRESS ASTROPHYS J; Kundu A, 2001, ASTRON J, V121, P2950, DOI 10.1086/321073; Larsen SS, 2001, ASTRON J, V121, P2974, DOI 10.1086/321081; Larsen SS, 2003, ASTROPHYS J, V585, P767, DOI 10.1086/346219; Larsen SS, 2002, ASTRON J, V123, P1488, DOI 10.1086/338900; Lilly SJ, 1996, ASTROPHYS J, V460, pL1, DOI 10.1086/309975; LUTZ D, 1991, ASTRON ASTROPHYS, V245, P31; Ma J, 2002, ASTRON ASTROPHYS, V385, P404, DOI 10.1051/0004-6361:20020141; Madau P, 1996, MON NOT R ASTRON SOC, V283, P1388, DOI 10.1093/mnras/283.4.1388; MAJEWSKI SR, 1994, ASTROPHYS J, V427, pL37, DOI 10.1086/187359; MARZKE RO, 1994, ASTROPHYS J, V428, P43, DOI 10.1086/174218; Mieske S, 2002, ASTRON ASTROPHYS, V383, P823, DOI 10.1051/0004-6361:20011833; MINNITI D, 1995, ASTRON J, V109, P1663, DOI 10.1086/117393; Moore B, 1999, ASTROPHYS J, V524, pL19, DOI 10.1086/312287; Morrison HL, 2003, ASTROPHYS J, V596, pL183, DOI 10.1086/379625; MUZZIO JC, 1984, ASTROPHYS J, V285, P7, DOI 10.1086/162471; Newberg HJ, 2002, ASTROPHYS J, V569, P245, DOI 10.1086/338983; Peng EW, 2002, ASTRON J, V124, P3144, DOI 10.1086/344308; Perrett KM, 2003, ASTROPHYS J, V589, P790, DOI 10.1086/374734; Puzia TH, 1999, ASTRON J, V118, P2734, DOI 10.1086/301141; RACINE R, 2000, J R ASTRON SOC CAN, V62, P367; SANTIAGO BX, 1993, MON NOT R ASTRON SOC, V261, P753, DOI 10.1093/mnras/261.4.753; SCHECHTER P, 1976, ASTROPHYS J, V203, P297, DOI 10.1086/154079; Schroder LL, 2002, ASTRON J, V123, P2473, DOI 10.1086/322994; Schulz J, 2002, ASTRON ASTROPHYS, V392, P1, DOI 10.1051/0004-6361:20020657; Schweizer F, 1996, ASTRON J, V112, P1839, DOI 10.1086/118146; SCHWEIZER F, 1987, NEARLY NORMAL GALAXI, P18; SEARLE L, 1978, ASTROPHYS J, V225, P357, DOI 10.1086/156499; STROM SE, 1981, ASTROPHYS J, V245, P416, DOI 10.1086/158820; Tsuchiya T, 2003, ASTROPHYS J, V589, pL29, DOI 10.1086/375805; van den Bergh S, 2001, ASTROPHYS J, V559, pL113, DOI 10.1086/323754; VANDENBERGH S, 1979, ASTROPHYS J, V230, P95, DOI 10.1086/157064; Weil ML, 2001, ASTROPHYS J, V556, P164, DOI 10.1086/321538; WEST MJ, 1995, ASTROPHYS J, V453, pL77, DOI 10.1086/309748; WHITMORE BC, 1993, ASTRON J, V106, P1354, DOI 10.1086/116732; WHITMORE BC, 1995, ASTRON J, V109, P960, DOI 10.1086/117334; ZEPF SE, 1993, MON NOT R ASTRON SOC, V264, P611, DOI 10.1093/mnras/264.3.611; Zepf SE, 2000, ASTRON J, V120, P2928, DOI 10.1086/316850; Zinnecker H., 1988, HARLOW SHAPLEY S GLO, P603	92	93	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					31	35		10.1038/nature02235	http://dx.doi.org/10.1038/nature02235			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702077	Green Submitted			2022-12-28	WOS:000187710000025
J	Pang, XH; Zhu, ZH; Xu, FJ; Guo, JY; Gong, XH; Liu, DL; Liu, ZJ; Chin, DP; Feikin, DR				Pang, XH; Zhu, ZH; Xu, FJ; Guo, JY; Gong, XH; Liu, DL; Liu, ZJ; Chin, DP; Feikin, DR			Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNDROME SARS	Context Beijing, China, experienced the world's largest outbreak of severe acute respiratory syndrome (SARS) beginning in March 2003, with the outbreak resolving rapidly, within 6 weeks of its peak in late April. Little is known about the control measures implemented during this outbreak. Objective To describe and evaluate the measures undertaken to control the SARS outbreak. Design, Setting, and Participants Data were reviewed from standardized surveillance forms from SARS cases (2521 probable cases) and their close contacts observed in Beijing between March 5, 2003, and May 29, 2003. Procedures implemented by health authorities were investigated through review of official documents and discussions with public health officials.' Main Outcome Measures Timeline of major control measures; number of cases and quarantined close contacts and attack rates, with changes in infection control measures, management, and triage of suspected cases; and time lag between illness onset and hospitalization with information dissemination. Results Healthcare worker training in use of personal protective equipment and management of patients with SARS and establishing fever clinics and designated SARS wards in hospitals predated the steepest decline in cases. During the outbreak, 30178 persons were quarantined. Among 2195 quarantined close contacts in 5 districts, the attack rate was 6.3 % (95% confidence interval [CI], 5.3 % -7.3 %), with a range of 15.4% (95% Cl, 11.5%-19.2%) among spouses to 0.36% (95% CI, 0%-0.77%) among work and school contacts. The attack rate among quarantined household members increased with age from 5.0% (95 % Cl, 0% -10.5%) in children younger than 10 years to 27.6% (95% Cl, 18.2%-37.0%) in adults aged 60 to 69 years. Among almost 14 million people screened for fever at the airport, train stations, and roadside checkpoints, only 12 were found to have probable SARS. The national and municipal governments held 13 press conferences about SARS. The time lag between illness onset and hospitalization decreased from a median of 5 to 6 days on or before April 20, 2003, the day the outbreak was announced to the public, to 2 days after April 20 (P<.001). Conclusions The rapid resolution of the SARS outbreak was multifactorial, involving improvements in management and triage in hospitals and communities of patients with suspected SARS and the dissemination of information to health care workers and the public.	CDCP, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Beijing Ctr Dis Prevent & Control, Beijing, Peoples R China; Beijing Municipal Hlth Bur, Beijing, Peoples R China; WHO, China Off, Beijing, Peoples R China	Centers for Disease Control & Prevention - USA; World Health Organization	Feikin, DR (corresponding author), CDCP, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd,Mailstop C23, Atlanta, GA 30333 USA.	drf0@cdc.gov						Ashraf H, 2003, LANCET, V361, P2212, DOI 10.1016/S0140-6736(03)13790-7; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P462; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P680; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P405; Hsu LY, 2003, EMERG INFECT DIS, V9, P713; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; LIANG W, 2003, EMERG INFECT DIS; *MIN HLTH ED COMM, 2002, CHIN HLTH YB 2002, P514; PEIRIS JSM, LANCET; Twu SJ, 2003, EMERG INFECT DIS, V9, P718; *WHO, UPD 87 WHO CHANG LAS; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P181; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P137; World Health Organization, SUMM PROB SARS CAS O; [谢淑云 Xie Shuyun], 2003, [中华流行病学杂志, Chinese Journal of Epidemiology], V24, P449; SARS CASE DISTRIBUTI	17	156	165	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2003	290	24					3215	3221		10.1001/jama.290.24.3215	http://dx.doi.org/10.1001/jama.290.24.3215			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756TR	14693874				2022-12-28	WOS:000187499300025
J	Venkateswarlu, D; Kasper, J; Mathews, R; Reis, C; Iacopino, V; Wise, P				Venkateswarlu, D; Kasper, J; Mathews, R; Reis, C; Iacopino, V; Wise, P		Phys Human Rights Child Rights Grp	Child labour in India: a health and human rights perspective	LANCET			English	Article									Phys Human Rights, Child Rights Grp, Boston, MA 02116 USA; Brigham & Womens Hosp, Dept Med, Div Social Med & Hlth Inequal, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Venkateswarlu, D (corresponding author), Phys Human Rights, Child Rights Grp, 100 Boylston St,Suite 702, Boston, MA 02116 USA.			Reis, Chen/0000-0003-4647-7149					0	5	5	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S32	S33		10.1016/S0140-6736(03)15067-2	http://dx.doi.org/10.1016/S0140-6736(03)15067-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698121				2022-12-28	WOS:000187790200017
J	Helfand, M				Helfand, M			Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; TOTAL HOMOCYSTEINE LEVELS; PLACEBO-CONTROLLED TRIAL; L-THYROXINE TREATMENT; BONE-MINERAL DENSITY; 20-YEAR FOLLOW-UP; SERUM THYROTROPIN; DOUBLE-BLIND; RISK-FACTOR; ATRIAL-FIBRILLATION	Background: Subclinical thyroid dysfunction is a risk factor for developing symptomatic thyroid disease. Advocates of screening argue that early treatment can prevent serious morbidity in individuals who are found to have laboratory evidence of subclinical thyroid dysfunction. Purpose: This article focuses on whether it is useful to order a thyroid function test for patients who have no history of thyroid disease and have, few or no signs or symptoms of thyroid dysfunction. Data Sources: A MEDLINE search, supplemented by searches of EMBASE and the Cochrane Library, reference lists, and a local database of thyroid-related articles. Study Selection: Controlled treatment studies that used thyroid-stimulating hormone (TSH) levels as an inclusion criterion and reported quality of life, symptoms, or lipid level outcomes were selected. Observational studies of the prevalence, progression, and consequences of subclinical thyroid dysfunction were also reviewed. Data Extraction: The quality of each trial was assessed by using preset criteria, and information about setting, patients, interventions, and outcomes was abstracted. Data Synthesis: The prevalence of unsuspected thyroid disease is lowest in men and highest in older women. Evidence regarding the efficacy of treatment in patients found by screening to have subclinical thyroid dysfunction is inconclusive. No trials of treatment of subclinical hyperthyroidism have been done. Several small, randomized trials of treatment of subclinical hypothyroidism have been done, but the results are inconclusive except in patients who have a history of treatment of Graves disease, a subgroup that is not a target of screening in the general population. Data on the adverse effects of broader use Of L-thyroxine are sparse. Conclusion: It is uncertain whether treatment will. improve quality of life in otherwise healthy patients who have abnormal TSH levels and normal free thyroxine levels.	Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97239 USA	Oregon Health & Science University	Helfand, M (corresponding author), Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97239 USA.				PHS HHS [290-97-0018] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Attia J, 1999, ARCH INTERN MED, V159, P658, DOI 10.1001/archinte.159.7.658; Auer J, 2001, AM HEART J, V142, P838, DOI 10.1067/mhj.2001.119370; Bauer DC, 1997, J CLIN ENDOCR METAB, V82, P2931, DOI 10.1210/jc.82.9.2931; Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003-4819-134-7-200104030-00009; Bauer DC, 1998, AM J MED, V104, P546, DOI 10.1016/S0002-9343(98)00116-8; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BILLEWICZ WZ, 1969, Q J MED, V38, P255; Bindels AJGH, 1999, CLIN ENDOCRINOL, V50, P217, DOI 10.1046/j.1365-2265.1999.00638.x; Biondi B, 1996, J CLIN ENDOCR METAB, V81, P4224, DOI 10.1210/jc.81.12.4224; Biondi B, 2002, ANN INTERN MED, V137, P904, DOI 10.7326/0003-4819-137-11-200212030-00011; Biondi B, 1999, J CLIN ENDOCR METAB, V84, P2064, DOI 10.1210/jc.84.6.2064; Biondi B, 2000, J CLIN ENDOCR METAB, V85, P4701, DOI 10.1210/jc.85.12.4701; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Caraccio N, 2002, J CLIN ENDOCR METAB, V87, P1533, DOI 10.1210/jc.87.4.1533; Catargi B, 1999, THYROID, V9, P1163, DOI 10.1089/thy.1999.9.1163; Chu JW, 2001, J CLIN ENDOCR METAB, V86, P4591, DOI 10.1210/jc.86.10.4591; Chuang CC, 1998, GERONTOLOGY, V44, P162, DOI 10.1159/000022002; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Cooper DS, 2001, NEW ENGL J MED, V345, P260, DOI 10.1056/NEJM200107263450406; CROOKS J, 1959, Q J MED, V28, P211; Danese D., 1997, Revue Internationale des Services de Sante des Forces Armees, V70, P32; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; Diekman MJM, 2001, CLIN ENDOCRINOL, V54, P197, DOI 10.1046/j.1365-2265.2001.01170.x; Eden S, 1988, Compr Gerontol A, V2, P40; ELDER J, 1990, ANN CLIN BIOCHEM, V27, P110, DOI 10.1177/000456329002700204; Faber J, 1998, CLIN ENDOCRINOL, V48, P285; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; Fahrenfort JJ, 2000, PSYCHONEUROENDOCRINO, V25, P201, DOI 10.1016/S0306-4530(99)00050-5; FIGGE J, 1994, AM J MED, V96, P229, DOI 10.1016/0002-9343(94)90147-3; FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365-2265.1993.tb02403.x; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Gurlek A, 1999, THYROID, V9, P539, DOI 10.1089/thy.1999.9.539; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HELFAND M, 1990, ANN INTERN MED, V112, P840, DOI 10.7326/0003-4819-112-11-840; Helfand M, 1998, ANN INTERN MED, V129, P144, DOI 10.7326/0003-4819-129-2-199807150-00020; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Jaeschke R, 1996, J GEN INTERN MED, V11, P744, DOI 10.1007/BF02598988; JOHNSTON J, 1993, ANN CLIN BIOCHEM, V30, P256, DOI 10.1177/000456329303000305; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Knudsen N, 1999, CLIN ENDOCRINOL, V51, P361, DOI 10.1046/j.1365-2265.1999.00816.x; Kong WM, 2002, AM J MED, V112, P348, DOI 10.1016/S0002-9343(02)01022-7; Kumeda Y, 2000, J CLIN ENDOCR METAB, V85, P4157, DOI 10.1210/jc.85.11.4157; Kung AWC, 1996, THYROID, V6, P111, DOI 10.1089/thy.1996.6.111; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; Lien EA, 2000, J CLIN ENDOCR METAB, V85, P1049, DOI 10.1210/jc.85.3.1049; Lindeman RD, 2003, THYROID, V13, P595, DOI 10.1089/105072503322238863; Lindeman RD, 1999, J AM GERIATR SOC, V47, P703, DOI 10.1111/j.1532-5415.1999.tb01593.x; Mason RL, 1930, NEW ENGL J MED, V203, P1273, DOI 10.1056/NEJM193012252032601; McDermott MT, 2001, J CLIN ENDOCR METAB, V86, P4585, DOI 10.1210/jc.86.10.4585; Meier C, 2001, J CLIN ENDOCR METAB, V86, P4860, DOI 10.1210/jc.86.10.4860; Michalopoulou G, 1998, EUR J ENDOCRINOL, V138, P141, DOI 10.1530/eje.0.1380141; Morris MS, 2001, ATHEROSCLEROSIS, V155, P195, DOI 10.1016/S0021-9150(00)00537-2; MUDDE AH, 1994, CLIN ENDOCRINOL, V41, P421, DOI 10.1111/j.1365-2265.1994.tb02571.x; MUDDE AH, 1992, CLIN ENDOCRINOL, V37, P35, DOI 10.1111/j.1365-2265.1992.tb02280.x; Nedrebo BG, 1998, METABOLISM, V47, P89, DOI 10.1016/S0026-0495(98)90198-6; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; O'Reilly DS, 2000, BRIT MED J, V320, P1332, DOI 10.1136/bmj.320.7245.1332; Osman F, 2002, J CLIN ENDOCR METAB, V87, P963, DOI 10.1210/jc.87.3.963; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; Pollock MA, 2001, BRIT MED J, V323, P891, DOI 10.1136/bmj.323.7318.891; Rivolta G, 1999, J ENDOCRINOL INVEST, V22, P693, DOI 10.1007/BF03343631; ROSS DS, 1993, AM J MED, V95, P385, DOI 10.1016/0002-9343(93)90307-B; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SAWIN CT, 1991, ARCH INTERN MED, V151, P165, DOI 10.1001/archinte.151.1.165; SCHLOTE B, 1992, EUR ARCH PSY CLIN N, V241, P357, DOI 10.1007/BF02191961; SCHLOTE B, 1992, BIOL PSYCHIAT, V32, P48, DOI 10.1016/0006-3223(92)90141-L; Sgarbi JA, 2003, J CLIN ENDOCR METAB, V88, P1672, DOI 10.1210/jc.2002-021046; Sherman SI, 1996, AM J MED, V101, P192, DOI 10.1016/S0002-9343(96)80076-3; Skinner G. R. B., 2000, Journal of Nutritional and Environmental Medicine (Abingdon), V10, P115, DOI 10.1080/13590840050043530; Stockigt JR, 2002, CLIN CHIM ACTA, V315, P111, DOI 10.1016/S0009-8981(01)00715-X; SUNDBECK G, 1991, ACTA ENDOCRINOL-COP, V125, P475, DOI 10.1530/acta.0.1250475; SUNDBECK G, 1991, ARCH INTERN MED, V151, P549, DOI 10.1001/archinte.151.3.549; Tanis BC, 1996, CLIN ENDOCRINOL, V44, P643, DOI 10.1046/j.1365-2265.1996.739560.x; Toft AD, 2001, NEW ENGL J MED, V345, P512, DOI 10.1056/NEJMcp010145; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Tunbridge WMG, 2000, ENDOCRIN METAB CLIN, V29, P239, DOI 10.1016/S0889-8529(05)70129-8; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VALDEMARSSON S, 1983, ACTA ENDOCRINOL-COP, V104, P50, DOI 10.1530/acta.0.1040050; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, THYROID, V6, P155; Vilchez FG, 1998, REV ESP CARDIOL, V51, P893, DOI 10.1016/S0300-8932(98)74836-5; Wang C, 1997, ENDOCRIN METAB CLIN, V26, P189, DOI 10.1016/S0889-8529(05)70240-1; Weetman AP, 1997, BRIT MED J, V314, P1175, DOI 10.1136/bmj.314.7088.1175	87	231	249	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					128	141		10.7326/0003-4819-140-2-200401200-00015	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00015			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734337				2022-12-28	WOS:000188211700009
J	Schwartz, AB; Moran, DW; Reina, GA				Schwartz, AB; Moran, DW; Reina, GA			Differential representation of perception and action in the frontal cortex	SCIENCE			English	Article							PRIMATE MOTOR CORTEX; PREFRONTAL CORTEX; CORTICAL REPRESENTATION; NEURONAL POPULATION; MOVEMENT; DIRECTION; VISION; ADAPTATION; DISCHARGE; MONKEYS	A motor illusion was created to separate human subjects' perception of arm movement from their actual movement during figure drawing. Trajectories constructed from cortical activity recorded in monkeys performing the same task showed that the actual movement was represented in the primary motor cortex, whereas the visualized, presumably perceived, trajectories were found in the ventral premotor cortex. Perception and action representations can be differentially recognized in the brain and may be contained in separate structures.	Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15203 USA; Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; Washington Univ, Dept Neurobiol, St Louis, MO 63130 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); Washington University (WUSTL)	Schwartz, AB (corresponding author), Univ Pittsburgh, Dept Neurobiol, 3025 E Carson St, Pittsburgh, PA 15203 USA.			Reina, G Anthony/0000-0001-9623-9259	NINDS NIH HHS [R01 NS26375] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHE J, 1994, CEREB CORTEX, V6, P590; Averbeck BB, 2002, P NATL ACAD SCI USA, V99, P13172, DOI 10.1073/pnas.162485599; Averbeck BB, 2003, EXP BRAIN RES, V150, P127, DOI 10.1007/s00221-003-1416-6; Carmichael ST, 1995, J COMP NEUROL, V363, P642, DOI 10.1002/cne.903630409; Carpenter AF, 1999, SCIENCE, V283, P1752, DOI 10.1126/science.283.5408.1752; CHAFEE MV, 2000, 30 ANN M SOC NEUR NE; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; FU QG, 1995, J NEUROPHYSIOL, V73, P836, DOI 10.1152/jn.1995.73.2.836; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; HARRIS CS, 1965, PSYCHOL REV, V72, P419, DOI 10.1037/h0022616; HELD R, 1963, SCIENCE, V142, P455, DOI 10.1126/science.142.3591.455; KALASKA JF, 1989, J NEUROSCI, V9, P2080; Kurata K, 1999, J NEUROPHYSIOL, V81, P1927, DOI 10.1152/jn.1999.81.4.1927; Lashley K., 1951, CEREBRAL MECH BEHAV, P112, DOI DOI 10.1093/RFS/HHQ153; Lateiner JE, 2003, EXP BRAIN RES, V151, P446, DOI 10.1007/s00221-003-1503-8; Lebedev Mikhail A, 2002, Behav Cogn Neurosci Rev, V1, P108, DOI 10.1177/1534582302001002002; LEE JH, 2001, 31 ANN M SOC NEUR SA; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; Moran DW, 1999, J NEUROPHYSIOL, V82, P2676, DOI 10.1152/jn.1999.82.5.2676; PELISSON D, 1986, EXP BRAIN RES, V62, P303; Reina GA, 2003, HUM MOVEMENT SCI, V22, P137, DOI 10.1016/S0167-9457(02)00156-2; Reina GA, 2001, J NEUROPHYSIOL, V85, P2576, DOI 10.1152/jn.2001.85.6.2576; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549	26	100	101	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					380	383		10.1126/science.1087788	http://dx.doi.org/10.1126/science.1087788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726593				2022-12-28	WOS:000188111800046
J	Dillingham, R; Guerrant, RL				Dillingham, R; Guerrant, RL			Childhood stunting: measuring and stemming the staggering costs of inadequate water and sanitation	LANCET			English	Editorial Material							DIARRHEAL DISEASE; GROWTH; CRYPTOSPORIDIOSIS; INFLAMMATION; CHILDREN; BRAZIL		Univ Virginia, Ctr Global Hlth, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA	University of Virginia	Guerrant, RL (corresponding author), Univ Virginia, Ctr Global Hlth, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.							Berkman DS, 2002, LANCET, V359, P564, DOI 10.1016/S0140-6736(02)07744-9; Campbell DI, 2003, J NUTR, V133, P1332; Checkley W, 1997, AM J EPIDEMIOL, V145, P156, DOI 10.1093/oxfordjournals.aje.a009086; ESREY SA, 1988, AM J PUBLIC HEALTH, V78, P1451, DOI 10.2105/AJPH.78.11.1451; Guerrant DI, 1999, AM J TROP MED HYG, V61, P707, DOI 10.4269/ajtmh.1999.61.707; GUERRANT RL, 1983, J INFECT DIS, V148, P986, DOI 10.1093/infdis/148.6.986; Guerrant RL, 2002, TRENDS PARASITOL, V18, P191, DOI 10.1016/S1471-4922(02)02253-5; Mara DD, 2003, PUBLIC HEALTH, V117, P452, DOI 10.1016/S0033-3506(03)00143-4; Mendez MA, 1999, J NUTR, V129, P1555, DOI 10.1093/jn/129.8.1555; Moore SR, 2001, INT J EPIDEMIOL, V30, P1457, DOI 10.1093/ije/30.6.1457; Niehaus MD, 2002, AM J TROP MED HYG, V66, P590, DOI 10.4269/ajtmh.2002.66.590; Steiner TS, 1998, J INFECT DIS, V177, P88, DOI 10.1086/513809	12	44	46	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					94	95		10.1016/S0140-6736(03)15307-X	http://dx.doi.org/10.1016/S0140-6736(03)15307-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726158				2022-12-28	WOS:000187939200002
J	Sarig, G; Brenner, B				Sarig, G; Brenner, B			Coagulation, inflammation, and pregnancy complications	LANCET			English	Editorial Material							RECURRENT MISCARRIAGE; WOMEN		Rambam Med Ctr, Dept Haematol, Thrombosis & Haemostasis Unit, IL-31096 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology	Brenner, B (corresponding author), Rambam Med Ctr, Dept Haematol, Thrombosis & Haemostasis Unit, IL-31096 Haifa, Israel.							BREMME K, 2002, WOMENS ISSUES THROMB, P151; Brenner B, 2000, THROMB HAEMOSTASIS, V83, P693; CLIFFORD K, 1994, HUM REPROD, V9, P1328, DOI 10.1093/oxfordjournals.humrep.a138703; Gris JC, 1999, THROMB HAEMOSTASIS, V81, P891; HATASAKA HH, 1994, CLIN OBSTET GYNECOL, V37, P625, DOI 10.1097/00003081-199409000-00016; Laird SM, 2003, HUM REPROD UPDATE, V9, P163, DOI 10.1093/humupd/dmg013; Laude I, 2001, THROMB HAEMOSTASIS, V85, P18, DOI 10.1055/s-0037-1612657; Makhseed M, 2000, HUM REPROD, V15, P2011, DOI 10.1093/humrep/15.9.2011; Marjono AB, 2003, PLACENTA, V24, P100, DOI 10.1053/plac.2002.0881; Rai RS, 1996, BRIT J OBSTET GYNAEC, V103, P842, DOI 10.1111/j.1471-0528.1996.tb09887.x; Sarig G, 2002, FERTIL STERIL, V77, P342, DOI 10.1016/S0015-0282(01)02971-5; STIRLING Y, 1984, THROMB HAEMOSTASIS, V52, P176; SzekeresBartho J, 1996, AM J REPROD IMMUNOL, V35, P348; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	14	13	13	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					96	97		10.1016/S0140-6736(03)15309-3	http://dx.doi.org/10.1016/S0140-6736(03)15309-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726160				2022-12-28	WOS:000187939200004
J	Perlman, PS; Boeke, JD				Perlman, PS; Boeke, JD			Ring around the retroelement	SCIENCE			English	Editorial Material							REVERSE TRANSCRIPTION		Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	Boeke, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.	jboeke@jhmi.edu		Boeke, Jef/0000-0001-5322-4946				CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Cheng Z, 2004, SCIENCE, V303, P240, DOI 10.1126/science.1087023; Cristofari G, 2002, EMBO J, V21, P4368, DOI 10.1093/emboj/cdf436; Gabriel A, 1996, P NATL ACAD SCI USA, V93, P7767, DOI 10.1073/pnas.93.15.7767; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; LAUERMANN V, 1995, J VIROL, V69, P7845, DOI 10.1128/JVI.69.12.7845-7850.1995; Salem LA, 2003, J VIROL, V77, P12795, DOI 10.1128/JVI.77.23.12795-12806.2003; Vogel J, 2002, EMBO J, V21, P3794, DOI 10.1093/emboj/cdf359; Wang YM, 2003, J AM CHEM SOC, V125, P6880, DOI 10.1021/ja035150z; Wilhelm M, 2001, CELL MOL LIFE SCI, V58, P1246, DOI 10.1007/PL00000937	10	18	19	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					182	184		10.1126/science.1093514	http://dx.doi.org/10.1126/science.1093514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716001				2022-12-28	WOS:000187908500035
J	Rodriguez-Navarro, S; Fischer, T; Luo, MJ; Antunez, O; Brettschneider, S; Lechner, J; Perez-Ortin, JE; Reed, R; Hurt, E				Rodriguez-Navarro, S; Fischer, T; Luo, MJ; Antunez, O; Brettschneider, S; Lechner, J; Perez-Ortin, JE; Reed, R; Hurt, E			Sus1, a functional component of the SAGA histone acetylase complex and the nuclear pore-associated mRNA export machinery	CELL			English	Article							HNRNP-LIKE PROTEINS; SACCHAROMYCES-CEREVISIAE; IN-VIVO; NUCLEOCYTOPLASMIC TRANSPORT; COUPLING TRANSCRIPTION; POLY(A)(+) RNA; YEAST; INTERACTS; COACTIVATOR; YRA1P	Gene expression is a coordinated multistep process that begins with transcription and RNA processing in the nucleus followed by mRNA export to the cytoplasm for translation. Here we report the identification of a protein, Sus1, which functions in both transcription and mRNA export. Sus1 is a nuclear protein with a concentration at the nuclear pores. Biochemical analyses show that Sus1 interacts with SAGA, a large intranuclear histone acetylase complex involved in transcription initiation, and with the Sac3-Thp1 complex, which functions in mRNA export with specific nuclear pore proteins at the nuclear basket. DNA macroarray analysis revealed that Sus1 is required for transcription regulation. Moreover, chromatin immunoprecipitation showed that Sus1 is associated with the promoter of a SAGA-dependent gene during transcription activation. Finally, mRNA export is impaired in sus1 mutants. These data provide an unexpected connection between the SAGA histone acetylase complex and the mRNA export machinery.	Heidelberg Univ, Biochem Zentrum, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Valencia, Dept Bioquim & Biol Mol, Valencia, Spain; Univ Valencia, Serv Chips DNA SCSIE, Valencia, Spain	Ruprecht Karls University Heidelberg; Harvard University; Harvard Medical School; University of Valencia; University of Valencia	Hurt, E (corresponding author), Heidelberg Univ, Biochem Zentrum, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz-uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019; Rodríguez-Navarro, Susana/B-5182-2014; Pérez-Ortín, José E./K-8582-2014; Fischer, Tamas/A-7729-2016	Ed Hurt, Dr./0000-0002-4535-8255; Rodríguez-Navarro, Susana/0000-0001-7472-3111; Pérez-Ortín, José E./0000-0002-1992-513X; Fischer, Tamas/0000-0002-7996-4042; Huch, Susanne/0000-0003-3956-7197				Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Bauer A, 1996, J CELL SCI, V109, P1575; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Duncan K, 2000, CURR BIOL, V10, P687, DOI 10.1016/S0960-9822(00)00527-3; Estruch F, 2003, MOL BIOL CELL, V14, P1664, DOI 10.1091/mbc.E02-09-0602; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Gallardo M, 2003, J BIOL CHEM, V278, P24225, DOI 10.1074/jbc.M302900200; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Georgieva S, 2001, MOL CELL BIOL, V21, P5223, DOI 10.1128/MCB.21.15.5223-5231.2001; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hauser NC, 1998, YEAST, V14, P1209, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1209::AID-YEA311>3.0.CO;2-N; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Ishii K, 2003, MOL CELL, V11, P237, DOI 10.1016/S1097-2765(03)00010-8; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; Jensen TH, 2003, MOL CELL, V11, P1129, DOI 10.1016/S1097-2765(03)00191-6; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Lei EP, 2002, GENE DEV, V16, P2761, DOI 10.1101/gad.1032902; Libri D, 2002, MOL CELL BIOL, V22, P8254, DOI 10.1128/MCB.22.23.8254-8266.2002; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rodriguez-Navarro S, 2002, EMBO REP, V3, P438, DOI 10.1093/embo-reports/kvf091; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	49	285	296	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					75	86		10.1016/S0092-8674(03)01025-0	http://dx.doi.org/10.1016/S0092-8674(03)01025-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718168	Green Submitted, Bronze			2022-12-28	WOS:000187960800010
J	Greene, MF; Ecker, JL				Greene, MF; Ecker, JL			Abortion, health, and the law	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES		Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Greene, MF (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Annas GJ, 2001, NEW ENGL J MED, V344, P152, DOI 10.1056/NEJM200101113440220; Callaghan WM, 2003, OBSTET GYNECOL, V102, P1015, DOI 10.1016/S0029-7844(03)00740-3; Davison JM, 1999, MATERNAL FETAL MED, P873; Elam-Evans Laurie D., 2002, Morbidity and Mortality Weekly Report, V51, P1; ELAMEVANS LD, 2002, MMWR SURVEILL SUMM, V51, P11; Finer LB, 2003, PERSPECT SEX REPRO H, V35, P6, DOI 10.1111/j.1931-2393.2003.tb00079.x; Gleicher N, 1979, Obstet Gynecol Surv, V34, P721, DOI 10.1097/00006254-197910000-00001; HASKELL M, 1992, NAT AB FED RISK MAN, P27; KAFRISSEN ME, 1984, JAMA-J AM MED ASSOC, V251, P916; STOCKMAN F, 2003, BOSTON GLOBE    1023, pB3; Stubblefield Philip G., 2000, GYNECOLOGIC OBSTET R, p[1033, 1043]	11	10	10	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					184	186		10.1056/NEJMsb035739	http://dx.doi.org/10.1056/NEJMsb035739			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711920				2022-12-28	WOS:000187858500016
J	Gruen, RL; Pearson, SD; Brennan, TA				Gruen, RL; Pearson, SD; Brennan, TA			Physician-citizens - Public roles and professional obligations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL PROFESSIONALISM; DOCTORS; HEALTH	Although leaders and other commentators have called for the medical profession's greater engagement in improving systems of care and population health, neither medical education nor the practice environment has fostered such engagement. Missing have been a clear definition of physicians' public roles, reasonable limits to what can be expected, and familiarity with tasks that are compatible with busy medical practices. We address these issues by proposing a definition and a conceptual model of public roles that require evidence of disease causation and are guided by the feasibility and efficacy of physician involvement. we then frame a public agenda for individual physicians and physician organizations that focuses on advocacy and community participation. By doing so, we aim to stimulate dialogue about the appropriateness of such roles and promote physician engagement with pressing health issues in the public arena.	Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Menzies Sch Hlth Res, Darwin, NT, Australia; Harvard Pilgrim Hlth Care, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Charles Darwin University; Menzies School of Health Research; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital	Gruen, RL (corresponding author), Menzies Sch Hlth Res, POB 41096, Casurina, NT 0811, Australia.	russell.gruen@menzies.edu.au						*AM MED ASS, 2002, COD MED ETH CURR OP; *AM MED ASS, DECL PROF RESP; Brennan TA, 2003, ANN INTERN MED, V138, P851, DOI 10.7326/0003-4819-138-10-200305200-00018; BRENNAN TA, 1987, ANN INTERN MED, V107, P741, DOI 10.7326/0003-4819-107-5-741; Cohen D., 2001, ADVOCACY SOCIAL JUST; Colby A., 2003, ED CITIZENS PREPARIN; Coulehan J, 2003, CAMB Q HEALTHC ETHIC, V12, P21, DOI 10.1017/S0963180103121044; Council of Medical Specialty Societies, ETH STAT; Cruess RL, 2000, LANCET, V356, P156, DOI 10.1016/S0140-6736(00)02458-2; Edwards N, 2002, BMJ-BRIT MED J, V324, P835, DOI 10.1136/bmj.324.7341.835; GERAGHTY KE, ADVOCACY COMMUNITY S; Heath I, 1998, BRIT MED J, V316, P1456, DOI 10.1136/bmj.316.7142.1456a; Horton R, 2002, LANCET, V359, P458, DOI 10.1016/S0140-6736(02)07670-5; *I MED, 2002, UN TREATM CONFR RAC; KLEINMAN LC, 1991, JAMA-J AM MED ASSOC, V265, P1991; Lasker RD, 1998, POCKET GUIDE CASES M; McCally M, 1998, ANN INTERN MED, V129, P726, DOI 10.7326/0003-4819-129-9-199811010-00009; PETERS KE, 2002, PRIMER POPULATION BA; Rothman DJ, 2000, NEW ENGL J MED, V342, P1284, DOI 10.1056/NEJM200004273421711; ROTHMAN DJ, 2002, PHYSICIANS BODY POLI, V2, P2; Schlesinger M, 2002, MILBANK Q, V80, P185, DOI 10.1111/1468-0009.t01-1-00010; SHARFSTEIN JM, 1994, NEW ENGL J MED, V330, P32, DOI 10.1056/NEJM199401063300107; Simpson J. A., 1989, OXFORD ENGLISH DICT; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Stevens RA, 2001, MILBANK Q, V79, P327, DOI 10.1111/1468-0009.00211; Sullivan WM, 1999, HASTINGS CENT REP, V29, P7, DOI 10.2307/3528344; Woolhandler S, 2003, JAMA-J AM MED ASSOC, V290, P798; Wynia MK, 1999, NEW ENGL J MED, V341, P1612, DOI 10.1056/NEJM199911183412112	28	158	159	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					94	98		10.1001/jama.291.1.94	http://dx.doi.org/10.1001/jama.291.1.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	760LX	14709581				2022-12-28	WOS:000187836000024
J	Altman, DE				Altman, DE			The new Medicare prescription-drug legislation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Henry J Kaiser Med Fdn, Menlo Pk, CA 94025 USA		Altman, DE (corresponding author), Henry J Kaiser Med Fdn, Menlo Pk, CA 94025 USA.								0	27	27	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					9	10		10.1056/NEJMp038224	http://dx.doi.org/10.1056/NEJMp038224			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702422				2022-12-28	WOS:000187659900004
J	Selkoe, DJ				Selkoe, DJ			Folding proteins in fatal ways	NATURE			English	Review							AMYLOID-BETA-PEPTIDE; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; GLUTAMINE REPEATS; HUMAN LYSOZYME; FIBRILLOSES; SUPPRESSION; DROSOPHILA; OLIGOMERS; MECHANISM	Human diseases characterized by insoluble extracellular deposits of proteins have been recognized for almost two centuries. Such amyloidoses were once thought to represent arcane secondary phenomena of questionable pathogenic significance. But it is has now become clear that many different proteins can misfold and form extracellular or intracellular aggregates that initiate profound cellular dysfunction. Particularly challenging examples of such disorders occur in the post-mitotic environment of the neuron and include Alzheimer's and Parkinson's diseases. Understanding some of the principles of protein folding has helped to explain how such diseases arise, with attendant therapeutic insights.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Selkoe, DJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.							Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HAEZEBROUCK P, 1995, J MOL BIOL, V246, P382, DOI 10.1006/jmbi.1994.0093; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hutton M, 2001, NEUROLOGY, V56, pS21, DOI 10.1212/WNL.56.suppl_4.S21; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Opal P, 2002, TRENDS MOL MED, V8, P232, DOI 10.1016/S1471-4914(02)02310-9; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; RADFORD SE, 1995, PHILOS T ROY SOC B, V348, P17, DOI 10.1098/rstb.1995.0041; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	26	1123	1166	1	166	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					900	904		10.1038/nature02264	http://dx.doi.org/10.1038/nature02264			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685251				2022-12-28	WOS:000187342000073
J	Birtwhistle, RV; Godwin, MS; Delva, MD; Casson, RI; Lam, M; MacDonald, SE; Seguin, R; Ruhland, L				Birtwhistle, RV; Godwin, MS; Delva, MD; Casson, RI; Lam, M; MacDonald, SE; Seguin, R; Ruhland, L		Hypertension Follow-up Study Grp	Randomised equivalence trial comparing three and six months of follow up of patients with hypertension by family practitioners	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VISIT FREQUENCY	Objective To compare blood pressure control, satisfaction, and adherence to drug treatment in patients with treated hypertension followed up by their family physicians either every three months or every six months for three years. Design Randomised equivalence clinical trial. Settings 50 family practices in south eastern Ontario, Canada. Participants 609 patients aged 30-74 years with essential hypertension receiving drug treatment whose hypertension had been controlled for at least three months before entry into the study. Results 302 patients were randomly assigned to follow up every three months and 307 to follow up every six months. Baseline variables in the two groups were similar. As expected, patients in the six month group had significantly fewer visits, but patients in both groups visited their doctor more frequently than their assigned interval. Mean blood pressure was similar in the groups, as was control of hypertension. Patient satisfaction and adherence to treatment were similar in the groups. About 20% of patients in each group had blood pressures that were out of control during the study. Conclusions Follow up of patients with treated essential hypertension every six months is equivalent to follow up every three months. Patient satisfaction and adherence to treatment are the same for these follow up intervals. As about 20% of patients' hypertension was out of control at any time during the study in both groups, the frequency of follow up may not the most important factor in the control of patients' hypertension by family practitioners.	Queens Univ, Ctr Studies Primary Care, Kingston, ON K7L 5E9, Canada; Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Birtwhistle, RV (corresponding author), Queens Univ, Ctr Studies Primary Care, PO Bag 8888, Kingston, ON K7L 5E9, Canada.							AGRESTI A, 1990, CATEGORICAL DATA ANA, P419; BAKER R, 1990, BRIT J GEN PRACT, V40, P487; BAKER R, 2001, DIALOGUE 3 EDITION M; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; Burton A, 2001, SOC HIST, V26, P60, DOI 10.1080/03071020122740; Campbell NRC, 2002, CAN J CARDIOL, V18, P591; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; FROHLICH ED, 1995, CAN J CARDIOL, V11, pH35; GREGOIRE JP, 1992, CAN FAM PHYSICIAN, V38, P2333; HSU JC, 1994, BIOMETRIKA, V81, P103; Joffres MR, 2001, AM J HYPERTENS, V14, P1099, DOI 10.1016/S0895-7061(01)02211-7; *JOINT NAT COMM PR, 1997, NIH PUBL; LICHTENSTEIN MJ, 1986, J FAM PRACTICE, V23, P331; LICHTENSTEIN MJ, 1989, J FAM PRACTICE, V28, P667; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; PETITTI DB, 1993, J FAM PRACTICE, V37, P235; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; TOBACMAN JK, 1992, J GEN INTERN MED, V7, P312, DOI 10.1007/BF02598090	21	55	58	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2004	328	7433					204	206B		10.1136/bmj.37967.374063.EE	http://dx.doi.org/10.1136/bmj.37967.374063.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	769LU	14726370	Green Published, Green Submitted			2022-12-28	WOS:000188652200016
J	Fitch, WT; Hauser, MD				Fitch, WT; Hauser, MD			Computational constraints on syntactic processing in a nonhuman primate	SCIENCE			English	Article							LANGUAGE; DISCRIMINATION; CLASSIFICATION; MONKEYS; RULE	The capacity to generate a limitless range of meaningful expressions from a finite set of elements differentiates human language from other animal communication systems. Rule systems capable of generating an infinite set of outputs ("grammars") vary in generative power. The weakest possess only local organizational principles, with regularities limited to neighboring units. We used a familiarization/discrimination paradigm to demonstrate that monkeys can spontaneously master such grammars. However, human language entails more sophisticated grammars, incorporating hierarchical structure. Monkeys tested with the same methods, syllables, and sequence lengths were unable to master a grammar at this higher, "phrase structure grammar" level.	Univ St Andrews, Sch Psychol, St Andrews KY16 9AJ, Fife, Scotland; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	University of St Andrews; Harvard University	Fitch, WT (corresponding author), Univ St Andrews, Sch Psychol, St Andrews KY16 9AJ, Fife, Scotland.	wtsf@st-andrews.ac.uk	Galantucci, Bruno/E-5770-2010					Bergman TJ, 2003, SCIENCE, V302, P1234, DOI 10.1126/science.1087513; Byrne RW, 1998, BEHAV BRAIN SCI, V21, P667, DOI 10.1017/S0140525X98001745; Chomsky N., 2002, JANUA LINGUARUM; Chomsky Noam, 1959, INFORM CONTR, V2, DOI [10.1016/S0019-9958(59)90362-6, DOI 10.1016/S0019-9958(59)90362-6]; DAMATO MR, 1988, MUSIC PERCEPT, V5, P453; Gomez RL, 1999, COGNITION, V70, P109, DOI 10.1016/S0010-0277(99)00003-7; GREENFIELD PM, 1991, BEHAV BRAIN SCI, V14, P531, DOI 10.1017/S0140525X00071235; GREENFIELD PM, 1972, COGNITIVE PSYCHOL, V3, P291, DOI 10.1016/0010-0285(72)90009-6; HAEGEMAN L, 1991, INTRO GOV BINDING TH; HAILMAN JP, 1986, ANIM BEHAV, V34, P1899, DOI 10.1016/S0003-3472(86)80279-2; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; Hauser MD, 2002, COGNITION, V86, pB23, DOI 10.1016/S0010-0277(02)00158-0; Hauser MD, 2002, COGNITION, V86, pB15, DOI 10.1016/S0010-0277(02)00139-7; Hauser MD, 2001, COGNITION, V78, pB53, DOI 10.1016/S0010-0277(00)00132-3; Kimura D., 1993, NEUROMOTOR MECH HUMA; Lashley K.S., 1951, PROBLEM SERIAL ORDER, V21; LIEBERMAN P, 1985, J HUM EVOL, V14, P657, DOI 10.1016/S0047-2484(85)80074-9; McDermott D., 1985, INTRO ARTIFICIAL INT; McGonigle B, 2003, ANIM COGN, V6, P185, DOI 10.1007/s10071-003-0174-y; Miller G.F., 1967, PSYCHOL COMMUNICATIO, P125; Miller George A., 1963, HDB MATH PSYCHOL, P419; MORGAN JL, 1989, J MEM LANG, V28, P360, DOI 10.1016/0749-596X(89)90039-9; MORGAN JL, 1981, J VERB LEARN VERB BE, V20, P67, DOI 10.1016/S0022-5371(81)90312-1; NEWPORT EL, IN PRESS COGNIT PSYC; Ramus F, 2000, SCIENCE, V288, P349, DOI 10.1126/science.288.5464.349; ROBINSON JG, 1984, BEHAVIOUR, V90, P46, DOI 10.1163/156853984X00551; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Terrace HS, 2003, PSYCHOL SCI, V14, P66, DOI 10.1111/1467-9280.01420; WRIGHT AA, 1985, SCIENCE, V229, P287, DOI 10.1126/science.9304205; Zuberbuhler K, 2002, ANIM BEHAV, V63, P293, DOI 10.1006/anbe.2001.1914	30	380	392	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					377	380		10.1126/science.1089401	http://dx.doi.org/10.1126/science.1089401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726592				2022-12-28	WOS:000188111800045
J	Parsonnet, J; Isaacson, PG				Parsonnet, J; Isaacson, PG			Bacterial infection and MALT lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Hlth Res & Policy, Stanford, CA 94305 USA; UCL, Royal Free & Univ Coll Med Sch, Dept Histopathol, London, England	Stanford University; Stanford University; University of London; University College London	Parsonnet, J (corresponding author), Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA.			Parsonnet, Julie/0000-0001-7342-5366				Skirrow M., 2002, INFECT GASTROINTESTI, P719	1	101	106	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					213	215		10.1056/NEJMp038200	http://dx.doi.org/10.1056/NEJMp038200			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724298	Green Published			2022-12-28	WOS:000188078400002
J	Strang, J; Fortson, R				Strang, J; Fortson, R			Commentary: Supervised fixing rooms, supervised injectable maintenance clinics - understanding the difference	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Coll London, Natl Addict Ctr, London SE5 8AF, England	University of London; King's College London	Strang, J (corresponding author), Kings Coll London, Natl Addict Ctr, London SE5 8AF, England.	johnstrang@iop.kcl.ac.uk	Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				BURRELL I, 2000, INDEPENDENT     0120; *SEL COMM HOM AFF, 2002, 3 SEL COMM HOM AFF; van Beek I, 2003, J DRUG ISSUES, V33, P625, DOI 10.1177/002204260303300305; van den Brink W, 2003, BRIT MED J, V327, P310, DOI 10.1136/bmj.327.7410.310; Zador D, 2001, ADDICTION, V96, P547, DOI 10.1046/j.1360-0443.2001.9645473.x	5	14	14	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 10	2004	328	7431					102	103		10.1136/bmj.328.7431.102	http://dx.doi.org/10.1136/bmj.328.7431.102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	762MP	14715607	Green Published			2022-12-28	WOS:000187976400023
J	Schwartz, LM; Woloshin, S; Fowler, FJ; Welch, HG				Schwartz, LM; Woloshin, S; Fowler, FJ; Welch, HG			Enthusiasm for cancer screening in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; MAMMOGRAPHY; HEALTH	Context Public health officials, physicians, and disease advocacy groups have worked hard to educate individuals living in the United States about the importance of cancer screening. Objective To determine the public's enthusiasm for early cancer detection. Design, Setting, and Participants Survey using a national telephone interview of adults selected by random digit dialing, conducted from December 2001 through July 2002. Five hundred individuals participated (women aged greater than or equal to40 years and men aged greater than or equal to50 years; without a history of cancer). Main Outcome Measures Responses to a survey with 5 modules: a general screening module (eg, value of early detection, total-body computed tomography); and 4 screening test modules: Papanicolaou test; mammography; prostate-specific antigen (PSA) test; and sigmoidoscopy or colonoscopy. Results Most adults (87%) believe routine cancer screening is almost always a good idea and that finding cancer early saves lives (74% said most or all the time). Less than one third believe that there will be a time when they will stop undergoing routine screening. A substantial proportion believe that an 80-year-old who chose not to be tested was irresponsible: ranging from 41% with regard to mammography to 32% for colonoscopy. Thirty-eight percent of respondents had experienced at least 1 false-positive screening test; more than 40% of these individuals characterized that experience as "very scary" or the "scariest time of my life." Yet, looking back, 98% were glad they had had the initial screening test. Most had a strong desire to know about the presence of cancer regardless of its implications: two thirds said they would want to be tested for cancer even if nothing could be done; and 56% said they would want to be tested for what is sometimes termed pseudodisease (cancers growing so slowly that they would never cause problems during the persons lifetime even if untreated). Seventy-three percent of respondents would prefer to receive a total-body computed tomographic scan instead of receiving $1000 in cash. Conclusions The public is enthusiastic about cancer screening. This commitment is not dampened by false-positive test results or the possibility that testing could lead to unnecessary treatment. This enthusiasm creates an environment ripe for the premature diffusion of technologies such as total-body computed tomographic scanning, placing the public at risk of overtesting and overtreatment.	VA Outcomes Grp, White River Jct, VT USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA; Univ Massachusetts, Norris Cotton Canc Ctr, Boston, MA 02125 USA	VA Outcomes Group; Dartmouth College; University of Massachusetts System; University of Massachusetts Boston; Norris Cotton Cancer Center; University of Massachusetts System; University of Massachusetts Boston	Woloshin, S (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp 111B, White River Jct, VT 05009 USA.				NCI NIH HHS [CA91052-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R18CA091052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM ASS PHYS MED, CT BOD SCANN NOT SCI; *AM ASS PUBL OP RE, STAND BEST PRACT STA; *AM CANC SOC, AM CANC SOC ISS NEW; *AM COLL RAD, ACR STAT CT SCREEN E; Black WC, 2000, J NATL CANCER I, V92, P1280, DOI 10.1093/jnci/92.16.1280; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BRODY JE, 2002, NY TIMES        0924, pF7; Centers for Disease Control and Prevention, 2002, BEH RISK FACT SURV S; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; Frame PS, 2000, JAMA-J AM MED ASSOC, V284, P1980, DOI 10.1001/jama.284.15.1980; Gollust SE, 2002, JAMA-J AM MED ASSOC, V288, P1762, DOI 10.1001/jama.288.14.1762; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; HASS N, 2001, NY TIMES        0826, P1; Kolata G, 2002, N Y Times Web, P18; Kramer BS, 2000, HEMATOL ONCOL CLIN N, V14, P831, DOI 10.1016/S0889-8588(05)70314-2; Lee TH, 2002, NEW ENGL J MED, V346, P529, DOI 10.1056/NEJM200202143460715; Lerner Barron H, 2001, BREAST CANC WARS HOP; Linnan LA, 2001, PREV MED, V33, P606, DOI 10.1006/pmed.2001.0933; *NIH, 1997, BREAST CANC SCREEN W; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Ransohoff DF, 1997, ANN INTERN MED, V127, P1029, DOI 10.7326/0003-4819-127-11-199712010-00016; Ransohoff DF, 2002, AM J MED, V113, P663, DOI 10.1016/S0002-9343(02)01235-4; RUGGLES S, 1997, CENSUS 2000 DATA INT; Schwartz Lisa M., 1999, Journal of the National Cancer Institute Monographs, P124; *US BUR CENS, STAT ABSTR US TABL 1; *US FDA, WHOL BOD SCANN US CO; Welch HG, 2001, JAMA-J AM MED ASSOC, V285, P2776, DOI 10.1001/jama.285.21.2776; Wolfe SM, 2002, NEW ENGL J MED, V346, P524, DOI 10.1056/NEJM200202143460713; Woloshin S, 1999, NEW ENGL J MED, V340, P884, DOI 10.1056/NEJM199903183401112; 2003, CERVICAL CANC RECOMM	30	488	491	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					71	78		10.1001/jama.291.1.71	http://dx.doi.org/10.1001/jama.291.1.71			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709578				2022-12-28	WOS:000187836000021
J	Hall, P; Adami, HO; Trichopoulos, D; Pedersen, NL; Lagiou, P; Ekbom, A; Ingvar, M; Lundell, M; Granath, F				Hall, P; Adami, HO; Trichopoulos, D; Pedersen, NL; Lagiou, P; Ekbom, A; Ingvar, M; Lundell, M; Granath, F			Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POOLED ANALYSIS; EXPOSURE; CHILDREN; IRRADIATION; TUMORS; RADIOTHERAPY; HEMANGIOMA; RADIUM; CANCER; RISK	Objective To determine whether exposure to low doses of ionising radiation in infancy affects cognitive function in adulthood. Design Population based cohort study. Setting Sweden. Participants 3094 men who had received radiation for cutaneous haemangioma before age 18 months during 1930-59. Main outcome measures Radiation dose to frontal and posterior parts of the brain, and association between dose and intellectual capacity at age 18 or 19 years based on cognitive tests (learning ability, logical reasoning, spatial recognition) and high school attendance. Results ne proportion of boys who attended high school decreased with increasing doses of radiation to both the frontal and the posterior parts of the brain from about 32% among those not exposed to around 17% in those who received >250 mGy. For the frontal dose, the multivariate odds ratio was 0.47 (95% confidence interval 0.26 to 0.85; P for trend 0.0003) and for the posterior dose it was 0.59 (0.23 to 1.47; 0.0005). A negative dose-response relation was also evident for the three cognitive tests for learning ability and logical reasoning but not for the test of spatial recognition. Conclusions Low doses of ionising radiation to the brain in infancy influence cognitive abilities in adulthood.	Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden; Harvard Univ, Sch Publ Hlth, Harvard Ctr Canc Prevent, Dept Epidemiol, Boston, MA 02115 USA; Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-10679 Athens, Greece; Karlinska Univ Hosp, Dept Clin Neurosci, SE-17176 Stockholm, Sweden; Karlinska Univ Hosp, Dept Hosp Phys, SE-17176 Stockholm, Sweden	Karolinska Institutet; Harvard University; Harvard T.H. Chan School of Public Health; Athens Medical School; National & Kapodistrian University of Athens	Hall, P (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.	Per.Hall@mep.ki.se		Ingvar, Martin/0000-0002-9041-5714				Anderson VA, 2000, BRIT J CANCER, V82, P255; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Carlstedt B., 2000, THESIS U GOTHENBURG; Duncan J, 2000, SCIENCE, V289, P457, DOI 10.1126/science.289.5478.457; FOGARTY K, 1988, CLIN PEDIATR, V27, P524, DOI 10.1177/000992288802701102; Hall P, 1999, RADIAT RES, V152, P190, DOI 10.2307/3580093; HUSEN T, 1944, TULSKRIFT PSYKOLOGI, V43, P114; Kallen B, 1998, RADIAT RES, V149, P202, DOI 10.2307/3579931; Karlsson P, 1998, RADIAT RES, V150, P357, DOI 10.2307/3579984; KOLB B, 1990, FUNDAMENTALS HUMAN N, P412; LEITZ W, 2001, PATIENT DOSES XRAYS; LEITZ W, 2001, PATIENTS DOSES XRAYS; Lundell M, 1999, RADIAT RES, V151, P626, DOI 10.2307/3580039; LUNDELL M, 1995, ACTA ONCOL, V34, P727, DOI 10.3109/02841869509127179; LUNDELL M, 1994, RADIAT RES, V140, P327, DOI 10.2307/3579109; LUNDELL M, 1990, ACTA ONCOL, V29, P551, DOI 10.3109/02841869009090049; *NAT BOARD HLTH WE, 1982, REP STAT COORD; OTAKE M, 1984, BRIT J RADIOL, V57, P409, DOI 10.1259/0007-1285-57-677-409; Riva D, 2000, CHILD NERV SYST, V16, P751, DOI 10.1007/s003810000332; RON E, 1982, AM J EPIDEMIOL, V116, P149, DOI 10.1093/oxfordjournals.aje.a113389; Schull WJ, 1999, TERATOLOGY, V59, P222, DOI 10.1002/(SICI)1096-9926(199904)59:4<222::AID-TERA6>3.0.CO;2-M; Schull WJ, 1997, STEM CELLS, V15, P129; Schultz H.-D., 1997, EUROPA REGIONAL, V5, P2; Skowronska-Gardas A, 1999, MED PEDIATR ONCOL, V33, P572; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, UNSCEAR 2000 REPORT; YOSHIMARU H, 1995, INT J RADIAT BIOL, V67, P359, DOI 10.1080/09553009514550411	26	230	239	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	2004	328	7430					19	21		10.1136/bmj.328.7430.19	http://dx.doi.org/10.1136/bmj.328.7430.19			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703539	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000187919000015
J	Klak, C; Reeves, G; Hedderson, T				Klak, C; Reeves, G; Hedderson, T			Unmatched tempo of evolution in Southern African semi-desert ice plants	NATURE			English	Article							DIVERSIFICATION RATES; AIZOACEAE	The Succulent Karoo is an arid region, situated along the west coast of southern Africa. Floristically this region is part of the Greater Cape Flora(1) and is considered one of the Earth's 25 biodiversity hotspots(2). Of about 5,000 species occurring in this region, more than 40% are endemic(3). Aizoaceae (ice plants) dominate the Succulent Karoo both in terms of species numbers (1,750 species in 127 genera) and density of coverage(3,4). Here we show that a well-supported clade within the Aizoaceae, representing 1,563 species almost exclusively endemic to southern Africa, has diversified very recently and very rapidly. The estimated age for this radiation lies between 3.8 and 8.7 million years (Myr) ago, yielding a per-lineage diversification rate of 0.77-1.75 per million years. Both the number of species involved and the tempo of evolution far surpass those of any previously postulated continental or island plant radiation(5-7). Diversification of the group is closely associated with the origin of several morphological features and one anatomical feature. Because species-poor clades lacking these features occur over a very similar distribution area, we propose that these characteristics are key innovations that facilitated this radiation.	Univ Cape Town, Dept Bot, Bolus Herbarium, ZA-7701 Rondebosch, South Africa; Natl Bot Inst Cape Town, Kirstenbosch Res Ctr, Leslie Hill Mol Systemat Lab, ZA-7735 Claremont, South Africa	University of Cape Town	Klak, C (corresponding author), Univ Cape Town, Dept Bot, Bolus Herbarium, ZA-7701 Rondebosch, South Africa.	klak@botzoo.uct.ac.za	Hedderson, Terry/AAD-8614-2021					Axelrod D. I., 1978, Monographiae Biologicae, V31, P79; Baldwin BG, 1998, P NATL ACAD SCI USA, V95, P9402, DOI 10.1073/pnas.95.16.9402; ERIKSSON O, 1992, EVOLUTION, V46, P258, DOI [10.2307/2409820, 10.1111/j.1558-5646.1992.tb02000.x]; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Hendey QB., 1982, LANGEBAANWEG RECORD; HULBERT RC, 1993, PALEOBIOLOGY, V19, P216, DOI 10.1017/S0094837300015888; IHLENFELDT HD, 1994, ANNU REV ECOL SYST, V25, P521; JURGENS N, 1991, VEGETATIO, V97, P21; Jurgens N., 1986, MITT I ALLG BOT HAMB, V21, P129; Klak C, 2003, AM J BOT, V90, P1433, DOI 10.3732/ajb.90.10.1433; Landrum JV, 2001, PLANT SYST EVOL, V227, P49, DOI 10.1007/s006060170056; Magallon S, 2001, EVOLUTION, V55, P1762, DOI 10.1111/j.0014-3820.2001.tb00826.x; Mauseth JD, 1995, J PLANT RES, V108, P517, DOI 10.1007/BF02344242; Mayhew PJ, 2002, P ROY SOC B-BIOL SCI, V269, P969, DOI 10.1098/rspb.2002.1957; McCune Amy R., 1997, P585; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Parolin P, 2001, FLORA, V196, P313; RAMBAUT A, 2000, TREEEDIT VERSION 1 0; Richardson JE, 2001, SCIENCE, V293, P2242, DOI 10.1126/science.1061421; Richardson JE, 2001, NATURE, V412, P181, DOI 10.1038/35084067; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; Schmiedel U, 1999, PLANT ECOL, V142, P57, DOI 10.1023/A:1009818210799; Scott L., 1997, P62; Scott L, 1995, QUATERNARY SCI REV, V14, P937, DOI 10.1016/0277-3791(95)00072-0; Swofford D.L., 1998, PAUP 4 0B2 PHYLOGENE; TANKARD AJ, 1978, J BIOGEOGR, V5, P319, DOI 10.2307/3038026; Ward J, 1990, MONOGRAPH TRANSVAAL, V7, P17; WARD JD, 1983, S AFR J SCI, V79, P175; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782	30	242	251	1	57	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					63	65		10.1038/nature02243	http://dx.doi.org/10.1038/nature02243			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702084	Green Submitted			2022-12-28	WOS:000187710000033
J	Aravind, L; Iyer, LM; Wellems, TE; Miller, LH				Aravind, L; Iyer, LM; Wellems, TE; Miller, LH			Plasmodium biology: Genomic gleanings	CELL			English	Review							GENE FAMILY; PROTEIN SEQUENCES; TOPOISOMERASE-VI; DNA-BINDING; FALCIPARUM; MALARIA; EVOLUTION; DOMAIN; POLYMERASE; EXPRESSION	The highly A+T rich genomes of human and rodent malarial parasites offer unprecedented glimpses of a lineage that is distinct from other model organisms. Plasmodium is distinguished by the presence of numerous low complexity inserts within globular domains of proteins. It displays several peculiarities in its transcription apparatus, and its DNA repair system appears to favor a certain innate level of mutability. Plasmodium possesses many cell surface molecules with "animal-like" adhesion modules. Potential genetic footprints of the ancestral eukaryotic algal precursor of the apicoplast are also detectable in its genome.	Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; Natl Inst Allergy & Infect Dis, Lab Malaria & Vector Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Aravind, L (corresponding author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.	aravind@ncbi.nlm.nih.gov; lmiller@niaid.nih.gov	Iyer, Lakshminarayan M./H-2996-2019	Aravind, L/0000-0003-0771-253X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000483, ZIAAI000483] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM092504] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Aravind L, 2000, P NATL ACAD SCI USA, V97, P11319, DOI 10.1073/pnas.200346997; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; COATNEY GR, 1971, PRIMATE MALARIAS; DASILVA E, 1994, MOL BIOCHEM PARASIT, V66, P59, DOI 10.1016/0166-6851(94)90036-1; Dechering KJ, 1999, MOL CELL BIOL, V19, P967; del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118; Dorin D, 1999, J BIOL CHEM, V274, P29912, DOI 10.1074/jbc.274.42.29912; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; ESCALANTE AA, 1995, P NATL ACAD SCI USA, V92, P5793, DOI 10.1073/pnas.92.13.5793; Fang J, 2002, NATURE, V418, P742, DOI 10.1038/418742a; Fast NM, 2002, J EUKARYOT MICROBIOL, V49, P30, DOI 10.1111/j.1550-7408.2002.tb00336.x; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Figueiredo LM, 2002, EMBO J, V21, P815, DOI 10.1093/emboj/21.4.815; Foth BJ, 2003, INT REV CYTOL, V224, P57, DOI 10.1016/S0074-7696(05)24003-2; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Garnham PCC., 1966, MALARIA PARASITES OT; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Haltiwanger BM, 2000, BIOCHEMISTRY-US, V39, P763, DOI 10.1021/bi9923151; Hartung F, 2002, CURR BIOL, V12, P1787, DOI 10.1016/S0960-9822(02)01218-6; HASEGAWA M, 1991, J MOL EVOL, V32, P443, DOI 10.1007/BF02101285; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kieschnick H, 2001, J BIOL CHEM, V276, P12369, DOI 10.1074/jbc.M011045200; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; Kuvardina ON, 2002, J EUKARYOT MICROBIOL, V49, P498, DOI 10.1111/j.1550-7408.2002.tb00235.x; Lawrence CW, 2001, BIOCHEM SOC T, V29, P187, DOI 10.1042/0300-5127:0290187; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Leander BS, 2003, INT J SYST EVOL MICR, V53, P345, DOI 10.1099/ijs.0.02284-0; Lespinet O, 2002, GENOME RES, V12, P1048, DOI 10.1101/gr.174302; Linder JU, 1999, EMBO J, V18, P4222, DOI 10.1093/emboj/18.15.4222; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Liu JF, 2002, J MOL BIOL, V322, P53, DOI 10.1016/S0022-2836(02)00736-2; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Markmann-Mulisch U, 1999, MOL GEN GENET, V262, P390, DOI 10.1007/s004380051098; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Michon P, 2002, MOL BIOL EVOL, V19, P1128, DOI 10.1093/oxfordjournals.molbev.a004171; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; Nishikura K, 2001, CELL, V107, P415, DOI 10.1016/S0092-8674(01)00581-5; Patankar S, 2001, MOL BIOL CELL, V12, P3114, DOI 10.1091/mbc.12.10.3114; Patthy Laszlo, 1999, PROTEIN EVOLUTION; Perkins SL, 2002, J PARASITOL, V88, P972, DOI 10.1645/0022-3395(2002)088[0972:AMPOMP]2.0.CO;2; Ponting CP, 1999, CURR BIOL, V9, pR911, DOI 10.1016/S0960-9822(00)80102-5; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Saitoh S, 2002, CELL, V109, P563, DOI 10.1016/S0092-8674(02)00753-5; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schaffer AA, 1999, BIOINFORMATICS, V15, P1000; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Simpson AGB, 2002, NATURE, V419, P270, DOI 10.1038/419270a; Sinden RE, 2002, CELL MICROBIOL, V4, P713, DOI 10.1046/j.1462-5822.2002.00229.x; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sugimoto-Shirasu K, 2002, CURR BIOL, V12, P1782, DOI 10.1016/S0960-9822(02)01198-3; Upcroft P, 1997, GENOME RES, V7, P37, DOI 10.1101/gr.7.1.37; VIVIER E, 1989, HDB PROTOSTISTA; WERNSDORFER WH, 1980, IMPORTANCE MALARIA W; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	83	248	258	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	2003	115	7					771	785		10.1016/S0092-8674(03)01023-7	http://dx.doi.org/10.1016/S0092-8674(03)01023-7			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697197	Bronze			2022-12-28	WOS:000187664700003
J	Bazan, HA; Kim, U				Bazan, HA; Kim, U			Emphysematous pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY 10128 USA; Elmhurst Hosp Ctr, Elmhurst, NY 11373 USA	Icahn School of Medicine at Mount Sinai	Bazan, HA (corresponding author), Mt Sinai Sch Med, New York, NY 10128 USA.		Bazan, Hernan A/D-4923-2011	Bazan, Hernan A/0000-0001-5128-7273					0	9	9	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					E25	E25		10.1056/ENEJMicm010312	http://dx.doi.org/10.1056/ENEJMicm010312			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695427				2022-12-28	WOS:000187529500010
J	Hyder, AA; Peden, M				Hyder, AA; Peden, M			Inequality and road-traffic injuries: call for action	LANCET			English	Editorial Material							SAFETY		Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; WHO, Dept Injuries & Violence Prevent, CH-1211 Geneva, Switzerland	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization	Hyder, AA (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	ahyder@jhsph.edu	Hyder, Adnan/AAT-9503-2021	Hyder, Adnan/0000-0002-7292-577X; Mary, Margaret/0000-0003-0872-9851				Ad Hoc Cabinet Committee on Training and Employment, 1987, FURTH ED TRAIN WHO S; Bishai D, 2003, HEALTH POLICY PLANN, V18, P232, DOI 10.1093/heapol/czg028; Evans L, 2003, AM J PUBLIC HEALTH, V93, P1384, DOI 10.2105/AJPH.93.9.1384; Evans T., 2001, CHALLENGING INEQUITI; GHAFFAR A, IN PRESS PUBLIC HLTH; Global Forum for Health Research, 2000, 1090 GLOB FOR HLTH R; Koptis E, 2003, 3035 WORLD BANK; Murray C., 1996, GLOBAL BURDEN DIS IN, V1; Peden M, 2002, BRIT MED J, V324, P1153, DOI 10.1136/bmj.324.7346.1153; Suriyawongpaisal Paibul, 2003, Inj Control Saf Promot, V10, P95, DOI 10.1076/icsp.10.1.95.14110; *WHO DEP INJ VIOL, 2002, NON DIIS MENT HLTH C; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; 2003, EPIDEMIOL REV, V25, P1	13	52	53	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2034	2035		10.1016/S0140-6736(03)15145-8	http://dx.doi.org/10.1016/S0140-6736(03)15145-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697797				2022-12-28	WOS:000187429600002
J	Mercereau-Puijalon, O				Mercereau-Puijalon, O			Antimalarial activity of artemisinins: identification of a novel target?	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM; MALARIA; ERYTHROCYTES		Inst Pasteur, Unite Immunol Mol Parasites, CNRS, URA 2581, F-75724 Paris 15, France; Inst Pasteur Cambodge, Lab Epidemiol Mol, Phnom Penh, Cambodia	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia	Mercereau-Puijalon, O (corresponding author), Inst Pasteur, Unite Immunol Mol Parasites, CNRS, URA 2581, F-75724 Paris 15, France.	omp@pasteur.fr	Hua, QX/HGE-3640-2022; Mercereau-Puijalon, Odile/AAA-2242-2020					Alleva LM, 2001, MOL BIOCHEM PARASIT, V117, P121, DOI 10.1016/S0166-6851(01)00338-3; Bhisutthibhan J, 2001, ANTIMICROB AGENTS CH, V45, P2397, DOI 10.1128/AAC.45.8.2397-2399.2001; Dow GS, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-4; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; ELLIS DS, 1985, ANN TROP MED PARASIT, V79, P367, DOI 10.1080/00034983.1985.11811933; Gazarini ML, 2003, J CELL BIOL, V161, P103, DOI 10.1083/jcb.200212130; GU HM, 1984, T ROY SOC TROP MED H, V78, P265, DOI 10.1016/0035-9203(84)90296-7; Hotta CT, 2000, NAT CELL BIOL, V2, P466, DOI 10.1038/35017112; KIMURA M, 1993, J CELL SCI, V104, P1129; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; Meshnick SR, 1996, MICROBIOL REV, V60, P301, DOI 10.1128/MMBR.60.2.301-315.1996; Olliaro PL, 2001, TRENDS PARASITOL, V17, P122, DOI 10.1016/S1471-4922(00)01838-9; Varotti FP, 2003, CELL CALCIUM, V33, P137, DOI 10.1016/S0143-4160(02)00224-5; Vyas N, 2002, ANTIMICROB AGENTS CH, V46, P105, DOI 10.1128/AAC.46.1.105-109.2002	14	13	14	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2035	2036		10.1016/S0140-6736(03)15146-X	http://dx.doi.org/10.1016/S0140-6736(03)15146-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697798				2022-12-28	WOS:000187429600003
J	Schott, GD				Schott, GD			William Blake's Milton, John Birch's "Electrical Magic", and the "falling star"	LANCET			English	Article									UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Schott, GD (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.	geoffrey.schott@uclh.org						ACKROYD P, 1995, BLAKE, P83; Adlard John, 1969, NEOPHILOLOGUS, V53, P422; BIRCH J, 1802, ESSAY MED APPL ELECT, V4, P1; BLAKE W, 1804, POEM; ESSICK RN, 1993, BLAKES ILLUMINATED B, V5, P27; FARA P, 2002, INTERTAINMENT ANGELS, P81; HYMES A, 1984, CLIN TRANSCUTANEOUS, P1; KANE K, 1975, PAIN, V1, P125, DOI 10.1016/0304-3959(75)90097-4; KEYNES G, 1965, W BLAKE POET PRINTER, P25; KEYNES G, 1966, COMPLETE WRITINGS VA, P590; Nduati R, 2001, LANCET, V358, P1096, DOI 10.1016/S0140-6736(01)06205-5; SCHUCHARD MK, 1989, BLAKE-ILLUSTRATED Q, V23, P20	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2114	2116		10.1016/S0140-6736(03)15115-X	http://dx.doi.org/10.1016/S0140-6736(03)15115-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697819				2022-12-28	WOS:000187429600033
J	Wolffers, I; Verghis, S; Marin, M				Wolffers, I; Verghis, S; Marin, M			Migration, human rights, and health	LANCET			English	Editorial Material									Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; CARAM Secretariat, Kuala Lumpur, Malaysia; CARAM Philippines, ACHIEVE, Manila, Philippines	Vrije Universiteit Amsterdam	Wolffers, I (corresponding author), Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.							*CARAM, IN PRESS MIGR HLTH A; *DEP EC SOC AFF, INT MIGR REP 2002; HUNT P, 2003, REPORT UN SPECIAL RA; PIPER N, 2003, IDENTIFICATION OBSTA; *USAID OFF WOM DEV, 2001, TRAFF PERS USAIDS RE; *WHO, IN PRESS INT MIGR HL; Wolffers I, 2002, CULT HEALTH SEX, V4, P459, DOI 10.1080/13691050110143356; 1995, ABUSE TORTURE DEHUMA	8	24	25	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 13	2003	362	9400					2019	2020		10.1016/S0140-6736(03)15026-X	http://dx.doi.org/10.1016/S0140-6736(03)15026-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	753BC	14686372				2022-12-28	WOS:000187210700028
J	Higham, J; Steer, PJ				Higham, J; Steer, PJ			Gender gap in undergraduate experience and performance in obstetrics and gynaecology: analysis of clinical experience logs	BRITISH MEDICAL JOURNAL			English	Article							UNITED-KINGDOM; DOCTORS; CHOICES		Univ London Imperial Coll Sci Technol & Med, Fac Med, Acad Dept Obstet & Gynaecol, London W2 1NY, England	Imperial College London	Higham, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Acad Dept Obstet & Gynaecol, London W2 1NY, England.	j.higham@imperial.ac.uk						Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; Lambert TW, 2003, MED EDUC, V37, P312, DOI 10.1046/j.1365-2923.2003.01473.x; Lambert TW, 2003, BRIT MED J, V326, P194, DOI 10.1136/bmj.326.7382.194; Nora LM, 2002, ACAD MED, V77, P1226, DOI 10.1097/00001888-200212000-00018; Pearse WH, 2001, OBSTET GYNECOL, V97, P794, DOI 10.1016/S0029-7844(01)01191-7	5	25	26	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					142	143		10.1136/bmj.328.7432.142	http://dx.doi.org/10.1136/bmj.328.7432.142			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726343	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000188249900020
J	Col, NF; Surks, MI; Daniels, GH				Col, NF; Surks, MI; Daniels, GH			Subclinical thyroid disease - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FOLLOW-UP; HYPOTHYROIDISM; HYPERTHYROIDISM; COMMUNITY; BONE; DEFICIENCY; PREVALENCE; THERAPY	Subclinical hypothyroidism and hyperthyroidism are diagnoses based on laboratory evaluation with few if any clinical signs or symptoms. Subclinical hypothyroidism is defined as an elevation in serum thyroid-stimulating hormone (TSH) above the upper limit of the reference range (0.45-4.5 mIU/L). with normal serum FT4 concentration; subclinical hyperthyroidism is defined as a decrease in serum TSH below the reference range with normal serum FT4- and T-3 Concentrations. Though these conditions represent the earliest stages of thyroid dysfunction, the benefits of detecting and treating subclinical thyroid disease are not well established. Most persons found to have subclinical thyroid disease will have TSH values between 0.1 and 0.45 mIU/L or between 4.5 and 10 mIU/L, for which the benefits of treatment are not clearly established; treatment may be beneficial in individuals with serum TSH lower than 0.1 mIU/L or higher than 10 mIU/L. This article illustrates approaches to managing patients with subclinical hypothyroidism and hyperthyroidism through 5 case scenarios that apply the principles of evidence-based medicine. Because of the substantial uncertainty concerning the consequences of untreated subclinical hypothyroidism and hyperthyroidism, as well as the benefit of initiating treatment, patient preferences are important in deciding, on management of subclinical disease.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Womens Hlth, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Montefiore Med Ctr, Dept Pathol & Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Thyroid Unit, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Surks, MI (corresponding author), Endocrine Soc, 8401 Connecticut Ave,Suite 900, Chevy Chase, MD 20815 USA.		Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X				BEMBEN DA, 1994, J FAM PRACTICE, V38, P583; Biondi B, 2002, ANN INTERN MED, V137, P904, DOI 10.7326/0003-4819-137-11-200212030-00011; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Cooper DS, 2003, LANCET, V362, P459, DOI 10.1016/S0140-6736(03)14073-1; Faber J, 1994, EUR J ENDOCRINOL, V41, P421; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Klein RZ, 2001, J MED SCREEN, V8, P18, DOI 10.1136/jms.8.1.18; Kumeda Y, 2000, J CLIN ENDOCR METAB, V85, P4157, DOI 10.1210/jc.85.11.4157; Lindeman RD, 1999, J AM GERIATR SOC, V47, P703, DOI 10.1111/j.1532-5415.1999.tb01593.x; Meier C, 2001, J CLIN ENDOCR METAB, V86, P4860, DOI 10.1210/jc.86.10.4860; Muller AF, 2001, ENDOCR REV, V22, P605, DOI 10.1210/er.22.5.605; Pantazi H, 2000, J CLIN ENDOCR METAB, V85, P1099, DOI 10.1210/jc.85.3.1099; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PARLE JV, 1993, BRIT J GEN PRACT, V43, P107; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Zulewski H, 1997, J CLIN ENDOCR METAB, V82, P771, DOI 10.1210/jc.82.3.771	21	109	117	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					239	243		10.1001/jama.291.2.239	http://dx.doi.org/10.1001/jama.291.2.239			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722151	Bronze			2022-12-28	WOS:000188040900033
J	Peterson, ED; Coombs, LP; DeLong, ER; Haan, CK; Ferguson, TB				Peterson, ED; Coombs, LP; DeLong, ER; Haan, CK; Ferguson, TB			Procedural volume as a marker of quality for CABG surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BYPASS GRAFT-SURGERY; NEW-YORK-STATE; HOSPITAL VOLUME; OPERATIVE MORTALITY; SURGICAL-PROCEDURES; THORACIC-SURGEONS; CARDIAC-SURGERY; UNITED-STATES; REGIONALIZATION; IMPROVEMENT	Context There have been recent calls for using hospital procedural volume as a quality indicator for coronary artery bypass graft (CABG) surgery, but further research into analysis and policy implication is needed before hospital procedural volume is accepted as a standard quality metric. Objective To examine the contemporary association between hospital CABG procedure volume and outcome in a large national clinical database. Design, Setting, and Participants Observational analysis of 267089 isolated CABG procedures performed at 439 US hospitals participating in the Society of Thoracic Surgeons National Cardiac Database between January 1, 2000, and December 31, 2001. Main Outcome Measure Association between hospital CABG procedural volume and all-cause operative mortality (in-hospital or 30-day, whichever was longer). Results The median (interquartile range) annual hospital-isolated CABG volume was 253 (165-417) procedures, with 82% of centers performing fewer than 500 procedures per year. The overall operative mortality was 2.66%. After adjusting for patient risk and clustering effects, rates of operative mortality decreased with increasing hospital CABG volume (0.07% for every 100 additional CABG procedures; adjusted odds ratio [OR], 0.98; 95% confidence interval [CI], 0.96-0.99; P=.004). While the association between volume and outcome was statistically significant overall, this association was not observed in patients younger than 65 years or in those at low operative risk and was confounded by surgeon volume. The ability of hospital volume to discriminate those centers with significantly better or worse mortality was limited due to the wide variability in risk-adjusted mortality among hospitals with similar volume. Closure of up to 100 of the lowest-volume centers (ie, those performing less than or equal to150 CABG procedures/year) was estimated to avert fewer than 50 of 7110 (<1% of total) CABG-related deaths. Conclusion in contemporary practice, hospital procedural volume is only modestly associated with CABG outcomes and therefore may not be an adequate quality metric for CABG surgery.	Duke Clin Res Inst, Outcomes Res & Assessment Grp, Durham, NC 27715 USA; Univ Florida, Hlth Sci Ctr, Jacksonville, FL 32209 USA; LSu Hlth Sci Ctr, New Orleans, LA USA	Duke University; State University System of Florida; University of Florida; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Peterson, ED (corresponding author), Duke Clin Res Inst, Outcomes Res & Assessment Grp, Box 17969, Durham, NC 27715 USA.		Peterson, Eric David/ABF-5033-2021					Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Chassin MR, 1997, HEALTH AFFAIR, V16, P151, DOI 10.1377/hlthaff.16.3.151; Clark RE, 1996, ANN THORAC SURG, V61, P21, DOI 10.1016/0003-4975(95)00734-2; Daley J, 2002, SURGERY, V131, P16, DOI 10.1067/msy.2002.120237; Draper N. R., 1998, APPL REGRESSION ANAL, P217; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Edwards FH, 1998, J INVASIVE CARDIOL, V10, P485; EDWARDS FH, 1994, ANN THORAC SURG, V58, P1841, DOI 10.1016/0003-4975(94)91724-8; Epstein AM, 2002, NEW ENGL J MED, V346, P1161, DOI 10.1056/NEJM200204113461512; Ferguson TB, 2003, JAMA-J AM MED ASSOC, V290, P49, DOI 10.1001/jama.290.1.49; Ferguson TB, 2000, ANN THORAC SURG, V69, P680, DOI 10.1016/S0003-4975(99)01538-6; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; Goodney PP, 2003, CIRCULATION, V107, P384, DOI 10.1161/01.CIR.0000051721.60127.EA; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V274, P1282, DOI 10.1001/jama.274.16.1282; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Hannan EL, 2003, CIRCULATION, V108, P795, DOI 10.1161/01.CIR.0000084551.52010.3B; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; KELLY JV, 1986, MED CARE, V24, P785, DOI 10.1097/00005650-198609000-00001; LITTELL RC, 1996, SAS SYSTEM MIXED MOD, P426; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; Nallamothu BK, 2001, J AM COLL CARDIOL, V38, P1923, DOI 10.1016/S0735-1097(01)01647-3; Riley G, 1985, Health Care Financ Rev, V7, P37; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; Shroyer ALW, 1996, ANN THORAC SURG, V61, P17, DOI 10.1016/0003-4975(95)00830-6; Shroyer ALW, 2003, ANN THORAC SURG, V75, P1856, DOI 10.1016/S0003-4975(03)00179-6; Sollano JA, 1999, J THORAC CARDIOV SUR, V117, P419, DOI 10.1016/S0022-5223(99)70320-X; The Leapfrog Group, LEAPFR GROUP FACT SH; WELKE K, IN PRESS ANN THORAC	31	243	244	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					195	201		10.1001/jama.291.2.195	http://dx.doi.org/10.1001/jama.291.2.195			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722145	Bronze			2022-12-28	WOS:000188040900027
J	Blum, A; Solberg, E; Wolinsky, H				Blum, A; Solberg, E; Wolinsky, H			The Surgeon General's report on smoking and health 40 years later: still wandering in the desert	LANCET			English	Editorial Material							LUNG-CANCER; PASSIVE SMOKING; CIGARETTE		Univ Alabama, Ctr Study Tobacco & Soc, Tuscaloosa, AL 35401 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Chicago Sun Times, Chicago, IL USA	University of Alabama System; University of Alabama Tuscaloosa; University of Texas System; UTMD Anderson Cancer Center	Blum, A (corresponding author), Univ Alabama, Ctr Study Tobacco & Soc, Tuscaloosa, AL 35401 USA.							BLUM A, 1980, HOSP PHYS, V16, P22; BURNEY LE, 1959, JAMA-J AM MED ASSOC, V171, P1829, DOI 10.1001/jama.1959.73010310005016; CORREA P, 1983, LANCET, V2, P595; DEAN RE, 1964, JAMA-J AM MED ASSOC, V187, P27; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; LEVIN ML, 1954, NEW YORK STATE J MED, V54, P769; MILLER GH, 1985, NEW YORK STATE J MED, V85, P313; Schuman L M, 1981, J Public Health Policy, V2, P19, DOI 10.2307/3342094; Study Group Smok. Health, 1957, SCIENCE, V125, P1129; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; WARNER KE, 1977, AM J PUBLIC HEALTH, V67, P645, DOI 10.2105/AJPH.67.7.645; 2002, MMWR MORB MORTAL WKL, V51, P409; 2003, MMWR MORB MORTAL WKL, V52, P953; 1959, JAMA, V171, P2104	14	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					97	98		10.1016/S0140-6736(03)15310-X	http://dx.doi.org/10.1016/S0140-6736(03)15310-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726161				2022-12-28	WOS:000187939200005
J	Wright, NMJ; Tompkins, CNE				Wright, NMJ; Tompkins, CNE			Supervised injecting centres	BRITISH MEDICAL JOURNAL			English	Article							DRUG-USERS; ROOMS		Ctr Res primary Care, Leeds LS2 9PL, W Yorkshire, England; NE Leeds Primary Care Trust, Leeds LS6 2HF, W Yorkshire, England	University of Leeds	Wright, NMJ (corresponding author), Ctr Res primary Care, Leeds LS2 9PL, W Yorkshire, England.							Buchanan J, 2000, DRUG-EDUC PREV POLIC, V7, P409, DOI 10.1080/713660130; Carlson RG, 2000, HUM ORGAN, V59, P325, DOI 10.17730/humo.59.3.w483t11p717473k6; *CONS ROOMS PROF S, 1999, GUID OP US CONS ROOM; De Jong W, 1999, INT J DRUG POLICY, V10, P99, DOI DOI 10.1016/S0955-3959(98)00072-73; European Monitoring Centre for Drugs and Drug Addiction, 2002, ANN REP STAT DRUGS P; Glantz LH, 1996, AM J PUBLIC HEALTH, V86, P1077, DOI 10.2105/AJPH.86.8_Pt_1.1077; *INT DROG, 1997, JAHR 1996; JACOB J, 1999, ENTSTEHUNG PRAXIS EI; *MSIC EV COMM, 2003, FIN REP EV REP SYDN; *NAT TREATM AG, INJ HER INJ METH POT; Stoever H, 2002, J DRUG ISSUES, V32, P597, DOI 10.1177/002204260203200217; Taylor A, 2000, J INFECTION, V40, P176, DOI 10.1053/jinf.2000.0647; van Ameijden EJC, 2001, J EPIDEMIOL COMMUN H, V55, P356, DOI 10.1136/jech.55.5.356; Yamey G, 2000, BRIT MED J, V320, P667	14	37	37	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 10	2004	328	7431					100	102		10.1136/bmj.328.7431.100	http://dx.doi.org/10.1136/bmj.328.7431.100			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	762MP	14715606	Green Published			2022-12-28	WOS:000187976400022
J	Abou Jawde, RM; Al-Ashkar, F				Abou Jawde, RM; Al-Ashkar, F			Progression of idiopathic pulmonary fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Abou Jawde, RM (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					165	165						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711915				2022-12-28	WOS:000187858500010
J	Herz, AM; Lahey, JM				Herz, AM; Lahey, JM			Optic neuritis due to Bartonella henselae infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Permanente Med Grp Inc, Hayward, CA 94545 USA	Permanente Medical Groups	Herz, AM (corresponding author), Permanente Med Grp Inc, Hayward, CA 94545 USA.								0	1	1	1	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					E1	E1		10.1056/ENEJMicm010038	http://dx.doi.org/10.1056/ENEJMicm010038			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711929				2022-12-28	WOS:000187858500011
J	Rydelek, PA; Tuttle, M				Rydelek, PA; Tuttle, M			Explosive craters and soil liquefaction - Curious dry craters formed irk the aftermath of a disastrous earthquake are explained.	NATURE			English	Editorial Material									Memphis State Univ, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA; M Tuttle & Associates, Georgetown, ME 04548 USA	University of Memphis	Rydelek, PA (corresponding author), Memphis State Univ, Ctr Earthquake Res & Informat, Memphis, TN 38152 USA.	par@ceri.memphis.edu						Allen J.R.L.., 1982, DEV SEDIMENTOL, V30, P593; Bartlett S.F., 1992, THESIS B YOUNG U PRO; Bendick R., 2001, SEISMOL RES LETT, V72, P328, DOI [DOI 10.1785/gssrl.72.3.328, 10.1785/gssrl.72.3.328, DOI 10.1785/GSSRL.72.3.328]; Elgamal A.W., 1989, SMALL SCALE SHAKING, P233; Seed H.B., 1982, EARTHQUAKE ENG RES I; Tuttle M.P., 2002, EARTHQ SPECTRA, V18, P79, DOI DOI 10.1193/1.2803908	6	10	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					115	116		10.1038/427115a	http://dx.doi.org/10.1038/427115a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712265				2022-12-28	WOS:000187863900024
J	Schoenbaum, SC; Bovbjerg, RR				Schoenbaum, SC; Bovbjerg, RR			Malpractice reform must include steps to prevent medical injury	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							IMPROVE PATIENT SAFETY; ADVERSE EVENTS; ERRORS; RESPONSIBILITY; NEGLIGENCE; PHYSICIANS; QUALITY	In the current malpractice insurance crisis, physicians have focused their advocacy and energy primarily on rapidly increasing liability premiums; problems in access to care; and demands for legal reform, especially caps on damages. An even more important focus, however, is prevention of injury and improvement of patient safety. Physicians largely control patient care and can play a critical role in systematically reducing injury. Reforms should go beyond liability issues; they should also harness and enhance physicians' ability to act. More visible efforts by physicians to reduce harm, better communication with patients and others, and true evidence of improved patient safety should reduce patient anger and litigiousness. Individually and collectively, physicians can and should ensure that "doing no harm" comes first in the malpractice debate.	Commonwealth Fund, New York, NY 10021 USA; Urban Inst, Washington, DC 20037 USA	Commonwealth Fund; Urban Institute	Schoenbaum, SC (corresponding author), Commonwealth Fund, 1 E 75th St, New York, NY 10021 USA.	scs@cmwf.org						BERWICK DM, 2003, I HEALTHC IMPR 13 AN; BOVBJERG RR, 2003, PATIENT SAFETY JUST; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 2003, ANN INTERN MED, V139, P267, DOI 10.7326/0003-4819-139-4-200308190-00009; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Classen DC, 2002, ACAD MED, V77, P963, DOI 10.1097/00001888-200210000-00007; CORRIGAN JM, FOSTERING RAPID ADV; DANZON PM, 1985, MED MALPRACTICE THEO; Davis K, 2002, ROOM IMPROVEMENT PAT; DOMINO KB, 2002, ASA NEWSLETTER, V66, P5; Gawande AA, 2003, NEW ENGL J MED, V348, P229, DOI 10.1056/NEJMsa021721; Goode LD, 2002, ACAD MED, V77, P947, DOI 10.1097/00001888-200210000-00004; HELLINGER FJ, 2003, IMPACT STATE LAWS LI; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; James B C, 1989, QA Rev, V1, P4; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOWES R, 2002, MED ECON, V13, P86; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; Mello MM, 2002, TEX LAW REV, V80, P1595; Miller RH, 2002, J HEALTH POLIT POLIC, V27, P401, DOI 10.1215/03616878-27-3-401; *NAT PAT SAF FDN, BIBLIOGRAPHY; *NEW JERS DEP BANK, 2003, MED MALPR PRE DAT SU; Pierce E C Jr, 1990, QRB Qual Rev Bull, V16, P61; PRAGER LO, 2000, AM MED NEWS     0612; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Silversin JB, 2000, LEADING PHYS CHANGE; STOLBERG SG, 2003, NY TIMES        0710; TAYLOR H, 2002, MOST DOCT REP FEAR M; *US C BUDG OFF, 2002, COST ESTIMATE HR 460; *US GEN ACC OFF, 2003, GAO03702; Wachter RM, 2002, ANN INTERN MED, V136, P850, DOI 10.7326/0003-4819-136-11-200206040-00015; Werner MJ, 1995, ANN INTERN MED, V122, P466, DOI 10.7326/0003-4819-122-6-199503150-00012; ZUCKERMAN S, 1990, INQUIRY-J HEALTH CAR, V27, P167	35	22	25	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					51	53		10.7326/0003-4819-140-1-200401060-00011	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706972				2022-12-28	WOS:000187855600007
J	Rosswog, S				Rosswog, S			Short gamma-ray bursts	SCIENCE			English	Editorial Material							NEUTRON-STARS; BLACK-HOLES		Int Univ Bremen, Sch Sci & Engn, Bremen, Germany	Jacobs University	Rosswog, S (corresponding author), Int Univ Bremen, Sch Sci & Engn, Bremen, Germany.	s.rosswog@iu-bremen.de	Rosswog, Stephan/G-6211-2018					DUNCAN RC, 1992, ASTROPHYS J, V392, pL9, DOI 10.1086/186413; EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126a0; Fryer CL, 1999, ASTROPHYS J, V526, P152, DOI 10.1086/307992; GOODMAN J, 1987, ASTROPHYS J, V314, pL7, DOI 10.1086/184840; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; KOUVELIOTOU C, 1993, ASTROPHYS J, V413, pL101, DOI 10.1086/186969; MacFadyen A, 2004, SCIENCE, V303, P45, DOI 10.1126/science.1091764; MAO S, 1994, ASTROPHYS J, V420, P171, DOI 10.1086/173550; Meszaros P, 1997, ASTROPHYS J, V482, pL29, DOI 10.1086/310692; NARAYAN R, 1992, ASTROPHYS J, V395, pL83, DOI 10.1086/186493; Norris JP, 2000, ASTROPHYS J, V534, P248, DOI 10.1086/308725; Paciesas WS, 2001, ESO ASTROPHY SYMP, P13, DOI 10.1007/10853853_3; Rosswog S, 2003, MON NOT R ASTRON SOC, V345, P1077, DOI 10.1046/j.1365-2966.2003.07032.x; Ruffert M, 1999, ASTRON ASTROPHYS, V344, P573; USOV VV, 1992, NATURE, V357, P472, DOI 10.1038/357472a0	15	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					46	47		10.1126/science.1091767	http://dx.doi.org/10.1126/science.1091767			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704415				2022-12-28	WOS:000187710600023
J	Aarts, M; Iihara, K; Wei, WL; Xiong, ZG; Arundine, M; Cerwinski, W; MacDonald, JF; Tymianski, M				Aarts, M; Iihara, K; Wei, WL; Xiong, ZG; Arundine, M; Cerwinski, W; MacDonald, JF; Tymianski, M			A key role for TRPM7 channels in anoxic neuronal death	CELL			English	Article							METHYL-D-ASPARTATE; CORTICAL CELL-CULTURE; CATION CHANNEL; CALCIUM NEUROTOXICITY; RECEPTOR ACTIVATION; RNA INTERFERENCE; CLINICAL-TRIALS; BRAIN INJURY; NITRIC-OXIDE; ACUTE STROKE	Excitotoxicity in brain ischemia triggers neuronal death and neurological disability, and yet these are not prevented by antiexcitotoxic therapy (AET) in humans. Here, we show that in neurons subjected to prolonged oxygen glucose deprivation (OGD), AET unmasks a dominant death mechanism perpetuated by a Ca2+-permeable nonselective cation conductance (I-OGD). I-OGD was activated by reactive oxygen/nitrogen species (ROS), and permitted neuronal Ca2+ overload and further ROS production despite AET. I-OGD currents corresponded to those evoked in HEK-293 cells expressing the nonselective cation conductance TRPM7. In cortical neurons, blocking I-OGD or suppressing TRPM7 expression blocked TRPM7 currents, anoxic Ca-45(2+) up-take, ROS production, and anoxic death. TRPM7 suppression eliminated the need for AET to rescue anoxic neurons and permitted the survival of neurons previously destined to die from prolonged anoxia. Thus, excitotoxicity is a subset of a greater overall anoxic cell death mechanism, in which TRPM7 channels play a key role.	Toronto Western Hosp, Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Surg, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Tymianski, M (corresponding author), Toronto Western Hosp, Res Inst, Toronto, ON M5T 2S8, Canada.		Aarts, Michelle/C-5766-2008	Aarts, Michelle/0000-0002-9171-0571; Tymianski, Mike/0000-0002-6311-9565	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039060] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39060] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Birmingham K, 2002, NAT MED, V8, P5, DOI 10.1038/nm0102-5a; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHOI DW, 1987, J NEUROSCI, V7, P357; Cullen BR, 2002, NAT IMMUNOL, V3, P597, DOI 10.1038/ni0702-597; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gao TM, 1998, NEUROSCIENCE, V87, P371, DOI 10.1016/S0306-4522(98)00150-X; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kerschbaum HH, 2003, BIOPHYS J, V84, P2293, DOI 10.1016/S0006-3495(03)75035-8; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Sensi SL, 1999, NEUROREPORT, V10, P1723, DOI 10.1097/00001756-199906030-00018; Sheline CT, 2002, NEUROBIOL DIS, V10, P41, DOI 10.1006/nbdi.2002.0497; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Ying WH, 2000, J CEREBR BLOOD F MET, V20, P359, DOI 10.1097/00004647-200002000-00018	43	615	649	2	70	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	2003	115	7					863	877		10.1016/S0092-8674(03)01017-1	http://dx.doi.org/10.1016/S0092-8674(03)01017-1			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697204	Bronze			2022-12-28	WOS:000187664700010
J	Dobson, CM				Dobson, CM			Protein folding and misfolding	NATURE			English	Review							TRANSITION-STATE; AMYLOID FIBRILS; HUMAN-DISEASE; NEURODEGENERATIVE DISEASE; COMMON MECHANISM; CONTACT ORDER; AGGREGATION; MODEL; CHAPERONES; STABILITY	The manner in which a newly synthesized chain of amino acids transforms itself into a perfectly folded protein depends both on the intrinsic properties of the amino-acid sequence and on multiple contributing influences from the crowded cellular milieu. Folding and unfolding are crucial ways of regulating biological activity and targeting proteins to different cellular locations. Aggregation of misfolded proteins that escape the cellular quality-control mechanisms is a common feature of a wide range of highly debilitating and increasingly prevalent diseases.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge	Dobson, CM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.							Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; BALDWIN RL, 1994, NATURE, V369, P183, DOI 10.1038/369183a0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Broome BM, 2000, J MOL BIOL, V296, P961, DOI 10.1006/jmbi.2000.3514; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Cheung MS, 2002, P NATL ACAD SCI USA, V99, P685, DOI 10.1073/pnas.022387699; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Csermely P, 2001, TRENDS GENET, V17, P701, DOI 10.1016/S0168-9525(01)02495-7; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2003, NAT REV DRUG DISCOV, V2, P154, DOI 10.1038/nrd1013; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870; Eaton WA, 1998, ACCOUNTS CHEM RES, V31, P745, DOI 10.1021/ar9700825; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P1525, DOI 10.1073/pnas.97.4.1525; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hardesty B, 2001, PROG NUCLEIC ACID RE, V66, P41; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Horwich A, 2002, J CLIN INVEST, V110, P1221, DOI 10.1172/JCI200216781; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 2003, J CELL BIOL, V161, P461, DOI 10.1083/jcb.200304074; Khan F, 2003, J MOL BIOL, V333, P169, DOI 10.1016/j.jmb.2003.08.024; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Macario AJL, 2002, AGEING RES REV, V1, P295, DOI 10.1016/S1568-1637(01)00005-8; Makarov DE, 2003, PROTEIN SCI, V12, P17, DOI 10.1110/ps.0220003; Mayor U, 2003, NATURE, V421, P863, DOI 10.1038/nature01428; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nilsson MR, 2002, PROTEIN SCI, V11, P342, DOI 10.1110/ps.48702; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Radford SE, 1999, CELL, V97, P291, DOI 10.1016/S0092-8674(00)80739-4; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Sanchez IE, 2003, J MOL BIOL, V325, P367, DOI 10.1016/S0022-2836(02)01230-5; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; Shea JE, 2001, ANNU REV PHYS CHEM, V52, P499, DOI 10.1146/annurev.physchem.52.1.499; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Snow CD, 2002, NATURE, V420, P102, DOI 10.1038/nature01160; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; Vendruscolo M, 2003, P NATL ACAD SCI USA, V100, P14817, DOI 10.1073/pnas.2036516100; Vendruscolo M, 2003, PHILOS T R SOC A, V361, P1205, DOI 10.1098/rsta.2003.1194; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; Yang WY, 2003, NATURE, V423, P193, DOI 10.1038/nature01609	71	3581	3683	26	1272	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					884	890		10.1038/nature02261	http://dx.doi.org/10.1038/nature02261			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685248				2022-12-28	WOS:000187342000070
J	Paschen, SA; Waizenegger, T; Stan, T; Preuss, M; Cyrklaff, M; Hell, K; Rapaport, D; Neupert, W				Paschen, SA; Waizenegger, T; Stan, T; Preuss, M; Cyrklaff, M; Hell, K; Rapaport, D; Neupert, W			Evolutionary conservation of biogenesis of beta-barrel membrane proteins	NATURE			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; TOM COMPLEX; IMPORT PORE; CHANNEL; COMPONENT; MACHINERY; RECEPTORS; YEAST	The outer membranes of mitochondria and chloroplasts are distinguished by the presence of beta-barrel membrane proteins(1,2). The outer membrane of Gram-negative bacteria also harbours beta-barrel proteins(3). In mitochondria these proteins fulfil a variety of functions such as transport of small molecules (porin/VDAC), translocation of proteins (Tom40) and regulation of mitochondrial morphology (Mdm10)(4-7). These proteins are encoded by the nucleus, synthesized in the cytosol, targeted to mitochondria as chaperone-bound species, recognized by the translocase of the outer membrane, and then inserted into the outer membrane where they assemble into functional oligomers(8-11). Whereas some knowledge has been accumulated on the pathways of insertion of proteins that span cellular membranes with alpha-helical segments, very little is known about how beta-barrel proteins are integrated into lipid bilayers and assembled into oligomeric structures(12). Here we describe a protein complex that is essential for the topogenesis of mitochondrial outer membrane beta-barrel proteins (TOB). We present evidence that important elements of the topogenesis of beta-barrel membrane proteins have been conserved during the evolution of mitochondria from endosymbiotic bacterial ancestors(13).	Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany	University of Munich; Max Planck Society	Neupert, W (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.							Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; Blachly-Dyson E, 2001, IUBMB LIFE, V52, P113; Brachat A, 2000, YEAST, V16, P241, DOI 10.1002/(SICI)1097-0061(200002)16:3<241::AID-YEA517>3.0.CO;2-T; De Carlo S, 2002, J STRUCT BIOL, V138, P216, DOI 10.1016/S1047-8477(02)00035-7; Ellis RJ, 1996, FOLD DES, V1, pR9, DOI 10.1016/S1359-0278(96)00004-1; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Genevrois S, 2003, EMBO J, V22, P1780, DOI 10.1093/emboj/cdg174; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; Marcotte EM, 2000, P NATL ACAD SCI USA, V97, P12115, DOI 10.1073/pnas.220399497; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Popp B, 1996, J BIOL CHEM, V271, P13593, DOI 10.1074/jbc.271.23.13593; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Raussens V, 2003, ANAL BIOCHEM, V319, P114, DOI 10.1016/S0003-2697(03)00285-9; Schleiff E, 2003, PROTEIN SCI, V12, P748, DOI 10.1110/ps.0237503; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753	29	334	347	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					862	866		10.1038/nature02208	http://dx.doi.org/10.1038/nature02208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685243				2022-12-28	WOS:000187342000064
J	Kitajima, TS; Kawashima, SA; Watanabe, Y				Kitajima, TS; Kawashima, SA; Watanabe, Y			The conserved kinetochore protein shugoshin protects centromeric cohesion during meiosis	NATURE			English	Article							SISTER-CHROMATID COHESION; REDUCTIONAL CHROMOSOME SEGREGATION; FISSION YEAST BUB1; AXIAL ELEMENTS; SPINDLE; REC8; MEI-S332; HETEROCHROMATIN; RECOMBINATION; MICROTUBULES	Meiosis comprises a pair of specialized nuclear divisions that produce haploid germ cells. To accomplish this, sister chromatids must segregate together during the first meiotic division (meiosis I), which requires that sister chromatid cohesion persists at centromeres. The factors that protect centromeric cohesion during meiosis I have remained elusive. Here we identify Sgo1 (shugoshin), a protector of the centromeric cohesin Rec8 in fission yeast. We also identify a homologue of Sgo1 in budding yeast. We provide evidence that shugoshin is widely conserved among eukaryotes. Moreover, we identify Sgo2, a paralogue of shugoshin in fission yeast, which is required for faithful mitotic chromosome segregation. Localization of Sgo1 and Sgo2 at centromeres requires the kinase Bub1, identifying shugoshin as a crucial target for the kinetochore function of Bub1. These findings provide insights into the evolution of meiosis and kinetochore regulation during mitosis and meiosis.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, SORST, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan.	ywatanab@ims.u-tokyo.ac.jp	Kawashima, Shigehiro/Q-6937-2017; Kitajima, Tomoya/A-7049-2016	Kitajima, Tomoya/0000-0002-6486-7143; Watanabe, Yoshinori/0000-0002-5488-4812				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; Bernard P, 2001, NAT CELL BIOL, V3, P522, DOI 10.1038/35074598; Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Eijpe M, 2003, J CELL BIOL, V160, P657, DOI 10.1083/jcb.200212080; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Glynn JM, 2001, CURR BIOL, V11, P836, DOI 10.1016/S0960-9822(01)00235-4; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Henikoff S, 1998, NUCLEIC ACIDS RES, V26, P309, DOI 10.1093/nar/26.1.309; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Kitajima TS, 2003, EMBO J, V22, P5643, DOI 10.1093/emboj/cdg527; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; LeBlanc HN, 1999, CHROMOSOMA, V108, P401, DOI 10.1007/s004120050392; Lee BH, 2002, GENE DEV, V16, P1672, DOI 10.1101/gad.989302; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Pasierbek P, 2001, GENE DEV, V15, P1349, DOI 10.1101/gad.192701; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Scanlan M J, 2001, Cancer Immun, V1, P4; Shonn MA, 2002, GENE DEV, V16, P1659, DOI 10.1101/gad.975802; Stoop-Myer C, 1999, NAT CELL BIOL, V1, pE125, DOI 10.1038/12956; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Uhlmann F, 2003, CURR BIOL, V13, pR104, DOI 10.1016/S0960-9822(03)00039-3; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Watanabe Y, 2001, NATURE, V409, P359, DOI 10.1038/35053103; Yamamoto A, 2003, EMBO J, V22, P2284, DOI 10.1093/emboj/cdg222; Yamamoto Y, 2001, J TURBUL, V2, P1; Yokobayashi S, 2003, MOL CELL BIOL, V23, P3965, DOI 10.1128/MCB.23.11.3965-3973.2003	44	437	452	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	2004	427	6974					510	517		10.1038/nature02312	http://dx.doi.org/10.1038/nature02312			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770KM	14730319				2022-12-28	WOS:000188721800033
J	Park, JY; Su, YQ; Ariga, M; Law, E; Jin, SLC; Conti, M				Park, JY; Su, YQ; Ariga, M; Law, E; Jin, SLC; Conti, M			EGF-like growth factors as mediators of LH action in the ovulatory follicle	SCIENCE			English	Article							RECEPTOR LIGANDS; GRANULOSA-CELLS; CUMULUS CELLS; CYCLIC-AMP; OOCYTES; MATURATION; RAT; EXPRESSION; EXPANSION; PATHWAYS	Before ovulation in mammals, a cascade of events resembling an inflammatory and/or tissue remodeling process is triggered by luteinizing hormone (LH) in the ovarian follicle. Many LH effects, however, are thought to be indirect because of the restricted expression of its receptor. Here, we demonstrate that LH stimulation induces the transient and sequential expression of the epidermal growth factor (EGF) family members amphiregulin, epiregulin, and beta-cellulin. Incubation of follicles with these growth factors recapitulates the morphological and biochemical events triggered by LH, including cumulus expansion and oocyte maturation. Thus, these EGF-related growth factors are paracrine mediators that propagate the LH signal throughout the follicle.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Stanford, CA 94305 USA	Stanford University; Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.	marco.conti@stanford.edu	Law, Evelyn C/AAM-4083-2020; Su, You-Qiang/C-6160-2019	Law, Evelyn C/0000-0003-4683-7220; Su, You-Qiang/0000-0003-3537-6246	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788, U54HD031398] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31398, HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; DEKEL N, 1985, ENDOCRINOLOGY, V116, P406, DOI 10.1210/endo-116-1-406; EPPIG JJ, 1979, J EXP ZOOL, V209, P345, DOI 10.1002/jez.1402090216; Eppig John J., 1994, Seminars in Developmental Biology, V5, P51, DOI 10.1006/sedb.1994.1007; Espey LL, 2002, BIOL REPROD, V67, P1662, DOI 10.1095/biolreprod.102.005173; Goud PT, 1998, HUM REPROD, V13, P1638, DOI 10.1093/humrep/13.6.1638; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HSU CJ, 1987, BIOCHEM BIOPH RES CO, V147, P242, DOI 10.1016/S0006-291X(87)80112-2; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Matzuk MM, 2002, NAT CELL BIOL, V4, pS41; Park J.C., UNPUB; Park JY, 2003, MOL ENDOCRINOL, V17, P1117, DOI 10.1210/me.2002-0435; PATHAK BG, 1995, GENOMICS, V28, P116, DOI 10.1006/geno.1995.1116; PENG XR, 1991, ENDOCRINOLOGY, V129, P3200, DOI 10.1210/endo-129-6-3200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Prochazka R, 2000, MOL REPROD DEV, V56, P63, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;63::AID-MRD8&gt;3.0.CO;2-D; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Robert C, 2000, MOL REPROD DEV, V57, P167, DOI 10.1002/1098-2795(200010)57:2&lt;167::AID-MRD8&gt;3.0.CO;2-P; Salustri A, 1996, ZYGOTE, V4, P313, DOI 10.1017/S0967199400003312; Tirone E, 1997, J BIOL CHEM, V272, P4787, DOI 10.1074/jbc.272.8.4787; TSAFRIRI A, 1972, J REPROD FERTIL, V31, P39, DOI 10.1530/jrf.0.0310039; TSAFRIRI A, 1994, MOL BIOL FEMALE REPR, V1, P207; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	24	734	763	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	2004	303	5658					682	684		10.1126/science.1092463	http://dx.doi.org/10.1126/science.1092463			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768EN	14726596				2022-12-28	WOS:000188530800044
J	Bachmann, LM; Haberzeth, S; Steurer, J; ter Riet, G				Bachmann, LM; Haberzeth, S; Steurer, J; ter Riet, G			The accuracy of the Ottawa knee rule to rule out knee fractures - A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							DIAGNOSTIC-TESTS; DECISION RULE; RADIOGRAPHY; VALIDATION; INJURIES	Background: The Ottawa knee rule is a clinical decision aid that helps rule out fractures and avoid unnecessary radiography. Purpose: To summarize evidence about the accuracy of the Ottawa knee rule. Data Sources: Relevant English- and non-English-language articles were identified from PreMEDLINE and MEDLINE (19662003), EMBASE (1980-2003), CINAHL (1982-2003), BIOSIS (1990-2003), the Cochrane Library (2002, Issue 3), the Science Citation Index database, reference lists of included studies, and experts. Study Selection: Articles were included if they reported enough information to determine the sensitivity and specificity of the Ottawa knee rule for detecting fractures confirmed either radiologically or in combination with follow-up. Data Extraction: Two reviewers independently extracted data on study samples, the ways that the Ottawa knee rule was used, and methodologic characteristics of studies. Data Synthesis: of 11 identified studies, 6 involving 4249 adult patients were considered appropriate for pooled analysis. The pooled negative likelihood ratio was 0.05 (95% CI, 0.02 to 0.23), the pooled sensitivity was 98.5% (CI, 93.2% to 100%), and the pooled specificity was 48.6% (CI, 43.4% to 51.0%). Conclusion: A negative result on an Ottawa knee rule test accurately excluded knee fractures after acute knee injury. However, because the rule is calibrated toward 100% sensitivity and actual fracture prevalences are usually low, large-scale, multicentered studies are still needed to establish the cost-effectiveness of routinely implementing the rule.	Univ Zurich, Horten Ctr, CH-8091 Zurich, Switzerland; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	University of Zurich; University of Amsterdam; Academic Medical Center Amsterdam	Bachmann, LM (corresponding author), Univ Zurich, Horten Ctr, Postfach Nord, CH-8091 Zurich, Switzerland.	lucas.bachmann@evimed.ch	Riet, Gerben ter/A-6943-2011; Bachmann, Lucas M/C-9686-2011	Riet, Gerben ter/0000-0002-2231-7637; Bottcher, Sophie/0000-0002-7713-9807				[Anonymous], [No title captured]; Cook SR, 2001, MED SCI SPORT EXER, V33, pS186, DOI 10.1097/00005768-200105001-01046; Deeks JJ., 2001, SYSTEMATIC REV HLTH, P248, DOI DOI 10.1002/9780470693926.CH14; DIERCKS DB, 1997, ACAD EMERG MED, V4, P408; Emparanza JI, 2001, ANN EMERG MED, V38, P364, DOI 10.1067/mem.2001.118011; *EXP PAN MUSC IM, AM COLL RAD ACR APPR; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; Ketelslegers E, 2002, EUR RADIOL, V12, P1218, DOI 10.1007/s00330-001-1198-9; Khine H, 2001, PEDIATR EMERG CARE, V17, P401, DOI 10.1097/00006565-200112000-00001; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Nichol G, 1999, ANN EMERG MED, V34, P438, DOI 10.1016/S0196-0644(99)80044-4; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Richman Peter B., 1997, Journal of Emergency Medicine, V15, P459, DOI 10.1016/S0736-4679(97)00073-5; Seaberg DC, 1998, ANN EMERG MED, V32, P8, DOI 10.1016/S0196-0644(98)70092-7; Stiell IG, 1997, JAMA-J AM MED ASSOC, V278, P2075, DOI 10.1001/jama.278.23.2075; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; Szucs PA, 2001, ACAD EMERG MED, V8, P112, DOI 10.1111/j.1553-2712.2001.tb01274.x; ter Riet G, 2001, BRIT MED J, V323, P1188; Tigges S, 1999, AM J ROENTGENOL, V172, P1069, DOI 10.2214/ajr.172.4.10587149	21	58	58	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					121	124		10.7326/0003-4819-140-5-200403020-00013	http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734335				2022-12-28	WOS:000188211700007
J	Young, T; Brailsford, S; Connell, C; Davies, R; Harper, P; Klein, JH				Young, T; Brailsford, S; Connell, C; Davies, R; Harper, P; Klein, JH			Using industrial processes to improve patient care	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; SIMULATION		Brunel Univ, Dept Informat Syst & Comp, Uxbridge UB8 3PH, Middx, England; Univ Southampton, Sch Management, Southampton SO17 1BJ, Hants, England; Univ Warwick, Warwick Business Sch, Coventry CV4 7AL, W Midlands, England; Univ Southampton, Sch Math, Southampton SO9 5NH, Hants, England	Brunel University; University of Southampton; University of Warwick; University of Southampton	Young, T (corresponding author), Brunel Univ, Dept Informat Syst & Comp, Uxbridge UB8 3PH, Middx, England.	terry.young@brunel.ac.uk		Brailsford, Sally/0000-0002-6665-8230; Young, Terry/0000-0001-9545-2269; Harper, Paul/0000-0001-7894-4907; Klein, Jonathan/0000-0002-5495-8738				BECKETT P, 2000, AEROSPACE INT    NOV, P12; CRAIGHEAD IB, 2001, BMJ; Davies R, 2002, DIABETIC MED, V19, P762, DOI 10.1046/j.1464-5491.2002.00773.x; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; Fontan JE, 2003, PHARM WORLD SCI, V25, P112, DOI 10.1023/A:1024053514359; *GEN EL, WHAT 6 SIGMA; Goldratt E, 2000, GOAL; Harry M., 1999, 6 SIGMA BREAKTHROUGH; Jun JB, 1999, J OPER RES SOC, V50, P109, DOI 10.1057/palgrave.jors.2600669; *NHS, 2000, INP ADM BED MAN NHS, P9; PENDLETON D, 2002, BRIT MED J, V325, P1354; Smith J, 2001, BRIT MED J, V322, P1257, DOI 10.1136/bmj.322.7297.1257; WILCON T, 2001, BMJ; Wolstenholme E, 1999, SYST DYNAM REV, V15, P253, DOI 10.1002/(SICI)1099-1727(199923)15:3<253::AID-SDR172>3.3.CO;2-G; Womack J.P., 1996, LEAN THINKING	15	148	149	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					162	164		10.1136/bmj.328.7432.162	http://dx.doi.org/10.1136/bmj.328.7432.162			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726351	Green Published			2022-12-28	WOS:000188249900030
J	Gottlieb, J; Mazzoni, P				Gottlieb, J; Mazzoni, P			Action, illusion, and perception	SCIENCE			English	Editorial Material							REPRESENTATION; MOVEMENTS		Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10027 USA; Columbia Univ, Mahoney Ctr Brain & Behav, New York, NY 10027 USA; Columbia Univ, Dept Neurol, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University	Gottlieb, J (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10027 USA.							GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; Gerardin E, 2000, CEREB CORTEX, V10, P1093, DOI 10.1093/cercor/10.11.1093; Hein A, 1958, PERCEPT MOTOR SKILL, V8, P87, DOI [DOI 10.2466/PMS.1958.8.3.87, 10.2466/pms.1958.8.3.87]; Jordan Michael I., 1995, P597; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Schwartz AB, 2004, SCIENCE, V303, P380, DOI 10.1126/science.1087788; Shen LM, 1997, J NEUROPHYSIOL, V77, P1195, DOI 10.1152/jn.1997.77.3.1195	7	3	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					317	318		10.1126/science.1093922	http://dx.doi.org/10.1126/science.1093922			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726577				2022-12-28	WOS:000188111800025
J	Chapados, BR; Hosfield, DJ; Han, S; Qiu, JZ; Yelent, B; Shen, BH; Tainer, JA				Chapados, BR; Hosfield, DJ; Han, S; Qiu, JZ; Yelent, B; Shen, BH; Tainer, JA			Structural basis for FEN-1 substrate specificity and PCNA-mediated activation in DNA replication and repair	CELL			English	Article							CELL NUCLEAR ANTIGEN; HUMAN FLAP ENDONUCLEASE-1; CRYSTAL-STRUCTURE; EXCISION-REPAIR; PYROCOCCUS-FURIOSUS; POLYMERASE-DELTA; SLIDING CLAMP; STRANDED-DNA; FACTOR-C; BINDING	Flap EndoNuclease-1 (FEN-1) and the processivity factor proliferating cell nuclear antigen (PCNA) are central to DNA replication and repair. To clarify the molecular basis of FEN-1 specificity and PCNA activation, we report here structures of FEN-1:DNA and PCNA: FEN-1-peptide complexes, along with fluorescence resonance energy transfer (FRET) and mutational results. FEN-1 binds the unpaired 3' DNA end (3' flap), opens and kinks the DNA, and promotes conformational closing of a flexible helical clamp to facilitate 5' cleavage specificity. Ordering of unstructured C-terminal regions in FEN-1 and PCNA creates an intermolecular beta sheet interface that directly links adjacent PCNA and DNA binding regions of FEN-1 and suggests how PCNA stimulates FEN-1 activity. The DNA and protein conformational changes, composite complex structures, FRET, and mutational results support enzyme-PCNA alignments and a kinked DNA pivot point that appear suitable to coordinate rotary handoffs of kinked DNA intermediates among enzymes localized by the three PCNA binding sites.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92122 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92122 USA; City Hope Natl Med Ctr, Div Mol Med, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA	Scripps Research Institute; Scripps Research Institute; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Tainer, JA (corresponding author), Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92122 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022; Classen, Scott/AAY-8176-2020	Tainer, John/0000-0003-1659-2429; Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [P01CA092584, R01CA081967] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA92584, CA081967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Dervan JJ, 2002, P NATL ACAD SCI USA, V99, P8542, DOI 10.1073/pnas.082241699; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Friedrich-Heineken E, 2003, J MOL BIOL, V328, P73, DOI 10.1016/S0022-2836(03)00270-5; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kim CY, 2001, BIOCHEMISTRY-US, V40, P3208, DOI 10.1021/bi002100n; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Matsui E, 2002, J BIOL CHEM, V277, P37840, DOI 10.1074/jbc.M205235200; Matsumiya S, 2002, GENES CELLS, V7, P911, DOI 10.1046/j.1365-2443.2002.00572.x; Matsumiya S, 2001, PROTEIN SCI, V10, P17, DOI 10.1110/ps.36401; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Qiu JZ, 2002, J BIOL CHEM, V277, P24659, DOI 10.1074/jbc.M111941200; Reynaldo LP, 2000, J MOL BIOL, V297, P511, DOI 10.1006/jmbi.2000.3573; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Storici F, 2002, EMBO J, V21, P5930, DOI 10.1093/emboj/cdf587; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x	50	226	233	28	227	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					39	50		10.1016/S0092-8674(03)01036-5	http://dx.doi.org/10.1016/S0092-8674(03)01036-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718165	Bronze			2022-12-28	WOS:000187960800007
J	Lakhani, SR				Lakhani, SR			Putting the brakes on cylindromatosis?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NF-KAPPA-B; CYLD		Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Royal Marsden Hosp, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Lakhani, SR (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.		Lakhani, Sunil R/I-1970-2018	Lakhani, Sunil R/0000-0003-4067-2760	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803	4	11	12	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					187	188		10.1056/NEJMcibr032650	http://dx.doi.org/10.1056/NEJMcibr032650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711921				2022-12-28	WOS:000187858500017
J	Rothenberg, SP; da Costa, MP; Sequeira, JM; Cracco, J; Roberts, JL; Weedon, J; Quadros, EV				Rothenberg, SP; da Costa, MP; Sequeira, JM; Cracco, J; Roberts, JL; Weedon, J; Quadros, EV			Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING-PROTEINS; FOLIC-ACID; CELLS; RISK; PURIFICATION; PREVENTION; ABORTION; VITAMIN; GENE; RAT	Background: In the absence of clinical folate deficiency, periconceptional supplementation with folic acid reduces a woman's risk of having an infant with a neural-tube defect. Since antiserum to folate receptors induces embryo resorption and malformations in rats, we hypothesized that autoantibodies against folate receptors in women may be associated with pregnancy complicated by a neural-tube defect. Methods: Serum from 12 women who were or had been pregnant with a fetus with a neural-tube defect and from 24 control women (20 with current or prior normal pregnancies and 4 who were nulligravid) was analyzed for autoantibodies by incubation with human placental folate receptors radiolabeled with [H-3]folic acid. The properties of these autoantibodies were characterized by incubating serum and the autoantibodies isolated from serum with placental membranes, ED27 cells, and KB cells, which express the folate receptors. Results: Serum from 9 of 12 women with a current or previous affected pregnancy (index subjects) and 2 of 20 control subjects contained autoantibodies against folate receptors (P<0.001). The autoantibodies blocked the binding of [H-3]folic acid to folate receptors on placental membranes and on ED27 and KB cells incubated at 4 &DEG;C and blocked the uptake of [H-3]folic acid by KB cells when incubated at 37 &DEG;C. Conclusions: Serum from women with a pregnancy complicated by a neural-tube defect contains autoantibodies that bind to folate receptors and can block the cellular uptake of folate. Further study is warranted to assess whether the observed association between maternal autoantibodies against folate receptors and neural-tube defects reflects a causal relation.	Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Obstet & Gynecol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Div Pediat Neurol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Ctr Comp Sci, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Rothenberg, SP (corresponding author), Suny Downstate Med Ctr, Dept Med, 450 Clarkson Ave,Box 20, Brooklyn, NY 11203 USA.							Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; Antony AC, 2000, TERATOLOGY, V62, P42, DOI 10.1002/1096-9926(200007)62:1&lt;42::AID-TERA9&gt;3.0.CO;2-U; Barber RC, 1998, AM J MED GENET, V76, P310, DOI 10.1002/(SICI)1096-8628(19980401)76:4<310::AID-AJMG6>3.0.CO;2-T; Barber RC, 1998, AM J MED GENET, V79, P231; CARMI R, 1994, AM J MED GENET, V51, P93, DOI 10.1002/ajmg.1320510203; Christensen B, 1999, AM J MED GENET, V84, P151, DOI 10.1002/(SICI)1096-8628(19990521)84:2<151::AID-AJMG12>3.3.CO;2-K; Cragan J D, 1995, MMWR CDC Surveill Summ, V44, P1; CUCKLE HS, 1983, PRENATAL DIAG, V3, P287, DOI 10.1002/pd.1970030404; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; da Costa M, 2003, BIRTH DEFECTS RES A, V67, P837, DOI 10.1002/bdra.10088; daCosta M, 1996, BBA-PROTEIN STRUCT M, V1292, P23, DOI 10.1016/0167-4838(95)00180-8; DANSKY LV, 1992, NEUROLOGY, V42, P32; De Marco P, 2000, AM J MED GENET, V95, P216, DOI 10.1002/1096-8628(20001127)95:3<216::AID-AJMG6>3.0.CO;2-F; EVANS DR, 1979, BRIT MED J, V1, P975, DOI 10.1136/bmj.1.6169.975; Finnell R H, 2000, Ann N Y Acad Sci, V919, P261; GILES C, 1966, J CLIN PATHOL, V19, P1, DOI 10.1136/jcp.19.1.1; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; Kniss DA, 2002, PLACENTA, V23, P32, DOI 10.1053/plac.2001.0749; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; Piedrahita JA, 1999, NAT GENET, V23, P228, DOI 10.1038/13861; SADASIVAN E, 1987, BIOCHIM BIOPHYS ACTA, V925, P36, DOI 10.1016/0304-4165(87)90145-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELLER MJ, 1995, CLIN DYSMORPHOL, V4, P202; Triplett A, 2002, CHEM BIOL PTERIDINES, P637; WALD N, 1991, LANCET, V338, P131; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	27	148	161	1	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					134	142		10.1056/NEJMoa031145	http://dx.doi.org/10.1056/NEJMoa031145			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711912				2022-12-28	WOS:000187858500007
J	Zhou, HL; Wertz, I; O'Rourke, K; Ultsch, M; Seshagiri, S; Eby, M; Xiao, W; Dixit, VM				Zhou, HL; Wertz, I; O'Rourke, K; Ultsch, M; Seshagiri, S; Eby, M; Xiao, W; Dixit, VM			Bcl10 activates the NF-kappa B pathway through ubiquitination of NEMO	NATURE			English	Article							CONJUGATING ENZYME COMPLEX; KINASE COMPLEX; MALT LYMPHOMA; IKK-GAMMA; GENE; CYLD	The NF-kappaB family of transcription factors is activated in response to many stimuli, including pro-inflammatory cytokines, environmental stresses and, in the case of B and T lymphocytes, by antigenic stimulation(1,2). Bcl10 is essential for NF-kappaB activation by T- and B-cell receptors. T and B lymphocytes from Bcl10-deficient mice fail to activate NF-kappaB in response to antigenreceptor stimulation and, as a consequence, are unable to proliferate(3). Bcl10 overexpression is sufficient to activate NF-kappaB, a process that requires the NF-kappaB essential modulator NEMO ( also known as IKK-gamma), which is the regulatory subunit of the IkappaB kinase complex(4). However, the cellular mechanism by which Bcl10 activates the NF-kappaB pathway remains unclear. Here we show that Bcl10 targets NEMO for lysine-63-linked ubiquitination. Notably, a mutant form of NEMO that cannot be ubiquitinated inhibited Bcl10-induced NF-kappaB activation. Paracaspase and a ubiquitin-conjugating enzyme (UBC13) were both required for Bcl10-induced NEMO ubiquitination and subsequent NF-kappaB activation. Furthermore, short interfering RNAs that reduced the expression of paracaspase and UBC13 abrogated the effects of Bcl10. Thus, the adaptor protein Bcl10 promotes activation of NF-kappaB transcription factors through paracaspase- and UBC13-dependent ubiquitination of NEMO.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California Davis; University of Saskatchewan	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Seshagiri, Somasekar/0000-0003-4272-6443; Xiao, Wei/0000-0001-7568-0782				Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Smahi A, 2000, NATURE, V405, P466; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	28	430	461	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					167	171		10.1038/nature02273	http://dx.doi.org/10.1038/nature02273			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14695475				2022-12-28	WOS:000187863900038
J	Pryor, KO; Fahey, TJ; Lien, CA; Goldstein, PA				Pryor, KO; Fahey, TJ; Lien, CA; Goldstein, PA			Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTOPERATIVE NAUSEA; SUPPLEMENTAL OXYGEN; LIPID-PEROXIDATION; WOUND-INFECTION; FREE-RADICALS; CESAREAN-SECTION; TISSUE-DAMAGE; PREVENTION; ANESTHESIA; AVAILABILITY	Context Surgical site infection (SSI) in the general surgical population is a significant public health issue. The use of a high fractional inspired concentration of oxygen (FIO2) during the perioperative period has been reported to be of benefit in selected patients, but its role as a routine intervention has not been investigated. Objective To determine whether the routine use of high FIO2 during the perioperative period alters the incidence of SSI in a general surgical population. Design, Setting, and Patients Double-blind, randomized controlled trial conducted between September 2001 and May 2003 at a large university hospital in metropolitan New York City of 165,patients undergoing major intra-abdominal surgical procedures under general anesthesia. Interventions Patients were randomly assigned to receive either 80% oxygen (FIO2 of 0.80) or 35% oxygen (FIO2 of 0.35) during surgery and for the first 2 hours after surgery. Main Outcome Measures Presence of clinically significant SSI in the first 14 days after surgery, as determined by clinical assessment, a management change, and at least 3 prospectively defined objective criteria. Results The study groups were closely matched in a large number of clinical variables. The overall incidence of SSI was 18.1%. In an intention-to-treat analysis, the incidence of infection was significantly higher in the group receiving FIO2 of 0.80 than in the group with FIO2 of 0.35 (25.0% vs 11.3%; P=.02). FIO2 remained a significant predictor of SSI (P=.03) in multivariate regression analysis. Patients who developed SSI had a significantly longer length of hospitalization after surgery (mean [SD], 13.3 [9.9] vs 6.0 [4.2] days; P<.001). Conclusions The routine use of high perioperative FIO2 in a general surgical population does not reduce the overall incidence of SSI and may have predominantly deleterious effects. General surgical patients should continue to receive oxygen with cardiorespiratory physiology as the principal determinant.	Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA	Cornell University; Cornell University	Pryor, KO (corresponding author), Cornell Univ, Weill Med Coll, Dept Anesthesiol, 525 E 68th St, New York, NY 10021 USA.		Pryor, Kane O/I-8632-2017	Pryor, Kane O/0000-0002-9212-5526; Goldstein, Peter/0000-0002-5973-9104				Allen DB, 1997, ARCH SURG-CHICAGO, V132, P991; Arkilic CF, 2003, SURGERY, V133, P49, DOI 10.1067/msy.2003.80; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Berger VW, 2000, STAT MED, V19, P1319, DOI 10.1002/(SICI)1097-0258(20000530)19:10<1319::AID-SIM490>3.0.CO;2-0; Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Buggy D, 2000, LANCET, V356, P355, DOI 10.1016/S0140-6736(00)02523-X; *CDC NNIS SYST, 2002, AM J INFECT CONTROL, V30, P458; Dean RT, 1997, BIOCHEM J, V324, P1; Denault A, 2001, CAN J ANAESTH, V48, P844, DOI 10.1007/BF03017346; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Gaynes RP, 2001, CLIN INFECT DIS, V33, pS69, DOI 10.1086/321860; Goll V, 2001, ANESTH ANALG, V92, P112, DOI 10.1097/00000539-200101000-00022; Gottrup F, 2000, NEW ENGL J MED, V342, P202, DOI 10.1056/NEJM200001203420310; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; HAOLL MJ, 2003, ADV DATA VITAL HLTH, V332; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; JARSTRAND C, 1990, J CLIN LAB IMMUNOL, V32, P37; JONSSON K, 1988, ANN SURG, V208, P783; Kallstrom Thomas J, 2002, Respir Care, V47, P717; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kee WDN, 2002, BRIT J ANAESTH, V89, P556, DOI 10.1093/bja/aef203; Khaw KS, 2002, BRIT J ANAESTH, V88, P18, DOI 10.1093/bja/88.1.18; Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572; Kober A, 2002, MAYO CLIN PROC, V77, P35, DOI 10.4065/77.1.35; Mylonas C, 1999, IN VIVO, V13, P295; O'Reilly PJ, 2003, AM J RESP CELL MOL, V28, P443, DOI 10.1165/rcmb.2002-0153OC; PHILLIPS PG, 1988, J APPL PHYSIOL, V64, P1196, DOI 10.1152/jappl.1988.64.3.1196; Purhonen S, 2003, ANESTH ANALG, V96, P91, DOI 10.1097/00000539-200301000-00020; RAVUSSIN E, 1992, LANCET, V340, P404, DOI 10.1016/0140-6736(92)91480-V; ROYSTON D, 1988, ANAESTHESIA, V43, P315; Sessler DI, 2002, CLIN INFECT DIS, V35, P1397, DOI 10.1086/344275; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; WAGNER PD, 1974, J CLIN INVEST, V54, P54, DOI 10.1172/JCI107750; WEBSTER NR, 1988, BRIT J ANAESTH, V60, P98, DOI 10.1093/bja/60.1.98; Weiser JN, 2001, INFECT IMMUN, V69, P5430, DOI 10.1128/IAI.69.9.5430-5439.2001; WELCH WD, 1984, ANESTHESIOLOGY, V61, P188, DOI 10.1097/00000542-198408000-00012; WELCH WD, 1982, ANESTHESIOLOGY, V57, P172, DOI 10.1097/00000542-198209000-00005; WINTER PM, 1972, ANESTHESIOLOGY, V37, P210, DOI 10.1097/00000542-197208000-00010	42	243	252	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					79	87		10.1001/jama.291.1.79	http://dx.doi.org/10.1001/jama.291.1.79			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709579	Bronze			2022-12-28	WOS:000187836000022
J	Beaber, JW; Hochhut, B; Waldor, MK				Beaber, JW; Hochhut, B; Waldor, MK			SOS response promotes horizontal dissemination of antibiotic resistance genes	NATURE			English	Article							VIBRIO-CHOLERAE O139; INTEGRATING ELEMENTS; ESCHERICHIA-COLI; R391; PLASMIDS; SXT; DETERMINANTS	Mobile genetic elements have a crucial role in spreading antibiotic resistance genes among bacterial populations. Environmental and genetic factors that regulate conjugative transfer of antibiotic resistance genes in bacterial populations are largely unknown(1). Integrating conjugative elements (ICEs) are a diverse group of mobile elements that are transferred by means of cell-cell contact and integrate into the chromosome of the new host(2). SXT is a similar to100-kilobase ICE derived from Vibrio cholerae that encodes genes that confer resistance to chloramphenicol, sulphamethoxazole, trimethoprim and streptomycin(3). SXT-related elements were not detected in V. cholerae before 1993 but are now present in almost all clinical V. cholerae isolates from Asia(4). ICEs related to SXT are also present in several other bacterial species and encode a variety of antibiotic and heavy metal resistance genes(4-7). Here we show that SetR, an SXT encoded repressor, represses the expression of activators of SXT transfer. The 'SOS response' to DNA damage alleviates this repression, increasing the expression of genes necessary for SXT transfer and hence the frequency of transfer. SOS is induced by a variety of environmental factors and antibiotics, for example ciprofloxacin, and we show that ciprofloxacin induces SXT transfer as well. Thus, we present a mechanism by which therapeutic agents can promote the spread of antibiotic resistance genes.	Tufts Univ, Sch Med, Dept Microbiol, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Howard Hughes Medical Institute	Waldor, MK (corresponding author), Tufts Univ, Sch Med, Dept Microbiol, 136 Harrison Ave, Boston, MA 02111 USA.	matthew.waldor@tufts.edu		Waldor, Matthew/0000-0003-1843-7000				Ausubel FA, 1990, CURRENT PROTOCOLS MO; Beaber JW, 2002, J BACTERIOL, V184, P4259, DOI 10.1128/JB.184.15.4259-4269.2002; Beaber JW, 2002, CELL MOL LIFE SCI, V59, P2065, DOI 10.1007/s000180200006; Boltner D, 2002, J BACTERIOL, V184, P5158, DOI 10.1128/JB.184.18.5158-5169.2002; Burrus V, 2002, MOL MICROBIOL, V46, P601, DOI 10.1046/j.1365-2958.2002.03191.x; COETZEE JN, 1972, J GEN MICROBIOL, V72, P543, DOI 10.1099/00221287-72-3-543; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; GIMBLE FS, 1985, J BACTERIOL, V162, P147, DOI 10.1128/JB.162.1.147-154.1985; Hochhut B, 2001, ANTIMICROB AGENTS CH, V45, P2991, DOI 10.1128/AAC.45.11.2991-3000.2001; Hochhut B, 2001, J BACTERIOL, V183, P1124, DOI 10.1128/JB.183.4.1124-1132.2001; Little John W., 1996, P453; Metcalf WW, 1996, PLASMID, V35, P1, DOI 10.1006/plas.1996.0001; Miller J.H., 1992, SHORT COURSE BACTERI, P150; PETERS SE, 1991, MOL GEN GENET, V228, P294, DOI 10.1007/BF00282479; PHILLIPS I, 1987, J ANTIMICROB CHEMOTH, V20, P631, DOI 10.1093/jac/20.5.631; Ptashne M., 1992, A GENETIC SWITCH; SCHNEIDER K, 1986, GENE, V42, P37, DOI 10.1016/0378-1119(86)90148-4; SINGER M, 1989, MICROBIOL REV, V53, P1; Waldor MK, 1996, J BACTERIOL, V178, P4157, DOI 10.1128/jb.178.14.4157-4165.1996; Walker GC., 1996, E COLI SALMONELLA CE, V2, P1400; Zatyka M, 1998, FEMS MICROBIOL REV, V21, P291, DOI 10.1016/S0168-6445(97)00061-2	21	675	751	24	351	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					72	74		10.1038/nature02241	http://dx.doi.org/10.1038/nature02241			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14688795				2022-12-28	WOS:000187710000036
J	Stiell, IG; Clement, CM; McKnight, RD; Brison, R; Schull, MJ; Rowe, BH; Worthington, JR; Eisenhauer, MA; Cass, D; Greenberg, G; MacPhail, I; Dreyer, J; Lee, JS; Bandiera, G; Reardon, M; Holroyd, B; Lesiuk, H; Wells, GA				Stiell, IG; Clement, CM; McKnight, RD; Brison, R; Schull, MJ; Rowe, BH; Worthington, JR; Eisenhauer, MA; Cass, D; Greenberg, G; MacPhail, I; Dreyer, J; Lee, JS; Bandiera, G; Reardon, M; Holroyd, B; Lesiuk, H; Wells, GA			The canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-PREDICTION RULES; CERVICAL-SPINE; DECISION RULES; BLUNT TRAUMA; RADIOGRAPHY; ALERT; INJURIES	Background: The Canadian C-Spine (cervical-spine) Rule (CCR) and the National Emergency X-Radiography Utilization Study (NEXUS) Low-Risk Criteria (NLC) are decision rules to guide the use of cervical-spine radiography in patients with trauma. It is unclear how the two decision rules compare in terms of clinical performance. Methods: We conducted a prospective cohort study in nine Canadian emergency departments comparing the CCR and NLC as applied to alert patients with trauma who were in stable condition. The CCR and NLC were interpreted by 394 physicians for patients before radiography. Results: Among the 8283 patients, 169 (2.0 percent) had clinically important cervical-spine injuries. In 845 (10.2 percent) of the patients, physicians did not evaluate range of motion as required by the CCR algorithm. In analyses that excluded these indeterminate cases, the CCR was more sensitive than the NLC (99.4 percent vs. 90.7 percent, P<0.001) and more specific (45.1 percent vs. 36.8 percent, P<0.001) for injury, and its use would have resulted in lower radiography rates (55.9 percent vs. 66.6 percent, P<0.001). In secondary analyses that included all patients, the sensitivity and specificity of CCR, assuming that the indeterminate cases were all positive, were 99.4 percent and 40.4 percent, respectively (P<0.001 for both comparisons with the NLC). Assuming that the CCR was negative for all indeterminate cases, these rates were 95.3 percent (P=0.09 for the comparison with the NLC) and 50.7 percent (P=0.001). The CCR would have missed 1 patient and the NLC would have missed 16 patients with important injuries. Conclusions: For alert patients with trauma who are in stable condition, the CCR is superior to the NLC with respect to sensitivity and specificity for cervical-spine injury, and its use would result in reduced rates of radiography.	Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Ottawa, Clin Epidemiol Program, Ottawa, ON, Canada; Univ Ottawa, Div Neurosurg, Ottawa, ON, Canada; Univ British Columbia, Div Emergency Med, Vancouver, BC V5Z 1M9, Canada; Queens Univ, Dept Emergency Med, Kingston, ON, Canada; Univ Toronto, Div Emergency Med, Toronto, ON, Canada; Univ Alberta, Div Emergency Med, Edmonton, AB, Canada; Univ Western Ontario, Div Emergency Med, London, ON, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of British Columbia; Queens University - Canada; University of Toronto; University of Alberta; Western University (University of Western Ontario)	Stiell, IG (corresponding author), Ottawa Hlth Res Inst, Clin Epidemiol Unit, F657,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.		Schull, Michael J/A-7955-2013; Reardon, Michael/ABF-8880-2021; Lee, Jacques/CAF-4380-2022	Schull, Michael J/0000-0002-1318-6364; Lee, Jacques/0000-0002-9143-6285; Holroyd, Brian/0000-0001-8221-1327; Stiell, Ian/0000-0002-2583-6408				*AM COLL SURG, 1997, ADV TRAUM LIF SUPP I; ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BAYLESS P, 1989, AM J EMERG MED, V7, P139, DOI 10.1016/0735-6757(89)90125-3; Canadian CT Head and C-Spine (CCC) Study Group, 2002, CJEM, V4, P185; Canadian CT Head and C-Spine (CCC) Study Group, 2002, CJEM, V4, P84; CHAN BTB, 2001, EMERGENCY DEP SERVIC; Daffner Richard H., 1993, Journal of Emergency Medicine, V11, P619, DOI 10.1016/0736-4679(93)90318-2; DICKINSON G, IN PRESS ANN EMERG M; DILIBERTI T, 1992, ORTHOPEDICS, V15, P179; Feinstein AR, 1987, CLINIMETRICS; FISCHER RP, 1984, ANN EMERG MED, V13, P905, DOI 10.1016/S0196-0644(84)80667-8; GBAANADOR GBM, 1986, AM J SURG, V152, P643, DOI 10.1016/0002-9610(86)90441-1; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Hoffman JR, 2001, NEW ENGL J MED, V344, P464; HOFFMAN JR, 1992, ANN EMERG MED, V21, P1454, DOI 10.1016/S0196-0644(05)80059-9; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LINDSAY P, 2001, HOSP REPORT 2001 EME, P29; Mahadevan S, 1998, ANN EMERG MED, V31, P197, DOI 10.1016/S0196-0644(98)70306-3; Marx JA, 2002, ROSENS EMERGENCY MED, V5th; MCCAIG LF, 2002, ADV DATA VITAL HLTH, V326; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; NEIFELD G L, 1988, Journal of Emergency Medicine, V6, P203, DOI 10.1016/0736-4679(88)90327-7; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; ROBERGE R J, 1991, Emergency Medicine Clinics of North America, V9, P733; Schull Michael J, 2002, CJEM, V4, P76; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stiell IG, 1997, CAN MED ASSOC J, V156, P1537; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; Stiell IG, 1997, JAMA-J AM MED ASSOC, V278, P2075, DOI 10.1001/jama.278.23.2075; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; TINTINALLI JE, 1999, EMERGENCY MED COMPRE; VANDEMARK RM, 1990, AM J ROENTGENOL, V155, P465, DOI 10.2214/ajr.155.3.2117342; Vandemheen K, 1999, ACAD EMERG MED, V6, P434; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	39	368	376	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2510	2518		10.1056/NEJMoa031375	http://dx.doi.org/10.1056/NEJMoa031375			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695411	Green Published			2022-12-28	WOS:000187529500006
J	Trapnell, BC; Whitsett, JA; Nakata, K				Trapnell, BC; Whitsett, JA; Nakata, K			Pulmonary alveolar proteinosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR PU.1; BRONCHOALVEOLAR LAVAGE FLUIDS; WHOLE-LUNG LAVAGE; COMMON BETA-CHAIN; GM-CSF; DEFICIENT MICE; SURFACTANT METABOLISM; IMMUNE-RESPONSE; C RECEPTOR		Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Neonatol, Cincinnati, OH 45229 USA; Int Med Ctr Japan, Dept Resp Dis, Tokyo, Japan	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; National Center for Global Health & Medicine - Japan	Trapnell, BC (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	bruce.trapnell@cchmc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, P50HL056387, R01HL028623, R01HL069549, R01HL071823] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56387, HL28623, HL71823, HL69549] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; ANDRIOLE VT, 1964, ANN INTERN MED, V60, P266, DOI 10.7326/0003-4819-60-2-266; Armitage JO, 1998, BLOOD, V92, P4491, DOI 10.1182/blood.V92.12.4491; Asamoto H, 1995, Nihon Kyobu Shikkan Gakkai Zasshi, V33, P835; BEDROSSIAN CWM, 1980, HUM PATHOL, V11, P527; Ben-Dov I, 1999, ISRAEL MED ASSOC J, V1, P75; Berclaz PY, 2002, J IMMUNOL, V169, P6332, DOI 10.4049/jimmunol.169.11.6332; Berclaz PY, 2002, BLOOD, V100, P4193, DOI 10.1182/blood-2002-04-1102; Bewig B, 2000, EUR RESPIR J, V15, P350, DOI 10.1034/j.1399-3003.2000.15b22.x; Bonfield TL, 2002, AM J RESP CELL MOL, V27, P481, DOI 10.1165/rcmb.2002-0023OC; BUECHNER HA, 1969, DIS CHEST, V55, P274, DOI 10.1378/chest.55.4.274; BURGESS AW, 1977, J BIOL CHEM, V252, P1998; BURY T, 1989, REV MAL RESPIR, V6, P373; Carraway MS, 2000, AM J RESP CRIT CARE, V161, P1294, DOI 10.1164/ajrccm.161.4.9906080; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; CHASE WH, 1959, EXP CELL RES, V18, P15, DOI 10.1016/0014-4827(59)90287-3; Cheng SL, 2002, CHEST, V122, P1480, DOI 10.1378/chest.122.4.1480; CORDONNIER C, 1994, AM J RESP CRIT CARE, V149, P788, DOI 10.1164/ajrccm.149.3.8118651; COSTELLO JF, 1975, THORAX, V30, P121, DOI 10.1136/thx.30.2.121; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DAVIDSON J M, 1969, British Journal of Diseases of the Chest, V63, P13, DOI 10.1016/S0007-0971(69)80040-9; DE SANCTIS P N, 1962, BMQ, V13, P19; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; deMello DE, 2001, PEDIATR PATHOL MOL M, V20, P413, DOI 10.1080/15513810109168623; Dirksen U, 1997, J CLIN INVEST, V100, P2211, DOI 10.1172/JCI119758; Dirksen U, 1998, BLOOD, V92, P1097; DOYLE AP, 1963, ARCH INTERN MED, V112, P940, DOI 10.1001/archinte.1963.03860060164018; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; DUBOIS RM, 1983, THORAX, V38, P360, DOI 10.1136/thx.38.5.360; FOUNTAIN FF, 1969, J AMER MED ASSOC, V210, P1283, DOI 10.1001/jama.210.7.1283; FRAIMOW W, 1960, ANN INTERN MED, V52, P1177, DOI 10.7326/0003-4819-52-6-1177; FRASER RS, 1999, FRASER PARES DIAGNOS, V4, P2700; FUJISHIMA T, 1995, RESPIRATION, V62, P317; Garcia Rio F, 1995, Monaldi Arch Chest Dis, V50, P12; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLDE DW, 1976, ANN INTERN MED, V85, P304, DOI 10.7326/0003-4819-85-3-304; GOLDE DW, 1979, CHEST, V76, P119, DOI 10.1378/chest.76.2.119; Goldstein LS, 1998, CHEST, V114, P1357, DOI 10.1378/chest.114.5.1357; GONZALEZROTHI RJ, 1986, CHEST, V90, P656, DOI 10.1378/chest.90.5.656; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; Hamvas A, 1997, J PEDIATR-US, V130, P231, DOI 10.1016/S0022-3476(97)70348-2; HARRIS JO, 1979, CHEST, V76, P156, DOI 10.1378/chest.76.2.156; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOFFMAN RM, 1989, AM REV RESPIR DIS, V139, P1030, DOI 10.1164/ajrccm/139.4.1030; HONDA Y, 1993, CHEST, V103, P496, DOI 10.1378/chest.103.2.496; HROMAS R, 1993, BLOOD, V82, P2998; Huffman JA, 1996, J CLIN INVEST, V97, P649, DOI 10.1172/JCI118461; Ikegami M, 1996, AM J PHYSIOL-LUNG C, V270, pL650, DOI 10.1152/ajplung.1996.270.4.L650; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Iyonaga K, 1999, EUR RESPIR J, V14, P383, DOI 10.1034/j.1399-3003.1999.14b24.x; Johkoh T, 1999, RADIOLOGY, V211, P155, DOI 10.1148/radiology.211.1.r99ap10155; KARIMAN K, 1984, LUNG, V162, P223, DOI 10.1007/BF02715650; Kavuru MS, 2000, AM J RESP CRIT CARE, V161, P1143, DOI 10.1164/ajrccm.161.4.9906044; KELLER CA, 1995, CHEST, V108, P277, DOI 10.1378/chest.108.1.277; Kitamura T, 1999, J EXP MED, V190, P875, DOI 10.1084/jem.190.6.875; Kitamura T, 2000, AM J RESP CRIT CARE, V162, P658, DOI 10.1164/ajrccm.162.2.9910032; KLAUS MH, 1961, P NATL ACAD SCI USA, V47, P1858, DOI 10.1073/pnas.47.11.1858; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kuroki Y, 1998, BBA-MOL BASIS DIS, V1408, P334, DOI 10.1016/S0925-4439(98)00079-9; Ladeb S, 1996, SUPPORT CARE CANCER, V4, P420, DOI 10.1007/BF01880639; LARSON RK, 1965, ANN INTERN MED, V62, P292, DOI 10.7326/0003-4819-62-2-292; Lee KN, 1997, CHEST, V111, P989, DOI 10.1378/chest.111.4.989; LeVine AM, 1999, J CLIN INVEST, V103, P563, DOI 10.1172/JCI5212; Lloberas J, 1999, IMMUNOL TODAY, V20, P184, DOI 10.1016/S0167-5699(99)01442-5; MAZZONE PJ, 2000, AM J RESP CRIT CARE, V161, pA888; MCCLENAHAN JB, 1974, ARCH INTERN MED, V133, P284, DOI 10.1001/archinte.133.2.284; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114, DOI 10.1165/ajrcmb.11.1.8018334; Minakata Y, 2001, INTERNAL MED, V40, P1024, DOI 10.2169/internalmedicine.40.1024; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MULLERQUERNHEIM J, 1987, KLIN WOCHENSCHR, V65, P893, DOI 10.1007/BF01745499; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; NUGENT KM, 1983, AM REV RESPIR DIS, V127, P780; Oerlemans WGH, 1998, ACTA NEUROL SCAND, V97, P138, DOI 10.1111/j.1600-0404.1998.tb00623.x; Paine R, 2000, J IMMUNOL, V164, P2602, DOI 10.4049/jimmunol.164.5.2602; Paine R, 2001, AM J PHYSIOL-LUNG C, V281, pL1210, DOI 10.1152/ajplung.2001.281.5.L1210; PATTLE RE, 1955, NATURE, V175, P1125, DOI 10.1038/1751125b0; PATTLE RE, 1961, NATURE, V189, P844, DOI 10.1038/189844a0; PRAKASH UBS, 1987, MAYO CLIN PROC, V62, P499, DOI 10.1016/S0025-6196(12)65477-9; PREGER L, 1969, RADIOLOGY, V92, P1291, DOI 10.1148/92.6.1291; RAMIREZR J, 1968, AM J MED, V45, P502, DOI 10.1016/0002-9343(68)90166-6; RAMIREZR J, 1963, ARCH INTERN MED, V112, P419, DOI 10.1001/archinte.1963.03860030173021; RAMIREZR J, 1963, NEW ENGL J MED, V268, P165, DOI 10.1056/NEJM196301242680401; RASKO JE, 1994, CYTOKINE HDB, P343; Reed JA, 1999, AM J PHYSIOL-LUNG C, V276, pL556, DOI 10.1152/ajplung.1999.276.4.L556; Reed JAH, 1997, AM J PHYSIOL-LUNG C, V273, pL715, DOI 10.1152/ajplung.1997.273.4.L715; ROBB L, 1995, P NATL ACAD SCI USA, V92, P9565, DOI 10.1073/pnas.92.21.9565; ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301; RUBEN FL, 1986, AM J MED, V80, P1187, DOI 10.1016/0002-9343(86)90683-2; RUEF C, 1990, REV INFECT DIS, V12, P41; Schoch OD, 2002, THORAX, V57, P277, DOI 10.1136/thorax.57.3.277; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SELECKY PA, 1977, ANN THORAC SURG, V24, P451, DOI 10.1016/S0003-4975(10)63440-6; Seymour JF, 2002, AM J RESP CRIT CARE, V166, P215, DOI 10.1164/rccm.2109105; Seymour JF, 2001, AM J RESP CRIT CARE, V163, P524, DOI 10.1164/ajrccm.163.2.2003146; Seymour JF, 1996, NEW ENGL J MED, V335, P1924, DOI 10.1056/NEJM199612193352513; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; SINGH G, 1983, CHEST, V83, P82, DOI 10.1378/chest.83.1.82; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; STRATTON JA, 1981, J CLIN LAB IMMUNOL, V5, P81; SUPENA R, 1974, ARCH NEUROL-CHICAGO, V30, P266, DOI 10.1001/archneur.1974.00490330074014; Takahashi T, 1998, AM J RESP CRIT CARE, V158, P1294, DOI 10.1164/ajrccm.158.4.9712003; Tanaka N, 1999, FEBS LETT, V442, P246, DOI 10.1016/S0014-5793(98)01668-8; Tarr PE, 1996, MED ONCOL, V13, P133, DOI 10.1007/BF02990841; TEJA K, 1981, NEW ENGL J MED, V305, P1390, DOI 10.1056/NEJM198112033052305; Trapnell BC, 2002, ANNU REV PHYSIOL, V64, P775, DOI 10.1146/annurev.physiol.64.090601.113847; UCHIDA K, IN PRESS BLOOD; WALKER DA, 1986, J AM OSTEOPATH ASSOC, V86, P447; Wang BM, 1997, CHEST, V111, P460, DOI 10.1378/chest.111.2.460; Wasserman K., 1994, TXB RESP MED, V2, P1933; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; Yoshida M, 2001, AM J PHYSIOL-LUNG C, V280, pL379, DOI 10.1152/ajplung.2001.280.3.L379; Zsengeller ZK, 1998, HUM GENE THER, V9, P2101, DOI 10.1089/hum.1998.9.14-2101	117	512	539	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2527	2539		10.1056/NEJMra023226	http://dx.doi.org/10.1056/NEJMra023226			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695413				2022-12-28	WOS:000187529500008
J	Giles, J				Giles, J			Nanotechnology - What is there to fear from something so small?	NATURE			English	News Item																		Liu HB, 2003, SCIENCE, V302, P868, DOI 10.1126/science.1088334	1	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					750	750		10.1038/426750a	http://dx.doi.org/10.1038/426750a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685189	Bronze			2022-12-28	WOS:000187342000012
J	Brady, M				Brady, M			Health care in remote Australian Indigenous communities	LANCET			English	Article									Australian Natl Univ, Ctr Aboriginal Econ Policy Res, Canberra, ACT 0200, Australia	Australian National University	Brady, M (corresponding author), Australian Natl Univ, Ctr Aboriginal Econ Policy Res, Canberra, ACT 0200, Australia.								0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S36	S37		10.1016/S0140-6736(03)15069-6	http://dx.doi.org/10.1016/S0140-6736(03)15069-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698123				2022-12-28	WOS:000187790200019
J	Chaitman, BR; Pepine, CJ; Parker, JO; Skopal, J; Chumakova, G; Kuch, J; Wang, WD; Skettino, SL; Wolff, AA				Chaitman, BR; Pepine, CJ; Parker, JO; Skopal, J; Chumakova, G; Kuch, J; Wang, WD; Skettino, SL; Wolff, AA		CARISA Investigators	Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAMPLE-SIZE REESTIMATION; CLINICAL-TRIALS; STABLE ANGINA; DOUBLE-BLIND; RAT HEARTS; COMBINATION; OUTCOMES; PECTORIS; DISEASE; BURDEN	Context Many patients with chronic angina experience anginal episodes despite revascularization and antianginal medications. In a previous trial, antianginal monotherapy with ranolazine, a drug believed to partially inhibit fatty acid oxidation, increased treadmill exercise performance; however, its long-term efficacy and safety have not been studied in combination with beta-blockers or calcium antagonists in a large patient population with severe chronic angina. Objectives To determine whether, at trough levels, ranolazine improves the total exercise time of patients who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina. onset and to electrocardiographic evidence of myocardial ischemia, effect on angina attacks and nitroglycerin use, and effect on long-term survival in an open-label observational study extension. Design, Setting, and Patients A randomized, 3-group parallel, double-blind, placebo-controlled trial of 823 eligible adults with symptomatic chronic angina who were randomly assigned to receive placebo or 1 of 2 doses of ranolazine. Patients treated at the 118 participating ambulatory outpatient settings in several countries were enrolled in the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial from July 1999 to August 2001 and followed up through October 31, 2002. Intervention Patients received twice-daily placebo or 750 mg or 1000 mg of ranolazine. Treadmill exercise 12 hours (trough) and 4 hours (peak) after dosing was assessed after 2, 6 (trough only), and 12 weeks of treatment. Main Outcome Measures Change in exercise duration, time to onset of angina, time to onset of ischemia, nitroglycerin use, and number of angina attacks. Results Trough exercise duration increased by 115.6 seconds from baseline in both ranolazine groups (pooled) vs 91.7 seconds in the placebo group (P=.01). The times to angina and to electrocardiographic ischemia also increased in the ranolazine groups, at peak more than at trough. The increases did not depend on changes in blood pressure, heart rate, or background antianginal therapy and persisted throughout 12 weeks. Ranolazine reduced angina attacks and nitroglycerin use by about 1 per week vs placebo (P<.02). Survival of 750 patients taking ranolazine during the CARISA trial or its associated long-term open-label study was 98.4% in the first year and 95.9% in the second year. Conclusion Twice-daily doses of ranolazine increased exercise capacity and provided additional antianginal relief to symptomatic patients with severe chronic angina taking standard doses of atenolol, amlodipine, or diltiazem, without evident adverse, long-term survival consequences over 1 to 2 years of therapy.	St Louis Univ, Hlth Sci Ctr, Div Cardiol, Sch Med,Dept Med, St Louis, MO 63110 USA; Univ Florida, Dept Med, Div Cardiol, Gainesville, FL USA; Kingston Gen Hosp, Dept Med, Div Cardiol, Kingston, ON K7L 2V7, Canada; Hosp Frantisku, Dept Med, Div Cardiol, Prague, Czech Republic; Altai State Med Univ, Dept Prevent Cardiol, Barnaul, Russia; Med Acad Hosp, Dept Cardiol, Warsaw, Poland; CV Therapeut, Palo Alto, CA USA	Saint Louis University; State University System of Florida; University of Florida; Queens University - Canada; Altai State Medical University	Chaitman, BR (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Cardiol, Sch Med,Dept Med, 15th Floor,3635 Vista Ave & Grand Blvd,POB 15250, St Louis, MO 63110 USA.	chaitman@slu.edu	Chumakova, Galina A/L-5677-2015	Chumakova, Galina A/0000-0002-2810-6531; Pepine, Carl/0000-0002-6011-681X				Alexander KP, 1998, J AM COLL CARDIOL, V32, P1657, DOI 10.1016/S0735-1097(98)00451-3; BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; Beinart SC, 2003, AM HEART J, V146, P646, DOI 10.1016/S0002-8703(03)00256-4; BODEN WE, 1985, CIRCULATION, V71, P1197, DOI 10.1161/01.CIR.71.6.1197; CARALIS DG, 1992, J ELECTROCARDIOL, V25, P101, DOI 10.1016/0022-0736(92)90114-F; CHAITMAN BR, IN PRESS J AM COLL C; Clarke B, 1996, J MOL CELL CARDIOL, V28, P341, DOI 10.1006/jmcc.1996.0032; COCCO G, 1992, J CARDIOVASC PHARM, V20, P131, DOI 10.1097/00005344-199220010-00017; DAVIES RF, 1995, J AM COLL CARDIOL, V25, P619, DOI 10.1016/0735-1097(94)00436-T; Di Diego JM, 2003, CIRCULATION, V108, P1027, DOI 10.1161/01.CIR.0000085066.05180.40; Fox KM, 1996, EUR HEART J, V17, P96; GIBBONS RJ, 2002, AHA 2002 GUIDELINE U; GOULD AL, 1995, STAT MED, V14, P1039, DOI 10.1002/sim.4780140922; GOULD AL, 1992, COMMUN STAT THEORY, V21, P2833, DOI 10.1080/03610929208830947; Holubkov R, 2002, AM HEART J, V144, P826, DOI 10.1067/mhj.2002.125505; HUNG J, 1983, CIRCULATION, V68, P560, DOI 10.1161/01.CIR.68.3.560; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kieser M, 2000, DRUG INF J, V34, P455, DOI 10.1177/009286150003400214; Koch G, 1996, DRUG INF J, V30, P523, DOI DOI 10.1177/009286159603000228; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; McCormack JG, 1996, CIRCULATION, V93, P135, DOI 10.1161/01.CIR.93.1.135; MJOS OD, 1974, J CLIN INVEST, V53, P1290, DOI 10.1172/JCI107676; Pehrsson SK, 2000, CLIN CARDIOL, V23, P763; Pell JP, 2001, HEART, V85, P662, DOI 10.1136/heart.85.6.662; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; SHEFFIELD LT, 1988, HEART DIS TXB CARDIO, V1, P223; *US DEP HHS, 1997, 3 NAT HLTH NUTR E 11; Wolff Andrew A, 2002, Heart Fail Rev, V7, P187, DOI 10.1023/A:1015384710373	28	487	510	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					309	316		10.1001/jama.291.3.309	http://dx.doi.org/10.1001/jama.291.3.309			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734593	Bronze			2022-12-28	WOS:000188243100030
J	Panning, M; Romanowicz, B				Panning, M; Romanowicz, B			Inferences on flow at the base of Earth's mantle based on seismic anisotropy	SCIENCE			English	Article							SHEAR-VELOCITY; LOWERMOST MANTLE; CORE; BOUNDARY; PACIFIC; BENEATH; CONSTRAINTS; MODEL; LAYER	We applied global waveform tomography to model radial anisotropy in the whole mantle. We found that in the last few hundred kilometers near the core-mantle boundary, horizontally polarized S-wave velocities (V(SH)) are, on average, faster (by similar to1%) than vertically polarized S-wave velocities (V(SV)), suggesting a large-scale predominance of horizontal shear. This confirms that the D" region at the base of the mantle is also a mechanical boundary layer for mantle convection. A notable exception to this average signature can be found at the base of the two broad low-velocity regions under the Pacific Ocean and under Africa, often referred to as "superplumes," where the anisotropic pattern indicates the onset of vertical flow.	Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Panning, M (corresponding author), Univ Calif Berkeley, Berkeley Seismol Lab, 215 McCone Hall, Berkeley, CA 94720 USA.	mpanning@seismo.berkeley.edu	Romanowicz, barbara A/H-6726-2017; Panning, Mark P/B-3805-2011	Romanowicz, barbara A/0000-0002-6208-6044; Panning, Mark P/0000-0002-2041-3190				BABUSKA V, 1991, SEISMIC ANISOTROPY E; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Fouch MJ, 2001, EARTH PLANET SC LETT, V190, P167, DOI 10.1016/S0012-821X(01)00380-6; Gu YJ, 2001, J GEOPHYS RES-SOL EA, V106, P11169, DOI 10.1029/2001JB000340; Gung YC, 2003, NATURE, V422, P707, DOI 10.1038/nature01559; Karato S, 1998, EARTH PLANETS SPACE, V50, P1019, DOI 10.1186/BF03352196; Kendall JM, 1996, NATURE, V381, P409, DOI 10.1038/381409a0; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; LAY T, 1998, CORE MANTLE BOUNDARY, P219; LI XD, 1995, GEOPHYS J INT, V121, P695, DOI 10.1111/j.1365-246X.1995.tb06432.x; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; McNamara AK, 2002, NATURE, V416, P310, DOI 10.1038/416310a; Megnin C, 2000, GEOPHYS J INT, V143, P709, DOI 10.1046/j.1365-246X.2000.00298.x; MONTAGNER JP, 1991, J GEOPHYS RES-SOL EA, V96, P20337, DOI 10.1029/91JB01890; MONTAGNER JP, 1989, PHYS EARTH PLANET IN, V54, P82, DOI 10.1016/0031-9201(89)90189-1; Russell SA, 1999, J GEOPHYS RES-SOL EA, V104, P13183, DOI 10.1029/1999JB900114; Stixrude L, 1998, GEODYNAMICS, V28, P83; Thomas C, 2002, GEOPHYS J INT, V151, P296, DOI 10.1046/j.1365-246X.2002.01760.x; VINNIK LP, 1989, GEOPHYS RES LETT, V16, P519, DOI 10.1029/GL016i006p00519; Wysession ME, 2001, GEOPHYS RES LETT, V28, P867, DOI 10.1029/2000GL008485	22	143	148	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					351	353		10.1126/science.1091524	http://dx.doi.org/10.1126/science.1091524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726586				2022-12-28	WOS:000188111800037
J	Dodson, TB; Caruso, PA; Nielsen, GP; Clark, HD; McIntyre, JF; Harmon, DC; Kaban, LB; Varvares, MA				Dodson, TB; Caruso, PA; Nielsen, GP; Clark, HD; McIntyre, JF; Harmon, DC; Kaban, LB; Varvares, MA			A man with pain and swelling of the jaw	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OSTEOGENIC-SARCOMA; OSTEOSARCOMA; NECK; HEAD		Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Dodson, TB (corresponding author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.		Dodson, Thomas Benton/L-6406-2019	Dodson, Thomas Benton/0000-0002-4659-8322				August M, 1997, INT J ORAL MAX SURG, V26, P198, DOI 10.1016/S0901-5027(97)80819-3; BERTONI F, 1991, CANCER-AM CANCER SOC, V68, P1555, DOI 10.1002/1097-0142(19911001)68:7<1555::AID-CNCR2820680717>3.0.CO;2-0; BROCKSTEN BE, 2002, HEAD NECK SARCOMAS; *CTR EV BAS MED, FOC CLIN QUEST; *CTR EV BAS MED, LEV EV GRAD REC; DELGADO R, 1994, HEAD NECK-J SCI SPEC, V16, P246, DOI 10.1002/hed.2880160307; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; Gadwal SR, 2001, CANCER, V91, P598, DOI 10.1002/1097-0142(20010201)91:3<598::AID-CNCR1040>3.3.CO;2-4; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT G, 2002, USERS GUIDES MED LIT, P21; Kassir RR, 1997, LARYNGOSCOPE, V107, P56, DOI 10.1097/00005537-199701000-00013; MCKIBBON A, 2002, USERS GUIDES MED LIT, P27; MCKIBBON A, 2002, USERS GUIDES MED LIT, P21; Patel SG, 2002, CANCER, V95, P1495, DOI 10.1002/cncr.10849; Sackett D. L., 1997, EVIDENCE BASED MED P, P3; Sackett DC., 1997, EVIDENCE BASED MED P, P21; Sackett DL, 1997, EVIDENCE BASED MED P, P2	17	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					267	275		10.1056/NEJMcpc030032	http://dx.doi.org/10.1056/NEJMcpc030032			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724307				2022-12-28	WOS:000188078400012
J	Egea, PF; Shan, SO; Napetschnig, J; Savage, DF; Walter, P; Stroud, RM				Egea, PF; Shan, SO; Napetschnig, J; Savage, DF; Walter, P; Stroud, RM			Substrate twinning activates the signal recognition particle and its receptor	NATURE			English	Article							THERMUS-AQUATICUS FFH; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; CONSERVED GTPASE; NG DOMAIN; RIBOSOME; COMPLEX; BINDING	Signal sequences target proteins for secretion from cells or for integration into cell membranes. As nascent proteins emerge from the ribosome, signal sequences are recognized by the signal recognition particle (SRP), which subsequently associates with its receptor (SR). In this complex, the SRP and SR stimulate each other's GTPase activity, and GTP hydrolysis ensures unidirectional targeting of cargo through a translocation pore in the membrane. To define the mechanism of reciprocal activation, we determined the 1.9 Angstrom structure of the complex formed between these two GTPases. The two partners form a quasi-two-fold symmetrical heterodimer. Biochemical analysis supports the importance of the extensive interaction surface. Complex formation aligns the two GTP molecules in a symmetrical, composite active site, and the 3' OH groups are essential for association, reciprocal activation and catalysis. This unique circle of twinned interactions is severed twice on hydrolysis, leading to complex dissociation after cargo delivery.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute	Egea, PF (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	pascal@mnsg.ucsf.edu; stroud@msg.ucsf.edu	Egea, Pascal Francois/AAI-2759-2020; Stroud, Rhonda/GQZ-0151-2022; egea, pascal/V-7662-2019; Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda/0000-0001-5242-8015; egea, pascal/0000-0003-4432-8625; Stroud, Rhonda M./0000-0001-5242-8015				Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W. L., 2002, PYMOL MOL GRAPHICS S; FOCIA PJ, IN PRESS SCIENCE; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Montoya G, 2000, STRUCTURE, V8, P515, DOI 10.1016/S0969-2126(00)00131-3; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; MUELLER K, 1988, B SOC CHIM BELG, V97, P655; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padmanabhan S, 2001, STRUCTURE, V9, P859, DOI 10.1016/S0969-2126(01)00641-4; Peluso P, 2001, BIOCHEMISTRY-US, V40, P15224, DOI 10.1021/bi011639y; PHILIPSSEN A, 2002, DINO VISUALIZING STR; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Ramirez UD, 2002, J MOL BIOL, V320, P783, DOI 10.1016/S0022-2836(02)00476-X; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rinke-Appel J, 2002, RNA, V8, P612, DOI 10.1017/S1355838202020095; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Shan SO, 2003, P NATL ACAD SCI USA, V100, P4480, DOI 10.1073/pnas.0737693100; Shepotinovskaya IV, 2002, BBA-PROTEIN STRUCT M, V1597, P107, DOI 10.1016/S0167-4838(02)00287-X; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112	38	242	246	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					215	221		10.1038/nature02250	http://dx.doi.org/10.1038/nature02250			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724630				2022-12-28	WOS:000188068100035
J	Penner, JE; Dong, XQ; Chen, Y				Penner, JE; Dong, XQ; Chen, Y			Observational evidence of a change in radiative forcing due to the indirect aerosol effect	NATURE			English	Article							STRATUS CLOUD PROPERTIES; SURFACE; MICROWAVE; PROFILES; NUMBER	Anthropogenic aerosols enhance cloud reflectivity by increasing the number concentration of cloud droplets, leading to a cooling effect on climate known as the indirect aerosol effect. Observational support for this effect is based mainly on evidence that aerosol number concentrations are connected with droplet concentrations, but it has been difficult to determine the impact of these indirect effects on radiative forcing(1-3). Here we provide observational evidence for a substantial alteration of radiative fluxes due to the indirect aerosol effect. We examine the effect of aerosols on cloud optical properties using measurements of aerosol and cloud properties at two North American sites that span polluted and clean conditions-a continental site in Oklahoma with high aerosol concentrations, and an Arctic site in Alaska with low aerosol concentrations. We determine the cloud optical depth required to fit the observed shortwave downward surface radiation. We then use a cloud parcel model to simulate the cloud optical depth from observed aerosol properties due to the indirect aerosol effect. From the good agreement between the simulated indirect aerosol effect and observed surface radiation, we conclude that the indirect aerosol effect has a significant influence on radiative fluxes.	Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA; Univ N Dakota, Dept Atmospher Sci, Grand Forks, ND 58202 USA	University of Michigan System; University of Michigan; University of North Dakota Grand Forks	Penner, JE (corresponding author), Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA.	penner@umich.edu	Chen, Yang/C-6529-2008; Penner, Joyce E/J-1719-2012; Keyes, Dennis/AAZ-9285-2021; Dong, Xiquan/C-5959-2016	Chen, Yang/0000-0002-0993-7081; Dong, Xiquan/0000-0002-3359-6117				Brenguier JL, 2000, J ATMOS SCI, V57, P803, DOI 10.1175/1520-0469(2000)057<0803:RPOBLC>2.0.CO;2; Brenguier JL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002682; Chuang CC, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000215; Delene DJ, 2001, J GEOPHYS RES-ATMOS, V106, P12579, DOI 10.1029/2000JD900800; Dong XQ, 2003, J CLIMATE, V16, P445, DOI 10.1175/1520-0442(2003)016<0445:ASCPAR>2.0.CO;2; Dong XQ, 2003, J ATMOS OCEAN TECH, V20, P42, DOI 10.1175/1520-0426(2003)020<0042:POLLSC>2.0.CO;2; Dong XQ, 2002, J ATMOS SCI, V59, P3265, DOI 10.1175/1520-0469(2002)059<3265:COSCPD>2.0.CO;2; Dong XQ, 1997, J GEOPHYS RES-ATMOS, V102, P23829, DOI 10.1029/97JD02119; Dong XQ, 2001, J GEOPHYS RES-ATMOS, V106, P15297, DOI 10.1029/2000JD900404; Dong XQ, 1998, J GEOPHYS RES-ATMOS, V103, P31681, DOI 10.1029/1998JD200047; Ghan S, 2001, J GEOPHYS RES-ATMOS, V106, P5317, DOI 10.1029/2000JD900501; Liljegren JC, 2001, J GEOPHYS RES-ATMOS, V106, P14485, DOI 10.1029/2000JD900817; Lin B, 1998, J GEOPHYS RES-ATMOS, V103, P3873, DOI 10.1029/97JD02816; Liu XH, 1998, J GEOPHYS RES-ATMOS, V103, P16145, DOI 10.1029/98JD00972; Liu YG, 2002, NATURE, V419, P580, DOI 10.1038/419580a; Lohmann U, 1999, J GEOPHYS RES-ATMOS, V104, P9169, DOI 10.1029/1999JD900046; Penner JE, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P289; Quinn PK, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001248; ROGERS E, 1995, WEATHER FORECAST, V10, P810, DOI 10.1175/1520-0434(1995)010<0810:TRASFT>2.0.CO;2; Rosenfeld D, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017684; Sheridan PJ, 2001, J GEOPHYS RES-ATMOS, V106, P20735, DOI 10.1029/2001JD000785; Twomey S., 1959, GEOFIS PURA APPL, V43, P243, DOI [10.1007/BF01993560, DOI 10.1007/BF01993560]	22	141	174	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					231	234		10.1038/nature02234	http://dx.doi.org/10.1038/nature02234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724634	Green Published			2022-12-28	WOS:000188068100039
J	Chang, LY; Tsao, KC; Hsia, SH; Shih, SR; Huang, CG; Chan, WK; Hsu, KH; Fang, TY; Huang, YC; Lin, TY				Chang, LY; Tsao, KC; Hsia, SH; Shih, SR; Huang, CG; Chan, WK; Hsu, KH; Fang, TY; Huang, YC; Lin, TY			Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOUTH-DISEASE; PULMONARY-EDEMA; RISK-FACTORS; EPIDEMIC; FOOT; HAND; POLIOMYELITIS; SURVEILLANCE; SINGAPORE; OUTBREAK	Context Although enterovirus 71 has caused epidemics associated with significant morbidity and mortality, its transmission has not been thoroughly investigated. Objectives To investigate enterovirus 71 transmission and determine clinical outcomes within households. Design, Setting, and Participants Prospective family cohort study to investigate patients at a children's hospital in Taiwan and family members of these patients who had signs and symptoms suggestive of enterovirus 71 between February 2001 and August 2002. Patients and household members underwent clinical evaluations, virological studies, questionnaire-based interviews, and were followed up for 6 months. Main Outcome Measures Enterovirus 71 infection, defined as a positive viral culture from a throat or rectal swab, or the presence of IgM or a 4-fold increase in neutralizing antibody in serum; and clinical syndromes, defined as asymptomatic; uncomplicated symptomatic; and complicated; with unfavorable outcomes of sequelae or death. Results Ninety-four families (433 family members) had at least 1 family member with evidence of enterovirus 71 infection. The overall enterovirus 71 transmission rate to household contacts was 52% (176/339 household contacts). Transmission rates were 84% for siblings (70/83); 83%, cousins (19/23); 41%, parents (72/175); 28%, grandparents (10/36); and 26%, uncles and aunts (5/19). Of 183 infected children, 11 (6%) were asymptomatic and 133 (73%) had uncomplicated illnesses (hand, foot, and mouth disease, herpangina, nonspecific febrile illness, upper respiratory tract infection, enteritis, or viral exanthema). Twenty-one percent (39/183) experienced complicated syndromes including the central nervous system or cardiopulmonary failure. During the 6-month follow-up, 10 died and 13 had long-term sequelae consisting of dysfunction in swallowing, cranial nerve palsies, central hypoventilation, or limb weakness and atrophy. Age younger than 3 years was the most significant factor associated with an unfavorable outcome in children (P=.004). Among 87 infected adults, 46 (53%) were asymptomatic, 34 (39%) had nonspecific illnesses of fever, sore throat, or gastrointestinal discomfort, and 7 (8%) had hand, foot, and mouth disease. There were no complicated cases in adults. Conclusions Enterovirus 71 household transmission rates were high for children in Taiwan and severe disease with serious complications, sequelae, and death occurred frequently. in contrast, adults had a much lower rate of acquisition of the infection and much less adverse sequelae.	Chang Gung Univ, Chang Gung Childrens Hosp, Dept Pediat, Kweishan, Taiwan; Chang Gung Univ, Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, Kweishan, Taiwan; Chang Gung Mem Hosp, Clin Virol Lab, Kweishan, Taiwan; Chang Gung Univ, Dept Hlth Care Management, Kweishan, Taiwan; Chang Gung Univ, Lab Epidemiol, Sch Med Technol, Kweishan, Taiwan; Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; National Taiwan University; National Taiwan University Hospital	Lin, TY (corresponding author), Chang Gung Univ, Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, 5 Fu Hsing St, Taoyuan 333, Taiwan.		Shih, Shin-Ru/M-9711-2016	CHANG, LUAN-YIN/0000-0003-2632-1956; Shih, Shin-Ru/0000-0003-4874-401X; Chan, Wing-Kai/0000-0002-5328-548X; Hsu, Kuang-Hung/0000-0003-2642-7689				[Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P629; Chan KP, 2003, EMERG INFECT DIS, V9, P78; Chan LG, 2000, CLIN INFECT DIS, V31, P678, DOI 10.1086/314032; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; Chang LY, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e88; Chang LY, 1999, PEDIATR INFECT DIS J, V18, P1092, DOI 10.1097/00006454-199912000-00013; Chang LY, 1999, LANCET, V354, P1682, DOI 10.1016/S0140-6736(99)04434-7; Chung Pei-Wen, 2001, Journal of Microbiology Immunology and Infection, V34, P167; Dolin R, 1999, NEW ENGL J MED, V341, P984, DOI 10.1056/NEJM199909233411309; GELFAND HM, 1957, AM J HYG, V65, P367, DOI 10.1093/oxfordjournals.aje.a119876; Grandien M, 1995, DIAGNOSTIC PROCEDURE, P279; Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301; KOGON A, 1969, AM J EPIDEMIOL, V89, P51, DOI 10.1093/oxfordjournals.aje.a120915; Lin TY, 2003, EMERG INFECT DIS, V9, P291, DOI 10.3201/eid0903.020285; Lu CY, 2002, J MED VIROL, V67, P217, DOI 10.1002/jmv.2210; MORENS DM, 1991, TXB HUMAN VIROLOGY, P427; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; Ooi EE, 2002, EMERG INFECT DIS, V8, P995, DOI 10.3201/eid0809.010397; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SCHNURR D, 1992, P351; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; Tsao KC, 2002, J MED VIROL, V68, P574, DOI 10.1002/jmv.10233; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	24	147	181	1	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					222	227		10.1001/jama.291.2.222	http://dx.doi.org/10.1001/jama.291.2.222			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722149				2022-12-28	WOS:000188040900031
J	Greenland, P; LaBree, L; Azen, SP; Doherty, TM; Detrano, RC				Greenland, P; LaBree, L; Azen, SP; Doherty, TM; Detrano, RC			Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEAM COMPUTED-TOMOGRAPHY; C-REACTIVE PROTEIN; HEART-DISEASE; PROGNOSTIC VALUE; PLAQUE RUPTURE; EVENTS; CALCIFICATION; PREVENTION; PROFILE; PEOPLE	Context Guidelines advise that all adults undergo coronary heart disease (CHD) risk assessment to guide preventive treatment intensity. Although the Framingham Risk Score (FRS) is often recommended for this, it has been suggested that risk assessment may be improved by additional tests such as coronary artery calcium scoring (CACS). Objectives To determine whether CACS assessment combined with FIRS in asymptomatic adults provides prognostic information superior to either method alone and whether the combined approach can more accurately guide primary preventive strategies in patients with CHID risk factors. Design, Setting, and Participants Prospective observational population-based study, of 146 asymptomatic adults with coronary risk factors. Participants with at least 1 coronary risk factor (>45 years) underwent computed tomography (CT) examination, were screened between 1990-1992, were contacted yearly for up to 8.5 years after CT scan, and were assessed for CHID. This analysis included 1312 participants with CACS results; excluded were 269 participants with diabetes and 14 participants with either missing data or had a coronary event before CACS was performed. Main Outcome Measure Nonfatal myocardial infarction (MI) or CHID death. Results During a median of 7.0 years of follow-up, 84 patients experienced MI or CHID death; 70 patients died of any cause. There were 291 (28%) participants with an FRS of more than 20% and 221 (21%) with a CACS of more than 300. Compared with an FRS of less than 10%, an FIRS of more than 20% predicted the risk of MI or CHID death (hazard ratio [HR], 14.3; 95% confidence interval [CI]; 2.0-104; P=.009). Compared with a CACS of zero, a CACS of more than 300 was predictive (HR, 3.9; 95% CI, 2.1-7.3; P<.001). Across categories of FIRS, CACS was predictive of risk among patients with an FRS higher than 10% (P<.001) but not with an FIRS less than 10%. Conclusion These data support the hypothesis that high CACS can modify predicted risk obtained from FIRS alone, especially among patients in the intermediate-risk category in whom clinical decision making is most uncertain.	Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Stat Consultat & Res Ctr, Los Angeles, CA USA; Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA USA; Harbor UCLA Res & Educ Inst, Dept Med, Torrance, CA USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Southern California; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Detrano, RC (corresponding author), Harbor UCLA Med Ctr, Div Cardiol, Bldg RB-2,1135 W Carson St, Torrance, CA 90502 USA.	rdetrano@rei.edu	Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063963] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; Alexopoulos D, 2003, AM HEART J, V145, P542, DOI 10.1067/mhj.2003.169; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Arad Y, 2000, J AM COLL CARDIOL, V36, P1253, DOI 10.1016/S0735-1097(00)00872-X; Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Detrano RC, 1999, CIRCULATION, V99, P2633, DOI 10.1161/01.CIR.99.20.2633; Doherty TM, 1999, J AM COLL CARDIOL, V34, P787, DOI 10.1016/S0735-1097(99)00258-2; DOHERTY TM, 1994, CALCIFIED TISSUE INT, V54, P224, DOI 10.1007/BF00301683; Doherty TM, 1999, LANCET, V353, P41, DOI 10.1016/S0140-6736(05)74866-2; Doherty TM, 1999, AM HEART J, V137, P806, DOI 10.1016/S0002-8703(99)70403-5; Forrester JS, 2002, ANN INTERN MED, V137, P823, DOI 10.7326/0003-4819-137-10-200211190-00012; Greenland P, 2001, CIRCULATION, V104, P1863, DOI 10.1161/hc4201.097189; Hawthorne V, 2002, HEART, V88, P222; Hecht H, 2003, CIRCULATION, V107, pE123, DOI 10.1161/01.CIR.0000071215.79943.0C; Kondos GT, 2003, CIRCULATION, V107, P2571, DOI 10.1161/01.CIR.0000068341.61180.55; O'Malley PG, 2000, AM J CARDIOL, V85, P945, DOI 10.1016/S0002-9149(99)00906-6; O'Malley PG, 2003, JAMA-J AM MED ASSOC, V289, P2215, DOI 10.1001/jama.289.17.2215; O'Rourke RA, 2000, CIRCULATION, V102, P126, DOI 10.1161/01.CIR.102.1.126; Park R, 2002, CIRCULATION, V106, P2073, DOI 10.1161/01.CIR.0000033819.29662.09; Qu WC, 2003, DIABETES CARE, V26, P905, DOI 10.2337/diacare.26.3.905; Raggi P, 2001, AM HEART J, V141, P375, DOI 10.1067/mhj.2001.113220; Rupard EJ, 2002, MIL MED, V167, P211, DOI 10.1093/milmed/167.3.211; Secci A, 1997, CIRCULATION, V96, P1122, DOI 10.1161/01.CIR.96.4.1122; Shah PK, 2002, PROG CARDIOVASC DIS, V44, P357, DOI 10.1053/pcad.2002.123473; Shaw LJ, 2003, RADIOLOGY, V228, P826, DOI 10.1148/radiol.2283021006; Smith S C Jr, 2000, Circulation, V101, P111; Wang SJ, 1996, AM HEART J, V132, P550, DOI 10.1016/S0002-8703(96)90237-9; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wong ND, 1996, AM J CARDIOL, V78, P1220, DOI 10.1016/S0002-9149(96)00599-1; Wong ND, 2000, AM J CARDIOL, V86, P495, DOI 10.1016/S0002-9149(00)01000-6	32	1333	1369	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					210	215		10.1001/jama.291.2.210	http://dx.doi.org/10.1001/jama.291.2.210			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722147				2022-12-28	WOS:000188040900029
J	Tong, S; Marjono, B; Brown, DA; Mulvey, S; Breit, SN; Manuelpillai, U; Wallace, EM				Tong, S; Marjono, B; Brown, DA; Mulvey, S; Breit, SN; Manuelpillai, U; Wallace, EM			Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage	LANCET			English	Article							PREGNANCY	Macrophage inhibitory cytokine 1 (MIC 1) is thought to have immunomodulatory actions favouring fetal viability. We measured serum concentrations of MIC 1 in asymptomatic women at 6-13 weeks' gestation who subsequently miscarried or who had already miscarried. MIC 1 concentrations in the miscarriage cohort (n=100), were a third of those who had ongoing pregnancies (n=197). Multiples of the median for miscarriage was 0.32 (95% CI 0.23-0.32) versus 1.00 (0.93-1.06) for ongoing pregnancies; p<0.0001. Concentrations were just as low 3 weeks before diagnosis as on the day of diagnosis. That MIC 1 serum concentrations seem to be low weeks before miscarriage suggests possible predictive and causative roles, as well as therapeutic potential.	Monash Univ, Monash Med Ctr, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW 2010, Australia	Monash University; St Vincents Hospital Sydney; University of New South Wales Sydney	Wallace, EM (corresponding author), Monash Univ, Monash Med Ctr, Dept Obstet & Gynaecol, 246 Clayton Rd, Clayton, Vic 3168, Australia.		Wallace, Euan M/K-6774-2015	Wallace, Euan M/0000-0002-4506-5233; Tong, Stephen/0000-0002-2319-0586; Brown, David/0000-0003-1382-9419				Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Brown DA, 2002, LANCET, V359, P2159, DOI 10.1016/S0140-6736(02)09093-1; Makhseed M, 2000, HUM REPROD, V15, P2011, DOI 10.1093/humrep/15.9.2011; Marjono AB, 2003, PLACENTA, V24, P100, DOI 10.1053/plac.2002.0881; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	5	71	77	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					129	130		10.1016/S0140-6736(03)15265-8	http://dx.doi.org/10.1016/S0140-6736(03)15265-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726168				2022-12-28	WOS:000187939200012
J	Aizawa, H; Hu, SC; Bobb, K; Balakrishnan, K; Ince, G; Gurevich, I; Cowan, M; Ghosh, A				Aizawa, H; Hu, SC; Bobb, K; Balakrishnan, K; Ince, G; Gurevich, I; Cowan, M; Ghosh, A			Dendrite development regulated by CREST, a calcium-regulated transcriptional activator	SCIENCE			English	Article							SYNOVIAL SARCOMA TRANSLOCATION; CAM KINASE-IV; MEDIATED TRANSCRIPTION; CBP; PROTEIN; SYT; COACTIVATOR; SSX; P300	The lasting effects of neuronal activity on brain development involve calcium-dependent gene expression. Using a strategy called transactivator trap, we cloned a calcium-responsive transactivator called CREST (for calcium-responsive transactivator). CREST is a SYT-related nuclear protein that interacts with adenosine 3',5'-monophosphate (cAMP) response element binding protein (CREB)-binding protein (CBP) and is expressed in the developing brain. Mice that have a targeted disruption of the crest gene are viable but display defects in cortical and hippocampal dendrite development. Cortical neurons from crest mutant mice are compromised in calcium-dependent dendritic growth. Thus, calcium activation of CREST-mediated transcription helps regulate neuronal morphogenesis.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Ghosh, A (corresponding author), Univ Calif San Diego, Div Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Balakrishnan, Karthik/0000-0001-8409-227X; Ince Dunn, Gulayse/0000-0003-1352-990X	NIMH NIH HHS [MH60598] Funding Source: Medline; NINDS NIH HHS [NS39993] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039993] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZAWA H, UNPUB; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu S.-J., UNPUB; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Nedivi E, 1999, J NEUROBIOL, V41, P135, DOI 10.1002/(SICI)1097-4695(199910)41:1<135::AID-NEU17>3.0.CO;2-F; Ptashne M., 1992, A GENETIC SWITCH; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	22	210	223	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					197	202		10.1126/science.1089845	http://dx.doi.org/10.1126/science.1089845			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716005				2022-12-28	WOS:000187908500039
J	Lum, PY; Armour, CD; Stepaniants, SB; Cavet, G; Wolf, MK; Butler, JS; Hinshaw, JC; Garnier, P; Prestwich, GD; Leonardson, A; Garrett-Engele, P; Rush, CM; Bard, M; Schimmack, G; Phillips, JW; Roberts, CJ; Shoemaker, DD				Lum, PY; Armour, CD; Stepaniants, SB; Cavet, G; Wolf, MK; Butler, JS; Hinshaw, JC; Garnier, P; Prestwich, GD; Leonardson, A; Garrett-Engele, P; Rush, CM; Bard, M; Schimmack, G; Phillips, JW; Roberts, CJ; Shoemaker, DD			Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes	CELL			English	Article							CELL-CYCLE ARREST; SACCHAROMYCES-CEREVISIAE; RIBOSOME BIOGENESIS; MOLECULAR-CLONING; PROTEIN; GENE; MOLSIDOMINE; 5-FLUOROURACIL; PROLIFERATION; MICROARRAYS	Modern medicine faces the challenge of developing safer and more effective therapies to treat human diseases. Many drugs currently in use were discovered without knowledge of their underlying molecular mechanisms. Understanding their biological targets and modes of action will be essential to design improved second-generation compounds. Here, we describe the use of a genome-wide pool of tagged heterozygotes to assess the cellular effects of 78 compounds in Saccharomyces cerevisiae. Specifically, lanosterol synthase in the sterol biosynthetic pathway was identified as a target of the antianginal drug molsi- domine, which may explain its cholesterol-lowering effects. Further, the rRNA processing exosome was identified as a potential target of the cell growth inhibitor 5-fluorouracil. This genome-wide screen validated previously characterized targets or helped identify potentially new modes of action for over half of the compounds tested, providing proof of this principle for analyzing the modes of action of clinically relevant compounds.	Rosetta Inpharmat LLC, Kirkland, WA 98034 USA; Merck & Co Inc, Rahway, NJ 07065 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, JP Wilmot Canc Ctr, Rochester, NY 14642 USA; Indiana Univ, Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA	Merck & Company; Merck & Company; University of Rochester; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Utah System of Higher Education; University of Utah	Lum, PY (corresponding author), Rosetta Inpharmat LLC, 12040 115th Ave NE, Kirkland, WA 98034 USA.	pek_lum@merck.com; shoemakd@stanford.alumni.org			NATIONAL CANCER INSTITUTE [R01CA095913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044836, R01GM059898, R01GM062104] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095913, CA95913] Funding Source: Medline; NIGMS NIH HHS [GM62104, R01 GM059898, GM59898, GM44836] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BAL M, 1998, BIOCHEM BIOPH RES CO, V185, P323; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; Briggs MW, 1998, J BIOL CHEM, V273, P13255, DOI 10.1074/jbc.273.21.13255; Butler JS, 2002, TRENDS CELL BIOL, V12, P90, DOI 10.1016/S0962-8924(01)02225-5; CHASSOUX G, 1998, J CARDIOVASC PHA S11, V14, pS137; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Edskes HK, 1998, J BIOL CHEM, V273, P28912, DOI 10.1074/jbc.273.44.28912; ENGELBRECHT C, 1984, BIOCHEM PHARMACOL, V33, P745, DOI 10.1016/0006-2952(84)90457-X; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; Foury F, 1997, GENE, V195, P1, DOI 10.1016/S0378-1119(97)00140-6; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Gilman A.G., 2001, GOODMAN GILMANS PHAR; GLAEVER G, 1999, NAT GENET, V21, P278; GRANZER E, 1984, ARZNEIMITTEL-FORSCH, V34-1, P191; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HUANG T, 1992, GENE, V121, P167, DOI 10.1016/0378-1119(92)90177-Q; Huels C, 2002, DRUG DISCOV TODAY, V7, pS119, DOI 10.1016/S1359-6446(02)02389-9; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; Knopp RH, 1999, NEW ENGL J MED, V341, P498, DOI 10.1056/NEJM199908123410707; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEES ND, 1995, LIPIDS, V30, P221, DOI 10.1007/BF02537824; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MacBeath G, 2000, SCIENCE, V289, P1760; MARCIREAU C, 1990, ANTIMICROB AGENTS CH, V34, P989, DOI 10.1128/AAC.34.6.989; Milla P, 2002, J BIOL CHEM, V277, P2406, DOI 10.1074/jbc.M104195200; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Moebius FF, 1996, BIOCHEMISTRY-US, V35, P16871, DOI 10.1021/bi961996m; MONK BC, 1995, BBA-BIOMEMBRANES, V1239, P81, DOI 10.1016/0005-2736(95)00133-N; Nardese V, 1996, BIOCHEM BIOPH RES CO, V218, P273, DOI 10.1006/bbrc.1996.0048; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; PARK JH, 1990, INT J GERIATR PSYCH, V5, P381, DOI 10.1002/gps.930050606; Patel O, 2003, MICROB DRUG RESIST, V9, P139, DOI 10.1089/107662903765826723; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; REDEN J, 1990, BLOOD VESSELS, V27, P282; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; RITTBERG DAH, 1989, BIOCHEM CELL BIOL, V67, P352, DOI 10.1139/o89-055; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Service RF, 2000, SCIENCE, V289, P1673, DOI 10.1126/science.289.5485.1673; Soler F, 2000, J BIOENERG BIOMEMBR, V32, P133, DOI 10.1023/A:1005519312463; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; STOCKLEIN W, 1980, ANTIMICROB AGENTS CH, V18, P863, DOI 10.1128/AAC.18.6.863; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; TANAYAMA S, 1974, XENOBIOTICA, V4, P175, DOI 10.3109/00498257409049357; TRUAN G, 1994, GENE, V142, P129; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Weir IE, 2003, CYTOM PART A, V54A, P109, DOI 10.1002/cyto.a.10054; White TC, 1998, CLIN MICROBIOL REV, V11, P382, DOI 10.1128/CMR.11.2.382; WILSON ID, 1987, XENOBIOTICA, V17, P93, DOI 10.3109/00498258709047179; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	68	366	388	2	31	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 9	2004	116	1					121	137		10.1016/S0092-8674(03)01035-3	http://dx.doi.org/10.1016/S0092-8674(03)01035-3			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718172	Bronze			2022-12-28	WOS:000187960800014
J	Baksh, MM; Jaros, M; Groves, JT				Baksh, MM; Jaros, M; Groves, JT			Detection of molecular interactions at membrane surfaces through colloid phase transitions	NATURE			English	Article							MODEL SYSTEM; RESONANCE; GLASS	The molecular architecture of - and biochemical processes within - cell membranes play important roles in all living organisms, with many drugs and infectious disease agents targeting membranes. Experimental studies of biochemical reactions on membrane surfaces are challenging, as they require a membrane environment that is fluid ( like cell membranes) but nevertheless allows for the efficient detection and characterization of molecular interactions. One approach uses lipid membranes supported on solid substrates such as silica or polymers(1,2): although the membrane is trapped near the solid interface, it retains natural fluidity and biological functionality(3) and can be implanted with membrane proteins for functional studies(4). But the detection of molecular interactions involving membrane-bound species generally requires elaborate techniques, such as surface plasmon resonance(5) or total internal reflection fluorescence microscopy(6). Here we demonstrate that colloidal phase transitions of membrane-coated silica beads provide a simple and label-free method for monitoring molecular interactions on lipid membrane surfaces. By adjusting the lipid membrane composition and hence the pair interaction potential between the membrane-supporting silica beads, we poise our system near a phase transition so that small perturbations on the membrane surface induce dramatic changes in the macroscopic organization of the colloid. We expect that this approach, used here to probe with high sensitivity protein binding events at membrane surfaces, can be applied to study a broad range of cell membrane processes.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Groves, JT (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	JTGroves@lbl.gov						Anderson VJ, 2002, NATURE, V416, P811, DOI 10.1038/416811a; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; Buranda T, 2003, LANGMUIR, V19, P1654, DOI 10.1021/la026405+; Dinsmore AD, 2002, SCIENCE, V298, P1006, DOI 10.1126/science.1074868; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; Fang Y, 2002, J AM CHEM SOC, V124, P2394, DOI 10.1021/ja017346+; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Groves JT, 2002, CURR OPIN DRUG DISC, V5, P606; Hoffman TL, 2000, P NATL ACAD SCI USA, V97, P11215, DOI 10.1073/pnas.190274097; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Ramos L, 1999, SCIENCE, V286, P2325, DOI 10.1126/science.286.5448.2325; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Wong AP, 2002, P NATL ACAD SCI USA, V99, P14147, DOI 10.1073/pnas.212392599; Yang PD, 1998, SCIENCE, V282, P2244, DOI 10.1126/science.282.5397.2244; Yang TL, 2001, ANAL CHEM, V73, P165, DOI 10.1021/ac000997o; Yethiraj A, 2003, NATURE, V421, P513, DOI 10.1038/nature01328	16	183	188	2	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					139	141		10.1038/nature02209	http://dx.doi.org/10.1038/nature02209			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712272				2022-12-28	WOS:000187863900031
J	Martin, MP; O'Neill, D				Martin, MP; O'Neill, D			Vascular higher-level gait disorders - a step in the right direction?	LANCET			English	Editorial Material							TRIAL		Adelaide & Meath Hosp Dublin, Trinity Coll Dublin, Dept Med Gerontol, Dublin 24, Ireland	Trinity College Dublin	Martin, MP (corresponding author), Adelaide & Meath Hosp Dublin, Trinity Coll Dublin, Dept Med Gerontol, Dublin 24, Ireland.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				Alexander NB, 1996, CLIN GERIATR MED, V12, P689; Baezner H, 2001, CEREBROVASC DIS, V11, P235, DOI 10.1159/000047645; JANTRA P, 1992, ARCH PHYS MED REHAB, V73, P95; Kenny RA, 1996, SYNCOPE OLDER PATIEN; Liston R, 2003, AGE AGEING, V32, P252, DOI 10.1093/ageing/32.3.252; MEYER JS, 1986, JAMA-J AM MED ASSOC, V256, P2203, DOI 10.1001/jama.256.16.2203; Mickelborough Jane, 1997, Physiotherapy Theory and Practice, V13, P127; Nikolaus T, 2003, J AM GERIATR SOC, V51, P300, DOI 10.1046/j.1532-5415.2003.51102.x; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; SUDARSKY L, 1983, ARCH NEUROL-CHICAGO, V40, P740, DOI 10.1001/archneur.1983.04050110058009; WILKIESON CA, 1994, REV CLIN GERONTOL, V4, P31	11	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					8	8		10.1016/S0140-6736(03)15246-4	http://dx.doi.org/10.1016/S0140-6736(03)15246-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723986				2022-12-28	WOS:000187711300007
J	Pawlowski, WP; Golubovskaya, IN; Timofejeva, L; Meeley, RB; Sheridan, WF; Cande, WZ				Pawlowski, WP; Golubovskaya, IN; Timofejeva, L; Meeley, RB; Sheridan, WF; Cande, WZ			Coordination of meiotic recombination, pairing, and synapsis by PHS1	SCIENCE			English	Article							CHROMOSOME SYNAPSIS; HOMOLOGOUS CHROMOSOMES; MEIOSIS; PROTEIN; GENE; YEAST; DMC1; ARABIDOPSIS; MOUSE; PROGRESSION	Pairing, synapsis, and recombination are prerequisites for accurate chromosome segregation in meiosis. The phs1 gene in maize is required for pairing to occur between homologous chromosomes. In the phs1 mutant, homologous chromosome synapsis is completely replaced by synapsis between nonhomologous partners. The phs1 gene is also required for installation of the meiotic recombination machinery on chromosomes, as the mutant almost completely lacks chromosomal foci of the recombination protein RAD51. Thus, in the phs1 mutant, synapsis is uncoupled from recombination and pairing. The protein encoded by the phs1 gene likely acts in a multistep process to coordinate pairing, recombination, and synapsis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Pioneer HiBred Int Inc, Johnston, IA 50131 USA; Univ N Dakota, Dept Biol, Grand Forks, ND 58202 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; DuPont; University of North Dakota Grand Forks	Pawlowski, WP (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.							Armstrong SJ, 2002, J CELL SCI, V115, P3645, DOI 10.1242/jcs.00048; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Bennetzen JL, 2000, PLANT MOL BIOL, V42, P251, DOI 10.1023/A:1006344508454; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Caryl AP, 2000, CHROMOSOMA, V109, P62, DOI 10.1007/s004120050413; DEJONG JH, 1991, GENOME, V34, P109, DOI 10.1139/g91-018; Eggler AL, 2002, J BIOL CHEM, V277, P39280, DOI 10.1074/jbc.M204328200; Franklin AE, 1999, PLANT CELL, V11, P809, DOI 10.1105/tpc.11.5.809; Golubovskaya IN, 2002, GENETICS, V162, P1979; Grelon M, 2001, EMBO J, V20, P589, DOI 10.1093/emboj/20.3.589; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; Moens PB, 2002, J CELL SCI, V115, P1611; Nabeshima K, 2001, EMBO J, V20, P3871, DOI 10.1093/emboj/20.14.3871; Page SL, 2003, SCIENCE, V301, P785, DOI 10.1126/science.1086605; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Schommer C, 2003, PLANT J, V36, P1, DOI 10.1046/j.1365-313X.2003.01850.x; Villeneuve AM, 2001, CELL, V106, P647, DOI 10.1016/S0092-8674(01)00500-1; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	24	108	123	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					89	92		10.1126/science.1091110	http://dx.doi.org/10.1126/science.1091110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704428				2022-12-28	WOS:000187710600040
J	Corey, L; Wald, A; Patel, R; Sacks, SL; Tyring, SK; Warren, T; Douglas, JM; Paavonen, J; Morrow, RA; Beutner, KR; Stratchounsky, LS; Mertz, G; Keene, ON; Watson, HA; Tait, D; Vargas-Cortes, M				Corey, L; Wald, A; Patel, R; Sacks, SL; Tyring, SK; Warren, T; Douglas, JM; Paavonen, J; Morrow, RA; Beutner, KR; Stratchounsky, LS; Mertz, G; Keene, ON; Watson, HA; Tait, D; Vargas-Cortes, M		Valacyclovir HSV Transmission Stud	Once-daily valacyclovir to reduce the risk of transmission of genital herpes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX-VIRUS TYPE-2; ULCER-DISEASE; UNITED-STATES; DOUBLE-BLIND; INFECTION; ACYCLOVIR; VALACICLOVIR; SUPPRESSION; ACQUISITION; EPISODE	BACKGROUND: Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV. METHODS: We followed 1484 immunocompetent, heterosexual, monogamous couples: one with clinically symptomatic genital HSV-2 and one susceptible to HSV-2. The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months. The susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes. Source partners were followed for recurrences of genital herpes; 89 were enrolled in a substudy of HSV-2 mucosal shedding. Both partners were counseled on safer sex and were offered condoms at each visit. The predefined primary end point was the reduction in transmission of symptomatic genital herpes. RESULTS: Clinically symptomatic HSV-2 infection developed in 4 of 743 susceptible partners who were given valacyclovir, as compared with 16 of 741 who were given placebo (hazard ratio, 0.25; 95 percent confidence interval, 0.08 to 0.75; P=0.008). Overall, acquisition of HSV-2 was observed in 14 of the susceptible partners who received valacyclovir (1.9 percent), as compared with 27 (3.6 percent) who received placebo (hazard ratio, 0.52; 95 percent confidence interval, 0.27 to 0.99; P=0.04). HSV DNA was detected in samples of genital secretions on 2.9 percent of the days among the HSV-2-infected (source) partners who received valacyclovir, as compared with 10.8 percent of the days among those who received placebo (P<0.001). The mean rates of recurrence were 0.11 per month and 0.40 per month, respectively (P<0.001). CONCLUSIONS: Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant couples.	Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Royal S Hants Hosp, Dept Genitourinary Med, Southampton SO9 4PE, Hants, England; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Viridae Clin Sci, Vancouver, BC, Canada; Univ Texas, Med Branch, Galveston, TX 77550 USA; Westover Hts Clin, Portland, OR USA; Denver Dept Publ Hlth, Dis Control Serv, Denver, CO USA; Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland; Dow Pharmaceut Sci, San Francisco, CA USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Smolensk State Med Acad, Dept Clin Pharmacol, Smolensk, Russia; Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA; GlaxoSmithKline Res & Dev, Dept Biomed Data Sci, Greenford, Middx, England; GlaxoSmithKline Res & Dev, Dept Antiviral Clin Res, Greenford, Middx, England	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of British Columbia; University of Texas System; University of Texas Medical Branch Galveston; University of Helsinki; University of California System; University of California San Francisco; University of New Mexico; GlaxoSmithKline; GlaxoSmithKline	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis, 1100 Fairview Ave N,Rm D3-100,POB 19024, Seattle, WA 98109 USA.		Wald, Anna/B-6272-2012; Warren, Terri/AAJ-1650-2021	Wald, Anna/0000-0003-3486-6438; Paavonen, Jorma/0000-0003-4775-606X; Keene, Oliver/0000-0003-0016-9773	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AM MED ASS, 1997, GEN HERP PAT GUID TR; Armstrong GL, 2001, AM J EPIDEMIOL, V153, P912, DOI 10.1093/aje/153.9.912; Ashley RL, 1999, CLIN MICROBIOL REV, V12, P1; Bacon TH, 2003, CLIN MICROBIOL REV, V16, P114, DOI 10.1128/CMR.16.1.114-128.2003; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Beyrer C, 1998, J INFECT DIS, V178, P243, DOI 10.1086/515603; BROWN ZA, 2003, JAMA-J AM MED ASSOC, V289, P2803; CARNEY O, 1994, GENITOURIN MED, V70, P40; Chen CY, 2000, SEX TRANSM DIS, V27, P21, DOI 10.1097/00007435-200001000-00005; Conant MA, 2002, INT J STD AIDS, V13, P12, DOI 10.1258/0956462021924550; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; Corey L, 1999, SEX TRANSM DIS, V3rd, P285; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; Fife KH, 1997, SEX TRANSM DIS, V24, P481, DOI 10.1097/00007435-199709000-00007; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; GARDELLA C, 2001, ANN RES M INF DIS SO; GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.1093/biomet/57.3.471; GOLDBERG LH, 1993, ARCH DERMATOL, V129, P582, DOI 10.1001/archderm.129.5.582; Jerome KR, 2002, J CLIN MICROBIOL, V40, P2609, DOI 10.1128/JCM.40.7.2609-2611.2002; Langenberg AGM, 1999, NEW ENGL J MED, V341, P1432, DOI 10.1056/NEJM199911043411904; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; Mwansasu A, 2002, J CLIN VIROL, V24, P183, DOI 10.1016/S1386-6532(01)00248-7; Patel R, 1997, GENITOURIN MED, V73, P105; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; RYNCARZ AJ, 2002, J CLIN MICROBIOL, V1941, P99; SACKS SL, 1997, 37 INT C ANT AG CHEM, P227; SHUSTER JJ, 1993, CONTROL CLIN TRIALS, V14, P198, DOI 10.1016/0197-2456(93)90003-V; Spruance SL, 1996, ARCH INTERN MED, V156, P1729, DOI 10.1001/archinte.156.15.1729; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; Wald A, 2000, NEW ENGL J MED, V342, P844, DOI 10.1056/NEJM200003233421203; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; Wald A, 2001, JAMA-J AM MED ASSOC, V285, P3100, DOI 10.1001/jama.285.24.3100; WALD A, 1998, 38 INT C ANT AG CHEM, P338; WALD A, 2000, STIS MILL JOINT M AM; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129	39	432	466	4	37	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					11	20		10.1056/NEJMoa035144	http://dx.doi.org/10.1056/NEJMoa035144			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702423	Bronze			2022-12-28	WOS:000187659900005
J	Dhaliwal, G; Schmidt, KE; Gilden, DJ; Saint, S				Dhaliwal, G; Schmidt, KE; Gilden, DJ; Saint, S			True, true, and related	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THYMOMA		Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA USA; Legacy Good Samaritan Hosp, Dept Med, Portland, OR USA; Emanuel Hosp & Hlth Ctr, Portland, OR USA; Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Ann Arbor, MI USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dhaliwal, G (corresponding author), Vet Affairs Med Ctr, Dept Med, 4150 Clement St 111, San Francisco, CA 94121 USA.		Saint, Sanjay/AAF-5126-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Charles RJ, 1996, BLOOD, V87, P4831, DOI 10.1182/blood.V87.11.4831.bloodjournal87114831; CHU KC, 1990, PUBLIC HEALTH REP, V105, P36; Croisille L, 2001, CURR OPIN HEMATOL, V8, P68, DOI 10.1097/00062752-200103000-00002; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; KASSIRER JP, 1978, ANN INTERN MED, V89, P245, DOI 10.7326/0003-4819-89-2-245; KASSIRER JP, 1991, LEARNING CLIN REASON, P32; LEWIS JE, 1987, CANCER, V60, P2727, DOI 10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D; Thomas CR, 1999, J CLIN ONCOL, V17, P2280, DOI 10.1200/JCO.1999.17.7.2280	8	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					60	65		10.1056/NEJMcps031606	http://dx.doi.org/10.1056/NEJMcps031606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702429				2022-12-28	WOS:000187659900011
J	Gillick, MR				Gillick, MR			Advance care planning	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Harvard Vanguard Med Associates, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Vanguard Medical Associates; Harvard University; Harvard Medical School	Gillick, MR (corresponding author), Harvard Univ, Sch Med, Harvard Vanguard Med Associates, Boston, MA 02115 USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; HAMMES B, 2003, UPDATE RESPECTING CH, P5	2	109	113	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					7	8		10.1056/NEJMp038202	http://dx.doi.org/10.1056/NEJMp038202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702421				2022-12-28	WOS:000187659900003
J	Qin, L; Kudla, U; Roze, EHA; Goverse, A; Popeijus, H; Nieuwland, J; Overmars, H; Jones, JT; Schots, A; Smant, G; Bakker, J; Helder, J				Qin, L; Kudla, U; Roze, EHA; Goverse, A; Popeijus, H; Nieuwland, J; Overmars, H; Jones, JT; Schots, A; Smant, G; Bakker, J; Helder, J			Plant degradation: A nematode expansin acting on plants	NATURE			English	Editorial Material							CELL WALLS		Univ Wageningen & Res Ctr, Nematol Lab, Grad Sch Expt Plant Sci, NL-6709 PD Wageningen, Netherlands; Univ Wageningen & Res Ctr, Lab Mol Recognit & Antibody Technol, Grad Sch Expt Plant Sci, NL-6709 PD Wageningen, Netherlands; Catholic Univ Nijmegen, Grad Sch Expt Plant Sci, Dept Expt Bot, NL-6525 ED Nijmegen, Netherlands; Scottish Crop Res Inst, Plant Pathogen Interact Programme, Dundee DD2 5DA, Scotland	Wageningen University & Research; Wageningen University & Research; Radboud University Nijmegen; James Hutton Institute	Qin, L (corresponding author), Univ Wageningen & Res Ctr, Nematol Lab, Grad Sch Expt Plant Sci, NL-6709 PD Wageningen, Netherlands.	hans.helder@wur.nl	Schots, Arjen/U-1839-2017; Schots, Arjen/ABF-8014-2020	Schots, Arjen/0000-0002-6036-7088; Schots, Arjen/0000-0002-6036-7088; Jones, John/0000-0003-2074-0551				Cosgrove DJ, 2000, CURR OPIN PLANT BIOL, V3, P73, DOI 10.1016/S1369-5266(99)00039-4; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; Davies M, 2000, S AFR J SURG, V38, P3; Jaubert S, 2002, FEBS LETT, V522, P109, DOI 10.1016/S0014-5793(02)02906-X; Laine MJ, 2000, PHYSIOL MOL PLANT P, V57, P221, DOI 10.1006/pmpp.2000.0301; MCQUEENMASON S, 1992, PLANT CELL, V4, P1425, DOI 10.1105/tpc.4.11.1425; Popeijus H, 2000, NATURE, V406, P36, DOI 10.1038/35017641; Qin L, 2000, MOL PLANT MICROBE IN, V13, P830, DOI 10.1094/MPMI.2000.13.8.830; Saloheimo M, 2002, EUR J BIOCHEM, V269, P4202, DOI 10.1046/j.1432-1033.2002.03095.x; Xu BZ, 2000, EUR J BIOCHEM, V267, P4970, DOI 10.1046/j.1432-1327.2000.01533.x	10	152	174	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					30	30		10.1038/427030a	http://dx.doi.org/10.1038/427030a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702076	Bronze			2022-12-28	WOS:000187710000024
J	Tian, E; Zhan, FH; Walker, R; Rasmussen, E; Ma, YP; Barlogie, B; Shaughnessy, JD				Tian, E; Zhan, FH; Walker, R; Rasmussen, E; Ma, YP; Barlogie, B; Shaughnessy, JD			The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE MORPHOGENETIC PROTEIN-2; RECEPTOR-RELATED PROTEIN-5; GLOBAL GENE-EXPRESSION; STEM-CELL NICHE; OSTEOCLAST DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; QUANTITATIVE HISTOLOGY; MONOCLONAL GAMMOPATHY; LIGAND; OSTEOPROTEGERIN	Background: Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both. Methods: We subjected purified plasma cells from the bone marrow of patients with newly diagnosed multiple myeloma and control subjects to oligonucleotide microarray profiling and biochemical and immunohistochemical analyses to identify molecular determinants of osteolytic lesions. Results: We studied 45 control subjects, 36 patients with multiple myeloma in whom focal lesions of bone could not be detected by magnetic resonance imaging (MRI), and 137 patients in whom MRI detected such lesions. Different patterns of expression of 57 of approximately 10,000 genes from purified myeloma cells could be used to distinguish the two groups of patients (P<0.001). Permutation analysis, which adjusts the significance level to account for multiple comparisons in the data sets, showed that 4 of these 57 genes were significantly overexpressed by plasma cells from patients with focal lesions. One of these genes, dickkopf 1 (DKK1), and its corresponding protein (DKK1) were studied in detail because DKK1 is a secreted factor that has been linked to the function of osteoblasts. Immunohistochemical analysis of bone marrow-biopsy specimens showed that only myeloma cells contained detectable DKK1. Elevated DKK1 levels in bone marrow plasma and peripheral blood from patients with multiple myeloma correlated with the gene-expression patterns of DKK1 and were associated with the presence of focal bone lesions. Recombinant human DKK1 or bone marrow serum containing an elevated level of DKK1 inhibited the differentiation of osteoblast precursor cells in vitro. Conclusions: The production of DKK1, an inhibitor of osteoblast differentiation, by myeloma cells is associated with the presence of lytic bone lesions in patients with multiple myeloma.	Univ Arkansas Med Sci, Donna D & Donald M Lambert Lab Myeloma Genet, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Coll Med, Dept Radiol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Coll Med, Dept Pathol, Little Rock, AR 72205 USA; Canc Res & Biostat, Seattle, WA USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Cancer Research & Biostatistics	Shaughnessy, JD (corresponding author), Univ Arkansas Med Sci, Donna D & Donald M Lambert Lab Myeloma Genet, Myeloma Inst Res & Therapy, 4301 W Markham St 776, Little Rock, AR 72205 USA.			Zhan, Fenghuang/0000-0001-6208-1676	NATIONAL CANCER INSTITUTE [R33CA097513, P01CA055819] Funding Source: NIH RePORTER; NCI NIH HHS [CA97513, CA55819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; BARLOGIE B, IN PRESS BLOOD; BATAILLE R, 1990, BRIT J HAEMATOL, V76, P484, DOI 10.1111/j.1365-2141.1990.tb07904.x; BATAILLE R, 1986, BRIT J CANCER, V53, P805, DOI 10.1038/bjc.1986.136; BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305; Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1995, J CELL BIOL, V128, pA713; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562; ROUX C, 1994, BONE, V15, P41, DOI 10.1016/8756-3282(94)90890-7; Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood-2002-09-2684; Shaughnessy J, 2003, BLOOD, V101, P3849, DOI 10.1182/blood-2002-09-2873; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAUBE T, 1992, EUR J HAEMATOL, V49, P192; Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood-2003-02-0380; VALENTINOPRAN A, 1982, BRIT J HAEMATOL, V52, P601, DOI 10.1111/j.1365-2141.1982.tb03936.x; Westfall P. H., 1993, RESAMPLING BASED MUL, P360; Yaccoby S, 2002, BLOOD, V100, p607A; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	41	1111	1223	0	59	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2483	2494		10.1056/NEJMoa030847	http://dx.doi.org/10.1056/NEJMoa030847			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695408				2022-12-28	WOS:000187529500003
J	Poynard, T; Yuen, MF; Ratziu, V; Lai, CL				Poynard, T; Yuen, MF; Ratziu, V; Lai, CL			Viral hepatitis C	LANCET			English	Review							LIVER FIBROSIS PROGRESSION; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATOCELLULAR-CARCINOMA; PEGINTERFERON ALPHA-2A; INITIAL TREATMENT; PEGYLATED INTERFERON-ALPHA-2B; EXTRAHEPATIC MANIFESTATIONS; SAMPLING VARIABILITY; RANDOMIZED-TRIAL	More than 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), which is responsible for more than 100 000 cases of liver cancer per year, with similar numbers of digestive haemorrhage and ascites episodes. Major breakthroughs have been made in diagnosis and treatment, and advances in molecular biology mean that the replicative state of the virus can now be assessed. Genotype and serum viral load are useful predictors of response to treatment. The combination of pegylated interferon and ribavirin can eradicate the virus in more than 50% of patients. These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment.	Univ Paris, Serv Hepatogastroenterol, Grp Hosp Pitie Salpetriere, F-75651 Paris 13, France; Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Hong Kong	Poynard, T (corresponding author), Univ Paris, Serv Hepatogastroenterol, Grp Hosp Pitie Salpetriere, 47-83 Blvd Hop, F-75651 Paris 13, France.	tpoynard@teaser.fr	Yuen, Man-Fung/C-4466-2009; Poynard, Thierry/C-1355-2010; Lai, Ching Lung/C-4298-2009	Yuen, Man-Fung/0000-0001-7985-7725; Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				Afdhal NH, 2003, HEPATOLOGY, V37, P972, DOI 10.1053/jhep.2003.50223; Alberti A, 2002, ANN INTERN MED, V137, P961, DOI 10.7326/0003-4819-137-12-200212170-00009; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Baffis V, 1999, ANN INTERN MED, V131, P696, DOI 10.7326/0003-4819-131-9-199911020-00011; Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Benhamou Y, 2001, HEPATOLOGY, V34, P283, DOI 10.1053/jhep.2001.26517; Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; Bissell DM, 1999, HEPATOLOGY, V29, P988, DOI 10.1002/hep.510290351; Bruno S, 2001, J HEPATOL, V34, P748, DOI 10.1016/S0168-8278(01)00062-9; Cacoub P, 1999, ARTHRITIS RHEUM-US, V42, P2204, DOI 10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D; Camma C, 2001, J HEPATOL, V34, P593, DOI 10.1016/S0168-8278(01)00005-8; Castillo I, 2003, HEPATOLOGY, V38, p187A; Corrao G, 1998, HEPATOLOGY, V27, P914, DOI 10.1002/hep.510270404; Datz C, 1999, GUT, V44, P563, DOI 10.1136/gut.44.4.563; Deuffic S, 1999, J VIRAL HEPATITIS, V6, P411, DOI 10.1046/j.1365-2893.1999.00178.x; Deuffic S, 1999, HEPATOLOGY, V29, P1596, DOI 10.1002/hep.510290528; DEUFFICBURBAN S, IN PRESS J HEPATOL; Dienstag JL, 2002, HEPATOLOGY, V36, pS152, DOI 10.1053/jhep.2002.36381; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; El-Serag HB, 2002, GASTROENTEROLOGY, V123, P476, DOI 10.1053/gast.2002.34750; El-Serag HB, 2002, HEPATOLOGY, V36, P1439, DOI 10.1053/jhep.2002.37191; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gebo KA, 2002, HEPATOLOGY, V36, pS161, DOI 10.1053/jhep.2002.36989; GUMBER SC, 1995, ANN INTERN MED, V123, P615, DOI 10.7326/0003-4819-123-8-199510150-00008; Hadziyannis SJ, 2002, J HEPATOL, V36, P3, DOI 10.1016/S0168-8278(02)80001-0; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Heydtmann M, 2001, CURR OPIN INFECT DIS, V14, P279, DOI 10.1097/00001432-200106000-00006; Hickman IJ, 2002, GUT, V51, P89, DOI 10.1136/gut.51.1.89; Hinrichsen Holger, 2002, Hepatology, V36, p379A; Hourigan LF, 1999, HEPATOLOGY, V29, P1215, DOI 10.1002/hep.510290401; Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232; Kjaergard LL, 2001, BMJ-BRIT MED J, V323, P1151, DOI 10.1136/bmj.323.7322.1151; Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2; LAMARRE D, NATURE          1026, DOI DOI 10.1038/NATURE02099; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; MAHARAJ B, 1986, LANCET, V1, P523; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Mathurin P, 1998, HEPATOLOGY, V27, P868, DOI 10.1002/hep.510270333; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MYERS RP, 2002, COCHRANE LIB; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Ortiz V, 2002, AM J GASTROENTEROL, V97, P2408, DOI 10.1111/j.1572-0241.2002.05995.x; Paradis V, 1996, J CLIN PATHOL, V49, P998, DOI 10.1136/jcp.49.12.998; Pawlotsky JM, 2002, HEPATOLOGY, V36, pS65, DOI 10.1053/jhep.2002.36815; Pawlotsky JM, 2000, HEPATOLOGY, V32, P654, DOI 10.1053/jhep.2000.16603; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 2000, CAN J GASTROENTEROL, V14, P543, DOI 10.1155/2000/107982; Poynard T, 2000, HEPATOLOGY, V31, P211, DOI 10.1002/hep.510310131; Poynard T, 2001, J HEPATOL, V34, P730, DOI 10.1016/S0168-8278(00)00097-0; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Poynard T, 2002, GASTROENTEROLOGY, V122, P1303, DOI 10.1053/gast.2002.33023; Poynard T, 2000, SEMIN LIVER DIS, V20, P47, DOI 10.1055/s-2000-9258; POYNARD T, 2002, COCHRANE LIB; Regev A, 2002, AM J GASTROENTEROL, V97, P2614, DOI 10.1111/j.1572-0241.2002.06038.x; Schalm SW, 1999, GASTROENTEROLOGY, V117, P408, DOI 10.1053/gast.1999.0029900408; Shiffman ML, 1999, GASTROENTEROLOGY, V117, P1164, DOI 10.1016/S0016-5085(99)70402-6; Shiratori Y, 2000, ANN INTERN MED, V132, P517, DOI 10.7326/0003-4819-132-7-200004040-00002; Siebert U, 2003, GUT, V52, P425, DOI 10.1136/gut.52.3.425; Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6; Soriano V, 2002, AIDS, V16, P813, DOI 10.1097/00002030-200204120-00001; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; Thevenot T, 2001, J VIRAL HEPATITIS, V8, P48, DOI 10.1046/j.1365-2893.2001.00271.x; Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447; Wiley TE, 1998, HEPATOLOGY, V28, P805, DOI 10.1002/hep.510280330; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; Yoshida H, 1999, ANN INTERN MED, V131, P174, DOI 10.7326/0003-4819-131-3-199908030-00003; Yoshida H, 2002, GASTROENTEROLOGY, V123, P483, DOI 10.1053/gast.2002.34785; Zylberberg H, 2000, GUT, V47, P694, DOI 10.1136/gut.47.5.694; [No title captured]	72	685	714	1	61	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 20	2003	362	9401					2095	2100		10.1016/S0140-6736(03)15109-4	http://dx.doi.org/10.1016/S0140-6736(03)15109-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697814				2022-12-28	WOS:000187429600028
J	Cohen, FE; Kelly, JW				Cohen, FE; Kelly, JW			Therapeutic approaches to protein-misfolding diseases	NATURE			English	Review							ALZHEIMERS-DISEASE; PHARMACOLOGICAL CHAPERONES; CHEMICAL CHAPERONES; PRION PROTEIN; IN-VIVO; CONFORMATIONAL DISEASES; FIBRIL FORMATION; AMYLOID DISEASE; ANTIBODIES; TRANSTHYRETIN	Several sporadic and genetic diseases are caused by protein misfolding. These include cystic fibrosis and other devastating diseases of childhood as well as Alzheimer's, Parkinson's and other debilitating maladies of the elderly. A unified view of the molecular and cellular pathogenesis of these conditions has led to the search for chemical chaperones that can slow, arrest or revert disease progression. Molecules are now emerging that link our biophysical insights with our therapeutic aspirations.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; Scripps Research Institute; Scripps Research Institute	Cohen, FE (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Genentech Hall,600 16th St N472J, San Francisco, CA 94107 USA.	cohen@cmpharm.ucsf.edu; jkelly@scripps.edu						ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Findeis Mark A., 2002, Current Topics in Medicinal Chemistry, V2, P417, DOI 10.2174/1568026024607508; Frustaci A, 2001, NEW ENGL J MED, V345, P25, DOI 10.1056/NEJM200107053450104; Golde TE, 2002, DRUG DEVELOP RES, V56, P415, DOI 10.1002/ddr.10093; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Howard Marybeth, 2002, Methods Mol Med, V70, P267; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly JW, 2003, J CELL BIOL, V161, P461, DOI 10.1083/jcb.200304074; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Ohno S, 2002, J IMMUNOL, V169, P4039, DOI 10.4049/jimmunol.169.7.4039; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Powell K, 2002, ADV DRUG DELIVER REV, V54, P1395, DOI 10.1016/S0169-409X(02)00148-5; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Sacchettini JC, 2002, NAT REV DRUG DISCOV, V1, P267, DOI 10.1038/nrd769; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Schneider F, 2001, PROTEIN SCI, V10, P1606, DOI 10.1110/ps.8901; Solomon B, 2002, DRUG NEWS PERSPECT, V15, P410, DOI 10.1358/dnp.2002.15.7.840076; Solomon B, 2002, CURR MED CHEM, V9, P1737; Spooner ET, 2002, VACCINE, V21, P290, DOI 10.1016/S0264-410X(02)00464-4; Springsteel MF, 2003, BIOORGAN MED CHEM, V11, P4113, DOI 10.1016/S0968-0896(03)00435-8; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Vassar R, 2002, ADV DRUG DELIVER REV, V54, P1589, DOI 10.1016/S0169-409X(02)00157-6; Vogtherr M, 2003, J MED CHEM, V46, P3563, DOI 10.1021/jm034093h; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; White JT, 2001, P NATL ACAD SCI USA, V98, P13019, DOI 10.1073/pnas.241406698; Wolfe Michael S., 2002, Current Topics in Medicinal Chemistry, V2, P371, DOI 10.2174/1568026024607535; Yang DS, 2001, AMYLOID, V8, P10	49	667	699	1	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					905	909		10.1038/nature02265	http://dx.doi.org/10.1038/nature02265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685252				2022-12-28	WOS:000187342000074
J	Minetti, AE				Minetti, AE			Efficiency of equine express postal systems - Relay riders over two millennia delivered mail with a remarkably consistent alacrity.	NATURE			English	Editorial Material							ENERGY-EXPENDITURE; OXYGEN-CONSUMPTION; HORSES; LOCOMOTION		Manchester Metropolitan Univ, Inst Biophys & Clin Res Human Movement, Alsager ST7 2HL, Cheshire, England	Manchester Metropolitan University	Minetti, AE (corresponding author), Manchester Metropolitan Univ, Inst Biophys & Clin Res Human Movement, Alsager ST7 2HL, Cheshire, England.		Minetti, Alberto Enrico/P-2320-2017	Minetti, Alberto Enrico/0000-0002-0120-4406				FOREMAN JH, 1988, VET CLIN N AM-EQUINE, V14, P205; GAZAGNADOU D, 1994, POSTE RELAIO; Hanak J, 2001, ACTA VET BRNO, V70, P133, DOI 10.2754/avb200170020133; HOYT DF, 1981, NATURE, V292, P239, DOI 10.1038/292239a0; Minetti AE, 1999, J EXP BIOL, V202, P2329; Potard USB, 1998, J APPL PHYSIOL, V84, P2052, DOI 10.1152/jappl.1998.84.6.2052; ROSE RJ, 1986, BRIT VET J, V142, P542; Saltin B, 1973, LIMITING FACTORS PHY, P235; SNOW DH, 1979, RES VET SCI, V27, P372, DOI 10.1016/S0034-5288(18)32810-8; SNOW DH, 1992, EQUINE VET J, V24, P162; Woledge RC., 1985, ENERGETIC ASPECTS MU; 12 CAESARS BOOK, V1, P57; CYROPAEDIA BOOK, V8, P17	13	18	19	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					785	786		10.1038/426785a	http://dx.doi.org/10.1038/426785a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685222				2022-12-28	WOS:000187342000041
J	Venter, H; Shilling, RA; Velamakanni, S; Balakrishnan, L; van Veen, HW				Venter, H; Shilling, RA; Velamakanni, S; Balakrishnan, L; van Veen, HW			An ABC transporter with a secondary-active multidrug translocator domain	NATURE			English	Article							P-GLYCOPROTEIN; FUNCTIONAL RECONSTITUTION; ANTIBIOTIC-RESISTANCE; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; INTRACELLULAR PH; DRUG TRANSPORT; BACTERIA; HOMOLOG; MSBA	Multidrug resistance, by which cells become resistant to multiple unrelated pharmaceuticals, is due to the extrusion of drugs from the cell's interior by active transporters such as the human multidrug resistance beta-glycoprotein(1). Two major classes of transporters mediate this extrusion(2,3). Primary-active transporters are dependent on ATP hydrolysis, whereas secondary-active transletters porters are driven by electrochemical ion gradients that exist across the plasma membrane. The ATP-binding cassette (ABC) transporter LmrA(4) is a primary drug transporter in Lactococcus lactis that can functionally substitute for P-glycoprotein in lung fibroblast cells(5). Here we have engineered a truncated LmrA protein that lacks the ATP-binding domain. Surprisingly, this truncated protein mediates a proton-ethidium symport reaction without the requirement for ATP. In other words, it functions as a secondary-active multidrug uptake system. These findings suggest that the evolutionary precursor of LmrA was a secondary-active substrate translocator that acquired an ATP-binding domain to enable primary-active multidrug efflux in L. lactis.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.		Venter, Rietie/E-4795-2013; van Veen, Hendrik W./A-4162-2008	Venter, Rietie/0000-0001-5569-7755; van Veen, Hendrik W./0000-0002-9658-8077				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; [Anonymous], [No title captured]; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; Breeuwer P, 1996, APPL ENVIRON MICROB, V62, P178, DOI 10.1128/AEM.62.1.178-183.1996; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Howard EM, 2003, BIOCHEMISTRY-US, V42, P3544, DOI 10.1021/bi026706i; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; KABACK HR, 1990, BACTERIA, V12, P151; KROLL RG, 1983, BIOCHEM J, V216, P709, DOI 10.1042/bj2160709; Kuroda M, 1997, J BIOL CHEM, V272, P326; Landwojtowicz E, 2002, BIOCHEMISTRY-US, V41, P8050, DOI 10.1021/bi025720s; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Novo D, 1999, CYTOMETRY, V35, P55, DOI 10.1002/(SICI)1097-0320(19990101)35:1<55::AID-CYTO8>3.0.CO;2-2; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Putman M, 2000, MOL MICROBIOL, V36, P772, DOI 10.1046/j.1365-2958.2000.01871.x; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Santai CT, 1999, BIOCHEMISTRY-US, V38, P4227, DOI 10.1021/bi981930m; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; THIEBAUT F, 1990, J HISTOCHEM CYTOCHEM, V38, P685, DOI 10.1177/38.5.1692055; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668	26	96	98	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					866	870		10.1038/nature02173	http://dx.doi.org/10.1038/nature02173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685244				2022-12-28	WOS:000187342000065
J	Moller, C				Moller, C			Deafblindness: living with sensory deprivation	LANCET			English	Article									Sahlgrens Univ Hosp, Dept Audiol, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Moller, C (corresponding author), Sahlgrens Univ Hosp, Dept Audiol, S-41345 Gothenburg, Sweden.								0	34	35	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S46	S47						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698128				2022-12-28	WOS:000187790200024
J	Wiebe, S				Wiebe, S			Brain surgery for epilepsy	LANCET			English	Article									London Hlth Sci Ctr, London, ON N6A 5A5, Canada	London Health Sciences Centre	Wiebe, S (corresponding author), London Hlth Sci Ctr, Univ Campus London, London, ON N6A 5A5, Canada.								0	11	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S48	S49		10.1016/S0140-6736(03)15075-1	http://dx.doi.org/10.1016/S0140-6736(03)15075-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698129				2022-12-28	WOS:000187790200025
J	Lyne, AG; Burgay, M; Kramer, M; Possenti, A; Manchester, RN; Camilo, F; McLaughlin, MA; Lorimer, DR; D'Amico, N; Joshi, BC; Reynolds, J; Freire, PCC				Lyne, AG; Burgay, M; Kramer, M; Possenti, A; Manchester, RN; Camilo, F; McLaughlin, MA; Lorimer, DR; D'Amico, N; Joshi, BC; Reynolds, J; Freire, PCC			A double-pulsar system: A rare laboratory for relativistic gravity and plasma physics	SCIENCE			English	Article							GEODETIC SPIN PRECESSION; POST-NEWTONIAN MOTION; PSR 1913&16; CELESTIAL MECHANICS; GENERAL-RELATIVITY; BINARY PULSARS; RADIO PULSARS; NEUTRON-STARS; EVOLUTION; DISCOVERY	The clocklike properties of pulsars moving in the gravitational fields of their unseen neutron-star companions have allowed unique tests of general relativity and provided evidence for gravitational radiation. We report here the detection of the 2.8-second pulsar J0737-3039B as the companion to the 23-millisecond pulsar J0737-3039A in a highly relativistic double neutron star system, allowing unprecedented tests of fundamental gravitational physics. We observed a short eclipse of J0737-3039A by J0737-3039B and orbital modulation of the flux density and the pulse shape of J0737-3039B, probably because of the influence of J0737-3039A's energy flux on its magnetosphere. These effects will allow us to probe magneto-ionic properties of a pulsar magnetosphere.	Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England; Univ Bologna, Dipartimento Astron, I-40127 Bologna, Italy; INAF, Osservatorio Astron Cagliari, I-09012 Capoterra, Italy; INAF, Osservatorio Astron Bologna, I-40127 Bologna, Italy; CSIRO, Australia Telescope Natl Facil, Epping, NSW 1710, Australia; Columbia Univ, Columbia Astrophys Lab, New York, NY 10027 USA; Univ Cagliari, Dipartimento Fis, I-09042 Monserrato, Italy; Natl Ctr Astrophys, Pune 411007, Maharashtra, India; ATNF, Parkes Observ, Parkes, NSW 2870, Australia	University of Manchester; Jodrell Bank Centre for Astrophysics; University of Bologna; Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Columbia University; University of Cagliari; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Lyne, AG (corresponding author), Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England.	agl@jb.man.ac.uk	Freire, Paulo/ABE-8926-2021; Lorimer, Duncan/ABH-7909-2020; D'Amico, Nichi/A-5715-2009	Freire, Paulo/0000-0003-1307-9435; Kramer, Michael/0000-0002-4175-2271; McLaughlin, Maura/0000-0001-7697-7422; Burgay, Marta/0000-0002-8265-4344; Joshi, Bhal Chandra/0000-0002-0863-7781				Arzoumanian Z, 1999, ASTROPHYS J, V520, P696, DOI 10.1086/307482; Bailes M, 2003, ASTROPHYS J, V595, pL49, DOI 10.1086/378939; BARKER BM, 1975, ASTROPHYS J, V199, pL25, DOI 10.1086/181840; BHATTACHARYA D, 1991, PHYS REP, V203, P1, DOI 10.1016/0370-1573(91)90064-S; Bisnovatyi-Kogan G. S., 1974, Soviet Astronomy, V18, P217; Burgay M, 2003, NATURE, V426, P531, DOI 10.1038/nature02124; DAMOUR T, 1991, ASTROPHYS J, V366, P501, DOI 10.1086/169585; DAMOUR T, 1986, ANN I H POINCARE-PHY, V44, P263; DAMOUR T, 1992, PHYS REV D, V45, P1840, DOI 10.1103/PhysRevD.45.1840; DAMOUR T, 1985, ANN I H POINCARE-PHY, V43, P107; DAMOUR T, 1974, CR ACAD SCI A MATH, V279, P971; DAMOUR T, 1988, NUOVO CIMENTO B, V101, P127, DOI 10.1007/BF02828697; FLANNERY BP, 1975, ASTRON ASTROPHYS, V39, P61; HULSE RA, 1975, ASTROPHYS J, V195, pL51, DOI 10.1086/181708; KALOGERA V, IN PRESS ASTROPHYS J; Kramer M, 1998, ASTROPHYS J, V509, P856, DOI 10.1086/306535; SHIBAZAKI N, 1989, NATURE, V342, P656, DOI 10.1038/342656a0; SRINIVASAN G, 1982, ASTRON ASTROPHYS, V108, P143; Stairs IH, 2002, ASTROPHYS J, V581, P501, DOI 10.1086/344157; TAYLOR JH, 1992, PHILOS T ROY SOC A, V341, P117, DOI 10.1098/rsta.1992.0088; TAYLOR JH, 1989, ASTROPHYS J, V345, P434, DOI 10.1086/167917; TAYLOR JH, 1993, ASTROPHYS J, V411, P674, DOI 10.1086/172870; Thorsett SE, 1999, ASTROPHYS J, V512, P288, DOI 10.1086/306742; VANDENHE.EP, 1973, ASTRON ASTROPHYS, V25, P387; WEISBERG JM, 1989, ASTROPHYS J, V347, P1030, DOI 10.1086/168193; WEX N, 1995, CLASSICAL QUANT GRAV, V12, P983, DOI 10.1088/0264-9381/12/4/009	28	597	609	3	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	2004	303	5661					1153	1157		10.1126/science.1094645	http://dx.doi.org/10.1126/science.1094645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775RP	14716022	Green Submitted			2022-12-28	WOS:000189074700035
J	Li, SM; Armstrong, CM; Bertin, N; Ge, H; Milstein, S; Boxem, M; Vidalain, PO; Han, JDJ; Chesneau, A; Hao, T; Goldberg, DS; Li, N; Martinez, M; Rual, JF; Lamesch, P; Xu, L; Tewari, M; Wong, SL; Zhang, LV; Berriz, GF; Jacotot, L; Vaglio, P; Reboul, J; Hirozane-Kishikawa, T; Li, QR; Gabel, HW; Elewa, A; Baumgartner, B; Rose, DJ; Yu, HY; Bosak, S; Sequerra, R; Fraser, A; Mango, SE; Saxton, WM; Strome, S; van den Heuvel, S; Piano, F; Vandenhaute, J; Sardet, C; Gerstein, M; Doucette-Stamm, L; Gunsalus, KC; Harper, JW; Cusick, ME; Roth, FP; Hill, DE; Vidal, M				Li, SM; Armstrong, CM; Bertin, N; Ge, H; Milstein, S; Boxem, M; Vidalain, PO; Han, JDJ; Chesneau, A; Hao, T; Goldberg, DS; Li, N; Martinez, M; Rual, JF; Lamesch, P; Xu, L; Tewari, M; Wong, SL; Zhang, LV; Berriz, GF; Jacotot, L; Vaglio, P; Reboul, J; Hirozane-Kishikawa, T; Li, QR; Gabel, HW; Elewa, A; Baumgartner, B; Rose, DJ; Yu, HY; Bosak, S; Sequerra, R; Fraser, A; Mango, SE; Saxton, WM; Strome, S; van den Heuvel, S; Piano, F; Vandenhaute, J; Sardet, C; Gerstein, M; Doucette-Stamm, L; Gunsalus, KC; Harper, JW; Cusick, ME; Roth, FP; Hill, DE; Vidal, M			A map of the interactome network of the metazoan C-elegans	SCIENCE			English	Article							PROTEIN-PROTEIN INTERACTIONS; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; GENOME; IDENTIFICATION; RESOURCE	To initiate studies on how protein-protein interaction (or "interactome") networks relate to multicellular functions, we have mapped a large fraction of the Caenorhabditis elegans interactome network. Starting with a subset of metazoan-specific proteins, more than 4000 interactions were identified from high-throughput, yeast two-hybrid (HT=Y2H) screens. Independent coaffinity purification assays experimentally validated the overall quality of this Y2H data set. Together with already described Y2H interactions and interologs predicted in silico, the current version of the Worm Interactome (WI5) map contains similar to5500 interactions. Topological and biological features of this interactome network, as well as its integration with phenome and transcriptome data sets, lead to numerous biological hypotheses.	Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Fac Notre Dame Paix, Unite Rech Biol Mol, B-5000 Namur, Belgium; Baylor Coll Med, Verna & Marrs Dept Biochem & Mol Biol, Program Cell & Mol Biol Biophys & Biol, Houston, TX 77030 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA; Agencourt Biosci Corp, Beverly, MA 01915 USA; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; NYU, Dept Biol, New York, NY 10003 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Harvard University; Harvard Medical School; Baylor College of Medicine; Indiana University System; Indiana University Bloomington; Yale University; Yale University; Wellcome Trust Sanger Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Harvard University; Massachusetts General Hospital; New York University	Vidal, M (corresponding author), Dana Farber Canc Inst, Ctr Canc Syst Biol, 44 Binney St, Boston, MA 02115 USA.	marc_vidal@dfci.harvard.edu	Roth, Frederick P/H-6308-2011; Reboul, Jerome/P-9103-2016; Bertin, Nicolas/O-9602-2019; Hill, David E/B-6617-2011; van den Heuvel, Sander J.L./B-8892-2011; Vidalain, Pierre-Olivier/F-9778-2019; Boxem, Mike/B-8857-2011; Bertin, Nicolas/C-3025-2008	Reboul, Jerome/0000-0002-5513-4546; van den Heuvel, Sander J.L./0000-0001-9015-7463; Vidalain, Pierre-Olivier/0000-0003-3082-7407; Elewa, Ahmed/0000-0002-1988-7970; Harper, Jeffrey/0000-0002-6944-7236; Vaglio, Philippe/0000-0003-2900-5596; Bertin, Nicolas/0000-0002-9835-9606; Roth, Frederick/0000-0002-6628-649X; Mango, Susan/0000-0002-2146-3237; Rual, Jean-Francois/0000-0003-4465-8819; Fraser, Andrew/0000-0001-9939-6014	NIA NIH HHS [R01 AG011085] Funding Source: Medline; NIGMS NIH HHS [R01 GM034059-18, R01 GM034059] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Ch'ng Q, 1999, DEVELOPMENT, V126, P3303; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Dozier C, 2001, DEV BIOL, V236, P289, DOI 10.1006/dbio.2001.0325; Gaudet J, 2002, SCIENCE, V295, P821, DOI 10.1126/science.1065175; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ge H, 2003, TRENDS GENET, V19, P551, DOI 10.1016/j.tig.2003.08.009; GE H, UNPUB; Goldberg DS, 2003, P NATL ACAD SCI USA, V100, P4372, DOI 10.1073/pnas.0735871100; Hanazawa M, 2001, P NATL ACAD SCI USA, V98, P8686, DOI 10.1073/pnas.141004698; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Matthews LR, 2001, GENOME RES, V11, P2120, DOI 10.1101/gr.205301; Pappu KS, 2003, DEVELOPMENT, V130, P3053, DOI 10.1242/dev.00534; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Urano F, 2002, J CELL BIOL, V158, P639, DOI 10.1083/jcb.200203086; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Walhout AJM, 2002, CURR BIOL, V12, P1952, DOI 10.1016/S0960-9822(02)01279-4; Wawersik S, 2000, HUM MOL GENET, V9, P917, DOI 10.1093/hmg/9.6.917	27	1300	1364	3	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					540	543		10.1126/science.1091403	http://dx.doi.org/10.1126/science.1091403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14704431	Green Accepted			2022-12-28	WOS:000188316400043
J	Staal, JB; Hlobil, H; Twisk, JWR; Smid, T; Koke, AJA; van Mechelen, W				Staal, JB; Hlobil, H; Twisk, JWR; Smid, T; Koke, AJA; van Mechelen, W			Graded activity for low back pain in occupational health care - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-ACTIVITY; DISABILITY; QUESTIONNAIRE; RELIABILITY; VALIDITY	Background: Low back pain is a common medical and social problem frequently associated with disability and absence from work. However, data on effective return to work after interventions for low back pain are scarce. Objective: To determine the effectiveness of a behavior-oriented graded activity program compared with usual care. Design: Randomized, controlled trial. Setting: Occupational health services department of an airline company in the Netherlands. Patients: 134 workers who were absent from work because of low back pain were randomly assigned to either graded activity (n = 67) or usual care (n = 67). Intervention: Graded activity, a physical exercise program based on operant-conditioning behavioral principles, to stimulate a rapid return to work. Measurements: Outcomes were the number of days of absence from work because of low back pain, functional status (Roland Disability Questionnaire), and severity of pain (11-point numerical scale). Results: The median number of days of absence from work over 6 months of follow-up was 58 days in the graded activity group and 87 days in the usual care group. From randomization onward, graded activity was effective after 50 days of absence from work (hazard ratio, 1.9 [95% Cl, 1.2 to 3.2]; P = 0.009). The graded activity group was more effective in improving functional status and pain than the usual care group. The effects, however, were small and not statistically significant. Conclusions: Graded activity was more effective than usual care in reducing the number of days of absence from work because of low back pain.	Free Univ Amsterdam, Med Ctr, Dept Social Med, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; KLM Hlth Safety & Environm, Schiphol, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands; TNO VUmc, Body Work Res Ctr Phys Act Work & Hlth, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC); Netherlands Organization Applied Science Research	van Mechelen, W (corresponding author), Free Univ Amsterdam, Med Ctr, Dept Social Med, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	W.vanMechelen@vumc.nl	van Mechelen, Willem/C-8463-2013; Staal, Bart/ABA-4313-2020; Staal, J. Bart/A-9632-2014	Staal, Bart/0000-0002-0083-6380; Staal, J. Bart/0000-0002-0083-6380; van Mechelen, Willem/0000-0001-7136-6382				BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; CARTER JT, 2004, OCCUPATION HLTH GUID; Chisholm D. M., 1978, PAR Q VALIDATION REP; *COLL STAT, 2001, STAT REF MAN REL 7; Faas A., 1996, HUIS WETEN, V39, P18; FLOR H, 1985, J CONSULT CLIN PSYCH, V53, P354, DOI 10.1037/0022-006X.53.3.354; Frank JW, 1996, SPINE, V21, P2918, DOI 10.1097/00007632-199612150-00025; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GOLDSTEIN H, 1998, USERS GUIDE LMLWIN; LINDSTROM I, 1995, SCAND J REHABIL MED, V27, P153; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; LINDSTROM I, 1992, PHYS THER, V72, P292, DOI 10.1093/ptj/72.4.292; Ostelo RWJG, 2000, J MANIP PHYSIOL THER, V23, P312, DOI 10.1016/S0161-4754(00)90205-7; Philippaerts RM, 1998, AM J EPIDEMIOL, V147, P982, DOI 10.1093/oxfordjournals.aje.a009389; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; SHEPHARD RJ, 1988, SPORTS MED, V5, P185, DOI 10.2165/00007256-198805030-00005; Staal JB, 2003, OCCUP ENVIRON MED, V60, P618, DOI 10.1136/oem.60.9.618; Stratford PW, 1998, PHYS THER, V78, P1186, DOI 10.1093/ptj/78.11.1186; Twisk JWR, 2003, APPL LONGITUDINAL DA	22	149	160	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					77	84		10.7326/0003-4819-140-2-200401200-00007	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734329				2022-12-28	WOS:000188211700001
J	Dave, UP; Jenkins, NA; Copeland, NG				Dave, UP; Jenkins, NA; Copeland, NG			Gene therapy insertional mutagenesis insights	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; LEUKEMIA		NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Copeland, NG (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010393] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887	7	200	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					333	333		10.1126/science.1091667	http://dx.doi.org/10.1126/science.1091667			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726584				2022-12-28	WOS:000188111800032
J	Renehan, AG; O'Dwyer, ST; Whynes, DK				Renehan, AG; O'Dwyer, ST; Whynes, DK			Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; RANDOMIZED-TRIAL; RADICAL SURGERY; COLON-CANCER; SURVEILLANCE; COLONOSCOPY; SURVIVAL	Objective To determine the cost effectiveness of intensive follow up compared with conventional follow up in patients with colorectal cancer. Design Incremental cost effectiveness analysis recognising differences in follow up strategies, based on effectiveness data from a meta-analysis of five randomised trials. Setting United Kingdom. Main outcome measures Taking a health service perspective, estimated incremental costs effectiveness ratios for each life year gained for five trials and four trials designed for early detection of extramural recurrences (targeted surveillance). Results Based on five year follow up, the numbers of life years gained by intensive follow up were 0.73 for the five trial model and 0.82 for the four trial model. For the five trials, the adjusted net (extra) cost for each patient was pound2479 (is an element of3550; $4288) and for each life year gained was 0402, substantially lower than the current threshold of NHS cost acceptability (pound30 000). The corresponding values for the four trial model were pound2529 and pound3077, suggesting that targeted surveillance is more cost effective. The main predictor of incremental cost effectiveness ratios was surveillance costs rather than treatment costs. Judged against die NHS threshold of cost acceptability, the predicted incremental cost threshold was ninefold and the effectiveness threshold was 3%. Conclusions Based on the available data and current costs, intensive follow up after curative resection for colorectal cancer is economically justified and should be normal practice. There is a continuing need to evaluate the efficacy of specific surveillance tools: this studv forms the basis for economic evaluations in such trials'.	Univ Nottingham, Dept Econ, Nottingham NG7 2RD, England; Christie Hosp NHS Trust, Dept Surg, Manchester M20 4BX, Lancs, England	University of Nottingham; Christie NHS Foundation Trust; Christie Hospital			Renehan, Andrew/K-5992-2015	Renehan, Andrew/0000-0003-4309-4396				Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; Atkin WS, 2002, LANCET, V359, P1291, DOI 10.1016/s0140-6736(02)08268-5; Beart R W Jr, 2000, Surg Oncol Clin N Am, V9, P827; BRUINVELS DJ, 1995, EUR J SURG, V161, P827; *DEP HLTH NHS, DEP HLTH NHS REF COS; Department Of Health, NHS REF COSTS; Edelman MJ, 1997, J GEN INTERN MED, V12, P318, DOI 10.1007/s11606-006-5070-0; Frew E, 1999, J MED SCREEN, V6, P119, DOI 10.1136/jms.6.3.119; Fusai G, 2003, Colorectal Dis, V5, P2, DOI 10.1046/j.1463-1318.2003.00410.x; Gilbert RE, 2001, BRIT MED J, V323, P423, DOI 10.1136/bmj.323.7310.423; Gold MR, 1996, COST EFFECTIVENESS H; Graham RA, 1998, ANN SURG, V228, P59, DOI 10.1097/00000658-199807000-00009; *ISD SCOTL, 1999, CANC FACTS FIG; JEFFREY GM, 2002, COCHRANE LIB; KIEVIT J, 1995, EUR J CANCER, V31A, P1222, DOI 10.1016/0959-8049(95)00155-C; Kievit J, 2002, EUR J CANCER, V38, P986, DOI 10.1016/S0959-8049(02)00061-8; Kjeldsen BJ, 1997, BRIT J SURG, V84, P666; Kjeldsen BJ, 1999, SCAND J GASTROENTERO, V34, P509, DOI 10.1080/003655299750026254; MAKELA JT, 1995, ARCH SURG-CHICAGO, V130, P1062; Mella J, 1997, ANN ROY COLL SURG, V79, P206; *NAT I CLIN EXC, REV EV CLIN COST EFF; *NAT I CLIN EXC, REV EV CLIN COST IR; Norum J, 1997, ANN ONCOL, V8, P1081, DOI 10.1023/A:1008265614183; *OFF NAT STAT, 1999, CANC STAT REG MB1; *OFF NAT STAT CTR, 1999, OFF NAT STAT CANC ST; OHLSSON B, 1995, DIS COLON RECTUM, V38, P619, DOI 10.1007/BF02054122; Pietra N, 1998, DIS COLON RECTUM, V41, P1127, DOI 10.1007/BF02239434; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; Renehan AG, 2002, BMJ-BRIT MED J, V324, P813, DOI 10.1136/bmj.324.7341.813; RENEHAN AG, 2004, EFFECTIVE MANAGEMENT; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; Scholefield JH, 2002, GUT, V51, pV3, DOI 10.1136/gut.51.suppl_5.v3; Secco GB, 2002, EUR J SURG ONCOL, V28, P418, DOI 10.1053/ejso.2001.1250; Stiggelbout AM, 1997, BRIT J CANCER, V75, P914, DOI 10.1038/bjc.1997.161; Torgerson DJ, 1999, BRIT MED J, V319, P914, DOI 10.1136/bmj.319.7214.914; *UK GOV ACT DEP, LIF TABL; *UK GOV ACT DEP LI, TABL; van den Hout WB, 2002, EUR J CANCER, V38, P953, DOI 10.1016/S0959-8049(02)00053-9; VIRGO KS, 1995, JAMA-J AM MED ASSOC, V273, P1837, DOI 10.1001/jama.273.23.1837; VIRGO KS, 1995, ANN SURG ONCOL, V2, P472, DOI 10.1007/BF02307079; WANCHO HJ, 1999, DIS COLON RECTUM, V42, P1438; Wanebo HJ, 1999, DIS COLON RECTUM, V42, P1438, DOI 10.1007/BF02235044; Wang H, 2001, CANCER CAUSE CONTROL, V12, P39, DOI 10.1023/A:1008999403069; Whynes DK, 1998, HEALTH ECON, V7, P21, DOI 10.1002/(SICI)1099-1050(199802)7:1<21::AID-HEC306>3.0.CO;2-9	45	82	83	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 10	2004	328	7431					81	84		10.1136/bmj.328.7431.81	http://dx.doi.org/10.1136/bmj.328.7431.81			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MP	14715603	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000187976400015
J	Hughen, K; Lehman, S; Southon, J; Overpeck, J; Marchal, O; Herring, C; Turnbull, J				Hughen, K; Lehman, S; Southon, J; Overpeck, J; Marchal, O; Herring, C; Turnbull, J			C-14 activity and global carbon cycle changes over the past 50,000 years	SCIENCE			English	Article							TROPICAL ATLANTIC; YOUNGER DRYAS; ICE-CORE; RADIOCARBON; CIRCULATION; CALIBRATION; OCEAN; SCALE; SEA; VENTILATION	A series of C-14 measurements in Ocean Drilling Program cores from the tropical Cariaco Basin, which have been correlated to the annual-layer counted chronology for the Greenland Ice Sheet Project 2 ( GISP2) ice core, provides a high-resolution calibration of the radiocarbon time scale back to 50,000 years before the present. Independent radiometric dating of events correlated to GISP2 suggests that the calibration is accurate. Reconstructed C-14 activities varied substantially during the last glacial period, including sharp peaks synchronous with the Laschamp and Mono Lake geomagnetic field intensity minimal and cosmogenic nuclide peaks in ice cores and marine sediments. Simulations with a geochemical box model suggest that much of the variability can be explained by geomagnetically modulated changes in C-14 production rate together with plausible changes in deep-ocean ventilation and the global carbon cycle during glaciation.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Univ Calif Irvine, Depe Earth Syst Sci, Irvine, CA 92697 USA; Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Univ Arizona, Inst Study Planet Earth, Tucson, AZ 85721 USA	Woods Hole Oceanographic Institution; Woods Hole Oceanographic Institution; University of Colorado System; University of Colorado Boulder; University of California System; University of California Irvine; University of Arizona; University of Arizona	Hughen, K (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.	khughen@whoi.edu	Turnbull, Jocelyn C/E-1426-2016	Turnbull, Jocelyn C/0000-0002-0306-9658				Alverson KD, 2003, PALEOCLIMATE GLOBAL; Bard E, 1998, RADIOCARBON, V40, P1085, DOI 10.1017/S0033822200019135; Beck JW, 2001, SCIENCE, V292, P2453, DOI 10.1126/science.1056649; Beer J, 2002, QUATERNARY SCI REV, V21, P1129, DOI 10.1016/S0277-3791(01)00135-4; Black DE, 1999, SCIENCE, V286, P1709, DOI 10.1126/science.286.5445.1709; Broecker WS, 2003, SCIENCE, V300, P1519, DOI 10.1126/science.1083797; Curry WB, 1988, PALEOCEANOGRAPHY, V3, P317, DOI 10.1029/PA003i003p00317; Curry WB, 1999, GEOPH MONOG SERIES, V112, P59; DAMON PE, 1989, RADIOCARBON, V31, P697; GANS PB, 1999, GEOL SOC AM ABSTR, V31, P56; Genty D, 2003, NATURE, V421, P833, DOI 10.1038/nature01391; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; Indermuhle A, 2000, GEOPHYS RES LETT, V27, P735, DOI 10.1029/1999GL010960; Johnsen SJ, 2001, J QUATERNARY SCI, V16, P299, DOI 10.1002/jqs.622; KEIGWIN LD, 1994, PALEOCEANOGRAPHY, V9, P185, DOI 10.1029/94PA00032; Kitagawa H, 1998, SCIENCE, V279, P1187, DOI 10.1126/science.279.5354.1187; Kromer B, 1998, RADIOCARBON, V40, P1117, DOI 10.1017/S0033822200019160; Laj C, 2002, EARTH PLANET SC LETT, V200, P177, DOI 10.1016/S0012-821X(02)00618-0; LAL D, 1988, P INT SCH PHYS, V95, P216; Marchal O, 2001, EARTH PLANET SC LETT, V185, P383, DOI 10.1016/S0012-821X(00)00383-6; Masarik J, 1999, J GEOPHYS RES-ATMOS, V104, P12099, DOI 10.1029/1998JD200091; MCMANUS JF, UNPUB; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Rind D, 1986, CLIM DYNAM, V1, P2; Schramm A, 2000, EARTH PLANET SC LETT, V175, P27, DOI 10.1016/S0012-821X(99)00279-4; Stocker TF, 1998, RADIOCARBON, V40, P359; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Ton-That T, 2001, EARTH PLANET SC LETT, V184, P645, DOI 10.1016/S0012-821X(00)00358-7; van Kreveld S, 2000, PALEOCEANOGRAPHY, V15, P425, DOI 10.1029/1999PA000464; Voelker AHL, 2000, RADIOCARBON, V42, P437, DOI 10.1017/S0033822200030368; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618	35	365	383	2	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					202	207		10.1126/science.1090300	http://dx.doi.org/10.1126/science.1090300			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716006				2022-12-28	WOS:000187908500040
J	King, DA				King, DA			Environment - Climate change science: Adapt, mitigate, or ignore?	SCIENCE			English	Editorial Material									HM Govt, Off Sci & Technol, London SW1H 0ET, England		King, DA (corresponding author), HM Govt, Off Sci & Technol, London SW1H 0ET, England.	mpst.king@dti.gsi.gov.uk						Arnell NW, 2002, CLIMATIC CHANGE, V53, P413, DOI 10.1023/A:1015277014327; Caldeira K, 2003, SCIENCE, V299, P2052, DOI 10.1126/science.1078938; *DEFRA, 2003, THAM BARR US DAT; *DEFRA, 2002, ENV YOUR POCK 2002; *DEFRA, 2003, GLOB ATM RES PROGR B; Folland CK, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P99; Hulme M., 2002, CLIMATE CHANGE SCENA; KING DA, 2002, ZUCK LECT LOND; Laxon S, 2003, NATURE, V425, P947, DOI 10.1038/nature02050; LOMBORG B, 2001, SCEPTICAL ENV; METZ B, 2001, CLIMATE CHANGE 2001, pCH8; Nicholls RJ, 1999, GLOBAL ENVIRON CHANG, V9, pS69, DOI 10.1016/S0959-3780(99)00019-9; *OFF SCI TECHN, 2002, FOR FUT 2002 REV SCE; *OFF SCI TECHN, 2003, AN FUT RISKS FLOOD C; PAAVOLA J, 2002, 23 U E ANGL TYND CTR; Parry M, 1999, GLOBAL ENVIRON CHANG, V9, pS51, DOI 10.1016/S0959-3780(99)00018-7; RIGHOT E, 2003, SCIENCE, V302, P434; Thompson LG, 2002, SCIENCE, V298, P589, DOI 10.1126/science.1073198; WADHAMS P, 1997, ICE OCEAN	19	179	194	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					176	177		10.1126/science.1094329	http://dx.doi.org/10.1126/science.1094329			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14715997				2022-12-28	WOS:000187908500031
J	Mao, CB; Solis, DJ; Reiss, BD; Kottmann, ST; Sweeney, RY; Hayhurst, A; Georgiou, G; Iverson, B; Belcher, AM				Mao, CB; Solis, DJ; Reiss, BD; Kottmann, ST; Sweeney, RY; Hayhurst, A; Georgiou, G; Iverson, B; Belcher, AM			Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires	SCIENCE			English	Article							CRYSTAL-GROWTH; NANOPARTICLES; FEPT; BIOMINERALIZATION; NANOCRYSTALS; ORGANIZATION; SPECIFICITY; DYNAMICS; PEPTIDES; DISPLAY	We report a virus-based scaffold for the synthesis of single-crystal ZnS, CdS, and freestanding chemically ordered CoPt and FePt nanowires, with the means of modifying substrate specificity through standard biological methods. Peptides (selected through an evolutionary screening process) that exhibit control of composition, size, and phase during nanoparticle nucleation have been expressed on the highly ordered filamentous capsid of the M13 bacteriophage. The incorporation of specific, nucleating peptides into the generic scaffold of the M13 coat structure provides a viable template for the directed synthesis of semiconducting and magnetic materials. Removal of the viral template by means of annealing promoted oriented aggregation-based crystal growth, forming individual crystalline nanowires. The unique ability to interchange substrate-specific peptides into the linear self-assembled filamentous construct of the M13 virus introduces a material tunability that has not been seen in previous synthetic routes. Therefore, this system provides a genetic toolkit for growing and organizing nanowires from semiconducting and magnetic materials.	MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Belcher, AM (corresponding author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.			Hayhurst, Andrew/0000-0003-4612-8707; Mao, Chuanbin/0000-0002-8142-3659				Alivisatos AP, 2000, SCIENCE, V289, P736, DOI 10.1126/science.289.5480.736; Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; Barmak K, 2002, APPL PHYS LETT, V80, P4268, DOI 10.1063/1.1483924; Cha JN, 2000, NATURE, V403, P289, DOI 10.1038/35002038; de Picciotto R, 2001, NATURE, V411, P51, DOI 10.1038/35075009; Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211; Duan XF, 2000, ADV MATER, V12, P298, DOI 10.1002/(SICI)1521-4095(200002)12:4<298::AID-ADMA298>3.0.CO;2-Y; Dujardin E, 2003, NANO LETT, V3, P413, DOI 10.1021/nl034004o; Flynn CE, 2003, J MATER CHEM, V13, P2414, DOI 10.1039/b307593a; Gao CS, 1999, P NATL ACAD SCI USA, V96, P6025, DOI 10.1073/pnas.96.11.6025; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Huang YH, 2002, J APPL PHYS, V91, P6869, DOI 10.1063/1.1447524; Lee SW, 2002, SCIENCE, V296, P892, DOI 10.1126/science.1068054; Luedtke WD, 1996, J PHYS CHEM-US, V100, P13323, DOI 10.1021/jp961721g; Malik P, 1997, NUCLEIC ACIDS RES, V25, P915, DOI 10.1093/nar/25.4.915; Manna L, 2000, J AM CHEM SOC, V122, P12700, DOI 10.1021/ja003055+; Mao CB, 2003, P NATL ACAD SCI USA, V100, P6946, DOI 10.1073/pnas.0832310100; Morales AM, 1998, SCIENCE, V279, P208, DOI 10.1126/science.279.5348.208; NAM K, 2003, IN PRESS NANO L 1216; Penn RL, 1999, GEOCHIM COSMOCHIM AC, V63, P1549, DOI 10.1016/S0016-7037(99)00037-X; Qadri SB, 1999, PHYS REV B, V60, P9191, DOI 10.1103/PhysRevB.60.9191; Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387; REISS BD, UNPUB; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Wang YW, 2002, CHEM PHYS LETT, V357, P314, DOI 10.1016/S0009-2614(02)00530-4; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; Xia YN, 2003, ADV MATER, V15, P353, DOI 10.1002/adma.200390087; Ye CH, 2002, J PHYS CHEM B, V106, P10338, DOI 10.1021/jp0255785; Yeadon M, 1998, APPL PHYS LETT, V73, P3208, DOI 10.1063/1.122720; Zhu HL, 1996, PHIL MAG LETT, V73, P27, DOI 10.1080/095008396181073	32	839	897	8	410	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					213	217		10.1126/science.1092740	http://dx.doi.org/10.1126/science.1092740			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716009				2022-12-28	WOS:000187908500043
J	Symington, LS; Holloman, WK				Symington, LS; Holloman, WK			New year's resolution - Resolving resolvases	SCIENCE			English	Editorial Material							5 RAD51 PARALOGS; RECOMBINATION; JUNCTIONS		Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Res, New York, NY 10032 USA; Cornell Univ, Weill Med Coll, Hearst Microbiol Res Ctr, Dept Microbiol & Immunol, New York, NY 10021 USA	Columbia University; Columbia University; Cornell University	Symington, LS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.							Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Heyer WD, 2003, TRENDS BIOCHEM SCI, V28, P548, DOI 10.1016/j.tibs.2003.08.011; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; LOCKSHON D, 1995, CELL, V81, P947, DOI 10.1016/0092-8674(95)90014-4; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; Yokoyama H, 2003, J BIOL CHEM, V278, P2767, DOI 10.1074/jbc.M210899200	11	8	8	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					184	185		10.1126/science.1093959	http://dx.doi.org/10.1126/science.1093959			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716002				2022-12-28	WOS:000187908500036
J	Karrai, K; Warburton, RJ; Schulhauser, C; Hogele, A; Urbaszek, B; McGhee, EJ; Govorov, AO; Garcia, JM; Gerardot, BD; Petroff, PM				Karrai, K; Warburton, RJ; Schulhauser, C; Hogele, A; Urbaszek, B; McGhee, EJ; Govorov, AO; Garcia, JM; Gerardot, BD; Petroff, PM			Hybridization of electronic states in quantum dots through photon emission	NATURE			English	Article							DEVICE	The self-assembly of semiconductor quantum dots has opened up new opportunities in photonics. Quantum dots are usually described as 'artificial atoms', because electron and hole confinement gives rise to discrete energy levels. This picture can be justified from the shell structure observed as a quantum dot is filled either with excitons(1) (bound electron - hole pairs) or with electrons(2). The discrete energy levels have been most spectacularly exploited in single photon sources that use a single quantum dot as emitter(3-6). At low temperatures, the artificial atom picture is strengthened by the long coherence times of excitons in quantum dots(7-9), motivating the application of quantum dots in quantum optics and quantum information processing. In this context, excitons in quantum dots have already been manipulated coherently(10-12). We show here that quantum dots can also possess electronic states that go far beyond the artificial atom model. These states are a coherent hybridization of localized quantum dot states and extended continuum states: they have no analogue in atomic physics. The states are generated by the emission of a photon from a quantum dot. We show how a new version of the Anderson model that describes interactions between localized and extended states can account for the observed hybridization.	Heriot Watt Univ, Sch Engn & Phys Sci, Edinburgh EH14 4AS, Midlothian, Scotland; Univ Munich, Ctr NanoSci, D-80539 Munich, Germany; Univ Munich, Sekt Phys, D-80539 Munich, Germany; Ohio Univ, Dept Phys & Astron, Athens, OH 45701 USA; Russian Acad Sci, Inst Semicond Phys, Siberian Branch, Novosibirsk 630090, Russia; PTM, CSIC, CNM, Inst Microelect Madrid, Madrid 28760, Spain; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	Heriot Watt University; University of Munich; University of Munich; University System of Ohio; Ohio University; Russian Academy of Sciences; Rzhanov Institute of Semiconductor Physics, Siberian Branch, Russian Academy of Sciences; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Microelectronica (CNM); CSIC - Instituto de Microelectronica de Madrid (IMM); University of California System; University of California Santa Barbara	Warburton, RJ (corresponding author), Heriot Watt Univ, Sch Engn & Phys Sci, Edinburgh EH14 4AS, Midlothian, Scotland.	R.J.Warburton@hw.ac.uk	Urbaszek, Bernhard/B-2285-2018; Gerardot, Brian D/D-2418-2009; Gerardot, Brian D./AHB-1102-2022; Garcia, Jorge M./B-5221-2008; Warburton, Richard/ABC-3609-2021; Hogele, Alexander/C-1080-2016	Urbaszek, Bernhard/0000-0003-0226-7983; Gerardot, Brian D/0000-0002-0279-898X; Garcia, Jorge M./0000-0001-6906-6268; Hogele, Alexander/0000-0002-0178-9117; Microelectronica de Madrid, Instituto de/0000-0003-4211-9045	Engineering and Physical Sciences Research Council [GR/A11472/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bayer M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.041308; Bayer M, 2000, NATURE, V405, P923, DOI 10.1038/35016020; Bonadeo NH, 1998, SCIENCE, V282, P1473, DOI 10.1126/science.282.5393.1473; Borri P, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.157401; DINGLE RB, 1952, PROC R SOC LON SER-A, V211, P500, DOI 10.1098/rspa.1952.0055; Fock V, 1928, Z PHYS, V47, P446, DOI 10.1007/BF01390750; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; Hewson A C, 1993, KONDO PROBLEM HEAVY; Kamada H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.246401; Kammerer C, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.207401; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Moreau E, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.183601; Schulhauser C, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.193303; SIMMONDS PE, 1992, PHYS REV B, V45, P9497, DOI 10.1103/PhysRevB.45.9497; Toda Y, 1999, PHYS REV LETT, V82, P4114, DOI 10.1103/PhysRevLett.82.4114; Vasanelli A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.216804; Warburton RJ, 2000, NATURE, V405, P926, DOI 10.1038/35016030; Warburton RJ, 1998, PHYS REV B, V58, P16221, DOI 10.1103/PhysRevB.58.16221; Yuan ZL, 2002, SCIENCE, V295, P102, DOI 10.1126/science.1066790; Zrenner A, 2002, NATURE, V418, P612, DOI 10.1038/nature00912	22	107	107	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 8	2004	427	6970					135	138		10.1038/nature02109	http://dx.doi.org/10.1038/nature02109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712271				2022-12-28	WOS:000187863900030
J	MacGillivray, TE; Vlahakes, GJ				MacGillivray, TE; Vlahakes, GJ			Patency and the pump - The risks and benefits of off-pump CABG	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	MacGillivray, TE (corresponding author), Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.								0	19	19	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					3	4		10.1056/NEJMp038185	http://dx.doi.org/10.1056/NEJMp038185			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702419				2022-12-28	WOS:000187659900001
J	Aronowitz, P; Cobarrubias, F				Aronowitz, P; Cobarrubias, F			Anterior cervical osteophytes causing airway compromise	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Calif Pacific Med Ctr, San Francisco, CA 94118 USA	California Pacific Medical Center	Aronowitz, P (corresponding author), Calif Pacific Med Ctr, San Francisco, CA 94118 USA.								0	13	14	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2540	2540		10.1056/NEJMicm980279	http://dx.doi.org/10.1056/NEJMicm980279			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695414				2022-12-28	WOS:000187529500009
J	Zhu, H; Zhu, JX; Lo, PS; Li, JM; Leung, KM; Rowlands, DK; Tsang, LL; Yu, MK; Jiang, JL; Lam, SY; Chung, YW; Zhou, ZM; Sha, JH; Chan, HC				Zhu, H; Zhu, JX; Lo, PS; Li, JM; Leung, KM; Rowlands, DK; Tsang, LL; Yu, MK; Jiang, JL; Lam, SY; Chung, YW; Zhou, ZM; Sha, JH; Chan, HC			Rescue of defective pancreatic secretion in cystic-fibrosis cells by suppression of a novel isoform of phospholipase C	LANCET			English	Article							CFTR CHLORIDE CHANNEL; PROTEIN-KINASE-C; DUCT CELLS; SURFACE EXPRESSION; ANION SECRETION; GENE; DELTA-F508-CFTR; PHOSPHORYLATION; MECHANISMS; MUTATION	Background Cystic fibrosis is caused by mutations in the gene encoding an ion-transport protein, the cystic-fibrosis transmembrane conductance regulator (CFTR). Defective secretion of anions is the primary cause of many of the clinical manifestations of cystic fibrosis, including pancreatic insufficiency. We aimed to identify a molecular mechanism from which a new method to circumvent defective pancreatic secretion could be derived. Methods Multiple-human-tissue RT-PCR and semiquantitative RT-PCR analyses were used to examine gene expression. An antisense technique was used in conjunction with radioimmunoassay, Fura-2 spectrofluorometry, immunohistochemistry, and the short-circuit current technique (Ussing chamber) for elucidation of gene function and its application in rescuing defective pancreatic secretion. Findings We cloned a newly identified gene, NYD-SP27, which has structural similarity to an isoform of phospholipase C. NYD-SP27 was expressed endogenously in human pancreatic-duct cells and upregulated in cystic fibrosis. Suppression of NYD-SP27, by transfection of its antisense into human cystic-fibrosis pancreatic-duct cells, resulted in augmentation of phospholipase-C-coupled calcium-ion release and protein kinase C activity, improvement in the amount of mutated CFTR reaching the plasma membrane, and restoration of cAMP-activated pancreatic anion secretion. Interpretation NYD-SP27 exerts an inhibitory effect on phospholipase-C-coupled processes that depend on calcium ions and protein kinase C, including CFTR trafficking and function. Its upregulation in pancreatic-duct cells may reveal a previously unsuspected defect in cystic fibrosis contributing to pancreatic insufficiency, and thus represents a new target for pharmacological intervention in cystic fibrosis.	Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; Nanjing Med Univ, Lab Reprod Med, Nanjing 210009, Peoples R China	Chinese University of Hong Kong; Nanjing Medical University	Chan, HC (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China.		Chan, Hsiao Chang/E-1507-2016	Rowlands, Dewi/0000-0001-5180-842X				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Case R. M., 1993, P301; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; Cheng HS, 1998, J MEMBRANE BIOL, V164, P155, DOI 10.1007/s002329900401; Cheng HS, 1999, BBA-BIOMEMBRANES, V1418, P31, DOI 10.1016/S0005-2736(99)00011-5; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Estell K, 2003, MOL CELL BIOL, V23, P594, DOI 10.1128/MCB.23.2.594-606.2003; GADSBY DC, 1995, ANNU REV PHYSIOL, V57, P387; HADORN B, 1968, CAN MED ASSOC J, V98, P377; Maitra R, 2001, AM J PHYSIOL-CELL PH, V280, pC1031, DOI 10.1152/ajpcell.2001.280.5.C1031; Nousia-Arvanitakis S, 1999, J CLIN GASTROENTEROL, V29, P138, DOI 10.1097/00004836-199909000-00007; Quinton Paul M., 1999, Physiological Reviews, V79, pS3; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schultz BD, 1999, PHYSL REV S, V79, P109; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; USSING HH, 1951, ACTA PHYSIOL SCAND, V23, P110, DOI 10.1111/j.1748-1716.1951.tb00800.x; Walkowiak J, 2001, EUR J CLIN INVEST, V31, P796, DOI 10.1046/j.1365-2362.2001.00876.x; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINPENNY JP, 1995, AM J PHYSIOL-CELL PH, V268, pC823, DOI 10.1152/ajpcell.1995.268.4.C823; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Zhou ZM, 2002, REPRODUCTION, V123, P227, DOI 10.1530/rep.0.1230227; Zsembery A, 2000, FASEB J, V14, P2345, DOI 10.1096/fj.99-0509com	26	15	19	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2059	2065		10.1016/S0140-6736(03)15100-8	http://dx.doi.org/10.1016/S0140-6736(03)15100-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697805				2022-12-28	WOS:000187429600010
J	Brumfiel, G; Knight, J				Brumfiel, G; Knight, J			Climate of conflict - In the shadow of war	NATURE			English	News Item																		Atlas R, 2003, NATURE, V421, P771, DOI 10.1038/nature01479	1	0	0	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					748	749		10.1038/426748a	http://dx.doi.org/10.1038/426748a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685187	Bronze			2022-12-28	WOS:000187342000011
J	Goldberg, AL				Goldberg, AL			Protein degradation and protection against misfolded or damaged proteins	NATURE			English	Review							MOLECULAR-WEIGHT PROTEASES; ATP-DEPENDENT PROTEASES; ABNORMAL PROTEINS; QUALITY-CONTROL; RETICULOCYTES; INHIBITION; BACTERIAL; PATHWAY; SYSTEM; CHIP	The ultimate mechanism that cells use to ensure the quality of intracellular proteins is the selective destruction of misfolded or damaged polypeptides. In eukaryotic cells, the large ATP-dependent proteolytic machine, the 26S proteasome, prevents the accumulation of non-functional, potentially toxic proteins. This process is of particular importance in protecting cells against harsh conditions (for example, heat shock or oxidative stress) and in a variety of diseases (for example, cystic fibrosis and the major neurodegenerative diseases). A full understanding of the pathogenesis of the protein-folding diseases will require greater knowledge of how misfolded proteins are recognized and selectively degraded.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu						ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goff SA, 1988, UBIQUITIN, P207; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLDBERG AL, 1986, MAXIMIZING GENE EXPR, P287; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hideshima T, 2001, CANCER RES, V61, P3071; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Huang HC, 2001, J BIOL CHEM, V276, P3920, DOI 10.1074/jbc.M002937200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kandror O, 1999, J BIOL CHEM, V274, P37743, DOI 10.1074/jbc.274.53.37743; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; KLEMES Y, 1981, J BIOL CHEM, V256, P8436; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Langer T, 2001, BIOCHEM SOC T, V29, P431, DOI 10.1042/BST0290431; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; PROUTY WF, 1972, NATURE-NEW BIOL, V240, P147, DOI 10.1038/newbio240147a0; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zwickl P, 2000, MOL B INT U, V12, P8	45	1582	1639	7	201	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					895	899		10.1038/nature02263	http://dx.doi.org/10.1038/nature02263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685250				2022-12-28	WOS:000187342000072
J	Heilbron, JL; Bynum, WF				Heilbron, JL; Bynum, WF			1904 and all that - This year's anniversaries include neurons, the kodak and enlightenment.	NATURE			English	Editorial Material									Univ Oxford Worcester Coll, Oxford OX1 2HB, England; UCL, Wellcome Trust Ctr Hist Med, London NW1 1AD, England	University of Oxford; University of London; University College London	Heilbron, JL (corresponding author), Univ Oxford Worcester Coll, Oxford OX1 2HB, England.								0	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					761	764		10.1038/426761a	http://dx.doi.org/10.1038/426761a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685204				2022-12-28	WOS:000187342000024
J	Lovelock, J				Lovelock, J			The living Earth	NATURE			English	Editorial Material							GAIA		Univ Oxford Green Coll, Oxford OX2 6HG, England	University of Oxford	Lovelock, J (corresponding author), Univ Oxford Green Coll, Woodstock Rd, Oxford OX2 6HG, England.							Hamilton WD, 1998, ETHOL ECOL EVOL, V10, P1, DOI 10.1080/08927014.1998.9522867; Kump Leo, 2004, EARTH SYSTEM; Lenton TM, 1998, NATURE, V394, P439, DOI 10.1038/28792; Lovelock J, 2000, AGES GAIA; Margulis L, 1999, SYMBIOTIC PLANET; SCHELLNHUBER HJ, 1998, EARTH SYSTEM ANAL IN; Turney Jon, 2003, LOVELOCK GAIA	7	67	70	5	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					769	770		10.1038/426769a	http://dx.doi.org/10.1038/426769a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685210				2022-12-28	WOS:000187342000030
J	Reichhardt, T				Reichhardt, T			NASA - Trawling through the wreckage	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					754	755		10.1038/426754b	http://dx.doi.org/10.1038/426754b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685195	Bronze			2022-12-28	WOS:000187342000017
J	Omari, A; Garner, P				Omari, A; Garner, P			Extracts from "Clinical Evidence Concise" - Severe life threatening malaria in endemic areas	BRITISH MEDICAL JOURNAL			English	Review									Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Omari, A (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.		Garner, Paul/Y-8385-2019; Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941; 					0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					154	154		10.1136/bmj.328.7432.154	http://dx.doi.org/10.1136/bmj.328.7432.154			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726347	Green Published, Green Accepted			2022-12-28	WOS:000188249900026
J	Galy, V; Gadal, O; Fromont-Racine, M; Romano, A; Jacquier, A; Nehrbass, U				Galy, V; Gadal, O; Fromont-Racine, M; Romano, A; Jacquier, A; Nehrbass, U			Nuclear retention of unspliced mRNAs in yeast is mediated by perinuclear Mlp1	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; COUPLING TRANSCRIPTION; QUALITY-CONTROL; PORE COMPLEX; PROTEINS; EXPORT; SITE; IDENTIFICATION; COMPONENT; DELETION	The molecular mechanism underlying the retention of intron-containing mRNAs in the nucleus is not understood. Here, we show that retention of intron-containing mRNAs in yeast is mediated by perinuclearly located Mlp1. Deletion of MLP1 impairs retention while having no effect on mRNA splicing. The Mlp1-dependent leakage of intron-containing RNAs is increased in presence of ts-prp18Delta, a splicing mutant. When overall pre-mRNA levels are increased by deletion of RRP6, a nuclear exosome component, MLP1 deletion augments leakage of only the intron-containing portion of mRNAs. Our data suggest, moreover, that Mlp1-dependent retention is mediated via the 5' splice site. Intriguingly, we found Mlp-proteins to be present only on sections of the NE adjacent to chromatin. We propose that at this confined site the perinuclear Mlp1 implements a quality control step prior to export, physically retaining faulty pre-mRNAs.	CNRS, URA 2582, Unite Biol Cellulaire Noyau, F-25724 Paris 15, France; Inst Pasteur, CNRS, URA 2171, Unite Genet Interact Macromol, F-25724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Jacquier, A (corresponding author), CNRS, URA 2582, Unite Biol Cellulaire Noyau, 25 Rue Docteur Roux, F-25724 Paris 15, France.	jacquier@pasteur.fr; nehrbass@pasteur.fr	Gadal, Olivier/A-4731-2008	Gadal, Olivier/0000-0001-9421-0831; JACQUIER, ALAIN/0000-0001-5707-9184; Fromont-Racine, Micheline/0000-0001-9906-0334; Nehrbass, Ulf/0000-0002-7028-8076				Andrulis ED, 2002, MOL CELL BIOL, V22, P8292, DOI 10.1128/MCB.22.23.8292-8301.2002; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Feuerbach F, 2002, NAT CELL BIOL, V4, P214, DOI 10.1038/ncb756; Gadal O, 2002, J CELL BIOL, V157, P941, DOI 10.1083/jcb.200111039; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; HOROWITZ DS, 1993, MOL CELL BIOL, V13, P2959, DOI 10.1128/MCB.13.5.2959; Iborra FJ, 2000, J CELL SCI, V113, P291; Jensen TH, 2003, MOL CELL, V11, P1129, DOI 10.1016/S1097-2765(03)00191-6; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Kosova B, 2000, J BIOL CHEM, V275, P343, DOI 10.1074/jbc.275.1.343; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Long RM, 1995, RNA, V1, P1071; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Rain JC, 1997, EMBO J, V16, P1759, DOI 10.1093/emboj/16.7.1759; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; Rutz B, 2000, EMBO J, V19, P1873, DOI 10.1093/emboj/19.8.1873; Siniossoglou S, 1998, EMBO J, V17, P6449, DOI 10.1093/emboj/17.22.6449; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; Winey M, 1997, MOL BIOL CELL, V8, P2119, DOI 10.1091/mbc.8.11.2119; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701	32	268	272	1	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	2004	116	1					63	73		10.1016/S0092-8674(03)01026-2	http://dx.doi.org/10.1016/S0092-8674(03)01026-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718167	Bronze			2022-12-28	WOS:000187960800009
J	Roe, SM; Ali, MMU; Meyer, P; Vaughan, CK; Panaretou, B; Piper, PW; Prodromou, C; Pearl, LH				Roe, SM; Ali, MMU; Meyer, P; Vaughan, CK; Panaretou, B; Piper, PW; Prodromou, C; Pearl, LH			The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37)	CELL			English	Article							N-TERMINAL DOMAIN; MOLECULAR CHAPERONE; ATPASE ACTIVITY; CLIENT PROTEIN; IN-VIVO; BINDING; CDC37; HYDROLYSIS; HEAT-SHOCK-PROTEIN-90; IDENTIFICATION	Recruitment of protein kinase clients to the Hsp90 chaperone involves the cochaperone p50(cdc37) acting as a scaffold, binding protein kinases via its N-terminal domain and Hsp90 via its C-terminal region. p50(cdc37) also has a regulatory activity, arresting Hsp90's ATPase cycle during client-protein loading. We have localized the binding site for p50(cdc37) to the N-terminal nucleotide binding domain of Hsp90 and determined the crystal structure of the Hsp90-p50(cdc37) core complex. Dimeric p50(cdc37) binds to surfaces of the Hsp90 N-domain implicated in ATP-dependent N-terminal dimerization and association with the middle segment of the chaperone. This interaction fixes the lid segment in an open conformation, inserts an arginine side chain into the ATP binding pocket to disable catalysis, and prevents trans-activating interaction of the N domains.	Inst Canc Res, Sect Struct Biol, Chester Beatty Labs, London SW3 6JB, England; Kings Coll London, Div Life Sci, London SE1 9NN, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; University of London; University College London	Prodromou, C (corresponding author), Inst Canc Res, Sect Struct Biol, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.	chris.prodromou@icr.ac.uk; laurence.pearl@icr.ac.uk	Meyer, Philippe/AAC-6038-2019; Prodromou, Chrisostomos/ABA-9133-2021	Meyer, Philippe/0000-0002-6220-0679; Prodromou, Chrisostomos/0000-0003-4320-1147; Piper, Peter William/0000-0003-4019-2329; Pearl, Laurence/0000-0002-6910-1809; Roe, Mark/0000-0002-7371-9855				An WG, 2000, CELL GROWTH DIFFER, V11, P355; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; BIJKMAKERS MJ, 2000, MOL BIOL CELL, V11, P1585; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chavany C, 1996, J BIOL CHEM, V271, P4974; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DeLano W.L, PYMOL MOL GRAPHICS S; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lange BMH, 2002, EMBO J, V21, P5364, DOI 10.1093/emboj/cdf531; Lee P, 2002, J CELL BIOL, V159, P1051, DOI 10.1083/jcb.200210121; LESLIE A, 1995, MOSFLM USERS GUIDE; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl FMG, 2000, NUCLEIC ACIDS RES, V28, P277, DOI 10.1093/nar/28.1.277; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scholz GM, 2001, J BIOL CHEM, V276, P30971, DOI 10.1074/jbc.M103889200; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Tatebe H, 2003, MOL CELL BIOL, V23, P5132, DOI 10.1128/MCB.23.15.5132-5142.2003; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Wegele H, 2003, J BIOL CHEM, V278, P39303, DOI 10.1074/jbc.M305751200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930	67	270	291	4	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					87	98		10.1016/S0092-8674(03)01027-4	http://dx.doi.org/10.1016/S0092-8674(03)01027-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718169	Bronze			2022-12-28	WOS:000187960800011
J	Muntner, P; Hamm, LL; Kusek, JW; Chen, J; Whelton, PK; He, J				Muntner, P; Hamm, LL; Kusek, JW; Chen, J; Whelton, PK; He, J			The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC-RENAL-FAILURE; GLOMERULAR-FILTRATION-RATE; 3RD NATIONAL-HEALTH; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; SERUM CREATININE; ARTERY-DISEASE; UNITED-STATES; MYOCARDIAL-INFARCTION	Background: Risk for coronary heart disease is high among patients with chronic kidney disease. Objective: To compare the prevalence of low apolipoprotein A1 levels and elevated apolipoprotein Ell, plasma fibrinogen, lipoprotein(a), homocysteine, and C-reactive protein levels by estimated glomerular filtration rate (GFR). Design: Cross-sectional study. Setting: Third National Health and Nutrition Examination survey. Participants: 12 547, 3180, and 744 persons with estimated GFRs of at least 90, 60 to 89, or less than 60 mL/min per 1.73 m(2), respectively, who were at least 18 years of age. Measurements: Chronic kidney disease was defined as an estimated GFR of less than 60 mL/min per 1.73 m(2) based on the abbreviated Modification of Diet in Renal Disease formula. Results: After standardization for age, race or ethnicity, and sex, lower estimated GFR (greater than or equal to90, 60 to 89, or <60 mL/min per 1.73 m 2) was associated with lower average levels of apolipoprotein A1 (1.44, 1.43, and 1.35 g/L) and higher levels of apolipoprotein B (1.03, 1.06, and 1.08 g/L), plasma fibrinogen (8.43, 8.44, and 9.53 mumol/L), homocysteine (8.5, 10.0, and 13.2 mumol/L), and C-reactive protein (3.0, 2.9, and 3.9 mg/L) (P < 0.05 for all values). The multivariate-adjusted odds ratios of an apolipoprotein A1 level of less than 1.2 g/L, a serum lipoprotein(a) level of at least 1.61 mumol/L (greater than or equal to45.3 mg/dL), a plasma fibrinogen level of at least 10.35 mumol/L, a serum homocysteine level of at least 15,mumol/L, and a C-reactive protein level of at least 10.0 mg/L for participants with chronic kidney disease compared with those with a GFR of at least 90 mL/min per 1.73 m(2) or greater were 1.92 (95% Cl, 1.02 to 3.63), 1.82 (Cl, 1.06 to 3.13), 1.74 (Cl, 1.35 to 2.24), 8.23 (Cl, 5.00 to 13.6), and 1.93 (Cl, 1.33 to 2.81), respectively. Conclusions: Levels of apolipoprotein A1 are decreased and levels of homocysteine, lipoprotein(a), fibrinogen, and C-reactive protein are increased among patients with chronic kidney disease.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70118 USA; NIDDKD, NIH, Bethesda, MD 20892 USA	Tulane University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave,SL18, New Orleans, LA 70118 USA.	jhe@tulane.edu	He, Jiang/AAF-5303-2020	He, Jiang/0000-0002-8286-9652	NCRR NIH HHS [P20 RR17659-01] Funding Source: Medline; NIDDK NIH HHS [U01 DK60963] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK060963] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, VITAL HLTH STAT, P1; Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140-6736(00)02456-9; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Bostom AG, 1996, ATHEROSCLEROSIS, V125, P91, DOI 10.1016/0021-9150(96)05865-0; Bostom AG, 1997, KIDNEY INT, V52, P10, DOI 10.1038/ki.1997.298; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2001, ARCH INTERN MED, V161, P1207, DOI 10.1001/archinte.161.9.1207; Coresh J, 1998, J Am Soc Nephrol, V9, pS24; CRESSMAN MD, 1992, CIRCULATION, V86, P475, DOI 10.1161/01.CIR.86.2.475; Culleton BF, 1999, KIDNEY INT, V56, P2214, DOI 10.1046/j.1523-1755.1999.00773.x; Danesh J, 2000, CIRCULATION, V102, P1082, DOI 10.1161/01.CIR.102.10.1082; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; Dennis VW, 1996, KIDNEY INT, V50, pS11; DENTONS, 2019, 2019 CHIN DAT PROT C, P17; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; GOLDWASSER P, 1993, AM J KIDNEY DIS, V22, P215, DOI 10.1016/S0272-6386(12)70189-0; Grimm R H Jr, 1997, Kidney Int Suppl, V63, pS10; HAFFNER SM, 1992, J AM SOC NEPHROL, V3, P1156; Henning BF, 1999, NEPHRON, V83, P314, DOI 10.1159/000045423; Irish A, 1998, ATHEROSCLEROSIS, V137, P133, DOI 10.1016/S0021-9150(97)00273-6; Kasiske BL, 1998, AM J KIDNEY DIS, V32, pS142, DOI 10.1053/ajkd.1998.v32.pm9820472; *KDOQI WORK GROUP, 2002, AM J KIDNEY DIS, V39, pS46; Kovesdy CP, 2002, AM J KIDNEY DIS, V40, P899, DOI 10.1053/ajkd.2002.36319; Kronenberg F, 1999, J AM SOC NEPHROL, V10, P1027; KWITEROVICH PO, 1992, AM J CARDIOL, V69, P1015, DOI 10.1016/0002-9149(92)90856-T; Levey AS, 1998, AM J KIDNEY DIS, V32, pS5, DOI 10.1053/ajkd.1998.v32.pm9820463; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levinskii YV, 2000, INORG MATER+, V36, P24, DOI 10.1007/BF02758374; Longenecker JC, 2002, CIRCULATION, V106, P2812, DOI 10.1161/01.CIR.0000038946.91899.BB; Moustapha A, 1998, CIRCULATION, V97, P138, DOI 10.1161/01.CIR.97.2.138; Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Reis SE, 2002, CIRCULATION, V105, P2826, DOI 10.1161/01.CIR.0000021597.63026.65; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Robinson K, 1996, CIRCULATION, V94, P2743, DOI 10.1161/01.CIR.94.11.2743; Samak MJ, 2002, CLIN NEPHROL, V57, P327; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; Sechi LA, 1999, KIDNEY INT, V56, P1049, DOI 10.1046/j.1523-1755.1999.00621.x; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; Stenvinkel P, 1998, KIDNEY INT, V53, P1336, DOI 10.1046/j.1523-1755.1998.00880.x; Tamura T, 1996, J AM SOC NEPHROL, V7, P2414; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x	48	313	323	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					9	17		10.7326/0003-4819-140-1-200401060-00006	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706967				2022-12-28	WOS:000187855600002
J	Graham, WJ; Fitzmaurice, AE; Bell, JS; Cairns, JA				Graham, WJ; Fitzmaurice, AE; Bell, JS; Cairns, JA			The familial technique for linking maternal death with poverty	LANCET			English	Article							HEALTH; MORTALITY; POOR	Background Recognition of the synergy between health and poverty is now apparent in the development strategies of many low-income countries, and markers are needed to monitor progress towards poverty-relevant goals. Maternal mortality has been proposed as a possible candidate but evidence is lacking on the link with poverty at the level of individuals. We introduce a new approach to exploring the relation-the familial technique. Methods We used data from 11 household surveys in ten developing countries to create percentage distributions of women according to their poverty-related characteristics and survival status (alive, non-maternal death, maternal death). These women were identified as the sisters of the adult female respondents in the surveys, and were assigned the same poverty status as their respondent sibling. Findings The analysis showed significant associations, across a diverse set of countries, between women's poverty status (proxied by educational level, source of water, and type of toilet and floor) and survival. These associations indicated a gradient within and across the survival categories. With increasing poverty, the proportion of women dying of non-maternal causes generally increased, and the proportion dying of maternal causes increased consistently. Further analysis reported here for one of the countries-Indonesia, revealed that about 32-34% of the maternal deaths occurred among women from the poorest quintile of the population. The risk of maternal death in this country was around 3-4 times greater in the poorest than the richest group. Interpretation This new method makes efficient use of existing survey data to explore the relation between maternal mortality and poverty, and has wider potential for examining the poor-rich gap.	Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen AB9 1FX, Scotland; Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB9 1FX, Scotland	University of Aberdeen; University of Aberdeen	Graham, WJ (corresponding author), Aberdeen Matern Hosp, Dugald Baird Ctr Res Womens Hlth, Aberdeen AB25 2ZL, Scotland.	w.graham@abdn.ac.uk	Cairns, John/AAD-1168-2020	Bell, Jacqueline/0000-0003-1784-0180; Graham, Wendy/0000-0003-1473-5342				BRUNDTLAND GH, 1999, WORLD HLTH REPORT 19; *DEP INT DEV, 1999, BREAK BARR WOM EL WO; GRAHAM W, 1989, STUD FAMILY PLANN, V20, P125, DOI 10.2307/1966567; Graham WJ, 2002, LANCET, V359, P701, DOI 10.1016/S0140-6736(02)07817-0; Graham WJ., 2002, MATERNAL MORBIDITY M; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747, DOI 10.1093/oxfordjournals.aje.a117069; Gwatkin DR, 2003, LANCET, V361, P540, DOI 10.1016/S0140-6736(03)12558-5; Hoyert DL, 2000, BIRTH-ISS PERINAT C, V27, P4, DOI 10.1046/j.1523-536x.2000.00004.x; Kunst A. E., 2001, STUDIES HLTH SERV OR, V17, P297; LOUDEN I, 1992, DEATH CHILDBIRTH INT; Mathews Z., 2001, ASSESSING HLTH POOR; MCDONAGH M, 2001, STUD HLTH SERV ORG P, V17, P317; Morris SS, 2000, J EPIDEMIOL COMMUN H, V54, P381, DOI 10.1136/jech.54.5.381; Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; Shen C, 1999, SOC SCI MED, V49, P197, DOI 10.1016/S0277-9536(99)00112-4; Stanton C, 2000, STUD FAMILY PLANN, V31, P111, DOI 10.1111/j.1728-4465.2000.00111.x; UN, 2000, ARES552 UN; UNDP, 2003, HUMAN DEV REPORT 200; *WHO UNICEF UNFPA, 2001, WHORHR019 UNICEF UNF; *WORLD BANK, COUNTR REP HLTH NUTR; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd; World Health Organization, 2001, MACR HLTH INV HLTH E	23	82	85	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					23	27		10.1016/S0140-6736(03)15165-3	http://dx.doi.org/10.1016/S0140-6736(03)15165-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	758YZ	14723990				2022-12-28	WOS:000187711300010
J	Aten, JA; Stap, J; Krawczyk, PM; van Oven, CH; Hoebe, RA; Essers, J; Kanaar, R				Aten, JA; Stap, J; Krawczyk, PM; van Oven, CH; Hoebe, RA; Essers, J; Kanaar, R			Dynamics of DNA double-strand breaks revealed by clustering of damaged chromosome domains	SCIENCE			English	Article							REPAIR; CHROMATIN; ABERRATIONS; COMPLEX; ALPHA; FOCI	Interactions between ends from different DNA double-strand breaks (DSBs) can produce tumorigenic chromosome translocations. Two theories for the juxtaposition of DSBs in translocations, the static "contact-first" and the dynamic "breakage-first" theory, differ fundamentally in their requirement for DSB mobility. To determine whether or not DSB-containing chromosome domains are mobile and can interact, we introduced linear tracks of DSBs in nuclei. We observed changes in track morphology within minutes after DSB induction, indicating movement of the domains. In a subpopulation of cells, the domains clustered. Juxtaposition of different DSB-containing chromosome domains through clustering, which was most extensive in G1 phase cells, suggests an adhesion process in which we implicate the Mre11 complex. Our results support the breakage-first theory to explain the origin of chromosomal translocations.	Erasmus MC Daniel den Hoed, Erasmus Med Ctr, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Erasmus MC Daniel den Hoed, Dept Radiat Oncol, NL-3000 DR Rotterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Ctr Microscopial Res, NL-1100 DE Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam	Kanaar, R (corresponding author), Erasmus MC Daniel den Hoed, Erasmus Med Ctr, Dept Cell Biol & Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	r.kanaar@erasmusmc.nl						Anderson RM, 2002, P NATL ACAD SCI USA, V99, P12167, DOI 10.1073/pnas.182426799; BARENDSEN GW, 1962, NATURE, V193, P1153, DOI 10.1038/1931153a0; Chubb JR, 2002, CURR BIOL, V12, P439, DOI 10.1016/S0960-9822(02)00695-4; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Dianov GL, 2001, BIOESSAYS, V23, P745, DOI 10.1002/bies.1104; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Holley WR, 2002, RADIAT RES, V158, P568, DOI 10.1667/0033-7587(2002)158[0568:AMFICA]2.0.CO;2; Jakob B, 2003, RADIAT RES, V159, P676, DOI 10.1667/0033-7587(2003)159[0676:BIOHCT]2.0.CO;2; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Ludwikow G, 2002, INT J RADIAT BIOL, V78, P239, DOI 10.1080/09553000110110086; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Savage JRK, 2000, SCIENCE, V290, P62, DOI 10.1126/science.290.5489.62; SAX K., 1941, COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, V9, P93; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Serebrovsky AS, 1929, AM NAT, V63, P374, DOI 10.1086/280271; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tashiro S, 1996, ONCOGENE, V12, P2165; Wyman C, 2002, CURR BIOL, V12, pR446, DOI 10.1016/S0960-9822(02)00941-7	23	373	387	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					92	95		10.1126/science.1088845	http://dx.doi.org/10.1126/science.1088845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704429				2022-12-28	WOS:000187710600041
J	Sarmiento, JL; Gruber, N; Brzezinski, MA; Dunne, JP				Sarmiento, JL; Gruber, N; Brzezinski, MA; Dunne, JP			High-latitude controls of thermocline nutrients and low latitude biological productivity	NATURE			English	Article							SOUTHERN-OCEAN; NORTH; SI; CYCLE; MODE	The ocean's biological pump strips nutrients out of the surface waters and exports them into the thermocline and deep waters. If there were no return path of nutrients from deep waters, the biological pump would eventually deplete the surface waters and thermocline of nutrients; surface biological productivity would plummet. Here we make use of the combined distributions of silicic acid and nitrate to trace the main nutrient return path from deep waters by upwelling in the Southern Ocean(1) and subsequent entrainment into subantarctic mode water. We show that the subantarctic mode water, which spreads throughout the entire Southern Hemisphere(2,3) and North Atlantic Ocean(3), is the main source of nutrients for the thermocline. We also find that an additional return path exists in the northwest corner of the Pacific Ocean, where enhanced vertical mixing, perhaps driven by tides(4), brings abyssal nutrients to the surface and supplies them to the thermocline of the North Pacific. Our analysis has important implications for our understanding of large-scale controls on the nature and magnitude of low-latitude biological productivity and its sensitivity to climate change.	Princeton Univ, Atmospher & Ocean Sci Program, Princeton, NJ 08544 USA; Univ Calif Los Angeles, IGPP, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Atmospher Sci, Los Angeles, CA 90095 USA; Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Oceanic Atmospheric Admin (NOAA) - USA	Sarmiento, JL (corresponding author), Princeton Univ, Atmospher & Ocean Sci Program, Princeton, NJ 08544 USA.	jls@princeton.edu	Gruber, Nicolas/B-7013-2009; Dunne, John P/F-8086-2012	Gruber, Nicolas/0000-0002-2085-2310; Dunne, John P/0000-0002-8794-0489				Belkin IM, 1996, J GEOPHYS RES-OCEANS, V101, P3675, DOI 10.1029/95JC02750; Brzezinski MA, 2003, DEEP-SEA RES PT II, V50, P619, DOI 10.1016/S0967-0645(02)00587-8; Dugdale RC, 2002, DEEP-SEA RES PT II, V49, P2513, DOI 10.1016/S0967-0645(02)00046-2; Franck VM, 2000, DEEP-SEA RES PT II, V47, P3315; Gnanadesikan A, 2001, DEEP-SEA RES PT II, V49, P363; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; Hanawa K., 2001, OCEAN CIRCULATION CL, P373, DOI DOI 10.1016/S0074-6142(01)80129-7; KARA AB, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/2000C000736; LEDWELL JR, 1993, NATURE, V364, P701, DOI 10.1038/364701a0; Levitus S., 1998, WORLD OCEAN DATABASE, V1; McCartney M. S., 1979, VOYAGE DISCOVERY G D, P103; McCartney MS, 1982, J MAR RES, V40, P427; Moore JK, 1999, J GEOPHYS RES-OCEANS, V104, P3059, DOI 10.1029/1998JC900032; Nakamura T, 2000, J PHYS OCEANOGR, V30, P1601, DOI 10.1175/1520-0485(2000)030<1601:TGOLAU>2.0.CO;2; Pollard RT, 2002, DEEP-SEA RES PT II, V49, P3289, DOI 10.1016/S0967-0645(02)00084-X; Ragueneau O, 2000, GLOBAL PLANET CHANGE, V26, P317, DOI 10.1016/S0921-8181(00)00052-7; Reid JL, 1997, PROG OCEANOGR, V39, P263, DOI 10.1016/S0079-6611(97)00012-8; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; SARMIENTO JL, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI DOI 10.1029/2002GB00191; Sigman DM, 1999, GLOBAL BIOGEOCHEM CY, V13, P1149, DOI 10.1029/1999GB900038; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Sloyan BM, 2001, J PHYS OCEANOGR, V31, P1005, DOI 10.1175/1520-0485(2001)031<1005:CRAMOA>2.0.CO;2; Speer K, 2000, J PHYS OCEANOGR, V30, P3212, DOI 10.1175/1520-0485(2000)030<3212:TDDC>2.0.CO;2; TALLEY LD, 1991, DEEP-SEA RES, V38, pS171, DOI 10.1016/S0198-0149(12)80009-4; Talley LD, 1997, J PHYS OCEANOGR, V27, P1795, DOI 10.1175/1520-0485(1997)027<1795:NPIWTI>2.0.CO;2; TOGGWEILER JR, 1991, J GEOPHYS RES-OCEANS, V96, P20467, DOI 10.1029/91JC02063; TOGGWEILER JR, 1993, GLOBAL CARBON CYCLE, P333; Tsunogai S, 2002, J OCEANOGR, V58, P245, DOI 10.1023/A:1015805607724; Yasuda I, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC001037; Yasuda I, 2001, J GEOPHYS RES-OCEANS, V106, P6931, DOI 10.1029/1999JC000154	30	862	877	4	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					56	60		10.1038/nature02127	http://dx.doi.org/10.1038/nature02127			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702082				2022-12-28	WOS:000187710000031
J	Gostin, LO; Bayer, R; Fairchild, AL				Gostin, LO; Bayer, R; Fairchild, AL			Ethical and legal challenges posed by severe acute respiratory syndrome - Implications for the control of severe infectious disease threats	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; TERRORISM; EPIDEMIC; CARE; LAW	The appearance and spread of severe acute respiratory syndrome (SARS) on a global level raised vital legal and ethical issues. National and international responses to SARS have profound implications for 3 important ethical values:, privacy, liberty, and the duty to protect the public's health. This article examines, through legal and ethical lenses, various methods that countries used in reaction to the SARS outbreak: surveillance and contact tracing, isolation and quarantine, and travel restrictions. These responses, at least in some combination, succeeded in bringing the outbreak to an end. The article articulates a set of legal and ethical recommendations for responding to infectious disease threats, seeking to reconcile the tension between the public's health and individual rights to privacy, liberty, and freedom of movement. The ethical values that inform the recommendations include the precautionary principle, the least restrictive/intrusive alternative, justice, and transparency. Development of a set of legal and ethical recommendations becomes even more essential when, as was true with SARS and will undoubtedly be the case with future epidemics, scientific uncertainty is pervasive,and urgent public health action is required.	Georgetown Univ, Ctr Law, Ctr Law & Publ Hlth, Washington, DC 20001 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Columbia Univ, Dept Sociomed Sci, Ctr Hist & Eth Publ Hlth, Joseph L Mailman Sch Publ Hlth, New York, NY USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Columbia University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, Ctr Law & Publ Hlth, 600 New Jersey Ave NW, Washington, DC 20001 USA.		Fairchild, Amy/F-1811-2018	Fairchild, Amy/0000-0002-1292-7212				ALTMAN LK, 2003, NY TIMES        0428, pA1; [Anonymous], 1991, Law Med Health Care, V19, P247; [Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P226; [Anonymous], 1995, CONTROL COMMUNICABLE; Applegate JS, 2000, HUM ECOL RISK ASSESS, V6, P413, DOI 10.1080/10807030091124554; Barbera J, 2001, JAMA-J AM MED ASSOC, V286, P2711, DOI 10.1001/jama.286.21.2711; BAYER R, 1986, JAMA-J AM MED ASSOC, V256, P1768, DOI 10.1001/jama.256.13.1768; Bloom BR, 2003, SCIENCE, V300, P701, DOI 10.1126/science.300.5620.701; Bradsher K, 2003, NY TIMES, pA1; BRADSHER K, 2003, NY TIMES        0425, pA20; BROWN DL, 2003, WASHINGTON POST 0424, pA20; *CDC, 2003, MMWR-MORBID MORTAL W, V52, P436; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P270; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P40; CHENG M, 2003, NEW YORK NEWSDA 0517, pA4; Cohn M. R., 2003, TORONTO STAR    0421, pAl; COOPER MH, 2003, CQ RES          0620; DONOVAN K, 2003, TORONTO STAR    0425, pA14; Feinberg J., 1987, MORAL LIMITS CRIMINA; Fidler DP, 2003, EMERG INFECT DIS, V9, P285, DOI 10.3201/eid0903.020336; FUJIWARA PI, TB CONTR NEW YORK CI; GARRETT L, 2003, NEWSDAY         0629, pA5; Gerberding JL, 2003, NEW ENGL J MED, V348, P2030, DOI 10.1056/NEJMe030067; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; Gostin LO, 2002, HEALTH AFFAIR, V21, P79, DOI 10.1377/hlthaff.21.6.79; Gostin LO, 2000, PUBLIC HLTH LAW POWE; *HARV U HLTH SERV, U ANN POL REG VIS SU; Kahn Joseph, 2003, NY TIMES        0701, pA; KRAUSS C, 2003, NY TIMES        0610, pA13; KUEPPER GJ, HONG KONG EXPERIENCE; LONG S, 2003, STRAITS TIMES S 0511; MARSHALL T, 2003, LOS ANGELES TIM 0428, P1; Masur H, 2003, JAMA-J AM MED ASSOC, V289, P2861, DOI 10.1001/jama.289.21.JED30036; MAYNARD M, 2003, NY TIMES        0511, P5; MAYNARD M, 2003, NY TIMES        0511, P6; MCNEIL DG, 2003, NYT             0314, pA1; MORRIS J, 2000, RETHINKING RISK PREC, P1; MURPHY DE, 2003, NY TIMES, pA12; NAKASHIMA E, 2003, WASHINGTON POST 0501, pA11; PADDOCK R, 2003, LOS ANGELES TIM 0508, P1; PERL T, 2003, REPORT TORONTO ETHIC; Rider D., 2003, OTTAWA CITIZEN  0404, pA10; RIDER D, 2003, OTTAWA CITIZEN  0420, pA1; SHELDON P, 2003, NY TIMES        0507, pA10; Sorenson C., 2003, TORONTO STAR    0404; STERNBERG S, 2003, US TODAY        0424, pA1; *UN EC SOC COUNC, ECN419854 UN; WAYNE A, 2003, NY TIMES        0610, pF4; WHO, GUID MASS GATH HOST; *WHO, UPD 70 SING REM LIST; *WHO, UPD 58 1 GLOB CONS S; *WHO, UPD 95 CHRON TRAV RE; *WHO, CURR INT HLTH REG IH; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P98; *WHO, CAS DEF SURV SEV AC; World Health Organization, REV INT HLTH REG SEV; World Health Organization, UPD 95 SARS CHRON SE; World Health Organization, 2003, SEV AC RESP SYNDR SA; World Health Organization, CUM NUMB REP PROB CA; World Health Organization (WHO), 2003, WKLY EPIDEMIOL REC, V78, P161; Wynia MK, 2002, SCIENCE, V296, P1613, DOI 10.1126/science.1072921; 1999, INT COVENANT CIVIL P; 2003, MMWR MORB MORTAL WKL, V52, P680; FREEDOM MOVEMENT TRA; SHELTERING PLACE; 2003, STRAITS TIMES S 0425; POLICE SYSTEM TRACKI	67	128	132	2	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2003	290	24					3229	3237		10.1001/jama.290.24.3229	http://dx.doi.org/10.1001/jama.290.24.3229			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756TR	14693876				2022-12-28	WOS:000187499300027
J	Ganesh, L; Burstein, E; Guha-Nijogi, A; Louder, MK; Mascola, JR; Klomp, LWJ; Wijmenga, C; Duckett, CS; Nabel, GJ				Ganesh, L; Burstein, E; Guha-Nijogi, A; Louder, MK; Mascola, JR; Klomp, LWJ; Wijmenga, C; Duckett, CS; Nabel, GJ			The gene product Murr1 restricts HIV-1 replication in resting CD4(+) lymphocytes	NATURE			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELLS; UBIQUITINATION; ACTIVATION; ALPHA; TRANSCRIPTION; INFECTION; COMPLEX; PHOSPHORYLATION	Although human immunodeficiency virus-1 (HIV-1) infects quiescent and proliferating CD4(+) lymphocytes, the virus replicates poorly in resting T cells(1-6). Factors that block viral replication in these cells might help to prolong the asymptomatic phase of HIV infection(7); however, the molecular mechanisms that control this process are not fully understood. Here we show that Murr1, a gene product known previously for its involvement in copper regulation(8,9), inhibits HIV-1 growth in unstimulated CD4(+) T cells. This inhibition was mediated in part through its ability to inhibit basal and cytokine-stimulated nuclear factor (NF)-kappaB activity. Knockdown of Murr1 increased NF-kappaB activity and decreased IkappaB-alpha concentrations by facilitating phospho-IkappaB-alpha degradation by the proteasome. Murr1 was detected in CD4(+) T cells, and RNA-mediated interference of Murr1 in primary resting CD4(+) lymphocytes increased HIV-1 replication. Through its effects on the proteasome, Murr1 acts as a genetic restriction factor that inhibits HIV-1 replication in lymphocytes, which could contribute to the regulation of asymptomatic HIV infection and the progression of AIDS.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Med Ctr Utrecht, NL-3584 EA Utrecht, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan; Utrecht University; Utrecht University Medical Center	Nabel, GJ (corresponding author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Room 4502,MSC-3005,40 Convent Dr, Bethesda, MD 20892 USA.		Wijmenga, Cisca/AAE-7719-2019; Burstein, Ezra/B-7247-2016; Mascola, John/AAI-7193-2021; Wijmenga, Cisca/D-2173-2009	Wijmenga, Cisca/0000-0002-5635-1614; Burstein, Ezra/0000-0003-4341-6367; Duckett, Colin/0000-0001-9413-2263				ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Klomp AEM, 2003, J HEPATOL, V39, P703, DOI 10.1016/S0168-8278(03)00380-5; Mascola JR, 2002, J VIROL, V76, P4810, DOI 10.1128/JVI.76.10.4810-4821.2002; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; RICHTER BW, 2000, SCI STKE; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	31	188	193	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					853	857		10.1038/nature02171	http://dx.doi.org/10.1038/nature02171			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685242	Green Published			2022-12-28	WOS:000187342000062
J	Hehenkamp, A; Hargreaves, S				Hehenkamp, A; Hargreaves, S			Tuberculosis treatment in complex emergencies: South Sudan	LANCET			English	Article									Med Sans Frontieres, London EC1N 8QX, England	Doctors Without Borders				Hargreaves, Sally/0000-0003-2974-4348					0	16	16	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S30	S31		10.1016/S0140-6736(03)15066-0	http://dx.doi.org/10.1016/S0140-6736(03)15066-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698120				2022-12-28	WOS:000187790200016
J	Nicogossian, A				Nicogossian, A			Medicine and space exploration	LANCET			English	Article									George Mason Univ, Sch Publ Policy, Int Med Policy Off, Fairfax, VA 22032 USA	George Mason University	Nicogossian, A (corresponding author), George Mason Univ, Sch Publ Policy, Int Med Policy Off, 4400 Univ Dr,MS 3C6, Fairfax, VA 22032 USA.							Nicogossian A.E., 1994, SPACE PHYSL MED	1	10	10	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S8	S9		10.1016/S0140-6736(03)15055-6	http://dx.doi.org/10.1016/S0140-6736(03)15055-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698109				2022-12-28	WOS:000187790200005
J	Tipton, M				Tipton, M			Cold water immersion: sudden death and prolonged survival	LANCET			English	Article									Univ Portsmouth, Portsmouth PO1 2DT, Hants, England; Inst Naval Med, Environm Med Div, Gosport PO12 2DL, Hants, England	University of Portsmouth	Tipton, M (corresponding author), Univ Portsmouth, Portsmouth PO1 2DT, Hants, England.			Tipton, Michael/0000-0002-7928-8451				Golden FStC., 2002, ESSENTIALS SEA SURVI	1	15	15	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S12	S13		10.1016/S0140-6736(03)15057-X	http://dx.doi.org/10.1016/S0140-6736(03)15057-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698111	Bronze			2022-12-28	WOS:000187790200007
J	Silaruks, S; Thinkhamrop, B; Kiatchoosakun, S; Wongvipaporn, C; Tatsanavivat, P				Silaruks, S; Thinkhamrop, B; Kiatchoosakun, S; Wongvipaporn, C; Tatsanavivat, P			Resolution of left atrial thrombus after 6 months of anticoagulation in candidates for percutaneous transvenous mitral commissurotomy	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; WARFARIN; MECHANISM; VALVULOPLASTY; STENOSIS; THERAPY; VALVE; TERM	Background: Resolution of left atrial thrombus after long-term oral anticoagulation enhances safe percutaneous transvenous mitral commissurotomy (PTMC); however, the short-term benefit has not been defined. Objectives: To estimate the resolution rate of left atrial thrombus among PTMC candidates after 6 months of oral anticoagulation and to determine its main predictors. Design: Prospective cohort. Setting: Community-based university medical center. Patients: 219 PTMC candidates with thrombus demonstrated by multiplane transesophageal echocardiographic studies. Measurements: The primary,outcome was the status of the thrombus at the first 6-month follow-up; secondary measures were bleeding or thromboembolic complications. Results: Among 219 PTMC candidates with left atrial thrombus (mean age [+/-SD], 39.6 +/- 7.4 years [range, 19 to 62 years]), complete resolution of thrombus, with an overall disappearance rate of 24.2% (95% CI, 18.5% to 29.9%), was demonstrated in 53 patients who subsequently underwent successful PTMC. In another 166 patients, the thrombus size was reduced by 24% (P < 0.001). No thrombus resolution was observed in the 27 patients with a left atrial body thrombus. Eighteen patients had minor bleeding. The significant predictors of thrombus resolution were a New York Heart Association class of 2 or less, a left atrial appendage thrombus size of 1.6 cm(2) or less, a left atrial spontaneous echocardiographic contrast grade of 1 or less, and an international normalized ratio (INR) of at least 2.5. Patients with all of these predictors had a 94.4% chance of complete thrombus resolution (CI, 84.4% to 98.1%). Conclusions: After 6 months of oral anticoagulation, the left atrial thrombus disappeared in about a quarter of PTMC candidates so they could safely undergo PTMC. Less clinical severity, lower grading of the left atrial spontaneous echocardiographic contrast, a smaller thrombus, and a higher INR level predict thrombus resolution.	Khon Kaen Univ, Fac Med, Dept Med, Khon Kaen 40002, Thailand	Khon Kaen University	Silaruks, S (corresponding author), Khon Kaen Univ, Fac Med, Dept Med, Khon Kaen 40002, Thailand.	sonsil@kku.ac.th	Silaruks, Songkwan/AAB-4166-2022					[Anonymous], 1998, Br J Haematol, V101, P374; CHEN CR, 1992, AM J CARDIOL, V70, P1445, DOI 10.1016/0002-9149(92)90297-C; *CRIT COMM NEW YOR, 1994, NOM CRIT DIAGN, P143; FATKIN D, 1994, J AM COLL CARDIOL, V23, P307, DOI 10.1016/0735-1097(94)90412-X; FEIGENBAUM H, 1986, ECHOCARDIOGR-J CARD, P592; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; Hirsh J, 1998, CHEST, V114, p445S, DOI 10.1378/chest.114.5_Supplement.445S; HOSMER DW, 2000, WILEY PS TX, P1; HUNG JS, 1991, AM J CARDIOL, V67, P854, DOI 10.1016/0002-9149(91)90619-V; HUNG JS, 1989, AM J CARDIOL, V64, P126; Kang DH, 1998, AM J CARDIOL, V81, P97, DOI 10.1016/S0002-9149(97)00858-8; KLEINBAUM DG, 1998, APPL REGRESSION ANAL, P330; Lin SL, 1999, CARDIOLOGY, V92, P145, DOI 10.1159/000006963; PALACIOS IF, 1989, CIRCULATION, V79, P573, DOI 10.1161/01.CIR.79.3.573; PYTLEWSKI G, 1994, AM HEART J, V128, P843, DOI 10.1016/0002-8703(94)90290-9; Silaruks S, 2002, J HEART VALVE DIS, V11, P346; Silaruks S, 2002, J AM COLL CARDIOL, V39, P886, DOI 10.1016/S0735-1097(02)01686-8; SOLOMON RE, 1992, CIRCULATION, V85, P448; TSAI LM, 1991, AM HEART J, V121, P1232, DOI 10.1016/0002-8703(91)90688-E; WILKINS GT, 1988, BRIT HEART J, V60, P299	20	14	19	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					101	105		10.7326/0003-4819-140-2-200401200-00010	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734332				2022-12-28	WOS:000188211700004
J	Jayawardhana, R				Jayawardhana, R			Unraveling brown dwarf origins	SCIENCE			English	Editorial Material							CIRCUMSTELLAR DISKS; ACCRETION; OBJECTS; MASS; FRAGMENTATION		Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Jayawardhana, R (corresponding author), Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA.			Jayawardhana, Ray/0000-0001-5349-6853				BARRADO D, IN PRESS ASTROPHYS J; Basri G, 2003, MERCURY MAGAZINE, V32, P27; Bate MR, 2002, MON NOT R ASTRON SOC, V332, pL65, DOI 10.1046/j.1365-8711.2002.05539.x; Boss AP, 2001, ASTROPHYS J, V551, pL167, DOI 10.1086/320033; Fernandez M, 2001, ASTRON ASTROPHYS, V380, P264, DOI 10.1051/0004-6361:20011443; Jayawardhana R, 2003, ASTRON J, V126, P1515, DOI 10.1086/377144; Jayawardhana R, 2003, ASTROPHYS J, V592, P282, DOI 10.1086/375573; Jayawardhana R, 2002, ASTROPHYS J, V578, pL141, DOI 10.1086/344707; Liu MC, 2003, ASTROPHYS J, V585, P372, DOI 10.1086/345895; Lodders K, 2004, SCIENCE, V303, P323, DOI 10.1126/science.1092865; LOW C, 1976, MON NOT R ASTRON SOC, V176, P367, DOI 10.1093/mnras/176.2.367; Mohanty S, 2003, ASTROPHYS J, V593, pL109, DOI 10.1086/378315; Muench AA, 2001, ASTROPHYS J, V558, pL51, DOI 10.1086/323420; Muzerolle J, 2003, ASTROPHYS J, V592, P266, DOI 10.1086/375704; Natta A, 2002, ASTRON ASTROPHYS, V393, P597, DOI 10.1051/0004-6361:20021065; Reipurth B, 2001, ASTRON J, V122, P432, DOI 10.1086/321121	16	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					322	323		10.1126/science.1091840	http://dx.doi.org/10.1126/science.1091840			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726580	Green Submitted			2022-12-28	WOS:000188111800028
J	Kim, E; Chan, MHW				Kim, E; Chan, MHW			Probable observation of a supersolid helium phase	NATURE			English	Article							BOSE-EINSTEIN CONDENSATION; POROUS VYCOR GLASS; CONFINED GEOMETRIES; HE-4 FILMS; SOLIDIFICATION; SUPERFLUIDITY; TRANSITION	When liquid He-4 is cooled below 2.176 K, it undergoes a phase transition-Bose-Einstein condensation-and becomes a superfluid with zero viscosity(1). Once in such a state, it can flow without dissipation even through pores of atomic dimensions. Although it is intuitive to associate superflow only with the liquid phase(2), it has been proposed theoretically(3-5) that superflow can also occur in the solid phase of He-4. Owing to quantum mechanical fluctuations, delocalized vacancies and defects are expected to be present in crystalline solid He-4, even in the limit of zero temperature. These zero-point vacancies can in principle allow the appearance of superfluidity in the solid(3,4). However, in spite of many attempts(6), such a 'supersolid' phase has yet to be observed in bulk solid He-4. Here we report torsional oscillator measurements on solid helium confined in a porous medium, a configuration that is likely to be more heavily populated with vacancies than bulk helium. We find an abrupt drop in the rotational inertia(5) of the confined solid below a certain critical temperature. The most likely interpretation of the inertia drop is entry into the supersolid phase. If confirmed, our results show that all three states of matter-gas(7), liquid(1) and solid-can undergo Bose Einstein condensation.	Penn State Univ, Dept Phys, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Chan, MHW (corresponding author), Penn State Univ, Dept Phys, 104 Davey Lab, University Pk, PA 16802 USA.	chan@phys.psu.edu	Kim, Eunseong/D-4698-2009					ADAMS ED, 1984, PHYS REV LETT, V52, P2249, DOI 10.1103/PhysRevLett.52.2249; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; ANDREEV AF, 1969, ZH EKSP TEOR FIZ, V29, P1107; BEAMISH JR, 1983, PHYS REV LETT, V50, P425, DOI 10.1103/PhysRevLett.50.425; BERTHOLD JE, 1977, PHYS REV LETT, V39, P348, DOI 10.1103/PhysRevLett.39.348; BISHOP DJ, 1981, PHYS REV B, V24, P2844, DOI 10.1103/PhysRevB.24.2844; BITTNER DN, 1994, J LOW TEMP PHYS, V97, P519, DOI 10.1007/BF00754306; BREWER DF, 1981, PHYSICA B & C, V107, P583, DOI 10.1016/0378-4363(81)90594-5; CHAN MHW, 1974, PHYS REV LETT, V32, P1347, DOI 10.1103/PhysRevLett.32.1347; CHESTER GV, 1970, PHYS REV A, V2, P256, DOI 10.1103/PhysRevA.2.256; Csathy GA, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.045301; HUANG K, 1967, STAT MECH; Kapitza P, 1938, NATURE, V141, P74, DOI 10.1038/141074a0; LEGGETT AJ, 1970, PHYS REV LETT, V25, P1543, DOI 10.1103/PhysRevLett.25.1543; LEVITZ P, 1991, J CHEM PHYS, V95, P6151, DOI 10.1063/1.461583; LIEZHAO C, 1986, PHYS REV B, V33, P106, DOI 10.1103/PhysRevB.33.106; MEHL JB, 1968, PHYS REV, V167, P214, DOI 10.1103/PhysRev.167.214; MEISEL MW, 1992, PHYSICA B, V178, P121, DOI 10.1016/0921-4526(92)90186-V; Molz EB, 1995, J LOW TEMP PHYS, V101, P1055, DOI 10.1007/BF00754524; PAALANEN MA, 1981, PHYS REV LETT, V46, P664, DOI 10.1103/PhysRevLett.46.664; PENROSE O, 1956, PHYS REV, V104, P576, DOI 10.1103/PhysRev.104.576	21	732	735	2	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					225	227		10.1038/nature02220	http://dx.doi.org/10.1038/nature02220			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724632				2022-12-28	WOS:000188068100037
J	Kelly, FJ; Sandstrom, T				Kelly, FJ; Sandstrom, T			Air pollution, oxidative stress, and allergic response	LANCET			English	Editorial Material							TRANSFERASE; POLYMORPHISMS; M1		Univ Hosp, Dept Resp Med & Allergy, SE-90185 Umea, Sweden; Kings Coll London, Sch Life & Hlth Sci, London WC2R 2LS, England	Umea University; University of London; King's College London	Sandstrom, T (corresponding author), Univ Hosp, Dept Resp Med & Allergy, SE-90185 Umea, Sweden.	thomas.sandstrom@lung.umu.se	Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403, DOI 10.1289/ehp.99107s3403; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P346, DOI 10.1164/rccm.2111048; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Hirvonen A, 1999, ENVIRON HEALTH PERSP, V107, P37, DOI 10.2307/3434470; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; KELLY FJ, 1999, EUR RESPIR REV, V9, P93; Mudway I. S., 2000, Molecular Aspects of Medicine, V21, P1, DOI 10.1016/S0098-2997(00)00003-0; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Ollier W, 1996, ARTHRITIS RHEUM, V39, P1763, DOI 10.1002/art.1780391023; Strange R C, 1999, IARC Sci Publ, P231	13	20	20	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					95	96		10.1016/S0140-6736(03)15308-1	http://dx.doi.org/10.1016/S0140-6736(03)15308-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726159				2022-12-28	WOS:000187939200003
J	Moreillon, P; Que, YA				Moreillon, P; Que, YA			Infective endocarditis	LANCET			English	Review							RESISTANT STAPHYLOCOCCUS-AUREUS; MITRAL-VALVE-PROLAPSE; FIBRONECTIN-BINDING PROTEIN; GRAM-POSITIVE BACTERIA; INJECTION-DRUG USERS; IN-VITRO ACTIVITIES; DUKE CRITERIA; SURFACE-PROTEINS; CELL-WALL; ANTIBIOTIC-PROPHYLAXIS	Despite improvements in health care, the incidence of infective endocarditis has not decreased over the past decades. This apparent paradox is explained by a progressive evolution in risk factors; while classic predisposing conditions such as rheumatic heart disease have been all but eradicated, new risk factors for infective endocarditis have emerged. These include intravenous drug use, sclerotic valve disease in elderly patients, use of prosthetic valves, and nosocomial disease. Newly identified pathogens, which are difficult to cultivate-eg, Bartonella spp and Tropheryma whipplei-are present in selected individuals, and resistant organisms are challenging conventional antimicrobial therapy. Keeping up with these changes depends on a comprehensive approach, allying understanding of the pathogenesis of disease with the development of new drugs for infective endocarditis. Infection by staphylococci and streptococci is being dissected at the molecular level. New ideas for antimicrobial agents are being developed. These novel insights should help redefine preventive and therapeutic strategies against infective endocarditis.	Univ Lausanne, Inst Fundamental Microbiol, CH-1015 Lausanne, Switzerland; Univ Lausanne, CHU Vaudois, Serv Malad Infect, CH-1015 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Moreillon, P (corresponding author), Univ Lausanne, Inst Fundamental Microbiol, Biol Bldg, CH-1015 Lausanne, Switzerland.	Philippe.Moreillon@imf.unil.ch	Que, Yok Ai/AAE-5474-2020	Que, Yok Ai/0000-0001-9443-6101				Abbott KC, 2002, NEPHRON, V91, P203, DOI 10.1159/000058393; Alexiou C, 2000, ANN THORAC SURG, V69, P1448, DOI 10.1016/S0003-4975(00)01139-5; Bancsi MJLMF, 1996, INFECT IMMUN, V64, P5166, DOI 10.1128/IAI.64.12.5166-5170.1996; Bauernschmitt R, 1998, ANN THORAC SURG, V65, P359, DOI 10.1016/S0003-4975(97)01092-8; BAYER AS, 1994, AM J MED, V96, P211, DOI 10.1016/0002-9343(94)90144-9; BAYER AS, 1995, INFECT IMMUN, V63, P3634, DOI 10.1128/IAI.63.9.3634-3641.1995; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; Bouza E, 2001, MEDICINE, V80, P298, DOI 10.1097/00005792-200109000-00003; Brouqui P, 2001, CLIN MICROBIOL REV, V14, P177, DOI 10.1128/CMR.14.1.177-207.2001; Cabell CH, 2002, ARCH INTERN MED, V162, P90, DOI 10.1001/archinte.162.1.90; CARON F, 1995, J INFECT DIS, V171, P106, DOI 10.1093/infdis/171.1.106; Chan PF, 1998, J BACTERIOL, V180, P6082; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; Cheung AL, 1998, INFECT IMMUN, V66, P5988, DOI 10.1128/IAI.66.12.5988-5993.1998; Cossart P, 2000, P NATL ACAD SCI USA, V97, P5013, DOI 10.1073/pnas.97.10.5013; CRAWFORD I, 1986, J APPL BACTERIOL, V60, P127, DOI 10.1111/j.1365-2672.1986.tb03369.x; DAGOSTINO RS, 1985, ANN THORAC SURG, V40, P429, DOI 10.1016/S0003-4975(10)60097-5; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; DeCastro S, 1997, AM J CARDIOL, V80, P1030, DOI 10.1016/S0002-9149(97)00598-5; DEGORGOLAS M, 1995, ANTIMICROB AGENTS CH, V39, P953, DOI 10.1128/AAC.39.4.953; Devereux RB, 2001, AM J MED, V111, P679, DOI 10.1016/S0002-9343(01)00981-0; Di Salvo G, 2001, J AM COLL CARDIOL, V37, P1069, DOI 10.1016/S0735-1097(00)01206-7; Disse S, 1999, AM J HUM GENET, V65, P1242, DOI 10.1086/302624; Dodds GA, 1996, AM J CARDIOL, V77, P403, DOI 10.1016/S0002-9149(97)89372-1; Dresser LD, 1998, PHARMACOTHERAPY, V18, P456; dUdekem Y, 1997, EUR J CARDIO-THORAC, V11, P46, DOI 10.1016/S1010-7940(96)01020-2; DURACK DT, 1995, NEW ENGL J MED, V332, P38, DOI 10.1056/NEJM199501053320107; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Dutly F, 2001, CLIN MICROBIOL REV, V14, P561, DOI 10.1128/CMR.14.3.561-583.2001; ENTENZA JM, 1995, ANTIMICROB AGENTS CH, V39, P1419, DOI 10.1128/AAC.39.7.1419; Entenza JM, 2002, ANTIMICROB AGENTS CH, V46, P171, DOI 10.1128/AAC.46.1.171-177.2002; Entenza JM, 1999, J ANTIMICROB CHEMOTH, V44, P775, DOI 10.1093/jac/44.6.775; Fenollar F, 2001, CLIN INFECT DIS, V33, P1309, DOI 10.1086/322666; Fischetti VA, 2001, NAT BIOTECHNOL, V19, P734, DOI 10.1038/90777; Flock JI, 1999, MOL MED TODAY, V5, P532, DOI 10.1016/S1357-4310(99)01597-X; Flores PA, 1997, CLEV CLIN J MED, V64, P527, DOI 10.3949/ccjm.64.10.527; Fournier PE, 2001, MEDICINE, V80, P245, DOI 10.1097/00005792-200107000-00003; Fowler VG, 1999, CLIN INFECT DIS, V28, P106; Fowler VG, 2000, J INFECT DIS, V182, P1251, DOI 10.1086/315812; FRANCIOLI P, 1992, JAMA-J AM MED ASSOC, V267, P264, DOI 10.1001/jama.267.2.264; Francioli P, 1995, CLIN INFECT DIS, V21, P1406, DOI 10.1093/clinids/21.6.1406; FRANCIOLLI M, 1991, J INFECT DIS, V163, P514, DOI 10.1093/infdis/163.3.514; Gagliardi JP, 1998, CLIN INFECT DIS, V26, P1165, DOI 10.1086/520304; Garandeau C, 2002, INFECT IMMUN, V70, P1382, DOI 10.1128/IAI.70.3.1382-1390.2002; Geisel R, 2001, EUR J CLIN MICROBIOL, V20, P685, DOI 10.1007/s100960100595; Goldenberger D, 1997, J CLIN MICROBIOL, V35, P2733, DOI 10.1128/JCM.35.11.2733-2739.1997; Gouello JP, 2000, CRIT CARE MED, V28, P377, DOI 10.1097/00003246-200002000-00015; Habib G, 1999, J AM COLL CARDIOL, V33, P2023, DOI 10.1016/S0735-1097(99)00116-3; Hadjinikolaou L, 2001, EUR J CARDIO-THORAC, V19, P806, DOI 10.1016/S1010-7940(01)00696-0; HAYDOCK D, 1992, J THORAC CARDIOV SUR, V103, P130; Heldman AW, 1996, AM J MED, V101, P68, DOI 10.1016/S0002-9343(96)00070-8; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HENDREN WG, 1992, J THORAC CARDIOV SUR, V103, P124; HERZBERG MC, 1992, INFECT IMMUN, V60, P4809, DOI 10.1128/IAI.60.11.4809-4818.1992; Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Hoen B, 2002, JAMA-J AM MED ASSOC, V288, P75, DOI 10.1001/jama.288.1.75; Houpikian P, 2002, INFECT DIS CLIN N AM, V16, P377, DOI 10.1016/S0891-5520(01)00010-1; Jacqueline C, 2002, ANTIMICROB AGENTS CH, V46, P3706, DOI 10.1128/AAC.46.12.3706-3711.2002; Jault F, 1997, ANN THORAC SURG, V63, P1737, DOI 10.1016/S0003-4975(97)00117-3; JOHNSON DH, 1975, CIRCULATION, V51, P581, DOI 10.1161/01.CIR.51.4.581; Jonsson IM, 2002, J INFECT DIS, V185, P1417, DOI 10.1086/340503; Kim S, 1996, AM HEART J, V132, P348, DOI 10.1016/S0002-8703(96)90432-9; Kitten T, 2002, INFECT IMMUN, V70, P422, DOI 10.1128/IAI.70.1.422-425.2002; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Koo SP, 1999, INFECT IMMUN, V67, P2475, DOI 10.1128/IAI.67.5.2475-2481.1999; Kupferwasser LI, 1999, CIRCULATION, V99, P2791, DOI 10.1161/01.CIR.99.21.2791; Lacassin F, 1995, EUR HEART J, V16, P1968, DOI 10.1093/oxfordjournals.eurheartj.a060855; LARBALESTIER RI, 1992, CIRCULATION, V86, P68; LEPORT C, 1995, EUR HEART J, V16, P126, DOI 10.1093/eurheartj/16.suppl_B.126; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; MALINVERNI R, 1988, CIRCULATION, V77, P182, DOI 10.1161/01.CIR.77.1.182; MAMO W, 1994, FEMS IMMUNOL MED MIC, V10, P47, DOI 10.1111/j.1574-695X.1994.tb00010.x; MARTINO P, 1990, REV INFECT DIS, V12, P250; Martone WJ, 1998, INFECT CONT HOSP EP, V19, P539; MATHEW J, 1995, ARCH INTERN MED, V155, P1641, DOI 10.1001/archinte.155.15.1641; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; McCormick JK, 2002, J INFECT DIS, V185, P994, DOI 10.1086/339604; MCGIFFIN DC, 1992, J THORAC CARDIOV SUR, V104, P511; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; Moreillon P, 2002, INFECT DIS CLIN N AM, V16, P297, DOI 10.1016/S0891-5520(01)00009-5; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; Moreillon P, 2000, SCHWEIZ MED WSCHR, V130, P1013; Morris CD, 1998, JAMA-J AM MED ASSOC, V279, P599, DOI 10.1001/jama.279.8.599; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; Nettles RE, 1997, CLIN INFECT DIS, V25, P1401, DOI 10.1086/516145; NICOLAU DP, 1993, INFECT IMMUN, V61, P1593, DOI 10.1128/IAI.61.4.1593-1595.1993; Nicolau DP, 1999, INT J ANTIMICROB AG, V11, P159, DOI 10.1016/S0924-8579(98)00092-2; Nicolau DP, 1998, INT J ANTIMICROB AG, V9, P227, DOI 10.1016/S0924-8579(97)00056-3; Nilsson IM, 1998, J CLIN INVEST, V101, P2640, DOI 10.1172/JCI1823; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; NORMAND J, 1995, EUR HEART J, V16, P28, DOI 10.1093/eurheartj/16.suppl_B.28; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; Olaison L, 1996, QJM-MON J ASSOC PHYS, V89, P267; Olaison L, 2002, INFECT DIS CLIN N AM, V16, P453, DOI 10.1016/S0891-5520(01)00006-X; ORNOS P, 1999, ARCH INTERN MED, V159, P473; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; Perez-Vazquez A, 2000, ARCH INTERN MED, V160, P1185, DOI 10.1001/archinte.160.8.1185; Que YA, 1998, J INFECT DIS, V177, P146, DOI 10.1086/513805; Que YA, 2001, INFECT IMMUN, V69, P6296, DOI 10.1128/IAI.69.10.6296-6302.2001; QUE YA, 2001, 41 ICAAC CHIC IL; Raoult D, 1999, ARCH INTERN MED, V159, P167, DOI 10.1001/archinte.159.2.167; Rehm SJ, 1998, INFECT DIS CLIN N AM, V12, P879, DOI 10.1016/S0891-5520(05)70026-X; Roder BL, 1999, ARCH INTERN MED, V159, P462, DOI 10.1001/archinte.159.5.462; Rybak MJ, 1998, ANTIMICROB AGENTS CH, V42, P721, DOI 10.1128/AAC.42.3.721; Sander A, 2002, INTENS CARE MED, V28, P1157, DOI 10.1007/s00134-002-1358-7; Sandre RM, 1996, CLIN INFECT DIS, V22, P276, DOI 10.1093/clinids/22.2.276; Schaff HV, 2002, ANN THORAC SURG, V73, P785, DOI 10.1016/S0003-4975(01)03442-7; SCHENNINGS T, 1993, MICROB PATHOGENESIS, V15, P227, DOI 10.1006/mpat.1993.1073; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; Sekeres MA, 1997, CLIN INFECT DIS, V24, P1185, DOI 10.1086/513657; SHEKAR R, 1985, J INFECT DIS, V151, P203, DOI 10.1093/infdis/151.2.203; Shinefield H, 2002, NEW ENGL J MED, V346, P491, DOI 10.1056/NEJMoa011297; Sidhu P, 2001, ANN THORAC SURG, V71, pS257, DOI 10.1016/S0003-4975(01)02522-X; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; SOMA Y, 1991, JPN CIRC J, V55, P799, DOI 10.1253/jcj.55.799; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; Stehbens WE, 2000, CARDIOVASC PATHOL, V9, P161, DOI 10.1016/S1054-8807(00)00037-5; Stone R, 2002, SCIENCE, V298, P728, DOI 10.1126/science.298.5594.728; Strom BL, 1998, ANN INTERN MED, V129, P761, DOI 10.7326/0003-4819-129-10-199811150-00002; Stutzmann Meier P, 2001, Infect Immun, V69, P657; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Tornos P, 1997, CLIN INFECT DIS, V24, P381, DOI 10.1093/clinids/24.3.381; UTTLEY AHC, 1988, LANCET, V1, P57; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1869, DOI 10.1001/archinte.152.9.1869; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863; Varstela E, 1998, ANN CHIR GYNAECOL FE, V87, P205; Veltrop MHAM, 1999, INFECT IMMUN, V67, P6130, DOI 10.1128/IAI.67.11.6130-6138.1999; Veltrop MHAM, 2000, INFECT IMMUN, V68, P4818, DOI 10.1128/IAI.68.8.4818-4821.2000; VIGNES S, 1995, ANTIMICROB AGENTS CH, V39, P2702, DOI 10.1128/AAC.39.12.2702; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; Vouillamoz J, 2000, ANTIMICROB AGENTS CH, V44, P1789, DOI 10.1128/AAC.44.7.1789-1795.2000; WATANAKUNAKORN C, 1993, MEDICINE, V72, P90, DOI 10.1097/00005792-199303000-00003; Wilson LE, 2002, J INFECT DIS, V185, P1761, DOI 10.1086/340827; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706; Yeaman MR, 1997, INFECT IMMUN, V65, P1023, DOI 10.1128/IAI.65.3.1023-1031.1997; Yeaman MR, 1997, CLIN INFECT DIS, V25, P951, DOI 10.1086/516120; YERSIN B, 1988, INFECT IMMUN, V56, P1273, DOI 10.1128/IAI.56.5.1273-1280.1988; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8; 2002, MMWR MORB MORTAL WKL, V51, P565; 2002, MMWR MORB MORTAL WKL, V51, P902	144	692	735	6	52	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					139	149		10.1016/S0140-6736(03)15266-X	http://dx.doi.org/10.1016/S0140-6736(03)15266-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726169				2022-12-28	WOS:000187939200019
J	Cheng, Z; Menees, TM				Cheng, Z; Menees, TM			RNA branching and debranching in the yeast retrovirus-like element Ty1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; REVERSE TRANSCRIPTION; MESSENGER-RNA; ENDS; RETROTRANSPOSITION; AMPLIFICATION; GENOME; ENZYME	Ty elements of Saccharomyces cerevisiae are long terminal repeat (LTR) retroelements related to retroviruses. Normal levels of Ty1 transposition require Dbr1p, a cellular enzyme that cleaves 2'-5' RNA bonds. We show that Ty1 RNAs lacking identifiable 5' ends accumulate in virus-like particles (VLPs) in dbr1 mutants. Debranching this RNA in vitro with Dbr1p creates an uncapped version of the normal Ty1 RNA 5' end. We show that the 5' nucleotide (nt) of Ty1 RNA forms a 2'-5' bond with a nt near the 3' end of the same RNA, creating a lariat. The properties of the lariat suggest it forms by a novel mechanism and that branching and debranching may play roles in Ty1 reverse transcription at the minus-strand transfer step.	Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Menees, TM (corresponding author), Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA.							Berkhout B, 2002, J BIOL CHEM, V277, P19967, DOI 10.1074/jbc.M200950200; Boeke J. D., 1997, P343; Boeke JD., 2002, MOBILE DNA-UK, P631, DOI [10.1128/9781555817954.ch26, DOI 10.1128/9781555817954.CH26]; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Cheng Z., UNPUB; Cristofari G, 2002, EMBO J, V21, P4368, DOI 10.1093/emboj/cdf436; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; Frohman Michael A., 1995, P381; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Karst SM, 2000, BIOCHEM BIOPH RES CO, V268, P112, DOI 10.1006/bbrc.1999.2048; LORSCH JR, 1995, NUCLEIC ACIDS RES, V23, P2811, DOI 10.1093/nar/23.15.2811; MARUYAMA K, 1994, GENE, V138, P171; Mosch HU, 1997, GENETICS, V145, P671; Mules EH, 1998, J VIROL, V72, P6490, DOI 10.1128/JVI.72.8.6490-6503.1998; Ooi SL, 2001, METHOD ENZYMOL, V342, P233, DOI 10.1016/S0076-6879(01)42548-1; Salem LA, 2003, J VIROL, V77, P12795, DOI 10.1128/JVI.77.23.12795-12806.2003; Sandmeyer S.B., 2002, MOBILE DNA-UK, P663; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Vogel J, 1997, NUCLEIC ACIDS RES, V25, P2030, DOI 10.1093/nar/25.10.2030; VOLLOCH V, 1994, NUCLEIC ACIDS RES, V22, P2507, DOI 10.1093/nar/22.13.2507	22	46	47	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					240	243		10.1126/science.1087023	http://dx.doi.org/10.1126/science.1087023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716018				2022-12-28	WOS:000187908500052
J	Corso, M; Auwarter, W; Muntwiler, M; Tamai, A; Greber, T; Osterwalder, J				Corso, M; Auwarter, W; Muntwiler, M; Tamai, A; Greber, T; Osterwalder, J			Boron nitride nanomesh	SCIENCE			English	Article							ELECTRONIC STATES; NI(111); SURFACE	A highly regular mesh of hexagonal boron nitride with a 3-nanometer periodicity and a 2-nanometer hole size was formed by self-assembly on a Rh(111) single crystalline surface. Two layers of mesh cover the surface uniformly after high-temperature exposure of the clean rhodium surface to borazine (HBNH)(3). The two layers are offset in such a way as to expose a minimum metal surface area. Hole formation is likely driven by the lattice mismatch of the film and the rhodium substrate. This regular nanostructure is thermally very stable and can serve as a template to organize molecules, as is exemplified by the decoration of the mesh by C-60 molecules.	Univ Zurich, Inst Phys, CH-8057 Zurich, Switzerland	University of Zurich	Osterwalder, J (corresponding author), Univ Zurich, Inst Phys, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	osterwal@physik.unizh.ch	Greber, Thomas/D-9509-2015; Auwärter, Willi/I-2551-2012; Corso, Martina/B-7768-2014; Tamai, Anna/Q-5902-2019; Muntwiler, Matthias/G-2122-2014	Greber, Thomas/0000-0002-5234-1937; Corso, Martina/0000-0002-8592-1284; Tamai, Anna/0000-0001-5239-6826; Muntwiler, Matthias/0000-0002-6628-3977; Auwarter, Willi/0000-0001-9452-4662				Auwarter W, 1999, SURF SCI, V429, P229, DOI 10.1016/S0039-6028(99)00381-7; Auwarter W, 2003, SURF SCI, V545, pL735, DOI 10.1016/j.susc.2003.08.046; BANHART F, 1994, CHEM PHYS LETT, V231, P98, DOI 10.1016/0009-2614(94)01215-6; Bengu E, 2001, PHYS REV LETT, V86, P2385, DOI 10.1103/PhysRevLett.86.2385; CHOPRA NG, 1995, SCIENCE, V269, P966, DOI 10.1126/science.269.5226.966; Gamou Y, 1997, SCI REP RES TOHOKU A, V44, P211; Grad GB, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.085404; Greber T, 2002, SURF REV LETT, V9, P1243, DOI 10.1142/S0218625X02001884; Gsell M, 1998, SCIENCE, V280, P717, DOI 10.1126/science.280.5364.717; Helveg S, 2000, PHYS REV LETT, V84, P951, DOI 10.1103/PhysRevLett.84.951; Muntwiler M, 2001, SURF SCI, V472, P125, DOI 10.1016/S0039-6028(00)00928-6; NAGASHIMA A, 1994, PHYS REV B, V50, P17487, DOI 10.1103/PhysRevB.50.17487; Nagashima A, 1996, PHYS REV B, V54, P13491, DOI 10.1103/PhysRevB.54.13491; NAGASHIMA A, 1995, PHYS REV LETT, V75, P3918, DOI 10.1103/PhysRevLett.75.3918; NAGASHIMA A, 1995, PHYS REV B, V51, P4606, DOI 10.1103/PhysRevB.51.4606; POUCH JJ, 1990, SYNTHESIS PROPERTIES	16	750	758	6	396	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					217	220		10.1126/science.1091979	http://dx.doi.org/10.1126/science.1091979			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716010				2022-12-28	WOS:000187908500044
J	Bekker, A; Holland, HD; Wang, PL; Rumble, D; Stein, HJ; Hannah, JL; Coetzee, LL; Beukes, NJ				Bekker, A; Holland, HD; Wang, PL; Rumble, D; Stein, HJ; Hannah, JL; Coetzee, LL; Beukes, NJ			Dating the rise of atmospheric oxygen	NATURE			English	Article							MASS-INDEPENDENT SULFUR; TIMEBALL HILL FORMATION; SOUTH-AFRICA; TRANSVAAL SUPERGROUP; ARCHEAN ATMOSPHERE; IRON-FORMATION; AUSTRALIA; BASIN; FRACTIONATION; MICROPROBE	Several lines of geological and geochemical evidence indicate that the level of atmospheric oxygen was extremely low before 2.45 billion years (Gyr) ago, and that it had reached considerable levels by 2.22 Gyr ago. Here we present evidence that the rise of atmospheric oxygen had occurred by 2.32 Gyr ago. We found that syngenetic pyrite is present in organic-rich shales of the 2.32-Gyr-old Rooihoogte and Timeball Hill formations, South Africa. The range of the isotopic composition of sulphur in this pyrite is large and shows no evidence of mass-independent fractionation, indicating that atmospheric oxygen was present at significant levels ( that is, greater than 10(-5) times that of the present atmospheric level) during the deposition of these units. The presence of rounded pebbles of sideritic iron formation at the base of the Rooihoogte Formation and an extensive and thick ironstone layer consisting of haematitic pisolites and oolites in the upper Timeball Hill Formation indicate that atmospheric oxygen rose significantly, perhaps for the first time, during the deposition of the Rooihoogte and Timeball Hill formations. These units were deposited between what are probably the second and third of the three Palaeoproterozoic glacial events.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Colorado State Univ, Dept Geosci, AIRIE Program, Ft Collins, CO 80523 USA; Rand Afrikaans Univ, Dept Geol, ZA-2006 Johannesburg, South Africa	Harvard University; Carnegie Institution for Science; Colorado State University; University of Johannesburg	Bekker, A (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	abekker@fas.harvard.edu	Rumble, Douglas/AAU-3930-2020; Hannah, Judith/AAE-5212-2020	Rumble, Douglas/0000-0002-7440-9189; WANG, PEI-LING/0000-0002-4392-3935; Bekker, Andrey/0000-0002-1154-0585				BAU M, 1998, MINERAL MAG A, V62, P127, DOI DOI 10.1180/MINMAG.1998.62A.1.67; Bekker A, 2001, AM J SCI, V301, P261, DOI 10.2475/ajs.301.3.261; BEKKER A, 2000, GEOL SOC AM ABSTR, V32, pA135; Beukes N.J., 1992, PROTEROZOIC BIOSPHER, P147; BEUKES NJ, 1990, PRECAMBRIAN RES, V47, P99, DOI 10.1016/0301-9268(90)90033-M; BEUKES NJ, 2002, GEOL SOC AM ABSTR, V34, P283; CAMERON EM, 1982, NATURE, V296, P145, DOI 10.1038/296145a0; Chandler F.W., 1980, CAN GEOL SURV B, V311; Chandler FW., 1988, CARBONATE EVAPORITE, V3, P75, DOI 10.1007/BF03174414; CLEMMEY H, 1982, GEOLOGY, V10, P141, DOI 10.1130/0091-7613(1982)10<141:OITPAA>2.0.CO;2; Coetzee L.L., 2001, THESIS RAND AFRIKAAN; DIMROTH E, 1976, CAN J EARTH SCI, V13, P1161, DOI 10.1139/e76-119; El Tabakh M, 1999, GEOLOGY, V27, P871, DOI 10.1130/0091-7613(1999)027<0871:PAEMIW>2.3.CO;2; England GL, 2002, SEDIMENTOLOGY, V49, P1133, DOI 10.1046/j.1365-3091.2002.00479.x; ERIKSSON KA, 1973, J SEDIMENT PETROL, V43, P1046; Eriksson PG, 1998, SEDIMENT GEOL, V120, P319, DOI 10.1016/S0037-0738(98)00038-4; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Farquhar J, 2002, SCIENCE, V298, P2369, DOI 10.1126/science.1078617; Farquhar J., 2001, J GEOPHYS RES, V106, P1; Farquhar J, 2003, GEOBIOLOGY, V1, P27, DOI 10.1046/j.1472-4669.2003.00007.x; Habicht KS, 2002, SCIENCE, V298, P2372, DOI 10.1126/science.1078265; HANNAH JL, 2003, GEOCHIMICA COSMOCHIM, V67, pA34; Holland H. D., 1994, EARLY LIFE EARTH, V84, P237; Hu GX, 2003, GEOCHIM COSMOCHIM AC, V67, P3101, DOI 10.1016/S0016-7037(02)00929-8; MACGREGOR AM, 1927, S AFR J SCI, V23, P155; MARTINI JEJ, 1976, ECON GEOL, V71, P625, DOI 10.2113/gsecongeo.71.3.625; Miller MF, 2002, GEOCHIM COSMOCHIM AC, V66, P1881, DOI 10.1016/S0016-7037(02)00832-3; Mojzsis SJ, 2003, GEOCHIM COSMOCHIM AC, V67, P1635, DOI 10.1016/S0016-7037(03)00059-0; Ohmoto H, 1996, GEOLOGY, V24, P1135, DOI 10.1130/0091-7613(1996)024<1135:EIPGPF>2.3.CO;2; Ono S, 2003, EARTH PLANET SC LETT, V213, P15, DOI 10.1016/S0012-821X(03)00295-4; Pavlov AA, 2002, ASTROBIOLOGY, V2, P27, DOI 10.1089/153110702753621321; PHILLIPS GN, 1987, GEOLOGY, V15, P1027, DOI 10.1130/0091-7613(1987)15<1027:PWTPMF>2.0.CO;2; Pickard AL, 2003, PRECAMBRIAN RES, V125, P275, DOI 10.1016/S0301-9268(03)00113-X; Rasmussen B, 1999, GEOLOGY, V27, P115, DOI 10.1130/0091-7613(1999)027<0115:RSOTAA>2.3.CO;2; ROMERO AB, 2002, EOS S, V83, DOI UNSP B71A-0731; Roscoe S.M., 1996, GEOLOGY CANADIAN MIN, P10; Rye R, 1998, AM J SCI, V298, P621, DOI 10.2475/ajs.298.8.621; Schieber J, 1999, PALAIOS, V14, P3, DOI 10.2307/3515357; Schweigart H., 1965, ECON GEOL, V60, P269; STRAUSS H, 2002, PRECAMBRIAN SEDIMENT, P67; Visser J.N.J., 1981, EARTHS PREPLEISTOCEN, P180; VISSER JNJ, 1971, ANN GEOLOGICAL SURVE, V9, P115; Wing BA, 2002, GEOCHIM COSMOCHIM AC, V66, pA840; YANG W, 2002, GEOL SOC AM ABSTR, V34, P381	44	935	995	16	289	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 8	2004	427	6970					117	120		10.1038/nature02260	http://dx.doi.org/10.1038/nature02260			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712267				2022-12-28	WOS:000187863900026
J	Raghu, G; Brown, KK; Bradford, WZ; Starko, K; Noble, PW; Schwartz, DA; King, TE; Adlakha, A; Tarczynski, S; Ainslie, G; Kalam, R; Bai, T; Truchan, H; Baughman, R; Wingst, D; Bhorade, S; Norwick, L; Brown, KK; Kervitsky, D; Calhoun, W; DiNella, L; Chan, C; Jamieson, L; Chan, K; Turpen, T; Chapman, J; Slattery, S; Chen, L; Turner, J; Clark, M; Sanders, R; Crain, M; Pate, D; Davis, G; Lynn, M; Dhar, A; Hrytsytk, M; Drent, M; Horr, ET; du Bois, R; Goh, N; Egan, J; Anthony, N; Enelow, R; Haram, T; Ettinger, N; Merli, S; Frost, A; Holy, R; Glassberg, M; Brown, A; Golden, J; DesMarais, M; Haim, YD; Rzeszutko, B; Hassoun, P; Finlay, G; Lawler, L; Hollingsworth, H; Goncalves, P; Jackson, R; Meadows, T; Kallay, M; Celebie, A; King-Biggs, M; Beyle, A; Lancaster, L; Sanderson, R; Lasky, J; Ditta, S; Lorch, D; Schoh, T; Lynch, J; Alousha, A; Mageto, Y; Meachom, M; Martinez, F; Dahlgren, D; McKee, C; Hamilton, T; Meyer, K; Wilson, S; Millar, A; Hann, A; Mohsenifar, Z; Balfe, D; Morell, F; Reyes, L; Nathan, S; Theodoslod, S; Noble, PW; Shrauger, K; Noth, I; Strek, M; Au, J; Olivier, K; Wells, R; Padilla, M; Behnegar, A; Polito, A; Bloom, C; Raghu, G; Snydsman, A; Rosen, G; Jacobs, S; Ryu, JH; Carlson, K; Sahn, SA; Oser, R; Schaumberg, T; Chesnutt, M; Leonard, S; Schluger, N; Jellen, P; Steele, M; Willis, C; Strieter, R; Christedoulou, V; Valentine, V; Lanning, T; Wencel, M; Sturgeon, D; Xaubert, A; Zisman, D; Douglas, L; Lynch, DA; Godwin, JD; Webb, WR; Fleming, T; Reis, A; Riley, D				Raghu, G; Brown, KK; Bradford, WZ; Starko, K; Noble, PW; Schwartz, DA; King, TE; Adlakha, A; Tarczynski, S; Ainslie, G; Kalam, R; Bai, T; Truchan, H; Baughman, R; Wingst, D; Bhorade, S; Norwick, L; Brown, KK; Kervitsky, D; Calhoun, W; DiNella, L; Chan, C; Jamieson, L; Chan, K; Turpen, T; Chapman, J; Slattery, S; Chen, L; Turner, J; Clark, M; Sanders, R; Crain, M; Pate, D; Davis, G; Lynn, M; Dhar, A; Hrytsytk, M; Drent, M; Horr, ET; du Bois, R; Goh, N; Egan, J; Anthony, N; Enelow, R; Haram, T; Ettinger, N; Merli, S; Frost, A; Holy, R; Glassberg, M; Brown, A; Golden, J; DesMarais, M; Haim, YD; Rzeszutko, B; Hassoun, P; Finlay, G; Lawler, L; Hollingsworth, H; Goncalves, P; Jackson, R; Meadows, T; Kallay, M; Celebie, A; King-Biggs, M; Beyle, A; Lancaster, L; Sanderson, R; Lasky, J; Ditta, S; Lorch, D; Schoh, T; Lynch, J; Alousha, A; Mageto, Y; Meachom, M; Martinez, F; Dahlgren, D; McKee, C; Hamilton, T; Meyer, K; Wilson, S; Millar, A; Hann, A; Mohsenifar, Z; Balfe, D; Morell, F; Reyes, L; Nathan, S; Theodoslod, S; Noble, PW; Shrauger, K; Noth, I; Strek, M; Au, J; Olivier, K; Wells, R; Padilla, M; Behnegar, A; Polito, A; Bloom, C; Raghu, G; Snydsman, A; Rosen, G; Jacobs, S; Ryu, JH; Carlson, K; Sahn, SA; Oser, R; Schaumberg, T; Chesnutt, M; Leonard, S; Schluger, N; Jellen, P; Steele, M; Willis, C; Strieter, R; Christedoulou, V; Valentine, V; Lanning, T; Wencel, M; Sturgeon, D; Xaubert, A; Zisman, D; Douglas, L; Lynch, DA; Godwin, JD; Webb, WR; Fleming, T; Reis, A; Riley, D		Idiopathic Pulmonary Fibrosis Stud	A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE PREDNISOLONE; IFN-GAMMA; EXPRESSION; COLLAGEN; THERAPY; DETERMINANTS; COLCHICINE; CYTOKINES; SURVIVAL	Background: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. Methods: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. Results: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. Conclusions: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.	Univ Washington, Div Pulm Med, Seattle, WA 98195 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; InterMune, Brisbane, CA USA; Yale Univ, New Haven, CT USA; Duke Univ, Sch Med, Durham, NC USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Washington; University of Washington Seattle; National Jewish Health; Yale University; Duke University; University of California System; University of California San Francisco	Raghu, G (corresponding author), Univ Washington, Div Pulm Med, BB 1237,Box 356522, Seattle, WA 98195 USA.	graghu@u.washington.edu	de Araujo Gonçalves, Pedro/K-7592-2019; Brown, Kevin/ABF-2544-2020; Drent, Marjolein/ABA-9526-2020; Schluger, Neil/ABA-1793-2021	de Araujo Gonçalves, Pedro/0000-0003-4301-3090; Drent, Marjolein/0000-0003-1586-0110; 				Agusti C, 2002, AM J RESP CRIT CARE, V166, P426; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]; BILLIAU A, 2001, CYTOKINE REFERENCE C, P641; Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Chang JA, 1999, CHEST, V116, P1175, DOI 10.1378/chest.116.5.1175; CLARK JG, 1989, J CLIN INVEST, V83, P1505, DOI 10.1172/JCI114045; Coker RK, 1998, EUR RESPIR J, V11, P1218, DOI 10.1183/09031936.98.11061218; Douglas WW, 2000, AM J RESP CRIT CARE, V161, P1172, DOI 10.1164/ajrccm.161.4.9907002; Duits LA, 2002, IMMUNOLOGY, V106, P517, DOI 10.1046/j.1365-2567.2002.01430.x; Flaherty KR, 2001, AM J MED, V110, P278, DOI 10.1016/S0002-9343(00)00711-7; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; HEIN R, 1992, BRIT J DERMATOL, V126, P496, DOI 10.1111/j.1365-2133.1992.tb15122.x; JOHNSON MA, 1989, THORAX, V44, P280, DOI 10.1136/thx.44.4.280; KAHAN A, 1989, AM J MED, V87, P273; Keane MP, 1997, J IMMUNOL, V159, P1437; King TE, 2001, AM J RESP CRIT CARE, V164, P1171, DOI 10.1164/ajrccm.164.7.2003140; KUROKI S, 1995, BRIT J RHEUMATOL, V34, P31; Lack G, 1996, ADV EXP MED BIOL, V409, P17; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; NARAYANAN AS, 1992, CHEST, V101, P1326, DOI 10.1378/chest.101.5.1326; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Neumann B, 1998, IMMUNOLOGY, V95, P512; OKADA T, 1993, LYMPHOKINE CYTOK RES, V12, P87; PRIOR C, 1992, CLIN EXP IMMUNOL, V88, P280; RAGHU G, 1991, AM REV RESPIR DIS, V144, P291, DOI 10.1164/ajrccm/144.2.291; SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1002/hep.1840130220; SCHWARTZ DA, 1994, AM J RESP CRIT CARE, V149, P450, DOI 10.1164/ajrccm.149.2.8306044; Selman M, 1998, CHEST, V114, P507, DOI 10.1378/chest.114.2.507; VANOORTEGEM K, 1994, EUR RESPIR J, V7, P1950; Wallace WAH, 1999, J PATHOL, V187, P475, DOI 10.1002/(SICI)1096-9896(199903)187:4<475::AID-PATH268>3.0.CO;2-N; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703; Ziesche R, 2000, NEW ENGL J MED, V342, P975	34	519	556	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					125	133		10.1056/NEJMoa030511	http://dx.doi.org/10.1056/NEJMoa030511			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711911				2022-12-28	WOS:000187858500006
J	Dodson, JA; Keller, AS				Dodson, JA; Keller, AS			Medical student care of indigent populations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDENTS; ATTITUDES; SERVICE		NYU, Sch Med, New York, NY 10012 USA	New York University	Dodson, JA (corresponding author), NYU, Sch Med, New York, NY 10012 USA.							Eckenfels EJ, 1997, ACAD MED, V72, P1043, DOI 10.1097/00001888-199712000-00013; Fishman LE, 1997, HEALTH AFFAIR, V16, P30, DOI 10.1377/hlthaff.16.4.30; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Hicks LK, 2001, BRIT MED J, V322, P709, DOI 10.1136/bmj.322.7288.709; Jecker NS, 1996, CAMB Q HEALTHC ETHIC, V5, P500, DOI 10.1017/S0963180100007398; Mann JM, 1997, HEALTH AFFAIR, V16, P223, DOI 10.1377/hlthaff.16.4.223; Marracino RK, 1998, J GEN INTERN MED, V13, P266, DOI 10.1046/j.1525-1497.1998.00078.x; O'Toole TP, 1999, J GEN INTERN MED, V14, P211, DOI 10.1046/j.1525-1497.1999.00319.x; ORENTLICHER D, 1993, JAMA-J AM MED ASSOC, V269, P2533; RICHARDSON PH, 1986, MED EDUC, V20, P314, DOI 10.1111/j.1365-2923.1986.tb01371.x; Weissman JS, 2001, J URBAN HEALTH, V78, P535, DOI 10.1093/jurban/78.3.535; 2003, MED STUDENT RUN CLIN	12	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					121	121		10.1001/jama.291.1.121	http://dx.doi.org/10.1001/jama.291.1.121			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	760LX	14709588				2022-12-28	WOS:000187836000030
J	Haines, A; Patz, JA				Haines, A; Patz, JA			Health effects of climate change	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MALARIA; DISEASE; FUTURE; TRANSMISSION; IMPACTS; VIRUS; RISK		Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; London Sch Hyg & Tropical Med, London, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of London; London School of Hygiene & Tropical Medicine	Patz, JA (corresponding author), Johns Hopkins Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St, Baltimore, MD 21205 USA.	jpatz@jhsph.edu		Haines, Andy/0000-0002-8053-4605				Bouma MJ, 1997, LANCET, V350, P1435, DOI 10.1016/S0140-6736(97)04509-1; Caffo E, 2003, CHILD ADOL PSYCH CL, V12, P493, DOI 10.1016/S1056-4993(03)00004-X; Chestnut LG, 1998, ENVIRON SCI POLICY, V1, P59, DOI DOI 10.1016/S1462-9011(98)00015-X; Curriero FC, 2001, AM J PUBLIC HEALTH, V91, P1194, DOI 10.2105/AJPH.91.8.1194; Department of Health, 2002, HLTH EFFECTS CLIMATE; Dorozynski A, 2003, BRIT MED J, V327, P411, DOI 10.1136/bmj.327.7412.411; Epstein PR, 2001, J URBAN HEALTH, V78, P367, DOI 10.1093/jurban/78.2.367; Glass GE, 2000, EMERG INFECT DIS, V6, P238, DOI 10.3201/eid0603.000303; Gleick Peter H., 1998, WORLDS WATER 1998 19; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Houghton J. T., 2001, CLIMATE CHANGE 2001; Kalkstein LS, 1997, ENVIRON HEALTH PERSP, V105, P84, DOI 10.2307/3433067; Kovats RS, 2003, LANCET, V362, P1481, DOI 10.1016/S0140-6736(03)14695-8; Lindgren E, 2000, ENVIRON HEALTH PERSP, V108, P119, DOI 10.2307/3454509; Lindsay SW, 1998, B WORLD HEALTH ORGAN, V76, P33; LoGiudice K, 2003, P NATL ACAD SCI USA, V100, P567, DOI 10.1073/pnas.0233733100; Martens P, 1999, GLOBAL ENVIRON CHANG, V9, pS89, DOI 10.1016/S0959-3780(99)00020-5; McMichael M, 2001, CLIMATE CHANGE IMPAC, P451; Metz B., 2001, CLIMATE CHANGE 2001; Patz JA, 1998, ENVIRON HEALTH PERSP, V106, P147, DOI 10.1289/ehp.98106147; Patz JA, 2000, INT J PARASITOL, V30, P1395, DOI 10.1016/S0020-7519(00)00141-7; Patz JA, 2000, ENVIRON HEALTH PERSP, V108, P367, DOI 10.2307/3454357; Randolph SE, 2000, P ROY SOC B-BIOL SCI, V267, P1741, DOI 10.1098/rspb.2000.1204; Rodo X, 2002, P NATL ACAD SCI USA, V99, P12901, DOI 10.1073/pnas.182203999; Rogers DJ, 2000, SCIENCE, V289, P1763, DOI 10.1126/science.289.5485.1763; Tanser FC, 2003, LANCET, V362, P1792, DOI 10.1016/S0140-6736(03)14898-2; Thurston GD, 2001, J EXPO ANAL ENV EPID, V11, P286, DOI 10.1038/sj.jea.7500169; Trevejo RT, 1998, J INFECT DIS, V178, P1457, DOI 10.1086/314424; Whitman S, 1997, AM J PUBLIC HEALTH, V87, P1515, DOI 10.2105/AJPH.87.9.1515; Ziska LH, 2003, J EXP BOT, V54, P395, DOI 10.1093/jxb/erg027; 1999, MMWR MORB MORTAL WKL, V48, P78	31	176	181	1	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					99	103		10.1001/jama.291.1.99	http://dx.doi.org/10.1001/jama.291.1.99			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709582	Green Accepted			2022-12-28	WOS:000187836000033
J	Perbal, B				Perbal, B			CCN proteins: multifunctional signalling regulators	LANCET			English	Review							TISSUE GROWTH-FACTOR; FACTOR CTGF; CELL-ADHESION; BINDING-SITE; FAMILY; CYR61; DIFFERENTIATION; IDENTIFICATION; DOMAIN	Context Although little is known as yet about the processes that coordinate cell-signalling pathways, matrix proteins are probably major players in this type of global control. The CCN (cyr61, ctgf, nov) proteins are an important family of matricellular regulatory factors involved in internal and external cell signalling. This family participates in angiogenesis, chondrogenesis, and osteogenesis, and they are probably involved in the control of cell proliferation and differentiation. Starting point Runping Gao and David Brigstock (Hepatol Res 2003; 27: 214-20) recently showed that CCN2 (CTGF, connective tissue growth factor) is a cell-adhesion factor for hepatic stellate cells. On exposure to transforming growth factor P, hepatic stellate cells produce distinct CCN2 isoforms. Gao and Brigstock assign to CCN2 module 3 the capacity to mediate binding to low-density-lipoprotein receptor-related protein (LRP), which was previously reported to interact with CCN2 and to be involved in various types of signalling. They also establish that CCN2 binding to LRP is heparin-dependent and that module 4 of CCN2 promotes LRP-independent adhesion of hepatic stellate cells. The differential binding of CCN2 isoforms to LRP highlights the importance of, functional interactions between individual modules, and reinforces the concept that different module combinations might confer agonistic or antagonistic activities. Where next? It is essential to understand how the distinct configuration of the various CCN isoform affects their biological activities and bioavailability, and to explore the mechanisms and the regulatory processes involved in the production of truncated CCN isoforms. A better understanding of the structural basis for their multifunctionality is a prerequisite to wider use of CCN proteins in molecular medicine.	Univ Paris 07, UFR Biochim, Lab Oncol Virale & Mol, F-75005 Paris, France	UDICE-French Research Universities; Universite Paris Cite	Perbal, B (corresponding author), Univ Paris 07, UFR Biochim, Lab Oncol Virale & Mol, F-75005 Paris, France.	perbal@ccr.jussieu.fr						Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Ball DK, 2003, J ENDOCRINOL, V176, pR1, DOI 10.1677/joe.0.176R001; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Li CL, 2002, J CLIN PATHOL-MOL PA, V55, P250, DOI 10.1136/mp.55.4.250; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Lombet Alain, 2003, Cell Commun Signal, V1, P1, DOI 10.1186/1478-811X-1-1; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2003, EXPERT REV MOL DIAGN, V3, P597, DOI 10.1586/14737159.3.5.597; Perbal B, 2003, J CLIN PATHOL-MOL PA, V56, P80, DOI 10.1136/mp.56.2.80; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Perbal Bernard, 2003, Cell Commun Signal, V1, P3, DOI 10.1186/1478-811X-1-3; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Riser BL, 2003, KIDNEY INT, V64, P451, DOI 10.1046/j.1523-1755.2003.00130.x; Safadi FF, 2003, J CELL PHYSIOL, V196, P51, DOI 10.1002/jcp.10319; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Scotlandi K., 2003, Molecular Pathology, V56, P73; Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302; Wahab NA, 2002, J AM SOC NEPHROL, V13, P2437, DOI 10.1097/01.ASN.0000031828.58276.02	27	583	628	1	48	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					62	64		10.1016/S0140-6736(03)15172-0	http://dx.doi.org/10.1016/S0140-6736(03)15172-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723997				2022-12-28	WOS:000187711300026
J	Hanashima, C; Li, SC; Shen, LJ; Lai, ES; Fishell, G				Hanashima, C; Li, SC; Shen, LJ; Lai, ES; Fishell, G			Foxg1 suppresses early cortical cell fate	SCIENCE			English	Article							CAJAL-RETZIUS CELLS; HELIX TRANSCRIPTION FACTOR; CEREBRAL-CORTEX; DEVELOPING NEOCORTEX; PROGENITOR CELLS; MESSENGER-RNA; RAT; EXPRESSION; PROTEIN; NEURONS	During mammalian cerebral corticogenesis, progenitor cells become progressively restricted in the types of neurons they can produce. The molecular mechanism that determines earlier versus later born neuron fate is unknown. We demonstrate here that the generation of the earliest born neurons, the Cajal-Retzius cells, is suppressed by the telencephalic transcription factor Foxg1. In Foxg1 null mutants, we observed an excess of Cajal-Retzius neuron production in the cortex. By conditionally inactivating Foxg1 in cortical progenitors that normally produce deep-layer cortical neurons, we demonstrate that Foxg1 is constitutively required to suppress Cajal-Retzius cell fate. Hence, the competence to generate the earliest born neurons during later cortical development is actively suppressed but not lost.	NYU, Med Ctr, Dev Genet Program, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA	New York University; New York University; Memorial Sloan Kettering Cancer Center; Cornell University	Lai, ES (corresponding author), NYU, Med Ctr, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.	eseng_lai@merck.com; fishell@saturn.med.nyu.edu		Fishell, Gordon/0000-0002-9640-9278	NEI NIH HHS [EY11124] Funding Source: Medline; NICHD NIH HHS [HD29584] Funding Source: Medline; NINDS NIH HHS [NS39007, NS32993] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD029584, R01HD029584] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032993, R01NS039007] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Belliveau MJ, 2000, J NEUROSCI, V20, P2247; Bourguignon C, 1998, DEVELOPMENT, V125, P4889; Brody T, 2002, DEVELOPMENT, V129, P3763; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Desai AR, 2000, DEVELOPMENT, V127, P2863; Ferland RJ, 2003, J COMP NEUROL, V460, P266, DOI 10.1002/cne.10654; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; Frantz GD, 1996, NEURON, V17, P55, DOI 10.1016/S0896-6273(00)80280-9; Frotscher M, 1998, CURR OPIN NEUROBIOL, V8, P570, DOI 10.1016/S0959-4388(98)80082-2; Hanashima C, 2002, J NEUROSCI, V22, P6526; Hebert JM, 2000, DEV BIOL, V222, P296, DOI 10.1006/dbio.2000.9732; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; LI J, 1995, CANCER RES, V55, P5540; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Marin-Padilla M, 1998, TRENDS NEUROSCI, V21, P64, DOI 10.1016/S0166-2236(97)01164-8; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Meyer G, 1998, J COMP NEUROL, V397, P493; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stumm RK, 2003, J NEUROSCI, V23, P5123; Sumi Y, 2002, NEUROSCI LETT, V320, P13, DOI 10.1016/S0304-3940(02)00011-3; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Valcanis H, 2003, J NEUROSCI, V23, P5113; WEISENHORN DMV, 1994, DEV BRAIN RES, V82, P293; Xu BJ, 2000, NEURON, V26, P233, DOI 10.1016/S0896-6273(00)81153-8; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7	33	288	297	3	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					56	59		10.1126/science.1090674	http://dx.doi.org/10.1126/science.1090674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704420				2022-12-28	WOS:000187710600029
J	Traub, SJ; Hoffman, RS; Nelson, LS				Traub, SJ; Hoffman, RS; Nelson, LS			Body packing - The internal concealment of illicit drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COCAINE-PACKET INGESTION; ABDOMINAL RADIOGRAPHY; MANAGEMENT; DIAGNOSIS; INTERVENTION; OBSTRUCTION; EXPERIENCE; SMUGGLER; TOXICITY; BOWEL		Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; NYU, Sch Med, Dept Emergency Med, Bellevue Hosp Ctr, New York, NY USA; New york City Poison Control Ctr, New York, NY USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Bellevue Hospital Center; New York University; Harvard University; Harvard Medical School	Traub, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.	straub@bidmc.harvard.edu		Nelson, Lewis/0000-0001-9551-3922; Hoffman, Robert/0000-0002-0091-9573				Albertson TE, 2001, ANN EMERG MED, V37, pS78, DOI 10.1067/mem.2001.114174; Aldrighetti L, 1996, PANMINERVA MED, V38, P111; Alzen G, 1987, Rofo, V146, P544, DOI 10.1055/s-2008-1048536; BECK NE, 1993, BRIT J SURG, V80, P1513, DOI 10.1002/bjs.1800801205; BEERMAN R, 1986, GASTROINTEST RADIOL, V11, P351, DOI 10.1007/BF02035108; BOGUSZ MJ, 1995, J FORENSIC SCI, V40, P811; Bulstrode N, 2002, ANN ROY COLL SURG, V84, P35; CARUANA DS, 1984, ANN INTERN MED, V100, P73, DOI 10.7326/0003-4819-100-1-73; CLAFFEY M, 2002, NEW YORK DAILY NEWS, P5; DASSEL PM, 1979, GASTROENTEROLOGY, V76, P166; DEITEL M, 1973, CAN MED ASSOC J, V109, P211; DUNNE JW, 1983, MED J AUSTRALIA, V2, P436, DOI 10.5694/j.1326-5377.1983.tb122568.x; GHERARDI RK, 1988, LANCET, V1, P1076; Gill JR, 2002, J FORENSIC SCI, V47, P843; Hahn I., 1999, Journal of Toxicology Clinical Toxicology, V37, P644; HARTOKO TJ, 1988, KLIN WOCHENSCHR, V66, P1116, DOI 10.1007/BF01727846; HIERHOLZER J, 1995, ABDOM IMAGING, V20, P333, DOI 10.1007/BF00203366; HOFFMAN RS, 1990, AM J EMERG MED, V8, P523, DOI 10.1016/0735-6757(90)90155-S; Hollander JE, 2002, GOLDFRANKS TOXICOLOG, P1004; HORROCKS AW, 1992, CLIN RADIOL, V45, P322, DOI 10.1016/S0009-9260(05)80084-4; Hutchins KD, 2000, J FORENSIC SCI, V45, P42; JOHNSON JA, 1991, AM SURGEON, V57, P723; Jones OM, 2002, ANN ROY COLL SURG, V84, P131; June R, 2000, J EMERG MED, V18, P221, DOI 10.1016/S0736-4679(99)00198-5; KARHUNEN PJ, 1991, J FORENSIC SCI, V36, P397; KERSSCHOT EAJ, 1985, FORTSCHR RONTG NEUEN, V142, P295, DOI 10.1055/s-2008-1052652; Krishnan A, 1999, J ACCID EMERG MED, V16, P381; MARC B, 1992, J TOXICOL-CLIN TOXIC, V30, P387, DOI 10.3109/15563659209021554; MARC B, 1990, J FORENSIC SCI, V35, P345; MCCARRON MM, 1983, JAMA-J AM MED ASSOC, V250, P1417; MCCLEAVE NR, 1993, MED J AUSTRALIA, V159, P750, DOI 10.5694/j.1326-5377.1993.tb141338.x; Olmedo R, 2001, AM J EMERG MED, V19, P593, DOI 10.1053/ajem.2001.21720; *PERS SEARCH REV C, 2000, REP PERS SEARCH US C; Pidoto RR, 2002, J EMERG MED, V23, P149, DOI 10.1016/S0736-4679(02)00505-X; PINSKY MF, 1978, J CAN ASSOC RADIOL, V29, P79; ROBINSON T, 1993, SURGERY, V113, P709; Shrethra, 2000, J TOXICOL-CLIN TOXIC, V2000, P176; SUAREZ CA, 1977, JAMA-J AM MED ASSOC, V238, P1391, DOI 10.1001/jama.238.13.1391; TOMASZEWSKI C, 1993, ANN EMERG MED, V22, P1804, DOI 10.1016/S0196-0644(05)80404-4; Traub SJ, 2003, AM J EMERG MED, V21, P607, DOI 10.1016/S0735-6757(03)00170-0; Traub SJ, 2003, AM J EMERG MED, V21, P511, DOI 10.1016/S0735-6757(03)00171-2; Traub SJ, 2003, ARCH PEDIAT ADOL MED, V157, P174, DOI 10.1001/archpedi.157.2.174; Utecht Michael J., 1993, Journal of Emergency Medicine, V11, P33, DOI 10.1016/0736-4679(93)90007-T; Visser L, 1998, LANCET, V352, P1352, DOI 10.1016/S0140-6736(98)08302-0; Wackerle B, 1986, Rofo, V145, P274, DOI 10.1055/s-2008-1048932; WATSON CJE, 1991, J ROY SOC MED, V84, P311, DOI 10.1177/014107689108400524; WETLI CV, 1981, J FORENSIC SCI, V26, P492; WHITE N, 1988, NATURE, V335, P19, DOI 10.1038/335019a0; Wilgoren J., 1998, NY TIMES        1206, P62; 1997, US CUSTOMS NEWS  JUN	50	190	200	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2519	2526		10.1056/NEJMra022719	http://dx.doi.org/10.1056/NEJMra022719			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695412				2022-12-28	WOS:000187529500007
J	Burns, RB; Hartman, EE				Burns, RB; Hartman, EE			A 58-year-old man with a diagnosis of chronic Lyme disease, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Steere AC, 2002, JAMA-J AM MED ASSOC, V288, P1002, DOI 10.1001/jama.288.8.1002	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2003	290	24					3247	3247		10.1001/jama.290.24.3247	http://dx.doi.org/10.1001/jama.290.24.3247			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756TR	14693878				2022-12-28	WOS:000187499300029
J	Abbott, A				Abbott, A			Neuroscience - Genomics on the brain	NATURE			English	News Item																		Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033	1	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					757	757		10.1038/426757a	http://dx.doi.org/10.1038/426757a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685199	Bronze			2022-12-28	WOS:000187342000020
J	Hanada, K; Kumagai, K; Yasuda, S; Miura, Y; Kawano, M; Fukasawa, M; Nishijima, M				Hanada, K; Kumagai, K; Yasuda, S; Miura, Y; Kawano, M; Fukasawa, M; Nishijima, M			Molecular machinery for non-vesicular trafficking of ceramide	NATURE			English	Article							ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; SPHINGOMYELIN SYNTHESIS; BINDING PROTEIN; TRANSPORT; STAR; IDENTIFICATION; PHOSPHORYLATES; ACCUMULATION; RESISTANT	Synthesis and sorting of lipids are essential for membrane biogenesis; however, the mechanisms underlying the transport of membrane lipids remain little understood. Ceramide is synthesized at the endoplasmic reticulum and translocated to the Golgi compartment for conversion to sphingomyelin. The main pathway of ceramide transport to the Golgi is genetically impaired in a mammalian mutant cell line, LY-A. Here we identify CERT as the factor defective in LY-A cells. CERT, which is identical to a splicing variant of Goodpasture antigen-binding protein, is a cytoplasmic protein with a phosphatidylinositol-4-monophosphate- binding (PtdIns4P) domain and a putative domain for catalysing lipid transfer. In vitro assays show that this lipid-transfer-catalysing domain specifically extracts ceramide from phospholipid bilayers. CERT expressed in LY-A cells has an amino acid substitution that destroys its PtdIns4P-binding activity, thereby impairing its Golgi-targeting function. We conclude that CERT mediates the intracellular trafficking of ceramide in a non-vesicular manner.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	hanak@nih.go.jp	Kumagai, Keigo/AAG-1385-2021	Hanada, Kentaro/0000-0003-1383-2781; YASUDA, Satoshi/0000-0002-1011-0815; Kumagai, Keigo/0000-0002-1663-2905; KAWANO-KAWADA, Miyuki/0000-0002-1168-9291				AKEROYD R, 1981, EUR J BIOCHEM, V114, P385, DOI 10.1111/j.1432-1033.1981.tb05158.x; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Ardail D, 2003, BIOCHEM J, V371, P1013, DOI 10.1042/BJ20021834; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; De Matteis MA, 2002, CURR OPIN CELL BIOL, V14, P434, DOI 10.1016/S0955-0674(02)00357-5; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Funakoshi T, 2000, J BIOL CHEM, V275, P29938, DOI 10.1074/jbc.M004470200; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KASPER AM, 1981, BIOCHIM BIOPHYS ACTA, V664, P22, DOI 10.1016/0005-2760(81)90025-4; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; Raya A, 2000, J BIOL CHEM, V275, P40392, DOI 10.1074/jbc.M002769200; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Viani P, 2003, J BIOL CHEM, V278, P9592, DOI 10.1074/jbc.M207729200; VOELKER DR, 2002, BIOCH LIPIDS LIPOPRO, P449; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200; Yasuda S, 2001, J BIOL CHEM, V276, P43994, DOI 10.1074/jbc.M104884200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	782	804	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					803	809		10.1038/nature02188	http://dx.doi.org/10.1038/nature02188			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685229				2022-12-28	WOS:000187342000048
J	Inada, N; Oguri, M; Pindor, B; Hennawi, JF; Chiu, KL; Zheng, W; Ichikawa, SI; Gregg, MD; Becker, RH; Suto, Y; Strauss, MA; Turner, EL; Keeton, CR; Annis, J; Castander, FJ; Eisenstein, DJ; Frieman, JA; Fukugita, M; Gunn, JE; Johnston, DE; Kent, SM; Nichol, RC; Richards, GT; Rix, HW; Sheldon, ES; Bahcall, NA; Brinkmann, J; Ivezic, Z; Lamb, DQ; McKay, TA; Schneider, DP; York, DG				Inada, N; Oguri, M; Pindor, B; Hennawi, JF; Chiu, KL; Zheng, W; Ichikawa, SI; Gregg, MD; Becker, RH; Suto, Y; Strauss, MA; Turner, EL; Keeton, CR; Annis, J; Castander, FJ; Eisenstein, DJ; Frieman, JA; Fukugita, M; Gunn, JE; Johnston, DE; Kent, SM; Nichol, RC; Richards, GT; Rix, HW; Sheldon, ES; Bahcall, NA; Brinkmann, J; Ivezic, Z; Lamb, DQ; McKay, TA; Schneider, DP; York, DG			A gravitationally lensed quasar with quadruple images separated by 14.62 arcseconds	NATURE			English	Article							DIGITAL SKY SURVEY; DENSITY PROFILE; ANGULAR SEPARATIONS; DARK HALOS; STATISTICS; CAMERA; SPECTROGRAPH; SYSTEM	Gravitational lensing is a powerful tool for the study of the distribution of dark matter in the Universe. The cold-dark-matter model of the formation of large-scale structures ( that is, clusters of galaxies and even larger assemblies) predicts(1-6) the existence of quasars gravitationally lensed by concentrations of dark matter(7) so massive that the quasar images would be split by over 7 arcsec. Numerous searches(8-11) for large-separation lensed quasars have, however, been unsuccessful. All of the roughly 70 lensed quasars known(12), including the first lensed quasar discovered(13), have smaller separations that can be explained in terms of galaxy-scale concentrations of baryonic matter. Although gravitationally lensed galaxies(14) with large separations are known, quasars are more useful cosmological probes because of the simplicity of the resulting lens systems. Here we report the discovery of a lensed quasar, SDSS J1004+4112, which has a maximum separation between the components of 14.62 arcsec. Such a large separation means that the lensing object must be dominated by dark matter. Our results are fully consistent with theoretical expectations(3-5) based on the cold-dark-matter model.	Univ Tokyo, Sch Sci, Dept Phys, Tokyo 1130033, Japan; Princeton Univ Observ, Princeton, NJ 08544 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Natl Astron Observ, Tokyo 1818588, Japan; Univ Calif Davis, Dept Phys, Davis, CA 95616 USA; Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA; Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; Fermilab Natl Accelerator Lab, Batavia, IL 60510 USA; CSIC, Inst Estudis Espacials Catalunya, ES-08034 Barcelona, Spain; Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; Univ Tokyo, Inst Cosm Ray Res, Chiba 2778582, Japan; Carnegie Mellon Univ, Dept Phys, Pittsburgh, PA 15213 USA; Max Planck Inst Astron, D-69117 Heidelberg, Germany; Apache Point Observ, Sunspot, NM 88349 USA; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16802 USA; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA	University of Tokyo; Princeton University; Johns Hopkins University; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Chicago; United States Department of Energy (DOE); University of Chicago; Fermi National Accelerator Laboratory; Consejo Superior de Investigaciones Cientificas (CSIC); Institut d'Estudis Espacials de Catalunya (IEEC); University of Arizona; University of Tokyo; Carnegie Mellon University; Max Planck Society; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Chicago	Inada, N (corresponding author), Univ Tokyo, Sch Sci, Dept Phys, Tokyo 1130033, Japan.	inada@utap.phys.u-tokyo.ac.jp	Fukugita, Masataka/A-4438-2011; Turner, Edwin L/A-4295-2011; Castander, Francisco Javier/E-8021-2017; Oguri, Masamune/C-6230-2011; Suto, Yasushi/G-5068-2014; McKay, Timothy/C-1501-2009	Castander, Francisco Javier/0000-0001-7316-4573; Suto, Yasushi/0000-0002-4858-7598; McKay, Timothy/0000-0001-9036-6150; PINDOR, BARTOSZ/0000-0003-3240-2437				Blanton MR, 2003, ASTRON J, V125, P2276, DOI 10.1086/344761; Cao L, 1999, ASTRON ASTROPHYS SUP, V135, P243, DOI 10.1051/aas:1999448; Colley WN, 1996, ASTROPHYS J, V461, pL83, DOI 10.1086/310015; Fukugita M, 1996, ASTRON J, V111, P1748, DOI 10.1086/117915; Gunn JE, 1998, ASTRON J, V116, P3040, DOI 10.1086/300645; Hogg DW, 2001, ASTRON J, V122, P2129, DOI 10.1086/323103; Kashikawa N, 2002, PUBL ASTRON SOC JPN, V54, P819, DOI 10.1093/pasj/54.6.819; KEETON CR, 2001, APJ, V549, P25; KEETON CR, 2001, COMPUTATIONAL METHOD; KOCHANEK CS, 2003, CASTLES SURVEY; Maoz D, 1997, ASTROPHYS J, V486, P75, DOI 10.1086/304503; Miyazaki S, 2002, PUBL ASTRON SOC JPN, V54, P833, DOI 10.1093/pasj/54.6.833; Narayan R., 1988, Monthly Notices of the Royal Astronomical Society, V231, P97; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Ofek EO, 2001, MON NOT R ASTRON SOC, V324, P463, DOI 10.1046/j.1365-8711.2001.04326.x; Oguri M, 2002, ASTROPHYS J, V580, P2, DOI 10.1086/343113; Oguri M, 2002, ASTROPHYS J, V568, P488, DOI 10.1086/339064; OKE JB, 1995, PUBL ASTRON SOC PAC, V107, P375, DOI 10.1086/133562; Phillips PM, 2001, MON NOT R ASTRON SOC, V328, P1001, DOI 10.1046/j.1365-8711.2001.04601.x; Pier JR, 2003, ASTRON J, V125, P1559, DOI 10.1086/346138; Richards GT, 2002, ASTRON J, V123, P2945, DOI 10.1086/340187; Smith JA, 2002, ASTRON J, V123, P2121, DOI 10.1086/339311; Stoughton C, 2002, ASTRON J, V123, P485, DOI 10.1086/324741; Takahashi R, 2001, ASTROPHYS J, V563, P489, DOI 10.1086/323961; TURNER EL, 1984, ASTROPHYS J, V284, P1, DOI 10.1086/162379; WALSH D, 1979, NATURE, V279, P381, DOI 10.1038/279381a0; WAMBSGANSS J, 1995, SCIENCE, V268, P274, DOI 10.1126/science.268.5208.274; Wyithe JSB, 2001, ASTROPHYS J, V555, P504, DOI 10.1086/321437; York DG, 2000, ASTRON J, V120, P1579, DOI 10.1086/301513; Zhdanov VI, 2001, ASTRON ASTROPHYS, V372, P1, DOI 10.1051/0004-6361:20010283	30	156	157	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					810	812		10.1038/nature02153	http://dx.doi.org/10.1038/nature02153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685230	Green Published, Green Submitted			2022-12-28	WOS:000187342000049
J	Finger, C				Finger, C			Health care in indigenous populations: The Xingu Indian park	LANCET			English	Article											Finger, C (corresponding author), R Pascoat Vita 405,Apt 83, BR-05445000 Sao Paulo, Brazil.								0	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S38	S39		10.1016/S0140-6736(03)15070-2	http://dx.doi.org/10.1016/S0140-6736(03)15070-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698124				2022-12-28	WOS:000187790200020
J	Griffiths, C; Foster, G; Barnes, N; Eldridge, S; Tate, H; Begum, S; Wiggins, M; Dawson, C; Livingstone, AE; Chambers, M; Coats, T; Harris, R; Feder, GS				Griffiths, C; Foster, G; Barnes, N; Eldridge, S; Tate, H; Begum, S; Wiggins, M; Dawson, C; Livingstone, AE; Chambers, M; Coats, T; Harris, R; Feder, GS			Specialist nurse intervention to reduce unscheduled asthma care in a deprived multiethnic area: the east London randomised controlled trial for high risk asthma (ELECTRA)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SELF-MANAGEMENT; GENERAL PRACTICES; EDUCATION; IMPROVE; ADMISSIONS; IMPACT	Objective To determine whether asthma specialist nurses, using a liaison model of. care, reduce unscheduled care in a deprived multiethnic area. Design Cluster randomised controlled trial. Setting 44 general practices in two boroughs in east London. Participants 324 people aged 4-60 years admitted to, or attending hospital or the general practitioner out of hours service with acute asthma; 164 (50%) were South Asian patients, 108 (34%) were white patients, and 52 (16%) were from other, largely African and Afro-Caribbean, ethnicities. Intervention Patient review in a nurse led clinic and liaison with general practitioners and practice nurses comprising educational outreach, promotion of guidelines for high risk asthma, and ongoing clinical support. Control practices received a visit promoting standard asthma guidelines; control patients were checked for inhaler technique. Main outcome measure's Percentage of participants receiving unscheduled care for acute asthma over one year and time to first unscheduled attendance. Results Primary outcome data were available for 319 of 324(98 %) participants. Intervention delayed time to first attendance with acute asthma (hazard ratio 0.73,95% confidence interval 0.54 to 1.00; median 194 days for intervention and 126 days for control) and reduced the percentage of participants attending with acute asthma (58% (101/174) v 68% (99/145); odds ratio 0.62, 0.38 to 1.0 1). In analyses of prespecified subgroups the difference in effect on, ethnic groups was not significant, but results were consistent with greater benefit for white patients than for South Asian patients or those from other ethnic groups. Conclusion Asthma specialist nurses using a liaison model of care reduced unscheduled care for asthma in a deprived multiethnic health district. Ethnic groups may not benefit equally from specialist nurse intervention.	Barts & London Med Sci, Queen Marys Sch Med & Dent, Ctr Gen Practice & Primary Care, Inst Community Hlth Sci, London E1 4NS, England; London Chest Hosp, Dept Resp Med, London E2 9JX, England; Gill St Hlth Ctr, London E14 8HQ, England; Amersham Hlth, Little chalfont HP7 9NA, Bucks, England; Royal London Hosp, London E1 1BB, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Griffiths, C (corresponding author), Barts & London Med Sci, Queen Marys Sch Med & Dent, Ctr Gen Practice & Primary Care, Inst Community Hlth Sci, London E1 4NS, England.	c.j.griffiths@qmul.ac.uk	Coats, Timothy/AAW-1254-2021	Coats, Timothy/0000-0003-2736-2784; Feder, Gene/0000-0002-7890-3926				Altman D.G., 1991, PRACTICAL STAT MED R; Barley EA, 1998, RESP MED, V92, P1207, DOI 10.1016/S0954-6111(98)90423-1; Bonner S, 2002, J ASTHMA, V39, P167, DOI 10.1081/JAS-120002198; EHRLICH RI, 1994, RESP MED, V88, P195, DOI 10.1016/S0954-6111(05)80347-6; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; Gallefoss F, 1999, AM J RESP CRIT CARE, V160, P2000, DOI 10.1164/ajrccm.160.6.9901028; Gilthorpe MS, 1998, RESP MED, V92, P642, DOI 10.1016/S0954-6111(98)90511-X; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Griffiths C, 2001, BRIT MED J, V323, P962, DOI 10.1136/bmj.323.7319.962; Griffiths C, 2000, EUR J GEN PRACT, V6, P130; Hobbs R, 1999, BRIT MED J, V318, P683; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Levy ML, 2000, RESP MED, V94, P900, DOI 10.1053/rmed.2000.0861; Madge P, 1997, THORAX, V52, P223, DOI 10.1136/thx.52.3.223; Moudgil H, 2000, THORAX, V55, P177, DOI 10.1136/thorax.55.3.177; Ng TP, 1999, THORAX, V54, P990, DOI 10.1136/thx.54.11.990; OBRIEN MAT, 2003, COCHRANE LIB; ORMEROD LP, 1995, RESP MED, V89, P415, DOI 10.1016/0954-6111(95)90209-0; Osman LM, 2002, THORAX, V57, P869, DOI 10.1136/thorax.57.10.869; Premaratne UN, 1999, BRIT MED J, V318, P1251; STEEN N, 1994, BRIT MED J, V309, P1065, DOI 10.1136/bmj.309.6961.1065; Stevens CA, 2002, THORAX, V57, P39, DOI 10.1136/thorax.57.1.39; Wesseldine LJ, 1999, ARCH DIS CHILD, V80, P110, DOI 10.1136/adc.80.2.110; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	24	70	70	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2004	328	7432					144	147		10.1136/bmj.37950.784444.EE	http://dx.doi.org/10.1136/bmj.37950.784444.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14718266	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000188249900021
J	Khaw, PT; Shah, P; Elkington, AR				Khaw, PT; Shah, P; Elkington, AR			ABC of Eyes - Glaucoma-2: treatment	BRITISH MEDICAL JOURNAL			English	Review									Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England; Univ Southampton, Southampton SO9 5NH, Hants, England	University of Southampton	Khaw, PT (corresponding author), Moorfields Eye Hosp, London, England.	p.khaw@ucl.ac.uk; p.f.shah@talk21.com	Khaw, Peng T/C-1881-2008	Khaw, Sir Peng Tee/0000-0002-8087-2268					0	23	32	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					156	158		10.1136/bmj.328.7432.156	http://dx.doi.org/10.1136/bmj.328.7432.156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726349	Green Published			2022-12-28	WOS:000188249900028
J	Premack, D				Premack, D			Is language the key to human intelligence?	SCIENCE			English	Editorial Material							CHIMPANZEES PAN-TROGLODYTES		Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Premack, D (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.	dpremack@aol.com						Boroditsky L, 2000, COGNITION, V75, P1, DOI 10.1016/S0010-0277(99)00073-6; Cheney D.L., 1990, MONKEYS SEE WORLD IN, DOI [10.7208/chicago/9780226218526.001.0001, DOI 10.7208/CHICAGO/9780226218526.001.0001]; Chomsky N., 2002, JANUA LINGUARUM; Fitch WT, 2004, SCIENCE, V303, P377, DOI 10.1126/science.1089401; GILLAN DJ, 1981, J EXP PSYCHOL ANIM B, V7, P1, DOI 10.1037/0097-7403.7.1.1; GOLD EM, 1967, INFORM CONTROL, V10, P447, DOI 10.1016/S0019-9958(67)91165-5; GOODALL J, 1986, CHIMPANZEES COMBE; Harris PL, 1996, COGNITION, V61, P233, DOI 10.1016/S0010-0277(96)00715-9; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; InoueNakamura N, 1997, J COMP PSYCHOL, V111, P159, DOI 10.1037/0735-7036.111.2.159; Kohler W., 1925, MENTALITY APES; KUMMER H, COMMUNICATION; Lakoff G., 1980, METAPHORS WE LIVE; MELTZOFF AN, 1977, SCIENCE, V198, P75, DOI 10.1126/science.198.4312.75; Myowa-Yamakoshi M, 1999, J COMP PSYCHOL, V113, P128, DOI 10.1037/0735-7036.113.2.128; Newport E. L., 1999, MIT ENCY COGNITIVE S, P758; Nowak MA, 2001, TRENDS COGN SCI, V5, P288, DOI 10.1016/S1364-6613(00)01683-1; Pinker Steven, 1994, LANGUAGE INSTINCT; PREMACK D, 1990, COGNITION, V37, P197, DOI 10.1016/0010-0277(90)90045-L; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Premack D., 2003, ORIGINAL INTELLIGENC; Premack D, 1976, INTELLIGENCE APE MAN; SCHILLER PH, 1957, INSTINCTIVE BEHAV, P00264; Tomasello M, 1997, PRIMATE COGNITION; Whiten Andrew, 1996, P291, DOI 10.1016/B978-012273965-1/50015-7	25	97	101	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					318	320		10.1126/science.1093993	http://dx.doi.org/10.1126/science.1093993			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	763QK	14726578				2022-12-28	WOS:000188111800026
J	Callou, C; Samzun, A; Zivie, A				Callou, C; Samzun, A; Zivie, A			Archaeology: A lion found in the Egyptian tomb of Maia	NATURE			English	Editorial Material									MNHN, Paris, France; CNRS, UMR 5197, Paris, France; UMR 7041, Nanterre, France; INRAP, Paris, France; CNRS, UMR 8567, Paris, France; Mission Archeol Francaise Bubaste, Saqqara, Egypt	Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Centre National de la Recherche Scientifique (CNRS)	Callou, C (corresponding author), MNHN, Paris, France.	az.hypogees@wanadoo.fr		Callou, Cecile/0000-0002-8540-8114				ARMITAGE P., 1980, MASCA J, V1, P185; Boessneck J, 1990, MITT DTSCH ARCHIOLOG, V46, P86; CHARRON A., 1997, B SOC EGYPTOLOGIC GE, V21, P5; FLOULIHAN PI, 1996, ANIMAL WORLD PHARAOH; THOMPSON D, 1988, MEMPHIS PTOLEMIES, V29; ZABKAR LV, 1980, MIYSIS LEXIKON AEGYP, V4, P163; ZIVIE A, 2003, P 8 INT C EG, V2, P605	7	5	7	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					211	212		10.1038/427211a	http://dx.doi.org/10.1038/427211a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724625				2022-12-28	WOS:000188068100030
J	Fender, R; Wu, KW; Johnston, H; Tzioumis, T; Jonker, P; Spencer, R; van der Klis, M				Fender, R; Wu, KW; Johnston, H; Tzioumis, T; Jonker, P; Spencer, R; van der Klis, M			An ultra-relativistic outflow from a neutron star accreting gas from a companion	NATURE			English	Article							CIRCINUS X-1; SCORPIUS X-1; RADIO; JETS; MICROQUASARS; MOTION	Collimated relativistic outflows-also known as jets-are amongst the most energetic phenomena in the Universe. They are associated with supermassive black holes in distant active galactic nuclei(1), accreting stellar-mass black holes and neutron stars in binary systems(2) and are believed to be responsible for gamma-ray bursts(3). The physics of these jets, however, remains something of a mystery in that their bulk velocities, compositions and energetics remain poorly determined. Here we report the discovery of an ultra-relativistic outflow from a neutron star accreting gas within a binary stellar system. The velocity of the outflow is comparable to the fastest-moving flows observed from active galactic nuclei, and its strength is modulated by the rate of accretion of material onto the neutron star. Shocks are energized further downstream in the flow, which are themselves moving at mildly relativistic bulk velocities and are the sites of the observed synchrotron emission from the jet. We conclude that the generation of highly relativistic outflows does not require properties that are unique to black holes, such as an event horizon.	Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; Univ Sydney, Sch Phys, Sydney, NSW 2006, Australia; CSIRO, Australia Telescope Natl Facil, Epping, NSW 1710, Australia; Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; Univ Manchester, Nuffield Radio Astron Labs, Jodrell Bank, Macclesfield SK11 9DL, Cheshire, England	University of Amsterdam; University of London; University College London; University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Cambridge; University of Manchester; Jodrell Bank Centre for Astrophysics	Fender, R (corresponding author), Univ Amsterdam, Astron Inst Anton Pannekoek, Kruislaan 403, NL-1098 SJ Amsterdam, Netherlands.	rpf@science.uva.nl	Johnston, Helen/U-3855-2017	Johnston, Helen/0000-0002-6169-614X				Corbel S, 2002, SCIENCE, V298, P196, DOI 10.1126/science.1075857; Fender R, 1998, ASTROPHYS J, V506, pL121, DOI 10.1086/311660; Fender RP, 2003, MON NOT R ASTRON SOC, V340, P1353, DOI 10.1046/j.1365-8711.2003.06386.x; Fender RP, 2001, MON NOT R ASTRON SOC, V324, P923, DOI 10.1046/j.1365-8711.2001.04345.x; Fomalont EB, 2001, ASTROPHYS J, V558, P283, DOI 10.1086/322479; Fomalont EB, 2001, ASTROPHYS J, V553, pL27, DOI 10.1086/320490; GHISELLINI G, 1993, ASTROPHYS J, V407, P65, DOI 10.1086/172493; HAYNES C, 1986, GENET EPIDEMIOL, P235; HAYNES RF, 1978, MON NOT R ASTRON SOC, V185, P661, DOI 10.1093/mnras/185.4.661; Johnston HM, 1999, MON NOT R ASTRON SOC, V308, P415, DOI 10.1046/j.1365-8711.1999.02702.x; Jorstad SG, 2001, ASTROPHYS J SUPPL S, V134, P181, DOI 10.1086/320858; Kaiser CR, 2000, ASTRON ASTROPHYS, V356, P975; KALUZIENSKI LJ, 1976, ASTROPHYS J, V208, pL71, DOI 10.1086/182235; Krolik J. H., 1999, ACTIVE GALACTIC NUCL; Livio M, 1999, PHYS REP, V311, P225, DOI 10.1016/S0370-1573(98)00102-1; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; OSTROWSKI M, 1997, RELATIVISTIC JETS AG; SAIKIA DJ, 1988, ANNU REV ASTRON ASTR, V26, P93; Sari R, 1999, ASTROPHYS J, V519, pL17, DOI 10.1086/312109; Shirey RE, 1999, ASTROPHYS J, V517, P472, DOI 10.1086/307188; STEWART RT, 1993, MON NOT R ASTRON SOC, V261, P593, DOI 10.1093/mnras/261.3.593; Tennant A. F., 1986, MNRAS, V221, P27	22	136	139	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					222	224		10.1038/nature02137	http://dx.doi.org/10.1038/nature02137			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724631	Green Submitted			2022-12-28	WOS:000188068100036
J	Moorthy, VS; Good, MF; Hill, AVS				Moorthy, VS; Good, MF; Hill, AVS			Malaria vaccine developments	LANCET			English	Review							PLASMODIUM-FALCIPARUM MALARIA; CIRCUMSPOROZOITE PROTEIN VACCINE; PLACEBO-CONTROLLED TRIAL; SPF66 VACCINE; PROTECTIVE EFFICACY; SPOROZOITE VACCINE; ACQUIRED-IMMUNITY; CLINICAL MALARIA; DNA VACCINES; IN-VITRO	Large gains in the reduction of malaria mortality in the early 20th century were lost in subsequent decades. Malaria now kills 2-3 million people yearly. Implementation of malaria control technologies such as insecticide-treated bednets and chemotherapy could reduce mortality substantially, but an effective malaria vaccine is also needed. Advances in vaccine technology and immunology are being used to develop malaria subunit vaccines. Novel approaches that might yield effective vaccines for other diseases are being evaluated first in malaria. We describe progress in malaria vaccine development in the past 5 years: reasons for cautious optimism, the type of vaccine that might realistically be expected, and how the process could be hastened. Although exact predictions are not possible, if sufficient funding were mobilised, a deployable, effective malaria vaccine is a realistic medium-term to long-term goal.	MRC Labs, Banjul, Gambia; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4006, Australia	MRC Laboratory Molecular Biology; University of Oxford; QIMR Berghofer Medical Research Institute	Moorthy, VS (corresponding author), Malaria Vaccine Initiat, 6290 Montrose Rd, Rockville, MD 20852 USA.	vmoorthy@malariavaccine.org	HILL, Adrian V>S>/C-1306-2008	Moorthy, Vasee/0000-0002-6535-2854				Acosta CJ, 1999, TROP MED INT HEALTH, V4, P368, DOI 10.1046/j.1365-3156.1999.00406.x; Alloueche A, 2003, AM J TROP MED HYG, V68, P97, DOI 10.4269/ajtmh.2003.68.97; ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BALLOU WR, 1987, LANCET, V1, P1277; Beverley PCL, 2002, BRIT MED BULL, V62, P15, DOI 10.1093/bmb/62.1.15; Birkett A, 2002, INFECT IMMUN, V70, P6860, DOI 10.1128/IAI.70.12.6860-6870.2002; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; BROWN AE, 1994, VACCINE, V12, P102, DOI 10.1016/0264-410X(94)90046-9; Cheng Q, 1997, AM J TROP MED HYG, V57, P495, DOI 10.4269/ajtmh.1997.57.495; Church LWP, 1997, J INFECT DIS, V175, P915, DOI 10.1086/513990; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; COCHRANE AH, 1980, MALARIA; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; CROSNIER J, 1981, LANCET, V1, P455; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; Doolan DL, 2001, INT J PARASITOL, V31, P753, DOI 10.1016/S0020-7519(01)00184-9; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342; GONZALEZ C, 1994, J INFECT DIS, V169, P927, DOI 10.1093/infdis/169.4.927; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Guerin PJ, 2002, LANCET INFECT DIS, V2, P564, DOI 10.1016/S1473-3099(02)00372-9; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HERRINGTON DA, 1992, VACCINE, V10, P841, DOI 10.1016/0264-410X(92)90047-N; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; HOFFMAN SL, 1994, AM J TROP MED HYG, V51, P603, DOI 10.4269/ajtmh.1994.51.603; Holder AA, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P409; KABILAN L, 1990, INFECT IMMUN, V58, P2989, DOI 10.1128/IAI.58.9.2989-2994.1990; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Kwiatkowski D, 1997, LANCET, V350, P1696, DOI 10.1016/S0140-6736(97)03256-X; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; leSueur D, 1996, S AFR MED J, V86, P936; LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214; Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7&lt;1989::AID-IMMU1989&gt;3.0.CO;2-M; Makobongo MO, 2003, P NATL ACAD SCI USA, V100, P2628, DOI 10.1073/pnas.0337629100; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; Martens P, 2000, EMERG INFECT DIS, V6, P103, DOI 10.3201/eid0602.000202; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; MCGREGOR IA, 1974, B WORLD HEALTH ORGAN, V50, P259; Miyahira Y, 1998, P NATL ACAD SCI USA, V95, P3954, DOI 10.1073/pnas.95.7.3954; Molano A, 2000, J IMMUNOL, V164, P5005, DOI 10.4049/jimmunol.164.10.5005; Moorthy V, 2002, BRIT MED BULL, V62, P59, DOI 10.1093/bmb/62.1.59; Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5; MOORTHY VS, IN PRESS J INFECT DI; Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; Muentener P, 1999, B WORLD HEALTH ORGAN, V77, P560; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; Nardin EH, 2001, J IMMUNOL, V166, P481, DOI 10.4049/jimmunol.166.1.481; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331; Oeuvray C, 2000, INFECT IMMUN, V68, P2617, DOI 10.1128/IAI.68.5.2617-2620.2000; OEUVRAY C, 1994, BLOOD, V84, P1594; Paoletti E, 1996, P NATL ACAD SCI USA, V93, P11349, DOI 10.1073/pnas.93.21.11349; PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8; Paul BA., 1955, HLTH CULTURE COMMUNI; Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2; PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; Rogers WO, 2002, INFECT IMMUN, V70, P4329, DOI 10.1128/IAI.70.8.4329-4335.2002; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; Sachs JD, 2002, SCIENCE, V298, P122, DOI 10.1126/science.1077900; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Schneider J, 1999, IMMUNOL REV, V170, P29, DOI 10.1111/j.1600-065X.1999.tb01326.x; Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937; Shanks GD, 2000, T ROY SOC TROP MED H, V94, P253, DOI 10.1016/S0035-9203(00)90310-9; SHERWOOD JA, 1991, T ROY SOC TROP MED H, V85, P336, DOI 10.1016/0035-9203(91)90281-3; Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Taylor WRJ, 2001, AM J TROP MED HYG, V64, P223, DOI 10.4269/ajtmh.2001.64.223; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VREDEN SGS, 1991, AM J TROP MED HYG, V45, P533, DOI 10.4269/ajtmh.1991.45.533; Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; *WHO, 1996, MAL FACT SHEET 94; *WHO, 2000, MAL GLOB CRIS	81	124	130	2	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					150	156		10.1016/S0140-6736(03)15267-1	http://dx.doi.org/10.1016/S0140-6736(03)15267-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726170				2022-12-28	WOS:000187939200020
J	Stafford, RS; Furberg, CD; Finkelstein, SN; Cockburn, IM; Alehegn, T; Ma, J				Stafford, RS; Furberg, CD; Finkelstein, SN; Cockburn, IM; Alehegn, T; Ma, J			Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; PHYSICIANS; DOXAZOSIN	Context Research on factors that influence prescribing patterns and the extent of change produced by clinical trial findings is limited. Objective To examine the changes in prescribing of alpha-blockers for hypertension treatment before and after the April 2000 publication of the unfavorable Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) early termination involving the study's doxazosin mesylate arm. Changes in prescribing were considered in the context of other potential concurrent influences on medication use between 1996 and 2002, including changes in alpha-blocker drug prices, generic conversion, drug promotion, and competition. Design, Setting, and Patients Using 2 national pharmaceutical market research reports published by IMS HEALTH, alpha-blocker prescription orders reported in the National Prescription Audit-a random computerized sample of about 20000 of 29000 retail, independent, and mail order pharmacies and mass merchandise and discount houses-and office-based physician alpha-blocker prescribing patterns reported in the National Disease and Therapeutic Index-a random stratified sample of about 3500 physician offices-were tracked. Outcome Measures Trends in physician-reported use of alpha-blockers and alpha-blocker prescribing and dispensing by US pharmacies. Results There were steady increases in alpha-blocker new prescriptions, dispensed prescriptions, and physician drug use from 1996 through 1999. There was a moderate reversal in these trends following ALLHAT early termination and subsequent publications in early 2000. Between 1999 and 2002, new annual alpha-blocker prescription orders declined by 26% (from 5.15 million to 3.79 million), dispensed prescriptions by 22% (from 17.2 million to 13.4 million), and physician-reported drug use by 54% (from 2.26 million to 1.03 million). Other potential influences did not appear to have contributed significantly to this decline although cessation of alpha-blocker marketing may have hastened the decline. Conclusions Modest yet statistically significant declines in the use of doxazosin and other alpha-blockers coincided with the early termination of the ALLHAT doxazosin arm. Although physicians responded to this new evidence, strategies to augment the impact of clinical trials on clinical practice are warranted.	Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; MIT, Program Pharmaceut Ind, Cambridge, MA 02139 USA; Boston Univ, Sch Management, Boston, MA 02215 USA	Stanford University; Wake Forest University; Wake Forest Baptist Medical Center; Massachusetts Institute of Technology (MIT); Boston University	Stafford, RS (corresponding author), Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.	rstafford@stanford.edu	Cockburn, Iain M/G-9524-2013; Stafford, Randall/F-3974-2017	Cockburn, Iain M/0000-0003-2034-0187; Stafford, Randall/0000-0003-1805-1271	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013405] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS013405] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1997, ARCH INTERN MED, V157, P2413; Cabana M, 1998, AM J MANAG CARE, V4, pS741; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chew LD, 2000, J GEN INTERN MED, V15, P478, DOI 10.1046/j.1525-1497.2000.08014.x; COLLINS R, 1991, BRIT HEART J, V66, P250; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P94; DUNN DRF, 1981, B MED LIBR ASSOC, V69, P301; Frank RG, 1997, J ECON MANAGE STRAT, V6, P75, DOI 10.1162/105864097567039; FRIEDMAN L, 1983, CONTROL CLIN TRIALS, V4, P513, DOI 10.1016/0197-2456(83)90032-6; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Furberg CD, 2001, CURR CONTR TRIALS C, V2, P249, DOI 10.1186/CVM-2-6-249; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Guldal D, 2000, INT J HEALTH SERV, V30, P585, DOI 10.2190/GYW9-XUMQ-M3K2-T31C; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hogben M, 2002, OBSTET GYNECOL, V100, P801, DOI 10.1016/S0029-7844(02)02167-1; HURWITZ MA, 1988, J LAW ECON, V31, P299, DOI 10.1086/467158; *IMS HEALTH, 2001, NAT PRESCR AUD PLUS; *IMS HEALTH, 2002, NAT DIS THER IND DIA; Lacy CR, 2001, AM J CARDIOL, V87, P203, DOI 10.1016/S0002-9149(00)01317-5; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; Libby EN, 2002, ARCH INTERN MED, V162, P1893, DOI 10.1001/archinte.162.16.1893; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; McCracken GH, 2001, AM J MANAG CARE, V7, pS183; Messerli F H, 2000, Curr Hypertens Rep, V2, P241, DOI 10.1007/s11906-000-0005-3; Messerli FH, 2001, J AM COLL CARDIOL, V38, P1295, DOI 10.1016/S0735-1097(01)01534-0; Mottur-Pilson C, 2001, Eff Clin Pract, V4, P207; *NAT I HLTH CAR MA, 1999, FACT AFF GROWTH PRES; National Institute for Health Care Management Research and Education Foundation, 2002, PRESCR DRUG EXP 2001; Nelson CR, 2000, HYPERTENSION, V36, P600, DOI 10.1161/01.HYP.36.4.600; *NIH, 2000, NHLBI STOPS PART STU; Pressel SL, 2001, CONTROL CLIN TRIALS, V22, P29, DOI 10.1016/S0197-2456(00)00109-4; REIFFEL JA, 1990, AM J CARDIOL, V66, P1262, DOI 10.1016/0002-9149(90)91115-M; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; Zoorab Roger, 2002, J La State Med Soc, V154, P136	35	69	69	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					54	62		10.1001/jama.291.1.54	http://dx.doi.org/10.1001/jama.291.1.54			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709576	Bronze			2022-12-28	WOS:000187836000019
J	Salazar-Martinez, E; Willett, WC; Ascherio, A; Manson, JE; Leitzmann, MF; Stampfer, MJ; Hu, FB				Salazar-Martinez, E; Willett, WC; Ascherio, A; Manson, JE; Leitzmann, MF; Stampfer, MJ; Hu, FB			Coffee consumption and risk for type 2 diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; GLUCOSE-TOLERANCE; CAFFEINE INGESTION; ENERGY-EXPENDITURE; DIETARY FIBER; DOUBLE-BLIND; WOMEN; HUMANS; METABOLISM; VOLUNTEERS	Background: in small, short-term studies, acute administration of caffeine decreases insulin sensitivity and impairs glucose tolerance. Objective: To examine the long-term relationship between consumption of coffee and other caffeinated beverages and incidence of type 2 diabetes mellitus. Design: Prospective cohort study. Setting: The Nurses' Health Study and Health Professionals' Follow-up Study. Participants: The authors followed 41934 men from 1986 to 1998 and 84 276 women from 1980 to 1998. These participants did not have diabetes, cancer, or cardiovascular disease at baseline. Measurements: Coffee consumption was assessed every 2 to 4 years through validated questionnaires. Results: The authors documented 1333 new cases of type 2 diabetes in men and 4085 new cases in women. The authors found an inverse association between coffee intake and type 2 diabetes after adjustment for age, body mass index, and other risk factors. The multivariate relative risks for diabetes according to regular coffee consumption categories (0, <1, I to 3, 4 to 5, or greater than or equal to6 cups per day) in men were 1.00, 0.98, 0.93, 0.71, and 0.46 (95% Cl, 0.26 to 0.82; P = 0.007 for trend), respectively. The corresponding multivariate relative risks in women were 1.00, 1.16, 0.99, 0.70, and 0.71 (Cl, 0.56 to 0.89; P < 0.001 for trend), respectively. For decaffeinated coffee, the multivariate relative risks comparing persons who drank 4 cups or more per day with nondrinkers were 0.74 (Cl, 0.48 to 1.12) for men and 0.85 (Cl, 0.61 to 1.17) for women. Total caffeine intake from coffee and other sources was associated with a statistically significantly lower risk for diabetes in both men and women. Conclusions: These data suggest that long-term coffee consumption is associated with a statistically significantly lower risk for type 2 diabetes.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Mexican Inst Social Secur, Cuernavaca, Morelos, Mexico	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Instituto Mexicano del Seguro Social	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	frank.hu@channing.harvard.edu	Hu, Frank/C-1919-2013		NCI NIH HHS [CA55075, CA87969] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; NIAAA NIH HHS [AA11181] Funding Source: Medline; NIDDK NIH HHS [DK58845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASTRUP A, 1992, INT J OBESITY, V16, P269; ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759; Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023; BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, pE671, DOI 10.1152/ajpendo.1995.269.4.E671; BROWN CR, 1989, PHARMACOL BIOCHEM BE, V34, P565, DOI 10.1016/0091-3057(89)90559-5; CHERASKIN E, 1968, LANCET, V2, P689; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; Cox D. R., 1984, ANAL SURVIVAL DATA; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44; FEINBERG LJ, 1968, METABOLISM, V17, P916, DOI 10.1016/0026-0495(68)90158-3; Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581; Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559; Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; HARRIS M, 1979, DIABETES, V28, P1039; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364; LUNDSBERG LS, 1998, CAFFEINE, P199; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; Meyer KA, 2000, AM J CLIN NUTR, V71, P921; Ramsey JJ, 1998, AM J CLIN NUTR, V68, P42, DOI 10.1093/ajcn/68.1.42; ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124; Ryu S, 2001, J NUTR SCI VITAMINOL, V47, P139, DOI 10.3177/jnsv.47.139; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SPRIET LL, 1992, AM J PHYSIOL, V262, pE891, DOI 10.1152/ajpendo.1992.262.6.E891; Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001; van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X	31	351	368	0	50	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					1	8		10.7326/0003-4819-140-1-200401060-00005	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706966	Green Published			2022-12-28	WOS:000187855600001
J	Gillespie, D				Gillespie, D			Making abortion rare and safe	LANCET			English	Article							MEDICAL ABORTION; CONTRACEPTION; MIFEPRISTONE		Daid & Lucille Packard Fdn, Los Altos, CA 94022 USA		Gillespie, D (corresponding author), Daid & Lucille Packard Fdn, 300 2nd St, Los Altos, CA 94022 USA.							*A GUTTM I, 1999, SHAR RESP WOM SOC AB; Bajos N, 2003, HUM REPROD, V18, P994, DOI 10.1093/humrep/deg215; *CDC, 2002, REPR MAT CHILD HLTH; Jones RK, 2002, PERSPECT SEX REPRO H, V34, P294, DOI 10.2307/3097748; Jones RK, 2002, PERSPECT SEX REPRO H, V34, P154, DOI 10.2307/3097714; Marston C, 2003, INT FAM PLAN PERSPEC, V29, P6, DOI 10.2307/3180995; *PRB, 2003, 2003 WORLD POP DAT S; Rahman M, 2001, LANCET, V358, P1051, DOI 10.1016/S0140-6736(01)06182-7; Ross JA, 2002, INT FAM PLAN PERSPEC, V28, P138, DOI 10.2307/3088256; United Nations Population Fund (UNFPA), 2002, FIN RES FLOWS POP AC; *WHO, 2002, SAF AB TECHN POL GUI; Winikoff B, 1997, AM J OBSTET GYNECOL, V176, P431, DOI 10.1016/S0002-9378(97)70511-8	12	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					74	74		10.1016/S0140-6736(03)15179-3	http://dx.doi.org/10.1016/S0140-6736(03)15179-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	758YZ	14724004				2022-12-28	WOS:000187711300033
J	Muller-Navarra, DC; Brett, MT; Park, S; Chandra, S; Ballantyne, AP; Zorita, E; Goldman, CR				Muller-Navarra, DC; Brett, MT; Park, S; Chandra, S; Ballantyne, AP; Zorita, E; Goldman, CR			Unsaturated fatty acid content in seston and tropho-dynamic coupling in lakes	NATURE			English	Article							FOOD QUALITY; STOICHIOMETRIC CONSTRAINTS; COMMUNITY STRUCTURE; PELAGIC ECOSYSTEMS; LIMITATION; CONSUMER	Determining the factors that control food web interactions is a key issue in ecology(1,2). The empirical relationship between nutrient loading (total phosphorus) and phytoplankton standing stock (chlorophyll a) in lakes was described about 30 years ago(3) and is central for managing surface water quality. The efficiency with which biomass and energy are transferred through the food web and sustain the production of higher trophic levels (such as fish) declines with nutrient loading and system productivity(4,5), but the underlying mechanisms are poorly understood. Here we show that in seston (fine particles in water) during summer, specific omega3-polyunsaturated fatty acids (omega3-PUFAs), which are important for zooplankton(6-10), are significantly correlated to the trophic status of the lake. The omega3-PUFAs octadecatetraenoic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid, but not alpha-linolenic acid, decrease on a double-logarithmic scale with increasing total phosphorus. By combining the empirical relationship between EPA-to-carbon content and total phosphorus with functional models relating EPA-to-carbon content to the growth and egg production of daphnids(8), we predict secondary production for this key consumer. Thus, the decreasing efficiency in energy transfer with increasing lake productivity can be explained by differences in omega3-PUFA-associated food quality at the plant-animal interface.	Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA; Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA; GKSS Forschungszentrum Geesthacht GmbH, Inst Coastal Res, D-21502 Geesthacht, Germany	University of California System; University of California Davis; University of Washington; University of Washington Seattle; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung	Muller-Navarra, DC (corresponding author), Univ Hamburg, Inst Hydrobiol & Fishery Sci, D-22767 Hamburg, Germany.	doerthe.mueller-navarra@uni-hamburg.de	Brett, Michael T/A-2066-2010	Park, Sangkyu/0000-0003-3049-0728				Ahlgren G, 1997, FRESHWATER BIOL, V38, P555, DOI 10.1046/j.1365-2427.1997.00219.x; Ahlgren G., 1996, Ecology of Freshwater Fish, V5, P15; AHLGREN G, 1993, VERHANDLUNGEN INT VE, V25, P144; Arts MT, 2001, CAN J FISH AQUAT SCI, V58, P122, DOI 10.1139/cjfas-58-1-122; Brett MT, 1997, FRESHWATER BIOL, V38, P483, DOI 10.1046/j.1365-2427.1997.00220.x; Brett MT, 1997, SCIENCE, V275, P384, DOI 10.1126/science.275.5298.384; CARPENTER SR, 1984, AM NAT, V124, P159, DOI 10.1086/284261; DeMott WR, 2002, ECOLOGY, V83, P3426, DOI 10.1890/0012-9658(2002)083[3426:SCVADT]2.0.CO;2; Elser JJ, 1998, ECOSYSTEMS, V1, P120, DOI 10.1007/s100219900009; GREENBERG AE, 1995, STANDARDS METHODS EX; GULATI RD, 1990, HYDROBIOLOGIA, V200; JONASDOTTIR SH, 1995, MAR ECOL PROG SER, V119, P87, DOI 10.3354/meps119087; KATTNER G, 1986, J CHROMATOGR, V361, P263, DOI 10.1016/S0021-9673(01)86914-4; Mardia KV, 1978, MULTIVARIATE ANAL; Marker A. F. H., 1980, ARCH HYDROBIOL S, V14, P52; Matson PA, 1992, SPECIAL FEATURE ECOL, V73; MCQUEEN DJ, 1986, CAN J FISH AQUAT SCI, V43, P1571, DOI 10.1139/f86-195; MCQUEEN DJ, 1989, ECOL MONOGR, V59, P289, DOI 10.2307/1942603; Micheli F, 1999, SCIENCE, V285, P1396, DOI 10.1126/science.285.5432.1396; Muller-Navarra DC, 2000, NATURE, V403, P74, DOI 10.1038/47469; MULLERNAVARRA D, 1995, ARCH HYDROBIOL, V132, P297; MullerNavarra D, 1996, J PLANKTON RES, V18, P1137, DOI 10.1093/plankt/18.7.1137; Polis G.A., 1996, FOOD WEBS INTEGRATIO; Ravet JL, 2003, LIMNOL OCEANOGR, V48, P1938, DOI 10.4319/lo.2003.48.5.1938; SCHINDLER DW, 1987, CAN J FISH AQUAT SCI, V44, P6; SOMMER U, 1986, ARCH HYDROBIOL, V106, P433; Sterner RW, 1997, AM NAT, V150, P663, DOI 10.1086/286088; STERNER RW, 2003, JECOLOGICAL STOICHIO; VOLLENWEIDER R A, 1976, Memorie dell'Istituto Italiano di Idrobiologia Dott Marco de Marchi, V33, P53; WANG KS, 1994, J APPL PHYCOL, V6, P415, DOI 10.1007/BF02182158	30	229	234	9	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 1	2004	427	6969					69	72		10.1038/nature02210	http://dx.doi.org/10.1038/nature02210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702086				2022-12-28	WOS:000187710000035
J	Espinosa-Reyes, J; Fonnegra, C; Cardona-Gonzalez, J; Rosselli, D				Espinosa-Reyes, J; Fonnegra, C; Cardona-Gonzalez, J; Rosselli, D			An explosive case	LANCET			English	Editorial Material									Univ Mil Nueva Granada, Bogota, Colombia	Universidad Militar Nueva Granada	Rosselli, D (corresponding author), Univ Mil Nueva Granada, Transversal 5 49-00, Bogota, Colombia.			Berrio Parra, Felipe Leopoldo/0000-0001-9297-6016; Rosselli, Diego/0000-0003-0960-9480				Dulger HE, 2001, MIL MED, V166, P557, DOI 10.1093/milmed/166.6.557; Lein B, 1999, MIL MED, V164, P163, DOI 10.1093/milmed/164.3.163	2	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2066	2066		10.1016/S0140-6736(03)15102-1	http://dx.doi.org/10.1016/S0140-6736(03)15102-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697807				2022-12-28	WOS:000187429600012
J	Kvalsvig, A				Kvalsvig, A			Ask the elephant	LANCET			English	Article											Kvalsvig, A (corresponding author), 600 Makara Rd, Wellington, New Zealand.								0	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2079	2080		10.1016/S0140-6736(03)15105-7	http://dx.doi.org/10.1016/S0140-6736(03)15105-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697810				2022-12-28	WOS:000187429600024
J	Dennis, C				Dennis, C			Genomics - Compare and contrast	NATURE			English	News Item							SEQUENCES; REGIONS											Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Dermitzakis ET, 2003, SCIENCE, V302, P1033, DOI 10.1126/science.1087047; Frazer KA, 2003, GENOME RES, V13, P341, DOI 10.1101/gr.554603; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Rozen S, 2003, NATURE, V423, P873, DOI 10.1038/nature01723; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858	8	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					750	751		10.1038/426750b	http://dx.doi.org/10.1038/426750b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685190	Bronze			2022-12-28	WOS:000187342000013
J	Allan, R				Allan, R			Medicine for refugees	LANCET			English	Article									Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Int Emergency Disaster & Refugee Studies, MENTOR Initiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Allan, R (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Int Emergency Disaster & Refugee Studies, MENTOR Initiat, Baltimore, MD 21205 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S34	S35		10.1016/S0140-6736(03)15068-4	http://dx.doi.org/10.1016/S0140-6736(03)15068-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698122				2022-12-28	WOS:000187790200018
J	Bahl, R; Strachan, B; Murphy, DJ				Bahl, R; Strachan, B; Murphy, DJ			Outcome of subsequent pregnancy three years after previous operative delivery in the second stage of labour: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; MODE; CHILDBIRTH; PREVALENCE; MORBIDITY; SYMPTOMS; IMPACT; VIEWS	Objective To evaluate die reproductive outcome and the mode of delivery in subsequent pregnancies after instrumental vaginal delivery in theatre or caesarean section at full dilatation. Design Prospective cohort study. Setting Two urban hospitals with a combined total of 10000 deliveries a year. Participants A cohort of 393 women with term, singleton, cephalic pregnancies who needed operative delivery in theatre during the second stage of labour from February 1999 to February 2000. Postal questionnaires were received from 283 women (72%) at three years after the initial delivery. Main outcome measure Mode of delivery in the subsequent pregnancy. Results 140 women (49%) achieved a further pregnancy at three years. 91/283 (32%) women wished to avoid a further pregnancy. Women were more likely to aim for vaginal delivery (87% (47/54) v 33% (18/54); adjusted odds ratio 15.55 (95% confidence interval 5.25 to 46.04)) and more likely to have a vaginal delivery (78% (42/54) v 31% (17/54); 9.50 (3.48 to 25.97)) if they had had a previous instrumental vaginal delivery rather than a caesarean section. There was a high rate of vaginal delivery after caesarean section among women who attempted vaginal delivery 17/18 (94%). In both groups, fear of childbirth was a frequently reported reason for avoiding a further pregnancy (51% after instrumental vaginal delivery, 42% after caesarean section; 1.75 (0.58 to 5.25). Conclusion Instrumental vaginal delivery offers advantages over caesarean section for future delivery outcomes. The psychological impact of operative delivery requires urgent attention.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; St Michaels Hosp, Bristol BS2 8EG, Avon, England	University of Dundee	Murphy, DJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	d.j.murphy@dundee.ac.uk		Murphy, Deirdre/0000-0001-6074-6718				American College of Obstetricians and Gynecologists, 2000, EV CES DEL; American College of Obstetricians and Gynecologists Task Force on Caesarean Delivery, 2000, EV CAES DEL; Bofill JA, 1996, OBSTET GYNECOL, V88, P1007; Creedy DK, 2000, BIRTH-ISS PERINAT C, V27, P104, DOI 10.1046/j.1523-536x.2000.00104.x; Czarnocka J, 2000, BRIT J CLIN PSYCHOL, V39, P35, DOI 10.1348/014466500163095; Donnelly V, 1998, OBSTET GYNECOL, V92, P955, DOI 10.1016/S0029-7844(98)00255-5; Gilliam M, 2002, OBSTET GYNECOL, V99, P976, DOI 10.1016/S0029-7844(02)02002-1; HALL MH, 1989, BRIT J OBSTET GYNAEC, V96, P1297, DOI 10.1111/j.1471-0528.1989.tb03227.x; Hemminki E, 1996, PAEDIATR PERINAT EP, V10, P366, DOI 10.1111/j.1365-3016.1996.tb00062.x; Jolly J, 1999, BRIT J OBSTET GYNAEC, V106, P227, DOI 10.1111/j.1471-0528.1999.tb08235.x; KADAR N, 1983, OBSTET GYNECOL, V62, P166; Lavender T, 1998, BIRTH-ISS PERINAT C, V25, P215, DOI 10.1046/j.1523-536X.1998.00215.x; Lydon-Rochelle M, 2001, NEW ENGL J MED, V345, P3, DOI 10.1056/NEJM200107053450101; MacLennan AH, 2000, BRIT J OBSTET GYNAEC, V107, P1460, DOI 10.1111/j.1471-0528.2000.tb11669.x; Maternity Center Association, 2002, LIST MOTH REP 1 NAT; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Murphy DJ, 2002, HUM REPROD, V17, P1914, DOI 10.1093/humrep/17.7.1914; Murphy DJ, 2001, LANCET, V358, P1203, DOI 10.1016/S0140-6736(01)06341-3; Murphy DJ, 2003, BRIT MED J, V327, P1132, DOI 10.1136/bmj.327.7424.1132; Murphy DJ, 2003, AM J OBSTET GYNECOL, V188, P542, DOI 10.1067/mob.2003.67; PATEL RR, IN PRESS BIRTH; Small R, 2000, BRIT MED J, V321, P1043, DOI 10.1136/bmj.321.7268.1043; Smith GCS, 2002, JAMA-J AM MED ASSOC, V287, P2684, DOI 10.1001/jama.287.20.2684; Thomas J., 2001, NATL SENTINEL CAESAR; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; Wijma K, 1997, J ANXIETY DISORD, V11, P587, DOI 10.1016/S0887-6185(97)00041-8	26	91	93	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					311	314		10.1136/bmj.37942.546076.44	http://dx.doi.org/10.1136/bmj.37942.546076.44			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773ME	14724128	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000188926900016
J	Mohn, A; Di Marzio, A; Capanna, R; Fioritoni, G; Chiarelli, F				Mohn, A; Di Marzio, A; Capanna, R; Fioritoni, G; Chiarelli, F			Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia	LANCET			English	Article							BONE-MARROW-TRANSPLANTATION; CHILDHOOD; GLUCOSE	Treatment for acute lymphoblastic leukaemia can induce alterations of glucose metabolism, but long-term follow-up data on this topic are still absent. We aimed to study glucose metabolism by intravenous and oral glucose tolerance testing in 32 children affected by acute lymphoblastic leukaemia and who were off-therapy for at least 1 year. 22 (69%) children presented with impaired first-phase insulin response, which in nine children was associated with impaired glucose tolerance and in one child with overt diabetes. Fasting insulin (4.65 mU/L, 95% CI 1.1-8.1; p=0.008), insulinogenic index (0.46; 0.02-0.98; p=0.03), and homoeostatic model assessment beta-cell function (80.1, 7.2-153; p=0.02) were reduced in the children with impaired insulin response. Chemotherapy for acute lymphoblastic leukaemia is associated with beta-cell function damage, which persists even after therapy has been stopped.	Univ Chieti, Dept Paediat, I-66100 Chieti, Italy; Univ Chieti, Osped Civile Pescara, Dept Haematol, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Mohn, A (corresponding author), Univ Chieti, Dept Paediat, Via Dei Vestini 15, I-66100 Chieti, Italy.							CLAUSEN N, 1989, PEDIATR RES, V26, P158, DOI 10.1203/00006450-198908000-00019; KHAN A, 1970, Hormone and Metabolic Research, V2, P275; Lorini R, 1996, DIABETOLOGIA, V39, P370, DOI 10.1007/BF00418358; Taskinen M, 2000, LANCET, V356, P993, DOI 10.1016/S0140-6736(00)02717-3; Traggiai C, 2003, MED PEDIATR ONCOL, V40, P128, DOI 10.1002/mpo.10098	5	30	31	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					127	128		10.1016/S0140-6736(03)15264-6	http://dx.doi.org/10.1016/S0140-6736(03)15264-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726167				2022-12-28	WOS:000187939200011
J	Yajnik, CS; Yudkin, JS				Yajnik, CS; Yudkin, JS			The Y-Y paradox	LANCET			English	Article									KEM Hosp Res Ctr, Diabet Unit, Pune 411011, Maharashtra, India; UCL, Int Hlth & Med Educ Ctr, London WC1E 6BT, England	University of London; University College London	Yajnik, CS (corresponding author), KEM Hosp Res Ctr, Diabet Unit, Pune 411011, Maharashtra, India.		Yudkin, John S/C-1988-2008						0	146	146	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					163	163		10.1016/S0140-6736(03)15269-5	http://dx.doi.org/10.1016/S0140-6736(03)15269-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726172				2022-12-28	WOS:000187939200022
J	Tagami, H; Ray-Gallet, D; Almouzni, G; Nakatani, Y				Tagami, H; Ray-Gallet, D; Almouzni, G; Nakatani, Y			Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis	CELL			English	Article							VARIANT SYNTHESIS; CHROMATIN STATES; MESSENGER-RNA; HUMAN HOMOLOG; HUMAN ASF1; IN-VITRO; S-PHASE; REPLICATION; PROTEIN; CAF-1	Deposition of the major histone H3 (H3.1) is coupled to DNA synthesis during DNA replication and possibly DNA repair, whereas histone variant H3.3 serves as the replacement variant for the DNA-synthesis-independent deposition pathway. To address how histories H3.1 and H3.3 are deposited into chromatin through distinct pathways, we have purified deposition machineries for these histories. The H3.1 and H3.3 complexes contain distinct histone chaperones, CAF-1 and HIRA, that we show are necessary to mediate DNA-synthesis-dependent and -independent nucleosome assembly, respectively. Notably, these complexes possess one molecule each of H3.1/H3.3 and H4, suggesting that histories H3 and H4 exist as dimeric units that are important intermediates in nucleosome formation. This finding provides new insights into possible mechanisms for maintenance of epigenetic information after chromatin duplication.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; CNRS, UMR 218, Inst Curie, Sect Rech, F-75248 Paris 05, France	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)	Nakatani, Y (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	yoshihiro_nakatani@dfci.harvard.edu	Ray-Gallet, Dominique/A-9224-2019; Almouzni, Genevieve/ABG-1029-2021	Almouzni, Genevieve/0000-0001-5570-0723	NIGMS NIH HHS [GM065939-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065939] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Aho S, 2000, J CELL BIOL, V148, P1165, DOI 10.1083/jcb.148.6.1165; Alekseev OM, 2003, J BIOL CHEM, V278, P8846, DOI 10.1074/jbc.M210352200; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1998, CHROMATIN PRACTICAL, P195; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; Baxevanis AD, 1998, NUCLEIC ACIDS RES, V26, P372, DOI 10.1093/nar/26.1.372; BROWN DT, 1985, MOL CELL BIOL, V5, P2879, DOI 10.1128/MCB.5.11.2879; BURHANS WC, 1991, EMBO J, V10, P4351, DOI 10.1002/j.1460-2075.1991.tb05013.x; CUSICK ME, 1984, J MOL BIOL, V178, P249, DOI 10.1016/0022-2836(84)90143-8; FRANKLIN SG, 1977, NATURE, V266, P273, DOI 10.1038/266273a0; Gaillard PH, 1999, METH MOL B, V119, P231; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Green CM, 2003, EMBO J, V22, P5163, DOI 10.1093/emboj/cdg478; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaufman P.D., 2000, CHROMATIN STRUCTURE, P24; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; LAMOUR V, 1995, HUM MOL GENET, V4, P791, DOI 10.1093/hmg/4.5.791; Lorain S, 1996, GENOME RES, V6, P43, DOI 10.1101/gr.6.1.43; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; NAKATANI Y, 2004, IN PRESS METHODS ENZ, V370; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Quivy JP, 2001, EMBO J, V20, P2015, DOI 10.1093/emboj/20.8.2015; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; RAYGELLET D, 2004, IN PRESS METHODS ENZ, V375; Richardson RT, 2000, J BIOL CHEM, V275, P30378, DOI 10.1074/jbc.M003781200; Ridgway P, 2000, J CELL SCI, V113, P2647; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Utley RT, 1996, METHOD ENZYMOL, V274, P276; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Verreault A, 2000, GENE DEV, V14, P1430; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wolffe A., 1998, CHROMATIN STRUCTURE; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WUNSCH AM, 1987, DEV BIOL, V119, P94, DOI 10.1016/0012-1606(87)90210-7; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; ZWEIDLER A, 1984, HISTONE GENES STRUCT	52	951	988	3	67	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					51	61		10.1016/S0092-8674(03)01064-X	http://dx.doi.org/10.1016/S0092-8674(03)01064-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718166	Bronze			2022-12-28	WOS:000187960800008
J	Hanto, DW				Hanto, DW			A 50-year-old man with hepatitis C and cirrhosis needing liver transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							QUALITY-OF-LIFE; INTRAHEPATIC PORTOSYSTEMIC SHUNT; RISK-FACTORS; HEPATOCELLULAR-CARCINOMA; ORGAN TRANSPLANTATION; DOUBLE-BLIND; DONOR LIVER; RIBAVIRIN; IMPACT; HOMOTRANSPLANTATION		Beth Israel Deaconess Med Ctr, Dept Surg, Transplantat Ctr, Div Transplantat, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hanto, DW (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Transplantat Ctr, Div Transplantat, Boston, MA 02215 USA.	dhanto@bidmc.harvard.edu	Hanto, Douglas/AAZ-5390-2021	Hanto, Douglas/0000-0003-4088-3568				[Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117; Azoulay D, 2001, J HEPATOL, V35, P590, DOI 10.1016/S0168-8278(01)00185-4; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Braun M, 2003, LIVER TRANSPLANT, V9, pS79, DOI 10.1053/jlts.2003.50257; BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007; Brown RS, 2003, LIVER TRANSPLANT, V9, pS10, DOI 10.1053/jlts.2003.50244; Bucuvalas JC, 2003, LIVER TRANSPLANT, V9, P62, DOI 10.1053/jlts.2003.50012; Charlton M, 2001, AM J TRANSPLANT, V1, P197, DOI 10.1034/j.1600-6143.2001.001003197.x; Crippin JS, 2002, LIVER TRANSPLANT, V8, P350, DOI 10.1053/jlts.2002.31748; CURLEY SA, 1995, ANN SURG, V222, P375, DOI 10.1097/00000658-199509000-00014; DAVIDSON BR, 1994, TRANSPLANTATION, V57, P1174, DOI 10.1097/00007890-199404270-00006; ECKHAUSER FE, 1997, SURG SCI PRINCIPLES, P972; Everson GT, 2002, HEPATOLOGY, V36, p297A; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; Fontana RJ, 2002, LIVER TRANSPLANT, V8, P1165, DOI 10.1053/jlts.2002.36394; Forman LM, 2002, GASTROENTEROLOGY, V122, P889, DOI 10.1053/gast.2002.32418; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gane E, 2003, LIVER TRANSPLANT, V9, pS28, DOI 10.1053/jlts.2003.50248; Gane E, 1997, LANCET, V350, P1729, DOI 10.1016/S0140-6736(97)05535-9; Ghobrial RM, 2001, ANN SURG, V234, P384, DOI 10.1097/00000658-200109000-00012; Hanto DW, 2000, SURGERY: BASIC SCIENCE AND CLINICAL EVIDENCE, P1473; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; Kahan BD, 2001, TRANSPLANTATION, V72, P1181, DOI 10.1097/00007890-200110150-00001; KALAYOGLU M, 1988, LANCET, V1, P617; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Karman JF, 2001, TRANSPLANTATION, V71, P1210, DOI 10.1097/00007890-200105150-00005; Kim WR, 2002, HEPATOLOGY, V36, P227, DOI 10.1053/jhep.2002.34734; Lake JR, 2003, LIVER TRANSPLANT, V9, pS63, DOI 10.1053/jlts.2003.50264; LEVY MF, 1995, TRANSPLANTATION, V59, P515; Lewis MB, 2003, LIVER TRANSPLANT, V9, P1145, DOI 10.1053/jlts.2003.50239; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; Lo CM, 2003, TRANSPLANTATION, V75, pS12, DOI 10.1097/01.TP.0000046534.45645.47; Malinchoc M, 2000, HEPATOLOGY, V31, P864, DOI 10.1053/he.2000.5852; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Merion RM, 2003, LIVER TRANSPLANT, V9, P12, DOI 10.1053/jlts.2003.50009; MOORE FD, 1960, ANN SURG, V152, P374, DOI 10.1097/00000658-196015230-00003; Moore KA, 2000, LIVER TRANSPLANT, V6, P633, DOI 10.1053/jlts.2000.9743; Neuhaus P, 2002, LIVER TRANSPLANT, V8, P132, DOI 10.1053/jlts.2002.30302; Organ Procurement and Transplantation Network, POL 3 6 ALL LIV; ORLOFF MJ, 1995, J AM COLL SURGEONS, V180, P257; PICHLMAYR R, 1994, HEPATOLOGY, V20, pS33, DOI 10.1016/0270-9139(94)90271-2; PIRSCH JD, 1990, TRANSPLANTATION, V49, P1015; Poynard T, 2002, GASTROENTEROLOGY, V122, P1303, DOI 10.1053/gast.2002.33023; Ramsay M A, 1997, Liver Transpl Surg, V3, P494, DOI 10.1002/lt.500030503; Rikkers LF, 1998, ANN SURG, V228, P536, DOI 10.1097/00000658-199810000-00010; Roland ME, 2003, TRANSPLANTATION, V75, P425, DOI 10.1097/01.TP.0000046943.35335.18; Rosado B, 2003, LIVER TRANSPLANT, V9, P207, DOI 10.1053/jlts.2003.50045; Rosen HR, 2002, MICROBES INFECT, V4, P1253, DOI 10.1016/S1286-4579(02)01653-2; SCHAFER DF, 1989, SEMIN LIVER DIS, V9, P189, DOI 10.1055/s-2008-1040512; STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009; STARZL TE, 1981, NEW ENGL J MED, V305, P266, DOI 10.1056/NEJM198107303050507; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659; STARZL TE, 1960, SURG GYNECOL OBSTET, V111, P733; STRASBERG SM, 1994, HEPATOLOGY, V20, P829, DOI 10.1002/hep.1840200410; TANAKA H, 1994, JPN J CANCER RES, V85, P485, DOI 10.1111/j.1349-7006.1994.tb02384.x; Trotter JF, 2002, NEW ENGL J MED, V346, P1074, DOI 10.1056/NEJMra011629; Umeshita K, 2003, LANCET, V362, P687, DOI 10.1016/S0140-6736(03)14230-4; *US DEP HHS, 2003, IN PRESS 2003 ANN RE; Vallera R A, 1995, Liver Transpl Surg, V1, P143, DOI 10.1002/lt.500010302; Wachs ME, 1998, TRANSPLANTATION, V66, P1313, DOI 10.1097/00007890-199811270-00008; Whiting J F, 1997, Liver Transpl Surg, V3, P563, DOI 10.1053/jlts.1997.v3.pm0009404954; Wiesner RH, 1998, HEPATOLOGY, V28, P638, DOI 10.1002/hep.510280306; Winston DJ, 1999, ANN INTERN MED, V131, P729, DOI 10.7326/0003-4819-131-10-199911160-00003; Wright TL, 2002, HEPATOLOGY, V36, pS185, DOI 10.1053/jhep.2002.36812; Yao FY, 2001, HEPATOLOGY, V33, P1394, DOI 10.1053/jhep.2001.24563; Zacks SL, 1999, HEPATOLOGY, V29, P1399, DOI 10.1002/hep.510290512	69	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2003	290	24					3238	3246		10.1001/jama.290.24.3238	http://dx.doi.org/10.1001/jama.290.24.3238			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756TR	14693877				2022-12-28	WOS:000187499300028
J	Soh, CH; Oleske, JM; Brady, MT; Spector, SA; Borkowsky, W; Burchett, SK; Foca, MD; Handelsman, E; Jimenez, E; Dankner, WM; Hughes, MD				Soh, CH; Oleske, JM; Brady, MT; Spector, SA; Borkowsky, W; Burchett, SK; Foca, MD; Handelsman, E; Jimenez, E; Dankner, WM; Hughes, MD		Pediat AIDS Clinical Trials Grp	Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CHILDREN; RANDOMIZED CONTROLLED-TRIAL; VIROLOGICAL RESPONSES; IMMUNE RECONSTITUTION; VIRAL-LOAD; INDINAVIR; DISEASE; COHORT	Background There is limited evidence about longer-term effects of combination antiretroviral therapy that includes protease inhibitors (Pls) on the immunological status of HIV-1-infected children. Better understanding might help to resolve questions on when to initiate treatment. Methods The change in percentage of CD4-positive T lymphocytes (CD4%) was investigated in 1012 previously treated HIV-1-infected children (aged 0-17 years) who were enrolled in research clinics in the USA before 1996 and followed up to 2000. 702 started Pl-based combination therapy. Data analyses ignored subsequent treatment changes. Findings Among the 1012 children, the median CD4% increased from 22% to 28% between 1996, when Pls were first prescribed, and 2000. For the 702 who started Pl-based therapy, the mean CD4% increase after 3 years was largest among participants with the greatest immunosuppression (15.7%, 10.6%, 5.1%, and 2.0% for participants with CD4% before therapy of <5%, 5-14%, 15-24%, and &GE;25%; p<0.0001). After adjustment for pre-PI CD4%, the mean increase was largest among the youngest participants (9.2%, 8.0%, and 4.3% for ages <5 years, 5-9 years, and &GE;10 years; p=0.001). However, only a minority of significantly immunocompromised participants (33%, 26%, and 49% of those with pre-Pl CD4% of <5%, 5-14%, or 15-24%) achieved CD4% values above 25%, whereas 84% of those with pre-PI values above 25% maintained such values. Interpretation Although Pl-based therapy was associated with substantial improvements in CD4%, initiation before severe immunosuppression and at younger ages may be more effective for recovery or maintenance of normal CD4%. Randomised investigation of when to start combination therapy in children, particularly infants, is needed.	Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ Med & Dent New Jersey, Div Allergy Immunol, Newark, NJ 07103 USA; Childrens Hosp, Dept Infect Dis, Columbus, OH 43205 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; NYU Med Ctr, New York, NY 10016 USA; Bellevue Hosp, New York, NY USA; Childrens Hosp, Boston, MA 02115 USA; Childrens Hosp New York, Div Infect Dis, New York, NY USA; Columbia Univ, New York, NY USA; Childrens Med Ctr Brooklyn, Brooklyn, NY USA; San Juan City Hosp, Rio Piedras, PR USA; Duke Univ, Med Ctr, Durham, NC USA	Harvard University; Harvard T.H. Chan School of Public Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of California System; University of California San Diego; New York University; Bellevue Hospital Center; Harvard University; Boston Children's Hospital; Columbia University; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Duke University	Hughes, MD (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA.		Oleske, James M/C-1951-2016	Oleske, James M/0000-0003-2305-5605				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Arpadi SM, 2001, J ACQ IMMUN DEF SYND, V27, P30, DOI 10.1097/00126334-200105010-00005; Barroga CF, 2000, J INFECT DIS, V182, P413, DOI 10.1086/315704; Blankson JN, 2001, J INFECT DIS, V183, P657, DOI 10.1086/318545; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Buchacz K, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e72; de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Essajee SM, 1999, AIDS, V13, P2523, DOI 10.1097/00002030-199912240-00005; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; Furrer H, 2000, AIDS, V14, P1409, DOI 10.1097/00002030-200007070-00014; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kline MW, 1998, J PEDIATR-US, V132, P543, DOI 10.1016/S0022-3476(98)70039-3; Lange CG, 2002, CLIN IMMUNOL, V102, P154, DOI 10.1006/clim.2001.5164; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Lin H M, 1997, Stat Methods Med Res, V6, P129, DOI 10.1191/096228097677956331; Melvin AJ, 1997, PEDIATR INFECT DIS J, V16, P968, DOI 10.1097/00006454-199710000-00013; Mueller BU, 1998, PEDIATRICS, V102, P101, DOI 10.1542/peds.102.1.101; Nachman SA, 2000, JAMA-J AM MED ASSOC, V283, P492, DOI 10.1001/jama.283.4.492; Nikolic-Djokic D, 2002, J INFECT DIS, V185, P290, DOI 10.1086/338567; Pontesilli O, 1999, J INFECT DIS, V180, P76, DOI 10.1086/314837; RUTSTEIN RM, 1997, AIDS, V11, P107; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Sharland M, 2002, HIV Med, V3, P215, DOI 10.1046/j.1468-1293.2002.00120.x; SHEARER WT, IN PRESS J ALLERGY C; Tasker SA, 2002, CLIN INFECT DIS, V34, P813, DOI 10.1086/339044; Van Dyke RB, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e61; Vigano A, 2000, AIDS, V14, P251, DOI 10.1097/00002030-200002180-00007; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006; Wiznia A, 2000, AIDS RES HUM RETROV, V16, P1113, DOI 10.1089/088922200414956; World Health Organization, 2002, SCAL ANT THER RES LT; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725; 2003, GUIDELINES USE ANTIR	38	64	65	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2045	2051		10.1016/S0140-6736(03)15098-2	http://dx.doi.org/10.1016/S0140-6736(03)15098-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697803				2022-12-28	WOS:000187429600008
J	Conard, NJ				Conard, NJ			Palaeolithic ivory sculptures from southwestern Germany and the origins of figurative art	NATURE			English	Article							RADIOCARBON; CHAUVET; EUROPE; CAVE	Archaeologists have always viewed the origin of figurative art as a crucial threshold in human evolution(1,2). Here I report the discovery of three figurines carved from mammoth ivory at Hohle Fels Cave in the Swabian Jura of southwestern Germany, which provides new evidence for the appearance of figurative art more than 30,000 years ago. The finds include the oldest known representation of a bird, a therianthropic sculpture and an animal that most closely resembles a horse. The Aurignacian sculptures of the Swabian Jura belong to one of the oldest traditions of figurative art known worldwide and point to the Upper Danube as an important centre of cultural innovation during the early Upper Palaeolithic period(3,4).	Univ Tubingen, Inst Ur & Fruhgeschichte & Archaol Mittelalters, Abt Altere Urgeschichte & Quartarokol, D-72070 Tubingen, Germany	Eberhard Karls University of Tubingen	Conard, NJ (corresponding author), Univ Tubingen, Inst Ur & Fruhgeschichte & Archaol Mittelalters, Abt Altere Urgeschichte & Quartarokol, Schloss Hohentubingen, D-72070 Tubingen, Germany.			Conard, Nicholas/0000-0002-4633-0385				Beck JW, 2001, SCIENCE, V292, P2453, DOI 10.1126/science.1056649; Bon F., 2002, AURIGNACIEN ENTRE ME, VXXIX; BROGLIO A., 2002, PREISTORIA VERONESE, V5, P11; Churchill SE, 2000, YEARB PHYS ANTHROPOL, V43, P61; Clottes J, 2001, GROTTE CHAUVET ART O; Conard NJ, 2003, J HUM EVOL, V44, P331, DOI 10.1016/S0047-2484(02)00202-6; CONARD NJ, 2003, ARCHAOL AUSGR BADEN, P21; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Fortea Perez F.J., 2001, ZEPHYRUS, V53, P177; Hahn J., 1986, KRAFT AGGRESSION BOT; Hahn J, 1977, FUNDAMENTA MONOGRAPH, VA9; Leroi-Gourhan A., 1995, PREHISTOIRE ART OCCI, V1; Lewis-Williams D., 2002, MIND CAVE; MUNZEL SC, 2002, ABHANDL KARST HOHLEN, V34, P36; Neugebauer-Maresch C., 1989, GERMANIA, V67, P551; Pettitt P, 2003, ANTIQUITY, V77, P134, DOI 10.1017/S0003598X00061421; PORR M, 2001, EISZEITKUNST SUDDEUT, P95; Richter D, 2000, J ARCHAEOL SCI, V27, P71, DOI 10.1006/jasc.1999.0458; RIEK G, 1934, EIZEITJAGERSTATION V, V1; Schmid E., 1989, FUNDBERICHTE BADEN W, V14, P33; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; Valladas H, 2003, ANTIQUITY, V77, P142, DOI 10.1017/S0003598X00061433; Voelker AHL, 2000, RADIOCARBON, V42, P437, DOI 10.1017/S0033822200030368; Vogelsang R.., 1998, MIDDLE STONE AGE FUN; ZUCHNER C, 1999, EDADES REV HIST, V6, P167	25	154	159	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					830	832		10.1038/nature02186	http://dx.doi.org/10.1038/nature02186			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	754QM	14685236				2022-12-28	WOS:000187342000055
J	Hubbuck, C				Hubbuck, C			Treatment of children with severe burns	LANCET			English	Article									Frenchay Hosp, Barbara Russell Childrens Unit, Bristol BS16 1LE, Avon, England		Hubbuck, C (corresponding author), Frenchay Hosp, Barbara Russell Childrens Unit, Bristol BS16 1LE, Avon, England.								0	2	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S44	S45		10.1016/S0140-6736(03)15073-8	http://dx.doi.org/10.1016/S0140-6736(03)15073-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698127				2022-12-28	WOS:000187790200023
J	Konishi, Y; Stegmuller, J; Matsuda, T; Bonni, S; Bonni, A				Konishi, Y; Stegmuller, J; Matsuda, T; Bonni, S; Bonni, A			Cdh1-APC controls axonal growth and patterning in the mammalian brain	SCIENCE			English	Article							ANAPHASE-PROMOTING COMPLEX; RNA INTERFERENCE; IN-VIVO; UBIQUITIN; ELECTROPORATION; REQUIREMENT; REGULATOR; PROTEIN; CDC20; EMI1	The anaphase-promoting complex (APC) is highly expressed in postmitotic neurons, but its function in the nervous system was previously unknown. We report that the inhibition of Cdh1-APC in primary neurons specifically enhanced axonal growth. Cdh1 knockdown in cerebellar slice overlay assays and in the developing rat cerebellum in vivo revealed cell-autonomous abnormalities in layer-specific growth of granule neuron axons and parallel fiber patterning. Cdh1 RNA interference in neurons was also found to override the inhibitory influence of myelin on axonal growth. Thus, Cdh1-APC appears to play a role in regulating axonal growth and patterning in the developing brain that may also limit the growth of injured axons in the adult brain.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Calgary	Bonni, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	azad_bonni@hms.harvard.edu	Holt, Janet E/B-2415-2013		NINDS NIH HHS [R01NS41021] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041021] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KONISHI Y, UNPUB; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Swartz M, 2001, DEV BIOL, V233, P13, DOI 10.1006/dbio.2001.0181; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Watts RJ, 2003, NEURON, V38, P871, DOI 10.1016/S0896-6273(03)00295-2; Weimann JM, 1999, NEURON, V24, P819, DOI 10.1016/S0896-6273(00)81030-2; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	23	306	317	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					1026	1030		10.1126/science.1093712	http://dx.doi.org/10.1126/science.1093712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14716021	Green Submitted			2022-12-28	WOS:000188918000050
J	Wilson, JF				Wilson, JF			New treatments for growing scourge of brittle bones	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							POSTMENOPAUSAL WOMEN; MINERAL DENSITY; OSTEOPOROTIC FRACTURES					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002-021122; Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755; JAMAL SA, 2003, AM SOC BON MIN RES A; LaCroix AZ, 2003, ANN INTERN MED, V139, P97, DOI 10.7326/0003-4819-139-2-200307150-00009; Lippuner K, 1997, OSTEOPOROSIS INT, V7, P414, DOI 10.1007/PL00004149; MOFFET A, 2002, RES CLIN EVIDENCE DE; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807	9	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					153	156		10.7326/0003-4819-140-2-200401200-00037	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734352				2022-12-28	WOS:000188211700027
J	Owen-Hughes, T; Bruno, M				Owen-Hughes, T; Bruno, M			Breaking the silence	SCIENCE			English	Editorial Material							ACETYLATION; CHROMATIN; HETEROCHROMATIN; TRANSCRIPTION; YEAST		Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Owen-Hughes, T (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland.			Owen-Hughes, Tom/0000-0002-0618-8185				Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; COTE J, COMMUNICATION; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; KOBOR MS, IN PRESS PLOS BIOL; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; NAKATANI P, COMMUNICATION; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493	14	11	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	2004	303	5656					324	325		10.1126/science.1093990	http://dx.doi.org/10.1126/science.1093990			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726582				2022-12-28	WOS:000188111800030
J	Matheny, SA; Chen, CY; Kortum, RL; Razidlo, GL; Lewis, RE; White, MA				Matheny, SA; Chen, CY; Kortum, RL; Razidlo, GL; Lewis, RE; White, MA			Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP	NATURE			English	Article							KINASE SUPPRESSOR; RNA INTERFERENCE; RAF-1 KINASE; ACTIVATION; SCAFFOLD; PHOSPHORYLATION; LOCALIZATION; TRANSDUCTION; KSR	The signal transduction cascade comprising Raf, mitogen-activated protein (MAP) kinase kinase (MEK) and MAP kinase is a Ras effector pathway that mediates diverse cellular responses to environmental cues and contributes to Ras-dependent oncogenic transformation. Here we report that the Ras effector protein Impedes Mitogenic signal Propagation (IMP) modulates sensitivity of the MAP kinase cascade to stimulus-dependent activation by limiting functional assembly of the core enzymatic components through the inactivation of KSR, a scaffold/adaptor protein that couples activated Raf to its substrate MEK1. IMP is a Ras-responsive E3 ubiquitin ligase that, on activation of Ras, is modified by auto-polyubiquitination, which releases the inhibition of Raf-MEK complex formation. Thus, Ras activates the MAP kinase cascade through simultaneous dual effector interactions: induction of Raf kinase activity and derepression of Raf-MEK complex formation. IMP depletion results in increased stimulus-dependent MEK activation without alterations in the timing or duration of the response. These observations suggest that IMP functions as a threshold modulator, controlling sensitivity of the cascade to stimulus and providing a mechanism to allow adaptive behaviour of the cascade in chronic or complex signalling environments.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Nebraska, Med Ctr, Dept Pathol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Nebraska System; University of Nebraska Medical Center	White, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.white@utsouthwestern.edu	Lewis, Robert E./H-3404-2019	Razidlo, Gina/0000-0002-9042-2738				Brennan JA, 2002, J BIOL CHEM, V277, P5369, DOI 10.1074/jbc.M109875200; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Stewart S, 1999, MOL CELL BIOL, V19, P5523; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	16	147	158	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					256	260		10.1038/nature02237	http://dx.doi.org/10.1038/nature02237			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724641				2022-12-28	WOS:000188068100046
J	Sander, HW; Castro, C				Sander, HW; Castro, C			Neurocysticercosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cornell Univ, Weill Coll Med, New York, NY 10022 USA	Cornell University	Sander, HW (corresponding author), Cornell Univ, Weill Coll Med, New York, NY 10022 USA.			Sander, Howard/0000-0002-9654-7849					0	4	4	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					266	266		10.1056/NEJMicm980710	http://dx.doi.org/10.1056/NEJMicm980710			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724306				2022-12-28	WOS:000188078400010
J	Schroeder, SA				Schroeder, SA			Tobacco control in the wake of the 1998 Master Settlement Agreement	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SMOKING; CIGARETTES; STATE		Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Schroeder, SA (corresponding author), Univ Calif San Francisco, Dept Med, 3333 Calif St,Suite 430, San Francisco, CA 94143 USA.	schroeder@medicine.ucsf.edu						*AM LUNG ASS AM CA, 2003, CAMP TOB FREE KIDS; [Anonymous], NIH PUBLICATION; Balbach ED, 2003, AM J PUBLIC HEALTH, V93, P822, DOI 10.2105/AJPH.93.5.822; Bauer UE, 2000, JAMA-J AM MED ASSOC, V284, P723, DOI 10.1001/jama.284.6.723; Bryan-Jones K, 2003, AM J PUBLIC HEALTH, V93, P585, DOI 10.2105/AJPH.93.4.585; *CDCP, 2003, TOB INF PREV SOURC; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P842; Chaloupka FJ, 2000, HANDB ECON, V17, P1539; *CTR TOB FREE KIDS, SPEC REP STAT TOB SE; DELEON J, 1995, BIOL PSYCHIAT, V37, P640, DOI 10.1016/0006-3223(95)94579-L; *DEP HLTH HUM SERV, 2000, RED TOB US REP SURG; Department of Health Human Services Washington DC. Healthy People 2010 (Group) and United States Government Printing Office., 2000, HLTH PEOPL 2010; DiFranza JR, 2003, J ADOLESCENT HEALTH, V32, P331, DOI 10.1016/S1054-139X(03)00085-5; DiFranza JR, 2001, ARCH PEDIAT ADOL MED, V155, P572, DOI 10.1001/archpedi.155.5.572; Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3; Farnam C R, 1999, J Psychosoc Nurs Ment Health Serv, V37, P36; *FED TRAD COMM, 2003, FED TRAD COMM CIG RE; Fichtenberg CM, 2002, PEDIATRICS, V109, P1088, DOI 10.1542/peds.109.6.1088; FIORE MC, 2000, TREATING TOBACCO USE; FIORE MC, 2003, PREVENTING 3 MILLION; GERSEMA E, 2003, TOBACCO PRODUCTION N; GIVEL G, IN PRESS AM J PUBLIC; Glied S, 2003, AM J PUBLIC HEALTH, V93, P412, DOI 10.2105/AJPH.93.3.412; Gross CP, 2002, NEW ENGL J MED, V347, P1080, DOI 10.1056/NEJMsa012743; HALLET C, 2002, PEOPLE ISSUES TOBACC; Healton C, 2001, AM J PUBLIC HEALTH, V91, P828; Hong MK, 2002, BRIT MED J, V325, P1413, DOI 10.1136/bmj.325.7377.1413; Hopkins DP, 2001, AM J PREV MED, V20, P16, DOI 10.1016/S0749-3797(00)00297-X; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; Hughes JR, 1996, AM J HEALTH BEHAV, V20, P286; ISAACS SL, 2001, AM PROSPECT     0604, P26; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; JHA P, 1999, CURBING EPIDEMIC GOV, P15; Joossens L, 2000, BRIT MED J, V321, P947, DOI 10.1136/bmj.321.7266.947; Joossens L, 2003, INT J TUBERC LUNG D, V7, P214; Kessler DA, 2001, NEW ENGL J MED, V345, P535, DOI 10.1056/NEJM200108163450710; KLUGER R, 1966, ASHES ASHES AM 100 Y; LANGLEY A, 2003, NY TIMES        0520, pA11; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Levy D T, 2001, J Public Health Manag Pract, V7, P87; LEVY DT, IN PRESS J PUBLIC HL; LINDBLOM EN, 1999, FALSE FRIENDS CIGARE; Ling PM, 2002, AM J PUBLIC HEALTH, V92, P908, DOI 10.2105/AJPH.92.6.908; MCMENAMIN SB, IN PRESS AM J PREV M; *NASS DEP AGR AGR, 2003, CROP PROD; *NAT CAMP TOB FREE, 2003, STAT CIG TAX PROJ BE; *NAT COMM QUAL ASS, 2003, STAT HLTH CAR QUAL 2, P23; *NAT CTR CHRON DIS, 1999, BEST PRACT COMPR TOB; National Cancer Policy Board Institute of Medicine National Research Council, 1998, TAK ACT RED TOB US; O'Connell V, 2003, WALL STREET J   1009, pA1; *OFF QUAL PERF, 2001, HLTH BEH VET VHA TOB; *OFF RES DEV OFF H, 1992, RESP HLTH EFF PASS S; Ossip-Klein DJ, 2003, AM J MED SCI, V326, P201, DOI 10.1097/00000441-200310000-00010; PENDER K, 2003, SAN FRANCISCO C 0902, pB1; Pertschuk M., 2001, SMOKE THEIR EYES; Ribisl KM, 2003, JAMA-J AM MED ASSOC, V290, P1356, DOI 10.1001/jama.290.10.1356; Rigotti NA, 2002, NEW ENGL J MED, V346, P506, DOI 10.1056/NEJMcp012279; Schroeder SA, 2002, NEW ENGL J MED, V347, P1106, DOI 10.1056/NEJMe020099; Waxman HA, 2002, NEW ENGL J MED, V346, P936, DOI 10.1056/NEJMsb020030; WOMACH J, 2001, TOBACCO PRICE SUPPOR; World Health Organisation, 2002, QUANT SEL MAJ RISKS; Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660; Zickler P., 2000, NIDA NOTES, V15, P1; 2002, MMWR MORB MORTAL WKL, V51, P300; 2003, MMWR MORB MORTAL WKL, V52, P303; 2003, BBC NEWS        0514; 1998, MAST SETTL AGRE 46 S; 2003, NY TIMES        0915, pA18; 2001, MMWR MORB MORTAL WKL, V50, P1103	69	116	117	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					293	301		10.1056/NEJMsr031421	http://dx.doi.org/10.1056/NEJMsr031421			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	763HF	14715919	Bronze			2022-12-28	WOS:000188078400016
J	Garcia-Viloca, M; Gao, J; Karplus, M; Truhlar, DG				Garcia-Viloca, M; Gao, J; Karplus, M; Truhlar, DG			How enzymes work: Analysis by modern rate theory and computer simulations	SCIENCE			English	Review							TRANSITION-STATE STABILIZATION; COLI DIHYDROFOLATE-REDUCTASE; QUANTUM MECHANICS/MOLECULAR MECHANICS; CANONICAL VARIATIONAL THEORY; LIVER ALCOHOL-DEHYDROGENASE; CHORISMATE MUTASE CATALYSIS; TRIOSEPHOSPHATE ISOMERASE; MOLECULAR-DYNAMICS; FREE-ENERGY; HYDRIDE TRANSFER	Advances in transition state theory and computer simulations are providing new insights into the sources of enzyme catalysis. Both lowering of the activation free energy and changes in the generalized transmission coefficient (recrossing of the transition state, tunneling, and nonequilibrium contributions) can play a role. A framework for understanding these effects is presented, and the contributions of the different factors, as illustrated by specific enzymes, are identified and quantified by computer simulations. The resulting understanding of enzyme catalysis is used to comment on alternative proposals of how enzymes work.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Supercomp, Minneapolis, MN 55455 USA; Univ Strasbourg, ISIS, Lab Chim Biophys, F-67000 Strasbourg, France	Harvard University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Karplus, M (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	marci@tammy.harvard.edu; truhlar@umn.edu	Truhlar, Donald G./G-7076-2015; Garcia-Viloca, Mireia/G-6683-2017	Truhlar, Donald G./0000-0002-7742-7294; Garcia-Viloca, Mireia/0000-0001-5415-0248				Admiraal SJ, 2001, BIOCHEMISTRY-US, V40, P403, DOI 10.1021/bi002472w; Agarwal PK, 2002, J PHYS CHEM B, V106, P3283, DOI 10.1021/jp020190v; Agarwal PK, 2002, P NATL ACAD SCI USA, V99, P2794, DOI 10.1073/pnas.052005999; Alhambra C, 2001, J PHYS CHEM B, V105, P11326, DOI 10.1021/jp0120312; Alhambra C, 1999, J AM CHEM SOC, V121, P2253, DOI 10.1021/ja9831655; Alhambra C, 1998, J AM CHEM SOC, V120, P3858, DOI 10.1021/ja972578n; Alhambra C, 2002, CHEM PHYS LETT, V355, P388, DOI 10.1016/S0009-2614(02)00057-X; Alhambra C, 2000, J AM CHEM SOC, V122, P8197, DOI 10.1021/ja001476l; Allison T. C, 1998, MODERN METHODS MULTI, P618; Alper KO, 2001, PROTEIN SCI, V10, P1319, DOI 10.1110/ps.220101; Anderson JB, 1995, ADV CHEM PHYS, V91, P381, DOI 10.1002/9780470141502.ch5; [Anonymous], 1978, TRANSITION STATES BI; ASHCROFT J, 1989, J CHEM PHYS, V90, P5386, DOI 10.1063/1.456445; Basran J, 1999, BIOCHEMISTRY-US, V38, P3218, DOI 10.1021/bi982719d; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Billeter SR, 2001, J CHEM PHYS, V114, P6925, DOI 10.1063/1.1356441; BOYD RK, 1977, CHEM REV, V77, P93, DOI 10.1021/cr60305a006; BROOKS CL, 1988, ADV CHEM PHYS, V71, P1; Bruice TC, 1999, ACCOUNTS CHEM RES, V32, P127, DOI 10.1021/ar960131y; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; Bugg TDH, 2001, NAT PROD REP, V18, P465, DOI 10.1039/b009205n; Cameron CE, 1997, BIOCHEMISTRY-US, V36, P15792, DOI 10.1021/bi9716231; Cannon WR, 1998, J BIOL CHEM, V273, P26257, DOI 10.1074/jbc.273.41.26257; CARERI G, 1975, Critical Reviews in Biochemistry, V3, P141, DOI 10.3109/10409237509102555; CHANDRASEKHAR J, 1985, J AM CHEM SOC, V107, P154, DOI 10.1021/ja00287a028; Cui Q, 2003, ADV PROTEIN CHEM, V66, P315; Cui Q, 2002, J PHYS CHEM B, V106, P2721, DOI 10.1021/jp013012v; Cui Q, 2002, J PHYS CHEM B, V106, P1768, DOI 10.1021/jp012659c; Cui Q, 2002, J AM CHEM SOC, V124, P3093, DOI 10.1021/ja0118439; Cui Q, 2001, J AM CHEM SOC, V123, P2284, DOI 10.1021/ja002886c; Davidson MM, 1996, J CHEM SOC PERK T 2, P525, DOI 10.1039/p29960000525; Devi-Kesavan LS, 2003, J AM CHEM SOC, V125, P1532, DOI 10.1021/ja026955u; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Dybala-Defratyka A, 2001, J INORG BIOCHEM, V86, P681, DOI 10.1016/S0162-0134(01)00230-6; Eyring H, 1939, CHEM REV, V24, P253, DOI 10.1021/cr60078a005; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P349; Feierberg I, 2002, THEOR CHEM ACC, V108, P71, DOI 10.1007/s00214-002-0365-7; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Forst W, 1973, THEORY UNIMOLECULAR; Fromme JC, 2003, NAT STRUCT BIOL, V10, P204, DOI 10.1038/nsb902; Gao JL, 2002, ANNU REV PHYS CHEM, V53, P467, DOI 10.1146/annurev.physchem.53.091301.150114; Gao JL, 2003, CURR OPIN STRUC BIOL, V13, P184, DOI 10.1016/S0959-440X(03)00041-1; Garcia-Viloca M, 2003, BIOCHEMISTRY-US, V42, P13558, DOI 10.1021/bi034824f; Garcia-Viloca M, 2002, J AM CHEM SOC, V124, P7268, DOI 10.1021/ja026383d; GARCIAVILOCA M, UNPUB; GARCIAVILOCA M, 2003, J COMPUT CHEM, V24, P643; GARRETT BC, 1979, J PHYS CHEM-US, V83, P1052, DOI 10.1021/j100471a031; GARRETT BC, 1980, J PHYS CHEM-US, V84, P805, DOI 10.1021/j100444a020; Guo H, 2003, ANGEW CHEM INT EDIT, V42, P1508, DOI 10.1002/anie.200219878; Guo H, 2001, P NATL ACAD SCI USA, V98, P9032, DOI 10.1073/pnas.141230998; Hall M. B., 1999, ACS SYM SER, V721, P2; Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839; Hammes-Schiffer S, 2002, BIOCHEMISTRY-US, V41, P13335, DOI 10.1021/bi0267137; Hansson T, 1997, J MOL BIOL, V265, P118, DOI 10.1006/jmbi.1996.0716; Harris TK, 2000, BIOCHEMISTRY-US, V39, P1655, DOI 10.1021/bi9918745; Hermans J, 1997, J AM CHEM SOC, V119, P2707, DOI 10.1021/ja963568+; Hur S, 2003, P NATL ACAD SCI USA, V100, P12015, DOI 10.1073/pnas.1534873100; Ishijima J, 2000, J BIOL CHEM, V275, P18939, DOI 10.1074/jbc.275.25.18939; Jonsson T, 1996, J AM CHEM SOC, V118, P10319, DOI 10.1021/ja961827p; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KARPLUS M, 1983, ANNU REV BIOCHEM, V52, P263, DOI 10.1146/annurev.bi.52.070183.001403; Kienhofer A, 2003, J AM CHEM SOC, V125, P3206, DOI 10.1021/ja0341992; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; Kollman PA, 2001, ACCOUNTS CHEM RES, V34, P72, DOI 10.1021/ar000032r; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; Kreevoy M., 1986, INVESTIGATION RATE 1, P13; Kuhn B, 2000, J AM CHEM SOC, V122, P2586, DOI 10.1021/ja992218v; LARSEN TM, 1996, BIOCHEMISTRY-US, V35, P1692; Lau EY, 2000, P NATL ACAD SCI USA, V97, P9937, DOI 10.1073/pnas.97.18.9937; LEVY RM, 1979, CHEM PHYS LETT, V65, P4, DOI 10.1016/0009-2614(79)80114-1; LI LY, 1992, BIOCHEMISTRY-US, V31, P7826, DOI 10.1021/bi00149a012; LIM C, 1985, J PHYS CHEM-US, V89, P5, DOI 10.1021/j100247a003; Liu HY, 2000, J AM CHEM SOC, V122, P6560, DOI 10.1021/ja9936619; LYNE PD, 1995, J AM CHEM SOC, V117, P11345, DOI 10.1021/ja00150a037; Ma BY, 2000, J THEOR BIOL, V203, P383, DOI 10.1006/jtbi.2000.1097; Mancia F, 1999, BIOCHEMISTRY-US, V38, P7999, DOI 10.1021/bi9903852; Marti S, 2001, THEOR CHEM ACC, V105, P207, DOI 10.1007/s002140000203; Matsuda SPT, 2000, ORG LETT, V2, P2261, DOI 10.1021/ol006018w; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; Mulholland AJ, 1997, PROTEINS, V27, P9; NAM K, IN PRESS J AM CHEM S; Narlikar GJ, 1998, BIOCHEMISTRY-US, V37, P9902, DOI 10.1021/bi980495t; Neria E, 1997, CHEM PHYS LETT, V267, P23, DOI 10.1016/S0009-2614(97)00068-7; NORTHROP DB, 1999, MECH ENZYME ACTION A, P25; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; Poulsen TD, 2003, J PHYS CHEM B, V107, P9567, DOI 10.1021/jp030107j; Pratt JM, 2001, HANDBOOK ON METALLOPROTEINS, P603; Radkiewicz JL, 2000, J AM CHEM SOC, V122, P225, DOI 10.1021/ja9913838; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Ranaghan KE, 2003, MOL PHYS, V101, P2695, DOI 10.1080/00268970310001593286; RICHARD JP, 1984, J AM CHEM SOC, V106, P4926, DOI 10.1021/ja00329a050; Ridder L, 2003, J PHYS CHEM B, V107, P2118, DOI 10.1021/jp026213n; Ridder L, 2002, J AM CHEM SOC, V124, P9926, DOI 10.1021/ja0256360; Ridder L, 2000, J AM CHEM SOC, V122, P8728, DOI 10.1021/ja0007814; Satz AL, 2002, ACCOUNTS CHEM RES, V35, P86, DOI 10.1021/ar0101032; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; Schowen RL, 2003, P NATL ACAD SCI USA, V100, P11931, DOI 10.1073/pnas.2235806100; SHIZGAL B, 1970, J CHEM PHYS, V52, P4262, DOI 10.1063/1.1673637; Shurki A, 2002, J AM CHEM SOC, V124, P4097, DOI 10.1021/ja012230z; Sun DP, 2002, PROG REACT KINET MEC, V27, P209, DOI 10.3184/007967402103165397; Sutcliffe MJ, 2002, EUR J BIOCHEM, V269, P3096, DOI 10.1046/j.1432-1033.2002.03020.x; TAKUSAGAWA F, 1998, COMPREHENSIVE BIOL C, V1, P1; Tresadern G, 2002, CHEM PHYS LETT, V358, P489, DOI 10.1016/S0009-2614(02)00654-1; Tresadern G, 2003, FARADAY DISCUSS, V122, P223, DOI 10.1039/b201183m; TROE J, 1975, PHYSICAL CHEM ADV B, V6, P835; Truhlar DG, 1996, J PHYS CHEM-US, V100, P12771, DOI 10.1021/jp953748q; Truhlar DG, 2002, ACCOUNTS CHEM RES, V35, P341, DOI 10.1021/ar0100226; TRUHLAR DG, 1983, J PHYS CHEM-US, V87, P2884; TSAI CJ, 1993, J PHYS CHEM-US, V97, P11227, DOI 10.1021/j100145a019; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; Villa J, 2001, J PHYS CHEM B, V105, P7887, DOI 10.1021/jp011048h; Warshel A, 2000, BIOCHEMISTRY-US, V39, P14728, DOI 10.1021/bi000987h; WARSHEL A, 1999, ACS SYM SER, V721, P489; Warshel A, 1991, COMPUTER MODELING CH; Watney JB, 2003, J AM CHEM SOC, V125, P3745, DOI 10.1021/ja028487u; WELCH GR, 1983, PROG BIOPHYS MOL BIO, V39, P109; WILSON MA, 1990, CHEM PHYS, V149, P11, DOI 10.1016/0301-0104(90)80127-J; WINTER G, 1982, NATURE, V299, P756, DOI 10.1038/299756a0; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Young L, 1996, BIOCHEMISTRY-US, V35, P15129, DOI 10.1021/bi961875m; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	125	873	898	16	451	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					186	195		10.1126/science.1088172	http://dx.doi.org/10.1126/science.1088172			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716003				2022-12-28	WOS:000187908500037
J	Schmidt, DN; Thierstein, HR; Bollmann, J; Schiebel, R				Schmidt, DN; Thierstein, HR; Bollmann, J; Schiebel, R			Abiotic forcing of plankton evolution in the Cenozoic	SCIENCE			English	Article							FORAMINIFERA; TRENDS; GRADUALISM; LINEAGE; RULE	We characterize the evolutionary radiation of planktic foraminifera by the test size distributions of entire assemblages in more than 500 Cenozoic marine sediment samples, including more than 1 million tests. Calibration of Holocene size patterns with environmental parameters and comparisons with Cenozoic paleoproxy data show a consistently positive correlation between test size and surface-water stratification intensity. We infer that the observed macroevolutionary increase in test size of planktic foraminifera through the Cenozoic was an adaptive response to intensifying surface-water strati. cation in low latitudes, which was driven by polar cooling.	ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; Univ Zurich, ETH Zentrum, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Schmidt, DN (corresponding author), Univ London, Royal Holloway & Bedford New Coll, Dept Geol, Egham TW20 OEX, Surrey, England.	d.schmidt@gl.rhul.ac.uk		Schiebel, Ralf/0000-0002-6252-7647; Schmidt, Daniela/0000-0001-8419-2721				ARNOLD AJ, 1983, PALEOBIOLOGY, V9, P390, DOI 10.1017/S0094837300007855; ARNOLD AJ, 1995, J PALEONTOL, V69, P203, DOI 10.1017/S0022336000034557; BOLLMANN J, IN PRESS IMAGE ANAL; Chapelle G, 1999, NATURE, V399, P114, DOI 10.1038/20099; CIFELLI R, 1969, SYST ZOOL, V18, P154, DOI 10.2307/2412601; DHONDT S, 1995, PALEOCEANOGRAPHY, V10, P123, DOI 10.1029/94PA02671; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; HECHT A D, 1976, Journal of Foraminiferal Research, V6, P295; Kaiho K, 1998, GEOLOGY, V26, P491, DOI 10.1130/0091-7613(1998)026<0491:GCFODS>2.3.CO;2; LIPPS JH, 1970, EVOLUTION, V24, P1, DOI 10.1111/j.1558-5646.1970.tb01737.x; LUTERBACHER H. P., 1964, RIV ITAL PALEONTOL STRATIGR, V70, P67; MacLeod KG, 2001, PALEOCEANOGRAPHY, V16, P133, DOI 10.1029/2000PA000514; MALMGREN BA, 1983, PALEOBIOLOGY, V9, P377, DOI 10.1017/S0094837300007843; Mulitza S, 1997, GEOLOGY, V25, P335, DOI 10.1130/0091-7613(1997)025<0335:PFAROP>2.3.CO;2; Norris RD, 1996, PALEOBIOLOGY, V22, P386, DOI 10.1017/S0094837300016341; NORRIS RD, 1991, PALEOBIOLOGY, V17, P388, DOI 10.1017/S0094837300010721; Pearson PN, 2000, NATURE, V406, P695, DOI 10.1038/35021000; Pearson PN, 2001, NATURE, V413, P481, DOI 10.1038/35097000; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SCHMIDT DMZ, UNPUB; SCHMIDT DN, IN PRESS MAR MICROPA; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; STANLEY SM, 1998, MACROEVOLUTION PATTE; STENSETH NC, 1984, EVOLUTION, V38, P870, DOI 10.1111/j.1558-5646.1984.tb00358.x; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; VINCENT E, 1981, SEA, V7, P1035; WEFER G, 1999, USE PROXIES PALEOCEA; Wei KY, 1986, PALEOCEANOGRAPHY, V1, P67, DOI 10.1029/PA001i001p00067; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	29	103	107	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	2004	303	5655					207	210		10.1126/science.1090592	http://dx.doi.org/10.1126/science.1090592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716007				2022-12-28	WOS:000187908500041
J	Staats, PS; Yearwood, T; Charapata, SG; Presley, RW; Wallace, MS; Byas-Smith, M; Fisher, R; Bryce, DA; Mangieri, EA; Luther, RR; Mayo, M; McGuire, D; Ellis, D				Staats, PS; Yearwood, T; Charapata, SG; Presley, RW; Wallace, MS; Byas-Smith, M; Fisher, R; Bryce, DA; Mangieri, EA; Luther, RR; Mayo, M; McGuire, D; Ellis, D			Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							N-TYPE; OMEGA-CONOTOXIN; ANTINOCICEPTION; ANTAGONISTS	Context Ziconotide (formerly SNX-111) selectively blocks N-type voltage-sensitive calcium channels and may be effective in patients with pain that is refractory to opioid therapy or those with intolerable opioid-related adverse effects. Objective To assess the safety and efficacy of intrathecal ziconotide in patients with pain that is refractory to conventional treatment. Design, Setting, and Patients Double-blind, placebo-controlled, randomized trial conducted from March 12, 1996, to July 11, 1998, at 32 study centers in the United States, Australia, and the Netherlands. Patients were 111 individuals ages 24 to 85 years with cancer or AIDS and a mean Visual Analog Scale of Pain Intensity (VASPI) score of 50 mm or greater. Patients were randomly assigned in a 2:1 ratio to receive ziconotide or placebo treatment. Interventions Intrathecal ziconotide was titrated over 5 to 6 days, followed by a 5-day maintenance phase for responders and crossover of nonresponders to the opposite treatment group. Main Outcome Measure Mean percentage change in VASPI score from baseline to the end of the initial titration period. Results Of the evaluable population, 67 (98.5%) of 68 patients receiving ziconotide and 38 (95%) of 40 patients receiving placebo were taking opioids at baseline (median morphine equivalent dosage of 300 mg/d for the ziconotide group and 600 mg/d for the placebo group; P=.63, based on mean values), and 36 had used intrathecal morphine. Mean (SD) VASPI scores were 73.6 (1.8) mm in the ziconotide group and 77.9 (2.3) mm in the placebo group (P=.18). Mean VASPI scores improved 53.1% (95% confidence interval [CI], 44.0%-62.2%) in the ziconotide group and 18.1% (95% CI, 4.8%31.4%) in the placebo group (P<.001), with no loss of efficacy of ziconotide in the maintenance phase. Pain relief was moderate to complete in 52.9% of patients in the ziconotide group compared with 17.5% in the placebo group (P<.001). Five patients receiving ziconotide achieved complete pain relief, and 50.0% of patients receiving ziconotide responded to therapy compared with 17.5% of those receiving placebo (P=.001). Conclusion Intrathecal ziconotide provided clinically and statistically significant analgesia in patients with pain from cancer or AIDS.	Johns Hopkins Univ, Sch Med, Div Pain Med, Baltimore, MD 21205 USA; Pain Management Associates, Med Res Ctr, Pain Inst, Kansas City, MO USA; Integrated Spine Clin, Daphne, AL USA; Pain Care Specialists, Colorado Springs, CO USA; Univ Calif San Diego, Ctr Pain & Palliat Med, La Jolla, CA 92093 USA; Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA USA; Sparks Reg Med Ctr, Goodman Inst Pain Management, Ft Smith, AR USA; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA; Anodyne Res Serv, Northport, AL USA; Rhino Pias Consulting LLC, Reno, NV USA; Eunoe Inc, Redwood City, CA USA; Elan Pharmaceut Inc, San Diego, CA USA	Johns Hopkins University; University of California System; University of California San Diego; Emory University; Marshfield Clinic	Staats, PS (corresponding author), Johns Hopkins Univ, Sch Med, Div Pain Med, 550 N Broadway,Suite 301, Baltimore, MD 21205 USA.	pstaats@jhmi.edu	Kinfe, Thomas/AAY-7093-2020	Kinfe, Thomas/0000-0002-4888-543X; Yearwood, Thomas/0000-0002-0814-8953				Bowersox SS, 1996, J PHARMACOL EXP THER, V279, P1243; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; BROSE W, 1996, 15 ANN M AM PAIN SOC; Jacox A, 1994, AHCPR PUBLICATION; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; Mathur VS, 2000, SEMIN ANESTH PERIO M, V19, P67, DOI DOI 10.1053/SA.2000.6787]; MATHUR VS, 1998, PHARM NEWS, V5, P25; McGuire D, 1997, J CARDIOVASC PHARM, V30, P400, DOI 10.1097/00005344-199709000-00019; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; Staats PS, 1998, J BACK MUSCULOSKELET, V10, P69, DOI 10.3233/BMR-1998-10203; VANDAELE SF, 1994, NEUROREPORT, V5, P1121, DOI 10.1097/00001756-199405000-00025; VENTAFRIDDA V, 1987, ACTA ANAESTH SCAND, V31, P47, DOI 10.1111/j.1399-6576.1987.tb02669.x; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	16	399	433	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					63	70		10.1001/jama.291.1.63	http://dx.doi.org/10.1001/jama.291.1.63			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709577	Bronze			2022-12-28	WOS:000187836000020
J	Jimenez, SA; Derk, CT				Jimenez, SA; Derk, CT			Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN DERMAL FIBROBLASTS; I COLLAGEN GENE; TGF-BETA; SCLERODERMA FIBROBLASTS; HUMAN CYTOMEGALOVIRUS; REGULATED EXPRESSION; AUTOIMMUNE-DISEASES; SKIN; ASSOCIATION; ANTIBODIES	This review discusses the clinical and physiologic principles of systemic sclerosis, a disease of unknown origin characterized by excessive deposition of Collagen and other connective tissue macromolecules in skin and many internal organs, prominent changes in the microvasculature, and humoral and cellular immunologic abnormalities.	Thomas Jefferson Univ, Div Rheumatol, Philadelphia, PA 19107 USA	Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Div Rheumatol, 233 S 10th St,Room 509 BLSB, Philadelphia, PA 19107 USA.			Jimenez, Sergio/0000-0001-5213-1203	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019616, T32AR007583] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR07583, AR19616] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arnett FC, 1996, ARTHRITIS RHEUM, V39, P1362, DOI 10.1002/art.1780390814; Artlett Carol M, 2003, Curr Rheumatol Rep, V5, P154, DOI 10.1007/s11926-003-0044-2; Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009; Block JA, 2001, LANCET, V357, P2042, DOI 10.1016/S0140-6736(00)05118-7; Burastero SE, 2003, ARTHRITIS RHEUM-US, V48, P1109, DOI 10.1002/art.10888; CAMPBELL P M, 1975, Seminars in Arthritis and Rheumatism, V4, P351, DOI 10.1016/0049-0172(75)90017-7; Chizzolini C, 1999, SPRINGER SEMIN IMMUN, V21, P431, DOI 10.1007/BF00870304; CIPOLETTI JF, 1977, ANN INTERN MED, V87, P535, DOI 10.7326/0003-4819-87-5-535; Co H T, 2000, Am J Ther, V7, P321, DOI 10.1097/00045391-200007050-00011; Coghlan JG, 2001, CURR OPIN RHEUMATOL, V13, P495, DOI 10.1097/00002281-200111000-00008; Crilly A, 2002, ANN RHEUM DIS, V61, P678, DOI 10.1136/ard.61.8.678; DANG H, 1991, ARTHRITIS RHEUM, V34, P1336, DOI 10.1002/art.1780341022; Deswal A, 1996, RHEUM DIS CLIN N AM, V22, P841, DOI 10.1016/S0889-857X(05)70304-5; Diot E, 2002, OCCUP ENVIRON MED, V59, P545, DOI 10.1136/oem.59.8.545; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; DRENK F, 1988, J RHEUMATOL, V15, P468; Feghali-Bostwick C, 2003, ARTHRITIS RHEUM, V48, P1956, DOI 10.1002/art.11173; FERRARINI M, 1990, CLIN EXP IMMUNOL, V79, P346; FLEISCHMAJER R, 1977, ARTHRITIS RHEUM, V20, P975, DOI 10.1002/art.1780200410; FRITZLER MJ, 1980, AM J MED, V69, P520, DOI 10.1016/0002-9343(80)90462-3; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; Garabrant DH, 2003, AM J EPIDEMIOL, V157, P493, DOI 10.1093/aje/kwf223; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; GORDON MB, 1981, ANN INTERN MED, V95, P431, DOI 10.7326/0003-4819-95-4-431; Hata RI, 2000, BIOCHEM BIOPH RES CO, V272, P36, DOI 10.1006/bbrc.2000.2731; Herrick AL, 2000, CURR OPIN RHEUMATOL, V12, P527, DOI 10.1097/00002281-200011000-00009; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Ho KT, 2003, ARTHRITIS RES THER, V5, P80, DOI 10.1186/ar628; Ihn H, 2000, ARTHRITIS RHEUM, V43, P2240, DOI 10.1002/1529-0131(200010)43:10<2240::AID-ANR11>3.0.CO;2-2; Ihn H, 2001, ARTHRITIS RHEUM, V44, P474, DOI 10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.3.CO;2-R; Jimenez S A, 1995, Int Rev Immunol, V12, P159, DOI 10.3109/08830189509056710; Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397; JIMENEZ SA, 1983, SEMIN ARTHRITIS RHEU, V13, P104, DOI 10.1016/0049-0172(83)90029-X; Johnson Randall W, 2002, Curr Rheumatol Rep, V4, P99, DOI 10.1007/s11926-002-0004-2; KAHALEH MB, 1983, J LAB CLIN MED, V101, P553; KRALING BM, 1995, PATHOBIOLOGY, V63, P48, DOI 10.1159/000163933; LALLY EV, 1981, ANN INTERN MED, V95, P150, DOI 10.7326/0003-4819-95-2-150; LALLY EV, 1988, SEMIN ARTHRITIS RHEU, V18, P1, DOI 10.1016/0049-0172(88)90030-3; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; LEROY EC, 1988, J RHEUMATOL, V15, P202; Maloney S, 1999, J CLIN INVEST, V104, P41, DOI 10.1172/JCI6611; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mayes MD, 1999, ENVIRON HEALTH PERSP, V107, P743, DOI 10.2307/3434336; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; Neidhart M, 1999, ARTHRITIS RHEUM-US, V42, P389, DOI 10.1002/1529-0131(199902)42:2<389::AID-ANR23>3.0.CO;2-P; Nelson J L, 2001, Curr Rheumatol Rep, V3, P222, DOI 10.1007/s11926-001-0022-5; Ohtsuka T, 2001, ARCH DERMATOL RES, V293, P387, DOI 10.1007/s004030100245; Pandey JP, 1998, ARTHRITIS RHEUM, V41, P10, DOI 10.1002/1529-0131(199801)41:1<10::AID-ART2>3.0.CO;2-P; Pope JE, 2003, RHEUM DIS CLIN N AM, V29, P391, DOI 10.1016/S0889-857X(03)00017-6; Postlethwaite A E, 1995, Int Rev Immunol, V12, P247, DOI 10.3109/08830189509056716; Renaudineau Y, 1999, CLIN DIAGN LAB IMMUN, V6, P156, DOI 10.1128/CDLI.6.2.156-160.1999; Reveille John D, 2003, Curr Rheumatol Rep, V5, P160, DOI 10.1007/s11926-003-0045-1; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; RODNAN G P, 1979, Clinics in Rheumatic Diseases, V5, P49; Rose S, 1998, GASTROENTEROL CLIN N, V27, P563, DOI 10.1016/S0889-8553(05)70021-2; ROUMM AD, 1984, ARTHRITIS RHEUM, V27, P645, DOI 10.1002/art.1780270607; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; Sakkas LI, 2002, J IMMUNOL, V168, P3649, DOI 10.4049/jimmunol.168.7.3649; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Steen VD, 2003, RHEUM DIS CLIN N AM, V29, P315, DOI 10.1016/S0889-857X(03)00016-4; Tan FK, 2001, ARTHRITIS RHEUM-US, V44, P893, DOI 10.1002/1529-0131(200104)44:4<893::AID-ANR146>3.3.CO;2-V; Trojanowska M, 2002, FRONT BIOSCI-LANDMRK, V7, pD608, DOI 10.2741/trojan; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; White B, 1996, RHEUM DIS CLIN N AM, V22, P695, DOI 10.1016/S0889-857X(05)70296-9; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; Xu SW, 1998, J CARDIOVASC PHARM, V31, pS360, DOI 10.1097/00005344-199800001-00101	70	245	256	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					37	+		10.7326/0003-4819-140-1-200401060-00010	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00010			86	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706971				2022-12-28	WOS:000187855600006
J	Raad, I; Hanna, HA; Alakech, B; Chatzinikolaou, I; Johnson, MM; Tarrand, J				Raad, I; Hanna, HA; Alakech, B; Chatzinikolaou, I; Johnson, MM; Tarrand, J			Differential time to positivity: A useful method for diagnosing catheter-related bloodstream infections	ANNALS OF INTERNAL MEDICINE			English	Article							HUB-BLOOD; CULTURES; SEPSIS	Background: Catheter-related bloodstream infections are associated with recognized morbidity and mortality, especially in critically ill patients. Accurate diagnosis of such infections results in proper management of patients and in reducing unnecessary removal of catheters. Objective: To evaluate differential time to positivity as a method for diagnosing catheter-related bacteremias caused by both short-term and long-term use of central venous catheters. Design: Prospective study design. Setting: M.D. Anderson Cancer Center, Houston, Texas, a tertiary care cancer center. Patients: All patients, between September 1999 and November 2000, who had the same organism isolated from blood cultures drawn simultaneously through the central venous catheter and the peripheral vein. Measurements: Time necessary for the blood cultures from the central venous catheter and the peripheral vein to become positive, as well as other relevant patient information. Results: 191 bloodstream infections with positive simultaneous central venous catheter and peripheral vein blood cultures were included. One hundred eight patients had catheter-related bacteremias, and 83 had non-catheter-related bacteremias. Catheter-related bacteremias were more frequently caused by staphylococci and less likely to be associated with underlying hematologic malignant conditions, neutropenia, and longer duration of hospitalization. As a diagnostic tool for catheter-related bacteremia (using a composite definition reference standard according to the infectious Diseases Society of America guidelines), differential time to positivity of 120 minutes or more was associated with 81% sensitivity and 92% specificity for short-term catheters and 93% sensitivity and 75% specificity for long-term catheters. Conclusion: Differential time to positivity of 120 minutes or more is highly sensitive and specific for catheter-related bacteremia in patients who have short- and long-term catheters.	Univ Texas, MD Anderson Canc Ctr, Dept Informat Dis Infect Control & Employee Hlth, Unit 402, Houston, TX 77030 USA; Texas Tech Univ, Sch Med, Lubbock, TX 79409 USA	University of Texas System; UTMD Anderson Cancer Center; Texas Tech University System; Texas Tech University	Hanna, HA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Informat Dis Infect Control & Employee Hlth, Unit 402, 1515 Holcombe Blvd, Houston, TX 77030 USA.	hhanna@mdanderson.org	Chatzinikolaou, Yorgos/K-2593-2015					Blot F, 1998, J CLIN MICROBIOL, V36, P105, DOI 10.1128/JCM.36.1.105-109.1998; Blot F, 1999, LANCET, V354, P1071, DOI 10.1016/S0140-6736(98)11134-0; CAPDEVILA JA, 1992, EUR J CLIN MICROBIOL, V11, P403, DOI 10.1007/BF01961854; DORN GL, 1979, J CLIN MICROBIOL, V9, P391; FAN ST, 1989, EUR J CLIN MICROBIOL, V8, P142, DOI 10.1007/BF01963898; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; Kluger DM, 1999, 39 INT C ANT AG CHEM; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1998, HOSP INFECT, P689; Mermel LA, 2001, CLIN INFECT DIS, V32, P1249, DOI 10.1086/320001; Mermel LA, 1998, 38 INT C ANT AG CHEM, P500; Pearson ML, 1996, INFECT CONT HOSP EP, V17, P438; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; Rijnders BJA, 2001, CRIT CARE MED, V29, P1399, DOI 10.1097/00003246-200107000-00016; Seifert H, 2003, J CLIN MICROBIOL, V41, P118, DOI 10.1128/JCM.41.1.118-123.2003; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; Sherertz RJ, 1997, J CLIN MICROBIOL, V35, P641, DOI 10.1128/JCM.35.3.641-646.1997; WIDMER AF, 1992, ARCH INTERN MED, V152, P1299, DOI 10.1001/archinte.152.6.1299	18	222	234	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2004	140	1					18	25		10.7326/0003-4819-140-1-200401060-00007	http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760VH	14706968				2022-12-28	WOS:000187855600003
J	Guiral, J; Rodrigo, A; Tello, E				Guiral, J; Rodrigo, A; Tello, E			Subcutaneous echinococcosis of the knee	LANCET			English	Editorial Material									Segovia Gen Hosp, Dept Orthopaed, E-40002 Segovia, Spain		Guiral, J (corresponding author), Segovia Gen Hosp, Dept Orthopaed, Ctra Avila S-N, E-40002 Segovia, Spain.							CHEVALIER X, 1994, AM J ROENTGENOL, V163, P645, DOI 10.2214/ajr.163.3.8079861; KING CH, 1995, MANDELL DOUGLAS BENN, V2, P2550; SANCHEZ JAM, 1982, MED CLIN-BARCELONA, V78, P421	3	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					38	38		10.1016/S0140-6736(03)15168-9	http://dx.doi.org/10.1016/S0140-6736(03)15168-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723993				2022-12-28	WOS:000187711300013
J	Isshiki, M; Irifune, T; Hirose, K; Ono, S; Ohishi, Y; Watanuki, T; Nishibori, E; Takata, M; Sakata, M				Isshiki, M; Irifune, T; Hirose, K; Ono, S; Ohishi, Y; Watanuki, T; Nishibori, E; Takata, M; Sakata, M			Stability of magnesite and its high-pressure form in the lowermost mantle	NATURE			English	Article							EARTH; DIAMOND; SYSTEM; ORIGIN; CARBON; GPA	Carbonates are important constituents of marine sediments and play a fundamental role in the recycling of carbon into the Earth's deep interior via subduction of oceanic crust and sediments(1-3). Study of the stability of carbonates under high pressure and temperature is thus important for modelling the carbon budget in the entire Earth system. Such studies, however, have rarely been performed under appropriate lower-mantle conditions and no experimental data exist at pressures greater than 80 GPa (refs 3-6). Here we report an in situ X-ray diffraction study of the stability of magnesite (MgCO3), which is the major component of subducted carbonates, at pressure and temperature conditions approaching those of the core-mantle boundary. We found that magnesite transforms to an unknown form at pressures above similar to115 GPa and temperatures of 2,100-2,200 K (depths of similar to2,600 km) without any dissociation, suggesting that magnesite and its high-pressure form may be the major hosts for carbon throughout most parts of the Earth's lower mantle.	Ehime Univ, Geodynam Res Ctr, Matsuyama, Ehime 7908577, Japan; Japan Synchrotron Radiat Res Inst, Sayo, Hyogo 6795148, Japan; Tokyo Inst Technol, Dept Earth & Planetary Sci, Tokyo 1528551, Japan; Japan Marine Sci & Technol Ctr, IFREE, Kanagawa 2370061, Japan; Japan Atom Energy Res Inst, Sayo, Hyogo 6795148, Japan; Nagoya Univ, Dept Appl Phys, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Ehime University; Japan Synchrotron Radiation Research Institute; Tokyo Institute of Technology; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Japan Atomic Energy Agency; Nagoya University	Isshiki, M (corresponding author), Ehime Univ, Geodynam Res Ctr, Matsuyama, Ehime 7908577, Japan.	isshiki@sci.ehime-u.ac.jp; irifune@dpc.ehime-u.ac.jp	Nishibori, Eiji/M-1362-2018; Hirose, Kei/C-2165-2009; Takata, Masaki/M-1525-2014	Nishibori, Eiji/0000-0002-4192-6577; Hirose, Kei/0000-0003-4366-7721; Ono, Shigeaki/0000-0003-1880-7569; Nishibori, Maiko/0000-0002-6743-786X				ANDERS E, 1977, SCIENCE, V198, P453, DOI 10.1126/science.198.4316.453; BECKER H, 1992, NATURE, V358, P745, DOI 10.1038/358745a0; BIELLMANN C, 1993, EARTH PLANET SC LETT, V118, P31, DOI 10.1016/0012-821X(93)90157-5; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; CHOPIN C, 1984, CONTRIB MINERAL PETR, V86, P107, DOI 10.1007/BF00381838; Domanik KJ, 2000, LITHOS, V52, P51, DOI 10.1016/S0024-4937(99)00084-5; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; EGGLER DH, 1976, CARNEGIE I WASHINGTO, V75, P631; Fiquet G, 2002, AM MINERAL, V87, P1261; FUKAO Y, 1992, J GEOPHYS RES-SOL EA, V97, P4809, DOI 10.1029/91JB02749; GILLET P, 1993, AM MINERAL, V78, P1328; Hammouda T, 2003, EARTH PLANET SC LETT, V214, P357, DOI 10.1016/S0012-821X(03)00361-3; Harte B., 1994, MINERAL MAG A, V58A, P384, DOI DOI 10.1180/MINMAG.1994.58A.1.201; Jamieson J. C., 1982, HIGH PRESSURE RES GE, P27, DOI DOI 10.1007/978-94-009-7867-63; KATSURA T, 1991, P JPN ACAD B-PHYS, V67, P57, DOI 10.2183/pjab.67.57; Lin CC, 1997, J PHYS CHEM SOLIDS, V58, P977, DOI 10.1016/S0022-3697(96)00201-6; Lin CC, 1997, PHYS CHEM MINER, V24, P149, DOI 10.1007/s002690050028; Liu LG, 1999, CONTRIB MINERAL PETR, V134, P170, DOI 10.1007/s004100050476; MAO HK, 1978, J APPL PHYS, V49, P3276, DOI 10.1063/1.325277; RINGWOOD AE, 1988, NATURE, V331, P131, DOI 10.1038/331131a0; Scott HP, 2001, GEOPHYS RES LETT, V28, P1875, DOI 10.1029/2000GL012606; VANDERHILST R, 1991, NATURE, V353, P37, DOI 10.1038/353037a0; Wang A, 1996, EARTH PLANET SC LETT, V141, P293, DOI 10.1016/0012-821X(96)00053-2; Watanuki T, 2001, REV SCI INSTRUM, V72, P1289, DOI 10.1063/1.1343869; WYLLIE PJ, 1976, CONTRIB MINERAL PETR, V54, P79, DOI 10.1007/BF00372117; Zhao D, 2001, EARTH PLANET SC LETT, V192, P251, DOI 10.1016/S0012-821X(01)00465-4	26	217	231	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 1	2004	427	6969					60	63		10.1038/nature02181	http://dx.doi.org/10.1038/nature02181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702083				2022-12-28	WOS:000187710000032
J	Vassilev, LT; Vu, BT; Graves, B; Carvajal, D; Podlaski, F; Filipovic, Z; Kong, N; Kammlott, U; Lukacs, C; Klein, C; Fotouhi, N; Liu, EA				Vassilev, LT; Vu, BT; Graves, B; Carvajal, D; Podlaski, F; Filipovic, Z; Kong, N; Kammlott, U; Lukacs, C; Klein, C; Fotouhi, N; Liu, EA			In vivo activation of the p53 pathway by small-molecule antagonists of MDM2	SCIENCE			English	Article							TUMOR; AMPLIFICATION; PROTEIN; GROWTH	MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.	Hoffmann La Roche Inc, Dept Discovery Oncol, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Roche Res Ctr, Dept Chem, Nutley, NJ 07110 USA; Roche Diagnost GmbH, Pharma Res, D-82372 Penzberg, Germany	Roche Holding; Roche Holding; Roche Holding	Vassilev, LT (corresponding author), Hoffmann La Roche Inc, Dept Discovery Oncol, 340 Kingsland St, Nutley, NJ 07110 USA.	lyubomir.vassilev@roche.com	Klein, Christian/G-1336-2010	Klein, Christian/0000-0001-7594-7280				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1999, BRIT J CANCER, V80, P1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Tortora G, 2000, INT J CANCER, V88, P804, DOI 10.1002/1097-0215(20001201)88:5<804::AID-IJC19>3.0.CO;2-Z; VASSILEV LT, 2001, ANTI-CANCER DRUG DES, V13, P359; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang Ruiwen, 2003, Methods Mol Med, V85, P205	24	3580	3834	22	566	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	2004	303	5659					844	848		10.1126/science.1092472	http://dx.doi.org/10.1126/science.1092472			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770WF	14704432				2022-12-28	WOS:000188753800060
J	Vesely, SK; Perdue, JJ; Rizvi, MA; Terrell, DR; George, JN				Vesely, SK; Perdue, JJ; Rizvi, MA; Terrell, DR; George, JN			Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy - A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							HIGH-DOSE DEXAMETHASONE; CHRONIC AUTOIMMUNE THROMBOCYTOPENIA; MONOCLONAL-ANTIBODY RITUXIMAB; IMMUNE THROMBOCYTOPENIA; ACCESSORY SPLENECTOMY; HEMOLYTIC-ANEMIA; DANAZOL THERAPY; SLOW INFUSION; OPSONIZED ERYTHROCYTES; ALPHA-INTERFERON	Background: Treatment of chronic refractory idiopathic thrombocytopenic purpura is a dilemma because many patients have minimal symptoms, response to treatment is uncertain, and treatments may have serious adverse effects. Purpose: To determine the effectiveness of treatments for adult patients with idiopathic thrombocytopenic purpura who have not responded to splenectomy. Data Sources: English-language reports from 1966 through 2003 that were retrieved from MEDLINE and Reference Update and bibliographies of retrieved articles. Study Selection: Articles reporting 5 or more total patients were reviewed to select eligible patients. Patients were eligible for inclusion if they were more than 16 years of age, had idiopathic thrombocytopenic purpura for more than 3 months, had a previous splenectomy, and had a platelet count less than 50 x 10(9) cells/L. Data Extraction: Patients were assessed for platelet count response, bleeding complications, duration of follow-up, and death. Complete remission was defined as a normal platelet count with no treatment for more than 3 months and for the duration of follow-up. Data Synthesis: 90 articles with 656 patients treated with 22 therapies met selection criteria. Azathioprine, cyclophosphamide, and rituximab had the most reported complete responses, but they were reported in only 41 to 109 patients. Reported complete response rates ranged from 17% to 27%, but 36% to 42% of patients had no response with these 3 treatments. Most reports described only platelet count responses; bleeding outcomes were reported in only 63 patients (10%). Only 111 (17%) of the 656 eligible patients had pretreatment platelet counts of less than 10 x 10(9) cells/L. No treatment method was reported in more than 20 patients. Conclusions: Evidence for the effectiveness of any treatment for patients with idiopathic thrombocytopenic purpura and persistent severe thrombocytopenia after splenectomy is minimal. Potentially effective treatments must be evaluated by randomized, controlled trials to determine both benefit and safety.	Univ Oklahoma, Hlth Sci Ctr, Hematol Oncol Sect, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	George, JN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Hematol Oncol Sect, POB 26901, Oklahoma City, OK 73190 USA.	James-George@OUHSC.edu		Vesely, Sara/0000-0003-3448-0156; Terrell, Deirdra/0000-0003-0794-5851				AHN YS, 1984, ANN INTERN MED, V100, P192, DOI 10.7326/0003-4819-100-2-192; AHN YS, 1974, NEW ENGL J MED, V291, P376, DOI 10.1056/NEJM197408222910802; AHN YS, 1983, NEW ENGL J MED, V308, P1396, DOI 10.1056/NEJM198306093082306; AHN YS, 1987, ANN INTERN MED, V107, P177, DOI 10.7326/0003-4819-107-2-177; AHN YS, 1978, NEW ENGL J MED, V298, P1001; AMBRIZ P, 1985, RADIOLOGY, V155, P793, DOI 10.1148/radiology.155.3.4039827; AMBRIZ R, 1986, NOUV REV FR HEMATOL, V28, P275; AMBRIZ R, 1987, ARCH INTERN MED, V147, P105, DOI 10.1001/archinte.147.1.105; AMBRIZFERNANDEZ R, 1985, ARCH INVEST MED, V16, P295; ANDERSEN JC, 1994, NEW ENGL J MED, V330, P1560, DOI 10.1056/NEJM199406023302203; Arruda VR, 1996, ANN HEMATOL, V73, P175, DOI 10.1007/s002770050223; BHARUCHA C, 1985, CLIN LAB HAEMATOL, V7, P119, DOI 10.1111/j.1365-2257.1985.tb00015.x; Bonnotte B, 1999, AM J MED, V107, P645, DOI 10.1016/S0002-9343(99)00251-X; BOURONCL.BA, 1969, J AMER MED ASSOC, V207, P2049, DOI 10.1001/jama.207.11.2049; BROX AG, 1988, BRIT J HAEMATOL, V70, P341, DOI 10.1111/j.1365-2141.1988.tb02492.x; BUELLI M, 1985, ACTA HAEMATOL-BASEL, V74, P97, DOI 10.1159/000206176; BURTON IE, 1976, BRIT MED J, V2, P918, DOI 10.1136/bmj.2.6041.918; BUSKARD NA, 1981, IMMUNOHEMOTHERAPY GU, P395; Bussel JB, 2001, AM J HEMATOL, V66, P172, DOI 10.1002/1096-8652(200103)66:3<172::AID-AJH1041>3.3.CO;2-H; CAULIER MT, 1995, BRIT J HAEMATOL, V91, P477, DOI 10.1111/j.1365-2141.1995.tb05326.x; Cines DB, 2002, NEW ENGL J MED, V346, P995, DOI 10.1056/NEJMra010501; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; CORLEY CC, 1966, AM J MED, V41, P404, DOI 10.1016/0002-9343(66)90086-6; CORTELAZZO S, 1991, BLOOD, V77, P31; Crossley AR, 1996, AUTOIMMUNITY, V24, P81, DOI 10.3109/08916939609001950; Demiroglu H, 1997, NEW ENGL J MED, V337, P425; DOKAL IS, 1990, CLIN LAB HAEMATOL, V12, P387; DUBBELD P, 1994, EUR J HAEMATOL, V52, P233; Dutta T K, 2001, J Assoc Physicians India, V49, P421; Emilia G, 2002, BLOOD, V99, P1482, DOI 10.1182/blood.V99.4.1482; Emilia G, 1996, BRIT J HAEMATOL, V93, P341, DOI 10.1046/j.1365-2141.1996.4871026.x; FACON T, 1994, BRIT J HAEMATOL, V86, P678, DOI 10.1111/j.1365-2141.1994.tb04810.x; FACON T, 1992, AM J HEMATOL, V41, P184, DOI 10.1002/ajh.2830410308; FENAUX P, 1990, NOUV REV FR HEMATOL, V32, P143; FIGUEROA M, 1993, BLOOD, V81, P3484; FIGUEROA M, 1993, NEW ENGL J MED, V328, P1226, DOI 10.1056/NEJM199304293281703; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; George JN, 1998, ANN INTERN MED, V129, P886, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00009; Giagounidis AAN, 2002, EUR J HAEMATOL, V69, P95, DOI 10.1034/j.1600-0609.2002.02686.x; GIBSON J, 1986, AUST NZ J MED, V16, P695, DOI 10.1111/j.1445-5994.1986.tb00015.x; GIERS G, 1990, BLUT, V61, P21, DOI 10.1007/BF01739429; Godeau B, 1996, AM J HEMATOL, V51, P334, DOI 10.1002/1096-8652(199604)51:4<334::AID-AJH2830510409>3.0.CO;2-V; GODEAU B, 1990, BRIT J HAEMATOL, V75, P289, DOI 10.1111/j.1365-2141.1990.tb02668.x; GODEAU B, 1993, AM J HEMATOL, V44, P70, DOI 10.1002/ajh.2830440117; GOEBEL KM, 1973, SCAND J HAEMATOL, V10, P28; Grossi A, 2000, BLOOD, V96, p253A; HERNANDEZ F, 1995, BRIT J HAEMATOL, V90, P473, DOI 10.1111/j.1365-2141.1995.tb05179.x; Hou M, 2003, EUR J HAEMATOL, V70, P353, DOI 10.1034/j.1600-0609.2003.00076.x; HUDSON JG, 1992, BRIT J HAEMATOL, V82, P630, DOI 10.1111/j.1365-2141.1992.tb06483.x; Huhn RD, 2003, BLOOD, V101, P71, DOI 10.1182/blood-2001-12-0171; ISHII H, 1992, INTERNAL MED, V31, P1343, DOI 10.2169/internalmedicine.31.1343; Jim R T, 1986, Hawaii Med J, V45, P221; JIM RT, 1986, HAWAII MED J, V45, P225; JUBELIRER SJ, 1993, AM J HEMATOL, V43, P44, DOI 10.1002/ajh.2830430110; Kappers-Klunne MC, 2001, BRIT J HAEMATOL, V114, P121, DOI 10.1046/j.1365-2141.2001.02893.x; KELTON JG, 1981, BLOOD, V57, P431; KONDO H, 1992, INT J HEMATOL, V55, P293; Kueh Y K, 1982, Ann Acad Med Singap, V11, P290; Kumar S, 2002, ANN HEMATOL, V81, P312, DOI 10.1007/s00277-002-0461-8; LIM SH, 1993, BRIT J HAEMATOL, V84, P542, DOI 10.1111/j.1365-2141.1993.tb03117.x; LINARES M, 1994, AM J HEMATOL, V46, P371, DOI 10.1002/ajh.2830460423; MANOHARAN A, 1986, AM J HEMATOL, V21, P135, DOI 10.1002/ajh.2830210203; MANOHARAN A, 1987, AUST NZ J MED, V17, P613, DOI 10.1111/j.1445-5994.1987.tb01276.x; MARDER VJ, 1981, TRANSFUSION, V21, P291, DOI 10.1046/j.1537-2995.1981.21381201800.x; MARMONT AM, 1971, ACTA HAEMATOL-BASEL, V46, P74, DOI 10.1159/000208563; MCVERRY BA, 1985, BRIT J HAEMATOL, V61, P145, DOI 10.1111/j.1365-2141.1985.tb04070.x; MUROI K, 1989, SEMIN HEMATOL, V26, P10; NOVITZKY N, 1992, S AFR MED J, V81, P44; Perotta A, 1999, BLOOD, V94, p14A; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; PIZZUTO J, 1984, BLOOD, V64, P1179; Portielje JEA, 2001, BLOOD, V97, P2549, DOI 10.1182/blood.V97.9.2549; Proctor SJ, 1997, LANCET, V350, P368, DOI 10.1016/S0140-6736(05)63427-7; PROCTOR SJ, 1991, EUR J CANCER, V27, pS63, DOI 10.1016/0277-5379(91)90577-Z; Provan D, 2002, BRIT J HAEMATOL, V118, P933, DOI 10.1046/j.1365-2141.2002.03669.x; Quadri M I, 1979, J Assoc Physicians India, V27, P99; QUIQUANDON I, 1990, BRIT J HAEMATOL, V74, P223, DOI 10.1111/j.1365-2141.1990.tb02569.x; Radaelli F, 1999, BRIT J HAEMATOL, V104, P641, DOI 10.1046/j.1365-2141.1999.01305.x; REID MM, 1995, ARCH DIS CHILD, V72, P125, DOI 10.1136/adc.72.2.125; REINER A, 1995, BLOOD, V85, P351; RUIZARGUELLES GJ, 1993, AM J HEMATOL, V43, P72, DOI 10.1002/ajh.2830430119; Saleh MN, 2000, SEMIN ONCOL, V27, P99; SCHREIBER AD, 1987, NEW ENGL J MED, V316, P503, DOI 10.1056/NEJM198702263160903; SIMON M, 1987, EUR J HAEMATOL, V39, P193; Stasi R, 2002, BLOOD, V99, P3872, DOI 10.1182/blood-2002-02-0392; Stasi R, 2001, BLOOD, V98, P952, DOI 10.1182/blood.V98.4.952; Stasi R, 2000, BLOOD CELL MOL DIS, V26, P582, DOI 10.1006/bcmd.2000.0336; STROTHER SV, 1984, ARCH INTERN MED, V144, P2198, DOI 10.1001/archinte.144.11.2198; SUSSMAN LN, 1967, J AMER MED ASSOC, V202, P259, DOI 10.1001/jama.202.4.259; Szold A, 2000, SURG ENDOSC, V14, P761, DOI 10.1007/s004640000209; TOYAMA K, 1990, BRIT J HAEMATOL, V75, P623, DOI 10.1111/j.1365-2141.1990.tb07814.x; VERHEYDEN CN, 1978, MAYO CLIN PROC, V53, P442; VERHOEF GEG, 1990, BRIT J HAEMATOL, V74, P234; VERLIN M, 1976, AM J HEMATOL, V1, P97, DOI 10.1002/ajh.2830010111; VIANELLI N, 1992, HAEMATOLOGICA, V77, P92; Vianelli N, 1998, HAEMATOLOGICA, V83, P761; Warner M, 1997, AM J HEMATOL, V54, P267, DOI 10.1002/(SICI)1096-8652(199704)54:4<267::AID-AJH1>3.0.CO;2-T; WINN, 1990, BRIT J HAEMATOL, V75, P626; Zaja F, 2002, HAEMATOLOGICA, V87, P189; 2003, BR J HAEMOTOL, V120, P574	100	95	102	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					112	120		10.7326/0003-4819-140-3-200402030-00012	http://dx.doi.org/10.7326/0003-4819-140-3-200402030-00012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734334				2022-12-28	WOS:000188211700006
J	Grant, VJ; Robinson, E; Muir, P				Grant, VJ; Robinson, E; Muir, P			Sex ratios in healthcare occupations: population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ Auckland, Fac Med & Hlth Sci, Dept Hlth Psychol, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Dept Community Hlth, Auckland 1, New Zealand	University of Auckland; University of Auckland	Grant, VJ (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Hlth Psychol, Private Bag 92019, Auckland 1, New Zealand.	vj.grant@auckland.ac.nz						Beauvoir Simone de, 1956, 2 SEX; Wootton BH, 1997, MON LABOR REV, V120, P15; 2001, NZ STAT	3	13	14	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					141	142		10.1136/bmj.328.7432.141	http://dx.doi.org/10.1136/bmj.328.7432.141			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726342	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000188249900019
J	Smith, LC; MacDonald, GM; Velichko, AA; Beilman, DW; Borisova, OK; Frey, KE; Kremenetski, KV; Sheng, Y				Smith, LC; MacDonald, GM; Velichko, AA; Beilman, DW; Borisova, OK; Frey, KE; Kremenetski, KV; Sheng, Y			Siberian peatlands a net carbon sink and global methane source since the early Holocene	SCIENCE			English	Article							ATMOSPHERIC CH4 GRADIENT; CLIMATE-CHANGE; ARCTIC TUNDRA; SOIL CARBON; GREENLAND; ACCUMULATION; ANTARCTICA; EMISSION; DYNAMICS; POOLS	Interpolar methane gradient (IPG) data from ice cores suggest the "switching on" of a major Northern Hemisphere methane source in the early Holocene. Extensive data from Russia's West Siberian Lowland show (i) explosive, widespread peatland establishment between 11.5 and 9 thousand years ago, predating comparable development in North America and synchronous with increased atmospheric methane concentrations and IPGs, (ii) larger carbon stocks than previously thought (70.2 Petagrams, up to similar to 26% of all terrestrial carbon accumulated since the Last Glacial Maximum), and (iii) little evidence for catastrophic oxidation, suggesting the region represents a long-term carbon dioxide sink and global methane source since the early Holocene.	Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA; Russian Acad Sci, Moscow 109017, Russia	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Russian Academy of Sciences	Smith, LC (corresponding author), Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA.	lsmith@geog.ucla.edu; macdonal@geog.ucla.edu	Borisova, Olga/AAF-5503-2021; Smith, Laurence C./E-7785-2012	Borisova, Olga/0000-0003-1728-7610; Smith, Laurence C./0000-0001-6866-5904				BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; BOTCH MS, 1995, GLOBAL BIOGEOCHEM CY, V9, P37, DOI 10.1029/94GB03156; Brook EJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P559, DOI 10.1029/1999GB001182; BUBIER JL, 1995, ECOLOGY, V76, P677, DOI 10.2307/1939336; CAMPBELL ID, 2001, QUATERNARY RES, V54, P155; CHAPPELLAZ J, 1990, NATURE, V345, P127, DOI 10.1038/345127a0; Chappellaz J, 1997, J GEOPHYS RES-ATMOS, V102, P15987, DOI 10.1029/97JD01017; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; Dallenbach A, 2000, GEOPHYS RES LETT, V27, P1005, DOI 10.1029/1999GL010873; Forman SL, 1999, GEOLOGY, V27, P807, DOI 10.1130/0091-7613(1999)027<0807:LQSOWY>2.3.CO;2; Freeman C, 2001, NATURE, V412, P785, DOI 10.1038/35090628; Gajewski K, 2001, GLOBAL BIOGEOCHEM CY, V15, P297, DOI 10.1029/2000GB001286; GORHAM E, 1991, ECOL APPL, V1, P182, DOI 10.2307/1941811; HARDEN JW, 1992, SCIENCE, V258, P1921, DOI 10.1126/science.258.5090.1921; Heyer J, 2002, TELLUS B, V54, P231, DOI 10.1034/j.1600-0889.2002.01280.x; Kennett JP, 2003, METHANE HYDRATES QUA; Kremenetski KV, 2003, QUATERNARY SCI REV, V22, P703, DOI 10.1016/S0277-3791(02)00196-8; MALTERER TJ, 1992, SOIL SCI SOC AM J, V56, P1200, DOI 10.2136/sssaj1992.03615995005600040033x; NEUSTADT MI, 1971, SERIA GEOGR, V1, P21; Oberlander EA, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000953; OECHEL WC, 1994, TRENDS ECOL EVOL, V9, P324, DOI 10.1016/0169-5347(94)90152-X; Peteet D, 1998, BOREAS, V27, P115, DOI 10.1111/j.1502-3885.1998.tb00872.x; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; SMITH LC, 2000, EOS, V497, P497; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Turunen J, 2001, GLOBAL BIOGEOCHEM CY, V15, P285, DOI 10.1029/2000GB001312; VOMPERSKY SE, 1994, POCHVOVEDENIE, V12, P7; Whiting GJ, 2001, TELLUS B, V53, P521, DOI 10.1034/j.1600-0889.2001.530501.x; Woodwell GM, 1998, CLIMATIC CHANGE, V40, P495, DOI 10.1023/A:1005345429236	30	310	346	9	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	2004	303	5656					353	356		10.1126/science.1090553	http://dx.doi.org/10.1126/science.1090553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763QK	14726587				2022-12-28	WOS:000188111800038
J	Schersten, A; Elliott, T; Hawkesworth, C; Norman, M				Schersten, A; Elliott, T; Hawkesworth, C; Norman, M			Tungsten isotope evidence that mantle plumes contain no contribution from the Earth's core	NATURE			English	Article							HAWAIIAN PICRITES; SYSTEMATICS; GEOCHEMISTRY; COMPONENTS; ACCRETION; PB	Osmium isotope ratios provide important constraints on the sources of ocean-island basalts, but two very different models have been put forward to explain such data. One model interprets Os-187-enrichments in terms of a component of recycled oceanic crust within the source material(1,2). The other model infers that interaction of the mantle with the Earth's outer core produces the isotope anomalies and, as a result of coupled Os-186-Os-187 anomalies, put time constraints on inner-core formation(3-5). Like osmium, tungsten is a siderophile ('iron-loving') element that preferentially partitioned into the Earth's core during core formation but is also 'incompatible' during mantle melting (it preferentially enters the melt phase), which makes it further depleted in the mantle. Tungsten should therefore be a sensitive tracer of core contributions in the source of mantle melts. Here we present high-precision tungsten isotope data from the same set of Hawaiian rocks used to establish the previously interpreted Os-186-Os-187 anomalies and on selected South African rocks, which have also been proposed to contain a core contribution(6). None of the samples that we have analysed have a negative tungsten isotope value, as predicted from the core-contribution model. This rules out a simple core-mantle mixing scenario and suggests that the radiogenic osmium in ocean-island basalts can better be explained by the source of such basalts containing a component of recycled crust.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia	University of Bristol; Australian National University	Schersten, A (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg, Bristol BS8 1RJ, Avon, England.	anders.schersten@bristol.ac.uk		Schersten, Anders/0000-0002-2105-6172; Elliott, Tim/0000-0002-0984-0191; Norman, Marc/0000-0002-1357-5415				Bennett VC, 1996, NATURE, V381, P221, DOI 10.1038/381221a0; Bennett VC, 2000, EARTH PLANET SC LETT, V183, P513, DOI 10.1016/S0012-821X(00)00295-8; Brandon AD, 1999, EARTH PLANET SC LETT, V174, P25, DOI 10.1016/S0012-821X(99)00251-4; Brandon AD, 2003, EARTH PLANET SC LETT, V206, P411, DOI 10.1016/S0012-821X(02)01101-9; Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; Burton KW, 1999, EARTH PLANET SC LETT, V171, P185, DOI 10.1016/S0012-821X(99)00139-9; Collerson KD, 2002, GEOCHIM COSMOCHIM AC, V66, pA148; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; Helffrich GR, 2001, NATURE, V412, P501, DOI 10.1038/35087500; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; Horan MF, 1998, GEOCHIM COSMOCHIM AC, V62, P545, DOI 10.1016/S0016-7037(97)00368-2; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; Liu MH, 2001, GEOCHIM COSMOCHIM AC, V65, P671, DOI 10.1016/S0016-7037(00)00558-5; McDonald-McGinn DM, 2001, GENET MED, V3, P23, DOI 10.1097/00125817-200101000-00006; MCKENZIE D, 1983, NATURE, V301, P229, DOI 10.1038/301229a0; Newsom HE, 1996, GEOCHIM COSMOCHIM AC, V60, P1155, DOI 10.1016/0016-7037(96)00029-4; Norman MD, 1999, EARTH PLANET SC LETT, V168, P27, DOI 10.1016/S0012-821X(99)00043-6; Peucker-Ehrenbrink B, 2000, TERRA NOVA, V12, P205, DOI 10.1046/j.1365-3121.2000.00295.x; REISBERG L, 1993, EARTH PLANET SC LETT, V120, P149, DOI 10.1016/0012-821X(93)90236-3; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Schaefer BF, 2002, NATURE, V420, P304, DOI 10.1038/nature01172; Schoenberg R, 2002, GEOCHIM COSMOCHIM AC, V66, P3151, DOI 10.1016/S0016-7037(02)00911-0; Schulze DJ, 2003, NATURE, V423, P68, DOI 10.1038/nature01615; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; SMITH CB, 1983, NATURE, V304, P51, DOI 10.1038/304051a0; Walker RJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4799, DOI 10.1016/S0016-7037(97)00270-6; WALKER RJ, 1995, SCIENCE, V269, P819, DOI 10.1126/science.269.5225.819; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995; Yoder C., 1995, GLOBAL EARTH PHYS HD, V1, P1	30	102	103	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					234	237		10.1038/nature02221	http://dx.doi.org/10.1038/nature02221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724635				2022-12-28	WOS:000188068100040
J	Robinson, NP; Dionne, I; Lundgren, M; Marsh, VL; Bernander, R; Bell, SD				Robinson, NP; Dionne, I; Lundgren, M; Marsh, VL; Bernander, R; Bell, SD			Identification of two origins of replication in the single chromosome of the Archaeon Sulfolobus solfataricus	CELL			English	Article							DNA-REPLICATION; RECOGNITION COMPLEX; HYPERTHERMOPHILIC ARCHAEON; PROTEIN; BINDING; INITIATION; XENOPUS; CYCLE; CHROMATIN; HELICASE	Eukaryotic chromosomes possess multiple origins of replication, whereas bacterial chromosomes are replicated from a single origin. The archaeon Pyrococcus abyssi also appears to have a single origin, suggesting a common rule for prokaryotes. However, in the current work, we describe the identification of two active origins of replication in the single chromosome of the hyperthermophilic archaeon Sulfolobus solfataricus. Further, we identify conserved sequence motifs within the origins that are recognized by a family of three Sulfolobus proteins that are homologous to the eukaryotic initiator proteins Orc1 and Cdc6. We demonstrate that the two origins are recognized by distinct subsets of these Orc1/Cdc6 homologs. These data, in conjunction with an analysis of the levels of the three Orc1/Cdc6 proteins in different growth phases and cell cycle stages, lead us to propose a model for the roles for these proteins in modulating origin activity.	Hutchison MRC Res Ctr, Med Res Council Canc Cell Unit, Cambridge CB2 2XZ, England; Uppsala Univ, Evolutionary Biol Ctr, Dept Mol Evolut, SE-75236 Uppsala, Sweden	Uppsala University	Bell, SD (corresponding author), Hutchison MRC Res Ctr, Med Res Council Canc Cell Unit, Hills Rd, Cambridge CB2 2XZ, England.	sb419@cam.ac.uk		Bell, Stephen/0000-0002-8474-6592; Robinson, Nick/0000-0002-6094-1924				Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; Bell SD, 2000, J BIOL CHEM, V275, P31624, DOI 10.1074/jbc.M005422200; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Benard M, 2001, MOL CELL, V7, P971, DOI 10.1016/S1097-2765(01)00237-4; Bernander R, 2000, TRENDS MICROBIOL, V8, P278, DOI 10.1016/S0966-842X(00)01760-1; Bernander R, 1997, J BACTERIOL, V179, P4963, DOI 10.1128/jb.179.16.4963-4969.1997; Berquist BR, 2003, J BACTERIOL, V185, P5959, DOI 10.1128/JB.185.20.5959-5966.2003; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Grabowski B, 2001, J BACTERIOL, V183, P5459, DOI 10.1128/JB.183.18.5459-5464.2001; Grainge I, 2003, NUCLEIC ACIDS RES, V31, P4888, DOI 10.1093/nar/gkg662; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; Jansson BPM, 2000, J BACTERIOL, V182, P1158, DOI 10.1128/JB.182.4.1158-1161.2000; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Lee JK, 2001, P NATL ACAD SCI USA, V98, P13589, DOI 10.1073/pnas.251530398; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Maisnier-Patin S, 2002, MOL MICROBIOL, V45, P1443, DOI 10.1046/j.1365-2958.2002.03111.x; Matsunaga F, 2003, EMBO REP, V4, P154, DOI 10.1038/sj.embor.embor732; Matsunaga F, 2001, P NATL ACAD SCI USA, V98, P11152, DOI 10.1073/pnas.191387498; Messer W, 2001, BIOCHIMIE, V83, P5, DOI 10.1016/S0300-9084(00)01216-5; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160; Zhang R, 2003, BIOCHEM BIOPH RES CO, V302, P728, DOI 10.1016/S0006-291X(03)00252-3	43	210	220	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	2004	116	1					25	38		10.1016/S0092-8674(03)01034-1	http://dx.doi.org/10.1016/S0092-8674(03)01034-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	762FL	14718164	Bronze			2022-12-28	WOS:000187960800006
J	Raya, A; Kawakami, Y; Rodriguez-Esteban, C; Ibanes, M; Rasskin-Gutman, D; Rodriguez-Leon, J; Buscher, D; Feijo, J; Belmonte, JCI				Raya, A; Kawakami, Y; Rodriguez-Esteban, C; Ibanes, M; Rasskin-Gutman, D; Rodriguez-Leon, J; Buscher, D; Feijo, J; Belmonte, JCI			Notch activity acts as a sensor for extracellular calcium during vertebrate left-right determination	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; LUNATIC-FRINGE; SEGMENTATION CLOCK; PATTERN-FORMATION; NODAL EXPRESSION; CHICK-EMBRYO; GLYCOSYLTRANSFERASE; ESTABLISHMENT; INHIBITION; MECHANISMS	During vertebrate embryo development, the breaking of the initial bilateral symmetry is translated into asymmetric gene expression around the node and/or in the lateral plate mesoderm. The earliest conserved feature of this asymmetric gene expression cascade is the left-sided expression of Nodal, which depends on the activity of the Notch signalling pathway. Here we present a mathematical model describing the dynamics of the Notch signalling pathway during chick embryo gastrulation, which reveals a complex and highly robust genetic network that locally activates Notch on the left side of Hensen's node. We identify the source of the asymmetric activation of Notch as a transient accumulation of extracellular calcium, which in turn depends on left right differences in H+/K+-ATPase activity. Our results uncover a mechanism by which the Notch signalling pathway translates asymmetry in epigenetic factors into asymmetric gene expression around the node.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Inst Gulbenkian Ciencias, P-2780901 Oeiras, Portugal; Univ Lisbon, Fac Ciencias, Ctr Biotecnol Vegetal, P-1749016 Lisbon, Portugal	Salk Institute; Instituto Gulbenkian de Ciencia; Universidade de Lisboa	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu	Ibanes, Marta/A-7657-2008; Leon, Joaquin Maria Rodriguez/S-9814-2019; Leon, Joaquin Maria Rodriguez/C-6957-2013; Raya, Angel/E-6205-2010; Feijo, Jose A./ADM-0262-2022	Ibanes, Marta/0000-0002-7913-7936; Leon, Joaquin Maria Rodriguez/0000-0002-9582-5480; Leon, Joaquin Maria Rodriguez/0000-0002-9582-5480; Raya, Angel/0000-0003-2189-9775; Feijo, Jose A./0000-0002-1100-5478; Kawakami, Yasuhiko/0000-0002-0043-9705				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bisgrove BW, 2003, ANNU REV GENOM HUM G, V4, P1, DOI 10.1146/annurev.genom.4.070802.110428; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; Brennan J, 2002, GENE DEV, V16, P2339, DOI 10.1101/gad.1016202; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Burdine RD, 2000, GENE DEV, V14, P763; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Collier JR, 1996, J THEOR BIOL, V183, P429, DOI 10.1006/jtbi.1996.0233; Dale JK, 2003, NATURE, V421, P275, DOI 10.1038/nature01244; Esteban CR, 1999, NATURE, V401, P243, DOI 10.1038/45738; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Gibson G, 2002, CURR BIOL, V12, pR347, DOI 10.1016/S0960-9822(02)00855-2; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Itasaki N, 1999, NAT CELL BIOL, V1, pE203, DOI 10.1038/70231; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Jaffe LF, 1999, BIOESSAYS, V21, P657, DOI 10.1002/(SICI)1521-1878(199908)21:8<657::AID-BIES5>3.3.CO;2-B; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jouve C, 2002, DEVELOPMENT, V129, P1107; Krebs LT, 2003, GENE DEV, V17, P1207, DOI 10.1101/gad.1084703; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Levin M, 2002, CELL, V111, P77, DOI 10.1016/S0092-8674(02)00939-X; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Mercola M, 2003, J CELL SCI, V116, P3251, DOI 10.1242/jcs.00668; Mercola M, 2001, ANNU REV CELL DEV BI, V17, P779, DOI 10.1146/annurev.cellbio.17.1.779; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Murray J. D., 1993, MATH BIOL, DOI [10.1007/b98869, DOI 10.1007/B98869]; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Owen MR, 2000, DEV BIOL, V217, P54, DOI 10.1006/dbio.1999.9536; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; RANDHAWA MA, 1997, JRMC, V1, P6; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Raya A, 2003, GENE DEV, V17, P1213, DOI 10.1101/gad.1084403; Robinson KR, 2003, BIOESSAYS, V25, P759, DOI 10.1002/bies.10307; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Saijoh Y, 2003, DEV BIOL, V256, P160, DOI 10.1016/S0012-1606(02)00121-5; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; STERN CD, 1995, DEV BIOL, V172, P192, DOI 10.1006/dbio.1995.0015; Stern CD, 2002, CURR BIOL, V12, pR802, DOI 10.1016/S0960-9822(02)01312-X; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Wagner MK, 2000, CURR BIOL, V10, pR149, DOI 10.1016/S0960-9822(00)00328-6; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	50	182	189	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					121	128		10.1038/nature02190	http://dx.doi.org/10.1038/nature02190			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712268				2022-12-28	WOS:000187863900027
J	Steinbrook, R				Steinbrook, R			Peer review and federal regulations	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Jasanoff Sheila, 1990, 5 BRANCH SCI ADVISER; Melbye M, 1997, NEW ENGL J MED, V336, P81, DOI 10.1056/NEJM199701093360201; *NAT AC, 2003, WORKSH PEER REV STAN; *OFF MAN BUDG, 2003, PROP B PEER REV INF	5	12	12	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					103	104		10.1056/NEJMp038230	http://dx.doi.org/10.1056/NEJMp038230			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711908				2022-12-28	WOS:000187858500003
J	Dasgupta, N				Dasgupta, N			Unclaimed bodies at the anatomy table	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Johns Hopkins Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Dasgupta, N (corresponding author), Johns Hopkins Sch Med, Baltimore, MD 21205 USA.							*AM MED ASS, AN GIFTS REP BOARD T; BUCHANAN K, 1997, PITTSBURGH POST 0210, pA6; Coelho DH, 1997, ACAD MED, V72, P741, DOI 10.1097/00001888-199709000-00006; *DEP SECR PUBL HLT, M00F0101 DEP SECR PU; GUTTMATCHER A, 1955, BOOTLEGGING BODIES H; JEFFREY N, 1998, WALL ST J       0625, pB1; LILES KL, 1998, AM ASS CLIN AN C JUN; RENSTROM J, 1997, MICHIGAN DAILY  0313, P9; ROACH M, 2003, STIFF CURIOUS LIVES, P50; SHULTZ S, 1992, BODY SNATCHING ROBBI, P78; CADAVER SHORTAGE JEO	11	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					122	122		10.1001/jama.291.1.122	http://dx.doi.org/10.1001/jama.291.1.122			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709589				2022-12-28	WOS:000187836000031
J	Hien, TT; Dolecek, C; Mai, PP; Dung, NT; Truong, NT; Thai, LH; An, DTH; Thanh, TT; Stepniewska, K; White, NJ; Farrar, J				Hien, TT; Dolecek, C; Mai, PP; Dung, NT; Truong, NT; Thai, LH; An, DTH; Thanh, TT; Stepniewska, K; White, NJ; Farrar, J			Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial	LANCET			English	Article							THAILAND; EFFICACY; BORDER	Background Southeast Asia has the most resistant malaria parasites in the world, which severely limits treatment options. There is general acceptance that to combat resistance, combinations of antimalarial drugs that include an artemisinin derivative should be used, and, if possible, these should be formulated in a single tablet. Methods We did a pilot randomised study in a tertiary referral hospital in Vietnam to compare the efficacy of 3-day regimens of dihydroartemisinin-trimethoprim-piperaquine (DHA-TP total dose 4.8/13.6/48 mg/kg, respectively) with the standard antimalarial regimen in Vietnam, artesunate-mefloquine (A3M total dose 12/25 mg/kg, respectively) in non-immune patients with uncomplicated Plasmodium falciparum malaria. 114 patients were randomised, 76 to DHA-TP and 38 to A3M. The subsequent open randomised trial at a Provincial Health Station compared DHA-TP, dihydroartemisinin-piperaquine, and A3M in 400 patients. In both studies all patients received directly observed therapy and were followed up for 56 days. The primary endpoint was reappearance of P falciparum malaria within 56 days of treatment. Analysis was by intention to treat. Findings The 56-day cure rate in the pilot study, adjusted for reinfections identified by PCR genotyping, was 97.4% (74/76) in the DHA-TP group and 100% (38/38) in the A3M group. In the second study, cure rates were similar in the three groups; DHA-TP 97.4% (153/157), dihydroartemisinin-piperaquine 98.7% (164/166), and A3M 98.7% (76/77). The DHA-TP and dihydroartemisinin-piperaquine regimens were well tolerated; fewer than 3% of patients had side-effects that might have been related to treatment, compared with 16% of A3M patients (p<0.001). No patients were lost to follow-up. Intrepretation Dihydroartemisinin-piperaquine is an inexpensive, safe, highly efficacious fixed-dose antimalarial combination treatment that could make an important contribution to the control of multidrug-resistant falciparum malaria.	Univ Oxford, Hosp Trop Dis, Clin Res Unit, Ho Chi Minh City, Vietnam; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Dis, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Farrar, J (corresponding author), Univ Oxford, Hosp Trop Dis, Clin Res Unit, 190 Ben Ham Tu Quan 5, Ho Chi Minh City, Vietnam.	jeremyjf@hcm.vnn.vn	White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012; Farrar, Jeremy J./HGA-7610-2022	White, Nick/0000-0002-1897-1978; DONG, An/0000-0003-3844-0549; Farrar, Jeremy/0000-0002-2700-623X; Stepniewska, Kasia/0000-0002-1713-6209; Tran Tan, Thanh/0000-0002-8096-7750				Brockman A, 1999, AM J TROP MED HYG, V60, P14, DOI 10.4269/ajtmh.1999.60.14; Brockman A, 2000, T ROY SOC TROP MED H, V94, P537, DOI 10.1016/S0035-9203(00)90080-4; CHANGXIONG L, 1989, CHIN J PARASITOL PAR, V7, P163; Denis MB, 2002, CLIN INFECT DIS, V35, P1469, DOI 10.1086/344647; GUO XB, 1989, CHINESE J INTEGR TRA, V9, P475; HIEN TT, 1994, T ROY SOC TROP MED H, V88, P7, DOI 10.1016/0035-9203(94)90461-8; Huong NM, 2001, T ROY SOC TROP MED H, V95, P325, DOI 10.1016/S0035-9203(01)90254-8; LIN C, 1982, CHIN MED J, V95, P281; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Nosten F, 1998, Med Trop (Mars), V58, P45; Nosten F, 2002, DRUGS, V62, P1315, DOI 10.2165/00003495-200262090-00003; Raynes K, 1999, INT J PARASITOL, V29, P367, DOI 10.1016/S0020-7519(98)00217-3; van Vugt M, 1999, AM J TROP MED HYG, V60, P936, DOI 10.4269/ajtmh.1999.60.936; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; *WHO, 2001, WHOCDSRBM200135	15	131	135	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					18	22		10.1016/S0140-6736(03)15163-X	http://dx.doi.org/10.1016/S0140-6736(03)15163-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723988				2022-12-28	WOS:000187711300009
J	Senanayake, P; Hamm, S				Senanayake, P; Hamm, S			Sexual and reproductive health funding: donors and restrictions	LANCET			English	Article									Regents Coll, IPPF, London, England		Senanayake, P (corresponding author), 4-8 Hyde Pk Residencies,79 Hyde Pk Corner, Colombo 2, Sri Lanka.							*UN, 1995, PROGR ACT INT C POP; *UN ECOSOC, 2003, ECN920034 UN ECOSOC; United Nations Population Fund (UNFPA), 2002, REPR HLTH ESS SEC SU; United Nations Population Fund (UNFPA), 2002, FIN RES FLOWS POP AC	4	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					70	70		10.1016/S0140-6736(03)15176-8	http://dx.doi.org/10.1016/S0140-6736(03)15176-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14724001				2022-12-28	WOS:000187711300030
J	Dwyer, JH; Allayee, H; Dwyer, KM; Fan, J; Wu, HY; Mar, R; Lusis, AJ; Mehrabian, M				Dwyer, JH; Allayee, H; Dwyer, KM; Fan, J; Wu, HY; Mar, R; Lusis, AJ; Mehrabian, M			Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYUNSATURATED FATTY-ACIDS; INTIMA-MEDIA THICKNESS; MYOCARDIAL-INFARCTION; LEUKOTRIENE SYNTHESIS; DOCOSAHEXAENOIC ACID; EXPRESSION; GENE; EICOSANOIDS; RESPONSES; LIPOXINS	BACKGROUND: Leukotrienes are inflammatory mediators generated from arachidonic acid (polyunsaturated n-6 fatty acid) by the enzyme 5-lipoxygenase. Since atherosclerosis involves arterial inflammation, we hypothesized that a polymorphism in the 5-lipoxygenase gene promoter could relate to atherosclerosis in humans and that this effect could interact with the dietary intake of competing 5-lipoxygenase substrates. METHODS: We determined 5-lipoxygenase genotypes, carotid-artery intima-media thickness, and markers of inflammation in a randomly sampled cohort of 470 healthy, middle-aged women and men from the Los Angeles Atherosclerosis Study. Dietary arachidonic acid and marine n-3 fatty acids (including a competing 5-lipoxygenase substrate that reduces the production of inflammatory leukotrienes) were measured with the use of six 24-hour recalls of food intake. RESULTS: Variant 5-lipoxygenase genotypes (lacking the common allele) were found in 6.0 percent of the cohort. Mean (+/-SE) intima-media thickness adjusted for age, sex, height, and racial or ethnic group was increased by 80+/-19 microm (95 percent confidence interval, 43 to 116; P<0.001) among carriers of two variant alleles, as compared with carriers of the common (wild-type) allele. In multivariate analysis, the increase in intima-media thickness among carriers of two variant alleles (62 microm, P<0.001) was similar in this cohort to that associated with diabetes (64 microm, P=0.01), the strongest common cardiovascular risk factor. Increased dietary arachidonic acid significantly enhanced the apparent atherogenic effect of genotype, whereas increased dietary intake of n-3 fatty acids blunted the effect. Finally, the plasma level of C-reactive protein, a marker of inflammation, was increased by a factor of 2 among carriers of two variant alleles as compared with that among carriers of the common allele. CONCLUSIONS: Variant 5-lipoxygenase genotypes identify a subpopulation with increased atherosclerosis. The observed diet-gene interactions further suggest that dietary n-6 polyunsaturated fatty acids promote, whereas marine n-3 fatty acids inhibit, leukotriene-mediated inflammation that leads to atherosclerosis in this subpopulation.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California	Dwyer, JH (corresponding author), Keck Sch Med, 1000 S Fremont Ave,Unit 8, Alhambra, CA 91803 USA.	jimdwye@usc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049910, P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008243] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30568, HL-49910] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08243-15] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918; Allen S, 1998, CIRCULATION, V97, P2406, DOI 10.1161/01.CIR.97.24.2406; Andreotti F, 1999, Cardiologia, V44, P341; Boekholdt SM, 2001, CIRCULATION, V104, P3063, DOI 10.1161/hc5001.100793; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Cantwell MM, 2000, P NUTR SOC, V59, P187, DOI 10.1017/S0029665100000203; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Cyrus T, 2001, CIRCULATION, V103, P2277; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1999, NEW ENGL J MED, V340, P663; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922; Dwyer JH, 1998, ULTRASOUND MED BIOL, V24, P981, DOI 10.1016/S0301-5629(98)00069-6; Ferretti A, 1997, LIPIDS, V32, P435, DOI 10.1007/s11745-997-0057-5; FESKANICH D, 1989, COMPUT METH PROG BIO, V30, P47, DOI 10.1016/0169-2607(89)90122-3; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kelley DS, 1999, LIPIDS, V34, P317, DOI 10.1007/s11745-999-0369-5; Kelley DS, 1998, LIPIDS, V33, P125, DOI 10.1007/s11745-998-0187-9; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Koller M, 2003, CLIN NUTR, V22, P59, DOI 10.1054/clnu.2002.0592; LEE TH, 1988, CLIN SCI, V74, P467, DOI 10.1042/cs0740467; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LI BY, 1994, J LIPID RES, V35, P1869; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; Prescott SM, 2002, ARTERIOSCL THROM VAS, V22, P727, DOI 10.1161/01.ATV.0000016153.47693.B2; Radmark O, 2003, ARTERIOSCL THROM VAS, V23, P1140, DOI 10.1161/01.ATV.0000082460.58448.01; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; Serhan CN, 2000, AM J RESP CRIT CARE, V161, pS95, DOI 10.1164/ajrccm.161.supplement_1.ltta-19; Serio KJ, 2000, AM J RESP CELL MOL, V23, P234, DOI 10.1165/ajrcmb.23.2.4042; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; SPERLING RI, 1993, J CLIN INVEST, V91, P651, DOI 10.1172/JCI116245; Sun P, 2000, ARTERIOSCL THROM VAS, V20, P2005, DOI 10.1161/01.ATV.20.8.2005; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; Zee RYL, 2002, ATHEROSCLEROSIS, V162, P217, DOI 10.1016/S0021-9150(01)00703-1	50	487	529	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					29	37		10.1056/NEJMoa025079	http://dx.doi.org/10.1056/NEJMoa025079			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702425				2022-12-28	WOS:000187659900007
J	Shi, YH; Lie, DC; Taupin, P; Nakashima, K; Ray, J; Yu, RT; Gage, FH; Evans, RM				Shi, YH; Lie, DC; Taupin, P; Nakashima, K; Ray, J; Yu, RT; Gage, FH; Evans, RM			Expression and function of orphan nuclear receptor TLX in adult neural stem cells	NATURE			English	Article							TAILLESS; BRAIN; NEUROGENESIS; COFACTOR; PROTEIN; SYSTEM; GENE; CNS	The finding of neurogenesis in the adult brain led to the discovery of adult neural stem cells(1). TLX was initially identified as an orphan nuclear receptor expressed in vertebrate forebrains(2) and is highly expressed in the adult brain(3). The brains of TLX-null mice have been reported to have no obvious defects during embryogenesis(4); however, mature mice suffer from retinopathies(5), severe limbic defects, aggressiveness, reduced copulation and progressively violent behaviour(4,6). Here we show that TLX maintains adult neural stem cells in an undifferentiated, proliferative state. We show that TLX-expressing cells isolated by fluorescence-activated cell sorting (FACS) from adult brains can proliferate, self-renew and differentiate into all neural cell types in vitro. By contrast, TLX-null cells isolated from adult mutant brains fail to proliferate. Reintroducing TLX into FACS-sorted TLX-null cells rescues their ability to proliferate and to self-renew. In vivo, TLX mutant mice show a loss of cell proliferation and reduced labelling of nestin in neurogenic areas in the adult brain. TLX can silence glia-specific expression of the astrocyte marker GFAP in neural stem cells, suggesting that transcriptional repression may be crucial in maintaining the undifferentiated state of these cells.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Cell Fate Modulat, Kumamoto 8600811, Japan	Salk Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute; Kumamoto University	Evans, RM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gage@salk.edu; evans@salk.edu	Evans, Ronald/AAF-4001-2019; Lie, Dieter Chichung/AAS-8604-2020; Lie, Dieter Chichung/S-7914-2017	Evans, Ronald/0000-0002-9986-5965; Lie, Dieter Chichung/0000-0002-6035-6442; Lie, Dieter Chichung/0000-0002-6035-6442; Yu, Ruth/0000-0002-9527-9627; Shi, Yanhong/0000-0002-3938-5839				Allen DR, 2001, GENE DEV, V15, P554, DOI 10.1101/gad.869001; Chiang M.Y., 1997, REVERSE GENETIC ANAL; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lie DC, 2002, J NEUROSCI, V22, P6639; Misawa K, 2000, P NATL ACAD SCI USA, V97, P3062, DOI 10.1073/pnas.060489597; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Monaghan AP, 1997, NATURE, V390, P515, DOI 10.1038/37364; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Palmer TD, 1999, J NEUROSCI, V19, P8487; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; YU RT, 1994, NATURE, V370, P375, DOI 10.1038/370375a0; Yu RT, 2000, P NATL ACAD SCI USA, V97, P2621, DOI 10.1073/pnas.050566897	19	319	339	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 1	2004	427	6969					78	83		10.1038/nature02211	http://dx.doi.org/10.1038/nature02211			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YP	14702088				2022-12-28	WOS:000187710000038
J	Amato, AA				Amato, AA			Sweet success - A treatment for McArdle's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Amato, AA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							Haller RG, 2000, ARCH NEUROL-CHICAGO, V57, P923, DOI 10.1001/archneur.57.7.923	1	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2481	2482		10.1056/NEJMp038183	http://dx.doi.org/10.1056/NEJMp038183			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695407				2022-12-28	WOS:000187529500002
J	Kandel, G				Kandel, G			Uses of error - Remember to look below	LANCET			English	Editorial Material									St Michaels Hosp, Div Gastroenterol, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Kandel, G (corresponding author), St Michaels Hosp, Div Gastroenterol, 30 Bond St, Toronto, ON M5B 1W8, Canada.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2109	2109		10.1016/S0140-6736(03)15112-4	http://dx.doi.org/10.1016/S0140-6736(03)15112-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697817				2022-12-28	WOS:000187429600031
J	Lee, JW				Lee, JW			Global health improvement and WHO: shaping the future	LANCET			English	Article								A world torn by gross health inequalities is in serious trouble. The global health community can do much to reduce suffering and death among vulnerable groups. WHO is changing its way of working, alongside member states and financial and technical partners, to reach key national health goals and strengthen equity. The most urgent objectives include the health-related Millennium Development Goals, the 3 by 5 target in HIV/AIDS treatment (to provide 3 million people in developing regions with access to antiretroviral treatment by the end of 2005), and addressing the growing epidemics of non-communicable diseases. The key to achieving these objectives is strengthening of health systems guided by the values of Health For All.	WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Lee, JW (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.							[Anonymous], 1978, INT C PRIM HLTH CAR; *AS DEV BANK, 2003, ASS IMP COSTS SARS D; Beaglehole R., 2003, WORLD HLTH REPORT 20; *DEP AT PRIM MIN S, 2002, OR PROGR LOC 2003; MUKHERJEE J, 2003, ACCESS TREATMENT CAR; National Intelligence Council, 2002, NEXT WAV HIV AIDS NI; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Szreter Simon, 2003, GLOBAL HLTH CHALLENG, P31; *U CAP TOWN DEP PU, 2003, ANT THER PRIM HLTH C; *WHO, 2001, REP COMM MACR HLTH; *WHO, 1998, HLTH PROM GLOSS, P6; *WHO, 2000, DES IMPL HLTH INF SY; *WHO, 2003, PRIM HLTH CAR FRAM F; World Health Organization, 2000, WORLD HLTH REP 2000; Yach D, 1998, AM J PUBLIC HEALTH, V88, P738, DOI 10.2105/AJPH.88.5.738; 2003, LANCET, V361, P1485	16	114	123	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2083	2088		10.1016/S0140-6736(03)15107-0	http://dx.doi.org/10.1016/S0140-6736(03)15107-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697812	Bronze, Green Published			2022-12-28	WOS:000187429600026
J	Brumfiel, G				Brumfiel, G			Cosmology - Welcome to the real world	NATURE			English	News Item																		Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; Luminet JP, 2003, NATURE, V425, P593, DOI 10.1038/nature01944; RIESS AG, ASTROPH0308185	3	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					751	751		10.1038/426751a	http://dx.doi.org/10.1038/426751a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685191	Bronze			2022-12-28	WOS:000187342000014
J	Skinner, M; Sanchorawala, V; Seldin, DC; Dember, LM; Falk, RH; Berk, JL; Anderson, JJ; O'Hara, C; Finn, KT; Libbey, CA; Wiesman, J; Quillen, K; Swan, N; Wright, DG				Skinner, M; Sanchorawala, V; Seldin, DC; Dember, LM; Falk, RH; Berk, JL; Anderson, JJ; O'Hara, C; Finn, KT; Libbey, CA; Wiesman, J; Quillen, K; Swan, N; Wright, DG			High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY SYSTEMIC AMYLOIDOSIS; LIGHT-CHAIN AMYLOIDOSIS; BONE-MARROW-TRANSPLANTATION; PHASE-II TRIAL; RANDOMIZED-TRIAL; INTRAVENOUS MELPHALAN; INTENSIVE MELPHALAN; LABORATORY FEATURES; G-CSF; THERAPY	Background: AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective. Objective: To test survival and organ response in a large sample of patients treated with high-dose intravenous melphalan (100 to 200 mg/m(2)) and autologous blood stem-cell transplantation. Design: 8-year longitudinal analysis of clinical effectiveness. Setting: University-affiliated specialty referral clinic. Patients: 701 consecutive new patients with AL amyloidosis. Intervention: High-dose chemotherapy and autologous stem-cell transplantation for patients who met eligibility requirements based on organ involvement and clinical status. Measurements: Survival analysis of all patients evaluated and a detailed analysis of treatment outcome in the subgroup that received high-dose melphalan and stem-cell transplantation. Results: Among 701 patients with AL amyloidosis, 394 (56%) were eligible for high-dose melphalan and stem-cell transplantation; 82 did not proceed with treatment because of patient choice or disease progression. Median survival of the 312 patients who initiated treatment was 4.6 years. A complete hematologic response, defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achieved in 40% of patients and was associated with prolonged survival. Statistically significant improvements occurred in end-organ disease and were greater in patients with a complete hematologic response. Mortality rate within 100 days of treatment with high-dose melphalan and stem-cell transplantation was 13%; patients with cardiomyopathy had the highest mortality rates. Conclusions: Treatment of selected patients with AL amyloidosis by using high-dose melphalan and stem-cell transplantation resulted in hematologic remission, improved 5-year survival, and reversal of amyloid-related disease in a substantial proportion.	Boston Univ, Sch Med, Amyloid Treatment & Res Program, Boston, MA 02118 USA	Boston University	Skinner, M (corresponding author), Boston Univ, Sch Med, Amyloid Treatment & Res Program, K503,715 Albany St, Boston, MA 02118 USA.	mskinner@bu.edu		Berk, John/0000-0002-1768-2373; Wiesman, Janice/0000-0003-3085-4827; O'Hara, Carl/0000-0001-7404-3597; Sanchorawala, Vaishali/0000-0002-6307-2445; Libbey, Caryn/0000-0003-4114-031X; Seldin, David C/0000-0003-0168-2333; Quillen, Karen/0000-0002-4243-0864	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068705] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68705] Funding Source: Medline; FDA HHS [FD-R-001346] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FDA HHS		Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; BARLOGIE B, 1995, SEMIN HEMATOL, V32, P31; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; Choufani EB, 2001, BLOOD, V97, P1885, DOI 10.1182/blood.V97.6.1885; Comenzo RL, 1999, BRIT J HAEMATOL, V104, P553, DOI 10.1046/j.1365-2141.1999.01216.x; Comenzo RL, 1996, BLOOD, V88, P2801, DOI 10.1182/blood.V88.7.2801.bloodjournal8872801; Comenzo RL, 1998, TRANSFUSION, V38, P60, DOI 10.1046/j.1537-2995.1998.38198141500.x; Comenzo RL, 1998, BLOOD, V91, P3662; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Dember LM, 2001, ANN INTERN MED, V134, P746, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00011; Desikan KR, 1997, LEUKEMIA LYMPHOMA, V27, P315, DOI 10.3109/10428199709059685; Dispenzieri A, 2001, J CLIN ONCOL, V19, P3350, DOI 10.1200/JCO.2001.19.14.3350; Dubrey SW, 1998, QJM-MON J ASSOC PHYS, V91, P141, DOI 10.1093/qjmed/91.2.141; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; Gertz MA, 2000, BONE MARROW TRANSPL, V26, P963, DOI 10.1038/sj.bmt.1702643; Gertz MA, 2002, AMYLOID, V9, P24, DOI 10.3109/13506120209072441; Gertz MA, 2002, AM J MED, V113, P549, DOI 10.1016/S0002-9343(02)01208-1; Gertz MA, 2000, BONE MARROW TRANSPL, V25, P465, DOI 10.1038/sj.bmt.1702178; Gertz MA, 1999, J CLIN ONCOL, V17, P262, DOI 10.1200/JCO.1999.17.1.262; Gertz MA, 1999, AM J HEMATOL, V61, P115, DOI 10.1002/(SICI)1096-8652(199906)61:2<115::AID-AJH7>3.0.CO;2-I; GIANNI L, 1995, BLOOD, V86, P855; Gillmore JD, 1999, AMYLOID AND AMYLOIDOSIS 1998, P102; KYLE RA, 1975, MEDICINE, V54, P271; Kyle RA, 1997, NEW ENGL J MED, V336, P1202, DOI 10.1056/NEJM199704243361702; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; KYLE RA, 1985, AM J MED, V79, P708, DOI 10.1016/0002-9343(85)90521-2; KYLE RA, 1992, BLOOD, V79, P1817; Lachmann HJ, 2002, NEW ENGL J MED, V346, P1786, DOI 10.1056/NEJMoa013354; Lokhorst HM, 1996, BRIT J HAEMATOL, V92, P44, DOI 10.1046/j.1365-2141.1996.00306.x; MAJOLINO I, 1993, HAEMATOLOGICA, V78, P68; MERLINI G, 1995, SEMIN HEMATOL, V32, P60; Moreau P, 1998, BRIT J HAEMATOL, V101, P766, DOI 10.1046/j.1365-2141.1998.00772.x; Moreau P, 1996, BLOOD, V87, P3063, DOI 10.1182/blood.V87.7.3063.bloodjournal8773063; Sanchorawala V, 2001, BONE MARROW TRANSPL, V28, P637, DOI 10.1038/sj.bmt.1703200; SIMMS RW, 1994, BAILLIERE CLIN RHEUM, V8, P627, DOI 10.1016/S0950-3579(05)80119-0; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9; van Gameren II, 2002, AMYLOID, V9, P165, DOI 10.3109/13506120209114818	38	454	479	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					85	93		10.7326/0003-4819-140-2-200401200-00008	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734330				2022-12-28	WOS:000188211700002
J	Florin, D; Dixon, J				Florin, D; Dixon, J			Public involvement in health care	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, Hlth Policy, London W1G 0AN, England		Florin, D (corresponding author), Kings Fund, Hlth Policy, London W1G 0AN, England.	d.florin@kingsfund.org.uk						Anderson W, 2002, EVERY VOICE COUNTS P; Appleby J., 2003, WHAT IS REAL COST MO; ARNSTEIN S, 1971, J ROY TOWN PLANN, V57, P176; BLEARS H, 2003, COMMUNITIES CONTROL; Collins Ben., 2015, FDN TRUSTS NHS TRUST; CORRY D, 2002, NEW LOCALISM REFASHI; Coulter A., 2002, AUTONOMOUS PATIENT E; Crawford MJ, 2002, BRIT MED J, V325, P1263, DOI 10.1136/bmj.325.7375.1263; Department of Foreign Affairs and Trade, 2003, GOV RESP HLTH SEL CO, V11, P13; Department of Health, 2003, GOV NHS GUID NHS BOA; Department of Health, 2001, EXP PAT NEW APPR CHR; DIXON J, IN PRESS IMPROVING C; HARRISON S, 2002, PATIENT PUBLIC INVOL; KLEIN R, 1996, 2 CHEERS DEMOCRACY; Le Grand J, 1998, LEARNING NHS INTERNA; NHS Management Executive, 1992, LOC VOIC VIEWS LOC P; Secretary of State for Health, 2000, NHS PLAN; SMITH P, 2003, HLTH SERV J, V113, P5	18	133	133	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					159	161		10.1136/bmj.328.7432.159	http://dx.doi.org/10.1136/bmj.328.7432.159			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726350	Green Published			2022-12-28	WOS:000188249900029
J	Garcia, HH; Pretell, EJ; Gilman, RH; Martinez, SM; Moulton, LH; Del Brutto, OH; Herrera, G; Evans, CAW; Gonzalez, AE				Garcia, HH; Pretell, EJ; Gilman, RH; Martinez, SM; Moulton, LH; Del Brutto, OH; Herrera, G; Evans, CAW; Gonzalez, AE		Cysticercosis Working Grp Peru	A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PORCINE CYSTICERCOSIS; SOLIUM CYSTICERCOSIS; MEDICAL-TREATMENT; TAENIA-SOLIUM; NEUROCYSTICERCOSIS; PRAZIQUANTEL; ALBENDAZOLE; RECURRENCE; EPILEPSY; THERAPY	BACKGROUND: Neurocysticercosis is the main cause of adult-onset seizures in the developing world. Whether therapy with antiparasitic agents results in improved seizure control has been questioned because of the lack of adequate, controlled studies. METHODS: We conducted a double-blind, placebo-controlled trial in which 120 patients who had living cysticerci in the brain and seizures treated with antiepileptic drugs were randomly assigned to receive either 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days (60 patients) or two placebos (60 patients). The patients were followed for 30 months or until they had been seizure-free for 6 months after the doses of the antiepileptic drugs had been tapered. The efficacy of treatment was measured as the decrease in the number of seizures after treatment. RESULTS: In the albendazole group, there was a 46 percent reduction in the number of seizures (95 percent confidence interval, -74 to 83 percent) during months 2 to 30 after treatment. This reduction, which was not statistically significant, was composed of a nonsignificant reduction of 41 percent in the number of partial seizures (95 percent confidence interval, -124 to 84 percent) and a significant 67 percent reduction in the number of seizures with generalization (95 percent confidence interval, 20 to 86 percent). Most of the difference in the number of partial seizures was attributable to a few patients who had many seizures during follow-up. The proportions of patients who had partial seizures during follow-up were similar in the two groups (19 of 57 in the albendazole group and 16 of 59 in the placebo group), but the patients in the placebo group had a greater tendency to have seizures with generalization (22 of 59, vs. 13 of 57 in the albendazole group; risk ratio, 1.63; 95 percent confidence interval, 0.91 to 2.92). More of the intracranial cystic lesions resolved in the albendazole group than in the placebo group. With the sole exception of abdominal pain, side effects did not differ significantly between the two groups. CONCLUSIONS: In patients with seizures due to viable parenchymal cysts, antiparasitic therapy decreases the burden of parasites and is safe and effective, at least in reducing the number of seizures with generalization.	Inst Nacl Ciencias Neurol, Dept Transmissible Dis, Lima, Peru; Univ Peruana Cayetano Heredia, Dept Microbiol, Lima, Peru; Univ Peruana Cayetano Heredia, Dept Radiol, Lima, Peru; Univ Nacl Mayor San Marcos, Sch Vet Med, Dept Publ Hlth, Lima 14, Peru; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Hosp Clin Kennedy, Dept Neurol Sci, Guayaquil, Ecuador; Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Microbiol, London, England	Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; Universidad Nacional Mayor de San Marcos; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Imperial College London	Garcia, HH (corresponding author), Inst Ciencias Neurol, Cysticercosis Unit, Jiron Ancash 1271, Lima 1, Peru.			Gonzalez, Armando/0000-0003-1909-1873; Moulton, Lawrence/0000-0001-7041-7387; Evans, Carlton/0000-0002-6873-5447	PHS HHS [U19-A145431] Funding Source: Medline; FDA HHS [FD-R-001107-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		BANCAUD J, 1981, EPILEPSIA, V22, P489, DOI 10.1111/j.1528-1157.1981.tb06159.x; Bern C, 1999, CLIN INFECT DIS, V29, P1203, DOI 10.1086/313470; BOTERO D, 1982, AM J TROP MED HYG, V31, P811, DOI 10.4269/ajtmh.1982.31.811; CARPIO A, 1995, ARCH INTERN MED, V155, P1982, DOI 10.1001/archinte.155.18.1982; Carpio A, 2002, NEUROLOGY, V59, P1730, DOI 10.1212/01.WNL.0000036320.69823.EA; Carpio A, 2002, LANCET INFECT DIS, V2, P751, DOI 10.1016/S1473-3099(02)00454-1; DELBRUTTO OH, 1992, NEUROLOGY, V42, P389, DOI 10.1212/WNL.42.2.389; DELBRUTTO OH, 1994, NEUROLOGY, V44, P1706, DOI 10.1212/WNL.44.9.1706; DELBRUTTO OH, 1988, REV INFECT DIS, V10, P1075; DIXON HBF, 1961, SPECIAL REPORT SERIE, V299; FRIEDMAN J, 1983, ARCH NEUROL-CHICAGO, V40, P257, DOI 10.1001/archneur.1983.04050040087022; Garcia HH, 2002, CLIN MICROBIOL REV, V15, P747, DOI 10.1128/CMR.15.4.747-756.2002; Garcia HH, 1997, NEUROLOGY, V48, P1421, DOI 10.1212/WNL.48.5.1421; Garcia HH, 2003, LANCET, V362, P547, DOI 10.1016/S0140-6736(03)14117-7; Garcia HH, 2000, INFECT DIS CLIN N AM, V14, P97, DOI 10.1016/S0891-5520(05)70220-8; GOLDBERG MA, 1984, NEW ENGL J MED, V311, P733; Gonzales AE, 1996, AM J TROP MED HYG, V54, P391, DOI 10.4269/ajtmh.1996.54.391; GONZALEZ AE, 1995, AM J TROP MED HYG, V53, P571, DOI 10.4269/ajtmh.1995.53.571; KRAMER LD, 1995, ARCH NEUROL-CHICAGO, V52, P101, DOI 10.1001/archneur.1995.00540250109020; KRAMER LD, 1989, RADIOLOGY, V173, P286; KRAMER LD, 1989, RADIOLOGY, V171, P459, DOI 10.1148/radiology.171.2.2704811; MCCORMICK GF, 1983, ARCH NEUROL-CHICAGO, V40, P258, DOI 10.1001/archneur.1983.04050040088024; MILLER B, 1983, NEUROLOGY, V33, P1377, DOI 10.1212/WNL.33.10.1377; MOODLEY M, 1989, LANCET, V1, P262, DOI 10.1016/S0140-6736(89)91268-3; Ong S, 2002, EMERG INFECT DIS, V8, P608, DOI 10.3201/eid0806.010377; Proano JV, 2001, NEW ENGL J MED, V345, P879, DOI 10.1056/NEJMoa010212; Robles C, 1979, Salud Publica Mex, V21, P603; Schantz PM, 1998, EMERG INFECT DIS, V2, P213, DOI [10.1128/9781555816957.ch12, DOI 10.1128/9781555816957.CH12]; Singh G, 1997, ARQ NEURO-PSIQUIAT, V55, P349, DOI 10.1590/S0004-282X1997000300001; Sirven JI, 2002, SEMIN NEUROL, V22, P237, DOI 10.1055/s-2002-36644; SOTELO J, 1990, J NEUROL, V237, P69, DOI 10.1007/BF00314663; SPINAFRANCA A, 1982, TROPENMED PARASITOL, V33, P1; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; VAZQUEZ V, 1992, NEW ENGL J MED, V327, P696, DOI 10.1056/NEJM199209033271005; WYLLIE E, 1997, TREATMENT EPILEPSY P	35	257	262	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	2004	350	3					249	258		10.1056/NEJMoa031294	http://dx.doi.org/10.1056/NEJMoa031294			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763HF	14724304	Green Accepted			2022-12-28	WOS:000188078400008
J	Chan, D; Sinniah, R; Irish, A				Chan, D; Sinniah, R; Irish, A			A prisoner with acute renal failure	LANCET			English	Article							ANTICONVULSANT HYPERSENSITIVITY SYNDROME; VASCULITIS		Royal Perth Hosp, Dept Nephrol, Perth, WA 6847, Australia; Royal Perth Hosp, Dept Pathol, Perth, WA 6847, Australia	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia	Chan, D (corresponding author), Royal Perth Hosp, Dept Nephrol, Perth, WA 6847, Australia.		Irish, Ashley/H-5468-2019	Irish, Ashley/0000-0002-9577-3764				GAFFEY CM, 1986, ARCH PATHOL LAB MED, V110, P131; Gungor E, 2001, NEUROL SCI, V22, P261, DOI 10.1007/s100720100024; Morkunas AR, 1997, CRIT CARE CLIN, V13, P727, DOI 10.1016/S0749-0704(05)70366-3; Parry RG, 1996, NEPHROL DIAL TRANSPL, V11, P357, DOI 10.1093/oxfordjournals.ndt.a027268; ten Holder SM, 2002, ANN PHARMACOTHER, V36, P130, DOI 10.1345/1542-6270(2002)036<0130:CASMOD>2.0.CO;2; VITTORIO CC, 1995, ARCH INTERN MED, V155, P2285, DOI 10.1001/archinte.155.21.2285	6	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					126	126		10.1016/S0140-6736(03)15263-4	http://dx.doi.org/10.1016/S0140-6736(03)15263-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761WV	14726166				2022-12-28	WOS:000187939200010
J	Harris, JE; Thun, MJ; Mondul, AM; Calle, EE				Harris, JE; Thun, MJ; Mondul, AM; Calle, EE			Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; FRENCH CASE-CONTROL; CARDIORESPIRATORY DISEASE; SMOKING-CESSATION; FILTER CIGARETTES; RISK FACTOR; SMOKERS; WOMEN; TOBACCO; MEN	Objective To assess the risk of lung cancer in smokers of medium tar filter cigarettes compared with smokers of low tar and very low tar cigarettes. Design Analysis of the association between the tar rating of the brand of cigarette smoked in 1982 and mortality from lung cancer over the next six years. Multivariate proportional hazards analyses used to assess hazard ratios, with adjustment for age at enrolment, race, educational level, marital status, blue collar employment, occupational exposure to asbestos, intake of vegetables, citrus fruits, and vitamins, and, in analyses of current and former smokers, for age when they started to smoke and number of cigarettes smoked per day. Setting Cancer prevention study H (CPS-II). Participants 364 239 men and 576 535 women, aged greater than or equal to 30 years, who had either never smoked, were former smokers, or were currently smoking a specific brand of cigarette when they were enrolled in the cancer prevention study. Main outcome measure Death from primary cancer of the lung among participants who had never smoked, former smokers, smokers of very low tar (less than or equal to 7 mg tar/cigarette) filter, low tar (8-14 mg) filter, high tar (greater than or equal to 22 mg) non-filter brands and medium tar conventional filter brands (15-21 mg). Results Irrespective of the tar level of their current brand, all current smokers had a far greater risk of lung cancer than people who had stopped smoking or had never smoked. Compared with smokers of medium tar (15-21 mg) filter cigarettes, risk was higher among men and women who smoked high tar (greater than or equal to 22 mg) non-filter brands (hazard ratio 1.44 95% confidence interval 1.20 to 1.73, and 1.64, 1.26 to 2.15, respectively). There was no difference in risk among men who smoked brands rated as very low tar (1.17, 0.95 to 1.45) or low tar (1.02, 0.90 to 1.16) compared with those who smoked medium tar brands. The same was seen for women (0.98, 0.80 to 1.21, and 0.95, 0.82 to 1.11, respectively). Conclusion The increase in lung cancer risk is similar in people who smoke medium tar cigarettes (15-21 mg), low tar cigarettes (8-14 mg), or very low tar cigarettes (less than or equal to 7 mg). Men and women who smoke non-filtered cigarettes with tar ratings greater than or equal to 22 mg have an even higher risk of lung cancer.	MIT, Dept Econ, Cambridge, MA 02139 USA; Amer Canc Soc, Atlanta, GA 30329 USA	Massachusetts Institute of Technology (MIT); American Cancer Society	Harris, JE (corresponding author), Massachusetts Gen Hosp, Internal Med Associates, Boston, MA 02114 USA.	jeharris@partners.org		Mondul, Alison/0000-0002-8843-1416				Agudo A, 2000, INT J CANCER, V88, P820, DOI 10.1002/1097-0215(20001201)88:5&lt;820::AID-IJC21&gt;3.0.CO;2-J; AGUDO A, 1994, INT J CANCER, V59, P165, DOI 10.1002/ijc.2910590204; ALDERSON MR, 1985, J EPIDEMIOL COMMUN H, V39, P286, DOI 10.1136/jech.39.4.286; Armadans-Gil L, 1999, INT J EPIDEMIOL, V28, P614, DOI 10.1093/ije/28.4.614; AUGUSTINE A, 1989, AM J PUBLIC HEALTH, V79, P188, DOI 10.2105/AJPH.79.2.188; BENHAMOU E, 1993, EUR J CANCER, V29A, P1778, DOI 10.1016/0959-8049(93)90124-X; BENHAMOU E, 1987, BRIT J CANCER, V55, P91, DOI 10.1038/bjc.1987.19; BENHAMOU E, 1989, BRIT J CANCER, V60, P601, DOI 10.1038/bjc.1989.322; BENHAMOU S, 1994, INT J EPIDEMIOL, V23, P437, DOI 10.1093/ije/23.3.437; BENHAMOU S, 1985, J NATL CANCER I, V74, P1169; BENOWITZ N, 2001, NCI SMOKING TOBACCO, V13, P39; BORLAND C, 1983, BRIT MED J, V287, P1583, DOI 10.1136/bmj.287.6405.1583; BROSS IDJ, 1968, AM J PUBLIC HEALTH N, V58, P1396, DOI 10.2105/AJPH.58.8.1396; BUFFLER PA, 1984, LUNG CANCER CAUSES P, P83; BURNS DR, 2001, NCI SMOKING TOBACCO, V13, P65; BURRIS DR, 2001, NATL CANCER I MONOGR, V13, P65; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; COX DR, 1972, J R STAT SOC B, V34, P187; DeStefani E, 1996, CANCER EPIDEM BIOMAR, V5, P515; Engeland A, 1996, CANCER CAUSE CONTROL, V7, P366, DOI 10.1007/BF00052943; Forey B., 2002, INT SMOKING STAT; Garfinkel L, 1985, Natl Cancer Inst Monogr, V67, P49; GARFINKEL L, 1988, CANCER RES, V48, P6951; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P38, DOI 10.1136/jech.42.1.38; HAMMOND EC, 1976, ENVIRON RES, V12, P263, DOI 10.1016/0013-9351(76)90036-0; Harris JE, 2001, PUBLIC HEALTH REP, V116, P336, DOI 10.1093/phr/116.4.336; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HIGENBOTTAM T, 1982, J EPIDEMIOL COMMUN H, V36, P113, DOI 10.1136/jech.36.2.113; HOFFMANN D, 1996, NCI SMOKING TOBACCO, V7, P15; HOFFMANN D, 1994, LUNG CANCER, P1; JOCKEL KH, 1992, INT J EPIDEMIOL, V21, P202, DOI 10.1093/ije/21.2.202; Kabat GC, 1996, LUNG CANCER, V15, P1, DOI 10.1016/0169-5002(95)00566-8; KAUFMAN DW, 1989, AM J EPIDEMIOL, V129, P703, DOI 10.1093/oxfordjournals.aje.a115185; Khuder SA, 1998, LUNG CANCER-J IASLC, V22, P15, DOI 10.1016/S0169-5002(98)00068-3; KIRYLUK S, 1989, NICOTINE SMOKING LOW; KOZLOWSKI LT, 2001, MON NCI, P13; KOZLOWSKI LT, 2001, MONOGRAPH USDHHS NAT, V13, P13; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; KUNZE M, 1980, BANBURY REPORT, V3, P29; LANGE P, 1992, EUR RESPIR J, V5, P1111; LEE PN, 1981, J EPIDEMIOL COMMUN H, V35, P16, DOI 10.1136/jech.35.1.16; Lee PN, 2001, INHAL TOXICOL, V13, P951, DOI 10.1080/089583701753210353; LUBIN JH, 1984, INT J CANCER, V33, P569, DOI 10.1002/ijc.2910330504; LUBIN JH, 1984, BRIT MED J, V288, P1953, DOI 10.1136/bmj.288.6435.1953; Matos E, 1998, LUNG CANCER-J IASLC, V21, P155, DOI 10.1016/S0169-5002(98)00055-5; OCKENE JK, 1990, AM J PUBLIC HEALTH, V80, P954, DOI 10.2105/AJPH.80.8.954; PATHAK DR, 1986, JNCI-J NATL CANCER I, V76, P597, DOI 10.1093/jnci/76.4.597; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PEZZOTTO SM, 1993, CANCER CAUSE CONTROL, V4, P231; RIMINGTON J, 1981, ENVIRON RES, V24, P162, DOI 10.1016/0013-9351(81)90142-0; Rothman K., 1998, MODERN EPIDEMIOLOGY; SIDNEY S, 1993, CANCER CAUSE CONTROL, V4, P3, DOI 10.1007/BF00051707; Simonato L, 2001, INT J CANCER, V91, P876, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1139>3.0.CO;2-7; Speizer FE, 1999, CANCER CAUSE CONTROL, V10, P475, DOI 10.1023/A:1008931526525; Stellman SD, 1997, CANCER-AM CANCER SOC, V80, P382, DOI 10.1002/(SICI)1097-0142(19970801)80:3<382::AID-CNCR5>3.0.CO;2-U; STELLMAN SD, 1986, JNCI-J NATL CANCER I, V76, P1057; TANG JL, 1995, BMJ-BRIT MED J, V311, P1530, DOI 10.1136/bmj.311.7019.1530; Thun MJ, 1997, PREV MED, V26, P422, DOI 10.1006/pmed.1997.0182; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Thun MJ, 2000, CANCER EPIDEM BIOMAR, V9, P861; TODD GF, 1978, J EPIDEMIOL COMMUN H, V32, P267, DOI 10.1136/jech.32.4.267; *US FED TRAD COMM, 2002, DOM MARK SHAR CIG TA; *US FED TRAD COMM, 1981, REP TAR NIC CARB MON; *USDA, 2002, TOB OUTL; *USDA EC RES SERV, 2002, TBS252 USDA EC RES S; VUTUC C, 1983, J NATL CANCER I, V71, P435; VUTUC C, 1982, PREV MED, V11, P713, DOI 10.1016/0091-7435(82)90033-0; WALD N, 1981, BRIT MED J, V282, P763, DOI 10.1136/bmj.282.6266.763; WILCOX HB, 1988, PREV MED, V17, P263, DOI 10.1016/0091-7435(88)90002-3; WYNDER EL, 1970, J AMER MED ASSOC, V213, P2221, DOI 10.1001/jama.213.13.2221; WYNDER EL, 1979, J NATL CANCER I, V62, P471, DOI 10.1093/jnci/62.3.471; WYNDER EL, 1988, CANCER, V62, P1223, DOI 10.1002/1097-0142(19880915)62:6<1223::AID-CNCR2820620630>3.0.CO;2-6; Yang GH, 1999, JAMA-J AM MED ASSOC, V282, P1247, DOI 10.1001/jama.282.13.1247; ZANG EA, 1992, CANCER, V70, P69, DOI 10.1002/1097-0142(19920701)70:1<69::AID-CNCR2820700112>3.0.CO;2-A	75	96	102	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2004	328	7431					72	76		10.1136/bmj.37936.585382.44	http://dx.doi.org/10.1136/bmj.37936.585382.44			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	762MP	14715602	Green Published, Green Submitted			2022-12-28	WOS:000187976400013
J	Din, JN; Newby, DE; Flapan, AD				Din, JN; Newby, DE; Flapan, AD			Science, medicine, and the future - Omega 3 fatty acids and cardiovascular disease - fishing for a natural treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POLYUNSATURATED FATTY-ACIDS; CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; DOUBLE-BLIND; EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; OIL SUPPLEMENTATION; RISK; CONSUMPTION; CHAIN	Omega 3 fatty acids from fish and fish oils can protect against coronary heart disease. This article reviews the evidence regarding fish oils and coronary disease and outlines the mechanisms through which fish oils might confer cardiac benefits.	Univ Edinburgh, Edinburgh EH16 4SB, Midlothian, Scotland; Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh	Din, JN (corresponding author), Univ Edinburgh, Edinburgh EH16 4SB, Midlothian, Scotland.	jehangirdin@hotmail.com	Newby, David Ernest/AAB-1364-2019					Albert CM, 2002, NEW ENGL J MED, V346, P1113, DOI 10.1056/NEJMoa012918; Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BURR ML, 1989, LANCET, V2, P757; Burr ML, 2003, EUR J CLIN NUTR, V57, P193, DOI 10.1038/sj.ejcn.1601539; Christensen JH, 1996, BMJ-BRIT MED J, V312, P677, DOI 10.1136/bmj.312.7032.677; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; DAVIS HR, 1987, ARTERIOSCLEROSIS, V7, P441, DOI 10.1161/01.ATV.7.5.441; De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S; DYERBERG J, 1975, AM J CLIN NUTR, V28, P958, DOI 10.1093/ajcn/28.9.958; Friedberg CE, 1998, DIABETES CARE, V21, P494, DOI 10.2337/diacare.21.4.494; Geleijnse JM, 2002, J HYPERTENS, V20, P1493, DOI 10.1097/00004872-200208000-00010; Grundy SM, 2003, CIRCULATION, V107, P1834, DOI 10.1161/01.CIR.0000059746.10326.09; Guallar E, 2002, NEW ENGL J MED, V347, P1747, DOI 10.1056/NEJMoa020157; Harris WS, 1997, AM J CLIN NUTR, V65, P1645, DOI 10.1093/ajcn/65.5.1645S; Harris WS, 2003, CURR OPIN LIPIDOL, V14, P9, DOI 10.1097/00041433-200302000-00003; Heller A, 1998, DRUGS, V55, P487, DOI 10.2165/00003495-199855040-00001; Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815; Hu FB, 2003, CIRCULATION, V107, P1852, DOI 10.1161/01.CIR.0000062644.42133.5F; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S; Kristensen SD, 2001, LIPIDS, V36, pS79, DOI 10.1007/s11745-001-0671-2; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; Leaf A, 2003, CIRCULATION, V107, P2646, DOI 10.1161/01.CIR.0000069566.78305.33; Leeson CPM, 2002, EUR HEART J, V23, P216, DOI 10.1053/euhj.2001.2728; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; Marckmann P, 1999, EUR J CLIN NUTR, V53, P585, DOI 10.1038/sj.ejcn.1600832; Montori VM, 2000, DIABETES CARE, V23, P1407, DOI 10.2337/diacare.23.9.1407; Mori TA, 1997, ARTERIOSCL THROM VAS, V17, P279, DOI 10.1161/01.ATV.17.2.279; Mori TA, 2000, CIRCULATION, V102, P1264, DOI 10.1161/01.CIR.102.11.1264; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; Nestel P, 2002, AM J CLIN NUTR, V76, P326, DOI 10.1093/ajcn/76.2.326; Nilsen DWT, 2001, AM J CLIN NUTR, V74, P50; Singh RB, 1997, CARDIOVASC DRUG THER, V11, P485, DOI 10.1023/A:1007757724505; Thies F, 2003, LANCET, V361, P477, DOI 10.1016/S0140-6736(03)12468-3; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; von Schacky C, 1999, ANN INTERN MED, V130, P554, DOI 10.7326/0003-4819-130-7-199904060-00003; WEINER BH, 1986, NEW ENGL J MED, V315, P841, DOI 10.1056/NEJM198610023151401	39	249	302	0	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	2004	328	7430					30	35		10.1136/bmj.328.7430.30	http://dx.doi.org/10.1136/bmj.328.7430.30			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703544	Green Published, Green Submitted			2022-12-28	WOS:000187919000020
J	Graffy, J; Taylor, J; Williams, A; Eldridge, S				Graffy, J; Taylor, J; Williams, A; Eldridge, S			Randomised controlled trial of support from volunteer counsellors for mothers considering breast feeding	BRITISH MEDICAL JOURNAL			English	Article							INTERVENTION TRIAL; EXPERIENCE; PROMOTION	Objective To investigate whether offering volunteer support from counsellors in breast feeding would result in more women breast feeding. Design Randomised controlled trial. Setting 32 general practices in London and south Essex. Participants 720 women considering breast feeding. Main outcome measures Primary outcome was prevalence of any breast feeding at six weeks. Secondary outcomes were the proportion of women giving any breast feeds, or bottle feeds at four months, duration of any breast feeding, time to introduction of bottle feeds, and satisfaction with breast feeding. Results Offering support in breast feeding did not significantly increase the prevalence of any breast feeding to six weeks (65% (218/336) in the intervention group and 63% (213/336) in the control group; relative risk 1.02, 95% confidence interval 0.84 to 1.24). Survival analysis up to four months confirmed that neither duration of breast feeding nor time to introduction of formula feeds differed significantly:between control and intervention groups. Not all women in the intervention group contacted counsellors postnatally, but 73% (123/179) of those who did rated them as very helpful. More women in the intervention group than in the control group said that their most helpful advice came from counsellors rather than from other sources. Conclusions Women valued the support of a counsellor in breast feeding, but the intervention did not significantly increase breastfeeding rates, perhaps because some women did not ask for help.	Univ London, Queen Mary, Barts & London, Dept Gen Practice & Primary Care, London E1 4NS, England; Statham Grove Surg, London N16 9DP, England; Univ London St Georges Hosp, Sch Med, London SW17 0QT, England	University of London; Queen Mary University London; St Georges University London	Graffy, J (corresponding author), Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.							BARROS FC, 1994, REV SAUDE PUBL, V28, P277, DOI 10.1590/S0034-89101994000400006; *BREASTF PROM GROU, 1992, COD COND BREASTF COU; BUNTON R, 1991, HEALTH EDUC RES, V6, P153, DOI 10.1093/her/6.2.153; Dennis CL, 2002, CAN MED ASSOC J, V166, P21; GRAFFY JP, 1992, BRIT J GEN PRACT, V42, P61; GRAFFY JP, 2002, THESIS U BIRMINGHAM; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; HAMLYN B, 2002, INFANT BREEDING 2000; *HLTH ED AUTH, 1992, BREASTF YOUR QUEST A; Houston M J, 1981, Health Bull (Edinb), V39, P166; JONES DA, 1986, J EPIDEMIOL COMMUN H, V40, P45, DOI 10.1136/jech.40.1.45; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Leff E W, 1994, J Hum Lact, V10, P105, DOI 10.1177/089033449401000217; McInnes RJ, 2001, MIDWIFERY, V17, P65, DOI 10.1054/midw.2000.0236; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; *NAT CHILDB TRUST, 1990, BREASTF GOOD START; Rajan L, 1993, Midwifery, V9, P197, DOI 10.1016/0266-6138(93)90003-B; SIKORSKI J, 2002, COCHRANE LIB; Tedstone A, 1998, EFFECTIVENESS INTERV; *WHO SECR, 2002, WHA5515 WHO SECR; WILLIAMS AF, 1994, ARCH DIS CHILD, V71, P376	21	72	75	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 3	2004	328	7430					26	29		10.1136/bmj.328.7430.26	http://dx.doi.org/10.1136/bmj.328.7430.26			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	761QG	14703543	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000187919000019
J	James, A; Horton, R; Collingridge, D; McConnell, J; Butcher, J				James, A; Horton, R; Collingridge, D; McConnell, J; Butcher, J			The Lancet's policy on conflicts of interest - 2004	LANCET			English	Editorial Material							AUTHORS		The Lancet, Lancet Oncol, Lancet Infect Dis, Lancet Neurol, London NW1 7BY, England		James, A (corresponding author), The Lancet, Lancet Oncol, Lancet Infect Dis, Lancet Neurol, London NW1 7BY, England.	astrid.james@lancet.com		Butcher, James/0000-0001-8546-6093; McConnell, John/0000-0002-9928-6568				Angeli M, 1996, NEW ENGL J MED, V335, P1055, DOI 10.1056/NEJM199610033351410; Angell M, 2000, NEW ENGL J MED, V342, P586, DOI 10.1056/NEJM200002243420812; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Davidoff F, 2001, LANCET, V358, P854, DOI 10.1016/S0140-6736(01)06035-4; Drazen JM, 2002, NEW ENGL J MED, V346, P1901, DOI 10.1056/NEJMe020074; Editorial, 2003, NAT NEUROSCI, V6, P997; *INT COMM MED J ED, 2001, UN REQ MAN SUBM BIOM; James A, 2003, LANCET, V361, P8, DOI 10.1016/S0140-6736(03)12184-8; RELMAN AS, 1990, NEW ENGL J MED, V323, P56, DOI 10.1056/NEJM199007053230111; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Vandenbroucke JP, 1998, LANCET, V352, P2001, DOI 10.1016/S0140-6736(98)10208-8; 2003, NY TIMES        0930, P28	13	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					2	3		10.1016/S0140-6736(03)15229-4	http://dx.doi.org/10.1016/S0140-6736(03)15229-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723981				2022-12-28	WOS:000187711300002
J	Khaw, PT; Shah, P; Elkington, AR				Khaw, PT; Shah, P; Elkington, AR			ABC of eyes - Injury to the eye	BRITISH MEDICAL JOURNAL			English	Article								An injury to the eye or its surrounding tissues is the most common cause for attendance at an eye hospital emergency department.	Moorfields Eye Hosp, London, England; Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England; Univ Southampton, Southampton SO9 5NH, Hants, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of Southampton	Khaw, PT (corresponding author), Moorfields Eye Hosp, London, England.		Khaw, Peng T/C-1881-2008	Khaw, Sir Peng Tee/0000-0002-8087-2268					0	24	25	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 3	2004	328	7430					36	38		10.1136/bmj.328.7430.36	http://dx.doi.org/10.1136/bmj.328.7430.36			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703545	Green Published			2022-12-28	WOS:000187919000022
J	Si, K; Giustetto, M; Etkin, A; Hsu, R; Janisiewicz, AM; Miniaci, MC; Kim, JH; Zhu, HX; Kandel, ER				Si, K; Giustetto, M; Etkin, A; Hsu, R; Janisiewicz, AM; Miniaci, MC; Kim, JH; Zhu, HX; Kandel, ER			A neuronal isoform of CPEB regulates local protein synthesis and stabilizes synapse-specific long-term facilitation in Aplysia	CELL			English	Article							XENOPUS OOCYTE MATURATION; ELEMENT-BINDING PROTEIN; CAMKII MESSENGER-RNA; DROSOPHILA ORB GENE; CYTOPLASMIC POLYADENYLATION; TRANSLATIONAL CONTROL; S6 KINASE; EXPRESSION; PHOSPHORYLATION; POTENTIATION	Synapse-specific facilitation requires rapamycin-dependent local protein synthesis at the activated synapse. In Aplysia, rapamycin-dependent local protein synthesis serves two functions: (1) it provides a component of the mark at the activated synapse and thereby confers synapse specificity and (2) it stabilizes the synaptic growth associated with long-term facilitation. Here we report that a neuron-specific isoform of cytoplasmic polyadenylation element binding protein (CPEB) regulates this synaptic protein synthesis in an activity-dependent manner. Aplysia CPEB protein is upregulated locally at activated synapses, and it is needed not for the initiation but for the stable maintenance of long-term facilitation. We suggest that Aplysia CPEB is one of the stabilizing components of the synaptic mark.	Columbia Univ, New York State Psychiat Inst, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, New York State Psychiat Inst, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; New York State Psychiatry Institute; Columbia University; New York State Psychiatry Institute	Si, K (corresponding author), Columbia Univ, New York State Psychiat Inst, Coll Phys & Surg, Howard Hughes Med Inst, 722 W 168th St, New York, NY 10032 USA.	ks560@columbia.edu; erk5@columbia.edu	Etkin, Amit/ABD-5761-2021; giustetto, maurizio/D-6606-2011	giustetto, maurizio/0000-0003-1323-4060; Miniaci, Maria/0000-0003-3844-0581				Bally-Cuif L, 1998, MECH DEVELOP, V77, P31, DOI 10.1016/S0925-4773(98)00109-9; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Chang JS, 1999, DEV BIOL, V215, P91, DOI 10.1006/dbio.1999.9444; Chang JS, 2001, DEVELOPMENT, V128, P3169; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; DESGROSEILLERS L, 1994, BBA-GENE STRUCT EXPR, V1217, P322, DOI 10.1016/0167-4781(94)90293-3; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Gebauer F, 1996, P NATL ACAD SCI USA, V93, P14602, DOI 10.1073/pnas.93.25.14602; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Khan A, 2001, J NEUROSCI, V21, P382, DOI 10.1523/JNEUROSCI.21-02-00382.2001; Kim CH, 1999, J NEUROSCI, V19, P4314; Kim JH, 2003, NEURON, V40, P151, DOI 10.1016/S0896-6273(03)00595-6; LANTZ V, 1992, DEVELOPMENT, V115, P75; Liu JM, 2003, BRAIN RES, V959, P68, DOI 10.1016/S0006-8993(02)03729-0; Liu QR, 1997, J NEUROSCI, V17, P755; Loreni F, 2000, EUR J BIOCHEM, V267, P6594, DOI 10.1046/j.1432-1327.2000.01753.x; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Moccia R, 2003, J NEUROSCI, V23, P9409; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Reverte CG, 2003, DEV BIOL, V255, P383, DOI 10.1016/S0012-1606(02)00089-1; Salles FJ, 1999, METH MOL B, V118, P441; Schroeder KE, 1999, DEV BIOL, V214, P288, DOI 10.1006/dbio.1999.9426; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Tan LH, 2001, DEVELOPMENT, V128, P1159; Theis M, 2003, P NATL ACAD SCI USA, V100, P9602, DOI 10.1073/pnas.1133424100; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; [No title captured]	43	322	333	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	2003	115	7					893	904		10.1016/S0092-8674(03)01021-3	http://dx.doi.org/10.1016/S0092-8674(03)01021-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	758RV	14697206	Bronze			2022-12-28	WOS:000187664700012
J	Vikram, HR; Buenconsejo, J; Hasbun, R; Quagliarello, VJ				Vikram, HR; Buenconsejo, J; Hasbun, R; Quagliarello, VJ			Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis - A propensity analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-DEATH-INDEX; ACTIVE INFECTIVE ENDOCARDITIS; ECHOCARDIOGRAPHIC FINDINGS; SURGICAL-TREATMENT; CONTROLLED-TRIALS; VITAL STATUS; REPLACEMENT; SURVIVAL; DIAGNOSIS; DISEASE	Context Complicated, left-sided native valve endocarditis causes significant morbidity and mortality in adults. The presumed benefits of valve surgery remain unproven due to lack of randomized controlled trials. Objective To determine whether valve surgery is associated with reduced mortality in adults with complicated, left-sided native valve endocarditis. Design and Setting Retrospective, observational cohort study conducted from January 1990 to January 2000 at 7 Connecticut hospitals. Propensity analyses were used to control for bias in treatment assignment and prognostic imbalances. Patients Of the 513 adults with complicated, left-sided native valve endocarditis, 230 (45%) underwent valve surgery and 283 (55%) received medical therapy alone. Main Outcome Measure All-cause mortality at 6 months after baseline. Results In the 6-month period after baseline, 131 patients (26%) died. in unadjusted analyses, valve surgery was associated with reduced mortality (16% vs 33%; hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.29-0.63; P<.001). After adjustment for baseline variables associated with mortality (including hospital site, comorbidity, congestive heart failure, microbial etiology, immunocompromised state, abnormal mental status, and refractory infection), valve surgery remained associated with reduced mortality (adjusted HR, 0.35; 95% Cl, 0.23-0.54; P<.02). In further analyses of 218 patients matched by propensity scores, valve surgery remained associated with reduced mortality (15% vs 28%; HR, 0.45; 95% Cl, 0.23-0.86; P=.01). After additional adjustment for variables that contribute to heterogeneity and confounding within the propensity-matched group, surgical therapy remained significantly associated with a lower mortality (HR, 0.40; 95% Cl, 0.18-0.91; P=.03). in this propensity-matched group, patients with moderate to severe congestive heart failure showed the greatest reduction in mortality with valve surgery (14% vs 51 %; HR, 0.22; 95% Cl, 0.09-0.53; P=.001). Conclusions Valve surgery for patients with complicated, left-sided native valve endocarditis was independently associated with reduced 6-month mortality after adjustment for both baseline variables associated with the propensity to undergo valve surgery and baseline variables associated with mortality. The reduced mortality was particularly evident among patients with moderate to severe congestive heart failure.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Quagliarello, VJ (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 208022,800 LCI, New Haven, CT 06520 USA.	vincent.quagliarello@yale.edu						Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Bayer AS, 1998, CIRCULATION, V98, P2936, DOI 10.1161/01.CIR.98.25.2936; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BRANIFF BA, 1967, NEW ENGL J MED, V276, P1464, DOI 10.1056/NEJM196706292762604; Cabell CH, 2001, AM HEART J, V142, P75, DOI 10.1067/mhj.2001.115790; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Choussat R, 1999, EUR HEART J, V20, P232, DOI 10.1053/euhj.1998.1240; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cotrufo M, 2001, J HEART VALVE DIS, V10, P478; CROFT CH, 1983, AM J CARDIOL, V51, P1650, DOI 10.1016/0002-9149(83)90203-5; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Delle Karth G, 2002, CRIT CARE, V6, P149, DOI 10.1186/cc1474; DINUBILE MJ, 1982, ANN INTERN MED, V96, P650, DOI 10.7326/0003-4819-96-5-650; dUdekem Y, 1997, EUR J CARDIO-THORAC, V11, P46, DOI 10.1016/S1010-7940(96)01020-2; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Ellis ME, 2001, CLIN INFECT DIS, V32, P50, DOI 10.1086/317550; Foody JM, 2001, AM J CARDIOL, V87, P706, DOI 10.1016/S0002-9149(00)01487-9; Gum PA, 2001, JAMA-J AM MED ASSOC, V286, P1187, DOI 10.1001/jama.286.10.1187; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hasbun R, 2003, JAMA-J AM MED ASSOC, V289, P1933, DOI 10.1001/jama.289.15.1933; Heiro M, 2000, ARCH INTERN MED, V160, P2781, DOI 10.1001/archinte.160.18.2781; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; KARALIS DG, 1991, AM J MED, V90, P193; Knosalla C, 2000, EUR HEART J, V21, P490, DOI 10.1053/euhj.1999.1877; Langley SM, 2000, J HEART VALVE DIS, V9, P697; Lash TL, 2001, EPIDEMIOLOGY, V12, P259, DOI 10.1097/00001648-200103000-00021; Lytle BW, 1999, J THORAC CARDIOV SUR, V117, P855, DOI 10.1016/S0022-5223(99)70365-X; Mathew J, 2001, ANGIOLOGY, V52, P801, DOI 10.1177/000331970105201201; MIDDLEMOST S, 1991, J AM COLL CARDIOL, V18, P663, DOI 10.1016/0735-1097(91)90785-8; MULLANY CJ, 1995, MAYO CLIN PROC, V70, P517, DOI 10.4065/70.6.517; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; Olaison L, 2002, INFECT DIS CLIN N AM, V16, P453, DOI 10.1016/S0891-5520(01)00006-X; Pompilio G, 1998, CARDIOVASC SURG, V6, P126, DOI 10.1016/S0967-2109(97)00139-7; RICHARDSON JV, 1978, CIRCULATION, V58, P589, DOI 10.1161/01.CIR.58.4.589; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SCHULZE G, 1990, NEUROCHEM INT, V17, P281, DOI 10.1016/0197-0186(90)90150-R; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Thalme A, 2000, SCAND J INFECT DIS, V32, P303, DOI 10.1080/00365540050165965; Tischler MD, 1997, J AM SOC ECHOCARDIOG, V10, P562, DOI 10.1016/S0894-7317(97)70011-7; WALLACE AG, 1965, CIRCULATION, V31, P450, DOI 10.1161/01.CIR.31.3.450; Wallace SM, 2002, HEART, V88, P53, DOI 10.1136/heart.88.1.53; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; YOUNG JB, 1979, CIRCULATION, V60, pI77	44	230	244	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2003	290	24					3207	3214		10.1001/jama.290.24.3207	http://dx.doi.org/10.1001/jama.290.24.3207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756TR	14693873				2022-12-28	WOS:000187499300024
J	Holbrook, A; Goldsmith, C				Holbrook, A; Goldsmith, C			Innovation and placebos in research: a new design of clinical trial	LANCET			English	Editorial Material							DISORDERS; ETHICS		St Josephs Healthcare, Ctr Evaluat Med, Hamilton, ON L8N 1G6, Canada; McMaster Univ, Div Clin Pharmacol, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University	Holbrook, A (corresponding author), St Josephs Healthcare, Ctr Evaluat Med, Hamilton, ON L8N 1G6, Canada.		anand, amit/A-7222-2009					Amdur RJ, 2001, INT J CANCER, V96, P261, DOI 10.1002/ijc.1026; Charney DS, 2002, ARCH GEN PSYCHIAT, V59, P262, DOI 10.1001/archpsyc.59.3.262; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; Fava M, 2003, PSYCHOTHER PSYCHOSOM, V72, P115, DOI 10.1159/000069738; Feinstein AR, 2002, J CLIN EPIDEMIOL, V55, P427, DOI 10.1016/S0895-4356(01)00495-4; GOLDSMITH CH, 2002, JOINT STAT M NEW YOR, P282; Huston P, 2001, NEW ENGL J MED, V345, P912, DOI 10.1056/NEJM200109203451210; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Weijer C, 2002, CAN MED ASSOC J, V166, P603	10	3	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2036	2037		10.1016/S0140-6736(03)15147-1	http://dx.doi.org/10.1016/S0140-6736(03)15147-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697799				2022-12-28	WOS:000187429600004
J	Horton, R				Horton, R			Read all about it: The Lancet's Paper of the Year, 2003	LANCET			English	Article									Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, 32 Jamestown Rd, London NW1 7BY, England.			Rosenberg, Noah/0000-0002-1829-8664				DAMADIAN R, 2003, NY TIMES        1103, pA9	1	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2101	2103		10.1016/S0140-6736(03)15110-0	http://dx.doi.org/10.1016/S0140-6736(03)15110-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697815	Green Published, Bronze			2022-12-28	WOS:000187429600029
J	Mintz, E				Mintz, E			A riddle wrapped in a mystery inside an enigma: Brainerd diarrhoea turns 20	LANCET			English	Editorial Material							CHRONIC IDIOPATHIC DIARRHEA; OUTBREAK		Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Mintz, E (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.							AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; Bryant DA, 1996, AM J SURG PATHOL, V20, P1102, DOI 10.1097/00000478-199609000-00008; Fine KD, 1999, GASTROENTEROLOGY, V116, P1464, DOI 10.1016/S0016-5085(99)70513-5; Mintz ED, 1998, J INFECT DIS, V177, P1041, DOI 10.1086/515237; MINTZ ED, 1993, NEW ENGL J MED, V328, P1713; MYERS LL, 1989, J INFECT DIS, V159, P133, DOI 10.1093/infdis/159.1.133; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; Pardi DS, 2003, MAYO CLIN PROC, V78, P614, DOI 10.4065/78.5.614; PARSONNET J, 1989, ANN INTERN MED, V110, P985, DOI 10.7326/0003-4819-110-12-985; PARSONNET J, 2002, INFECT GASTROINTESTI, P267; Taylor DN, 1999, MED CLIN N AM, V83, P1033	11	10	10	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2037	2038		10.1016/S0140-6736(03)15148-3	http://dx.doi.org/10.1016/S0140-6736(03)15148-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697800				2022-12-28	WOS:000187429600005
J	Miranda, JJ				Miranda, JJ			TB and you and me ... personal reflections	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England	University of London; University College London	Miranda, JJ (corresponding author), UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England.		Miranda, J. Jaime/A-8482-2008	Miranda, J. Jaime/0000-0002-4738-5468					0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2081	2082		10.1016/S0140-6736(03)15106-9	http://dx.doi.org/10.1016/S0140-6736(03)15106-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697811				2022-12-28	WOS:000187429600025
J	Novoselov, KS; Geim, AK; Dubonos, SV; Hill, EW; Grigorieva, IV				Novoselov, KS; Geim, AK; Dubonos, SV; Hill, EW; Grigorieva, IV			Subatomic movements of a domain wall in the Peierls potential	NATURE			English	Article							INTRINSIC COERCIVE FIELD; HALL-MAGNETOMETRY; PROPAGATION	The discrete nature of crystal lattices plays a role in virtually every material property. But it is only when the size of entities hosted by a crystal becomes comparable to the lattice period - as occurs for dislocations(1-3), vortices in superconductors(4-6) and domain walls(7-9) - that this discreteness is manifest explicitly. The associated phenomena are usually described in terms of a background Peierls 'atomic washboard' energy potential, which was first introduced for the case of dislocation motion(1,2) in the 1940s. This concept has subsequently been invoked in many situations to describe certain features in the bulk behaviour of materials, but has to date eluded direct detection and experimental scrutiny at a microscopic level. Here we report observations of the motion of a single magnetic domain wall at the scale of the individual peaks and troughs of the atomic energy landscape. Our experiments reveal that domain walls can become trapped between crystalline planes, and that they propagate by distinct jumps that match the lattice periodicity. The jumps between valleys are found to involve unusual dynamics that shed light on the microscopic processes underlying domain-wall propagation. Such observations offer a means for probing experimentally the physics of topological defects in discrete lattices - a field rich in phenomena that have been subject to extensive theoretical study(10-12).	Univ Manchester, Dept Phys, Manchester M13 9PL, Lancs, England; Univ Manchester, Dept Comp Sci, Manchester M13 9PL, Lancs, England; Russian Acad Sci, Inst Microelect Technol, Chernogolovka 142432, Russia	University of Manchester; University of Manchester; Russian Academy of Sciences	Geim, AK (corresponding author), Univ Manchester, Dept Phys, Manchester M13 9PL, Lancs, England.	geim@man.ac.uk	Hill, Ernie/K-6942-2015; Geim, Andre K/J-7888-2012; Novoselov, Kostya S/G-9581-2014	Hill, Ernie/0000-0001-9412-6795; Geim, Andre K/0000-0003-2861-8331; Novoselov, Kostya S/0000-0003-4972-5371; hai yan, he/0000-0003-0366-6185				ACHESON D, 1997, CALCULUS CHAOS; ARNAUDAS JI, 1986, J MAGN MAGN MATER, V61, P370, DOI 10.1016/0304-8853(86)90051-X; AUBRY S, 1983, J PHYS-PARIS, V44, P147, DOI 10.1051/jphys:01983004402014700; BARBARA B, 1973, J PHYS-PARIS, V34, P1039, DOI 10.1051/jphys:019730034011-120103900; BISHOP AR, 1979, J PHYS C SOLID STATE, V12, P3811, DOI 10.1088/0022-3719/12/18/027; Braun OM, 1998, PHYS REP, V306, P1, DOI 10.1016/S0370-1573(98)00029-5; EGAMI T, 1973, PHYS STATUS SOLIDI A, V19, P747, DOI 10.1002/pssa.2210190242; EGAMI T, 1971, J APPL PHYS, V42, P1299, DOI 10.1063/1.1660224; Geim AK, 1997, APPL PHYS LETT, V71, P2379, DOI 10.1063/1.120034; Geim AK, 1997, NATURE, V390, P259, DOI 10.1038/36797; Hengstmann TM, 2001, J APPL PHYS, V90, P6542, DOI 10.1063/1.1413238; HILZINGER HR, 1972, PHYS STATUS SOLIDI B, V54, P593, DOI 10.1002/pssb.2220540223; IVLEV BI, 1990, PHYS REV LETT, V64, P1828, DOI 10.1103/PhysRevLett.64.1828; KENT AD, 1994, J APPL PHYS, V76, P6656, DOI 10.1063/1.358160; Kim DH, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.087203; Kolar HR, 1996, PHYS REV LETT, V77, P4031, DOI 10.1103/PhysRevLett.77.4031; Li YQ, 2002, APPL PHYS LETT, V80, P4644, DOI 10.1063/1.1487921; Magnus K., 1965, VIBRATIONS; MUSBNISKOV NV, 2002, J ALLOY COMPD, V305, P188; NABARRO FRN, 1947, P PHYS SOC LOND, V59, P256, DOI 10.1088/0959-5309/59/2/309; Novoselov KS, 2002, IEEE T MAGN, V38, P2583, DOI 10.1109/TMAG.2002.801959; OUSSENA M, 1994, PHYS REV LETT, V72, P3606, DOI 10.1103/PhysRevLett.72.3606; Pavlov VV, 1997, PHYS REV LETT, V78, P2004, DOI 10.1103/PhysRevLett.78.2004; Peeters FM, 1998, APPL PHYS LETT, V72, P572, DOI 10.1063/1.120759; Peierls R, 1940, P PHYS SOC, V52, P34, DOI 10.1088/0959-5309/52/1/305; PISAREV RV, 1993, J PHYS-CONDENS MAT, V5, P8621, DOI 10.1088/0953-8984/5/45/015; Schuh D, 2001, IEEE T MAGN, V37, P2091, DOI 10.1109/20.951063; VANDENBROEK JJ, 1971, IEEE T MAGN, VMAG7, P226, DOI 10.1109/TMAG.1971.1067036; VERGNE R, 1981, REV PHYS APPL, V16, P449, DOI 10.1051/rphysap:01981001609044900; Wunderlich J, 2001, IEEE T MAGN, V37, P2104, DOI 10.1109/20.951067	31	80	82	2	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					812	816		10.1038/nature02180	http://dx.doi.org/10.1038/nature02180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685231	Green Submitted			2022-12-28	WOS:000187342000050
J	Wu, L; Hickson, ID				Wu, L; Hickson, ID			The Bloom's syndrome helicase suppresses crossing over during homologous recombination	NATURE			English	Article							SYNDROME GENE-PRODUCT; TOPOISOMERASE-III-ALPHA; STRAND-BREAK REPAIR; HOLLIDAY JUNCTION RESOLUTION; RECQ HELICASES; ESCHERICHIA-COLI; BRANCH MIGRATION; MAMMALIAN-CELLS; MEIOSIS; YEAST	Mutations in BLM, which encodes a RecQ helicase, give rise to Bloom's syndrome, a disorder associated with cancer predisposition and genomic instability(1). A defining feature of Bloom's syndrome is an elevated frequency of sister chromatid exchanges(2). These arise from crossing over of chromatid arms during homologous recombination, a ubiquitous process that exists to repair DNA double-stranded breaks and damaged replication forks. Whereas crossing over is required in meiosis, in mitotic cells it can be associated with detrimental loss of heterozygosity. BLM forms an evolutionarily conserved complex with human topoisomerase IIIalpha (hTOPO IIIalpha)(3,4), which can break and rejoin DNA to alter its topology. Inactivation of homologues of either protein leads to hyper-recombination in unicellular organisms(5). Here, we show that BLM and hTOPO IIIalpha together effect the resolution of a recombination intermediate containing a double Holliday junction. The mechanism, which we term double-junction dissolution, is distinct from classical Holliday junction resolution and prevents exchange of flanking sequences. Loss of such an activity explains many of the cellular phenotypes of Bloom's syndrome. These results have wider implications for our understanding of the process of homologous recombination and the mechanisms that exist to prevent tumorigenesis.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England.		Hickson, Ian/AAJ-7548-2020					Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; BENSON FE, 1994, J BIOL CHEM, V269, P5195; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FU TJ, 1994, J MOL BIOL, V236, P91, DOI 10.1006/jmbi.1994.1121; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Johnson FB, 2000, CANCER RES, V60, P1162; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2001, CELL MOL LIFE SCI, V58, P894, DOI 10.1007/PL00000909	28	848	863	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					870	874		10.1038/nature02253	http://dx.doi.org/10.1038/nature02253			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685245				2022-12-28	WOS:000187342000066
J	Schar, C; Vidale, PL; Luthi, D; Frei, C; Haberli, C; Liniger, MA; Appenzeller, C				Schar, C; Vidale, PL; Luthi, D; Frei, C; Haberli, C; Liniger, MA; Appenzeller, C			The role of increasing temperature variability in European summer heatwaves	NATURE			English	Article							CLIMATE-CHANGE; MODEL; DRYNESS; EVENTS; HADCM3	Instrumental observations(1,2) and reconstructions(3,4) of global and hemispheric temperature evolution reveal a pronounced warming during the past similar to150 years. One expression of this warming is the observed increase in the occurrence of heatwaves(5,6). Conceptually this increase is understood as a shift of the statistical distribution towards warmer temperatures, while changes in the width of the distribution are often considered small(7). Here we show that this framework fails to explain the record- breaking central European summer temperatures in 2003, although it is consistent with observations from previous years. We find that an event like that of summer 2003 is statistically extremely unlikely, even when the observed warming is taken into account. We propose that a regime with an increased variability of temperatures ( in addition to increases in mean temperature) may be able to account for summer 2003. To test this proposal, we simulate possible future European climate with a regional climate model in a scenario with increased atmospheric greenhouse- gas concentrations, and find that temperature variability increases by up to 100%, with maximum changes in central and eastern Europe.	Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland; MeteoSwiss, CH-8044 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schar, C (corresponding author), Swiss Fed Inst Technol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	schaer@env.ethz.ch	Appenzeller, Christof/AAA-8989-2022; Nahas, Alberth/C-8379-2013; Appenzeller, Christof/B-3015-2013; Liniger, Mark/K-7757-2013; Vidale, Pier Luigi/AAF-6468-2019; Schar, Christoph/A-1033-2008	Appenzeller, Christof/0000-0002-9939-9845; Appenzeller, Christof/0000-0002-9939-9845; Liniger, Mark/0000-0003-4294-6868; Vidale, Pier Luigi/0000-0002-1800-8460; Schar, Christoph/0000-0002-4171-1613				Allen M, 2003, NATURE, V421, P891, DOI 10.1038/421891a; Aschwanden A, 1996, BEREINIGTE ZEITREIHE; BERGERT M, 2003, VEROFFENTLICHUNGEN M, V67; Christensen JH, 2003, NATURE, V421, P805, DOI 10.1038/421805a; Collins M, 2001, CLIM DYNAM, V17, P61, DOI 10.1007/s003820000094; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Easterling DR, 2000, B AM METEOROL SOC, V81, P417, DOI 10.1175/1520-0477(2000)081<0417:OVATIE>2.3.CO;2; ENTEKHABI D, 1992, J CLIMATE, V5, P798, DOI 10.1175/1520-0442(1992)005&lt;0798:VILSWB&gt;2.0.CO;2; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Folland CK, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P99; Folland CK, 2001, GEOPHYS RES LETT, V28, P2621, DOI 10.1029/2001GL012877; Frich P, 2002, CLIMATE RES, V19, P193, DOI 10.3354/cr019193; HARTMANN DL, 1994, GLOBAL PHYSICAL CLIM; Jacobeit J, 1999, CLIMATIC CHANGE, V43, P201, DOI 10.1023/A:1005594216878; Johns TC, 2003, CLIM DYNAM, V20, P583, DOI 10.1007/s00382-002-0296-y; Jones PD, 2001, SCIENCE, V292, P662, DOI 10.1126/science.1059126; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Jones R, 2001, ENSEMBLE MEAN CHANGE; KATZ RW, 1992, CLIMATIC CHANGE, V21, P289, DOI 10.1007/BF00139728; Nakicenovic N., 2000, IPCC SPECIAL REPORT; Pfister C, 1999, CLIMATIC CHANGE, V43, P55, DOI 10.1023/A:1005540707792; Pope VD, 2000, CLIM DYNAM, V16, P123, DOI 10.1007/s003820050009; Rodwell MJ, 2001, J CLIMATE, V14, P3192, DOI 10.1175/1520-0442(2001)014<3192:SAASM>2.0.CO;2; Schar C, 1999, J CLIMATE, V12, P722, DOI 10.1175/1520-0442(1999)012<0722:TSPFAP>2.0.CO;2; Seneviratne SI, 2002, CLIM DYNAM, V20, P69, DOI 10.1007/s00382-002-0258-4; SIMMONS AJ, 2000, PROJECT REPORT SERIE, V1; VIDALE PL, 2003, J GEOPHYS RES D, V108, DOI DOI 10.1029/2000JD002810; Wetherald RT, 1995, J CLIMATE, V8, P3096, DOI 10.1175/1520-0442(1995)008<3096:TMOSDI>2.0.CO;2; Wild M, 1996, CLIM DYNAM, V12, P755, DOI 10.1007/s003820050141	29	2005	2055	13	388	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	2004	427	6972					332	336		10.1038/nature02300	http://dx.doi.org/10.1038/nature02300			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765KE	14716318				2022-12-28	WOS:000188266200035
J	Broder, MS; Simon, LP; Brook, RH				Broder, MS; Simon, LP; Brook, RH			Surgical quality: review of Californian measures	BRITISH MEDICAL JOURNAL			English	Review							VOLUME		Zynx Hlth, Beverly Hills, CA 90212 USA; RAND Hlth, Santa Monica, CA USA; Calif Healthcare Fdn, San Francisco, CA USA	RAND Corporation	Broder, MS (corresponding author), Zynx Hlth, Beverly Hills, CA 90212 USA.	mbroder@cerner.com						Epstein AM, 2002, NEW ENGL J MED, V346, P1161, DOI 10.1056/NEJM200204113461512; Gillum B S, 1996, Vital Health Stat 13, P1; Khuri SF, 1999, ANN SURG, V230, P414, DOI 10.1097/00000658-199909000-00014; *OFF STAT HLTH PLA, HOSP ANN UT	4	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2004	328	7432					152	153		10.1136/bmj.328.7432.152	http://dx.doi.org/10.1136/bmj.328.7432.152			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765CQ	14726345	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000188249900024
J	Pace, ML; Cole, JJ; Carpenter, SR; Kitchell, JF; Hodgson, JR; Van de Bogert, MC; Bade, DL; Kritzberg, ES; Bastviken, D				Pace, ML; Cole, JJ; Carpenter, SR; Kitchell, JF; Hodgson, JR; Van de Bogert, MC; Bade, DL; Kritzberg, ES; Bastviken, D			Whole-lake carbon-13 additions reveal terrestrial support of aquatic food webs	NATURE			English	Article							ORGANIC-MATTER; GROWTH-RATE; CARBON; FRACTIONATION; ZOOPLANKTON; ENERGY; TRACE; FLOW	Ecosystems are supported by organic carbon from two distinct sources. Endogenous carbon is produced by photosynthesis within an ecosystem by autotrophic organisms. Exogenous carbon is produced elsewhere and transported into ecosystems. Consumers may use exogenous carbon with consequent influences on population dynamics, predator-prey relationships and ecosystem processes(1). For example, exogenous inputs provide resources that may enhance consumer abundance beyond levels supported by within-system primary production(2). Exogenous fluxes of organic carbon to ecosystems are often large, but this material is recalcitrant and difficult to assimilate, in contrast to endogenously produced organic matter, which is used more easily(3,4). Here we show, by the experimental manipulation of dissolved inorganic C-13 in two lakes, that internal primary production is insufficient to support the food webs of these ecosystems. Additions of NaH (CO3)-C-13 enriched the C-13 content of dissolved inorganic carbon, particulate organic carbon, zooplankton and fish. Dynamics of C-13 indicate that 40-55% of particulate organic carbon and 22-50% of zooplankton carbon are derived from terrestrial sources, showing that there is significant subsidy of these ecosystems by organic carbon produced outside their boundaries.	Inst Ecosyst Studies, Box AB, Millbrook, NY 12545 USA; Univ Wisconsin, Ctr Limnol, Madison, WI 53706 USA; St Norbert Coll, Dept Biol, De Pere, WI 54115 USA; Lund Univ, Dept Ecol Limnol, S-22362 Lund, Sweden; Linkoping Univ, Dept Water & Environm Studies, SE-58183 Linkoping, Sweden	Cary Institute of Ecosystem Studies; University of Wisconsin System; University of Wisconsin Madison; Lund University; Linkoping University	Pace, ML (corresponding author), Inst Ecosyst Studies, Box AB, Millbrook, NY 12545 USA.	pacem@ecostudies.org	Van de Bogert, Matthew/J-2616-2012; Cole, Jonathan Jay/G-4566-2011; Carpenter, Stephen/AAQ-6404-2020	Cole, Jonathan Jay/0000-0003-4633-7402; Bastviken, David/0000-0003-0038-2152; Pace, Michael/0000-0001-5945-6131				[Anonymous], [No title captured]; Bastviken D, 2003, ECOLOGY, V84, P969, DOI 10.1890/0012-9658(2003)084[0969:MAASOC]2.0.CO;2; Bidigare RR, 1997, GLOBAL BIOGEOCHEM CY, V11, P279, DOI 10.1029/96GB03939; BIRGE EA, 1927, P AM PHILOS SOC, V66, P357; Carpenter S.R., 1993, TROPHIC CASCADE LAKE; Cole JJ, 1998, ECOSYSTEMS, V1, P310, DOI 10.1007/s100219900024; COLE JJ, 1990, LIMNOL OCEANOGR, V35, P1230, DOI 10.4319/lo.1990.35.6.1230; Cole JJ, 2002, LIMNOL OCEANOGR, V47, P1664, DOI 10.4319/lo.2002.47.6.1664; Cole JJ, 2000, LIMNOL OCEANOGR, V45, P1718, DOI 10.4319/lo.2000.45.8.1718; CYR H, 1993, NATURE, V361, P148, DOI 10.1038/361148a0; Efron B., 1994, MONOGRAPHS STAT APPL; Grey J, 2001, LIMNOL OCEANOGR, V46, P505, DOI 10.4319/lo.2001.46.3.0505; HESSEN DO, 1998, AQUATIC HUMIC SUBSTA, P285; Hilborn Ray, 1997, V28; Jones RI, 1999, OIKOS, V86, P97, DOI 10.2307/3546573; KALFF J, 2002, LIMNOLOGY INLAND WAT, P366; Kerner M, 2003, NATURE, V422, P150, DOI 10.1038/nature01469; LAWS EA, 1995, GEOCHIM COSMOCHIM AC, V59, P1131, DOI 10.1016/0016-7037(95)00030-4; Lindeman RL, 1942, ECOLOGY, V23, P399, DOI 10.2307/1930126; MOOK WG, 1974, EARTH PLANET SC LETT, V22, P169, DOI 10.1016/0012-821X(74)90078-8; Nakano S, 2001, P NATL ACAD SCI USA, V98, P166, DOI 10.1073/pnas.98.1.166; PETERSON BJ, 1985, SCIENCE, V227, P1361, DOI 10.1126/science.227.4692.1361; Polis GA, 1997, ANNU REV ECOL SYST, V28, P289, DOI 10.1146/annurev.ecolsys.28.1.289; Post DM, 1997, LIMNOL OCEANOGR, V42, P722, DOI 10.4319/lo.1997.42.4.0722; Roditi HA, 2000, NATURE, V407, P78, DOI 10.1038/35024069; Tranvik L.J., 1998, AQUATIC HUMIC SUBSTA, P259, DOI [DOI 10.1007/978-3-662-03736-2_11, 10.1007/978-3-662-03736-2_11]; Wallace JB, 1997, SCIENCE, V277, P102, DOI 10.1126/science.277.5322.102; WETZEL RG, 1995, FRESHWATER BIOL, V33, P83, DOI 10.1111/j.1365-2427.1995.tb00388.x	28	437	452	6	233	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					240	243		10.1038/nature02227	http://dx.doi.org/10.1038/nature02227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724637				2022-12-28	WOS:000188068100042
J	Klein, RF; Allard, J; Avnur, Z; Nikolcheva, T; Rotstein, D; Carlos, AS; Shea, M; Waters, RV; Belknap, JK; Peltz, G; Orwoll, ES				Klein, RF; Allard, J; Avnur, Z; Nikolcheva, T; Rotstein, D; Carlos, AS; Shea, M; Waters, RV; Belknap, JK; Peltz, G; Orwoll, ES			Regulation of bone mass in mice by the lipoxygenase gene Alox15	SCIENCE			English	Article							ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; MINERAL DENSITY; OXIDIZED LDL; 15-LIPOXYGENASE; EXPRESSION; DIFFERENTIATION; 5-LIPOXYGENASE; OSTEOPOROSIS; MACROPHAGES	The development of osteoporosis involves the interaction of multiple environmental and genetic factors. Through combined genetic and genomic approaches, we identified the lipoxygenase gene Alox15 as a negative regulator of peak bone mineral density in mice. Crossbreeding experiments with Alox15 knockout mice confirmed that 12/15-lipoxygenase plays a role in skeletal development. Pharmacologic inhibitors of this enzyme improved bone density and strength in two rodent models of osteoporosis. These results suggest that drugs targeting the 12/15-lipoxygenase pathway merit investigation as a therapy for osteoporosis.	Oregon Hlth & Sci Univ, Sch Med, Dept Med, Bone & Mineral Res Unit, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Orthopaed & Rehabil, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Behav Neurosci, Portland, OR 97239 USA; Vet Affairs Med Ctr, Portland, OR 97207 USA; Roche Palo Alto, Dept Genet & Gen, Palo Alto, CA 94303 USA; Roche Palo Alto, Dept Chem, Palo Alto, CA 94303 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding; Roche Holding	Klein, RF (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Med, Bone & Mineral Res Unit, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.		Rotstein, David/K-6691-2019	Orwoll, Eric/0000-0002-8520-7355	NHGRI NIH HHS [HG02322] Funding Source: Medline; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline; NIAMS NIH HHS [AR44659, R01 AR044659-08, R01 AR044659] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bonewald LF, 1997, ADV EXP MED BIOL, V433, P299; Cornicelli JA, 1999, CURR PHARM DESIGN, V5, P11; Devoto M, 1998, EUR J HUM GENET, V6, P151, DOI 10.1038/sj.ejhg.5200169; Feng JW, 2000, J LIPID RES, V41, P688; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Huang QY, 2003, OSTEOPOROSIS INT, V14, P701, DOI 10.1007/s00198-003-1445-9; Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560; Khan E, 2003, J LAB CLIN MED, V142, P29, DOI 10.1016/S0022-2143(03)00058-1; Klein RF, 2001, J BONE MINER RES, V16, P1953, DOI 10.1359/jbmr.2001.16.11.1953; Kuhn H, 2002, PROSTAG OTH LIPID M, V68-9, P263, DOI 10.1016/S0090-6980(02)00035-7; Lecka-Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; Mackay TFC, 2001, ANNU REV GENET, V35, P303, DOI 10.1146/annurev.genet.35.102401.090633; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Montero A, 2000, EXP NEPHROL, V8, P14; Nosjean O, 2002, CELL SIGNAL, V14, P573, DOI 10.1016/S0898-6568(01)00281-9; Ogawa S, 1999, BIOCHEM BIOPH RES CO, V260, P122, DOI 10.1006/bbrc.1999.0896; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; Peacock M, 2002, ENDOCR REV, V23, P303, DOI 10.1210/er.23.3.303; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; SHANNON VR, 1993, AM REV RESPIR DIS, V147, P1024, DOI 10.1164/ajrccm/147.4.1024; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; Turek JJ, 2003, J NUTR BIOCHEM, V14, P24, DOI 10.1016/S0955-2863(02)00221-8	27	220	231	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	2004	303	5655					229	232		10.1126/science.1090985	http://dx.doi.org/10.1126/science.1090985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761KT	14716014				2022-12-28	WOS:000187908500048
J	Teno, JM; Clarridge, BR; Casey, V; Welch, LC; Wetle, T; Shield, R; Mor, V				Teno, JM; Clarridge, BR; Casey, V; Welch, LC; Wetle, T; Shield, R; Mor, V			Family perspectives on end-of-life care at the last place of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GOOD DEATH; QUALITY; STATEMENT; HOSPICE; PATIENT	Context Over the past century, nursing homes and hospitals increasingly have become the site of death, yet no national studies have examined the adequacy or quality of end-of-life care in institutional settings compared with deaths at home. Objective To evaluate the US dying experience at home and in institutional settings. Design, Setting, and Participants Mortality follow-back survey of family members or other knowledgeable informants representing 1578 decedents, with a 2-stage probability sample used to estimate end-of-life care outcomes for 1.97 million deaths from chronic illness in the United States in 2000. Informants were asked via telephone about the patient's experience at the last place of care at which the patient spent more than 48 hours. Main Outcome Measures Patient- and family-centered end-of-life care outcomes, including whether health care workers (1) provided the desired physical comfort and emotional support to the dying person, (2) supported shared decision making, (3) treated the dying person with respect, (4) attended to the emotional needs of the family, and (5) provided coordinated care. Results For 1059 of 1578 decedents (67.1%), the last place of care was an institution. Of 519 (32.9%) patients dying at home represented by this sample, 198 (38.2%) did not receive nursing services; 65 (12.5%) had home nursing services, and 256 (49.3%) had home hospice services. About one quarter of all patients with pain or dyspnea did not receive adequate treatment, and one quarter reported concerns with physician communication. More than one third of respondents cared for by a home health agency, nursing home, or hospital reported insufficient emotional support for the patient and/or 1 or more concerns with family emotional support, compared with about one fifth of those receiving home hospice services. Nursing home residents were less likely than those cared for in a hospital or by home hospice services to always have been treated with respect at the end of life (68.2% vs 79.6% and 96.2%, respectively). Family members of patients receiving hospice services were more satisfied with overall quality of care: 70.7% rated care as "excellent" compared with less than 50% of those dying in an institutional setting or with home health services (P<.001). Conclusions Many people dying in institutions have unmet needs for symptom amelioration, physician communication, emotional support, and being treated with respect. Family members of decedents who received care at home with hospice services were more likely to report a favorable dying experience.	Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; Brown Univ, Brown Med Sch, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	Brown University; Brown University; University of Massachusetts System; University of Massachusetts Boston	Teno, JM (corresponding author), 2 Stimson Ave, Providence, RI 02912 USA.		Welch, Lisa Christine/GZK-6246-2022	Welch, Lisa/0000-0001-6269-9310				Addington-Hall J, 2001, J PAIN SYMPTOM MANAG, V22, P784, DOI 10.1016/S0885-3924(01)00330-X; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Cochran W.G., 2007, SAMPLING TECHNIQUES; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ, 1997, APPROACHING DEATH IM; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Harrington C, 2000, GERONTOLOGIST, V40, P5; Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885-3924(01)00406-7; Kish L, 1965, SURVEY SAMPLING; Lynn J, 1997, J AM GERIATR SOC, V45, P526; McPherson CJ, 2003, SOC SCI MED, V56, P95, DOI 10.1016/S0277-9536(02)00011-4; Singer PA, 2002, BMJ-BRIT MED J, V324, P1291, DOI 10.1136/bmj.324.7349.1291; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Teno JM, 1999, J PAIN SYMPTOM MANAG, V17, P109, DOI 10.1016/S0885-3924(98)00132-8; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; TENO JM, 2000, FACTS DYING POLICY R; Weitzen S, 2003, MED CARE, V41, P323, DOI 10.1097/00005650-200302000-00013; Zerzan J, 2000, JAMA-J AM MED ASSOC, V284, P2489, DOI 10.1001/jama.284.19.2489; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	21	1061	1071	5	125	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	2004	291	1					88	93		10.1001/jama.291.1.88	http://dx.doi.org/10.1001/jama.291.1.88			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760LX	14709580	Bronze			2022-12-28	WOS:000187836000023
J	Eid, T; Thomas, MJ; Spencer, DD; Runden-Pran, E; Lai, JCK; Malthankar, GV; Kim, JH; Danbolt, NC; Ottersen, OP; de Lanerolle, NC				Eid, T; Thomas, MJ; Spencer, DD; Runden-Pran, E; Lai, JCK; Malthankar, GV; Kim, JH; Danbolt, NC; Ottersen, OP; de Lanerolle, NC			Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy	LANCET			English	Article							FIBROBLAST-GROWTH-FACTOR; MESSENGER-RNA; BRAIN; TRANSPORTERS; ASTROCYTES; EXPRESSION; SEIZURES; DEXAMETHASONE; PATHOLOGY; CULTURES	Background High extracellular glutamate concentrations have been identified as a likely trigger of epileptic seizures in mesial temporal lobe epilepsy (MTLE), but the underlying mechanism remains unclear. We investigated whether a deficiency in glutamine synthetase, a key enzyme in catabolism of extracellular glutamate in the brain, could explain the perturbed glutamate homoeostasis in MTLE. Methods The anteromedial temporal lobe is the focus of the seizures in MTLE, and surgical resection of this structure, including the hippocampus, leads to resolution of seizures in many cases. By means of immunohistochemistry, western blotting, and functional enzyme assays, we assessed the distribution, quantity, and activity of glutamine synthetase in the MTLE hippocampus. Findings In western blots, the expression of glutamine synthetase in the hippocampus was 40% lower in MTLE than in non-MTLE samples (median 44 [IQR 30-58] vs 69 [56-87]% of maximum concentration in standard curve; p=0.043; n=8 and n=6, respectively). The enzyme activity was lower by 38% in MTLE vs non-MTLE (mean 0.0060 [SD 0.0031] vs 0.0097 [0.0042] U/mg protein; p=0.045; n=6 and n=9, respectively). Loss of glutamine synthetase was particularly pronounced in areas of the MTLE hippocampus with astroglial proliferation, even though astrocytes normally have high content of the enzyme. Quantitative immunoblotting showed no significant change in the amount of EAAT2, the predominant glial glutamate transporter in the hippocampus. Interpretation A deficiency in glutamine synthetase in astrocytes is a possible molecular basis for extracellular glutamate accumulation and seizure generation in MTLE. Further studies are needed to define the cause, but the loss of glutamine synthetase may provide a new focus for therapeutic interventions in MTLE.	Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Oslo, Ctr Mol Biol & Neurosci, Oslo, Norway; Univ Oslo, Dept Anat, Oslo, Norway; Idaho State Univ, Coll Pharm, Dept Pharmaceut Sci, Pocatello, ID 83209 USA	Yale University; Yale University; University of Oslo; University of Oslo; Idaho; Idaho State University	Eid, T (corresponding author), Yale Univ, Sch Med, Dept Neurosurg, 333 Cedar St,POB 208082, New Haven, CT 06520 USA.	tore.eid@yale.edu	Rundén-Pran, Elise/AAE-6290-2019; Danbolt, Niels Christian/A-1907-2014; Rundén-Pran, Elise/AAN-2490-2020	Danbolt, Niels Christian/0000-0003-4227-4520; Rundén-Pran, Elise/0000-0002-5541-4513	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039092] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39092] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beckstrom H, 1999, J NEUROSCI RES, V55, P218, DOI 10.1002/(SICI)1097-4547(19990115)55:2<218::AID-JNR9>3.3.CO;2-C; Beer J, 1998, BRAIN RES, V794, P255, DOI 10.1016/S0006-8993(98)00233-9; BLONDET B, 1995, NEUROSCI LETT, V183, P179, DOI 10.1016/0304-3940(94)11145-9; Broman J, 2000, HAND CHEM N, V18, P1; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; Danbolt NC, 1998, METHOD ENZYMOL, V296, P388; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; de Lanerolle NC, 1998, EUR J NEUROSCI, V10, P1687, DOI 10.1046/j.1460-9568.1998.00171.x; de Lanerolle NC, 2003, EPILEPSIA, V44, P677, DOI 10.1046/j.1528-1157.2003.32701.x; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; DELANEROLLE NC, 1994, CLIN NEUROSCI, V2, P64; DENNIS SC, 1980, BRAIN RES, V197, P469, DOI 10.1016/0006-8993(80)91131-2; DEROUICHE A, 1993, EUR J NEUROSCI, V5, P122, DOI 10.1111/j.1460-9568.1993.tb00477.x; DURING MJ, 1993, LANCET, V341, P1607; EID T, 2002, EPILEPSIA S, V43; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; FOLBERGROVA J, 1969, J NEUROCHEM, V16, P191, DOI 10.1111/j.1471-4159.1969.tb05937.x; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang TL, 1998, J NEUROCHEM, V71, P1436; JACKSON MJ, 1995, NEUROCHEM RES, V20, P201, DOI 10.1007/BF00970545; Kim JH, 2001, EXP MOL PATHOL, V70, P345, DOI 10.1006/exmp.2001.2372; Kruchkova Y, 2001, J NEUROCHEM, V77, P1641, DOI 10.1046/j.1471-4159.2001.00390.x; LAAKE JH, 1995, J NEUROCHEM, V65, P871; LAMING PR, 1989, COMP BIOCHEM PHYS C, V94, P399, DOI 10.1016/0742-8413(89)90088-1; Liu Z, 1997, NEUROSCI LETT, V233, P85, DOI 10.1016/S0304-3940(97)00627-7; Mathern G.W., 1997, EPILEPSY COMPREHENSI, P133; MEISTER A, 1978, ENZYME ACTIVATED IRR, P187; Olney J W, 1986, Adv Neurol, V44, P857; OLNEY JW, 1978, KAINIC ACID TOOL NEU, P37; Otis TS, 1998, J NEUROSCI, V18, P7099; Petroff OAC, 2002, EPILEPSIA, V43, P703, DOI 10.1046/j.1528-1157.2002.38901.x; Shaked I, 2002, J NEUROCHEM, V83, P574, DOI 10.1046/j.1471-4159.2002.01168.x; Shaw CA, 1999, CAN J PHYSIOL PHARM, V77, P871, DOI 10.1139/cjpp-77-11-871; Sommer W, 1880, ARCHIV F R PSYCHIATR, V10, P631, DOI [10.1007/BF02224538, DOI 10.1007/BF02224538]; SPENCER DD, 1984, NEUROSURGERY, V15, P667, DOI 10.1227/00006123-198411000-00005; SPENCER DD, 1994, CLIN NEUROSCI, V2, P104; Stanimirovic DB, 1999, INT J DEV NEUROSCI, V17, P173, DOI 10.1016/S0736-5748(99)00028-3; SZEGEDY L, 1978, CELL MOL BIOL, V23, P43; THEODORE WH, 1991, SURG EPILEPSY, P3; VANDENBE.CJ, 1971, BIOCHEM J, V123, P211, DOI 10.1042/bj1230211; Vardimon L, 1999, J NEUROBIOL, V40, P513, DOI 10.1002/(SICI)1097-4695(19990915)40:4<513::AID-NEU8>3.0.CO;2-D; Walz W, 1998, NEUROSCI LETT, V257, P127, DOI 10.1016/S0304-3940(98)00813-1; WILLIAMSON A, 1994, CLIN NEUROSCI, V2, P47	44	304	315	2	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					28	37		10.1016/S0140-6736(03)15166-5	http://dx.doi.org/10.1016/S0140-6736(03)15166-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723991				2022-12-28	WOS:000187711300011
J	Soares, HP; Daniels, S; Kumar, A; Clarke, M; Scott, C; Swann, S; Djulbegovic, B				Soares, HP; Daniels, S; Kumar, A; Clarke, M; Scott, C; Swann, S; Djulbegovic, B			Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group	BRITISH MEDICAL JOURNAL			English	Article							CONSORT STATEMENT; QUALITY	Objective To determine whether poor reporting of, methods in randomised controlled trials reflects on poor methods. Design Observational study. Setting Reports of randomised controlled trials conducted by the Radiation Therapy Oncology Group since its establishment in 1968. Participants The Radiation Therapy Oncology Group. Outcome measures Content of reports compared with the design features described in the protocols for all randomised controlled trials. Results The methodological quality of 56 randomised controlled trials was better than reported. Adequate allocation concealment was achieved in all trials but reported in only 42% of papers. An intention to treat analysis was done in 83% of trials but reported in only 69% of papers. The sample size calculation was performed in 76% of the studies, but reported in only 16% of papers. End points were clearly defined and cc and beta errors were prespecified in 76% and 74% of the trials, respectively, but only reported in 10% of the papers. The one exception was the description of drop outs, where the frequency of reporting was similar to that contained in the original statistical files of the Radiation Therapy Oncology Group. Conclusions The reporting of methodological aspects of randomised controlled trials does not necessarily reflect the conduct of the trial. Reviewing research protocols and contacting trialists for more information may improve quality assessment.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Eastern Cooperat Oncol Grp, Tampa, FL 33612 USA; UK Cochrane Ctr, Oxford OX2 7LG, England; Radiat Therapy Oncol Grp, Stat Unit, Philadelphia, PA 19107 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Cochrane Centre; Radiation Therapy Oncology Group (RTOG)	Djulbegovic, B (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Kumar, Ambuj/U-5268-2019; Kumar, Ambuj/I-4940-2012; Djulbegovic, Benjamin/I-3661-2012; KUMAR, ASHOK/AAF-4055-2021	Djulbegovic, Benjamin/0000-0003-0671-1447; KUMAR, ASHOK/0000-0002-9244-0622	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044417] Funding Source: NIH RePORTER; NINDS NIH HHS [1R01NS/NR44417-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CLARKE M, 2003, COCHRANE LIB; Egger M, 2001, SYSTEMATIC REV HLTH; Godlee F, 2001, BMC NEWS VIEWS, V2; HERSON J, 1980, CONTROL CLIN TRIALS, V1, P101, DOI 10.1016/0197-2456(80)90013-6; Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; *RAD THER ONC GROU, 2003, RTOG PROC MAN; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Silagy CA, 2002, JAMA-J AM MED ASSOC, V287, P2831, DOI 10.1001/jama.287.21.2831	12	229	231	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 3	2004	328	7430					22	24		10.1136/bmj.328.7430.22	http://dx.doi.org/10.1136/bmj.328.7430.22			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703540	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000187919000016
J	Heglund, NC				Heglund, NC			Running a-fowl of the law	SCIENCE			English	Editorial Material							TERRESTRIAL LOCOMOTION; ENERGETICS; MECHANICS; SPEED		Univ Catholique Louvain, Unite Physiol & Biomecan Locomot Loco, B-1348 Louvain, Belgium	Universite Catholique Louvain	Heglund, NC (corresponding author), Univ Catholique Louvain, Unite Physiol & Biomecan Locomot Loco, B-1348 Louvain, Belgium.							CAVAGNA GA, 1988, J PHYSIOL-LONDON, V399, P81; HEGLUND NC, 1982, J EXP BIOL, V97, P57; HEGLUND NC, 1987, AM J PHYSIOL, V253, pC22, DOI 10.1152/ajpcell.1987.253.1.C22; KRAM R, 1990, NATURE, V346, P265, DOI 10.1038/346265a0; Marsh RL, 2004, SCIENCE, V303, P80, DOI 10.1126/science.1090704; TAYLOR CR, 1985, J EXP BIOL, V115, P253; TAYLOR CR, 1982, ANNU REV PHYSIOL, V44, P97, DOI 10.1146/annurev.ph.44.030182.000525	7	3	3	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					47	48		10.1126/science.1093588	http://dx.doi.org/10.1126/science.1093588			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704416				2022-12-28	WOS:000187710600024
J	Khan, NE; De Souza, A; Mister, R; Flather, M; Clague, J; Davies, S; Collins, P; Wang, DL; Sigwart, U; Pepper, J				Khan, NE; De Souza, A; Mister, R; Flather, M; Clague, J; Davies, S; Collins, P; Wang, DL; Sigwart, U; Pepper, J			A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOPULMONARY BYPASS; BEATING-HEART; REVASCULARIZATION; OUTCOMES	BACKGROUND: The effect of the use of coronary-artery bypass surgery without cardiopulmonary bypass and cardiac arrest ("off pump'') on graft patency remains uncertain. We undertook a prospective, randomized, controlled study to compare graft-patency rates and clinical outcomes in off-pump surgery with conventional, "on-pump'' surgery. METHODS: We randomly assigned 50 patients to undergo on-pump coronary-artery bypass grafting and 54 to undergo off-pump surgery. Surgical and anesthetic techniques were standardized for both groups. Clinical outcomes and troponin T levels were measured. Three months later, the patients underwent coronary angiography, including quantitative analysis. RESULTS: The mean age of the patients was 63 years, and 87 percent were men. The on-pump group received a mean of 3.4 grafts, and the off-pump group 3.1 (P=0.41). There were no deaths. There was no significant difference in the median postoperative length of stay between the two groups (seven days in each group). The area under the curve of troponin T levels was higher during the first 72 hours in the on-pump group than in the off-pump group (30.96 hr (bullet) microg per liter vs. 19.33 hr (bullet) microg per liter, P=0.02). At three months, 127 of 130 grafts were patent in the on-pump group (98 percent), as compared with 114 of 130 in the off-pump group (88 percent, P=0.002). The patency rate was higher for all graft territories in the on-pump group than in the off-pump group. CONCLUSIONS: In this randomized study, off-pump coronary surgery was as safe as on-pump surgery and caused less myocardial damage. However, the graft-patency rate was lower at three months in the off-pump group than in the on-pump group, and this difference has implications with respect to the long-term outcome.	Royal Brompton & Harefield NHS Trust, London, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; London Sch Hyg & Trop Med, London WC1, England; Univ Hosp Geneva, Ctr Cardiol, Geneva, NY USA; Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland	Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; University of Geneva	Khan, NE (corresponding author), Royal Brompton Hosp, Clin Trials & Evaluat Unit, London SW3 6NP, England.	r.mister@rbh.nthames.nhs.uk	Clague, John/L-3619-2019					Angelini GD, 2002, LANCET, V359, P1194, DOI 10.1016/S0140-6736(02)08216-8; Ascione R, 1999, ANN THORAC SURG, V68, P493, DOI 10.1016/S0003-4975(99)00566-4; Ascione R, 1999, EUR J CARDIO-THORAC, V15, P685, DOI 10.1016/S1010-7940(99)00072-X; BENETTI FJ, 1991, CHEST, V100, P312, DOI 10.1378/chest.100.2.312; Bock JL, 1999, AM J CLIN PATHOL, V112, P739; Bonchek LI, 2002, J THORAC CARDIOV SUR, V124, P431, DOI 10.1067/mtc.2002.124240; Borst C, 1996, J AM COLL CARDIOL, V27, P1356, DOI 10.1016/0735-1097(96)00039-3; Buffolo E, 1996, ANN THORAC SURG, V61, P63, DOI 10.1016/0003-4975(95)00840-3; Calafiore AM, 1999, ANN THORAC SURG, V67, P450, DOI 10.1016/S0003-4975(98)01194-1; Diegeler A, 2002, NEW ENGL J MED, V347, P561, DOI 10.1056/NEJMoa013563; Hernandez F, 2001, ANN THORAC SURG, V72, P1528, DOI 10.1016/S0003-4975(01)03202-7; Jansen EWL, 1998, J THORAC CARDIOV SUR, V116, P60, DOI 10.1016/S0022-5223(98)70243-0; Lloyd CT, 2000, J THORAC CARDIOV SUR, V119, P148, DOI 10.1016/S0022-5223(00)70230-3; Mack M, 2002, J THORAC CARDIOV SUR, V124, P598, DOI 10.1067/mtc.2002.124884; Magee MJ, 2002, CIRCULATION, V106, P637; Nathoe HM, 2003, NEW ENGL J MED, V348, P394, DOI 10.1056/NEJMoa021775; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Puskas JD, 2001, ANN THORAC SURG, V71, P1477, DOI 10.1016/S0003-4975(01)02473-0; Puskas JD, 2003, J THORAC CARDIOV SUR, V125, P797, DOI 10.1067/mtc.2003.324; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; Sabik JF, 2002, J THORAC CARDIOV SUR, V124, P698, DOI 10.1067/mtc.2002.121975; Subramanian VA, 1997, ANN THORAC SURG, V64, P1648, DOI 10.1016/S0003-4975(97)01099-0; VANDIJK D, 2002, CIRCULATION, V104, P1761	23	435	460	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	2004	350	1					21	28		10.1056/NEJMoa031282	http://dx.doi.org/10.1056/NEJMoa031282			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758PT	14702424	Green Accepted			2022-12-28	WOS:000187659900006
J	Loutfy, MR; Blatt, LM; Siminovitch, KA; Ward, S; Wolff, B; Lho, H; Pham, DH; Deif, H; LaMere, EA; Chang, M; Kain, KC; Farcas, GA; Ferguson, P; Latchford, M; Levy, G; Dennis, JW; Lai, EKY; Fish, EN				Loutfy, MR; Blatt, LM; Siminovitch, KA; Ward, S; Wolff, B; Lho, H; Pham, DH; Deif, H; LaMere, EA; Chang, M; Kain, KC; Farcas, GA; Ferguson, P; Latchford, M; Levy, G; Dennis, JW; Lai, EKY; Fish, EN			Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome - A preliminary study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SARS; OUTBREAK; ALPHA; MANAGEMENT; MECHANISMS; RIBAVIRIN; EFFICACY; OUTCOMES; THERAPY; TORONTO	Context Severe acute respiratory syndrome (SARS) is anew clinical entity for which no effective therapeutic strategy has been developed. Objective To provide preliminary results on the potential therapeutic benefit and tolerability of interferon alfacon-1 plus corticosteroids for SARS. Design, Setting, and Patients Open-label study of 22 patients diagnosed as having probable SARS at North York General Hospital, Toronto, Ontario, between April 11 and May 30, 2003. Interventions Thirteen patients were treated with corticosteroids alone and 9 patients were treated with corticosteroids plus subcutaneous interferon alfacon-1. Main Outcome Measures Clinical parameters, including oxygen saturation and requirement, laboratory measures, and serial chest radiography results. Results Resolution of fever and lymphopenia were similar between the 2 treatment groups. Of the 13 patients treated with corticosteroids alone, 5 (38.5%) were transferred to the intensive care unit, 3 (23.1 %) required intubation and mechanical ventilation, and 1 (7.7%) died. Of the 9 patients in the interferon alfacon-1 treatment group, 3 (33.3 %) were transferred to the intensive care unit, 1 (11.1 %) required intubation and mechanical ventilation, and none died. The interferon alfacon-1 treatment group had a shorter time to 50% resolution of lung radiographic abnormalities (median time, 4 days vs 9 days; P=.001), had, better oxygen saturation (P=.02), resolved their need for supplemental oxygen more rapidly (median, 10 days vs 16 days; P=.02), had less of an increase in creatine kinase levels (P=.03), and showed a trend toward more rapid resolution of lactate dehydrogenase levels compared with the group receiving corticosteroids alone. Conclusions In this preliminary, uncontrolled study of patients with SARS, Use of interferon alfacon-1 plus corticosteroids was associated with reduced disease-associated impaired oxygen saturation, more rapid resolution of radiographic lung abnormalities, and lower levels of creatine kinase. These findings suggest that further investigation may be warranted to determine the role of interferon alfacon-1 as a therapeutic agent for the treatment of SARS.	Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; N York Gen Hosp, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Intermune Corp, Brisbane, CA USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; North York General Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Fish, EN (corresponding author), Toronto Gen Res Inst, Div Cell & Mol Biol, Canadian Blood Serv Bldg,Room 424,67 Coll St, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca	Siminovitch, Katherine/K-1475-2013; Dennis, James/E-7268-2013	Kain, Kevin/0000-0001-6068-1272				Alton K., 1983, BIOL INTERFERON SYST, P119; Avendano M, 2003, CAN MED ASSOC J, V168, P1649; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Blatt LM, 1996, J INTERF CYTOK RES, V16, P489, DOI 10.1089/jir.1996.16.489; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; *CDCP, UPD INT US CAS DEF S; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; Cornberg M, 2001, Forum (Genova), V11, P154; Cotler SJ, 2003, J VIRAL HEPATITIS, V10, P43, DOI 10.1046/j.1365-2893.2003.00401.x; Friis RH, 1996, EPIDEMIOLOGY PUBLIC; Fujimori K, 2002, J GASTROENTEROL, V37, P40, DOI 10.1007/s535-002-8131-9; HIGGINS PG, 1983, ANTIMICROB AGENTS CH, V24, P713, DOI 10.1128/AAC.24.5.713; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; Melian EB, 2001, DRUGS, V61, P1661, DOI 10.2165/00003495-200161110-00009; Nguyen MH, 2001, CURR OPIN INFECT DIS, V14, P593, DOI 10.1097/00001432-200110000-00014; Oba Y, 2003, NEW ENGL J MED, V348, P2034; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Pockros PJ, 2003, J VIRAL HEPATITIS, V10, P55, DOI 10.1046/j.1365-2893.2003.00402.x; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5; Soza A, 2002, HEPATOLOGY, V36, P1273, DOI 10.1053/jhep.2002.36502; SPERBER SJ, 1989, J INTERFERON RES, V9, P285, DOI 10.1089/jir.1989.9.285; TURNER RB, 1986, J INFECT DIS, V154, P443, DOI 10.1093/infdis/154.3.443; TYRRELL DAJ, 1986, J ANTIMICROB CHEMOTH, V18, P153, DOI 10.1093/jac/18.Supplement_B.153; *WHO, REV CAS DEF SARS; World Health Organization, CUM NUMB REP PROB CA; Wu W, 2003, CHINESE MED J-PEKING, V116, P811	30	279	310	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2003	290	24					3222	3228		10.1001/jama.290.24.3222	http://dx.doi.org/10.1001/jama.290.24.3222			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	756TR	14693875				2022-12-28	WOS:000187499300026
J	Halliwell, B				Halliwell, B			Plasma antioxidants - Health benefits of eating chocolate?	NATURE			English	Editorial Material									Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore	National University of Singapore	Halliwell, B (corresponding author), Natl Univ Singapore, Dept Biochem, 8 Med Dr,MD 7 03-08, Singapore 117597, Singapore.	bchbh@nus.edu.sg	Halliwell, Barry/C-8318-2009	Halliwell, Barry/0000-0002-3560-7123				Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; Halliwell B, 1999, NUTR REV, V57, P104, DOI 10.1111/j.1753-4887.1999.tb06933.x; Johnson RJ, 2003, HYPERTENSION, V41, P1183, DOI 10.1161/01.HYP.0000069700.62727.C5; Rechner AR, 2002, FREE RADICAL RES, V36, P1229, DOI 10.1080/246-1071576021000016472; ROTI KT, 2003, JAMA-J AM MED ASSOC, V289, P2857; Serafini M, 2003, NATURE, V424, P1013, DOI 10.1038/4241013a; Weir CJ, 2003, STROKE, V34, P1951, DOI 10.1161/01.STR.0000081983.34771.D2	8	31	31	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					787	787		10.1038/426787a	http://dx.doi.org/10.1038/426787a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685224				2022-12-28	WOS:000187342000043
J	Kruger, M; Meyerdierks, A; Glockner, FO; Amann, R; Widdel, F; Kube, M; Reinhardt, R; Kahnt, R; Bocher, R; Thauer, RK; Shima, S				Kruger, M; Meyerdierks, A; Glockner, FO; Amann, R; Widdel, F; Kube, M; Reinhardt, R; Kahnt, R; Bocher, R; Thauer, RK; Shima, S			A conspicuous nickel protein in microbial mats that oxidize methane anaerobically	NATURE			English	Article							CORAL-LIKE STRUCTURES; MARINE-SEDIMENTS; BLACK-SEA; SULFATE REDUCTION; MCRA GENES; OXIDATION; BACTERIA; SEEPS; CONSORTIUM; ARCHAEA	Anaerobic oxidation of methane (AOM) in marine sediments is an important microbial process in the global carbon cycle and in control of greenhouse gas emission. The responsible organisms supposedly reverse the reactions of methanogenesis(1-8), but cultures providing biochemical proof of this have not been isolated. Here we searched for AOM-associated cell components in microbial mats from anoxic methane seeps in the Black Sea(9-11). These mats catalyse AOM rather than carry out methanogenesis. We extracted a prominent nickel compound displaying the same absorption spectrum as the nickel cofactor F(430) of methyl-coenzyme M reductase, the terminal enzyme of methanogenesis(12); however, the nickel compound exhibited a higher molecular mass than F430. The apparent variant of F430 was part of an abundant protein that was purified from the mat and that consists of three different subunits. Determined amino-terminal amino acid sequences matched a gene locus cloned from the mat. Sequence analyses revealed similarities to methyl-coenzyme M reductase from methanogenic archaea. The abundance of the nickel protein (7% of extracted proteins) in the mat suggests an important role in AOM.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany	Max Planck Society; Max Planck Society; Max Planck Society	Widdel, F (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr 1, D-28359 Bremen, Germany.	fwiddel@mpi-bremen.de; thauer@mailer.uni-marburg.de	Amann, Rudolf I/C-6534-2014	Amann, Rudolf I/0000-0002-0846-7372; Reinhardt, Richard/0000-0001-9376-2132				BARNES RO, 1976, GEOLOGY, V4, P297, DOI 10.1130/0091-7613(1976)4<297:MPACIA>2.0.CO;2; Bian LQ, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000112; Boetius A, 2000, NATURE, V407, P623, DOI 10.1038/35036572; Elvert M, 1999, NATURWISSENSCHAFTEN, V86, P295, DOI 10.1007/s001140050619; Hallam SJ, 2003, APPL ENVIRON MICROB, V69, P5483, DOI 10.1128/AEM.69.9.5483-5491.2003; Hansen LB, 1998, AQUAT MICROB ECOL, V14, P195, DOI 10.3354/ame014195; Harder J, 1997, MAR GEOL, V137, P13, DOI 10.1016/S0025-3227(96)00075-8; Hinrichs KU, 1999, NATURE, V398, P802, DOI 10.1038/19751; HOEHLER TM, 1994, GLOBAL BIOGEOCHEM CY, V8, P451, DOI 10.1029/94GB01800; IVERSEN N, 1985, LIMNOL OCEANOGR, V30, P944, DOI 10.4319/lo.1985.30.5.0944; Lueders T, 2001, ENVIRON MICROBIOL, V3, P194, DOI 10.1046/j.1462-2920.2001.00179.x; Lynn DJ, 2002, NUCLEIC ACIDS RES, V30, P4272, DOI 10.1093/nar/gkf546; MARTENS CS, 1974, SCIENCE, V185, P1167, DOI 10.1126/science.185.4157.1167; Meyer F, 2003, NUCLEIC ACIDS RES, V31, P2187, DOI 10.1093/nar/gkg312; Michaelis W, 2002, SCIENCE, V297, P1013, DOI 10.1126/science.1072502; Nauhaus K, 2002, ENVIRON MICROBIOL, V4, P296, DOI 10.1046/j.1462-2920.2002.00299.x; Niewohner C, 1998, GEOCHIM COSMOCHIM AC, V62, P455, DOI 10.1016/S0016-7037(98)00055-6; Orphan VJ, 2002, P NATL ACAD SCI USA, V99, P7663, DOI 10.1073/pnas.072210299; Orphan VJ, 2001, SCIENCE, V293, P484, DOI 10.1126/science.1061338; Pancost RD, 2001, GEOCHIM COSMOCHIM AC, V65, P1611, DOI 10.1016/S0016-7037(00)00562-7; Pimenov NV, 1997, MICROBIOLOGY+, V66, P354; Pride DT, 2003, GENOME RES, V13, P145, DOI 10.1101/gr.335003; REEBURGH W, 1976, EARTH PLANET SC LETT, V28, P345; Schbath S, 1997, J COMPUT BIOL, V4, P189, DOI 10.1089/cmb.1997.4.189; Sorensen KB, 2001, MICROBIAL ECOL, V42, P1; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; Tourova TP, 2002, MICROBIOLOGY+, V71, P196, DOI 10.1023/A:1015102422144; Valentine DL, 2000, ENVIRON MICROBIOL, V2, P477, DOI 10.1046/j.1462-2920.2000.00135.x; ZEHNDER AJB, 1979, J BACTERIOL, V137, P420, DOI 10.1128/JB.137.1.420-432.1979; Zhou JZ, 1996, APPL ENVIRON MICROB, V62, P316, DOI 10.1128/AEM.62.2.316-322.1996	30	257	275	4	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					878	881		10.1038/nature02207	http://dx.doi.org/10.1038/nature02207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685246				2022-12-28	WOS:000187342000068
J	Chelton, DB; Schlax, MG; Freilich, MH; Milliff, RF				Chelton, DB; Schlax, MG; Freilich, MH; Milliff, RF			Satellite measurements reveal persistent small-scale features in ocean winds	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; SEASONAL CYCLE; PACIFIC; STRESS; CIRCULATION; CURRENTS; AMERICA; FRONT; WAVES	Four-year averages of 25-kilometer-resolution measurements of near-surface wind speed and direction over the global ocean from the QuikSCAT satellite radar scatterometer reveal the existence of surprisingly persistent small-scale features in the dynamically and thermodynamically important curl and divergence of the wind stress. Air-sea interaction over sea surface temperature fronts throughout the world ocean is evident in both the curl and divergence fields, as are the influences of islands and coastal mountains. Ocean currents such as the Gulf Stream generate distinctive patterns in the curl field. These previously unresolved features have important implications for oceanographic and air-sea interaction research.	Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; NW Res Associates Inc, Colorado Res Associates Div, Boulder, CO 80301 USA	Oregon State University; NorthWest Research Associates	Chelton, DB (corresponding author), Oregon State Univ, Coll Ocean & Atmospher Sci, 104 Ocean Adm Bldg, Corvallis, OR 97331 USA.		Milliff, Ralph F/C-4398-2013	MILLIFF, RALPH/0000-0003-3177-1206				BAKUN A, 1991, J PHYS OCEANOGR, V21, P1815, DOI 10.1175/1520-0485(1991)021<1815:TSCOWS>2.0.CO;2; Barton E.D., 1993, OCEANOGRAPHY, V6, P23, DOI [10.5670/oceanog.1993.19, DOI 10.5670/OCEANOG.1993.19, DOI 10.5670/OCEANOG]; Chelton DB, 2001, J CLIMATE, V14, P1479, DOI 10.1175/1520-0442(2001)014<1479:OOCBSW>2.0.CO;2; Chelton DB, 2000, MON WEATHER REV, V128, P1993, DOI 10.1175/1520-0493(2000)128<1993:SOOTWJ>2.0.CO;2; Cornillon P, 2001, GEOPHYS RES LETT, V28, P575, DOI 10.1029/2000GL011487; Cronin MF, 2003, J CLIMATE, V16, P3050, DOI 10.1175/1520-0442(2003)016<3050:BPVAWE>2.0.CO;2; DESER C, 1993, J CLIMATE, V6, P1172, DOI 10.1175/1520-0442(1993)006<1172:TIOSST>2.0.CO;2; DESZOEKE SP, IN PRESS J ATMOS SCI; DiMarco SF, 2000, GEOPHYS RES LETT, V27, P3965, DOI 10.1029/2000GL012012; Doyle JD, 1999, TELLUS A, V51, P728, DOI 10.1034/j.1600-0870.1996.00014.x; Estournel C, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2001JC000825; Fiedler PC, 2002, DEEP-SEA RES PT I, V49, P321, DOI 10.1016/S0967-0637(01)00057-7; Freilich MH, 1999, J GEOPHYS RES-OCEANS, V104, P11231, DOI 10.1029/1998JC900091; Gill AE, 1982, ATMOSPHERE OCEAN DYN; Hashizume H, 2001, J GEOPHYS RES-ATMOS, V106, P10173, DOI 10.1029/2000JD900684; HAYES SP, 1989, J CLIMATE, V2, P1500, DOI 10.1175/1520-0442(1989)002<1500:TIOSST>2.0.CO;2; Johns E, 1999, J GEOPHYS RES-OCEANS, V104, P25805, DOI 10.1029/1999JC900235; Kawamura H, 1998, J GEOPHYS RES-OCEANS, V103, P21611, DOI 10.1029/98JC01948; Kelly KA, 2001, GEOPHYS RES LETT, V28, P2469, DOI 10.1029/2000GL012610; MCCREARY JP, 1987, J MAR RES, V45, P1, DOI 10.1357/002224087788400945; MECHOSO CR, 1995, MON WEATHER REV, V123, P2825, DOI 10.1175/1520-0493(1995)123<2825:TSCOTT>2.0.CO;2; Milliff RF, 2001, J ATMOS SCI, V58, P109, DOI 10.1175/1520-0469(2001)058<0109:TGDOTT>2.0.CO;2; MILLIFF RF, UNPUB; MULLER P, 1981, J PHYS OCEANOGR, V11, P287, DOI 10.1175/1520-0485(1981)011<0287:DAFOGE>2.0.CO;2; Nonaka M, 2003, J CLIMATE, V16, P1404, DOI 10.1175/1520-0442(2003)16<1404:COSSTA>2.0.CO;2; O'Neill LW, 2003, J CLIMATE, V16, P2340, DOI 10.1175/2780.1; PACANOWSKI RC, 1987, J PHYS OCEANOGR, V17, P833, DOI 10.1175/1520-0485(1987)017<0833:EOECOS>2.0.CO;2; Pickart RS, 2003, NATURE, V424, P152, DOI 10.1038/nature01729; Rouault M., 2000, GLOBAL ATMOS OCEAN S, V7, P125; Schlax MG, 2001, J ATMOS OCEAN TECH, V18, P1014, DOI 10.1175/1520-0426(2001)018<1014:SEIWFC>2.0.CO;2; Small RJ, 2003, J CLIMATE, V16, P3723, DOI 10.1175/1520-0442(2003)016<3723:NSOART>2.0.CO;2; SWEET W, 1981, MON WEATHER REV, V109, P1042, DOI 10.1175/1520-0493(1981)109<1042:ASIEIT>2.0.CO;2; Thum N, 2002, J CLIMATE, V15, P3361, DOI 10.1175/1520-0442(2002)015<3361:ASHEAT>2.0.CO;2; VECCHI GA, IN PRESS J CLIM; WALLACE JM, 1989, J CLIMATE, V2, P1492, DOI 10.1175/1520-0442(1989)002<1492:TIOSST>2.0.CO;2; Wentz, 2000, Science, V288, P847, DOI 10.1126/science.288.5467.847; Wentz F. J., 2000, 121599A1 RSS; Xie SP, 1998, GEOPHYS RES LETT, V25, P3863, DOI 10.1029/1998GL900014; Xie SP, 2004, B AM METEOROL SOC, V85, P195, DOI 10.1175/BAMS-85-2-195; Xie SP, 2001, SCIENCE, V292, P2057, DOI 10.1126/science.1059781	40	666	695	7	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2004	303	5660					978	983		10.1126/science.1091901	http://dx.doi.org/10.1126/science.1091901			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773JJ	14726595				2022-12-28	WOS:000188918000036
J	Emmen, MJ; Schippers, GM; Bleijenberg, G; Wollersheim, H				Emmen, MJ; Schippers, GM; Bleijenberg, G; Wollersheim, H			Effectiveness of opportunistic brief interventions for problem drinking in a general hospital setting: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROBLEM DRINKERS; ALCOHOL-PROBLEMS; METAANALYSIS; CONSUMPTION; POPULATIONS; ADVICE; WARDS	Objective To determine the effectiveness of opportunistic brief interventions for problem drinking in a general hospital setting. Design Systematic review. Data sources Medline, PsychInfo, Cochrane Library, reference lists from identified studies and review articles, and contact with experts. Main outcome measure Change in alcohol consumption. Results Eight studies were retrieved. Most had methodological weaknesses. Only one study, with a relatively intensive intervention and a short follow up period, showed a significantly large reduction in alcohol consumption in the intervention group. Conclusion Evidence for the effectiveness of opportunistic brief interventions in a general hospital setting for problem drinkers is still inconclusive.	Amsterdam Inst Addict Res, NL-1001 AS Amsterdam, Netherlands; Radboud Univ Nijmegen Med Ctr, Expert Ctr Chron Fatigue, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Qual Care, Nijmegen, Netherlands	University of Amsterdam; Radboud University Nijmegen; Radboud University Nijmegen	Emmen, MJ (corresponding author), Amsterdam Inst Addict Res, POB 3907, NL-1001 AS Amsterdam, Netherlands.	emmen@aiar.nl	Wollersheim, H.C.H./L-4769-2015; Bleijenberg, Gijs/E-6984-2010					ANDERSON P, 1992, BRIT J ADDICT, V87, P891; Babor T.F., 1992, PROGRAMME SUBSTANCE; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; CHICK J, 1985, BRIT MED J, V290, P965, DOI 10.1136/bmj.290.6473.965; ELVY GA, 1984, NEW ZEAL MED J, V97, P111; ELVY GA, 1988, BRIT J ADDICT, V83, P83; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Freemantle N, 1993, Qual Health Care, V2, P267, DOI 10.1136/qshc.2.4.267; Heather N, 1996, DRUG ALCOHOL REV, V15, P29, DOI 10.1080/09595239600185641; HEATHER N, 1995, HDB ALCOHOLISM TREAT, P105; *HLTH ED AUTH, 1989, THATS LIMIT GUIDE SE; KAHAN M, 1995, CAN MED ASSOC J, V152, P851; MAHESWARAN R, 1992, HYPERTENSION, V19, P79, DOI 10.1161/01.HYP.19.1.79; Miller W.R., 1995, HDB ALCOHOLISM TREAT, V2nd ed., P12; Moyer A, 2002, ADDICTION, V97, P279, DOI 10.1046/j.1360-0443.2002.00018.x; PERSSON J, 1991, ALCOHOL ALCOHOLISM, P473; PERSSON J, 1989, ALCOHOL, V6, P403, DOI 10.1016/0741-8329(89)90011-6; Poikolainen K, 1999, PREV MED, V28, P503, DOI 10.1006/pmed.1999.0467; RICHMOND R, 1995, ADDICTION, V90, P119, DOI 10.1046/j.1360-0443.1995.90111915.x; Rowland N., 1993, HEALTH PROMOT INT, V8, P5; Watson HE, 1999, INT J NURS STUD, V36, P425, DOI 10.1016/S0020-7489(99)00028-0; Welte JW, 1998, ADDICTION, V93, P573, DOI 10.1046/j.1360-0443.1998.93457312.x; Wilk AI, 1997, J GEN INTERN MED, V12, P274	24	89	90	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2004	328	7435					318	320B		10.1136/bmj.37956.562130.EE	http://dx.doi.org/10.1136/bmj.37956.562130.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	773ME	14729657	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000188926900018
J	Orlowski, JM				Orlowski, JM			Update in nephrology	ANNALS OF INTERNAL MEDICINE			English	Review									Rush Med Coll, Chicago, IL 60612 USA	Rush University	Orlowski, JM (corresponding author), Rush Med Coll, 60 S Paulina, Chicago, IL 60612 USA.	janis_orlowski@rush.edu						Hilgers KF, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341100; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Wright RS, 2002, ANN INTERN MED, V137, P563, DOI 10.7326/0003-4819-137-7-200210010-00007	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 20	2004	140	2					106	111		10.7326/0003-4819-140-2-200401200-00011	http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764MY	14734333				2022-12-28	WOS:000188211700005
J	Vose, RS; Karl, TR; Easterling, DR; Williams, CN; Menne, MJ				Vose, RS; Karl, TR; Easterling, DR; Williams, CN; Menne, MJ			Climate - Impact of land-use change on climate	NATURE			English	Editorial Material							UNITED-STATES		Natl Climat Ctr, Asheville, NC 28801 USA	National Center Atmospheric Research (NCAR) - USA	Vose, RS (corresponding author), Natl Climat Ctr, Asheville, NC 28801 USA.	russell.vose@noaa.gov	Vose, Russell/GSI-5687-2022					EASTERLING DR, 1996, PUBLICATION OAK RIDG, V4500; Hansen J, 2001, J GEOPHYS RES-ATMOS, V106, P23947, DOI 10.1029/2001JD000354; IPCC, 2001, IPCC CLIM CHANG 2001; Kalnay E, 2003, NATURE, V423, P528, DOI 10.1038/nature01675; KARL TR, 1986, J CLIM APPL METEOROL, V25, P145, DOI 10.1175/1520-0450(1986)025<0145:AMTETT>2.0.CO;2; Owen TW, 1998, INT J REMOTE SENS, V19, P3451, DOI 10.1080/014311698214127	6	55	66	4	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	2004	427	6971					213	214		10.1038/427213b	http://dx.doi.org/10.1038/427213b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763HE	14724628				2022-12-28	WOS:000188068100033
J	Germain, A				Germain, A			Reproductive health and human rights	LANCET			English	Article									Int Womens Hlth Coalit, New York, NY 10010 USA		Germain, A (corresponding author), Int Womens Hlth Coalit, New York, NY 10010 USA.	agermain@iwhc.org						Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; *BRAZ MIN HLTH, 2003, PRINC DIR INT ATT WO; CHEN LC, 1974, STUD FAMILY PLANN, V5, P334, DOI 10.2307/1965185; Datta KK, 1980, MORB PATTERN RURAL W, V3, P282; Dayaratna V, 2000, REPROD HLTH INTERVEN; GIRARD F, 2003, QUALITY CALIDAD QUAL, P14; GOLDIE S, 2001, JAMA-J AM MED ASSOC, V258, P3107; Hashimoto H, 2002, J OBSTET GYNAECOL RE, V28, P313, DOI 10.1046/j.1341-8076.2002.00062.x; *ICRW, 2003, CHILD MARR; Jahan R, 2003, REPROD HEALTH MATTER, V11, P183, DOI 10.1016/S0968-8080(03)02173-6; Miller S, 2003, J MIDWIFERY WOM HEAL, V48, P10, DOI 10.1016/S1526-9523(02)00369-0; Satcher D., 2001, SURG GEN CALL ACTION; United Nations Development Fund for Women (UNIFEM), 2003, NOT MIN MOR END VIOL; United Nations Population Fund (UNFPA), 2003, STAT WORLD POP 2003; WHO, 2002, MULT STUD WOM HLTH D; WHO UNICEF and UNFPA, 2003, MAT MORT 2000 EST DE; World Health Organization, 2003, SAF AB TECHN POL GUI	17	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	2004	363	9402					65	66		10.1016/S0140-6736(03)15173-2	http://dx.doi.org/10.1016/S0140-6736(03)15173-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14723998	Green Published, Bronze			2022-12-28	WOS:000187711300027
J	Yan, DY; Zhou, YF; Hou, J				Yan, DY; Zhou, YF; Hou, J			Supramolecular self-assembly of macroscopic tubes	SCIENCE			English	Article							BLOCK-COPOLYMERS; VESICLES	The macroscopic molecular self-assembly of an amphiphilic hyperbranched copolymer in acetone generated multiwalled tubes millimeters in diameter and centimeters in length. The thickness of the tube walls approaches 400 nanometers, and the walls have an inhomogeneous lamella structure that alternates between ordered hydrophilic domains and amorphous, partly irregular hydrophilic domains.	Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, Shanghai 200240, Peoples R China	Shanghai Jiao Tong University	Yan, DY (corresponding author), Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.							ABE A, 1976, J AM CHEM SOC, V98, P6468, DOI 10.1021/ja00437a006; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; Goldacker T, 1999, NATURE, V398, P137, DOI 10.1038/18191; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; Kato T, 2002, SCIENCE, V295, P2414, DOI 10.1126/science.1070967; MENGER FM, 1995, ADV MATER, V7, P669, DOI 10.1002/adma.19950070716; MENGER FM, 1995, ANGEW CHEM INT EDIT, V34, P2091, DOI 10.1002/anie.199520911; Oda R, 1999, NATURE, V399, P566, DOI 10.1038/21154; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; THOMAS BN, 1995, SCIENCE, V267, P1635, DOI 10.1126/science.267.5204.1635; Wong GCL, 2000, SCIENCE, V288, P2035, DOI 10.1126/science.288.5473.2035; ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777	15	431	449	9	447	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					65	67		10.1126/science.1090763	http://dx.doi.org/10.1126/science.1090763			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704422				2022-12-28	WOS:000187710600032
J	Mwaba, P; Cassol, S; Nunn, A; Pilon, R; Chintu, C; Janes, M; Zumla, A				Mwaba, P; Cassol, S; Nunn, A; Pilon, R; Chintu, C; Janes, M; Zumla, A			Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients	LANCET			English	Article							RNA	The increasing availability of antiretroviral drugs to HIV-infected populations in developing countries highlights the need to develop field-friendly practical methods for HIV-1 viral load measurements to monitor the effects of treatment. We compared use of whole-blood spots versus plasma dried on filter paper to quantify HIV-1 viral load in 51 African patients with HIV-1. The mean log. HIV-1 viral loads were 4.22 for dried plasma spots (DPS) and 4.20 for dried whole-blood spots (DBS). The difference between the pairs of log., viral load for DPS and DRS were significantly correlated with their mean (Spearman's r=0.31, p=0.03). This correlation between the difference and mean of viral load was no longer evident for values of log(10) DPS that were less than 5 (r=0.01, p=0.93). For the 38 paired values with log(10)DPS of less than 5, the mean difference (log(10)DPS-log(10)DBS) was -0.04 (SD 0.29). Dried whole blood stored on filter paper at room temperature shows potential as a field-friendly alternative to plasma for measurement of HIV-1 viral load.	Univ Teaching Hosp, UNZA UCLMS Res & Training Project, Lusaka, Zambia; Ottawa Gen Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa, ON, Canada; MRC, Clin Trials Unit, London, England; UCL Royal Free & UCL Med Sch, Ctr Infect Dis & Int Hlth, London, England; UCLH Trust, London, England	University of Zambia; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Medical Research Council Clinical Trials Unit; University of London; University College London; University College London Hospitals NHS Foundation Trust	Mwaba, P (corresponding author), Univ Teaching Hosp, UNZA UCLMS Res & Training Project, Lusaka, Zambia.	pbmwaba2000@yahoo.com	Mwaba, Peter/V-6017-2019; ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Pilon, Richard/0000-0003-0100-6917				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brambilla D, 2003, J CLIN MICROBIOL, V41, P1888, DOI 10.1128/JCM.41.5.1888-1893.2003; Cassol S, 1997, J CLIN MICROBIOL, V35, P2795, DOI 10.1128/JCM.35.11.2795-2801.1997; Mwaba P, 2003, LANCET, V362, P1459, DOI 10.1016/S0140-6736(03)14693-4; Tucker T, 2001, S AFR MED J, V91, P615	5	56	58	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 20	2003	362	9401					2067	2068		10.1016/S0140-6736(03)15103-3	http://dx.doi.org/10.1016/S0140-6736(03)15103-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755UJ	14697808				2022-12-28	WOS:000187429600013
J	Ursano, RJ				Ursano, RJ			Prisoners of war: long-term health outcomes	LANCET			English	Article									Uniformed Serv Univ Hlth Sci, Sch Med, Dept Psychiat, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Forens Psychiat Fellowship Program, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Sch Med, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Natl Capital Consortium, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Ursano, RJ (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Psychiat, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Ursano, Robert J/ABE-6533-2020	Ursano, Robert/0000-0002-1861-9173				Nice DS, 1996, JAMA-J AM MED ASSOC, V276, P375, DOI 10.1001/jama.276.5.375; Page WF, 2000, LANCET, V355, P843, DOI 10.1016/S0140-6736(05)72455-7; Page WF, 1992, HLTH FORMER PRISONER; Ursano R. J., 1996, EMOTIONAL AFTERMATH, P443	4	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S22	S23		10.1016/S0140-6736(03)15062-3	http://dx.doi.org/10.1016/S0140-6736(03)15062-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698116				2022-12-28	WOS:000187790200012
J	Welsh, J				Welsh, J			The death penalty	LANCET			English	Article									Amnesty Int, London WC1X 0DW, England		Welsh, J (corresponding author), Amnesty Int, 1 Easton St, London WC1X 0DW, England.							BRITISH MEDICAL ASSOCIATION, 2002, MED PROF HUM RIGHTS	1	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2003	362			S			S24	S25		10.1016/S0140-6736(03)15063-5	http://dx.doi.org/10.1016/S0140-6736(03)15063-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760BG	14698117				2022-12-28	WOS:000187790200013
J	Tariot, PN; Farlow, MR; Grossberg, GT; Graham, SM; McDonald, S; Gergel, I				Tariot, PN; Farlow, MR; Grossberg, GT; Graham, SM; McDonald, S; Gergel, I		Memantine Study Grp	Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE IMPAIRMENT BATTERY; NMDA RECEPTOR ANTAGONIST; VASCULAR DEMENTIA; INHIBITORS; INVENTORY; EFFICACY; VALIDITY	Context Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed. Objective To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil. Design, Setting, and Participants A randomized, double-blind, placebo-controlled clinical trial of 404 patients with moderate to severe AD and Mini-Mental State Examination scores of 5 to 14, who received stable doses of donepezil, conducted at 37 US sites between June 11, 2001, and June 3, 2002. A total of 322 patients (80%) completed the trial. Interventions Participants were randomized to receive memantine (starting dose 5 mg/d, increased to 20 mg/d, n =203) or placebo (n =201) for 24 weeks. Main Outcome Measures Change from baseline on the Severe Impairment Battery (SIB), a measure of cognition, and on a modified 19-item AD Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL(19)). Secondary outcomes included a Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), the Neuropsychiatric Inventory, and the Behavioral Rating Scale for Geriatric Patients (BGP Care Dependency Subscale). Results The change in total mean (SE) scores favored memantine vs placebo treatment for SIB (possible score range, 0-100), 0.9 (0.67) vs -2.5 (0.69), respectively (P<.001); ADCS-ADL(19) (possible score range, 0-54), -2.0 (0.50) vs -3.4 (0.51), respectively (P=.03); and the CIBIC-Plus (possible score range, 1-7), 4.41 (0.074) vs 4.66 (0.075), respectively (P=.03). All other secondary measures showed significant benefits of memantine treatment. Treatment discontinuations because of adverse events for memantine vs placebo were 15 (7.4%) vs 25 (12.4%), respectively. Conclusions inpatients with moderate to severe AD receiving stable doses of donepezil, memantine resulted in significantly better outcomes than placebo on measures of cognition, activities of daily living, global outcome, and behavior and was well tolerated. These results, together with previous studies, suggest that memantine represents a new approach for the treatment of patients with moderate to severe AD.	Univ Rochester, Med Ctr, Monroe Community Hosp, Dept Psychiat, Rochester, NY 14620 USA; Univ Rochester, Med Ctr, Monroe Community Hosp, Dept Med, Rochester, NY 14620 USA; Univ Rochester, Med Ctr, Monroe Community Hosp, Dept Neurol, Rochester, NY 14620 USA; Univ Rochester, Med Ctr, Monroe Community Hosp, Ctr Aging & Dev Biol, Rochester, NY 14620 USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; St Louis Univ, Sch Med, Dept Geriatr Psychiat, St Louis, MO USA; Forest Labs Inc, Jersey City, NJ USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Indiana University System; Indiana University-Purdue University Indianapolis; Saint Louis University	Tariot, PN (corresponding author), Univ Rochester, Med Ctr, Monroe Community Hosp, Dept Psychiat, 435 E Henrietta Rd, Rochester, NY 14620 USA.	pierre_tariot@urmc.rochester.edu	Group, Prescott Medical Communications/AAE-7494-2019		NIA NIH HHS [U19 AG010483] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U19AG010483] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Cummings JL, 2002, JAMA-J AM MED ASSOC, V287, P2335, DOI 10.1001/jama.287.18.2335; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Danysz W, 1997, NEUROSCI BIOBEHAV R, V21, P455, DOI 10.1016/S0149-7634(96)00037-1; DYSKEN MW, 1992, J AM GERIATR SOC, V40, P503, DOI 10.1111/j.1532-5415.1992.tb02019.x; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; GALASKO DR, 2000, NEUROBIOL AGING, V21, P168; GREENAMYRE JT, 1988, PROG NEURO-PSYCHOPH, V12, P421, DOI 10.1016/0278-5846(88)90102-9; Hartmann S, 2003, INT CLIN PSYCHOPHARM, V18, P81, DOI 10.1097/00004850-200303000-00003; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; LAAKE K, 2002, COCHRANE DB SYST REV; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; PANISSET M, 1994, ARCH NEUROL-CHICAGO, V51, P41, DOI 10.1001/archneur.1994.00540130067012; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Periclou A, 2003, J AM GERIATR SOC, V51, pS225; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; Schmitt FA, 1997, ALZ DIS ASSOC DIS, V11, pS51; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; Sclan S G, 1992, Int Psychogeriatr, V4 Suppl 1, P55; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; VANDERKAM P, 1971, BEOORDELINGSSCHAAL O; Wenk GL, 2000, LIFE SCI, V66, P1079, DOI 10.1016/S0024-3205(00)00411-2; Wilcock G, 2002, INT CLIN PSYCHOPHARM, V17, P297, DOI 10.1097/00004850-200211000-00005; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; Winblad B, 2002, J NEURAL TRANSM-SUPP, P217	26	933	1029	0	96	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	2004	291	3					317	324		10.1001/jama.291.3.317	http://dx.doi.org/10.1001/jama.291.3.317			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764ZZ	14734594	Bronze			2022-12-28	WOS:000188243100031
J	McBride, BF; Karapanos, AK; Krudysz, A; Kluger, J; Coleman, CI; White, CM				McBride, BF; Karapanos, AK; Krudysz, A; Kluger, J; Coleman, CI; White, CM			Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATRIAL-FIBRILLATION; ESSENTIAL-HYPERTENSION; HEALTHY-VOLUNTEERS; QTC INTERVAL; TERFENADINE; PARAMETERS; CISAPRIDE; EFFICACY; SAFETY; DRUGS	Context Metabolife 356, a multicomponent dietary supplement containing ephedra and caffeine (DSEC) in addition to several other components, is the top-selling dietary weight loss supplement. Given its common use, anecdotal reports of cardiovascular and cerebrovascular adverse events, and paucity of safety data, further research with this DSEC was warranted. Objective To determine the impact of the DSEC on corrected QT (QTc) interval duration and systolic blood pressure (SBP). Design Randomized, double-blind, placebo-controlled, crossover study conducted from January to May 2003. Setting and Participants Fifteen healthy volunteers (mean [SD] age, 26.7 [2.52] years; weight, 72.7 [14.93] kg), 6 (40%) of whom were women, recruited from the University of Connecticut, Storrs campus. Intervention A single dose of the DSEC (containing 19 ingredients including ephedra [12 mg] and caffeine [40 mg]) or matching placebo were administered in a crossover fashion with a 7-day washout period between treatments, Main Outcome Measures Maximal QTc interval and SBP assessed at 1, 3, and 5 hours after dosing for the DSEC relative to placebo. Results Individuals receiving the DSEC had a longer maximal QTc interval (mean [SD], 419.4 [11.8] vs 396.1 [15.7] milliseconds; P<.001) and higher SBP (mean [SD], 123.5 [10.98] vs 118.93 [9.62] mm Hg; P=.009) compared with placebo. Participants who received the DSEC were more likely to experience a QTc interval increase of at least 30 milliseconds vs placebo (8 individuals [53.3%] vs 1 individual [6.7%]; relative risk, 2.67 [95% confidence interval, 1.40-5.10]). There were no significant sex-related differences. Conclusions The ephedra- and caffeine-containing dietary supplement Metabolife 356 increased the mean maximal QTc interval and SBP. Since the actual ingredient or ingredients in Metabolife 356 responsible for these findings are not known, patients should be instructed to avoid this and similar dietary supplements until more information is known about their safety.	Hartford Hosp, Drug Informat Ctr, Div Cardiol, Hartford, CT 06102 USA; Hartford Hosp, Div Drug Informat, Hartford, CT 06102 USA; Univ Connecticut, Sch Pharm, Storrs, CT USA; Univ Connecticut, Sch Med, Storrs, CT 06268 USA; Univ Connecticut, Sch Pharm, Farmington, CT USA; Univ Connecticut, Sch Med, Farmington, CT USA	Hartford Hospital; Hartford Hospital; University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	White, CM (corresponding author), Hartford Hosp, Drug Informat Ctr, Div Cardiol, 80 Seymour St, Hartford, CT 06102 USA.			Coleman, Craig/0000-0003-4868-7158				*AG HEALTHC RES QU, 2001, EPH EPH WEIGHT LOSS; Ammar R, 2001, PHARMACOTHERAPY, V21, P437, DOI 10.1592/phco.21.5.437.34502; Caron MF, 2002, ANN PHARMACOTHER, V36, P758, DOI 10.1345/aph.1A411; Ciaroni S, 2000, AM HEART J, V139, P814, DOI 10.1016/S0002-8703(00)90012-7; CLELAND RL, 2002, WEIGHT LOSS ADV ANAL; Committee for Proprietary Medicinal Products, 1997, POINTS CONS ASS POT; Corea L, 1996, CLIN PHARMACOL THER, V60, P341, DOI 10.1016/S0009-9236(96)90061-2; Dilaveris PE, 1998, AM HEART J, V135, P733, DOI 10.1016/S0002-8703(98)70030-4; *DISC AN, MUSCL HYDR EPH; Drazner MH, 2002, AM J CARDIOL, V89, P993, DOI 10.1016/S0002-9149(02)02257-9; Gardner SF, 2003, AM J CARDIOL, V91, P1510, DOI 10.1016/S0002-9149(03)00413-2; Gillen MS, 2001, BRIT J CLIN PHARMACO, V52, P201, DOI 10.1046/j.0306-5251.2001.01345.x; Glassman AH, 2001, AM J PSYCHIAT, V158, P1774, DOI 10.1176/appi.ajp.158.11.1774; Hoffman BB, 2001, GOODMAN GILMANS PHAR, P215; Hohnloser SH, 1997, AM J CARDIOL, V80, pG82, DOI 10.1016/S0002-9149(97)00717-0; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; *IRI, OV SUPPL SAL SLIGHTL; Miller LG, 2000, PHARMACOTHERAPY, V20, P877, DOI 10.1592/phco.20.9.877.35200; Molnar J, 1996, J AM COLL CARDIOL, V27, P76, DOI 10.1016/0735-1097(95)00426-2; Moss AJ., 1993, AM J CARDIOL, V72, p23B; *NUTR, TRIMSP INGR; Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537; Trans H. T., 1998, Annals of Noninvasive Electrocardiology, V3, P228, DOI 10.1111/j.1542-474X.1998.tb00347.x; Undem BJ, 2001, GOODMAN GILMANS PHAR, P733; *US FDA, PREL CONC PAP CLIN E; van Haarst AD, 1998, CLIN PHARMACOL THER, V64, P542, DOI 10.1016/S0009-9236(98)90137-0; Wang SH, 2001, INT J CARDIOL, V80, P179, DOI 10.1016/S0167-5273(01)00485-5; Zaman AG, 1997, HEART, V77, P527, DOI 10.1136/hrt.77.6.527; 2000, FED REG, V65, P17510	29	62	65	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					216	221		10.1001/jama.291.2.216	http://dx.doi.org/10.1001/jama.291.2.216			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722148	Bronze			2022-12-28	WOS:000188040900030
J	Surks, MI; Ortiz, E; Daniels, GH; Sawin, CT; Col, NF; Cobin, RH; Franklyn, JA; Hershman, JM; Burman, KD; Denke, MA; Gorman, C; Cooper, RS; Weissman, NJ				Surks, MI; Ortiz, E; Daniels, GH; Sawin, CT; Col, NF; Cobin, RH; Franklyn, JA; Hershman, JM; Burman, KD; Denke, MA; Gorman, C; Cooper, RS; Weissman, NJ			Subclinical thyroid disease - Scientific review and guidelines for diagnosis and management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	74th Annual Meeting of the American-Thyroid-Association	OCT 09-13, 2002	LOS ANGELES, CALIFORNIA	Amer Thyroid Assoc			PLACEBO-CONTROLLED TRIAL; SICK EUTHYROID SYNDROME; L-THYROXINE TREATMENT; SERUM THYROTROPIN; STIMULATING HORMONE; ATRIAL-FIBRILLATION; DOUBLE-BLIND; RISK-FACTOR; FOLLOW-UP; NONTHYROIDAL ILLNESS	Context Patients with serum thyroid-stimulating hormone (TSH) levels outside the reference range and levels of free thyroxine (FT4) and triiodothyronine (T-3) within the reference range are common in clinical practice. The necessity for further evaluation, possible treatment, and the urgency of treatment have not been clearly established. Objectives To define subclinical thyroid disease, review its epidemiology, recommend an appropriate evaluation, explore the risks and benefits of treatment and consequences of nontreatment, and determine whether population-based screening is warranted. Data Sources MEDLINE, EMBASE, Biosis, the Agency for Healthcare Research and Quality, National Guideline Clearing House, the Cochrane Database of Systematic Reviews and Controlled Trials Register, and several National Health Services (UK) data bases were searched for articles on subdinical thyroid disease published between 1995 and 2002. Articles published before 1995 were recommended by expert consultants. Study Selection and Data Extraction A total of 195 English-language or translated papers were reviewed. Editorials, individual case studies, studies enrolling fewer than 10 patients, and nonsystematic reviews were excluded. Information related to authorship, year of publication, number of subjects, study design, and results were extracted and formed the basis for an evidence report, consisting of tables and summaries of each subject area. Data Synthesis The strength of the evidence that untreated subdinical thyroid disease is associated with clinical symptoms and adverse clinical outcomes was assessed and recommendations for clinical practice developed. Data relating the progression of subdinical to overt hypothyroidism were rated as good, but data relating treatment to prevention of progression were inadequate to determine a treatment benefit. Data relating a serum TSH level higher than 10 mIU/L to elevations in serum cholesterol were rated as fair but data relating to benefits of treatment were rated as insufficient. All other associations of symptoms and benefit of treatment were rated as insufficient or absent. Data relating a serum TSH concentration lower than 0.1 mIU/L to the presence of atrial fibrillation and progression to overt hyperthyroidism were rated as good, but no data supported treatment to prevent these outcomes. Data relating restoration of the TSH level to within the reference range with improvements in bone mineral density were rated as fair. Data addressing all other associations of subdinical hyperthyroid disease and adverse clinical outcomes or treatment benefits were rated as insufficient or absent. Subclinical hypothyroid disease in pregnancy is a special case and aggressive case finding and treatment in pregnant women can be justified. Conclusions Data supporting associations of subdinical thyroid disease with symptoms or adverse clinical outcomes or benefits of treatment are few. The consequences of subdinical thyroid disease (serum TSH 0.1-0.45 mIU/L or 4.5-10.0 mIU/L) are minimal and we recommend against routine treatment of patients with TSH levels in these ranges. There is insufficient evidence to support population-based screening. Aggressive case finding is appropriate in pregnant women, women older than 60 years, and others at high risk for thyroid dysfunction.	Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA; Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Agcy Healthcare Res & Qual, Ctr Primary Care Prevent & Clin Partnerships, Rockville, MD USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Thyroid Unit, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA; Vet Adm, Washington, DC USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Womens Hlth, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Med, New York, NY USA; Univ Birmingham, Div Med Sci, Birmingham, W Midlands, England; Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Endocrinol & Diabet Div, Los Angeles, CA 90024 USA; Washington Hosp Ctr, Endocrine Sect, Washington, DC 20010 USA; Univ Texas, SW Med Ctr Dallas, Dept Med, Dallas, TX 75235 USA; Mayo Clin & Mayo Fdn, Res Dev, Rochester, MN 55905 USA; Loyola Univ, Sch Med, Chicago, IL 60611 USA; Georgetown Univ, Coll Med, Dept Med, Washington, DC USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Agency for Healthcare Research & Quality; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Icahn School of Medicine at Mount Sinai; University of Birmingham; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; MedStar Washington Hospital Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Mayo Clinic; Loyola University Chicago; Georgetown University	Surks, MI (corresponding author), Endocrine Soc, 8401 Connecticut Ave,Suite 900, Chevy Chase, MD 20815 USA.		Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X				Auer J, 2001, AM HEART J, V142, P838, DOI 10.1067/mhj.2001.119370; BASKIN HJ, 2002, ENDOCRINE PRACT, V8, P458; Bauer DC, 1997, J CLIN ENDOCR METAB, V82, P2931, DOI 10.1210/jc.82.9.2931; Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003-4819-134-7-200104030-00009; BECKPECCOZ P, 1985, NEW ENGL J MED, V312, P1085, DOI 10.1056/NEJM198504253121703; BEMBEN DA, 1994, J FAM PRACTICE, V38, P583; BENKER G, 1990, CLIN ENDOCRINOL, V33, P777, DOI 10.1111/j.1365-2265.1990.tb03915.x; BHAKRI HL, 1990, GERONTOLOGY, V36, P140, DOI 10.1159/000213189; Biondi B, 1996, J CLIN ENDOCR METAB, V81, P4224, DOI 10.1210/jc.81.12.4224; Biondi B, 2002, ANN INTERN MED, V137, P904, DOI 10.7326/0003-4819-137-11-200212030-00011; Biondi B, 1999, J CLIN ENDOCR METAB, V84, P2064, DOI 10.1210/jc.84.6.2064; Biondi B, 2000, J CLIN ENDOCR METAB, V85, P4701, DOI 10.1210/jc.85.12.4701; BOUTIN JM, 1986, CLIN ENDOCRINOL, V25, P579, DOI 10.1111/j.1365-2265.1986.tb03612.x; BRENNAN MD, 1987, MAYO CLIN PROC, V62, P894, DOI 10.1016/S0025-6196(12)65044-7; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Caraccio N, 2002, J CLIN ENDOCR METAB, V87, P1533, DOI 10.1210/jc.87.4.1533; Chu JW, 2001, J CLIN ENDOCR METAB, V86, P4591, DOI 10.1210/jc.86.10.4591; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Cooper DS, 2001, NEW ENGL J MED, V345, P260, DOI 10.1056/NEJM200107263450406; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; Faber J, 1998, CLIN ENDOCRINOL, V48, P285; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; Faber J, 2001, EUR J ENDOCRINOL, V145, P391, DOI 10.1530/eje.0.1450391; FAZIO S, 1995, J CLIN ENDOCR METAB, V80, P2222, DOI 10.1210/jc.80.7.2222; FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365-2265.1993.tb02403.x; Foldes J, 1997, EUR J ENDOCRINOL, V136, P277, DOI 10.1530/eje.0.1360277; FORFAR JC, 1981, INT J CARDIOL, V1, P43, DOI 10.1016/0167-5273(81)90047-4; FRANKLYN JA, 1994, J CLIN ENDOCR METAB, V78, P1368, DOI 10.1210/jc.78.6.1368; GHARIB H, 1972, LANCET, V2, P734; GLINOER D, 1990, J CLIN ENDOCR METAB, V71, P276, DOI 10.1210/jcem-71-2-276; GRUND FM, 1989, ARCH INTERN MED, V149, P921, DOI 10.1001/archinte.149.4.921; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Haden ST, 1996, ENDOCRINOLOGIST, V6, P322, DOI 10.1097/00019616-199607000-00008; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Hallengren B, 1999, J INTERN MED, V246, P139, DOI 10.1046/j.1365-2796.1999.00497.x; Hangaard J, 1996, J CLIN ENDOCR METAB, V81, P2502, DOI 10.1210/jc.81.7.2502; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Huber G, 2002, J CLIN ENDOCR METAB, V87, P3221, DOI 10.1210/jc.87.7.3221; ISMAIL AAA, 1989, CLIN ENDOCRINOL, V30, P225, DOI 10.1111/j.1365-2265.1989.tb02230.x; Kahaly GJ, 2000, THYROID, V10, P665, DOI 10.1089/10507250050137743; Kanaya AM, 2002, ARCH INTERN MED, V162, P773, DOI 10.1001/archinte.162.7.773; Kong WM, 2002, AM J MED, V112, P348, DOI 10.1016/S0002-9343(02)01022-7; Kumeda Y, 2000, J CLIN ENDOCR METAB, V85, P4157, DOI 10.1210/jc.85.11.4157; Kung AWC, 1996, THYROID, V6, P111, DOI 10.1089/thy.1996.6.111; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573; Ladenson PW, 1997, NEW ENGL J MED, V337, P888, DOI 10.1056/NEJM199709253371304; LAURBERG P, 1991, J INTERN MED, V229, P415, DOI 10.1111/j.1365-2796.1991.tb00368.x; Lee E, 1999, CLIN ENDOCRINOL, V50, P487, DOI 10.1046/j.1365-2265.1999.00678.x; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; Lindeman RD, 1999, J AM GERIATR SOC, V47, P703, DOI 10.1111/j.1532-5415.1999.tb01593.x; Marqusee E, 1998, ENDOCRIN METAB CLIN, V27, P37, DOI 10.1016/S0889-8529(05)70296-6; McDermott MT, 2001, J CLIN ENDOCR METAB, V86, P4585, DOI 10.1210/jc.86.10.4585; Meier C, 2001, J CLIN ENDOCR METAB, V86, P4860, DOI 10.1210/jc.86.10.4860; Monzani F, 2001, J CLIN ENDOCR METAB, V86, P1110, DOI 10.1210/jc.86.3.1110; Monzani F, 1999, CLIN ENDOCRINOL, V51, P237, DOI 10.1046/j.1365-2265.1999.00790.x; MUDDE AH, 1994, CLIN ENDOCRINOL, V41, P421, DOI 10.1111/j.1365-2265.1994.tb02571.x; *NAT AC CLIN BIOCH, NACB LAB MED PRACT G; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; Pantazi H, 2000, J CLIN ENDOCR METAB, V85, P1099, DOI 10.1210/jc.85.3.1099; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PARLE JV, 1993, BRIT J GEN PRACT, V43, P107; PRESTI CF, 1989, AM HEART J, V117, P976, DOI 10.1016/0002-8703(89)90642-X; ROBUSCHI G, 1987, ENDOCR REV, V8, P142, DOI 10.1210/edrv-8-2-142; ROCKEL M, 1987, KLIN WOCHENSCHR, V65, P264, DOI 10.1007/BF01773447; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; Ross DS, 2001, ENDOCRIN METAB CLIN, V30, P245, DOI 10.1016/S0889-8529(05)70186-9; Samuels MH, 1998, THYROID, V8, P803, DOI 10.1089/thy.1998.8.803; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SAWIN CT, 1995, CLIN GERIATR MED, V11, P231, DOI 10.1016/S0749-0690(18)30293-3; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; SAWIN CT, 1991, ARCH INTERN MED, V151, P165, DOI 10.1001/archinte.151.1.165; SCHLOTE B, 1992, BIOL PSYCHIAT, V32, P48, DOI 10.1016/0006-3223(92)90141-L; Shapiro LE, 1997, J CLIN ENDOCR METAB, V82, P2592, DOI 10.1210/jc.82.8.2592; Spencer CA, 1996, CLIN CHEM, V42, P2051; STAFFURTH JS, 1977, BRIT MED J, V2, P688, DOI 10.1136/bmj.2.6088.688; Stanbury JB, 1998, THYROID, V8, P83, DOI 10.1089/thy.1998.8.83; STOTT DJ, 1991, Q J MED, V78, P77; Surks MI, 1996, AM J MED, V100, P217, DOI 10.1016/S0002-9343(97)89462-4; SURKS MI, 1971, J CLIN ENDOCR METAB, V33, P612, DOI 10.1210/jcem-33-4-612; TENERZ A, 1990, J INTERN MED, V228, P229; Toft AD, 2001, NEW ENGL J MED, V345, P512, DOI 10.1056/NEJMcp010145; *US PREV SERV TASK, 3 USPSTF STRENGTH OV; *US PREV SERV TASK, 2002, PUBL AG HEALTHC RES; UY HL, 1995, AM J MED, V99, P173, DOI 10.1016/S0002-9343(99)80137-5; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VANDENBERGHE G, 1994, CLIN ENDOCRINOL, V41, P731; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vestergaard P, 2002, THYROID, V12, P411, DOI 10.1089/105072502760043503; Ward G, 1997, AM J CLIN PATHOL, V108, P417; Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904; WIERSINGA WM, 1995, NETH J MED, V46, P197, DOI 10.1016/0300-2977(94)00089-R; WONG ET, 1981, ARCH INTERN MED, V141, P873, DOI 10.1001/archinte.141.7.873; WOOD JM, 1991, AM J MED, V90, P261; Zulewski H, 1997, J CLIN ENDOCR METAB, V82, P771, DOI 10.1210/jc.82.3.771	96	1253	1396	4	98	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2004	291	2					228	238		10.1001/jama.291.2.228	http://dx.doi.org/10.1001/jama.291.2.228			11	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762YZ	14722150	Bronze			2022-12-28	WOS:000188040900032
J	Checkley, W; Gilman, RH; Black, RE; Epstein, LD; Cabrera, L; Sterling, CR; Moulton, LH				Checkley, W; Gilman, RH; Black, RE; Epstein, LD; Cabrera, L; Sterling, CR; Moulton, LH			Effect of water and sanitation on childhood health in a poor Peruvian peri-urban community	LANCET			English	Article							NUTRITIONAL-STATUS; RURAL BANGLADESH; YOUNG-CHILDREN; ENVIRONMENTAL SANITATION; DEVELOPING-COUNTRIES; DIARRHEAL DISEASES; INFANT-MORTALITY; GROWTH; DETERMINANTS; INFECTION	Background Inadequate water and sanitation adversely affect the health of children in developing countries. We aimed to assess the effects of water and sanitation on childhood health in a birth cohort of Peruvian children. Methods We followed up children once a day for diarrhoea and once a month for anthropometry, and obtained data for household water and sanitation at baseline. Findings At 24 months of age, children with the worst conditions for water source, water storage, and sanitation were 1.0 cm (95% CI 0.1-0.8) shorter and had 54% (-1 to 240) more diarrhoeal episodes than did those with the best conditions. Children from households with small storage containers had 28% (1-63) more diarrhoeal episodes than did children from households with large containers. Lack of adequate sewage disposal explained a height deficit of 0.9 cm (0.2-1.7) at 24 months of age. Better water source alone did not accomplish full health benefits. In 24-month-old children from households with a water connection, those in households without adequate sewage disposal and with small storage containers were 1.8 cm (0.1-3.6) shorter than children in households with sewage and with large storage containers. Interpretation Our findings show that nutritional status is a useful endpoint for water and sanitation interventions and underscores the need to improve sanitation in developing countries. Improved and more reliable water sources should discourage water storage at risk of becoming contaminated, decrease diarrhoeal incidence, and improve linear growth in children.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Proyectos Informat Salud Med & Agr, Lima, Peru; Catholic Univ Chile, Dept Estadist, Santiago, Chile; Univ Arizona, Dept Vet Sci, Tucson, AZ 85721 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pontificia Universidad Catolica de Chile; University of Arizona	Checkley, W (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St W5515, Baltimore, MD 21205 USA.	wcheckle@jhsph.edu		Checkley, William/0000-0003-1106-8812; Moulton, Lawrence/0000-0001-7041-7387; Black, Robert/0000-0001-9926-7984	NICHD NIH HHS [F31-HD08488] Funding Source: Medline; PHS HHS [U01-A135894] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F31HD008488] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; ANDRIANZEN BT, 1974, ARCH ENVIRON HEALTH, V28, P312; ARROWOOD MJ, 1997, CRYPTOSPORIDIUM CRYP, P43; AZIZ KMA, 1990, T ROY SOC TROP MED H, V84, P433, DOI 10.1016/0035-9203(90)90353-G; Berkman DS, 2002, LANCET, V359, P564, DOI 10.1016/S0140-6736(02)07744-9; Checkley W, 1997, AM J EPIDEMIOL, V145, P156, DOI 10.1093/oxfordjournals.aje.a009086; Checkley W, 2003, AM J EPIDEMIOL, V157, P166, DOI 10.1093/aje/kwf179; Checkley W, 2002, J PEDIATR-US, V140, P210, DOI 10.1067/mpd.2002.121820; CHRISTIANSEN N, 1975, BRIT J PREV SOC MED, V29, P121; ESREY SA, 1985, B WORLD HEALTH ORGAN, V63, P757; ESREY SA, 1988, AM J PUBLIC HEALTH, V78, P1451, DOI 10.2105/AJPH.78.11.1451; ESREY SA, 1986, EPIDEMIOL REV, V8, P117, DOI 10.1093/oxfordjournals.epirev.a036290; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Esrey SA, 1996, AM J EPIDEMIOL, V143, P608, DOI 10.1093/oxfordjournals.aje.a008791; GILMAN RH, 1993, AM J PUBLIC HEALTH, V83, P1554, DOI 10.2105/AJPH.83.11.1554; Guerrant DI, 1999, AM J TROP MED HYG, V61, P707, DOI 10.4269/ajtmh.1999.61.707; Guerrant RL, 2002, TRENDS PARASITOL, V18, P191, DOI 10.1016/S1471-4922(02)02253-5; HASAN KZ, 1989, EUR J CLIN NUTR, V43, P837; HENRY FI, 1981, T ROY SOC TROP MED H, V75, P507, DOI 10.1016/0035-9203(81)90187-5; HERBERT J R, 1984, Tropical and Geographical Medicine, V36, P375; Herbert JR., 1985, B WORLD HEALTH ORGAN, V63, P143; HUTTLY S R A, 1990, World Health Statistics Quarterly, V43, P118; Huttly SRA, 1997, B WORLD HEALTH ORGAN, V75, P163; HUTTLY SRA, 1990, T ROY SOC TROP MED H, V84, P316, DOI 10.1016/0035-9203(90)90300-4; Jonnalagadda Padmaja R., 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P789; LINDSKOG U, 1987, HUM NUTR-CLIN NUTR, V41C, P409; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M; MINTZ ED, 1996, JAMA-J AM MED ASSOC, V273, P948; Moulton LH, 1997, INT J EPIDEMIOL, V26, P1334, DOI 10.1093/ije/26.6.1334; Niehaus MD, 2002, AM J TROP MED HYG, V66, P590, DOI 10.4269/ajtmh.2002.66.590; PICKERING H, 1985, SOC SCI MED, V21, P121, DOI 10.1016/0277-9536(85)90080-2; PRESTON SH, 1978, POP STUD-J DEMOG, V32, P275, DOI 10.2307/2173562; RAHMAN M, 1985, LANCET, V2, P28, DOI 10.1016/S0140-6736(85)90068-6; Steiner TS, 1998, J INFECT DIS, V177, P88, DOI 10.1086/513809; TOMKINS AM, 1978, T ROY SOC TROP MED H, V72, P239, DOI 10.1016/0035-9203(78)90201-8; VANPOPPEL, 1997, HLTH TRANSIT REV, V7, P113; VICTORA CG, 1988, INT J EPIDEMIOL, V17, P651, DOI 10.1093/ije/17.3.651; *WHO, 1992, WHOCWS9212; YEAGER BAC, 1991, J DIARRHOEAL DIS RES, V9, P186	41	164	175	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	2004	363	9403					112	118		10.1016/S0140-6736(03)15261-0	http://dx.doi.org/10.1016/S0140-6736(03)15261-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	761WV	14726164				2022-12-28	WOS:000187939200008
J	Hussey, S; Hoddinott, P; Wilson, P; Dowell, J; Barbour, R				Hussey, S; Hoddinott, P; Wilson, P; Dowell, J; Barbour, R			Sickness certification system in the United Kingdom: qualitative study of views of general practitioners in Scotland	BRITISH MEDICAL JOURNAL			English	Article							PROFESSIONALS; ABSENTEEISM; ABSENCE; PAIN	Objectives To explore how general practitioners operate the sickness certification system, their views on the system, and suggestions for change. Design Qualitative focus group study consisting of 11 focus groups with 67 participants. Setting General practitioners in practices in Glasgow, Tayside, and Highland regions, Scotland. Sample Purposive sample of general practitioners, with further theoretical sampling of key informant general practitioners to examine emerging themes. Results General practitioners believed that the sickness certification system failed to address complex, chronic, or doubtful cases. They appeared to develop various operational strategies for its implementation. There seemed to be important deliberate misuse of the system by general practitioners, possibly related to conflicts about roles and incongruities in the system. The doctor-patient relationship was perceived to conflict with the current role of general practitioners in sickness certification. When making decisions about certification, the general practitioners considered a wide variety of factors. They experienced contradictory demands from other system stakeholders and felt blamed for failing to make impossible reconciliations. They clearly identified the difficulties of operating the system when there was no continuity of patient care. Many wished either to relinquish their gatekeeper role or to continue only with major changes. Conclusions Policy makers need to recognise and accommodate the range and complexity of factors that influence the behaviour of general practitioners operating as gatekeepers to the sickness certification system before making changes. Such changes are otherwise unlikely to result in improvement. Models other than the primary care gatekeeper model should be considered.	Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland; Sch Nursing & Midwifery, Dundee DD1 4HJ, Scotland	University of Dundee; University of Dundee		Susan.Hussey@GP55361.highland-hb.scot.nhs.uk	Hoddinott, Pat/F-9090-2011; Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248; Hoddinott, Pat/0000-0002-4372-9681				Burchardt T., 2000, ENDURING EC EXCLUSIO; Chew-Graham C, 1999, FAM PRACT, V16, P46, DOI 10.1093/fampra/16.1.46; Chew-Graham CA, 2002, FAM PRACT, V19, P285, DOI 10.1093/fampra/19.3.285; *DEP WORK PENS, 2002, CLIENT GROUP AN Q B; *EX AG, 2000, GUID REG MED PRACT; Feeney A, 1998, OCCUP ENVIRON MED, V55, P91, DOI 10.1136/oem.55.2.91; Green J., 1999, DEV FOCUS GROUP RES; Haldorsen EMH, 1996, SCAND J RHEUMATOL, V25, P224; Hiscock J, 2001, 148 DEP WORK PENS; Kitzinger J, 1995, BMJ-BRIT MED J, V311, P182; KUZEL AJ, 1992, RES METH PR, V3, P31; Larsen Bernt Arne, 1994, Tidsskrift for den Norske Laegeforening, V114, P1442; Luz J, 1997, Public Health Rev, V25, P89; MAYHEW HE, 1988, J FAM PRACTICE, V26, P651; MCCORMICK J, 2000, SICK INCAPACITY INCL; MCEWAN IM, 1991, POSTGRAD MED J, V67, P1067, DOI 10.1136/pgmj.67.794.1067; MCORMICK J, 2000, SICK INCAPACITY INCL; *NAT ASS CIT ADV B, 2000, EV SOC SEC SEL COMM; Patton M. Q., 1990, QUALITATIVE EVALUATI; Reiso H, 2000, FAM PRACT, V17, P139, DOI 10.1093/fampra/17.2.139; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [10.4324/9780203413081, DOI 10.4324/9780203413081_CHAPTER_9]; TELLNES G, 1990, Scandinavian Journal of Primary Health Care, V8, P45, DOI 10.3109/02813439008994928; WOLINSKY FD, 1981, J HEALTH SOC BEHAV, V22, P229, DOI 10.2307/2136518	23	149	149	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 10	2004	328	7431					88	91		10.1136/bmj.37949.656389.EE	http://dx.doi.org/10.1136/bmj.37949.656389.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MP	14691065	Green Submitted, Green Accepted, Bronze, Green Published			2022-12-28	WOS:000187976400017
J	Chad, DA; Hedley-Whyte, ET; Dawson, KT; Amato, A; Basgoz, N				Chad, DA; Hedley-Whyte, ET; Dawson, KT; Amato, A; Basgoz, N			A 49-year-old woman with asymmetric painful neuropathy - Borderline leprosy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MIGRANT SENSORY NEURITIS; PERIPHERAL NEUROPATHY; PERINEURITIS; DIAGNOSIS		UMass Mem Hlth Care, Dept Neurol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA; Massachusetts Gen Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Harvard University	Chad, DA (corresponding author), UMass Mem Hlth Care, Dept Neurol, Worcester, MA 01605 USA.		Hedley-Whyte, E Tessa/AAJ-9975-2021	Hedley-Whyte, E Tessa/0000-0002-1687-8905				Apartis E, 1996, J NEUROL NEUROSUR PS, V60, P661, DOI 10.1136/jnnp.60.6.661; ASBURY AK, 1972, ARCH NEUROL-CHICAGO, V26, P302, DOI 10.1001/archneur.1972.00490100032002; Barohn RJ, 1998, SEMIN NEUROL, V18, P7, DOI 10.1055/s-2008-1040857; Chimelli L, 1997, J NEUROL, V244, P318, DOI 10.1007/s004150050094; DAWSON DM, 1979, NEW ENGL J MED, V300, P546; Dyck PJ, 1996, NEUROLOGY, V47, P10, DOI 10.1212/WNL.47.1.10; GLASS J, 1993, CANCER-AM CANCER SOC, V71, P3156, DOI 10.1002/1097-0142(19930515)71:10<3156::AID-CNCR2820711043>3.0.CO;2-O; KAPLAN JG, 1990, MUSCLE NERVE, V13, P570, DOI 10.1002/mus.880130703; KELLY JJ, 1979, ANN NEUROL, V6, P1, DOI 10.1002/ana.410060102; KISSEL JT, 1992, NEUROL CLIN, V10, P761, DOI 10.1016/S0733-8619(18)30207-X; Lacomis D, 1999, J Clin Neuromuscul Dis, V1, P2, DOI 10.1097/00131402-199909000-00002; LEWIS RA, 1982, NEUROLOGY, V32, P958, DOI 10.1212/WNL.32.9.958; Lockwood DNJ, 2001, QJM-INT J MED, V94, P207, DOI 10.1093/qjmed/94.4.207; MATTHEWS WB, 1983, J NEUROL NEUROSUR PS, V46, P1, DOI 10.1136/jnnp.46.1.1; Nations SP, 1998, SEMIN NEUROL, V18, P113, DOI 10.1055/s-2008-1040867; Nicolle MW, 2001, MUSCLE NERVE, V24, P438, DOI 10.1002/1097-4598(200103)24:3<438::AID-MUS1020>3.0.CO;2-Y; Oh SJ, 1997, NEUROL CLIN, V15, P849, DOI 10.1016/S0733-8619(05)70351-0; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; SABIN TD, 1969, ARCH NEUROL-CHICAGO, V20, P257, DOI 10.1001/archneur.1969.00480090045006; SABIN TD, 1993, PERIPHERAL NEUROPATH, V2, P1354; Schaumburg H. H., 1992, DISORDERS PERIPHERAL; SMITH BE, 1992, NEUROL CLIN, V10, P735, DOI 10.1016/S0733-8619(18)30206-8; Sorenson EJ, 1997, MUSCLE NERVE, V20, P1153, DOI 10.1002/(SICI)1097-4598(199709)20:9<1153::AID-MUS10>3.0.CO;2-U; Younger DS, 1998, SEMIN NEUROL, V18, P95, DOI 10.1055/s-2008-1040865	24	7	7	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2004	350	2					166	176		10.1056/NEJMcpc030034	http://dx.doi.org/10.1056/NEJMcpc030034			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	760WP	14711916				2022-12-28	WOS:000187858500012
J	Sung, SB; Amasino, RM				Sung, SB; Amasino, RM			Vernalization in Arabidopsis thaliana is mediated by the PHD finger protein VIN3	NATURE			English	Article							FLOWERING-LOCUS-C; DNA METHYLATION; MOLECULAR-BASIS; FRIGIDA; GENE; MUTATIONS; PHENOTYPE; REPRESSOR; ACTS	In biennials and winter annuals, flowering is typically blocked in the first growing season. Exposure to the prolonged cold of winter, through a process called vernalization, is required to alleviate this block and permit flowering in the second growing season(1). In winter-annual types of Arabidopsis thaliana, a flowering repressor, FLOWERING LOCUS C (FLC), is expressed at levels that inhibit flowering in the first growing season(2). Vernalization promotes flowering by causing a repression of FLC that is mitotically stable after return to warmgrowing conditions(2). Here we identify a gene with a function in the measurement of the duration of cold exposure and in the establishment of the vernalized state. We show that this silencing involves changes in the modification of histones in FLC chromatin.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Amasino, RM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	amasino@biochem.wisc.edu	Sung, Sibum/AAM-6500-2020					BURN JE, 1993, P NATL ACAD SCI USA, V90, P287, DOI 10.1073/pnas.90.1.287; CHOUARD P, 1960, ANNU REV PLANT PHYS, V11, P191, DOI 10.1146/annurev.pp.11.060160.001203; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Gazzani S, 2003, PLANT PHYSIOL, V132, P1107, DOI 10.1104/pp.103.021212; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; LANG A, 1947, Z NATURFORSCH B, V2, P444, DOI 10.1515/znb-1947-11-1212; Lang A, 1965, ENCY PLANT PHYSL, P1371, DOI DOI 10.1007/978-3-642-50088-6_39; LEE I, 1994, PLANT J, V6, P903, DOI 10.1046/j.1365-313X.1994.6060903.x; Levy YY, 2002, SCIENCE, V297, P243, DOI 10.1126/science.1072147; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Michaels SD, 2000, PLANT CELL ENVIRON, V23, P1145, DOI 10.1046/j.1365-3040.2000.00643.x; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Michaels SD, 2003, P NATL ACAD SCI USA, V100, P10102, DOI 10.1073/pnas.1531467100; Michaels SD, 2003, PLANT J, V33, P867, DOI 10.1046/j.1365-313X.2003.01671.x; Michaels SD, 2001, PLANT CELL, V13, P935, DOI 10.1105/tpc.13.4.935; Micheals SD, 1999, DEV GENET, V25, P194, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;194::AID-DVG2&gt;3.0.CO;2-2; Reyes JC, 2002, PLANT PHYSIOL, V130, P1090, DOI 10.1104/pp.006791; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Sheldon CC, 2002, PLANT CELL, V14, P2527, DOI 10.1105/tpc.004564; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Thomashow MF, 2001, PLANT PHYSIOL, V125, P89, DOI 10.1104/pp.125.1.89; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; WELLENSIEK SJ, 1962, NATURE, V195, P307, DOI 10.1038/195307a0	30	627	700	8	167	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 8	2004	427	6970					159	164		10.1038/nature02195	http://dx.doi.org/10.1038/nature02195			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760YY	14712276				2022-12-28	WOS:000187863900036
J	del Giglio, A; Costa, LJ				del Giglio, A; Costa, LJ			Commentary: The quality of randomised controlled trials may be better than assumed	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									ABC Fdn Sch Med, BR-05410040 Sao Paulo, Brazil; Univ Colorado, Hlth Sci Ctr, Div Med Oncol, ABC Fdn Sch Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	del Giglio, A (corresponding author), ABC Fdn Sch Med, Ave Reboucas 3387, BR-05410040 Sao Paulo, Brazil.	sandrabr@netpoint.com.br						DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Pignon JP, 2001, LANCET ONCOL, V2, P475, DOI 10.1016/S1470-2045(01)00453-3	4	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	2004	328	7430					24	25		10.1136/bmj.328.7430.24	http://dx.doi.org/10.1136/bmj.328.7430.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761QG	14703541	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000187919000017
J	Miranda, JJ; Yamin, AE				Miranda, JJ; Yamin, AE			Reproductive health without rights in Peru	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London, England; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; EDHUCASalud, Lima, Peru	University of London; University College London; Harvard University; Harvard T.H. Chan School of Public Health	Miranda, JJ (corresponding author), UCL, Int Hlth & Med Educ Ctr, London, England.	j.miranda@ucl.ac.uk	Miranda, J. Jaime/A-8482-2008	Miranda, J. Jaime/0000-0002-4738-5468				Bosch X, 2002, BRIT MED J, V325, P236; Coe A. B., 2002, GOVT EXTREMISTS PERU; *DEF PUEBL, 2000, INF DEF 27; *DEF PUEBL, 2002, INF DEF 7; DYER C, 2002, BRIT MED J, V325, P674; *I NAC EST INF, 2000, ENC NAC DEM SAL 2000; *I NAC EST INF, PER CIFR; 2001, REPUBLICA       0923; 1997, INTER PRESS SER 1114; [No title captured]	10	23	25	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 3	2004	363	9402					68	69		10.1016/S0140-6736(03)15175-6	http://dx.doi.org/10.1016/S0140-6736(03)15175-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758YZ	14724000				2022-12-28	WOS:000187711300029
J	MacFadyen, A				MacFadyen, A			Long gamma-ray bursts	SCIENCE			English	Editorial Material							SUPERNOVAE; COLLAPSARS; PULSARS		CALTECH, Dept Theoret Astrophys, Pasadena, CA 91125 USA	California Institute of Technology	MacFadyen, A (corresponding author), CALTECH, Dept Theoret Astrophys, Pasadena, CA 91125 USA.			MacFadyen, Andrew/0000-0002-0106-9013				COLGATE SA, 1968, CAN J PHYS, V46, pS476, DOI 10.1139/p68-274; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; Rosswog S, 2004, SCIENCE, V303, P46, DOI 10.1126/science.1091767; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; USOV VV, 1992, NATURE, V357, P472, DOI 10.1038/357472a0; Vietri M, 1998, ASTROPHYS J, V507, pL45, DOI 10.1086/311674; Wheeler JC, 2000, ASTROPHYS J, V537, P810, DOI 10.1086/309055; WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359; Zhang WQ, 2003, ASTROPHYS J, V586, P356, DOI 10.1086/367609	10	4	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					45	46		10.1126/science.1091764	http://dx.doi.org/10.1126/science.1091764			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704414				2022-12-28	WOS:000187710600022
J	Pitulko, VV; Nikolsky, PA; Girya, EY; Basilyan, AE; Tumskoy, VE; Koulakov, SA; Astakhov, SN; Pavlova, EY; Anisimov, MA				Pitulko, VV; Nikolsky, PA; Girya, EY; Basilyan, AE; Tumskoy, VE; Koulakov, SA; Astakhov, SN; Pavlova, EY; Anisimov, MA			The Yana RHS site: Humans in the Arctic before the Last Glacial Maximum	SCIENCE			English	Article							COLONIZATION; PLEISTOCENE	A newly discovered Paleolithic site on the Yana River, Siberia, at 71degreesN, lies well above the Arctic circle and dates to 27,000 radiocarbon years before present, during glacial times. This age is twice that of other known human occupations in any Arctic region. Artifacts at the site include a rare rhinoceros foreshaft, other mammoth foreshafts, and a wide variety of tools and flakes. This site shows that people adapted to this harsh, high-latitude, Late Pleistocene environment much earlier than previously thought.	Russian Acad Sci, Inst Hist Mat Culture, St Petersburg 191186, Russia; Russian Acad Sci, Inst Geol, Moscow 119017, Russia; Moscow MV Lomonosov State Univ, Fac Geog, Geol Res Lab N, Moscow 119992, Russia; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia	Russian Academy of Sciences; Institute for the History of Material Culture, Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Geological Institute, Russian Academy of Sciences; Russian Academy of Sciences; Lomonosov Moscow State University; Arctic & Antarctic Research Institute	Pitulko, VV (corresponding author), Russian Acad Sci, Inst Hist Mat Culture, 18 Dvortsovaya Nab St, St Petersburg 191186, Russia.	archeo@archeo.ru	Nikolskiy, Pavel A/C-5041-2012; Pavlova, Elena/AAA-3291-2019; Pitulko, Vladimir/N-4009-2019; Girya, Evgeniy/AAC-5774-2020; Pitulko, Vladimir/E-2200-2015; Tumskoy, Vladimir E./Y-5682-2018; Astakhov, Sergej/AAC-5889-2020	Pitulko, Vladimir/0000-0001-5672-2756; Tumskoy, Vladimir E./0000-0002-1462-1444; Astakhov, Sergej/0000-0001-9266-3001; Pavlova, Elena/0000-0002-3010-6290				ANDERSON PM, 2001, QUATERNARY SCI REV, V20, P99; Bradley B., 1995, TRAVAIL USAGE IVOIRE, P114; Dunbar J., 1989, BONE MODIFICATION, P473; DUNBUR J, 1991, HALF MILE RISE TIMES, V1, P10; Goebel T, 1999, EVOL ANTHROPOL, V8, P208; Goebel T, 2003, SCIENCE, V301, P501, DOI 10.1126/science.1086555; HOFFECKER JF, 1993, SCIENCE, V259, P46, DOI 10.1126/science.259.5091.46; Hoffecker JF, 2003, EVOL ANTHROPOL, V12, P34, DOI 10.1002/evan.10103; Kaplina T.N., 1982, IZVESTIYA SSSR P SSS, V2, P84; KARTASHOVA GG, 1983, VESTN MOSK U GEOGR, V6, P37; LAUKHIN SA, 1991, INQUA INT S STRAT CO, P133; MIKHALEV V, 1992, ARCHAEOLOGICAL RES Y, P47; MOCHANOV YA, 1977, EARLY STAGES HUMAN O; PAVLIDIS YA, 1992, SHELF MIROVOGO OKEAN; Pitul'ko V, 2001, QUATERNARY SCI REV, V20, P267, DOI 10.1016/S0277-3791(00)00117-7; Scherbakova N.M., 1980, NOVOYE ARKHEOLOGII Y, P62; SULERZHITSKY L, 1997, CRYOSPHERA EARTH, V1, P27; VANGHENHEIM EA, SPECIES IDENTIFICATI; Vereschagin N. K., 1972, SOVETSKAYA ARKHEOLOG, V3, P332; WEST FH, 1996, AM BEGINNINGS	20	207	221	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					52	56		10.1126/science.1085219	http://dx.doi.org/10.1126/science.1085219			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14704419				2022-12-28	WOS:000187710600028
J	Glass, DA; Patel, MS; Karsenty, G				Glass, DA; Patel, MS; Karsenty, G			A new insight into the formation of osteolytic lesions in multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Glass, DA (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Glass, Donald/AGI-6735-2022; Glass, Donald A/A-1908-2013	Glass, Donald/0000-0003-0866-770X; /0000-0001-7061-6837					0	23	25	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	2003	349	26					2479	2480		10.1056/NEJMp038176	http://dx.doi.org/10.1056/NEJMp038176			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757BT	14695406				2022-12-28	WOS:000187529500001
J	Ajami, D; Oeckler, O; Simon, A; Herges, R				Ajami, D; Oeckler, O; Simon, A; Herges, R			Synthesis of a Mobius aromatic hydrocarbon	NATURE			English	Article							METATHESIS; CHARACTER; SYSTEMS; TETRADEHYDRODIANTHRACENE; CORONENE; ISOMERS; DENSITY; HUCKEL; STRIP	The defining feature of aromatic hydrocarbon compounds is a cyclic molecular structure stabilized by the delocalization of pi electrons that, according to the Huckel rule, need to total 4n + 2 (n = 1,2,.,,); cyclic compounds with 4n pi electrons are antiaromatic and unstable. But in 1964, Heilbronner predicted(1) on purely theoretical grounds that cyclic molecules with the topology of a Mobius band - a ring constructed by joining the ends of a rectangular strip after having given one end half a twist - should be aromatic if they contain 4n, rather than 4n 1 2, p electrons. The prediction stimulated attempts to synthesize Mobius aromatic hydrocarbons, but twisted cyclic molecules are destabilized by large ring strains, with the twist also suppressing overlap of the p orbitals involved in electron delocalization and stabilization. In larger cyclic molecules, ring strain is less pronounced but the structures are very flexible and flip back to the less-strained Huckel topology(2,3). Although transition-state species(4), an unstable intermediate(5) and a non-conjugated cyclic molecule(6), all with a Mobius topology, have been documented, a stable aromatic Mobius system has not yet been realized. Here we report that combining a 'normal' aromatic structure (with p orbitals orthogonal to the ring plane) and a 'belt-like' aromatic structure (with p orbitals within the ring plane) yields a Mobius compound stabilized by its extended pi system.	Univ Kiel, Inst Organ Chem, D-24098 Kiel, Germany; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	University of Kiel; Max Planck Society	Herges, R (corresponding author), Univ Kiel, Inst Organ Chem, Otto Hahn Pl 4, D-24098 Kiel, Germany.	rherges@oc.uni-kiel.de	Ajami, Dariush/A-1312-2014					AVRAM M, 1964, CHEM BER-RECL, V97, P382, DOI 10.1002/cber.19640970210; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Castro C, 2002, ORG LETT, V4, P3431, DOI 10.1021/ol026610g; Dobrowolski JC, 2002, J CHEM INF COMP SCI, V42, P490, DOI 10.1021/ci0100853; Frisch MJ, 2003, GAUSSIAN03; Garrat P. J., 1986, AROMATICITY; Guillaume M, 2001, THEOR CHEM ACC, V105, P431, DOI 10.1007/s002140000245; Havenith RWA, 2001, INT J QUANTUM CHEM, V85, P52, DOI 10.1002/qua.1089; HEILBRONNER E, 1964, TETRAHEDRON LETT, V29, P1923; Johnson RP, 1996, J AM CHEM SOC, V118, P7381, DOI 10.1021/ja961066q; Kammermeier S, 1996, ANGEW CHEM INT EDIT, V35, P417, DOI 10.1002/anie.199604171; Kammermeier S, 1996, ANGEW CHEM INT EDIT, V35, P2669, DOI 10.1002/anie.199626691; Kammermeier S, 1997, ANGEW CHEM INT EDIT, V36, P2200, DOI 10.1002/anie.199722001; Kastrup CJ, 2002, J CHEM SOC DALTON, P2421, DOI 10.1039/b203996f; Katritzky AR, 2001, CHEM REV, V101, P1421, DOI 10.1021/cr990327m; KRYGOWSKI TM, 1993, J CHEM INF COMP SCI, V33, P70, DOI 10.1021/ci00011a011; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Martin-Santamaria S, 2000, CHEM COMMUN, P1089, DOI 10.1039/b002462g; Martin-Santamaria S, 2000, J CHEM SOC PERK T 2, P1415, DOI 10.1039/b002082f; Mauksch M, 1998, ANGEW CHEM INT EDIT, V37, P2395, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2395::AID-ANIE2395>3.0.CO;2-W; Nendel M, 1998, J PHYS CHEM A, V102, P7191, DOI 10.1021/jp9820976; OTH JFM, 1968, TETRAHEDRON LETT, V60, P6259; STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208; VONSCHLEYER PR, 2003, ORG LETT, V4, P865; WALBA DM, 1993, NEW J CHEM, V17, P661; Wannere CS, 2003, ORG LETT, V5, P2983, DOI 10.1021/ol034979f; ZIMMERMAN HE, 1966, J AM CHEM SOC, V88, P1564, DOI 10.1021/ja00959a052; ZOELLNER RW, 1994, J CHEM INF COMP SCI, V34, P252, DOI 10.1021/ci00018a004	28	316	317	8	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					819	821		10.1038/nature02224	http://dx.doi.org/10.1038/nature02224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	754QM	14685233				2022-12-28	WOS:000187342000052
J	Raxworthy, CJ; Martinez-Meyer, E; Horning, N; Nussbaum, RA; Schneider, GE; Ortega-Huerta, MA; Peterson, AT				Raxworthy, CJ; Martinez-Meyer, E; Horning, N; Nussbaum, RA; Schneider, GE; Ortega-Huerta, MA; Peterson, AT			Predicting distributions of known and unknown reptile species in Madagascar	NATURE			English	Article							BIODIVERSITY HOTSPOTS; FUTURE	Despite the importance of tropical biodiversity(1), informative species distributional data are seldom available for biogeographical study or setting conservation priorities(2,3). Modelling ecological niche distributions of species offers a potential soluion(4-7); however, the utility of old locality data from museums, and of more recent remotely sensed satellite data, remains poorly explored, especially for rapidly changing tropical landscapes. Using 29 modern data sets of environmental land coverage and 621 chameleon occurrence localities from Madagascar ( historical and recent), here we demonstrate a significant ability of our niche models in predicting species distribution. At 11 recently inventoried sites, highest predictive success (85.1%) was obtained for models based only on modern occurrence data (74.7% and 82.8% predictive success, respectively, for pre-1978 and all data combined). Notably, these models also identified three intersecting areas of over-prediction that recently yielded seven chameleon species new to science. We conclude that ecological niche modelling using recent locality records and readily available environmental coverage data provides informative biogeographical data for poorly known tropical landscapes, and offers innovative potential for the discovery of unknown distributional areas and unknown species.	Amer Museum Nat Hist, New York, NY 10024 USA; Univ Nacl Autonoma Mexico, Inst Biol, Mexico City 04510, DF, Mexico; Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA; Univ Kansas, Nat Hist Museum, Lawrence, KS 66045 USA; Univ Kansas, Biodivers Res Ctr, Lawrence, KS 66045 USA	American Museum of Natural History (AMNH); Universidad Nacional Autonoma de Mexico; University of Michigan System; University of Michigan; University of Kansas; University of Kansas	Raxworthy, CJ (corresponding author), Amer Museum Nat Hist, Cent Pk W & 79th St, New York, NY 10024 USA.	rax@amnh.org	Peterson, A. Townsend/I-5697-2013; Martinez-Meyer, Enrique/B-1464-2008	Peterson, A. Townsend/0000-0003-0243-2379; Martinez-Meyer, Enrique/0000-0003-1184-9264				Anderson RP, 2002, GLOBAL ECOL BIOGEOGR, V11, P131, DOI 10.1046/j.1466-822X.2002.00275.x; Anderson RP, 2003, ECOL MODEL, V162, P211, DOI 10.1016/S0304-3800(02)00349-6; Andreone F, 2001, ITAL J ZOOL, V68, P235, DOI 10.1080/11250000109356414; ANGAP (Association nationale pour la Gestion des Aires protegees), 2001, PLAN GEST RES NAT AI; Brygoo E. R., 1971, Faune de Madagascar, V33, P1; Brygoo E.-R., 1978, Faune de Madagascar, V47, P1; Crisci JV, 2001, J BIOGEOGR, V28, P157, DOI 10.1046/j.1365-2699.2001.00523.x; *ESRI, 1997, ARCATLAS; Goodman S.M., 1998, AKONNY ALA, V24, P19; GOODMAN S. M., 2002, AKONNY ALA, V28, P1; GREEN GM, 1990, SCIENCE, V248, P212, DOI 10.1126/science.248.4952.212; Martinez-Meyer E., 2002, THESIS U KANSAS; Mayaux P, 2000, INT J REMOTE SENS, V21, P3139, DOI 10.1080/01431160050145018; Mittermeier RA, 1998, CONSERV BIOL, V12, P516, DOI 10.1046/j.1523-1739.1998.012003516.x; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; NELSON R, 1993, INT J REMOTE SENS, V14, P1463, DOI 10.1080/01431169308953981; New M., 1997, 1961 1990 MEAN MONTH; Peterson AT, 1999, ECOL MODEL, V117, P159, DOI 10.1016/S0304-3800(99)00023-X; Peterson AT, 2002, PREDICTING SPECIES OCCURRENCES: ISSUES OF ACCURACY AND SCALE, P617; Peterson AT, 1999, SCIENCE, V285, P1265, DOI 10.1126/science.285.5431.1265; Peterson AT, 2002, NATURE, V416, P626, DOI 10.1038/416626a; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; RAKOTOMALALA D, 2001, RECH DEV SERIE SCI B, V17, P133; Rakotomalala Domoina, 2002, Boissiera, V59, P339; Raselimanana A.P., 1998, RECHERCHES DEV SB, V13, P43; RASELIMANANA AP, 1998, RECHERCHES DEV SB, V14, P183; Rasolonandrasana AP, 1999, RECHERCHES POUR LE D, V15; Raxworthy CJ, 2002, NATURE, V415, P784, DOI 10.1038/415784a; Stockwell D, 1999, INT J GEOGR INF SCI, V13, P143, DOI 10.1080/136588199241391; STOCKWELL DRB, 1992, MATH COMPUT SIMULAT, V33, P385, DOI 10.1016/0378-4754(92)90126-2	30	381	418	5	121	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 18	2003	426	6968					837	841		10.1038/nature02205	http://dx.doi.org/10.1038/nature02205			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14685238	Green Published			2022-12-28	WOS:000187342000058
